<SEC-DOCUMENT>0000355019-24-000009.txt : 20240214
<SEC-HEADER>0000355019-24-000009.hdr.sgml : 20240214
<ACCEPTANCE-DATETIME>20240214171355
ACCESSION NUMBER:		0000355019-24-000009
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		63
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240214
DATE AS OF CHANGE:		20240214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FONAR CORP
		CENTRAL INDEX KEY:			0000355019
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				112464137
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-10248
		FILM NUMBER:		24640505

	BUSINESS ADDRESS:	
		STREET 1:		110 MARCUS DR
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747
		BUSINESS PHONE:		6316942929

	MAIL ADDRESS:	
		STREET 1:		110 MARCUS DRIVE
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>fonar_10-q.htm
<DESCRIPTION>FORM 10-Q FOR THE PERIOD ENDED DECEMBER 31, 2023
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:FONR="http://fonar.com/20231231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_031_FONR_fonar.com_20231231 -->
<!-- Field: Set; Name: xdx; ID: xdx_041_20230701_20231231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0wNi0zMA== -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DDocumentFiscalYearFocus_2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DDocumentFiscalPeriodFocus_Q2 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DEntityCentralIndexKey_0000355019 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-07-01to2023-12-31" name="dei:AmendmentFlag" id="ixv-6327">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-07-01to2023-12-31" name="dei:CurrentFiscalYearEndDate" id="ixv-6328">--06-30</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-07-01to2023-12-31" name="dei:DocumentFiscalYearFocus" id="ixv-6329">2024</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-07-01to2023-12-31" name="dei:DocumentFiscalPeriodFocus" id="ixv-6330">Q2</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-07-01to2023-12-31" name="dei:EntityCentralIndexKey" id="ixv-6331">0000355019</ix:nonNumeric>
  <ix:nonFraction name="FONR:AccountReceivableRelatedParties" contextRef="AsOf2023-06-30" id="xdx2ixbrl0064" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:NoteReceivableRelatedParty" contextRef="AsOf2023-06-30" id="xdx2ixbrl0088" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:UnearnedRevenueOnServiceContractsRelatedParty" contextRef="AsOf2023-06-30" id="xdx2ixbrl0130" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_custom_ClassANonVotingPreferredStockMember" id="xdx2ixbrl0190" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-06-30_custom_ClassANonVotingPreferredStockMember" id="xdx2ixbrl0192" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0210" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0212" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember" id="xdx2ixbrl0250" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-06-30_us-gaap_CommonClassBMember" id="xdx2ixbrl0252" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31_us-gaap_CommonClassCMember" id="xdx2ixbrl0270" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-06-30_us-gaap_CommonClassCMember" id="xdx2ixbrl0272" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-10-012023-12-31" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:OtherIncomeRelatedParty" contextRef="From2022-10-012022-12-31" id="xdx2ixbrl0360" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:OtherIncomeRelatedParty" contextRef="From2022-07-012022-12-31" id="xdx2ixbrl0480" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0562" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0563" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0565" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012023-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0566" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0569" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-10-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0570" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-10-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0571" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-10-012023-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0573" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:CancellationOfShares" contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0578" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:CancellationOfShares" contextRef="From2023-10-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0580" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:CancellationOfShares" contextRef="From2023-10-012023-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0582" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:CancellationOfShares" contextRef="From2023-10-012023-12-31" id="xdx2ixbrl0583" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0589" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="From2023-10-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0590" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="From2023-10-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0591" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="From2023-10-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0592" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0596" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2023-10-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0597" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2023-10-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0598" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2023-10-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0599" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0649" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0650" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012022-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0652" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012022-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0653" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0656" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0657" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0658" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-10-012022-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0660" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:CancellationOfShares" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0665" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:CancellationOfShares" contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0667" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:CancellationOfShares" contextRef="From2022-10-012022-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0669" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0676" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0677" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0678" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="From2022-10-012022-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0679" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0683" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0684" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0685" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2022-10-012022-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0686" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0736" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0737" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0739" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0740" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0743" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-07-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0744" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-07-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0745" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-07-012023-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0747" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:CancellationOfShares" contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0752" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:CancellationOfShares" contextRef="From2023-07-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0754" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:CancellationOfShares" contextRef="From2023-07-012023-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0756" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:CancellationOfShares" contextRef="From2023-07-01to2023-12-31" id="xdx2ixbrl0757" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0763" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="From2023-07-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0764" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="From2023-07-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0765" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="From2023-07-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0766" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0770" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2023-07-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0771" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2023-07-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0772" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2023-07-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0773" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0823" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0824" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0826" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0827" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0830" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-07-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0831" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-07-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0832" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-07-012022-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0834" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:CancellationOfShares" contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0839" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:CancellationOfShares" contextRef="From2022-07-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0841" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:CancellationOfShares" contextRef="From2022-07-012022-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0843" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0850" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="From2022-07-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0851" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="From2022-07-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0852" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="From2022-07-012022-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0853" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0857" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2022-07-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0858" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2022-07-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0859" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2022-07-012022-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0860" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:GainOnSaleOfEquipmentRelatedParty" contextRef="From2022-07-012022-12-31" id="xdx2ixbrl0909" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="From2022-07-012022-12-31" id="xdx2ixbrl0927" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:ConvertibleClassCStock" contextRef="From2023-10-012023-12-31_us-gaap_CommonClassCMember" id="xdx2ixbrl1091" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:ConvertibleClassCStock" contextRef="From2022-10-012022-12-31_us-gaap_CommonClassCMember" id="xdx2ixbrl1095" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:ConvertibleClassCStock" contextRef="From2023-07-012023-12-31_us-gaap_CommonClassCMember" id="xdx2ixbrl1159" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:ConvertibleClassCStock" contextRef="From2022-07-012022-12-31_us-gaap_CommonClassCMember" id="xdx2ixbrl1163" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:AccountsReceivableNetRelatedParty" contextRef="AsOf2023-12-31_us-gaap_DoubtfulMember" id="xdx2ixbrl1213" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:MedicalReceivable" contextRef="AsOf2023-12-31_us-gaap_DoubtfulMember" id="xdx2ixbrl1219" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:MedicalReceivable" contextRef="AsOf2023-06-30_us-gaap_DoubtfulMember" id="xdx2ixbrl1243" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2023-12-31_custom_FinancingLeasePaymentsMember" id="xdx2ixbrl1382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2023-12-31_custom_FinancingLeasePaymentsMember" id="xdx2ixbrl1386" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:IntersegmentNetRevenues" contextRef="From2023-10-012023-12-31_custom_ManagementOfDiagnosticImagingCentersMember" id="xdx2ixbrl1520" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:IntersegmentNetRevenues" contextRef="From2022-10-012022-12-31_custom_ManagementOfDiagnosticImagingCentersMember" id="xdx2ixbrl1550" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:IntersegmentNetRevenues" contextRef="From2023-07-012023-12-31_custom_ManagementOfDiagnosticImagingCentersMember" id="xdx2ixbrl1580" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FONR:IntersegmentNetRevenues" contextRef="From2022-07-012022-12-31_custom_ManagementOfDiagnosticImagingCentersMember" id="xdx2ixbrl1610" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="fonr-20231231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-07-01to2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-09_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-09_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-09_us-gaap_CommonClassCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-09_custom_ClassAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ClassANonVotingPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassANonVotingPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_ClassANonVotingPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassANonVotingPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CommonStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:CommonStocksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_CommonStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:CommonStocksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonClassCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonClassCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-12-31_custom_CommonStockholdersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:CommonStockholdersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_custom_CommonStockholdersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:CommonStockholdersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-12-31_custom_ClassANonVotingPreferredStockholdersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassANonVotingPreferredStockholdersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_custom_ClassANonVotingPreferredStockholdersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassANonVotingPreferredStockholdersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-12-31_us-gaap_CommonClassCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_us-gaap_CommonClassCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-12-31_custom_CommonStockholdersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:CommonStockholdersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-12-31_custom_CommonStockholdersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:CommonStockholdersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-12-31_custom_ClassANonVotingPreferredStockholdersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassANonVotingPreferredStockholdersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-12-31_custom_ClassANonVotingPreferredStockholdersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassANonVotingPreferredStockholdersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-12-31_us-gaap_CommonClassCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-12-31_us-gaap_CommonClassCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember-1258588437">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember-1258588312">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-07-01_custom_ControllingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">FONR:ControllingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-07-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-07-01_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-07-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_ControllingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">FONR:ControllingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_ControllingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">FONR:ControllingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_DoubtfulMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:DoubtfulMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_DoubtfulMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:DoubtfulMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-12-31_custom_CommercialInsuranceManagedCareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:CommercialInsuranceManagedCareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_custom_CommercialInsuranceManagedCareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:CommercialInsuranceManagedCareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-12-31_custom_MedicareMedicaidMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:MedicareMedicaidMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_custom_MedicareMedicaidMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:MedicareMedicaidMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-12-31_custom_WorkersCompensationPersonalInjuryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:WorkersCompensationPersonalInjuryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_custom_WorkersCompensationPersonalInjuryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:WorkersCompensationPersonalInjuryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-12-31_custom_OtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:OtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_custom_OtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:OtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-12-31_custom_CommercialInsuranceManagedCareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:CommercialInsuranceManagedCareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-12-31_custom_CommercialInsuranceManagedCareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:CommercialInsuranceManagedCareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-12-31_custom_MedicareMedicaidMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:MedicareMedicaidMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-12-31_custom_MedicareMedicaidMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:MedicareMedicaidMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-12-31_custom_WorkersCompensationPersonalInjuryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:WorkersCompensationPersonalInjuryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-12-31_custom_WorkersCompensationPersonalInjuryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:WorkersCompensationPersonalInjuryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-12-31_custom_OtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:OtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-12-31_custom_OtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:OtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_OperatingLeasePaymentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">FONR:OperatingLeasePaymentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_FinancingLeasePaymentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">FONR:FinancingLeasePaymentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PatentsAndCopyrightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:PatentsAndCopyrightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_PatentsAndCopyrightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:PatentsAndCopyrightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_NoncompeteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_NoncompeteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-12-31_custom_PatentsAndCopyrightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:PatentsAndCopyrightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_custom_PatentsAndCopyrightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:PatentsAndCopyrightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-12-31_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-12-31_custom_PatentsAndCopyrightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:PatentsAndCopyrightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-12-31_custom_PatentsAndCopyrightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:PatentsAndCopyrightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-12-31_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-12-31_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-12-31_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">FONR:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-12-31_custom_ManagementOfDiagnosticImagingCentersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">FONR:ManagementOfDiagnosticImagingCentersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">FONR:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_custom_ManagementOfDiagnosticImagingCentersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">FONR:ManagementOfDiagnosticImagingCentersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-12-31_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">FONR:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-12-31_custom_ManagementOfDiagnosticImagingCentersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">FONR:ManagementOfDiagnosticImagingCentersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-12-31_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">FONR:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-12-31_custom_ManagementOfDiagnosticImagingCentersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">FONR:ManagementOfDiagnosticImagingCentersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MagneticResonanceManagementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FONR:MagneticResonanceManagementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-12-31_custom_MagneticResonanceManagementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FONR:MagneticResonanceManagementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000355019</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 10pt; margin-bottom: 3pt"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<p style="font: 14pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">FORM <span id="xdx_905_edei--DocumentType_c20230701__20231231_zq3IVRrOgftk"><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" name="dei:DocumentType" id="ixv-7489">10-Q</ix:nonNumeric></span></p>

<p style="font: 14pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">SECURITIES AND
EXCHANGE COMMISSION</p>

<p style="font: 12pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Washington, D.C. 20549</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span id="xdx_90B_edei--DocumentQuarterlyReport_c20230701__20231231_zWYb4SQ5rEFh" title="Document Quarterly Report"><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport" id="ixv-7490">&#9746;</ix:nonNumeric></span> QUARTERLY REPORT UNDER SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="xdx_907_edei--DocumentTransitionReport_c20230701__20231231_z76jTXzg3P29" title="Document Transition Report" style="display: none"><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" id="ixv-7491">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;For
the quarterly period ended <span id="xdx_901_edei--DocumentPeriodEndDate_c20230701__20231231_ztSSzFX3Q194"><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-7492">DECEMBER 31, 2023</ix:nonNumeric></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 31.5pt; text-align: center; text-indent: -36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Commission file number <span id="xdx_906_edei--EntityFileNumber_c20230701__20231231_zzs8n111OYV"><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" name="dei:EntityFileNumber" id="ixv-7493">0-10248</ix:nonNumeric></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><img src="fonar_logo.jpg" alt="" style="height: 20px; width: 132px"/>&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 24pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span id="xdx_90F_edei--EntityRegistrantName_c20230701__20231231_zbQEs6zM7Rah"><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" name="dei:EntityRegistrantName" id="ixv-7494">FONAR CORPORATION</ix:nonNumeric></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Exact name of registrant as specified
in its charter)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20230701__20231231_z0oSSQ8ESIUl" style="text-transform: uppercase"><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-7495">delaware</ix:nonNumeric></span></span></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20230701__20231231_zBxya3ts1yS3"><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" name="dei:EntityTaxIdentificationNumber" id="ixv-7496">11-2464137</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction of </span><br/>
<span style="font: 10pt Times New Roman, Times, Serif">incorporation or organization)</span></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="padding-left: 5.4pt; text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">(I.R.S. Employer </span><br/>
<span style="font: 10pt Times New Roman, Times, Serif">Identification No.)</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; text-align: center; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="padding-left: 5.4pt; text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 45%; padding-left: 5.4pt; text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--EntityAddressAddressLine1_c20230701__20231231" title="Entity Address, Address Line One"><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" name="dei:EntityAddressAddressLine1" id="ixv-7497">110 Marcus Drive</ix:nonNumeric></span> <span id="xdx_903_edei--EntityAddressCityOrTown_c20230701__20231231" title="Entity Address, City or Town"><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" name="dei:EntityAddressCityOrTown" id="ixv-7498">Melville</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressStateOrProvince_c20230701__20231231" title="Entity Address, State or Province"><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-7499">New York</ix:nonNumeric></span></span></td>
    <td style="width: 10%; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 45%; padding-left: 5.4pt; text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_edei--EntityAddressPostalZipCode_c20230701__20231231" title="Entity Address, Postal Zip Code"><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" name="dei:EntityAddressPostalZipCode" id="ixv-7500">11747</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Address of principal executive offices)</span></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="padding-left: 5.4pt; text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">(Zip Code)</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant&#8217;s telephone number,
including area code: <span id="xdx_90A_edei--CityAreaCode_c20230701__20231231_zmzsmO2811Ej"><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" name="dei:CityAreaCode" id="ixv-7501">(631)</ix:nonNumeric></span> <span id="xdx_902_edei--LocalPhoneNumber_c20230701__20231231_zmZldfptdxIc"><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" name="dei:LocalPhoneNumber" id="ixv-7502">694-2929</ix:nonNumeric></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9746;  No &#9744;.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Indicate by check mark if the registrant is not required
to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. <span id="xdx_90B_edei--EntityCurrentReportingStatus_c20230701__20231231_ztTRHxvzHppe"><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" name="dei:EntityCurrentReportingStatus" id="ixv-7503">Yes</ix:nonNumeric></span> &#9746;  No &#9744;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the
registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(232.405 of this chapter) during the preceding 12 months (or for shorter period that the registrant was required to submit such
files <span id="xdx_901_edei--EntityInteractiveDataCurrent_c20230701__20231231_z87lTFEMsPU2"><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" name="dei:EntityInteractiveDataCurrent" id="ixv-7504">Yes</ix:nonNumeric></span> &#9746; No &#9744;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the
registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging
growth company. See definition of accelerated filer, large accelerated filer, smaller reporting company and emerging growth company
in Rule 12b-2 of the Exchange Act. (Check one): Large accelerated filer &#9744; Accelerated filer &#9744; <span id="xdx_904_edei--EntityFilerCategory_c20230701__20231231_zTDdOuzfTpZi"><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-7505">Non-accelerated filer</ix:nonNumeric></span> &#9746;,
Smaller reporting company <span id="xdx_900_edei--EntitySmallBusiness_c20230701__20231231_zVzecRUiZQJ9"><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness" id="ixv-7506">&#9746;</ix:nonNumeric></span>  Emerging growth company <span id="xdx_902_edei--EntityEmergingGrowthCompany_c20230701__20231231_zYfShz0aeWce"><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="ixv-7507">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744;  No <span id="xdx_90A_edei--EntityShellCompany_dbF_c20230701__20231231_zGDA3N2tQvIk"><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="ixv-7508">&#9746;</ix:nonNumeric></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Securities registered pursuant to Section
12(b) of the Act:&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; width: 30%; padding-left: 5.4pt; text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Title of each class</span></td>
    <td style="width: 7%; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 28%; padding-left: 5.4pt; text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Trading symbol</span></td>
    <td style="width: 7%; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 28%; padding-left: 5.4pt; text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Name of each exchange on which registered</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 5.4pt; text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_edei--Security12bTitle_c20230701__20231231_zieyU65MIedj"><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" name="dei:Security12bTitle" id="ixv-7509">Common Stock, $.0001 par value</ix:nonNumeric></span></span></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="padding-left: 5.4pt; text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_edei--TradingSymbol_c20230701__20231231_zRunzI52FHb1"><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" name="dei:TradingSymbol" id="ixv-7510">FONR</ix:nonNumeric></span></span></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="padding-left: 5.4pt; text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_edei--SecurityExchangeName_c20230701__20231231_zRZd3kQ9QdE5"><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-7511">NASDAQ</ix:nonNumeric></span> Capital Market</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate the number of shares outstanding
of each of the issuer&#8217;s classes of common stock, as of the close of the latest practicable date.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Class</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Outstanding at February 9, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Common Stock, par value $.0001</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 28%; text-align: right"><span id="xdx_907_edei--EntityCommonStockSharesOutstanding_iI_c20240209__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhrhvRIh28Z7" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-02-09_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7512">6,328,294</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Class B Common Stock, par value $.0001</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_edei--EntityCommonStockSharesOutstanding_iI_c20240209__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z3mGXXbMqfKi" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-02-09_us-gaap_CommonClassBMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7513">146</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Class C Common Stock, par value $.0001</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_edei--EntityCommonStockSharesOutstanding_iI_c20240209__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zGdvVOWNFQq5" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-02-09_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7514">382,513</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Class A Preferred Stock, par value $.0001</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_edei--EntityCommonStockSharesOutstanding_iI_c20240209__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zolUnt0xb0M2" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-02-09_custom_ClassAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7515">313,438</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">INDEX</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 87%; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">PART I - FINANCIAL INFORMATION</span></td>
    <td style="width: 6%; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 7%; text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">PAGE</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 40pt; text-indent: -9pt; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Item 1. Financial Statements </span></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 45.05pt; text-indent: -9pt; line-height: 115%"><a href="#a_001"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Condensed Consolidated Balance Sheets - December 31, 2023 (Unaudited) and June 30, 2023</span> </span></a></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">3</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 45.05pt; text-indent: -9pt; line-height: 115%"><a href="#a_002"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Condensed Consolidated Statements of Income for the Three Months Ended December 31, 2023 and December 31, 2022 (Unaudited)</span> </span></a></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">6</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 45.05pt; text-indent: -9pt; line-height: 115%"><a href="#a_003"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Condensed Consolidated Statements of Income for the Six Months Ended December 31, 2023 and December 31, 2022 (Unaudited)</span> </span></a></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">7</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 45.05pt; text-indent: -9pt; line-height: 115%"><a href="#a_004"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Condensed Consolidated Statements of Changes in Equity for the Three Months Ended December 31, 2023 and December 31, 2022 (Unaudited)</span> </span></a></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">8</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 45.05pt; text-indent: -9pt; line-height: 115%"><a href="#a_005"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Condensed Consolidated Statements of Changes in Equity for the Six Months Ended December 31, 2023 and December 31, 2022 (Unaudited)</span> </span></a></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">9</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 45.05pt; text-indent: -9pt; line-height: 115%"><a href="#a_006"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Condensed Consolidated Statements of Cash Flows for the Six Months Ended December 31, 2023 and December 31, 2022 (Unaudited)</span> </span></a></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">10</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 45.05pt; text-indent: -9pt; line-height: 115%"><a href="#a_007"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Notes to Condensed Consolidated Financial Statements (Unaudited)</span> </span></a></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">11</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 40pt; text-indent: -9pt; line-height: 115%"><a href="#a_008"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span> </span></a></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">24</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 40pt; text-indent: -9pt; line-height: 115%"><a href="#a_009"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></span></a></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">30</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 40pt; text-indent: -9pt; line-height: 115%"><a href="#a_010"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Item 4. Controls and Procedures</span></span></a></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">30</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; text-indent: -4.45pt; line-height: 115%"><a href="#a_011"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">PART II - OTHER INFORMATION</span> </span></a></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">31</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 40pt; text-indent: -9pt; line-height: 115%"><a href="#a_019"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Item 1. Legal Proceedings</span> </span></a></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">31</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 40pt; text-indent: -9pt; line-height: 115%"><a href="#a_012"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Item 1A. Risk Factors</span> </span></a></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">31</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 40pt; text-indent: -9pt; line-height: 115%"><a href="#a_013"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span> </span></a></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">33</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 40pt; text-indent: -9pt; line-height: 115%"><a href="#a_014"><span style="font: 10pt Times New Roman, Times, Serif">I<span style="text-decoration: underline">tem 3. Defaults Upon Senior Securities</span> </span></a></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">33</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 40pt; text-indent: -9pt; line-height: 115%"><a href="#a_015"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Item 4. Mine Safety Disclosures</span> </span></a></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">33</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 40pt; text-indent: -9pt; line-height: 115%"><a href="#a_016"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Item 5. Other Information</span> </span></a></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">33</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 40pt; text-indent: -9pt; line-height: 115%"><a href="#a_017"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Item 6. Exhibits</span> </span></a></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">33</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 40pt; text-indent: -9pt; line-height: 115%"><a href="#a_018"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Signatures</span></span></a></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">34</span></td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="a_001"></span>CONDENSED CONSOLIDATED BALANCE SHEETS</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Amounts and shares in thousands, except
per share amounts)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(UNAUDITED)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">ASSETS</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_111_pn3n3_zb9f2Zp6kjK6" summary="xdx: Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20231231_zSGNL69SGSge" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20230630_zt5X1iq6lxO5" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">December 31, <br/> 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">June 30, <br/> 2023 *</td></tr>
<tr id="xdx_40A_eus-gaap--AssetsCurrentAbstract_iB_zhSyiTIiILKc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_i01I_maCz43g_zTf0QJZMvuIi" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; width: 56%; text-align: left">&#160;Cash and cash equivalents</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7516">53,225</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7517">51,280</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--ShortTermInvestments_i01I_maCz43g_zPZSFYmPOB5k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt">&#160;Short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7518">33</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7519">33</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--AccountsReceivableServiceAndRepairFees_i01I_maCz43g_zqmKYlR8ErF" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Accounts receivable &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:AccountsReceivableServiceAndRepairFees" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7520">3,881</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:AccountsReceivableServiceAndRepairFees" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7521">3,861</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--AccountReceivableRelatedParties_i01I_maCz43g_zsQ0MOfEmGb4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Accounts receivable - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:AccountReceivableRelatedParties" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7522">60</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0064">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--MedicalReceivable_i01I_maCz43g_zYczk17juPU7" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Medical receivable &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:MedicalReceivable" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7523">22,548</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:MedicalReceivable" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7524">21,259</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_ecustom--ManagementAndOtherFees_i01I_maCz43g_zsxPxrWl91O3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Management and other fees receivable &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:ManagementAndOtherFees" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7525">39,352</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:ManagementAndOtherFees" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7526">35,888</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_i01I_maCz43g_z9QGYV3lkiG" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Management and other fees receivable &#8211; related medical practices &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7527">9,267</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7528">9,162</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--InventoryFinishedGoodsAndWorkInProcess_i01I_maCz43g_z7D8jOqPzIEb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt">&#160;Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsAndWorkInProcess" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7529">2,835</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsAndWorkInProcess" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7530">2,570</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01I_maCz43g_zjfe8CNHw4C7" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7531">1,341</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7532">1,608</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--AssetsCurrent_i01TI_mtCz43g_maCzssa_zs926PSyMZP" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Total Current Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7533">132,542</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7534">125,661</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_ecustom--AccountsReceivableNetLongTerm_i01I_maCzssa_zXfbKNjTBLn1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Accounts receivable &#8211; long term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:AccountsReceivableNetLongTerm" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7535">376</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:AccountsReceivableNetLongTerm" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7536">710</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--NoteReceivableRelatedParty_i01I_maCzssa_zS4DmM5RCK6h" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Note receivable &#8211; related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:NoteReceivableRelatedParty" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7537">577</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0088">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--DeferredTaxAssetsDeferredIncome_i01I_maCzssa_z4eI7B7MHTJd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Deferred income tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7538">7,758</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7539">10,042</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzssa_zoiycNoaSJ9i" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Property and equipment &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7540">20,109</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7541">22,146</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maCzssa_zeTaAlShjDWl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Right-of-use Asset &#8211; operating lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7542">32,234</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7543">33,069</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--FinanceLeaseRightOfUseAsset_i01I_maCzssa_zJatsCiFLSA3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Right-of-use Asset &#8211; financing lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7544">630</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7545">729</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--Goodwill_i01I_maCzssa_zTlOb7xVN1f1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt">&#160;Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7546">4,269</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7547">4,269</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i01I_maCzssa_zy55sqSZU4Ed" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Other intangible assets &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7548">3,266</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7549">3,432</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--OtherAssets_i01I_maCzssa_zrSYdAgglqB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Other assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7550">501</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7551">524</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--Assets_i01TI_mtCzssa_zZIaGFbGaQyd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Total Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7552">202,262</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7553">200,582</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">*Condensed from audited financial statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">See accompanying notes to condensed consolidated financial
statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">CONDENSED CONSOLIDATED BALANCE SHEETS</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Amounts and shares in thousands, except
per share amounts)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(UNAUDITED)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">December 31, <br/> 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">June 30, <br/> 2023 *</td></tr>
<tr id="xdx_404_eus-gaap--LiabilitiesCurrentAbstract_iB_zqqqSAC19pnb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--LongTermDebtCurrent_i01I_maCzQd7_zESHUxTqeXU" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; width: 56%; text-align: left">Current portion of long-term debt</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7554">45</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7555">44</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--AccountsPayableCurrent_i01I_maCzQd7_zoYTv8EbTWac" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7556">1,335</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7557">1,579</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--OtherLiabilitiesCurrent_i01I_maCzQd7_zkLUHSWZ3eca" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7558">3,460</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7559">5,444</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DeferredRevenueCurrent_i01I_maCzQd7_zYgz8xaeWR12" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Unearned revenue on service contracts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7560">3,804</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7561">3,832</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_ecustom--UnearnedRevenueOnServiceContractsRelatedParty_i01I_pn3n3_maCzQd7_z4Ti0W8T7m6j" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Unearned revenue on service contracts &#8211; related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:UnearnedRevenueOnServiceContractsRelatedParty" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7562">55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0130">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_maCzQd7_zgHFx7MTbQf8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Operating lease liability - current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7563">4,658</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7564">3,905</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityCurrent_i01I_maCzQd7_zz5OYOA5Ngmc" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Financing lease liability - current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7565">222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7566">218</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_ecustom--CustomerDeposits_i01I_maCzQd7_zjZvhEBrNhjj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Customer deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CustomerDeposits" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7567">600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CustomerDeposits" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7568">602</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--LiabilitiesCurrent_i01TI_mtCzQd7_maCze3h_zLDFjgidpWyg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Current Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7569">14,179</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7570">15,624</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--LiabilitiesNoncurrentAbstract_iB_zqGO6vFlVQL7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Long-Term Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--DeferredRevenueNoncurrent_i01I_maCzMnf_zgK6Ba7uVAzc" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Unearned revenue on service contracts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7571">376</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7572">760</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent_i01I_maCzMnf_zCOeHbPppN02" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Deferred income tax liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7573">395</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7574">395</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_ecustom--AccountsPayableRelatedPartyNoncurrent_i01I_maCzMnf_zjnao5nhjrl9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Due to related medical practices</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:AccountsPayableRelatedPartyNoncurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7575">93</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:AccountsPayableRelatedPartyNoncurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7576">93</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_pn3n3_maCzMnf_zAKcBM7wTS0j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Operating lease liability &#8211; net of current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7577">30,299</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7578">32,105</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityNoncurrent_i01I_pn3n3_maCzMnf_ztLqzdq40oOb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Financing lease liability &#8211; net of current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7579">508</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7580">620</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--LongTermDebtNoncurrent_i01I_maCzMnf_zrYx0jZ4d1H7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Long-term debt, less current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7581">92</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7582">115</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--OtherLiabilities_i01I_maCzMnf_zwqBuei76tik" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Other liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7583">23</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7584">42</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--LiabilitiesNoncurrent_i01TI_mtCzMnf_maCze3h_z8qXmDlxTdY" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total Long-Term Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7585">31,786</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7586">34,130</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--Liabilities_i01TI_mtCze3h_maCzpSn_zL0Rte0dquk8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Total Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7587">45,965</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7588">49,754</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">*Condensed from audited financial statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">See accompanying notes to condensed consolidated financial
statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">CONDENSED CONSOLIDATED BALANCE SHEETS</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Amounts and shares in thousands, except
per share amounts)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(UNAUDITED)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY
(Continued)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: left">STOCKHOLDERS&#8217; EQUITY:</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">June 30, <br/> 2023*</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Class A non-voting preferred stock $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20231231__us-gaap--StatementClassOfStockAxis__custom--ClassANonVotingPreferredStockMember_ztuzSxRL1dS3" title="Preferred stock, par value"><span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20230630__us-gaap--StatementClassOfStockAxis__custom--ClassANonVotingPreferredStockMember_zCUyAh53olp5" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_custom_ClassANonVotingPreferredStockMember" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7589"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-06-30_custom_ClassANonVotingPreferredStockMember" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7590">.0001</ix:nonFraction></ix:nonFraction> </span></span>par value; <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pn3n3_c20231231__us-gaap--StatementClassOfStockAxis__custom--ClassANonVotingPreferredStockMember_ztxU2wS4nva9" title="Preferred stock, shares authorized"><span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pn3n3_c20230630__us-gaap--StatementClassOfStockAxis__custom--ClassANonVotingPreferredStockMember_z6sJDepxMksf" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_ClassANonVotingPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7591"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-06-30_custom_ClassANonVotingPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7592">453</ix:nonFraction></ix:nonFraction></span></span> shares authorized at December 31, 2023 and June 30, 2023, <span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_pn3n3_c20231231__us-gaap--StatementClassOfStockAxis__custom--ClassANonVotingPreferredStockMember_z9SjPob5hp2j" title="Preferred stock, shares issued"><span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_pn3n3_c20231231__us-gaap--StatementClassOfStockAxis__custom--ClassANonVotingPreferredStockMember_z82GjKMVcukh" title="Preferred stock, shares outstanding"><span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_pn3n3_c20230630__us-gaap--StatementClassOfStockAxis__custom--ClassANonVotingPreferredStockMember_zJskekx82h4l" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_pn3n3_c20230630__us-gaap--StatementClassOfStockAxis__custom--ClassANonVotingPreferredStockMember_z1XWilGjI088" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_custom_ClassANonVotingPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7593"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_ClassANonVotingPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7594"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-06-30_custom_ClassANonVotingPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7595"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-06-30_custom_ClassANonVotingPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7596">313</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued and outstanding at December 31, 2023 and June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--PreferredStockValue_iI_pn3n3_maSEzHmb_c20231231__us-gaap--StatementClassOfStockAxis__custom--ClassANonVotingPreferredStockMember_zn6ur2NxA7W2" title="Preferred stock value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0190">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--PreferredStockValue_iI_pn3n3_maSEzHmb_c20230630__us-gaap--StatementClassOfStockAxis__custom--ClassANonVotingPreferredStockMember_zwl7VhS0hRN" title="Preferred stock value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0192">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Preferred stock $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zdW7QVBWcAP9" title="Preferred stock, par value"><span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zcLRGEWwEVrh" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7597"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7598">.001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_pn3n3_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zVRU86B5mbK2" title="Preferred stock, shares authorized"><span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pn3n3_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_z39p5B2rdGX7" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7599"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7600">567</ix:nonFraction></ix:nonFraction></span></span> shares authorized at December 31, 2023 and June 30, 2023, issued and outstanding &#8211; <span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_pn3n3_dn_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zJLMhCo7aawf" title="Preferred stock, shares issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_pn3n3_dn_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zjDhSixFp0Wb" title="Preferred stock, shares outstanding"><span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_pn3n3_dn_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zTHyedTcB135" title="Preferred stock, shares issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pn3n3_dn_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zdTR57IbnWj9" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="Shares" id="ixv-7601"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="Shares" id="ixv-7602"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="Shares" id="ixv-7603"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="Shares" id="ixv-7604">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--PreferredStockValue_iI_pn3n3_maSEzHmb_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_z3BR2tVAlEW5" title="Preferred stock value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0210">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PreferredStockValue_iI_pn3n3_maSEzHmb_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_z6Aem6BNxfp9" title="Preferred stock value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0212">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Common Stock $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zjD7mDQypr86" title="Common stock, par value"><span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zEf8t5yHiscb" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7605"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7606">.0001</ix:nonFraction></ix:nonFraction> </span></span>par value; <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pn3n3_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zIDWFGZh09j4" title="Common stock, shares authorized"><span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pn3n3_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z916TqLU4eqj" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7607"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7608">8,500</ix:nonFraction></ix:nonFraction></span></span> shares authorized at December 31, 2023 and June 30, 2023, <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_pn3n3_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_ziUWg2Z2WhHj" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7609">6,332</ix:nonFraction></span> and <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_pn3n3_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zgQhDcTHphqi" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7610">6,462</ix:nonFraction></span> issued at December 31, 2023 and June 30, 2023, respectively <span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_pn3n3_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z0iYPSdcXAyd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7611">6,328</ix:nonFraction></span> and <span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_pn3n3_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zgR2wxFJoI4i" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7612">6,451</ix:nonFraction></span> outstanding at December 31, 2023 and June 30, 2023 respectively</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--CommonStockValue_iI_pn3n3_maSEzHmb_c20231231__us-gaap--StatementClassOfStockAxis__custom--CommonStocksMember_zWJIvDks0lXa" title="Common stock value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31_custom_CommonStocksMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7613">1</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--CommonStockValue_iI_pn3n3_maSEzHmb_c20230630__us-gaap--StatementClassOfStockAxis__custom--CommonStocksMember_z2GSSsp5y7Vh" title="Common stock value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-06-30_custom_CommonStocksMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7614">1</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Class B Common Stock (10 votes per share) $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zUDudFEeh8P" title="Common stock, par value"><span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z9qEi5gW7Hwe" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7615"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-06-30_us-gaap_CommonClassBMember" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7616">.0001</ix:nonFraction></ix:nonFraction> </span></span>par value; <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pn3n3_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zAN81tDAzzb1" title="Common stock, shares authorized"><span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pn3n3_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zIlOBqdIIOOd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7617"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-06-30_us-gaap_CommonClassBMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7618">227</ix:nonFraction></ix:nonFraction></span></span> shares authorized at December 31, 2023 and June 30, 2023; .<span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zV3HFWCvYCq6" title="Common stock, shares issued"><span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zDVvvb1L2IT5" title="Common stock, shares outstanding"><span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_pp0p0_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z2G6S0lH9byb" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_pp0p0_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zEh0xmarXbdl" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares" id="ixv-7619"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares" id="ixv-7620"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-06-30_us-gaap_CommonClassBMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares" id="ixv-7621"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonClassBMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares" id="ixv-7622">146</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued and outstanding at December 31, 2023 and June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--CommonStockValue_iI_pn3n3_maSEzHmb_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zi59R8I58lFe" title="Common stock value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0250">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--CommonStockValue_iI_pn3n3_maSEzHmb_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z6fD9NiaTkm1" title="Common stock value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0252">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;Class C Common Stock (25 votes per share) $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zfgJRiGSBLoj" title="Common stock, par value"><span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zFUrFxUhEYqd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_us-gaap_CommonClassCMember" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7623"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-06-30_us-gaap_CommonClassCMember" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7624">.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pn3n3_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zQgztcKn4kVf" title="Common stock, shares authorized"><span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pn3n3_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zAwlk3HK2oph" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7625"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-06-30_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7626">567</ix:nonFraction></ix:nonFraction></span></span> shares authorized at December 31, 2023 and June 30, 2023, <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_pn3n3_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zsI8zTMDgdEe" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pn3n3_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zRQfVcEsMzp7" title="Common stock, shares outstanding"><span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_pn3n3_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zAExOmnPLdgc" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_pn3n3_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zOWBiIuAzZEb" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7627"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7628"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-06-30_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7629"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7630">383</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued and outstanding at December 31, 2023 and June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--CommonStockValue_iI_pn3n3_maSEzHmb_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zurBFTd3MxK4" title="Common stock value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0270">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--CommonStockValue_iI_pn3n3_maSEzHmb_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zoSL72qmYNxd" title="Common stock value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0272">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--AdditionalPaidInCapital_iI_maSEzHmb_zLd3iSPtedl7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;Paid-in capital in excess of par value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7631">180,607</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7632">182,613</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_maSEzHmb_zAtR4nUZSa15" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7633">16,326</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7634">24,191</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_407_eus-gaap--TreasuryStockValue_iNI_pn3n3_di_msSEzHmb_zBKex471q0rb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Treasury stock, at cost - <span id="xdx_901_eus-gaap--TreasuryStockCommonShares_iI_pn3n3_c20231231_zfptEpfMMMsi" title="Treasury stock, shares"><ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7635">4</ix:nonFraction></span> shares of common stock at December 31, 2023 and <span id="xdx_90D_eus-gaap--TreasuryStockCommonShares_iI_pn3n3_c20230630_z8FfhJp8a46e" title="Treasury stock, shares"><ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7636">11</ix:nonFraction></span> shares of common stock at June 30, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7637">395</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7638">516</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_405_eus-gaap--StockholdersEquity_iTI_pn3n3_mtSEzHmb_maCz7un_zmFWTTmbE214" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;Total Fonar Corporation&#8217;s Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7639">163,887</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7640">157,907</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--MinorityInterest_iI_pn3n3_maCz7un_zeoTRNB39GD8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;Non controlling interests</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7641">7,590</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7642">7,079</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iTI_mtCz7un_maCzpSn_zbY0wPLvKHq5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7643">156,297</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7644">150,828</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCzpSn_zsMkDDkhS8Ld" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Total Liabilities and Stockholders&#8217; Equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7645">202,262</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7646">200,582</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">*Condensed from audited financial statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">See accompanying notes to condensed consolidated financial
statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="a_002"></span>CONDENSED CONSOLIDATED STATEMENTS OF
INCOME</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Amounts and shares in thousands, except
per share amounts)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(UNAUDITED)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_113_pn3n3_z4WDfWqkMPM8" summary="xdx: Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20231001__20231231_z4woH0k0RHR5" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20221001__20221231_zZLwBUT2U7kh" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center">FOR THE THREE MONTHS ENDED DECEMBER 31,</td></tr>
<tr id="xdx_400_eus-gaap--RevenuesAbstract_iB_zMpT7pxXQil6" style="vertical-align: bottom">
    <td style="text-align: left">REVENUES</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td></tr>
<tr id="xdx_400_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscounts_i01_pn3n3_maRzL5a_zI8Gcmsjotta" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; width: 56%; text-align: left">Patient fee revenue &#8211; net of contractual allowances and discounts</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscounts" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7647">8,221</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscounts" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7648">7,129</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_400_ecustom--ProductSalesNet_i01_pn3n3_maRzL5a_z1YLKDMFXnR4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Product sales &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:ProductSalesNet" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7649">55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:ProductSalesNet" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7650">170</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_ecustom--ServiceAndRepairFeesNet_i01_pn3n3_maRzL5a_zYFAasJVQfU5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Service and repair fees &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:ServiceAndRepairFeesNet" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7651">1,778</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:ServiceAndRepairFeesNet" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7652">1,838</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--ServiceAndRepairFeesRelatedPartiesNet_i01_pn3n3_maRzL5a_zS5CzcJfCE18" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Service and repair fees - related parties &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:ServiceAndRepairFeesRelatedPartiesNet" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7653">28</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:ServiceAndRepairFeesRelatedPartiesNet" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7654">28</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--ManagementAndOtherFeesNet_i01_pn3n3_maRzL5a_zhPf83Q6wHEd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Management and other fees &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:ManagementAndOtherFeesNet" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7655">12,316</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:ManagementAndOtherFeesNet" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7656">12,092</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_ecustom--ManagementAndOtherFeesRelatedMedicalPracticesNet_i01_pn3n3_maRzL5a_zIqs1O6UHAl7" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Management and other fees - related medical practices &#8211; net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="FONR:ManagementAndOtherFeesRelatedMedicalPracticesNet" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7657">2,988</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="FONR:ManagementAndOtherFeesRelatedMedicalPracticesNet" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7658">2,999</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--Revenues_iT_pn3n3_mtRzL5a_maCzIW6_z5S2C03yQhta" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Total Revenues &#8211; Net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7659">25,386</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7660">24,256</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--CostsAndExpensesAbstract_iB_zSz24texji9i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">COSTS AND EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--OtherCostOfOperatingRevenue_i01_maCzpZV_zK8d9KWjEme6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Costs related to patient fee revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherCostOfOperatingRevenue" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7661">4,602</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherCostOfOperatingRevenue" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7662">4,023</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--CostsRelatedToProductSales_i01_maCzpZV_zY30LzfUy47l" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Costs related to product sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CostsRelatedToProductSales" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7663">302</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CostsRelatedToProductSales" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7664">214</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--CostsRelatedToServiceAndRepairFees_i01_maCzpZV_zgXEZAuCpH3h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Costs related to service and repair fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CostsRelatedToServiceAndRepairFees" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7665">784</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CostsRelatedToServiceAndRepairFees" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7666">722</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--CostsRelatedToServiceAndRepairFeesRelatedParties_i01_maCzpZV_z1oU86WEdgP2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Costs related to service and repair fees - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CostsRelatedToServiceAndRepairFeesRelatedParties" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7667">12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CostsRelatedToServiceAndRepairFeesRelatedParties" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7668">11</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--CostsRelatedToManagementAndOtherFees_i01_maCzpZV_zEJoqXINDZc2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Costs related to management and other fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CostsRelatedToManagementAndOtherFees" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7669">7,208</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CostsRelatedToManagementAndOtherFees" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7670">6,622</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices_i01_pn3n3_maCzpZV_z8IKylX06wke" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Costs related to management and other fees &#8211; related medical practices</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7671">1,590</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7672">1,492</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzpZV_zO0mpw5USteg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7673">416</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7674">342</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_maCzpZV_zU1H6Xh1XYae" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Selling, general and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7675">5,587</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7676">6,598</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--CostsAndExpenses_i01T_mtCzpZV_msCzIW6_zQ5GkziStjmg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Total Costs and Expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7677">20,501</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7678">20,024</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet_iT_mtCzIW6_maCzJoC_zAoQ9PS8k1f3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Income From Operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7679">4,885</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7680">4,232</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--OtherNonoperatingIncomeExpense_maCzJoC_z0Bo5iHBmaW" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Other Expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7681">208</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_400_ecustom--OtherIncomeRelatedParty_pn3n3_maCzJoC_z93cDDl8G7ib" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Other Income &#8211; Related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:OtherIncomeRelatedParty" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7682">577</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0360">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--InterestExpense_iN_di_msCzJoC_zdR7E78wVJFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Interest Expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7683">10</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7684">12</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_407_eus-gaap--InvestmentIncomeNet_maCzJoC_zldWMXcivkS4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Investment Income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7685">534</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7686">263</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCzJoC_maCzkHi_z0uhhuV2xukd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Income Before Provision for Income Taxes and Non controlling Interests</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7687">5,986</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7688">4,275</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msCzkHi_zWsDzUJIzY0i" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Provision for Income Taxes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7689">1,366</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7690">1,463</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40E_eus-gaap--ProfitLoss_iT_mtCzkHi_maNILznER_zx2Vrl4WnCv1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Net Income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7691">4,620</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7692">2,812</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_di_msNILznER_z1BJ6I5lzvze" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Net Income &#8211; Non controlling Interests</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7693">861</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7694">580</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_401_eus-gaap--NetIncomeLoss_iT_mtNILznER_zmEtzmkR6RSg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Net Income &#8211; Attributable to FONAR</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7695">3,759</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7696">2,232</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Net Income Available to Common Stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--NetIncomeLoss_c20231001__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonStockholdersMember_z2ZA4FRKkNsj"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012023-12-31_custom_CommonStockholdersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7697">3,525</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--NetIncomeLoss_c20221001__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonStockholdersMember_zr8Bkfh4TzV3"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012022-12-31_custom_CommonStockholdersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7698">2,097</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Net Income Available to Class A Non-Voting Preferred Stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--NetIncomeLoss_c20231001__20231231__us-gaap--StatementClassOfStockAxis__custom--ClassANonVotingPreferredStockholdersMember_zk3EqUioW9U4"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012023-12-31_custom_ClassANonVotingPreferredStockholdersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7699">175</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--NetIncomeLoss_c20221001__20221231__us-gaap--StatementClassOfStockAxis__custom--ClassANonVotingPreferredStockholdersMember_z2zXC8qLqEP7"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012022-12-31_custom_ClassANonVotingPreferredStockholdersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7700">101</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Net Income Available to Class C Common Stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--NetIncomeLoss_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zQAo1fYRZ2W6"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7701">59</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--NetIncomeLoss_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zNvMQmchkwLd"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012022-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7702">34</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Basic Net Income Per Common Share Available to Common Stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_pip0_c20231001__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonStockholdersMember_zdOZmKvWqgWk" title="Basic Net Income Per Common Share Available to Common Stockholders"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-10-012023-12-31_custom_CommonStockholdersMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7703">0.55</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_pip0_c20221001__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonStockholdersMember_z3OHHMWUnFsd" title="Basic Net Income Per Common Share Available to Common Stockholders"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-10-012022-12-31_custom_CommonStockholdersMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7704">0.32</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Diluted Net Income Per Common Share Available to Common Stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pip0_c20231001__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonStockholdersMember_zGg2BgqjmFs5" title="Diluted Net Income Per Common Share Available to Common Stockholders"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-10-012023-12-31_custom_CommonStockholdersMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7705">0.54</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pip0_c20221001__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonStockholdersMember_zimWTg8nupri" title="Diluted Net Income Per Common Share Available to Common Stockholders"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-10-012022-12-31_custom_CommonStockholdersMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7706">0.32</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Basic and Diluted Income Per Share &#8211; Class C Common</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_pip0_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zVkNmj9zBwkb" title="Basic Net Income Per Common Share Available to Common Stockholders"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_pip0_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zJWrcoLRhpp" title="Diluted Net Income Per Common Share Available to Common Stockholders"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-10-012023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7707"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-10-012023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7708">0.16</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_pip0_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zw8oenvBZhag" title="Basic Net Income Per Common Share Available to Common Stockholders"><span id="xdx_900_eus-gaap--EarningsPerShareDiluted_pip0_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zmJMaqOMlkkk" title="Diluted Net Income Per Common Share Available to Common Stockholders"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-10-012022-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7709"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-10-012022-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7710">0.09</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Weighted Average Basic Shares Outstanding &#8211; Common Stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonStockholdersMember_zSkt0t3RYnH4"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-10-012023-12-31_custom_CommonStockholdersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7711">6,437</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonStockholdersMember_zymitoas12b7"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-10-012022-12-31_custom_CommonStockholdersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7712">6,527</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Weighted Average Diluted Shares Outstanding - Common Stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonStockholdersMember_zGvQtIdD3t23" title="Weighted Average Diluted Shares Outstanding - Common Stockholders"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-10-012023-12-31_custom_CommonStockholdersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7713">6,565</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonStockholdersMember_zmdSrJq9G4N4" title="Weighted Average Diluted Shares Outstanding - Common Stockholders"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-10-012022-12-31_custom_CommonStockholdersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7714">6,655</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Weighted Average Basic and Diluted Shares Outstanding &#8211; Class C Common</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zknQTmk5VP79" title="Weighted Average Basic Shares Outstanding"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zouMNfiKqHf1" title="Weighted Average Diluted Shares Outstanding - Common Stockholders"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-10-012023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7715"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-10-012023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7716">383</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_ziIEyBJR1lq3" title="Weighted Average Basic Shares Outstanding"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zfbnwMPC9q8" title="Weighted Average Diluted Shares Outstanding - Common Stockholders"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-10-012022-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7717"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-10-012022-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7718">383</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>




<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to condensed consolidated
financial statements.&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="a_003"></span>CONDENSED CONSOLIDATED STATEMENTS OF
INCOME</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Amounts and shares in thousands, except
per share amounts)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(UNAUDITED)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20230701__20231231_z6N3IF3P6OOb" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20220701__20221231_zTlmrtNKzua4" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center">FOR THE SIX MONTHS ENDED DECEMBER 31,</td></tr>
<tr id="xdx_404_eus-gaap--RevenuesAbstract_iB_zB5vJtkSqbbh" style="vertical-align: bottom">
    <td style="text-align: left">REVENUES</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td></tr>
<tr id="xdx_400_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscounts_i01_pn3n3_maRzL5a_zGVX8LjFWBPi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; width: 56%; text-align: left">Patient fee revenue &#8211; net of contractual allowances and discounts</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscounts" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7719">16,896</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscounts" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7720">13,205</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_400_ecustom--ProductSalesNet_i01_pn3n3_maRzL5a_zwMzosJdHagl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Product sales &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:ProductSalesNet" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7721">219</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:ProductSalesNet" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7722">200</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_ecustom--ServiceAndRepairFeesNet_i01_pn3n3_maRzL5a_zPKRiogJDzyj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Service and repair fees &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:ServiceAndRepairFeesNet" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7723">3,643</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:ServiceAndRepairFeesNet" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7724">3,658</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--ServiceAndRepairFeesRelatedPartiesNet_i01_pn3n3_maRzL5a_zTzXLll313a8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Service and repair fees - related parties &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:ServiceAndRepairFeesRelatedPartiesNet" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7725">55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:ServiceAndRepairFeesRelatedPartiesNet" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7726">55</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--ManagementAndOtherFeesNet_i01_pn3n3_maRzL5a_ze148mvwqwv1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Management and other fees &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:ManagementAndOtherFeesNet" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7727">24,436</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:ManagementAndOtherFeesNet" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7728">24,342</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_ecustom--ManagementAndOtherFeesRelatedMedicalPracticesNet_i01_pn3n3_maRzL5a_zh1x1ADiQCe" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Management and other fees - related medical practices &#8211; net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="FONR:ManagementAndOtherFeesRelatedMedicalPracticesNet" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7729">5,975</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="FONR:ManagementAndOtherFeesRelatedMedicalPracticesNet" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7730">5,987</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--Revenues_iT_pn3n3_mtRzL5a_mtCzZQz_z6HiUvGwNIAb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Total Revenues &#8211; Net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7731">51,224</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7732">47,447</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--CostsAndExpensesAbstract_iB_zYTacOcsqF3i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">COSTS AND EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--OtherCostOfOperatingRevenue_i01_maCzEbF_zbITUsjYybtb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Costs related to patient fee revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherCostOfOperatingRevenue" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7733">9,029</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherCostOfOperatingRevenue" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7734">7,822</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--CostsRelatedToProductSales_i01_maCzEbF_znFIWxpGIO2e" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Costs related to product sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CostsRelatedToProductSales" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7735">405</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CostsRelatedToProductSales" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7736">383</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--CostsRelatedToServiceAndRepairFees_i01_maCzEbF_z8PIO5EZqi22" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Costs related to service and repair fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CostsRelatedToServiceAndRepairFees" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7737">1,633</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CostsRelatedToServiceAndRepairFees" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7738">1,440</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--CostsRelatedToServiceAndRepairFeesRelatedParties_i01_maCzEbF_zyhzXgsb5Kv9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Costs related to service and repair fees - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CostsRelatedToServiceAndRepairFeesRelatedParties" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7739">25</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CostsRelatedToServiceAndRepairFeesRelatedParties" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7740">22</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--CostsRelatedToManagementAndOtherFees_i01_maCzEbF_zqi7tkAjUWp8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Costs related to management and other fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CostsRelatedToManagementAndOtherFees" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7741">14,231</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CostsRelatedToManagementAndOtherFees" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7742">13,124</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices_i01_pn3n3_maCzEbF_zb49PjSgEsw1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Costs related to management and other fees &#8211; related medical practices</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7743">3,109</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7744">2,890</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzEbF_zie8RKLKjn81" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7745">883</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7746">691</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_maCzEbF_zTkgralZ9mjc" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Selling, general and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7747">10,453</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7748">12,932</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--CostsAndExpenses_i01T_mtCzEbF_msCzZQz_zz437a83RBSg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Total Costs and Expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7749">39,768</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7750">39,304</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet_iT_mtCzZQz_maCzqEl_zTzPPDEsWU64" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Income From Operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7751">11,456</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7752">8,143</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--OtherNonoperatingIncomeExpense_maCzqEl_zWgfOgIBmdSd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Other Income (Expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7753">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7754">197</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_ecustom--OtherIncomeRelatedParty_pn3n3_maCzqEl_zfCeP95aw9si" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Other Income &#8211; Related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:OtherIncomeRelatedParty" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7755">577</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0480">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--InterestExpense_iN_di_msCzqEl_zWl4UmnJSn9i" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Interest Expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7756">58</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7757">27</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_403_eus-gaap--InvestmentIncomeNet_maCzqEl_zkm11j1z8rXg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Investment Income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7758">1,040</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7759">414</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCzqEl_maCzcWv_zPT7nDC06py2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Income Before Provision for Income Taxes and Non controlling Interests</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7760">13,016</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7761">8,333</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msCzcWv_zFyAj3IzI6Sa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Provision for Income Taxes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7762">3,036</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7763">2,871</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40B_eus-gaap--ProfitLoss_iT_mtCzcWv_maNILznER_znUJdUdi6Kpb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Net Income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7764">9,980</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7765">5,462</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_di_msNILznER_zPYsHBqZUfta" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Net Income &#8211; Non controlling Interests</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7766">2,115</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7767">1,183</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--NetIncomeLoss_iT_mtNILznER_zYN61MGR07l9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Net Income &#8211; Attributable to FONAR</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7768">7,865</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7769">4,279</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Net Income Available to Common Stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--NetIncomeLoss_c20230701__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonStockholdersMember_ziLTM5ZHheM3"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-12-31_custom_CommonStockholdersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7770">7,375</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--NetIncomeLoss_c20220701__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonStockholdersMember_zcdlDdoTis8g"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-12-31_custom_CommonStockholdersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7771">4,020</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Net Income Available to Class A Non-Voting Preferred Stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--NetIncomeLoss_c20230701__20231231__us-gaap--StatementClassOfStockAxis__custom--ClassANonVotingPreferredStockholdersMember_zl49rF4rkBm6"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-12-31_custom_ClassANonVotingPreferredStockholdersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7772">365</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--NetIncomeLoss_c20220701__20221231__us-gaap--StatementClassOfStockAxis__custom--ClassANonVotingPreferredStockholdersMember_zRB4NKgLVJn1"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-12-31_custom_ClassANonVotingPreferredStockholdersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7773">193</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Net Income Available to Class C Common Stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--NetIncomeLoss_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zdeDx40E4UPc"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7774">125</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--NetIncomeLoss_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zgdRxbWXUbQ"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7775">66</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Basic Net Income Per Common Share Available to Common Stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pip0_c20230701__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonStockholdersMember_z66uB8C80ita" title="Basic Net Income Per Common Share Available to Common Stockholders"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-07-012023-12-31_custom_CommonStockholdersMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7776">1.14</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_pip0_c20220701__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonStockholdersMember_zzDSJxFzs154" title="Basic Net Income Per Common Share Available to Common Stockholders"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-07-012022-12-31_custom_CommonStockholdersMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7777">0.62</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Diluted Net Income Per Common Share Available to Common Stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_pip0_c20230701__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonStockholdersMember_ztgLWFkUSdxh" title="Diluted Net Income Per Common Share Available to Common Stockholders"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-07-012023-12-31_custom_CommonStockholdersMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7778">1.12</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pip0_c20220701__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonStockholdersMember_zrDXtM61Ieof" title="Diluted Net Income Per Common Share Available to Common Stockholders"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-07-012022-12-31_custom_CommonStockholdersMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7779">0.60</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Basic and Diluted Income Per Share &#8211; Class C Common</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_pip0_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zDQUsqxmOb8j" title="Basic Net Income Per Common Share Available to Common Stockholders"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pip0_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zo6mqo9g6f6h" title="Diluted Net Income Per Common Share Available to Common Stockholders"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-07-012023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7780"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-07-012023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7781">0.33</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_pip0_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zaKe7xeMLjrd" title="Basic Net Income Per Common Share Available to Common Stockholders"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pip0_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zeEiLQ99o6Ih" title="Diluted Net Income Per Common Share Available to Common Stockholders"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-07-012022-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7782"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-07-012022-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-7783">0.17</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Weighted Average Basic Shares Outstanding &#8211; Common Stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonStockholdersMember_zFwpt3HXoNMi"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-07-012023-12-31_custom_CommonStockholdersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7784">6,448</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonStockholdersMember_z1Hp7yo0tn41"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-07-012022-12-31_custom_CommonStockholdersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7785">6,534</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Weighted Average Diluted Shares Outstanding - Common Stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonStockholdersMember_zjjEKRnx6mx8" title="Weighted Average Diluted Shares Outstanding - Common Stockholders"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-07-012023-12-31_custom_CommonStockholdersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7786">6,576</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonStockholdersMember_zwy5klGlvhq1" title="Weighted Average Diluted Shares Outstanding - Common Stockholders"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-07-012022-12-31_custom_CommonStockholdersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7787">6,662</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Weighted Average Basic and Diluted Shares Outstanding &#8211; Class C Common</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z200p2zcFzla" title="Weighted Average Basic Shares Outstanding"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zlEfvgiqFwkd" title="Weighted Average Diluted Shares Outstanding - Common Stockholders"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-07-012023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7788"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-07-012023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7789">383</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zo6BdhwtNF0j" title="Weighted Average Basic Shares Outstanding"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zKYbdnkdLdgb" title="Weighted Average Diluted Shares Outstanding - Common Stockholders"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-07-012022-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7790"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-07-012022-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7791">383</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;See accompanying
notes to condensed consolidated financial statements.&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt">&#160;</div>

<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt">&#160;</div>

<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">FONAR CORPORATION AND SUBSIDIARIES</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="a_004"></span>CONDENSED CONSOLIDATED STATEMENT OF
CHANGES IN EQUITY</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Amounts and shares in thousands, except per share amounts)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(UNAUDITED)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the Three Months Ending December 31, 2023</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_304_114_pn3n3_ztba1woMbe08" summary="xdx: Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zI1w043oGjVl" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zKgWNomGVLl" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_ztlLzwA84Rtk" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--TreasuryStockCommonMember_zvI8ybM8mu5k" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--NoncontrollingInterestMember_zreyoVqdzrB1" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" id="xdx_4BD_z6UkyCvmjNm2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Common Stock</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Common Stock (Shares)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Paid in <br/> capital in excess of par value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Accumulated Deficit</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Treasury Stock</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Treasury Stock (Shares)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Non Controlling Interests</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Total</td></tr>
  <tr id="xdx_432_c20231001__20231231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zUj5doUrAqa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-indent: -10pt; padding-left: 10pt">Balance &#150; September 30, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znEqwoJkJzz3" title="Beginning balance, value" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7792"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7793">1</ix:nonFraction></ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zd55GVIts9O7" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7794">6,450,882</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zBGtdu4Tcayc" title="Beginning balance, value" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7795"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7796">182,613</ix:nonFraction></ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zSrLueSJoCdb" title="Beginning balance, value" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7797"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7798">20,085</ix:nonFraction></ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_z8uLkn4fjrt8" title="Beginning balance, value" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-09-30_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7799"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-09-30_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7800">1,230</ix:nonFraction></ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zyjjdw3zaVT1" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7801">54,674</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--NoncontrollingInterestMember_zZ15NX1Dda0a" title="Beginning balance, value" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-09-30_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7802"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-09-30_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7803">7,226</ix:nonFraction></ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_pn3n3_c20231001__20231231_zEtsMu1cUBbj" title="Beginning balance, value" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7804"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7805">154,073</ix:nonFraction></ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_zBBQJRo4kv0l" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Net income</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0562">&#151;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0563">&#151;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012023-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7806">3,759</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0565">&#151;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0566">&#151;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7807">3,759</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockRepurchasedDuringPeriodValue_iN_di_zUgXpOUQK881" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Purchase of Treasury stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0569">&#151;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0570">&#151;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0571">&#151;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-10-012023-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7808">1,171</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_ecustom--PurchaseOfTreasuryStockShares_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zMu7kZ1pbmA2" title="Purchase of Treasury stock, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="FONR:PurchaseOfTreasuryStockShares" contextRef="From2023-10-012023-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7809">72,297</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0573">&#151;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7810">1,171</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--CancellationOfShares_zgylTmjvnET3" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">Cancellation of shares</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0578">&#151;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_ecustom--CancellationOfSharesShares_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLW7foSFJ5Xl" title="Cancellation of shares, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="FONR:CancellationOfSharesShares" contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares" id="ixv-7811">122,588</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="FONR:CancellationOfShares" contextRef="From2023-10-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7812">2,006</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0580">&#151;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="FONR:CancellationOfShares" contextRef="From2023-10-012023-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7813">2,006</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--CancellationOfSharesShares_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_z1fMblSmaxO4" title="Cancellation of shares, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="FONR:CancellationOfSharesShares" contextRef="From2023-10-012023-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares" id="ixv-7814">122,588</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0582">&#151;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0583">&#151;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_iN_di_zqEIAUayDsxi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Distributions - Non controlling interests</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0589">&#151;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0590">&#151;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0591">&#151;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0592">&#151;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="From2023-10-012023-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7815">1,225</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7816">1,225</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_zdTTB45v4m8g" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Income - Non controlling interests</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0596">&#151;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0597">&#151;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0598">&#151;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0599">&#151;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2023-10-012023-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7817">861</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7818">861</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_436_c20231001__20231231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zO3AwcTeJju4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance &#150; December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwHFHcHkpCQf" title="Ending balance, value" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember-1258588312" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7819"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember-1258588312" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7820">1</ix:nonFraction></ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN6KCy71lexa" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember-1258588312" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7821">6,328,294</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zoecmXgI81Jg" title="Ending balance, value" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7822"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7823">180,607</ix:nonFraction></ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z2gMAXVb17L2" title="Ending balance, value" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7824"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7825">16,326</ix:nonFraction></ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zgFTWWOGzXRl" title="Ending balance, value" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7826"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7827">395</ix:nonFraction></ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_z7FQ283HMsth" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7828">4,383</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--NoncontrollingInterestMember_zLcH6GRB7zjb" title="Ending balance, value" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7829"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7830">7,590</ix:nonFraction></ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_pn3n3_c20231001__20231231_zhkub6b11XXc" title="Ending balance, value" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7831"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7832">156,297</ix:nonFraction></ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the Three Months Ending December 31, 2022</span></td></tr>
  </table>
<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Common Stock (Shares)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Paid in capital in excess of par value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Accumulated Deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Treasury Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Treasury Stock (Shares)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Non Controlling Interests</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td></tr>
  <tr id="xdx_43F_c20221001__20221231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zd5Af96Mh1p5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 28%; text-indent: -10pt">Balance &#150; September 30, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWnZSzbVQEt" title="Beginning balance, value" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7833"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7834">1</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXLccaBq9VYc" title="Beginning balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7835">6,554,210</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zULVCtzoT3d" title="Beginning balance, value" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7836"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7837">184,531</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zcg6LB3QVit2" title="Beginning balance, value" style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7838"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7839">31,520</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zi2cSFJRZXOd" title="Beginning balance, value" style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-09-30_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7840"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-09-30_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7841">797</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zYpYZ3XETfHa" title="Beginning balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7842">20,445</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--NoncontrollingInterestMember_zIz2g7opZHS" title="Beginning balance, value" style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-09-30_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7843"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-09-30_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7844">5,085</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_pn3n3_c20221001__20221231_z9X89dKAjV3l" title="Beginning balance, value" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7845"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7846">147,130</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_zQm0shMFoGLe" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0649">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0650">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7847">2,232</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0652">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0653">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7848">2,232</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockRepurchasedDuringPeriodValue_iN_di_zpmPaiJIC41a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Purchase of Treasury stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0656">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0657">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0658">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-10-012022-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7849">356</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--PurchaseOfTreasuryStockShares_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zERxvou6Coj4" title="Purchase of Treasury stock, shares" style="text-align: right"><ix:nonFraction name="FONR:PurchaseOfTreasuryStockShares" contextRef="From2022-10-012022-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7850">20,819</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0660">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7851">356</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--CancellationOfShares_zifNV5UPiDq6" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Cancellation of shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0665">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--CancellationOfSharesShares_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zs0teeo6LTS3" title="Cancellation of shares, shares" style="text-align: right">(<ix:nonFraction name="FONR:CancellationOfSharesShares" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares" id="ixv-7852">16,062</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="FONR:CancellationOfShares" contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7853">401</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0667">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CancellationOfShares" contextRef="From2022-10-012022-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7854">402</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--CancellationOfSharesShares_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zpshhVs2Odg9" title="Cancellation of shares, shares" style="text-align: right">(<ix:nonFraction name="FONR:CancellationOfSharesShares" contextRef="From2022-10-012022-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares" id="ixv-7855">16,062</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0669">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CancellationOfShares" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7856">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_iN_di_zNmGb0FEoyt2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Distributions - Non controlling interests</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0676">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0677">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0678">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0679">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="From2022-10-012022-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7857">1,517</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7858">1,517</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_zFbl0zFp69Tf" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Income - Non controlling interests</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0683">&#151;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0684">&#151;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0685">&#151;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0686">&#151;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2022-10-012022-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7859">580</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7860">580</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_439_c20221001__20221231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_z9qnAHC6hIz8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Balance &#150; December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOZwJcQ5COOk" title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7861"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7862">1</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zspeJ5NBAwr3" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7863">6,538,148</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_z0tUVyppqF3f" title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7864"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7865">184,130</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zKUPIwxILM8g" title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7866"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7867">29,288</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zZ6LVCIGeYCf" title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7868"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7869">751</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zkIKtGas0HV1" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7870">25,202</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--NoncontrollingInterestMember_zuxVmKlIFNB9" title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7871"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7872">6,022</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_pn3n3_c20221001__20221231_zjeeGCCsogig" title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7873"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7874">148,070</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 12.2pt">See accompanying notes to condensed
consolidated financial statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="a_005"></span>CONDENSED CONSOLIDATED STATEMENT OF
CHANGES IN EQUITY</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Amounts and shares in thousands, except per share amounts)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(UNAUDITED)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the Six Months Ending December 31, 2023</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Common Stock (Shares)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Paid in capital in excess of par value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Accumulated Deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Treasury Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Treasury Stock (Shares)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Non Controlling Interests</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td></tr>
  <tr id="xdx_430_c20230701__20231231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_z3FA8hwvuHJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 28%; text-indent: -10pt">Balance - June 30, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXzjx1WRWdwa" title="Beginning balance, value" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember-1258588437" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7875"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember-1258588437" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7876">1</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zigf3TsFmbE6" title="Beginning balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember-1258588437" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7877">6,450,882</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zjbusbMOkPN7" title="Beginning balance, value" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7878"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7879">182,613</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zIbT8vme6iR" title="Beginning balance, value" style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7880"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7881">24,191</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$&#160;</td><td id="xdx_988_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zwYZMCSRiLpd" title="Beginning balance, value" style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-06-30_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7882"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-06-30_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7883">516</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zvKao91TiVql" title="Beginning balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7884">11,463</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$&#160;</td><td id="xdx_980_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--NoncontrollingInterestMember_zT4x4L9t862k" title="Beginning balance, value" style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-06-30_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7885"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-06-30_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7886">7,079</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_pn3n3_c20230701__20231231_zpGJ0XioU52j" title="Beginning balance, value" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7887"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7888">150,828</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_zD8axof1bZK6" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0736">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0737">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7889">7,865</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0739">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0740">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7890">7,865</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockRepurchasedDuringPeriodValue_iN_di_zpfSBPWlBbJ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Purchase of Treasury stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0743">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0744">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0745">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-07-012023-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7891">1,885</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--PurchaseOfTreasuryStockShares_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zIFsXUAECjbd" title="Purchase of Treasury stock, shares" style="text-align: right"><ix:nonFraction name="FONR:PurchaseOfTreasuryStockShares" contextRef="From2023-07-012023-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7892">115,508</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0747">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7893">1,885</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--CancellationOfShares_zdeq8S0HSCa" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Cancellation of shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0752">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--CancellationOfSharesShares_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyqOFDEvbL08" title="Cancellation of shares, shares" style="text-align: right">(<ix:nonFraction name="FONR:CancellationOfSharesShares" contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares" id="ixv-7894">122,588</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="FONR:CancellationOfShares" contextRef="From2023-07-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7895">2,006</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0754">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CancellationOfShares" contextRef="From2023-07-012023-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7896">2,006</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--CancellationOfSharesShares_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zzLsIEWGCCmb" title="Cancellation of shares, shares" style="text-align: right">(<ix:nonFraction name="FONR:CancellationOfSharesShares" contextRef="From2023-07-012023-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares" id="ixv-7897">122,588</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0756">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0757">&#151;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_iN_di_zOWiHxTX1eb8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Distributions - Non controlling interests</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0763">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0764">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0765">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0766">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="From2023-07-012023-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7898">2,626</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7899">2,626</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_zo0zaQQVQh9l" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Income - Non controlling interests</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0770">&#151;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0771">&#151;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0772">&#151;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0773">&#151;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2023-07-012023-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7900">2,115</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7901">2,115</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43E_c20230701__20231231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zNr51qc1s3W9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Balance - December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMkOKbGFbkji" title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember-1258588312" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7902"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember-1258588312" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7903">1</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zU6VijMrzDDi" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember-1258588312" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7904">6,328,294</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zhnESh3hx7ye" title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7905"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7906">180,607</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;$</td><td id="xdx_981_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zBuk7sBqsak1" title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7907"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7908">16,326</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;$</td><td id="xdx_983_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zzDzBJKdj043" title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7909"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7910">395</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zqYYbK1wcoFh" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7911">4,383</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;$</td><td id="xdx_98A_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--NoncontrollingInterestMember_zfALHqyGBBYc" title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7912"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7913">7,590</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_pn3n3_c20230701__20231231_zIZQBgxraakd" title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7914"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7915">156,297</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">For the Six Months Ending December 31,
2022</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Common Stock (Shares)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Paid in capital in excess of par value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Accumulated Deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Treasury Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Treasury Stock (Shares)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Non Controlling Interests</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td></tr>
  <tr id="xdx_432_c20220701__20221231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zGZls4qdyZt6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 28%; text-indent: -10pt">Balance - June 30, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsN8vIc2GYHc" title="Beginning balance, value" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7916"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7917">1</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpfHnQgaF4Qc" title="Beginning balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7918">6,554,210</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zjH0cge8KM79" title="Beginning balance, value" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7919"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7920">184,531</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_z0nD7jeEafTh" title="Beginning balance, value" style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7921"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7922">33,567</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zdfl1cGp9jpe" title="Beginning balance, value" style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-06-30_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7923"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-06-30_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7924">675</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_z7ub37soJ0Bc" title="Beginning balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7925">11,643</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--NoncontrollingInterestMember_znpEw0NstVKj" title="Beginning balance, value" style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-06-30_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7926"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-06-30_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7927">4,054</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_pn3n3_c20220701__20221231_zN19GaLQF0x9" title="Beginning balance, value" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7928"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7929">146,236</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_zLwt2LtizUG5" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0823">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0824">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7930">4,279</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0826">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0827">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7931">4,279</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockRepurchasedDuringPeriodValue_iN_di_zVzISdooSLyd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Purchase of Treasury stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0830">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0831">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0832">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-07-012022-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7932">478</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--PurchaseOfTreasuryStockShares_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_z78iebdQhPFf" title="Purchase of Treasury stock, shares" style="text-align: right"><ix:nonFraction name="FONR:PurchaseOfTreasuryStockShares" contextRef="From2022-07-012022-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7933">29,621</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0834">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7934">478</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--CancellationOfShares_zzCUE4uMS07h" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Cancellation of shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0839">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--CancellationOfSharesShares_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjsIcSQl5cAi" title="Cancellation of shares, shares" style="text-align: right">(<ix:nonFraction name="FONR:CancellationOfSharesShares" contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares" id="ixv-7935">16,062</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="FONR:CancellationOfShares" contextRef="From2022-07-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7936">401</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0841">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CancellationOfShares" contextRef="From2022-07-012022-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7937">402</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--CancellationOfSharesShares_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zgJqbvGKkqrb" title="Cancellation of shares, shares" style="text-align: right">(<ix:nonFraction name="FONR:CancellationOfSharesShares" contextRef="From2022-07-012022-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares" id="ixv-7938">16,062</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0843">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:CancellationOfShares" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7939">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_iN_di_z0fBcLDUySwb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Distributions - Non controlling interests</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0850">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0851">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0852">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0853">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="From2022-07-012022-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7940">3,151</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7941">3,151</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_zyYsJSKACHAb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Income - Non controlling interests</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">&#151;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0858">&#151;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0859">&#151;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0860">&#151;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2022-07-012022-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7942">1,183</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7943">1,183</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43D_c20220701__20221231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zvargASjtpXf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Balance - December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgBXoIoVoAi2" title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7944"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7945">1</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwRcCrrPD2Na" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7946">6,538,148</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zaWIjfs9pK97" title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7947"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7948">184,130</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--RetainedEarningsMember_zySezp68A2tj" title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7949"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7950">29,288</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zKNojSNcRCQl" title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7951"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7952">751</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_ztUdLfKvzSKb" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-7953">25,202</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--NoncontrollingInterestMember_zbkGsxXK4GG7" title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7954"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7955">6,022</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_pn3n3_c20220701__20221231_zEoYnPwy8Qp7" title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7956"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7957">148,070</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 10.45pt">See accompanying notes to condensed
consolidated financial statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="a_006"></span>CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Amounts and shares in thousands)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(UNAUDITED)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_306_112_pn3n3_zqZIvI8sZhNk" summary="xdx: Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 40pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20230701__20231231_zTE6QZF9hl7g" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20220701__20221231_zp6yKtnZGUJh" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center">FOR THE SIX MONTHS<br/>
ENDED DECEMBER 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td></tr>
<tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_ziB82tw9cLKg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash Flows from Operating Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--ProfitLoss_maCzBqy_z4k0uRwzoOI4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 40pt; width: 56%; text-align: left">&#160;Net income</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7958">9,980</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7959">5,462</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Adjustments to reconcile net income to net cash provided by operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OtherDepreciationAndAmortization_i01_maCzBqy_z2r1xxiKRWdj" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 30pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherDepreciationAndAmortization" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7960">2,415</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherDepreciationAndAmortization" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7961">2,218</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i01_pn3n3_maCzBqy_zHsqdoQB0Od9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 30pt; text-align: left">Amortization on right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7962">2,146</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7963">2,238</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--ProvisionForBadDebts_i01_pn3n3_maCzBqy_zokcsIPZhbN5" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 30pt; text-align: left">Provision for bad debts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:ProvisionForBadDebts" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7964">355</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:ProvisionForBadDebts" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7965">2,891</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01_pn3n3_maCzBqy_zIT3jNcQdVyl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 30pt; text-align: left">Deferred income tax &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7966">2,284</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7967">2,306</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_ecustom--GainOnSaleOfEquipmentRelatedParty_i01N_pn3n3_di_msCzBqy_z99mI3beMtWc" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 30pt; text-align: left">Gain on sale of equipment &#8211; related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="FONR:GainOnSaleOfEquipmentRelatedParty" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7968">577</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0909">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--IncreaseDecreaseInOperatingAssetsAbstract_iB_zLC0kjMElpoe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">(Increase) decrease in operating assets, net:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--IncreaseDecreaseInAccountsReceivable_i01N_di_msCzBqy_zxcF1Tqo7z51" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 30pt; text-align: left">Accounts, medical and management fee receivable(s)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7969">4,958</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7970">3,375</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40B_ecustom--IncreaseDecreaseInNotesReceivable_i01_maCzBqy_zRIGrKJZ1o5f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 30pt; text-align: left">Notes receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:IncreaseDecreaseInNotesReceivable" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7971">50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:IncreaseDecreaseInNotesReceivable" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7972">11</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--IncreaseDecreaseInInventories_i01N_di_msCzBqy_z9vF5AyOpNV" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 30pt">Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7973">265</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7974">274</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_409_eus-gaap--IncreaseDecreaseInPrepaidExpensesOther_i01N_di_msCzBqy_z4eyAHxCBF9d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 30pt; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7975">217</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7976">60</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--IncreaseDecreaseInOtherNoncurrentAssets_i01N_di_msCzBqy_zT6az6PacuMg" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 30pt; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7977">22</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0927">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--IncreaseDecreaseInOperatingLiabilitiesAbstract_iB_zyUPEav6UvTa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Increase (decrease) in operating liabilities, net:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccountsPayable_i01_maCzBqy_zAjkDwnOC6jf" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 30pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7978">244</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7979">685</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_407_eus-gaap--IncreaseDecreaseInOtherCurrentLiabilities_i01_maCzBqy_z4rDPMsdnMPa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 30pt; text-align: left">Other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7980">2,341</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7981">3,228</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40C_ecustom--IncreaseDecreaseInOperatingLeaseLiabilities_i01_maCzBqy_zUG9TfMZjDo8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 30pt; text-align: left">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="FONR:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7982">2,265</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="FONR:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7983">1,874</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_406_ecustom--IncreaseDecreaseInFinancingLiabilities_i01N_di_msCzBqy_zSuhHunHbAA" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 30pt; text-align: left">Financing lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="FONR:IncreaseDecreaseInFinancingLiabilities" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7984">108</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="FONR:IncreaseDecreaseInFinancingLiabilities" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7985">126</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_401_ecustom--IncreaseDecreaseInCustomerAdvance_i01_maCzBqy_zXd0gHlHRi5f" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 30pt; text-align: left">Customer deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="FONR:IncreaseDecreaseInCustomerAdvance" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7986">3</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:IncreaseDecreaseInCustomerAdvance" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7987">271</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i01_maCzBqy_zJM7LkyVM6Z4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 30pt; text-align: left">Other liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7988">19</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7989">33</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtCzBqy_maCzzLQ_zYLUSKvwV34f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash provided by operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7990">6,689</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7991">5,862</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Cash Flows from Investing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCzfjE_zdZWtpfH0wa8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 30pt; text-align: left">Purchases of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7992">192</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7993">1,362</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40E_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_msCzfjE_zkh3Byc4KjJj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 30pt">Cost of patents</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7994">20</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7995">74</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzfjE_maCzzLQ_zG73vFejflkk" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 30pt; text-align: left">Net cash used in investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7996">212</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-7997">1,436</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Cash Flows from Financing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--RepaymentsOfNotesPayable_i01N_di_msCzgfX_z3Bcz0XO254e" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 30pt; text-align: left">&#160;Repayment of borrowings and capital lease obligations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7998">21</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-7999">15</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40E_eus-gaap--PaymentsForRepurchaseOfConvertiblePreferredStock_i01N_di_msCzgfX_z0NOE0FRB8Wa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 30pt; text-align: left">&#160;Purchase of treasury stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8000">1,885</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8001">478</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--PaymentsOfDividendsMinorityInterest_i01N_pn3n3_di_msCzgfX_zDhNrs26ldB5" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 30pt; text-align: left">&#160;Distributions to non controlling interests</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfDividendsMinorityInterest" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8002">2,626</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfDividendsMinorityInterest" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8003">3,151</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzgfX_maCzzLQ_zH8bubcC6xsh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Net cash used in financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-8004">4,532</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-8005">3,644</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_405_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_i01T_pn3n3_mtCzzLQ_zgLaIUZKUg2l" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;Net Increase in Cash and Cash Equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8006">1,945</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8007">782</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_i01S_zCdUdOgW9h5k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Cash and Cash Equivalents - Beginning of Period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8008">51,280</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8009">48,723</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_i01E_zVL24K0uUnw8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Cash and Cash Equivalents - End of Period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8010">53,225</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8011">49,505</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">See accompanying notes to condensed consolidated financial
statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="a_007"></span>NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">DECEMBER 31, 2023 and 2022</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Amounts and shares in thousands, except
per share amounts)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(UNAUDITED)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="ixv-3464"><p id="xdx_804_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zD7NJOEByiPg" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">NOTE 1 &#8211;<span id="xdx_821_zM1J0N2WC2Cf"> DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Description of Business</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective July 1, 2015, the Company
restructured the corporate organization of the management of diagnostic imaging centers segment of our business. The reorganization
was structured to more completely integrate the operations of Health Management Corporation of America and HDM. Imperial contributed
all of its assets (which were utilized in the business of Health Management Corporation of America) to HDM and received a <span id="xdx_90B_ecustom--HmcaOwnershipSizeOfImperialManagementServicesPercent_iI_pip0_dp_c20150701__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ControllingInterestMember_zkhz9tq6PUFh" title="The ownership interest of Imperial Management Services after reorganization of newly expanded HDM"><ix:nonFraction name="FONR:HmcaOwnershipSizeOfImperialManagementServicesPercent" contextRef="AsOf2015-07-01_custom_ControllingInterestMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8012">24.2</ix:nonFraction></span>%
interest in HDM. Health Management Corporation of America retained a direct ownership interest of <span id="xdx_901_ecustom--OwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent_iI_pip0_dp_c20150701__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ControllingInterestMember_ziDsZKn2LBv7" title="The ownership interest of Health Management Corporation of America after reorganization of newly expanded HDM"><ix:nonFraction name="FONR:OwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent" contextRef="AsOf2015-07-01_custom_ControllingInterestMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8013">45.8</ix:nonFraction></span>% in HDM, and the original
investors in HDM retained a <span id="xdx_90F_ecustom--OwnershipInterestOfOriginalInvestorsOfHdm_iI_pip0_dp_c20150701__us-gaap--StatementEquityComponentsAxis__us-gaap--NoncontrollingInterestMember_zt4bG1dQeMUk" title="The ownership interest of the original investors of HDM"><ix:nonFraction name="FONR:OwnershipInterestOfOriginalInvestorsOfHdm" contextRef="AsOf2015-07-01_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8014">30.0</ix:nonFraction></span>% ownership interest in the newly expanded HDM. During the fiscal year ended June 30, 2022, the
Company purchased non-controlling interests from the minority shareholders for $<span id="xdx_903_ecustom--DirectPurchaseOfNoncontrollingInterests_pn3n3_c20210701__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ControllingInterestMember_zGebHjWX59Td" title="Direct purchase of Noncontrolling Interests"><ix:nonFraction name="FONR:DirectPurchaseOfNoncontrollingInterests" contextRef="From2021-07-012022-06-30_custom_ControllingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8015">546,000</ix:nonFraction></span>. Currently the Company has a direct ownership
interest of <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pip0_dp_c20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ControllingInterestMember_zKRpdsQ0eK71" title="Direct ownership interest percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-06-30_custom_ControllingInterestMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8016">70.8</ix:nonFraction></span>% and the investors&#8217; have a <span id="xdx_900_ecustom--InvestorsOwnershipInterest_iI_pip0_dp_c20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--NoncontrollingInterestMember_zEWdxXjPmOU5" title="Investors ownership interest percentage"><ix:nonFraction name="FONR:InvestorsOwnershipInterest" contextRef="AsOf2022-06-30_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8017">29.2</ix:nonFraction></span>% ownership interest. The entire management of diagnostic imaging centers
business segment is now being conducted by HDM, operating under the name &#8220;Health Management Company of America&#8221;.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Basis of Presentation</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed
consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial
information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the
information and footnotes required by accounting principles generally accepted in the United States of America for complete financial
statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a
fair presentation have been included. Operating results for the six months ended December 31, 2023, are not necessarily indicative
of the results that may be expected for the fiscal year ending June 30, 2024. For further information, refer to the consolidated
financial statements and footnotes thereto included in the Company&#8217;s Annual Report on Form 10-K filed on September 28, 2023
for the fiscal year ended June 30, 2023.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The global pandemic of COVID-19 has
caused turbulence and uncertainty in the United States and international markets and economies which has adversely affected our
workforce, liquidity, financial conditions, revenues, profitability and business operations. The Company was able to enact certain
decisions to allow the Company to navigate the global pandemic and from further losses, additional decreases in scan volume and
avoid any significant disruption of the business. The Company must now take into account the severity, duration and recurrence
of new strains of the COVID-19 virus which adds a new dimension to the challenges and uncertainty facing our business and the world
economy in general. Although we are unable to predict if there will be additional consequences on our operations from the continuing
global pandemic of COVID-19, the Company believes with positive cash flows, low debt and cash on hand, it will be able to continue
operations going forward.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-3484"><p id="xdx_803_eus-gaap--SignificantAccountingPoliciesTextBlock_z5oIJ2V561of" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 2 -<span id="xdx_820_zeGSqZ9uhMQ3"> SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock" id="ixv-3488"><p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_z3sxBoQ5ZaXk" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><span id="xdx_860_zCQUcePOn8e4">Principles of Consolidation</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited condensed consolidated
financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships (collectively
the &#8220;Company&#8221;). All significant intercompany accounts and transactions have been eliminated in consolidation.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_234_zhA5PuhWK0Kl" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 11; Value: 2 -->
    <div id="xdx_237_z76guHJgTCN7" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_238_zYQjthitve88" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div id="xdx_230_zOUtuckQ3H5i" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_234_zxjRff2EmcYe" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zMM5CJXWLNJk" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zV71eVHgcyJ9" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p></ix:exclude>

<ix:exclude><p id="xdx_231_zvfimfX0W8ij" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zPfHTk00pLEf" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">DECEMBER 31, 2023 and 2022</p></ix:exclude>

<ix:exclude><p id="xdx_236_zb5O420fXVQk" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Amounts and shares in thousands, except
per share amounts)</p></ix:exclude>

<ix:exclude><p id="xdx_235_zCYD88G4qgo7" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(UNAUDITED)</p></ix:exclude>


<ix:exclude><p id="xdx_238_zFJuNm8riAva" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zrWKwOJRfgG9" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)</p></ix:exclude>

<ix:exclude><p id="xdx_237_zcg6FK6ZRbg" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="ixv-3519"><p id="xdx_847_eus-gaap--RevenueRecognitionPolicyTextBlock_za2twcMHz04j" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><span id="xdx_868_z54JY0l9LKAf">Revenues</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The revenue recognition standard in
ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a
customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires
expanded disclosures regarding the Company&#8217;s revenue recognition policies and significant judgements employed in the determination
of revenue.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our revenues generally relate to net
patient fees&#160;received from various payers and patients themselves under contracts in which our performance obligations are
to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services
are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day.
The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care
health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction
prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care
health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the
services we provide to the related patients typically specify payments at amounts less than our standard charges and generally
provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually
reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes
in managed care contractual terms resulting from contract renegotiations and renewals.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:BusinessCombinationsPolicy" id="ixv-3527"><p id="xdx_84E_eus-gaap--BusinessCombinationsPolicy_zK3cw6rLlle3" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_86B_zhfHChWzvfrh">BUSINESS COMBINATION</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">When the qualifications for business
combination accounting treatment are met, it requires us to recognize separately from goodwill the assets acquired and the liabilities
assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred
over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates
and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently
uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition
date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the
conclusion of the measurement period of final determination of the values of assets acquired or liabilities assumed, whichever
comes first, any subsequent adjustments are recorded to our consolidated statements of income.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-3533"><p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zUietNjjOXEf" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_864_zoDNeMxqPNPc">Earnings Per Share</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic earnings per share (&#8220;EPS&#8221;)
is computed based upon the weighted average number of shares of common stock and stock equivalents outstanding, net of common stock.
In accordance with ASC topic 260-10, &#8220;Participating Securities and the Two-Class method&#8221;, the Company used the Two-Class
method for calculating basic income per share and applied the if converted method in calculating diluted income per share for the
three and six months ended December 31, 2023 and 2022.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Diluted EPS reflects the potential dilution
from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares
outstanding during the period. For the three and six months ended December 31, 2023 and 2022, diluted EPS for common shareholders
includes <span id="xdx_90D_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_pn3n3_c20231001__20231231_zWDdDMNArwzi" title="Shares included upon conversion of Class C Common"><span id="xdx_906_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_pn3n3_c20230701__20231231_zObqDGAhtB9" title="Shares included upon conversion of Class C Common"><span id="xdx_908_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_pn3n3_c20221001__20221231_znE2S1tSW9xl" title="Shares included upon conversion of Class C Common"><span id="xdx_907_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_pn3n3_c20220701__20221231_zuBHVG23ZLM4" title="Shares included upon conversion of Class C Common"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8018"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8019"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8020"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8021">128</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares upon conversion of Class C Common.</p>

<ix:exclude><p id="xdx_23E_z8xPcn0wDS6d" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_za1MJbNjmEO9" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 12; Value: 2 -->
    <div id="xdx_23E_zeFen5VeO4Q5" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23A_z2oSpCnbVVU5" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div id="xdx_232_zEOv1o6GZixe" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_230_zD7tKK3xThfd" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zy0JPNnB4g19" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zBUL4XLP7ml9" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p></ix:exclude>

<ix:exclude><p id="xdx_236_z5StPRzrla8i" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_239_zr516olWxgsg" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">DECEMBER 31, 2023 and 2022</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zQ8PrDj7kzBc" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Amounts and shares in thousands, except
per share amounts)</p></ix:exclude>

<ix:exclude><p id="xdx_234_z5hy56xsi16g" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(UNAUDITED)</p></ix:exclude>


<ix:exclude><p id="xdx_23F_z9E6msMGeObl" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zvoR6vUFpNlb" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zj0cbeuF8Zrl" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zRFQ2LXo0tTa" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span>Earnings
            Per Share (Continued)</span></p></ix:exclude>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ixv-3575"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_z0hpep08RVlj" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share - (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td id="xdx_8BB_znGt4olpKusa" style="display: none; padding-top: 0; padding-right: 0; text-align: left">Schedule of earning per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">Three months ended <br/> December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">Three months ended <br/> December 31, 2022</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Class C Common <br/> Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Class C Common <br/> Stock</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">Numerator: <br/> Net income available to common stockholders</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20231001__20231231_z24aXYwIjQak" title="Basic Numerator: Net income available to common stockholders" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right"><ix:nonFraction name="FONR:NetIncomeLossAvailableToCommonStockholderBasic" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8022">3,759</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zG8ROYPm99jj" title="Basic Numerator: Net income available to common stockholders" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right"><ix:nonFraction name="FONR:NetIncomeLossAvailableToCommonStockholderBasic" contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8023">3,525</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zYeAgS3vtVDj" title="Basic Numerator: Net income available to common stockholders" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right"><ix:nonFraction name="FONR:NetIncomeLossAvailableToCommonStockholderBasic" contextRef="From2023-10-012023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8024">59</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20221001__20221231_zDCm7XWQngv4" title="Basic Numerator: Net income available to common stockholders" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right"><ix:nonFraction name="FONR:NetIncomeLossAvailableToCommonStockholderBasic" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8025">2,232</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdVoSqQYuEu6" title="Common Stock and Basic Numerator: Net income available to common stockholders" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right"><ix:nonFraction name="FONR:NetIncomeLossAvailableToCommonStockholderBasic" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8026">2,097</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zVmK7Tx46aDc" title="Basic Numerator: Net income available to common stockholders" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right"><ix:nonFraction name="FONR:NetIncomeLossAvailableToCommonStockholderBasic" contextRef="From2022-10-012022-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8027">34</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Weighted average shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20231001__20231231_zujqgbfVHdib" title="Basic Denominator: Weighted average shares outstanding"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8028">6,437</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQ3s5Ss1T211" title="Basic Denominator: Weighted average shares outstanding"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8029">6,437</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zAdeCfpLn6Nc" title="Basic Denominator: Weighted average shares outstanding"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-10-012023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8030">383</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20221001__20221231_zlorfe1PBIP2" title="Basic Denominator: Weighted average shares outstanding"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8031">6,527</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2qzTva5HHvj" title="Basic Denominator: Weighted average shares outstanding"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8032">6,527</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zI5Yn8RanB8f" title="Basic Denominator: Weighted average shares outstanding"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-10-012022-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8033">383</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Basic income per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20231001__20231231_zKWdQXgSLdq3" title="Basic income per common share"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-8034">0.58</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zp7d2uqfUzjc" title="Basic income per common share"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-8035">0.55</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zgbXQMSjCuVk" title="Basic income per common share"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2023-10-012023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-8036">0.16</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20221001__20221231_zeIHjnC2kICf" title="Basic income per common share"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-8037">0.34</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmSH7f1f7109" title="Basic income per common share"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-8038">0.32</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z7F2Pqhgpvy1" title="Basic income per common share"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2022-10-012022-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-8039">0.09</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator: <br/> Weighted average shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2pyXMXkRWo3" title="Diluted Denominator: Weighted average shares outstanding"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8040">6,437</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zpTuzrYJwkK3" title="Diluted Denominator: Weighted average shares outstanding"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-10-012023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8041">383</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8lgAsR8fRzh" title="Diluted Denominator: Weighted average shares outstanding"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8042">6,527</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zqh4XEwVBlVc" title="Diluted Denominator: Weighted average shares outstanding"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-10-012022-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8043">383</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible Class C Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_ecustom--ConvertibleClassCStock_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoXRWoEMXNbb" title="Convertible Class C Stock"><ix:nonFraction name="FONR:ConvertibleClassCStock" contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8044">128</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_ecustom--ConvertibleClassCStock_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_ztk1kuEXjKh6" title="Convertible Class C Stock"><span style="-sec-ix-hidden: xdx2ixbrl1091">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_ecustom--ConvertibleClassCStock_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrZgsPwWJQWk" title="Convertible Class C Stock"><ix:nonFraction name="FONR:ConvertibleClassCStock" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8045">128</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--ConvertibleClassCStock_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zgXkhSfSxKAk" title="Convertible Class C Stock"><span style="-sec-ix-hidden: xdx2ixbrl1095">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Denominator for diluted earnings per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBPNn6fnSBtc" title="Total Denominator for Diluted Earnings Per Share"><ix:nonFraction name="FONR:WeightedAverageNumberOfDilutedEarningsPerShare" contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8046">6,565</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zrXAnwqNZxD8" title="Total Denominator for Diluted Earnings Per Share"><ix:nonFraction name="FONR:WeightedAverageNumberOfDilutedEarningsPerShare" contextRef="From2023-10-012023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8047">383</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKGI6QcltMc1" title="Total Denominator for Diluted Earnings Per Share"><ix:nonFraction name="FONR:WeightedAverageNumberOfDilutedEarningsPerShare" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8048">6,655</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z0JBAcMMr25g" title="Total Denominator for Diluted Earnings Per Share"><ix:nonFraction name="FONR:WeightedAverageNumberOfDilutedEarningsPerShare" contextRef="From2022-10-012022-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8049">383</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Diluted income per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pip0_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxl63AX6VXg7" title="Diluted Income per Common Share"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-8050">0.54</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pip0_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zBFs3GvldEoh" title="Diluted Income per Common Share"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-10-012023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-8051">0.16</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareDiluted_pip0_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2AJgM43Xhcl" title="Diluted Income per Common Share"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-8052">0.32</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pip0_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zQade4RR3t9e" title="Diluted Income per Common Share"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-10-012022-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-8053">0.09</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">Six months ended <br/> December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">Six months ended <br/> December 31, 2022</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Class C Common <br/> Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Class C Common <br/> Stock</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">Numerator: <br/> Net income available to common stockholders</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20230701__20231231_z4UTQH7hUxL4" title="Basic Numerator: Net income available to common stockholders" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right"><ix:nonFraction name="FONR:NetIncomeLossAvailableToCommonStockholderBasic" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8054">7,865</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsqY9NXVLV2c" title="Basic Numerator: Net income available to common stockholders" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right"><ix:nonFraction name="FONR:NetIncomeLossAvailableToCommonStockholderBasic" contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8055">7,375</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z3RMb85H0qkl" title="Basic Numerator: Net income available to common stockholders" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right"><ix:nonFraction name="FONR:NetIncomeLossAvailableToCommonStockholderBasic" contextRef="From2023-07-012023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8056">125</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20220701__20221231_zrCyjoAYN5q8" title="Basic Numerator: Net income available to common stockholders" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right"><ix:nonFraction name="FONR:NetIncomeLossAvailableToCommonStockholderBasic" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8057">4,279</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLw3LCxpKoPj" title="Common Stock and Basic Numerator: Net income available to common stockholders" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right"><ix:nonFraction name="FONR:NetIncomeLossAvailableToCommonStockholderBasic" contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8058">4,020</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zvIHrcyBvIPk" title="Basic Numerator: Net income available to common stockholders" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right"><ix:nonFraction name="FONR:NetIncomeLossAvailableToCommonStockholderBasic" contextRef="From2022-07-012022-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8059">66</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Weighted average shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20231231_zmZ93078iO8d" title="Basic Denominator: Weighted average shares outstanding"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8060">6,448</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z21yzFIuoLf6" title="Basic Denominator: Weighted average shares outstanding"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8061">6,448</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zQA2gc0u4Amk" title="Basic Denominator: Weighted average shares outstanding"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-07-012023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8062">383</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220701__20221231_ztm6KSYAChm6" title="Basic Denominator: Weighted average shares outstanding"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8063">6,534</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkFlslAJn2qk" title="Basic Denominator: Weighted average shares outstanding"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8064">6,534</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zL7NtDF1AoTf" title="Basic Denominator: Weighted average shares outstanding"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-07-012022-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8065">383</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Basic income per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20230701__20231231_zmW1oBcSsg83" title="Basic income per common share"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-8066">1.22</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4dCSpS3695b" title="Basic income per common share"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-8067">1.14</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z7vSLvBYsxqe" title="Basic income per common share"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2023-07-012023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-8068">0.33</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20220701__20221231_zJoGxGVg5CHa" title="Basic income per common share"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-8069">0.65</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIo4QQjg035a" title="Basic income per common share"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-8070">0.62</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zpvgvPcov6bg" title="Basic income per common share"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2022-07-012022-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-8071">0.17</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator: <br/> Weighted average shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9evyBlljdUa" title="Diluted Denominator: Weighted average shares outstanding"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8072">6,448</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zDfugAnIRGu7" title="Diluted Denominator: Weighted average shares outstanding"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-07-012023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8073">383</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2yNF3S72Dh3" title="Diluted Denominator: Weighted average shares outstanding"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8074">6,534</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zdvFkKhi6fDf" title="Diluted Denominator: Weighted average shares outstanding"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-07-012022-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8075">383</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible Class C Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_ecustom--ConvertibleClassCStock_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVjyzxkTFd1" title="Convertible Class C Stock"><ix:nonFraction name="FONR:ConvertibleClassCStock" contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8076">128</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_ecustom--ConvertibleClassCStock_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zq4Sfu9LeOv5" title="Convertible Class C Stock"><span style="-sec-ix-hidden: xdx2ixbrl1159">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_ecustom--ConvertibleClassCStock_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zz6S4pR8sNT2" title="Convertible Class C Stock"><ix:nonFraction name="FONR:ConvertibleClassCStock" contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8077">128</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_ecustom--ConvertibleClassCStock_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zsmEWygCsbKi" title="Convertible Class C Stock"><span style="-sec-ix-hidden: xdx2ixbrl1163">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Denominator for diluted earnings per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8meuCzW846g" title="Total Denominator for Diluted Earnings Per Share"><ix:nonFraction name="FONR:WeightedAverageNumberOfDilutedEarningsPerShare" contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8078">6,576</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zC7x0fJBLE45" title="Total Denominator for Diluted Earnings Per Share"><ix:nonFraction name="FONR:WeightedAverageNumberOfDilutedEarningsPerShare" contextRef="From2023-07-012023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8079">383</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znQ1wEDYsoi7" title="Total Denominator for Diluted Earnings Per Share"><ix:nonFraction name="FONR:WeightedAverageNumberOfDilutedEarningsPerShare" contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8080">6,662</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zJ8UZGlHPd3k" title="Total Denominator for Diluted Earnings Per Share"><ix:nonFraction name="FONR:WeightedAverageNumberOfDilutedEarningsPerShare" contextRef="From2022-07-012022-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8081">383</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Diluted income per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_pip0_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEoN3hUy1ybk" title="Diluted Income per Common Share"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-8082">1.12</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_pip0_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zUXFtANM8l4g" title="Diluted Income per Common Share"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-07-012023-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-8083">0.33</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_pip0_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHNRYTugpdhi" title="Diluted Income per Common Share"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-8084">0.60</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_pip0_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zZd01Sfe84th" title="Diluted Income per Common Share"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-07-012022-12-31_us-gaap_CommonClassCMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-8085">0.17</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>



</ix:nonNumeric><p id="xdx_8A2_zDO6CHuBR1Ub" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><p id="xdx_23C_zYmAWzaCaQE8" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 13; Value: 2 -->
    <div id="xdx_238_z7GDU9QNuAr" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_234_zb526wsA8ME8" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_zSwy7BWUl2fe" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_234_zLvonhwWa8ve" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zBjj8PCFqiXb" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zRh58bWyLYM6" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zYLe1dKItwWh" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_235_zsoeTtlUJwfh" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">DECEMBER 31, 2023 and 2022</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zN0PqSpbq9x6" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Amounts and shares in thousands, except
per share amounts)</p></ix:exclude>

<ix:exclude><p id="xdx_230_zfKrgFKKg21h" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(UNAUDITED)</p></ix:exclude>


<ix:exclude><p id="xdx_233_zFuXfimIOpEh" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zirrHoyb9zf5" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zj2bGc2ynpE5" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-4264"><p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z40QeTkHA1Ff" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><span id="xdx_869_zIQBDaKejqX2">Recent Accounting Standards</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2023, the Financial Accounting
Standards Board (&#8220;FASB&#8221;) issued ASU 2023-09, &#8220;Income Taxes (740) &#8220;Improvements to Income Tax Disclosures&#8221;,
which requires the annual financial statements to include consistent categories and greater disaggregation of information in the
rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company&#8217;s annual
reporting beginning after December 15, 2024, with early adoption permitted, and should be applied on a prospective basis, with
a retrospective option. We are currently evaluating the effect that adoption of ASU 2023-09 will have on our disclosures.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2023, FASB issued ASU 2023-07, &#8220;Segment Reporting (Topic
280)&#8221;, which is intended to improve reportable segment disclosure requirements through enhanced disclosures about significant segment
expenses. The amendments require disclosure of significant segment expenses regularly provided to the chief operating decision maker (CODM)
as well as other segment items, extended certain annual disclosures to interim periods, clarify the applicability to single reportable
segment entities, permit, more than one measure of profit or loss to be reported under certain conditions, and require disclosure of the
title and position of the CODM. The effective date for public entities is beginning after December 15, 2023 and interim periods with fiscal
years beginning after December 15, 2024. We expect to adopt the new disclosures as required and are currently evaluating the impact on
the related disclosures.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2016, FASB issued ASU 2016-13, &#8220;Financial
Instruments &#8211; Credit Loses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221;, which replaces the incurred
loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader
range of reasonable and supportable information to assess credit loss estimates. This ASU is effective for fiscal years beginning after
December 15, 2022. The Company adopted this standard on July 1, 2023 using the modified retrospective approach and it did not have a material
impact of the Company&#8217;s financial statements, resulting in no adjustment to prior year earnings.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">FASB, the Emerging Issues Task Force
and the SEC have issued certain other accounting standards, updates, and regulations as of December 31, 2023 that will become effective
in subsequent periods; however, management does not believe that any of those updates would have significantly affected the Company&#8217;s
financial accounting measures or disclosures had they been in effect during 2023 or 2022, and it does not believe that any of those
standards will have a significant impact on our consolidated condensed financial statements at the time they become effective.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_234_z4dQn26OtJs1" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 14; Value: 2 -->
    <div id="xdx_23B_zZAzBlZRRk98" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_234_zsWo3uEGfdT6" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div id="xdx_23E_zETqzlLWucI9" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23E_z8IMwqDO5cL9" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_z2wxeBejfZrd" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zbiZKxb4Sqt9" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p></ix:exclude>

<ix:exclude><p id="xdx_235_zyde44bOGeld" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_234_zVeln9lnsWXa" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">DECEMBER 31, 2023 and 2022</p></ix:exclude>

<ix:exclude><p id="xdx_235_zUCHybte1Eu2" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Amounts and shares in thousands, except
per share amounts)</p></ix:exclude>

<ix:exclude><p id="xdx_232_zye2KasLpCz9" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(UNAUDITED)</p></ix:exclude>


<ix:exclude><p id="xdx_23E_zcSU9DtdW6fi" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="ixv-4297"><p id="xdx_801_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_zbHoqXT9wLrf" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 3 &#8211;<span id="xdx_822_zTitbNjOT6Rf"> ACCOUNTS RECEIVABLE,
MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Receivables, net is comprised of the
following at December 31, 2023, and June 30, 2023:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock" id="ixv-4303"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock_pn3n3_zrsuW80RcOK6" summary="xdx: Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B4_z3JRElElnWUa" style="display: none; text-align: left; padding-top: 0; padding-right: 0">Schedule of financing
    receivable noncurrent allowance for credit loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Gross Receivable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Allowance for doubtful accounts</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Net</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Accounts receivable</td><td style="width: 5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--AccountsReceivableServiceAndRepairFees_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" title="Accounts receivable" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"><ix:nonFraction name="FONR:AccountsReceivableServiceAndRepairFees" contextRef="AsOf2023-12-31_us-gaap_AccountsReceivableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8086">4,080</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--AccountsReceivableServiceAndRepairFees_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" title="Accounts receivable" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"><ix:nonFraction name="FONR:AccountsReceivableServiceAndRepairFees" contextRef="AsOf2023-12-31_us-gaap_DoubtfulMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8087">199</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--AccountsReceivableServiceAndRepairFees_c20231231_pn3n3" title="Accounts receivable" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"><ix:nonFraction name="FONR:AccountsReceivableServiceAndRepairFees" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8088">3,881</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts receivable - related party</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--AccountsReceivableNetRelatedParty_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" title="Accounts receivable - Related party" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="FONR:AccountsReceivableNetRelatedParty" contextRef="AsOf2023-12-31_us-gaap_AccountsReceivableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8089">60</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_ecustom--AccountsReceivableNetRelatedParty_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" title="Accounts receivable - Related party" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1213">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--AccountsReceivableNetRelatedParty_c20231231_pn3n3" title="Accounts receivable - Related party" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="FONR:AccountsReceivableNetRelatedParty" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8090">60</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Medical receivable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--MedicalReceivable_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" title="Medical Receivables" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="FONR:MedicalReceivable" contextRef="AsOf2023-12-31_us-gaap_AccountsReceivableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8091">22,548</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--MedicalReceivable_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" title="Medical Receivables" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1219">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--MedicalReceivable_c20231231_pn3n3" title="Medical Receivables" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="FONR:MedicalReceivable" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8092">22,548</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Management and other fees receivable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ManagementAndOtherFeesNonRelatedParties_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" title="Management and other fees receivable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="FONR:ManagementAndOtherFeesNonRelatedParties" contextRef="AsOf2023-12-31_us-gaap_AccountsReceivableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8093">51,092</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ManagementAndOtherFeesNonRelatedParties_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" title="Management and other fees receivable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="FONR:ManagementAndOtherFeesNonRelatedParties" contextRef="AsOf2023-12-31_us-gaap_DoubtfulMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8094">11,740</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ManagementAndOtherFeesNonRelatedParties_c20231231_pn3n3" title="Management and other fees receivable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="FONR:ManagementAndOtherFeesNonRelatedParties" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8095">39,352</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Management and other fees receivable from related medical practices (&#8220;PC&#8217;s&#8221;)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" title="Management and other fees receivable from related medical practices (&quot;PC's&quot;)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" contextRef="AsOf2023-12-31_us-gaap_AccountsReceivableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8096">14,480</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" title="Management and other fees receivable from related medical practices (&quot;PC's&quot;)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" contextRef="AsOf2023-12-31_us-gaap_DoubtfulMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8097">5,213</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20231231_pn3n3" title="Management and other fees receivable from related medical practices (&quot;PC's&quot;)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8098">9,267</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2023</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Gross Receivable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Allowance for doubtful accounts</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Net</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Accounts receivable</td><td style="width: 5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--AccountsReceivableServiceAndRepairFees_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" title="Accounts receivable" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"><ix:nonFraction name="FONR:AccountsReceivableServiceAndRepairFees" contextRef="AsOf2023-06-30_us-gaap_AccountsReceivableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8099">4,060</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--AccountsReceivableServiceAndRepairFees_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" title="Accounts receivable" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"><ix:nonFraction name="FONR:AccountsReceivableServiceAndRepairFees" contextRef="AsOf2023-06-30_us-gaap_DoubtfulMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8100">199</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--AccountsReceivableServiceAndRepairFees_c20230630_pn3n3" title="Accounts receivable" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"><ix:nonFraction name="FONR:AccountsReceivableServiceAndRepairFees" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8101">3,861</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Medical receivable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--MedicalReceivable_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" title="Medical Receivables" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="FONR:MedicalReceivable" contextRef="AsOf2023-06-30_us-gaap_AccountsReceivableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8102">21,259</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--MedicalReceivable_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" title="Medical Receivables" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1243">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--MedicalReceivable_c20230630_pn3n3" title="Medical Receivables" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="FONR:MedicalReceivable" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8103">21,259</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Management and other fees receivable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--ManagementAndOtherFeesNonRelatedParties_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" title="Management and other fees receivable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="FONR:ManagementAndOtherFeesNonRelatedParties" contextRef="AsOf2023-06-30_us-gaap_AccountsReceivableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8104">48,497</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ManagementAndOtherFeesNonRelatedParties_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" title="Management and other fees receivable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="FONR:ManagementAndOtherFeesNonRelatedParties" contextRef="AsOf2023-06-30_us-gaap_DoubtfulMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8105">12,609</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ManagementAndOtherFeesNonRelatedParties_c20230630_pn3n3" title="Management and other fees receivable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="FONR:ManagementAndOtherFeesNonRelatedParties" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8106">35,888</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Management and other fees receivable from related medical practices (&#8220;PC&#8217;s&#8221;)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" title="Management and other fees receivable from related medical practices (&quot;PC's&quot;)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" contextRef="AsOf2023-06-30_us-gaap_AccountsReceivableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8107">13,152</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" title="Management and other fees receivable from related medical practices (&quot;PC's&quot;)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" contextRef="AsOf2023-06-30_us-gaap_DoubtfulMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8108">3,990</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20230630_pn3n3" title="Management and other fees receivable from related medical practices (&quot;PC's&quot;)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8109">9,162</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A4_zcjkfdHsFDnb" style="margin-top: 0; margin-bottom: 0">&#160;</p>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Company&#8217;s customers are concentrated in the healthcare industry.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Accounts
Receivable&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p><p style="text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Credit
                                            risk with respect to the Company&#8217;s accounts receivable related to product sales and
                                            service and repair fees is limited due to the customer advances received prior to the commencement
                                            of work performed and the billing of amounts to customers as sub-assemblies are completed.
                                            Service and repair fees are billed on a monthly or quarterly basis and the Company does not
                                            continue providing these services if accounts receivable become past due. The Company controls
                                            credit risk with respect to accounts receivable from service and repair fees through its
                                            credit evaluation process, credit limits, monitoring procedures and reasonably short collection
                                            terms. The Company performs ongoing credit authorizations before a product sales contract
                                            is entered into or service and repair fees are provided.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;&#160;Long
Term Accounts Receivable&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Long term accounts receivable balances at
December 31, 2023 and June 30, 2023 amounted to approximately $<span id="xdx_901_ecustom--AccountsReceivableNetLongTerm_iI_pn3n3_c20231231_z8Tp1YVIbIUl" title="Long term accounts receivable"><ix:nonFraction name="FONR:AccountsReceivableNetLongTerm" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8110">376</ix:nonFraction>
</span>and $<span id="xdx_904_ecustom--AccountsReceivableNetLongTerm_iI_pn3n3_c20230630_zCX0hqWSS1h" title="Long term accounts receivable"><ix:nonFraction name="FONR:AccountsReceivableNetLongTerm" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8111">710</ix:nonFraction>
</span>respectively. The Company will generate revenue from long-term, non-cancellable contracts to provide service and repair services.
Future revenue to be recognized over the following two years as of December 31, 2023 is as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="FONR:TotalFacilitiesOwnedOrManagedTableTextBlock" id="ixv-4494"><table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--TotalFacilitiesOwnedOrManagedTableTextBlock_pn3n3_zOPb9OOHAwE4" summary="xdx: Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td id="xdx_8B5_z8RI1U23wU33" style="display: none; text-align: right">Schedule of Future revenue</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 43%; text-align: right">2025</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ContractReceivableDueOneToTwoYears_iI_pn3n3_c20231231_zI9Rs5aCmDnb" title="2025" style="width: 43%; text-align: right"><ix:nonFraction name="us-gaap:ContractReceivableDueOneToTwoYears" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8112">319</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2026</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ContractReceivableDueTwoToThreeYears_iI_pn3n3_c20231231_zOVVUU2LH5sk" title="2026" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ContractReceivableDueTwoToThreeYears" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8113">57</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AccountsReceivableBilledForLongTermContractsOrPrograms_pn3n3_c20231231_ztlcCINnoJ1l" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableBilledForLongTermContractsOrPrograms" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8114">376</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A5_zeSqkM0srNJd" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Medical Receivables</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Medical receivables are due under fee-for-service
contracts from third party payors, such as hospitals, government sponsored healthcare programs, patient&#8217;s legal counsel and
directly from patients. Substantially all the revenue relates to patients residing in Florida. The carrying amount of the medical
receivable is reduced by an allowance that reflects management&#8217;s best estimate of the amounts that will not be collected.
The Company determines allowances for contractual adjustments and uncollectible accounts based on specific agings, specific payor
collection issues that have been identified and based on payor classifications and historical experience at each site.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_232_zbAql2c1mTUk" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 15; Value: 2 -->
    <div id="xdx_238_zZTO9XweHEm" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23A_zxcatKQAfKFe" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div id="xdx_23A_z3Zb6J6SXH7h" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_233_zLIBRfrbBlc2" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zivVRaZaDgnk" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zeMJ9eVV8Zj7" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p></ix:exclude>

<ix:exclude><p id="xdx_236_zwYarRGAq0xb" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_234_zC3KLTW4uUAh" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">DECEMBER 31, 2023 and 2022</p></ix:exclude>

<ix:exclude><p id="xdx_230_zx2qhJ748Pd7" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Amounts and shares in thousands, except
per share amounts)</p></ix:exclude>

<ix:exclude><p id="xdx_236_ztXwdhVtnmc4" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(UNAUDITED)</p></ix:exclude>


<ix:exclude><p id="xdx_236_zHCk9l64uAQb" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zVl7zzlvEdH8" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 3 &#8211; ACCOUNTS RECEIVABLE,
MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (CONTINUED)</p></ix:exclude>

<ix:exclude><p id="xdx_231_zstKSqAixRg1" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Management and Other Fees Receivable</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s receivables from
the related and non-related professional corporations (PC&#8217;s) substantially consist of fees outstanding under management agreements.
Payment of the outstanding fees is dependent on collection by the PC&#8217;s of fees from third party medical reimbursement organizations,
principally insurance companies and health management organizations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Payment of the management fee receivables from the PC&#8217;s
may be impaired by the inability of the PC&#8217;s to collect in a timely manner their medical fees from the third-party payors,
particularly insurance carriers covering automobile no-fault and workers compensation claims due to longer payment cycles and rigorous
informational requirements and certain other disallowed claims. Approximately <span id="xdx_902_ecustom--PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims_pip0_dp_c20231001__20231231_zdLeRFDtzGUf" title="Percentage of net revenue"><ix:nonFraction name="FONR:PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8115">66</ix:nonFraction></span>% and <span id="xdx_907_ecustom--PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims_pip0_dp_c20221001__20221231_zYJAWfx84oga" title="Percentage of net revenue"><ix:nonFraction name="FONR:PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8116">67</ix:nonFraction></span>% of the PCs&#8217; net revenues for the
three months ended December 31, 2023 and 2022, respectively, were derived from no-fault and personal injury protection claims.
Approximately <span id="xdx_905_ecustom--PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims_pip0_dp_c20230701__20231231_z9KunA8agoje" title="Percentage of net revenue"><ix:nonFraction name="FONR:PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8117">67</ix:nonFraction></span>% and <span id="xdx_90C_ecustom--PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims_pip0_dp_c20220701__20221231_zUeZnhDd95nd" title="Percentage of net revenue"><ix:nonFraction name="FONR:PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8118">68</ix:nonFraction></span>% of the PCs&#8217; net revenue for the six months ended December 31, 2023 and 2022, respectively, were
derived from no-fault and personal injury protection claims. The Company considers the aging of its accounts receivable in determining
the amount of allowance for doubtful accounts. The Company generally takes all legally available steps to collect its receivables.
Credit losses associated with the receivables are provided for in the condensed consolidated financial statements and have historically
been within management&#8217;s expectations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Net revenues from management and other
fees charged to the related PCs accounted for approximately <span id="xdx_90B_ecustom--PercentageOfConsolidatedNetRevenueFromManagementFees_pip0_dp_c20231001__20231231_z6HmEe0zaoW9" title="Percentage of consolidated net revenue"><ix:nonFraction name="FONR:PercentageOfConsolidatedNetRevenueFromManagementFees" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8119">11.8</ix:nonFraction></span>% and <span id="xdx_904_ecustom--PercentageOfConsolidatedNetRevenueFromManagementFees_pip0_dp_c20221001__20221231_zrrNEAwUomGb" title="Percentage of consolidated net revenue"><ix:nonFraction name="FONR:PercentageOfConsolidatedNetRevenueFromManagementFees" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8120">12.4</ix:nonFraction></span>% of the consolidated net revenues for the three months
ended December 31, 2023 and 2022, respectively. Net revenues from management and other fees charged to the related PCs accounted
for approximately <span id="xdx_908_ecustom--PercentageOfConsolidatedNetRevenueFromManagementFees_pip0_dp_c20230701__20231231_zU97CGldWpQa" title="Percentage of consolidated net revenue"><ix:nonFraction name="FONR:PercentageOfConsolidatedNetRevenueFromManagementFees" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8121">11.7</ix:nonFraction></span>% and <span id="xdx_907_ecustom--PercentageOfConsolidatedNetRevenueFromManagementFees_pip0_dp_c20220701__20221231_zSa1MW6kZytj" title="Percentage of consolidated net revenue"><ix:nonFraction name="FONR:PercentageOfConsolidatedNetRevenueFromManagementFees" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8122">12.6</ix:nonFraction></span>% of the consolidated net revenues for the six months ended December 31, 2023 and 2022, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Tallahassee Magnetic Resonance Imaging,
Inc., Stand Up MRI of Boca Raton, Inc. and Stand Up MRI &amp; Diagnostic Center, Inc. (all related medical practices) entered into
a guaranty agreement, pursuant to which they cross guaranteed all management fees which are payable to the Company, which have
arisen under each individual management agreement. Additional Company managed entities also operate under a guaranty agreement,
pursuant to which management fees are payable to the Company.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;&#160;&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s patient fee revenue,
net of contractual allowances and discounts for the three and six months ended December 31, 2023 and 2022 are summarized in the
following table.&#160;</p>

<ix:exclude><p id="xdx_231_zcGThJdR5xVj" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zFo34cD70lb7" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_238_ziehIdsOiXn5" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div id="xdx_231_zgtFVaFUghYg" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_232_zAZHfGDfiQA5" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_z2crXIOkPyzb" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zRMmDJgfkIP" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p></ix:exclude>

<ix:exclude><p id="xdx_233_zYZbj2WqHyq7" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_239_zkq6Abpi0Vnj" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">DECEMBER 31, 2023 and 2022</p></ix:exclude>

<ix:exclude><p id="xdx_232_zUapXBWjGoh3" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Amounts and shares in thousands, except
per share amounts)</p></ix:exclude>

<ix:exclude><p id="xdx_235_zKyda0NqZ7o9" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(UNAUDITED)</p></ix:exclude>


<ix:exclude><p id="xdx_232_zKZLVyvdvZ2g" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zzTtZa7dDTOc" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 3 &#8211; ACCOUNTS RECEIVABLE,
MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (CONTINUED)</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zHz15bi9H1Y4" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="FONR:ScheduleOfPatientFeeRevenueTableTextBlock" id="ixv-4605"><table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfPatientFeeRevenueTableTextBlock_zlRut4kBWtai" summary="xdx: Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B7_z5TLT0GbxGA4" style="display: none">Schedule of patient fee revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center">For the Three Months Ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Commercial Insurance/ Managed Care</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_znhjakEssmI9" title="Patient Fee Revenue, net of contractual allowances and discounts" style="width: 12%; text-align: right"><ix:nonFraction name="FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount" contextRef="From2023-10-012023-12-31_custom_CommercialInsuranceManagedCareMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8123">1,243</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_zo3vvZD7nGP9" title="Patient Fee Revenue, net of contractual allowances and discounts" style="width: 12%; text-align: right"><ix:nonFraction name="FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount" contextRef="From2022-10-012022-12-31_custom_CommercialInsuranceManagedCareMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8124">958</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Medicare/Medicaid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zJuB4xVfqhE5" title="Patient Fee Revenue, net of contractual allowances and discounts" style="text-align: right"><ix:nonFraction name="FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount" contextRef="From2023-10-012023-12-31_custom_MedicareMedicaidMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8125">284</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zXyVF66WunI1" title="Patient Fee Revenue, net of contractual allowances and discounts" style="text-align: right"><ix:nonFraction name="FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount" contextRef="From2022-10-012022-12-31_custom_MedicareMedicaidMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8126">247</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Workers&#8217; Compensation/Personal Injury</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_z5wxjXHQ4B2h" title="Patient Fee Revenue, net of contractual allowances and discounts" style="text-align: right"><ix:nonFraction name="FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount" contextRef="From2023-10-012023-12-31_custom_WorkersCompensationPersonalInjuryMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8127">4,907</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_z4JLoGVYKosf" title="Patient Fee Revenue, net of contractual allowances and discounts" style="text-align: right"><ix:nonFraction name="FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount" contextRef="From2022-10-012022-12-31_custom_WorkersCompensationPersonalInjuryMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8128">4,262</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherMember_zlC5xC7Qe0B8" title="Patient Fee Revenue, net of contractual allowances and discounts" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount" contextRef="From2023-10-012023-12-31_custom_OtherMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8129">1,787</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherMember_zKmmXI7dL4E1" title="Patient Fee Revenue, net of contractual allowances and discounts" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount" contextRef="From2022-10-012022-12-31_custom_OtherMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8130">1,662</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Patient Fee Revenue, net of contractual allowances and discounts</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231_zLIChWdBejDd" title="Patient Fee Revenue, net of contractual allowances and discounts" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8131">8,221</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231_zQUZ9qSPnm41" title="Patient Fee Revenue, net of contractual allowances and discounts" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8132">7,129</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center">For the Six Months Ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Commercial Insurance/ Managed Care</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_zCMYrCl87ynh" title="Patient Fee Revenue, net of contractual allowances and discounts" style="width: 12%; text-align: right"><ix:nonFraction name="FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount" contextRef="From2023-07-012023-12-31_custom_CommercialInsuranceManagedCareMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8133">2,416</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_zowmtzn9Vbe3" title="Patient Fee Revenue, net of contractual allowances and discounts" style="width: 12%; text-align: right"><ix:nonFraction name="FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount" contextRef="From2022-07-012022-12-31_custom_CommercialInsuranceManagedCareMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8134">1,869</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Medicare/Medicaid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zbVJ4nfhTCx6" title="Patient Fee Revenue, net of contractual allowances and discounts" style="text-align: right"><ix:nonFraction name="FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount" contextRef="From2023-07-012023-12-31_custom_MedicareMedicaidMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8135">555</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zjiT9qoryZp9" title="Patient Fee Revenue, net of contractual allowances and discounts" style="text-align: right"><ix:nonFraction name="FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount" contextRef="From2022-07-012022-12-31_custom_MedicareMedicaidMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8136">484</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Workers&#8217; Compensation/Personal Injury</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_znpyENPcKD3d" title="Patient Fee Revenue, net of contractual allowances and discounts" style="text-align: right"><ix:nonFraction name="FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount" contextRef="From2023-07-012023-12-31_custom_WorkersCompensationPersonalInjuryMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8137">10,044</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_zHANQcrYMv6b" title="Patient Fee Revenue, net of contractual allowances and discounts" style="text-align: right"><ix:nonFraction name="FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount" contextRef="From2022-07-012022-12-31_custom_WorkersCompensationPersonalInjuryMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8138">8,497</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherMember_zwyKUlvde0yi" title="Patient Fee Revenue, net of contractual allowances and discounts" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount" contextRef="From2023-07-012023-12-31_custom_OtherMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8139">3,881</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherMember_zog5V7oL01Ni" title="Patient Fee Revenue, net of contractual allowances and discounts" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount" contextRef="From2022-07-012022-12-31_custom_OtherMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8140">2,355</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Patient Fee Revenue, net of contractual allowances and discounts</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231_zNxkXEDlORt9" title="Patient Fee Revenue, net of contractual allowances and discounts" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8141">16,896</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231_z6goTqEukcRe" title="Patient Fee Revenue, net of contractual allowances and discounts" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8142">13,205</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8AD_zvmSEl7yCrnc" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" id="ixv-4740"><p id="xdx_809_eus-gaap--LesseeOperatingLeasesTextBlock_zbguJ97N0ab6" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 4 &#8211;<span id="xdx_828_zm0GT65ONDza"> OPERATING &amp; FINANCING
LEASES</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2019, the Company adopted ASU
2016-02, &#8220;Leases&#8221; (Topic 842). This standard requires lessees to apply a dual approach, classifying leases as either
finance or operating leases based upon the principle of whether or not the lease is effectively a financed purchase by the lessee.
We have also elected the transition package of the practical expedients permitted within the standard which eliminates the requirements
to reassess prior conclusions about lease identification, lease classification and indirect costs.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for its various
operating leases in accordance with Topic 842, as updated by ASU 2016-02. At the inception of a lease, the Company recognizes right-of-use
lease assets and related lease liabilities measured at present value of future lease payments on its balance sheet. Lease expense
is recognized on a straight-line basis over the term of the lease. Our most common initial term varies in length from 2 to 10 years.
Including renewal options negotiated with the landlord, we have a total span of 2 to 16 years at the facilities we lease. The Company
reviewed its contracts with vendors and customers, determining that its right-to-use lease assets consisted of only office space
operating leases. In determining the right-to-use lease assets and liabilities, the Company did recognize lease extension options
which the Company feels would be reasonably exercised. Our incremental borrowing rate (&#8220;IBR&#8221;) used to discount the
stream of operating lease payments is closely related to the interest rates available to the Company.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation of operating and financing
lease payments undiscounted cash flows to lease liabilities recognized as of December 31, 2023 is as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_230_zA5W7dSElct6" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 17; Value: 2 -->
    <div id="xdx_230_zxmGBrafiCgf" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_231_zUv3bEPxJII1" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div id="xdx_234_zcf3mvxwp361" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_231_zI784HIBUhob" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_z6RruuZ7Nc7b" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_ztskBK9l3f8k" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p></ix:exclude>

<ix:exclude><p id="xdx_234_zkoeq6aAOvG" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zASAMVoQS8f8" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">DECEMBER 31, 2023 and 2022</p></ix:exclude>

<ix:exclude><p id="xdx_232_zycHter9cSb4" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Amounts and shares in thousands, except
per share amounts)</p></ix:exclude>

<ix:exclude><p id="xdx_239_ztovjX6WciZ" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(UNAUDITED)</p></ix:exclude>


<ix:exclude><p id="xdx_23E_zNUFmFfWg1d3" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zpD84er3qOTa" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 4 &#8211; OPERATING &amp; FINANCING
LEASES (CONTINUED)</p></ix:exclude>

<ix:exclude><p id="xdx_237_zkl0EN7EOm19" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-4775"><table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_z0fRutkiWkId" summary="xdx: Disclosure - OPERATING &amp; FINANCING LEASES - Lease Payments (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_8B3_zIHJDJmb4wWh" style="display: none; text-align: right">Lessee operating leases liability maturity</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Twelve Months Ending<br/>
December 31,</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Operating Lease<br/>
Payments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Financing Lease<br/>
Payments</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 26%; text-align: right">2024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" title="Lessee, Operating Lease, Liability, to be Paid, Year One" style="width: 26%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2023-12-31_custom_OperatingLeasePaymentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8143">6,319</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" title="Finance Lease, Liability, to be Paid, Year One" style="width: 26%; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2023-12-31_custom_FinancingLeasePaymentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8144">244</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" title="Lessee, Operating Lease, Liability, to be Paid, Year Two" style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2023-12-31_custom_OperatingLeasePaymentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8145">5,672</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" title="Finance Lease, Liability, to be Paid, Year Two" style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2023-12-31_custom_FinancingLeasePaymentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8146">244</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2026</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" title="Lessee, Operating Lease, Liability, to be Paid, Year Three" style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2023-12-31_custom_OperatingLeasePaymentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8147">4,902</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" title="Finance Lease, Liability, to be Paid, Year Three" style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2023-12-31_custom_FinancingLeasePaymentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8148">244</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2027</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" title="Lessee, Operating Lease, Liability, to be Paid, Year Four" style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2023-12-31_custom_OperatingLeasePaymentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8149">3,677</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" title="Finance Lease, Liability, to be Paid, Year Four" style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2023-12-31_custom_FinancingLeasePaymentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8150">41</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2028</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" title="Lessee, Operating Lease, Liability, to be Paid, Year Five" style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2023-12-31_custom_OperatingLeasePaymentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8151">3,426</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" title="Finance Lease, Liability, to be Paid, Year Five" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1382">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">Thereafter</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" title="Lessee, Operating Lease, Liability, to be Paid, after Year Five" style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2023-12-31_custom_OperatingLeasePaymentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8152">20,698</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" title="Finance Lease, Liability, to be Paid, after Year Five" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1386">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">Present value discount</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--PresentValueDiscount_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" title="Present value discount" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="FONR:PresentValueDiscount" contextRef="AsOf2023-12-31_custom_OperatingLeasePaymentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-8153">9,737</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--PresentValueDiscountFinancingLease_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" title="Present value discount" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="FONR:PresentValueDiscountFinancingLease" contextRef="AsOf2023-12-31_custom_FinancingLeasePaymentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-8154">43</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">Total lease liability</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingLeaseLiability_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" title="Operating Lease, Liability" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-12-31_custom_OperatingLeasePaymentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8155">34,957</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FinanceLeaseLiability_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" title="Finance Lease, Liability" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2023-12-31_custom_FinancingLeasePaymentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8156">730</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:InventoryDisclosureTextBlock" id="ixv-4900"><p id="xdx_800_eus-gaap--InventoryDisclosureTextBlock_zoEL3sLGOCo2" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">NOTE 5 -<span id="xdx_82F_zzvq9GNuB1I"> INVENTORIES</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories included in the accompanying
condensed consolidated balance sheets consist of the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="ixv-4906"><table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_zGboBOL1Wf87" summary="xdx: Disclosure - INVENTORIES - Inventories (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BF_zkII9TzyV9t7" style="display: none; padding-top: 0; padding-right: 0">Schedule of inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20231231_zWo932XnF1T4" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20230630_z4tq9kpA2VE5" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">December 31,<br/>
2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">June 30,<br/>
2023</td></tr>
<tr id="xdx_40E_eus-gaap--OtherInventorySupplies_iI_maIFGAWzdt0_zhrbC4b89MZc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Purchased parts, components and supplies</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:OtherInventorySupplies" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8157">2,582</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:OtherInventorySupplies" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8158">2,346</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--InventoryWorkInProcess_iI_maIFGAWzdt0_zjJwXejdTLQ4" style="vertical-align: bottom; background-color: White">
    <td>Work-in-process</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8159">253</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8160">224</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--InventoryFinishedGoodsAndWorkInProcess_iTI_mtIFGAWzdt0_zVRC2sPk6n9l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Inventories</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsAndWorkInProcess" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8161">2,835</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsAndWorkInProcess" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8162">2,570</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="ixv-4957"><p id="xdx_808_eus-gaap--IntangibleAssetsDisclosureTextBlock_zkobtvaaAgUj" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 6 &#8211;<span id="xdx_823_zlwpLMSMVjic"> OTHER INTANGIBLE ASSETS</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Other intangible assets, net of accumulated
amortization, in the accompanying condensed consolidated balance sheets consist of the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="ixv-4963"><table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_pn3n3_zHnA5sGQb175" summary="xdx: Disclosure - OTHER INTANGIBLE ASSETS - Other intangible assets net of amortization (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BF_zyqX1uLwEcw1" style="display: none; text-align: left">Schedule of other intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">December 31,<br/>
2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">June 30, <br/>
2023</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Capitalized software development costs</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_z3x14ASoMG3f" title="Gross other intangible assets" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8163">7,005</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_pn3n3" title="Gross other intangible assets" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-06-30_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8164">7,005</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Patents and copyrights</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zvNIq4ynXZx6" title="Gross other intangible assets" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_custom_PatentsAndCopyrightsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8165">5,472</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_pn3n3" title="Gross other intangible assets" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-06-30_custom_PatentsAndCopyrightsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8166">5,452</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Non-compete</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zY8Va9wjG4A8" title="Gross other intangible assets" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_us-gaap_NoncompeteAgreementsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8167">4,150</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_pn3n3" title="Gross other intangible assets" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-06-30_us-gaap_NoncompeteAgreementsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8168">4,150</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Customer relationships</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zyt57x5TTL6f" title="Gross other intangible assets" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_us-gaap_CustomerRelationshipsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8169">3,900</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" title="Gross other intangible assets" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-06-30_us-gaap_CustomerRelationshipsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8170">3,900</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross Other intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231_znsHM6vhm7va" title="Gross other intangible assets" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8171">20,527</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20230630_zNyHjhgPhRH5" title="Gross other intangible assets" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8172">20,507</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: Accumulated amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_pn3n3_c20231231_zd56JZnmfOsl" title="Less: Accumulated amortization" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8173">17,261</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20230630_z7jK2eMULv81" title="Less: Accumulated amortization" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8174">17,075</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other Intangible Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_pn3n3_c20231231_z7rZD3VQcbX9" title="Other intangible assets-net" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8175">3,266</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20230630_z7nmcTachwOf" title="Other intangible assets-net" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8176">3,432</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<ix:exclude><p id="xdx_230_z1cu92KGcjE6" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 18; Value: 2 -->
    <div id="xdx_232_zhtUiVM4och6" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_231_z9i1k0ea6Ok8" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_z5zNX0EgQ831" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23D_zFvD8bJ58Thi" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zOfzu6tMhM97" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zUqhuvbBvzW8" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p></ix:exclude>

<ix:exclude><p id="xdx_238_zkXg70mCB489" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zwZSoi01XgQb" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">DECEMBER 31, 2023 and 2022</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zU1yIk6HpS59" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Amounts and shares in thousands, except
per share amounts)</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zIeWq1eUcbyl" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(UNAUDITED)</p></ix:exclude>


<ix:exclude><p id="xdx_237_zFYBTuLrlU6e" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zlSmfaSyArle" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left">NOTE 6 &#8211; OTHER INTANGIBLE ASSETS (CONTINUED)</p></ix:exclude>

<ix:exclude><p id="xdx_232_zIW3iQIRO1Zh" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p></ix:exclude>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization of patents and copyrights
for the three months ended December 31, 2023 and 2022 amounted to $<span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20231001__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zJ6lkEFohRk" title="Amortization of Intangible Assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-10-012023-12-31_custom_PatentsAndCopyrightsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8177">43</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20221001__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_z8zEjgXiClC2" title="Amortization of Intangible Assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-10-012022-12-31_custom_PatentsAndCopyrightsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8178">47</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization of customer relationships
for the three months ended December 31, 2023 and 2022 amounted to $<span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20231001__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zQ1DhqoXYKRb" title="Amortization of Intangible Assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-10-012023-12-31_us-gaap_CustomerRelationshipsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8179">50</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20221001__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zXdcADWBVco4" title="Amortization of Intangible Assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-10-012022-12-31_us-gaap_CustomerRelationshipsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8180">50</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization of patents and copyrights
for the six months ended December 31, 2023 and 2022 amounted to $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20230701__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zG7ggbFFZEt9" title="Amortization of Intangible Assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-07-012023-12-31_custom_PatentsAndCopyrightsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8181">86</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20220701__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zXE72AifZQzj" title="Amortization of Intangible Assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-07-012022-12-31_custom_PatentsAndCopyrightsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8182">101</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization of customer relationships
for the six months ended December 31, 2023 and 2022 amounted to $<span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20230701__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zSsQLrQlgEbc" title="Amortization of Intangible Assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-07-012023-12-31_us-gaap_CustomerRelationshipsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8183">100</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20220701__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zGrTy4Lx0aV1" title="Amortization of Intangible Assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-07-012022-12-31_us-gaap_CustomerRelationshipsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8184">100</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="ixv-5095"><p id="xdx_805_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zGPBbxLvokkl" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 7 &#8211;<span id="xdx_82D_zukqRL4aBzLl"> OTHER CURRENT LIABILITIES</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Other current liabilities in the accompanying
condensed consolidated balance sheets consist of the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="ixv-5101"><table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_pn3n3_zeP1UrQ0Dm77" summary="xdx: Disclosure - OTHER CURRENT LIABILITIES - Other Current Liabilities - (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B9_zHCcyPHyOwF5" style="display: none; text-align: left">Schedule of other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20231231_zHR1XX7zypxe" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20230630_z9cYelbSkp3g" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">December 31,<br/>
2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">June 30,<br/>
2023</td></tr>
<tr id="xdx_400_eus-gaap--AccruedSalariesCurrent_iI_pn3n3_maOLCzdop_z5WqcgkMCPFc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Accrued salaries, commissions and payroll taxes</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8185">2,078</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8186">4,413</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_pn3n3_maOLCzdop_zISZUiZsxMgl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Sales tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SalesAndExciseTaxPayableCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8187">222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SalesAndExciseTaxPayableCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8188">193</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--StateIncomeTaxesPayable_iI_pn3n3_maOLCzdop_zh61EtQveQXj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"> Income taxes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:StateIncomeTaxesPayable" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8189">196</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FONR:StateIncomeTaxesPayable" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8190">48</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maOLCzdop_zQIGdXEGnn4b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Legal and other professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8191">11</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8192">11</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_pn3n3_maOLCzdop_zmqgUBuULDbi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounting fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8193">54</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8194">100</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--SelfInsuranceReserve_iI_pn3n3_maOLCzdop_zwlv9e72VSwl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Self-funded health insurance reserve</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SelfInsuranceReserve" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8195">86</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SelfInsuranceReserve" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8196">101</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesNoncurrent_iI_pn3n3_maOLCzdop_zbqhVQUeLE27" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued interest and penalty</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesNoncurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8197">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesNoncurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8198">4</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OtherSundryLiabilitiesCurrent_iI_pn3n3_maOLCzdop_zXfcTexvjhL3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other general and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherSundryLiabilitiesCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8199">809</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherSundryLiabilitiesCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8200">574</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OtherLiabilitiesCurrent_iTI_pn3n3_mtOLCzdop_zlJPzs1Vexha" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other Current Liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8201">3,460</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8202">5,444</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock" id="ixv-5212"><p id="xdx_803_eus-gaap--SegmentReportingDisclosureTextBlock_zL0RfZteg9q9" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">NOTE 8 - <span id="xdx_827_z66xBDPQi827">SEGMENT AND RELATED INFORMATION</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Company operates in two industry segments - manufacturing
and the servicing of medical equipment and management of diagnostic imaging centers. The accounting policies of the segments are
the same as those described in the summary of significant accounting policies as disclosed in the Company&#8217;s 10-K as of June
30, 2023. All inter-segment sales are market-based. The Company evaluates performance based on income or loss from operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><p id="xdx_23E_zi8VPg3POh76" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 19; Value: 2 -->
    <div id="xdx_238_ztpUvxlxCPb6" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div id="xdx_235_zOCJXrJyfkRi" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zb81TnzTvKJb" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zK1z8ScTamA1" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zw00bPyMOgYl" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zjZXSz61PVX8" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">DECEMBER 31, 2023 and 2022</p></ix:exclude>

<ix:exclude><p id="xdx_235_zUTdUH66VZ5e" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Amounts and shares in thousands, except
per share amounts)</p></ix:exclude>

<ix:exclude><p id="xdx_23E_z1yTRHqKfu8d" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(UNAUDITED)</p></ix:exclude>


<ix:exclude><p id="xdx_23C_zQAgzPaAvjsk" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_z4kGUI6XhcZd" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 8 - SEGMENT AND RELATED INFORMATION (CONTINUED)</p></ix:exclude>

<ix:exclude><p id="xdx_236_zQ8lfdBE4NP4" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Summarized financial information concerning
the Company&#8217;s reportable segments is shown in the following table:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="ixv-5245"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zsW5z5VdLnKj" summary="xdx: Disclosure - SEGMENT AND RELATED INFORMATION - Summarized Segments - (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BB_zZValMBlhpu2" style="display: none">Schedule
    of summarized segment financial information</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Medical <br/> Equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Management <br/> of Diagnostic <br/> Imaging <br/> Centers</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Totals</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; padding-top: 0; padding-right: 0">For the three months ended Dec. 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Net revenues from external customers</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zYBxfzg2kR0g" title="Net revenues from external customers" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-10-012023-12-31_custom_MedicalEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8203">1,861</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--Revenues_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zSYkIm1RS3h8" title="Net revenues from external customers" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-10-012023-12-31_custom_ManagementOfDiagnosticImagingCentersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8204">23,525</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_pn3n3_c20231001__20231231_zlUglcd1BO8b" title="Net revenues from external customers" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8205">25,386</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Inter-segment net revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_ecustom--IntersegmentNetRevenues_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zk8Xi2CrDcq7" title="Inter-segment net revenues" style="text-align: right"><ix:nonFraction name="FONR:IntersegmentNetRevenues" contextRef="From2023-10-012023-12-31_custom_MedicalEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8206">254</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_ecustom--IntersegmentNetRevenues_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zKIEVE9fbm87" title="Inter-segment net revenues" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1520">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_ecustom--IntersegmentNetRevenues_pn3n3_c20231001__20231231_zddsruZKQpEh" title="Inter-segment net revenues" style="text-align: right"><ix:nonFraction name="FONR:IntersegmentNetRevenues" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8207">254</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">(Loss) Income from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zr4APB0CFLod" title="(Loss) Income from operations" style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="From2023-10-012023-12-31_custom_MedicalEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-8208">993</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z9gsBrxFZm04" title="(Loss) Income from operations" style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="From2023-10-012023-12-31_custom_ManagementOfDiagnosticImagingCentersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8209">5,878</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20231001__20231231_zfjpYB9v3j6j" title="(Loss) Income from operations" style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8210">4,885</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zEre8Aww9Vie" title="Depreciation and amortization" style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-10-012023-12-31_custom_MedicalEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8211">60</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zxaE3s6mMBdj" title="Depreciation and amortization" style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-10-012023-12-31_custom_ManagementOfDiagnosticImagingCentersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8212">1,160</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20231001__20231231_zYSMpu46ZV3f" title="Depreciation and amortization" style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8213">1,220</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Capital expenditures</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zupZNmxdrKm8" title="Capital expenditures" style="text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2023-10-012023-12-31_custom_MedicalEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8214">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zyLNYP99ULt5" title="Capital expenditures" style="text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2023-10-012023-12-31_custom_ManagementOfDiagnosticImagingCentersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8215">129</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20231001__20231231_zQmfrNSPnb29" title="Capital expenditures" style="text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8216">133</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">For the three months ended Dec. 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net revenues from external customers</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--Revenues_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zFxznI4734b1" title="Net revenues from external customers" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-10-012022-12-31_custom_MedicalEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8217">2,035</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zGekRqiHTlgd" title="Net revenues from external customers" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-10-012022-12-31_custom_ManagementOfDiagnosticImagingCentersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8218">22,221</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--Revenues_pn3n3_c20221001__20221231_zw6mZEGuNPqf" title="Net revenues from external customers" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8219">24,256</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Inter-segment net revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_ecustom--IntersegmentNetRevenues_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zvdYFhwzc9jk" title="Inter-segment net revenues" style="text-align: right"><ix:nonFraction name="FONR:IntersegmentNetRevenues" contextRef="From2022-10-012022-12-31_custom_MedicalEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8220">245</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--IntersegmentNetRevenues_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z09BirmDHQ28" title="Inter-segment net revenues" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1550">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--IntersegmentNetRevenues_pn3n3_c20221001__20221231_zGwXA4Fbz9da" title="Inter-segment net revenues" style="text-align: right"><ix:nonFraction name="FONR:IntersegmentNetRevenues" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8221">245</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">(Loss) Income from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_z51YjY3T50Ie" title="(Loss) Income from operations" style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="From2022-10-012022-12-31_custom_MedicalEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-8222">551</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zmV8AdnXmUV8" title="(Loss) Income from operations" style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="From2022-10-012022-12-31_custom_ManagementOfDiagnosticImagingCentersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8223">4,783</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20221001__20221231_zqQwVfraq8jf" title="(Loss) Income from operations" style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8224">4,232</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_z2XDFJA5yQBg" title="Depreciation and amortization" style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-10-012022-12-31_custom_MedicalEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8225">65</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zRsocsNsD02k" title="Depreciation and amortization" style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-10-012022-12-31_custom_ManagementOfDiagnosticImagingCentersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8226">1,035</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20221001__20221231_zxyeiNq7Y1q7" title="Depreciation and amortization" style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8227">1,100</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Capital expenditures</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zFjPVnk45Ap2" title="Capital expenditures" style="text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2022-10-012022-12-31_custom_MedicalEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8228">50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zzq5tmVzjiHl" title="Capital expenditures" style="text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2022-10-012022-12-31_custom_ManagementOfDiagnosticImagingCentersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8229">423</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20221001__20221231_zMqTazUcDbfd" title="Capital expenditures" style="text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8230">473</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Medical <br/> Equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Management <br/> of Diagnostic <br/> Imaging <br/> Centers</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Totals</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left">For the six months ended Dec. 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Net revenues from external customers</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--Revenues_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zv1hxeQVrfgb" title="Net revenues from external customers" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-07-012023-12-31_custom_MedicalEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8231">3,917</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--Revenues_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zhGblQ8e47t9" title="Net revenues from external customers" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-07-012023-12-31_custom_ManagementOfDiagnosticImagingCentersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8232">47,307</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--Revenues_pn3n3_c20230701__20231231_zsrktXjJ68fi" title="Net revenues from external customers" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8233">51,224</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Inter-segment net revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--IntersegmentNetRevenues_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zTIZOHH4F1cf" title="Inter-segment net revenues" style="text-align: right"><ix:nonFraction name="FONR:IntersegmentNetRevenues" contextRef="From2023-07-012023-12-31_custom_MedicalEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8234">508</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_ecustom--IntersegmentNetRevenues_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z9bWZK6jBe96" title="Inter-segment net revenues" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1580">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--IntersegmentNetRevenues_pn3n3_c20230701__20231231_z4VKmEP61u15" title="Inter-segment net revenues" style="text-align: right"><ix:nonFraction name="FONR:IntersegmentNetRevenues" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8235">508</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">(Loss) Income from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_z6h1rbd7XwMe" title="(Loss) Income from operations" style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="From2023-07-012023-12-31_custom_MedicalEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-8236">1,731</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zyePHhZzZMie" title="(Loss) Income from operations" style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="From2023-07-012023-12-31_custom_ManagementOfDiagnosticImagingCentersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8237">13,187</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20230701__20231231_z0McvqgoVuL9" title="(Loss) Income from operations" style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8238">11,456</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zxmEVa14eGrj" title="Depreciation and amortization" style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-07-012023-12-31_custom_MedicalEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8239">121</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zxMsCziXPFJ8" title="Depreciation and amortization" style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-07-012023-12-31_custom_ManagementOfDiagnosticImagingCentersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8240">2,294</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20230701__20231231_z54OR3vVuP95" title="Depreciation and amortization" style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8241">2,415</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Capital expenditures</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zPQA3hOM7Iib" title="Capital expenditures" style="text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2023-07-012023-12-31_custom_MedicalEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8242">20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zdpsXMOLYsPg" title="Capital expenditures" style="text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2023-07-012023-12-31_custom_ManagementOfDiagnosticImagingCentersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8243">192</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20230701__20231231_zvy3SiQL5w2g" title="Capital expenditures" style="text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8244">212</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">For the six months ended Dec. 31, 2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net revenues from external customers</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--Revenues_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zdd5jVxctIxf" title="Net revenues from external customers" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-07-012022-12-31_custom_MedicalEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8245">3,913</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zBhKNZ7a00N4" title="Net revenues from external customers" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-07-012022-12-31_custom_ManagementOfDiagnosticImagingCentersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8246">43,534</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--Revenues_pn3n3_c20220701__20221231_zwhY0pR5Akvf" title="Net revenues from external customers" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8247">47,447</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Inter-segment net revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_ecustom--IntersegmentNetRevenues_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zoffHxamlESl" title="Inter-segment net revenues" style="text-align: right"><ix:nonFraction name="FONR:IntersegmentNetRevenues" contextRef="From2022-07-012022-12-31_custom_MedicalEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8248">490</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--IntersegmentNetRevenues_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z6z2QJQnYWkk" title="Inter-segment net revenues" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1610">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_ecustom--IntersegmentNetRevenues_pn3n3_c20220701__20221231_zESpkKwQXykg" title="Inter-segment net revenues" style="text-align: right"><ix:nonFraction name="FONR:IntersegmentNetRevenues" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8249">490</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">(Loss) Income from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zPF7z4Z6W2Lh" title="(Loss) Income from operations" style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="From2022-07-012022-12-31_custom_MedicalEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-8250">1,353</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zPpoBpVgKqok" title="(Loss) Income from operations" style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="From2022-07-012022-12-31_custom_ManagementOfDiagnosticImagingCentersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8251">9,496</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20220701__20221231_zPYFCNc56th3" title="(Loss) Income from operations" style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8252">8,143</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zPIFykb6hMId" title="Depreciation and amortization" style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-07-012022-12-31_custom_MedicalEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8253">137</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z8cmlHzT5sL8" title="Depreciation and amortization" style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-07-012022-12-31_custom_ManagementOfDiagnosticImagingCentersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8254">2,081</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20220701__20221231_zMfkSiLXdYP6" title="Depreciation and amortization" style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8255">2,218</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Capital expenditures</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zpEqtkQ7HQ93" title="Capital expenditures" style="text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2022-07-012022-12-31_custom_MedicalEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8256">74</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zGdkIlgc0f17" title="Capital expenditures" style="text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2022-07-012022-12-31_custom_ManagementOfDiagnosticImagingCentersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8257">1,362</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20220701__20221231_z2Enb1MPBt7l" title="Capital expenditures" style="text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8258">1,436</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table>



</ix:nonNumeric><p id="xdx_8AF_z37NdTvkcvD9" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 20; Value: 2 -->
    <div id="xdx_238_zNpmfytmzssh" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div id="xdx_232_zkWB87Xj4Pl4" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_z4Usp9ch9YBf" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zAh5QkNl6fK1" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zW8C7NUYmy3h" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_231_z2JPV6XNBdAh" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">DECEMBER 31, 2023 and 2022</p></ix:exclude>

<ix:exclude><p id="xdx_231_zLsbaaFWjYK8" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Amounts and shares in thousands, except
per share amounts)</p></ix:exclude>

<ix:exclude><p id="xdx_239_zroifxZMXsz2" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(UNAUDITED)</p></ix:exclude>

<ix:exclude><p id="xdx_233_zkcDzLJT9mbd" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-5665"><p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zHWnZ22CaqHa" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">NOTE 9 &#8211; <span id="xdx_82C_zQvkvwl2vwv3">RELATED PARTY TRANSACTION</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">On December 31, 2023, the Company entered into an agreement
with Magnetic Resonance Management, LLC (&#8220;MRM&#8221;) for the sale of a MRI scanner. MRM is owned by the CEO and President of
the Company. The sales price of the equipment was $<span id="xdx_900_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20231231__us-gaap--TypeOfArrangementAxis__custom--MagneticResonanceManagementMember_zfzvHax66Pfi" title="Sale of price of the equipment"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2023-12-31_custom_MagneticResonanceManagementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8259">577</ix:nonFraction> </span>which
is payable based upon a promissory note dated December 1, 2023. The note bears interest at a rate of <span id="xdx_905_eus-gaap--DerivativeFixedInterestRate_iI_dp_c20231231__us-gaap--TypeOfArrangementAxis__custom--MagneticResonanceManagementMember_zNADqpJm70He" title="Bears interest rate"><ix:nonFraction name="us-gaap:DerivativeFixedInterestRate" contextRef="AsOf2023-12-31_custom_MagneticResonanceManagementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8260">9</ix:nonFraction></span>%
and is payable in full at the maturity of the note in December 2028. The MRI scanner had zero  basis,which resulted ina gain of
$<span id="xdx_901_ecustom--GainOnSaleOfEquipmentsRelatedParty_pn3n3_c20230701__20231231__us-gaap--TypeOfArrangementAxis__custom--MagneticResonanceManagementMember_zD3aBtiEar0h" title="Gain on sale of equipments"><ix:nonFraction name="FONR:GainOnSaleOfEquipmentsRelatedParty" contextRef="From2023-07-012023-12-31_custom_MagneticResonanceManagementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8261">577</ix:nonFraction></span>.
The Company has the option but not the obligation to re-take possession of the scanner in lieu of payment upon maturity of the
note.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="ixv-5674"><p id="xdx_80D_eus-gaap--CashFlowSupplementalDisclosuresTextBlock_zMUapTuqk1c7" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">NOTE 10 &#8211; <span id="xdx_82C_z0YpBtiGdf95">SUPPLEMENTAL CASH FLOW INFORMATION</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December
31, 2023 and December 31, 2022, the Company paid $<span id="xdx_908_eus-gaap--InterestPaidNet_pn3n3_c20230701__20231231_zIq5hehxG7zg" title="Interest paid"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8262">58</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--InterestPaidNet_pn3n3_c20220701__20221231_zSYfYY2p5XS4" title="Interest paid"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8263">27</ix:nonFraction></span> for interest, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December
31, 2023 and December 31, 2022, the Company paid $<span id="xdx_908_eus-gaap--IncomeTaxesPaid_pn3n3_c20230701__20231231_zMiNrxfLyRtg" title="Income taxes paid"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8264">150</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--IncomeTaxesPaid_pn3n3_c20220701__20221231_zZXAhzt0DVWa" title="Income taxes paid"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8265">647</ix:nonFraction></span> for income taxes, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-5686"><p id="xdx_80C_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zvzBqLcHjQo1" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">NOTE 11 &#8211; <span id="xdx_82C_zFbmrWQyLhwi">COMMITMENTS AND CONTINGENCIES</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Litigation</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is subject to legal proceedings
and claims arising from the ordinary course of its business, including personal injury, customer contract and employment claims.
In the opinion of management, the aggregate liability, if any, with respect to such actions, will not have a material adverse effect
on the consolidated financial position or results of operations of the Company.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">There were no material changes in litigation
from that reported in our Form 10-K for the fiscal year ended June 30, 2023.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Other Matters</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 13, 2022, the Company adopted
a stock repurchase plan. The plan has no expiration date and cannot determine the number of shares which will be repurchased. On
September 26, 2022, the Board of Directors has approved up to $<span id="xdx_906_eus-gaap--StockRepurchaseProgramAuthorizedAmount1_iI_pn6n6_c20220926_zHN5t317jN9i" title="Stock purchase plan"><ix:nonFraction name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="AsOf2022-09-26" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD" id="ixv-8266">9</ix:nonFraction></span> million to be repurchased under the plan which will be purchased
on the publicly traded open market at prevailing prices. During the six months ended December 31, 2023 and 2022, the Company repurchased
<span id="xdx_905_eus-gaap--StockRepurchasedDuringPeriodShares_pn3n3_c20230701__20231231_zyBLqJfRvmEf" title="Number of shares repurchased"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8267">116</ix:nonFraction></span> and <span id="xdx_907_eus-gaap--StockRepurchasedDuringPeriodShares_pn3n3_c20220701__20221231_zzCeEy7DCR7f" title="Number of shares repurchased"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8268">30</ix:nonFraction></span> shares at a cost of $<span id="xdx_908_eus-gaap--StockRepurchasedDuringPeriodValue_pn3n3_c20230701__20231231_ze00iQh7Hz73" title="Number of shares repurchased, value"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8269">1,885</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--StockRepurchasedDuringPeriodValue_pn3n3_c20220701__20221231_z4sW2ojJs1Wb" title="Number of shares repurchased, value"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8270">478</ix:nonFraction></span>, respectively. The Company cancelled <span id="xdx_909_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_pn3n3_c20230701__20231231_zJ9Ojs9M54E2" title="Shares cancelled"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8271">123</ix:nonFraction></span> shares and <span id="xdx_906_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_pn3n3_c20220701__20221231_zRey31O42mqg" title="Shares cancelled"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares" id="ixv-8272">16</ix:nonFraction></span> shares at a cost of $<span id="xdx_905_eus-gaap--StockRepurchasedAndRetiredDuringPeriodValue_pn3n3_c20230701__20231231_z3F898iE26M3" title="Shares cancelled"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8273">2,005</ix:nonFraction></span>
and $<span id="xdx_90C_eus-gaap--StockRepurchasedAndRetiredDuringPeriodValue_pn3n3_c20220701__20221231_z4GUJKnBOll8" title="Shares cancelled"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8274">402</ix:nonFraction></span> for the six months ended December 31, 2023 and 2022, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company maintains a self-funded
health insurance program with a stop-loss umbrella policy with a third party insurer to limit the maximum potential liability for
individual claims to $<span id="xdx_90F_ecustom--StoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims_pn3n3_c20230701__20231231_zepMfctlFoL9" title="Liability for individual claims"><ix:nonFraction name="FONR:StoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8275">150</ix:nonFraction></span> per person and for a maximum potential claim liability based on member enrollment. With respect to this
program, the Company considers historical and projected medical utilization data when estimating its health insurance program liability
and related expense. As of December 31, 2023 and June 30, 2023, the Company had approximately $<span id="xdx_905_eus-gaap--LiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth_iI_pn3n3_c20231231_zJtH6cAEXXOa" title="Reserve for self-funded"><ix:nonFraction name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8276">86</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--LiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth_iI_pn3n3_c20230630_zmnSW29S6X4j" title="Reserve for self-funded"><ix:nonFraction name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8277">101</ix:nonFraction></span>, respectively, in reserve
for its self-funded health insurance programs. The reserves are included in &#8220;Other current liabilities&#8221; in the condensed
consolidated balance sheets.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23D_zzbvvFHWrFv8" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 21; Value: 2 -->
    <div id="xdx_231_z5zKzG8yHZq6" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div id="xdx_238_zzpEqrby0Vgk" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zzevCQndfnFk" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zD0mUIjCpGg4" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p></ix:exclude>

<ix:exclude><p id="xdx_235_zAm3vcfNgR5f" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_235_z6tCLtw1p3Q" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">DECEMBER 31, 2023 and 2022</p></ix:exclude>

<ix:exclude><p id="xdx_239_zrI18iYZYqfk" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Amounts and shares in thousands, except
per share amounts)</p></ix:exclude>

<ix:exclude><p id="xdx_230_zEVVRG3sVSP2" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(UNAUDITED)</p></ix:exclude>

<ix:exclude><p id="xdx_239_zdqWNJzvFTSi" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zBtGa3a8EzMd" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">NOTE 11 &#8211; COMMITMENTS AND CONTINGENCIES (CONTINUED)</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zf6RyIkxvLf2" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zH4xN812wgT5" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Other Matters - Continued</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zVu1ZO6NvcP5" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company regularly analyzes its reserves
for incurred but not reported claims, and for reported but not paid claims related to its reinsurance and self-funded insurance
programs. The Company believes its reserves are adequate. However, significant judgment is involved in assessing these reserves
such as assessing historical paid claims, average lags between the claims&#8217; incurred date, reported dates and paid dates,
and the frequency and severity of claims. There may be differences between actual settlement amounts and recorded reserves and
any resulting adjustments are included in expense once a probable amount is known. There were no significant adjustments recorded
in the periods covered by this report.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-5745"><p id="xdx_805_eus-gaap--IncomeTaxDisclosureTextBlock_z9PIY1Vi0NYh" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">NOTE 12 - <span id="xdx_82A_zgbJBS8rTg9b">INCOME TAXES</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 740-270, &#8220;Income
Taxes &#8211; Interim Reporting&#8221;, the Company is required at the end of each interim period to determine the best estimate
of its annual effective tax rate and apply that rate to year-to-date ordinary income or loss. The resulting tax expense (or benefit)
is adjusted for the tax effect of specific events, if any, required to be discretely recognized in the interim period as they occur.
For the six months ended December 31, 2023 and 2022, the Company recorded income tax expense of $<span id="xdx_907_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_pn3n3_c20230701__20231231_z77gKMqvDt4" title="Income tax expense"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8278">3,036</ix:nonFraction></span> in 2023 as compared to $<span id="xdx_908_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_pn3n3_c20220701__20221231_z8TUAeevUDu6" title="Income tax expense"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" contextRef="From2022-07-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8279">2,871</ix:nonFraction></span>
in 2022. For the three months ended December 31, 2023 and 2022, the Company recorded income tax expense of $<span id="xdx_90E_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_pn3n3_c20231001__20231231_z8UrFTQw6Pr1" title="Income tax expense"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8280">1,366</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_pn3n3_c20221001__20221231_zsEqBUD1dJfl" title="Income tax expense"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8281">1,462</ix:nonFraction></span> respectively.
The six month and three month 2023 provision is comprised of a current income tax component of $<span id="xdx_900_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_c20230701__20231231_z7SZpscRnZs8" title="Income tax component - current"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8282">751</ix:nonFraction></span> and a deferred income tax component
of $<span id="xdx_906_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_c20230701__20231231_zABWvBKGT7Ai" title="Income tax component - deferred"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8283">2,285</ix:nonFraction></span> and a current income tax component of $<span id="xdx_903_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_c20231001__20231231_z5e5nTcgNSle" title="Income tax component - current"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8284">323</ix:nonFraction></span> and a deferred income tax component of $<span id="xdx_90B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_c20231001__20231231_zU1Tpt0sz2gf" title="Income tax component - deferred"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2023-10-012023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8285">1,043</ix:nonFraction></span> respectively. Obligations for
any liability associated with the current income tax provision, has been reduced, primarily resulting from the benefits and utilization
of net operating loss carryforwards.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC Topic 740 prescribes a recognition
threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected
to be taken in a corporate tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained
upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the
benefit recognized and measured pursuant to the interpretation are referred to as unrecognized benefits. A liability is recognized
(or amount of net operating loss carryforward or amount of tax refundable is reduced) for an unrecognized tax benefit because it
represents an enterprise&#8217;s potential future obligation to the taxing authority for a tax position that was not recognized
as a result of applying the provisions of ASC Topic 740. The Company believes there are no uncertain tax positions in prior year
tax filings and therefore it has not recorded a liability for unrecognized tax benefits.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC Topic 740, interest
costs related to unrecognized tax benefits are required to be calculated (if applicable) and would be classified as &#8220;Interest
expense, net&#8221;. Penalties if incurred would be recognized as a component of &#8220;Selling, general and administrative&#8221;
expenses.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company files corporate income tax
returns in the United States (federal) and in various state and local jurisdictions. In most instances, the Company is no longer
subject to federal, state and local income tax examinations by tax authorities for years prior to 2018.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_234_zgiuMfA8NuZ" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 22; Value: 2 -->
    <div id="xdx_232_z00aFW1XRzI2" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div id="xdx_23D_zshIENJFsxE5" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zuFWiHuQSnnj" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zmkeLUdiJj37" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zA3NCCJAQD4b" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_23F_z13jh7AVyi88" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">DECEMBER 31, 2023 and 2022</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zLbBjXBOcP8l" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Amounts and shares in thousands, except
per share amounts)</p></ix:exclude>

<ix:exclude><p id="xdx_239_zVDD0GKKmRoh" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(UNAUDITED)</p></ix:exclude>


<ix:exclude><p id="xdx_235_zSjpWTnCHD8d" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zFdpxZQL2KQf" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 12 - INCOME TAXES (CONTINUED)</p></ix:exclude>

<ix:exclude><p id="xdx_232_zoqC4V5dMhff" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded a deferred tax
asset of $<span id="xdx_904_eus-gaap--DeferredTaxAssetsNet_iI_pn3n3_c20231231_zJPrUJmNilga" title="Deferred tax asset"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8286">7,758</ix:nonFraction></span> and a deferred tax liability of $<span id="xdx_901_eus-gaap--DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityPolicyholdersSurplus_iI_pn3n3_c20231231_zCECO4hJ1tG3" title="Deferred tax liability"><ix:nonFraction name="us-gaap:DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityPolicyholdersSurplus" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-8287">395</ix:nonFraction></span> as of December 31, 2023, primarily relating to allowance for doubtful accounts
and tax credits. The net operating losses begin to expire in 2028 for federal tax and state income tax purposes. The Company anticipates
that their Federal operating loss will be utilized in the current fiscal year.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Future ownership changes as determined
under Section 382 of the Internal Revenue code could further limit the utilization of net operating loss carryforwards. As of December
31, 2023, no such changes in ownership have occurred.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Inflation Reduction Act (&#8220;IRA&#8221;)
was enacted on August 16, 2022. The IRA includes provisions imposing a 1% excise tax on share repurchases that occur after December
31, 2022 and introduces a <span id="xdx_90E_ecustom--CorporateAlternativeMinimumTaxPercentage_dp_c20230701__20231231_z1lnHxfgDlI1" title="Corporate alternative minimum tax percentage"><ix:nonFraction name="FONR:CorporateAlternativeMinimumTaxPercentage" contextRef="From2023-07-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8288">15</ix:nonFraction></span>% corporate alternative minimum tax (&#8220;CAMT&#8221;) on adjusted financial statement income. The
CAMT will be effective for tax years beginning after December 31, 2022. Currently, the Company is expecting the IRA not to have
a material impact to the Company&#8217;s financial statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The ultimate realization of deferred tax assets is dependent on the generation
of future taxable income during the periods in which those temporary differences become deductible or when such net operating losses can
be utilized. The Company considers projected future taxable income, the regulatory environment of the industry and tax planning strategies
in making this assessment. At present, the Company believes that it is more likely than not that the benefits from certain deferred tax
asset carryforwards, will not all be fully realized. In recognition of this inherent risk, a valuation allowance was established for separate
state net operating losses that are not expected to be fully utilized. A valuation allowance will be maintained until sufficient positive
evidence exists to support the reversal of the remainder of the valuation.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2023-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-5801"><p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_z6fCf5UJhFC8" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 13 &#8211; <span id="xdx_822_ze5k9iU8ZZ5j">SUBSEQUENT EVENTS</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated events that
occurred subsequent to December 31, 2023 and through the date the condensed consolidated financial statements were issued.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During February 2024, the Company signed
an amendment to a property lease for its principal office in Melville, New York. The agreement extends the term of the lease until
November 2033.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><p id="xdx_818_zOya1grg7d7l" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="a_008"></span>Item 2. &#8211; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The following discussion
and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed financial
statements and notes thereto included in Part I, item 1 of the Quarterly Report on Form 10-Q and with our audited consolidated
financial statements and notes thereto for the year ended June 30, 2023 included in our Annual Report on Form 10-K for the fiscal
year ended June 30, 2023 filed with the U.S. Securities and Exchange Commission (SEC) on September 28, 2023.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Forward Looking Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Certain statements made in this
Quarterly Report on Form 10-Q are &#8220;forward-looking statements&#8221; (within the meaning of the Private Securities Litigation Reform
Act of 1995) regarding the plans and objectives of Management for future operations. Such statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future
results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included
herein are based on current expectations that involve numerous risks and uncertainties. Our plans and objectives are based, in part, on
assumptions involving the expansion of business. Assumptions relating to the foregoing involve judgments with respect to, among other
things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to
predict accurately and many of which are beyond our control. Although we believe that our assumptions underlying the forward-looking statements
are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the forward-looking statements
included in this Report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statement
included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives
and plans will be achieved.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">For the six month
period ended December 31, 2023, we reported a net income of $10.0 million on revenues of $51.2 million as compared to net income
of $5.5 million on revenues of $47.4 million for the six month period ended December 31, 2022. Operating income increased from
$8.1 million for the six month period ended December 31, 2022 to $11.5 million for the six month period ended December 31, 2023.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">For the three month
period ending December 31, 2023, we reported a net income of $4.6 million on revenues of $25.4 as compared to net income of $2.8
on revenues of $24.3 million for the three month period ended December 31, 2022.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The revenue increase,
from $47.4 million for the first six months of fiscal 2023 to $51.2 million for the first six months of fiscal 2024, was primarily
due to increases in patient fee revenue of $3.7 million, from $13.2 million<span style="color: red"> </span>for the first six months
of fiscal 2023 to $16.9 million for the first six months of fiscal 2024. Revenues from product sales and service and repair fees
remained constant at $3.9 million for the first six months of fiscal 2023 and for the first six months of fiscal 2024.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The revenue increase,
from $24.3 million for the three month period ending December 31, 2022 to $25.4 million for the three month period ending December
31, 2023 was also primarily due to increases in patient fee revenue of $1.1 million, from $7.1 million for the three month period
ending December 31, 2022 to $8.2 million for the three month period ending December 31, 2023.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">While our revenues
increased, our costs and expenses increased at a lower rate resulting in our operating income increasing to $11.5 million for the
six months ended December 31, 2023 as compared to $8.1 million for the six months ended December 31, 2022. In terms of percentages,
costs and expenses increased 1.2% to $39.8 million for the first six months of fiscal 2024 as compared to $39.3 million for the
first six months of fiscal 2023, while revenues increased 8.0%, from $47.4 million for the first six months of fiscal 2023 to $51.2
million for the first six months of fiscal 2024.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Fonar&#8217;s wholly
owned subsidiary, Health Management Corporation of America (&#8220;HMCA&#8221;), has the controlling interest in Health Diagnostics
Management, LLC (&#8220;HDM&#8221;). HMCA presently has a direct ownership interest of 70.8% in HDM, and the investors in HDM have
a 29.2% ownership interest. The management of the diagnostic imaging centers business segment is being conducted by HDM, operating
under the name &#8220;Health Management Company of America&#8221;. For the sake of simplicity, HMCA, and HDM are referred to as
&#8220;HMCA&#8221;, unless otherwise indicated.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The lingering effects
of the COVID-19 pandemic continue to impact our business in fiscal 2024. Mask mandates are returning to public hospitals in New
York City, and we must remain prepared to respond to changing guidance from regulatory authorities. This is by no means a problem
confined to our Company, but the impact on<span style="color: red"> </span>our results of operations and financial condition is
potentially volatile and severe.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Although we are unable
to predict if there will be additional consequences on our operations from the continuing global pandemic of COVID-19, the Company
believes with its positive cash flows, low debt and cash on hand, it will be able to continue operations going forward.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">During the first
half of fiscal 2024, the aggregate number of scans performed by the sites we manage or own increased to 101,990 scans from 89,888
scans in the first half of fiscal 2023. This increase was due to the opening of a new stand-alone facility in Florida along with
our return to a full operating schedule after addressing our technologist staffing shortfall.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Results of Operations</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We operate in two
industry segments: the manufacture and servicing of medical (MRI) equipment, which is conducted by Fonar, and diagnostic facilities
management services, which is conducted through HMCA.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Manufacturing and Service of MRI Equipment</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Revenues from MRI
product sales increased to $219,000 for the first six months of fiscal 2024 from $200,000 for the first six months of fiscal 2023.
Costs related to product sales increased from $383,000 for the six month period ended December 31, 2022 to $405,000 for the six
month period ended December 31, 2023. Economic uncertainty and lower reimbursement rates for MRI scans, have depressed the market
for our MRI scanner products, notwithstanding our scanners&#8217; unique technological capabilities (e.g., multi positional scanning).
Due to the low sales volumes of our MRI product, period to period comparisons are not necessarily indicative of any trends.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Service revenues
remained constant at $3.7 million for the six month period ended December 31, 2023 and the six month period ended December 31,
2022.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Costs relating to
providing service were $1.7 million in the first six months of fiscal 2024 and $1.5 million in the first six months of fiscal 2023.
Because of our ability to monitor the performance of customers&#8217; scanners from our facilities in Melville, New York on a daily
basis and to detect and repair any irregularities before more serious and costly problems develop, we have been able to contain
our costs of providing service.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Foreign revenues
remained constant at $263,000 for the first six months of fiscal 2024 and for the first six months of fiscal 2023. We do not regard
this as a material trend, but as part of a normal although sometimes volatile variation resulting from low volumes of foreign sales.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We recognize MRI
scanner sales revenues on the &#8220;percentage of completion&#8221; basis, which means the revenues are recognized as the scanner
is manufactured. Revenues recognized in a particular quarter do not necessarily reflect new orders or progress payments made by
customers in that quarter. We build the scanner as the customer meets certain benchmarks in site preparation and our installation
of the scanner, in order to minimize the time lag between incurring costs of manufacturing and our receipt of the cash progress
payments from the customer which are due upon delivery. Consequently, there can be a disparity between the revenues recognized
in a fiscal period and the number of product sales. Generally, the revenues from a scanner sale are recognized in a fiscal quarter
or quarters following the quarter in which the sale was made.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Revenues for the
medical equipment segment remained constant at $3.9 million for the first six months of fiscal 2024 and for the first six months
of fiscal 2023. Operating losses for our medical equipment segment increased to an operating loss of $1.7 million, for the first
six months of fiscal 2024 as compared to an operating loss of $1.4 million for the first six months of fiscal 2023.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Diagnostic Facilities Management Services</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">HMCA revenues increased
in the first six months of fiscal 2024 by 8.7% to $47.3 million from $43.5 million for the first six months of fiscal 2023. The
percentage of our revenues derived from our diagnostic facilities management segment relative to the percentage of our total revenues
increased slightly to 92.4% for the first six months of fiscal 2024, from 91.8% for the first six months of fiscal 2023.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The number of scans
performed at our centers and at our clients&#8217; centers has recovered to pre-COVID-19 levels and has increased from approximately
90,000 in the first six months of fiscal 2023 to approximately 102,000 in the first six months of fiscal 2024. The increase in
scans was due to the additional of a new stand-alone facility which opened in Florida, as well as our investment in software to
enhance the quality of MRI images and enable the reduction of MRI scan times.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We now manage or
own a total of 42 MRI scanners. Twenty-five (25) MRI scanners are located in New York and seventeen (17) are located in Florida.
HMCA experienced an operating income of $13.2 million for the first six months of fiscal 2024 compared to operating income of $9.5
million for the first six months of fiscal 2023.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The ability of HMCA
to maintain its profitability is principally due to HMCA&#8217;s success in marketing the scanning services of the facilities managed
or owned by HMCA, notwithstanding the decrease in reimbursement rates paid for MRI scans by insurers, Medicare and other government
programs. The reductions in reimbursement rates are not unique to HMCA or HMCA&#8217;s clients but are being experienced by the
industry in general.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">HMCA&#8217;s cost
of revenues for the first six months of fiscal 2024 increased to $26.4 million as compared to $23.8 million for the first six months
of fiscal 2023.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Consolidated</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">For the first six
months of fiscal 2024, our consolidated net revenues increased by 8.0% to $51.2 million from $47.4 million for the first six months
of fiscal 2023, and total costs and expenses increased by 1.2% to $39.8 million from the first six months of fiscal 2024 as compared
to $39.3 million for the first six months of fiscal 2023 respectively. As a result, our operating income increased to $11.5 million
in the first six months of fiscal 2024 as compared to $8.1 million in the first six months of fiscal 2023. A decrease in selling,
general and other administrative costs in particular resulted in cost and expenses increase at a much lower percentage as compared
to the increase in net revenues.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Selling, general
and administrative expenses decreased to $10.5 million in the first six months of fiscal 2024 from $12.9 million in the first six
months of fiscal 2023. This decrease in selling, general and administrative expenses was due mainly to less reserves taken on management
fees. Some of these reserves had been taken in the ordinary course of business and some in connection with the impact of the COVID-19
virus.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Research and development
expenses increased by 27.8% to $883,000 for the first six months of fiscal 2024 from $691,000 for the first six months of fiscal
2023.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Interest expense
in the first six months of fiscal 2024 increased by 116.2% to $58,000 from $27,000 in the first six  months of fiscal 2023.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Inventories increased
to $2.8 million at December 31, 2023 as compared to $2.6 million at June 30, 2023.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Net management fee
and medical receivables increased by 7.3% to $71.2 million at December 31, 2023 from $66.3 million at June 30, 2023 as a result
of slower collections and increased scan volume. The slower collections were primarily due to an increase in no-fault and workers&#8217;
compensation revenue, which typically takes longer to collect.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The results of operations
for the first six months of fiscal 2024 reflect an increase in revenues from management, patient and other fees, as compared to
the first six months of fiscal 2023 ($47.3 million for the first six months of fiscal 2024 as compared to $43.5 million for the
first six months of fiscal 2023), coupled with a smaller increase in the total cost and expenses ($39.8 million for the first six
months of fiscal 2024 as compared to $39.3 million for the first six months of fiscal 2023). Revenues were 7.6% from the MRI equipment
segment and 92.4% from HMCA, for the first six months of fiscal 2024, as compared to 8.2% from the MRI equipment segment and 91.8%
from HMCA for the first six months of fiscal 2023.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">As a result of the
Patient Protection and Affordable Care Act (PPACA) we have experienced a reduction of reimbursement rates and less interest in
our MRI equipment. Any changes to the PPACA may result in further changes in the healthcare industry and our business.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We are committed
to improving our operating results and dealing with the challenges posed by legislative and regulatory requirements. Nevertheless,
factors beyond our control, such as the COVID-19 virus, the timing and rate of market growth, economic conditions, the availability
of credit and payor reimbursement rates, or unexpected expenditures and the timing of such expenditures, make it difficult to forecast
future operating results.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">As mentioned, one
of the effects of the PPACA on our business has been the reduction in Medicare reimbursement rates for MRI scans. This also has
resulted in a reduction in the reimbursement rates by commercial insurers and government programs which tie their reimbursement
rates to the Medicare rates. Nevertheless, the patient volume of the scanning centers we manage or own has enabled us to maintain
healthy operating results in spite of these challenges. We believe we are pursuing the correct policies to cope with these problems
and to improve the Company&#8217;s operating results.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our Upright&#174;
MRI (also referred to as the Stand-Up&#174; MRI), together with our works-in-progress, are intended to significantly improve our
competitive position.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Upright&#174;
MRI scanner, which operates at 6000 gauss (.6 Tesla) field strength, allows patients to be scanned while standing, sitting, reclining
and in multiple flexion and extension positions. It is common in visualizing the spine that abnormalities are visualized in some
positions and not others. This enables surgical corrections that heretofore would not have been addressable for lack of visualizing
the symptom causing the pathology and therefore, in general enables the treating physician to achieve a better treatment outcome
for his patient. A floor-recessed elevator brings the patient to the height appropriate for the targeted image region. A custom-built
multi-position adjustable bed will allow patients to sit or lie on their backs, sides or stomachs at any angle. This allows the
MRI technologist to ask the patient to position himself/herself in the exact position that generates his/her pain so that images
of the patient in the position that explicitly generates the patient&#8217;s pain can be nailed down. Full-range-of-motion studies
of the joints in virtually any direction are possible, a particularly promising feature for sports injuries.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Liquidity and Capital
Resources</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Cash and cash equivalents,
and short term investments increased from $51.3 million at June 30, 2023 to $53.2 million at December 31, 2023.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Cash provided by operating activities for the first six months of fiscal
2024 was $6.7 million. Cash provided by operating activities was attributable principally to net income of $10.0 million, depreciation
and amortization of $2.4 million, amortization on right-to-use assets of $2.1 million, and deferred income tax of $2.3 million, offset
by an increase in accounts, management fee receivables and medical receivables of $5.0 million, a decrease of operating lease liabilities
of $2.3 million and a decrease in other current liabilities of $2.3 million.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 34.05pt">Cash used in investing activities for
the first six months of fiscal 2024 was $212,000. Cash used<span style="color: red"> </span>in investing activities during the
first six months of fiscal 2024 consisted<span style="color: red"> </span>of patent costs of $20,000 and the purchase of property
and equipment of $192,000.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Cash used in financing
activities for the first six months of fiscal 2024 was $4.5 million. The principal uses of cash in financing activities during
the first six months of fiscal 2024 were the repayment of principal on long-term debt and capital lease obligations of $21,000,
the purchase of treasury stock of $1.9 million and distributions to non-controlling interests of $2.6 million.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Total liabilities decreased by 7.6% to $46.0 million at December 31, 2023 from
$49.8 million at June 30, 2023. &#8220;Other&#8221; current liabilities decreased by 36.4% to $3.5 million at December 31, 2023 from $5.4
million at June 30, 2023. The current portion of our service contract liabilities increased by 0.7% to $3.9 million at December 31, 2023
as compared to $3.8 million at June 30, 2023. The current portion of operating lease liability increased from $3.9 million at June 30,
2023 to $4.7 million at December 31, 2023.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">As of December 31,
2023, the total of $3.5 million in &#8220;other&#8221; current liabilities included accrued salaries and payroll taxes of $2.1
million, sales taxes payable of $222,000 and other general and administrative expenses of $809,000.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our working capital
increased to $118.4 million at December 31, 2023 from $110.0 million at June 30, 2023. This resulted from an increase in current
assets ($125.7 million at June 30, 2023 as compared to $132.5 million at December 31, 2023), and a decrease in current liabilities
from $15.6 million at June 30, 2023 to $14.1 million at December 31, 2023.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The ultimate realization of deferred tax assets is dependent on the generation
of future taxable income during the periods in which those temporary differences become deductible or when such net operating losses can
be utilized. The Company considers projected future taxable income, the regulatory environment of the industry, and tax planning strategies
in making this assessment. At the present, the Company believes that it is more likely than not that the benefits from certain deferred
tax asset carryforwards, will not all be fully realized. In recognition of this inherent risk, a valuation allowance was established for
separate state net operating losses that are not expected to be utilized. A valuation allowance will be maintained until sufficient positive
evidence exists to support the reversal of any portion or all of the valuation allowance.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company&#8217;s
effective income tax rate is based on expected income, statutory rates and tax planning opportunities available in the various
jurisdictions in which it operates. For interim financial reporting, the Company estimates the annual income tax rate based on
projected taxable income for the full year and records a quarterly income tax provision or benefit in accordance with the anticipated
annual rate. The Company refines the estimates of the year&#8217;s taxable income on a periodic basis as new information becomes
available, including actual year-to-date financial results. This continual estimation process often results in a change to the
expected effective income tax rate for the year. When this occurs, the Company adjusts the income tax provision during the quarter
in which the change in estimate occurs so that the year-to-date provision reflects the expected income tax rate. Significant judgment
is required in determining the effective tax rate and in evaluating tax positions.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Fonar is not committed
to making any significant capital expenditures for the remainder of the 2024 fiscal year.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Critical to our business
plan are the improvement and expansion of the MRI facilities managed or owned by HMCA, and increasing the number of scans performed
at those facilities. In addition, our business plan calls for a continuing commitment to providing our customers with enhanced
equipment service and maintenance capabilities and delivering state-of-the-art, innovative and high quality equipment and upgrades
at competitive prices.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In pursuit of those
goals, Fonar has entered into an agreement with AIRS Medical to install its SwiftMR&#8482; product on all Fonar Upright&#174; scanners
operating at the facilities HMCA owns or manages. Fonar will also make the AIRS SwiftMR&#8482; product available to the installed
base of Fonar scanners operating in the United States. The AIRS SwiftMR&#8482; product enhances image quality using AI-powered
denoising and sharpening. Management believes this product will improve the quality of the images produced by Fonar equipment,
including the scanners operated by HMCA facilities.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Management is seeking
to promote wider market recognition of Fonar&#8217;s scanner products, and to increase demand for Upright&#174; scanning at the
facilities HMCA owns or manages. Given the liquidity and credit constraints in the markets, the uncertainty resulting from the
Patient Protection and Affordable Care Act or its repeal or modification, and the impact of the COVID-19 virus on the economy in
general, the sale of medical equipment has and may continue to suffer.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">FONAR CORPORATION
AND SUBSIDIARIES</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company believes
that its business plan has been responsible for its profitability in the past nine consecutive fiscal years and first half quarter
of fiscal 2024, and that its capital resources will be adequate to support operations through at least February 14, 2025. The future
effects on our business of healthcare legislation, the 2.3% excise tax on sales of medical equipment, reimbursement rates, public
health conditions and the general economic and business climate are not known at the present time. Nevertheless, there is a possibility
of adverse consequences to our business operations from these causes. Although the Company cannot predict the full effect of COVID-19
for the first half or any later period, the Company believes that it has adequate revenues, cash reserves and other assets that
will enable it to continue to operate until at least February 14, 2025.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="a_009"></span>Item 3. Quantitative and Qualitative
Disclosures About Market Risk</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company maintains
its funds in liquid accounts. None of our investments are in fixed rate instruments.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">All of our revenue,
expense and capital purchasing activities are transacted in United States dollars.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="a_010"></span>Item 4. Controls and Procedures.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Disclosure Controls and Procedures</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We carried out an
evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, under the supervision and with the participation
of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation
of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934,
as amended (the &#8216;&#8216;Exchange Act&#8217;&#8217;). Disclosure controls and procedures include, without limitation, controls
and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits
under the Exchange Act is accumulated and communicated to the issuer&#8217;s management, including its principal executive and
principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required
disclosure. Based upon our evaluation, our chief executive officer and chief financial officer have concluded that the Company&#8217;s
disclosure controls and procedures were effective as of December 31, 2023, in ensuring that material information that we are required
to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the
same time periods specified in the Securities and Exchange Commission rules and forms.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Changes in Internal Control over Financial
Reporting</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">There were no changes
in our system of internal control over financial reporting during our most recently completed fiscal quarter that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="a_011"></span>PART II &#8211; OTHER INFORMATION</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_019"></span>Item 1 &#8211; Legal Proceedings: There were no material changes in litigation from that reported in our Form 10-K for the fiscal year ended June 30, 2023 and Form 10-Q for the fiscal quarter ended September 30, 2023. </span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="a_012"></span>Item 1A &#8211; Risk Factors: An investment
in the securities of the Company is subject to various risks, the most significant of which are summarized below.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">1. Reduced Reimbursement Rates. Most
of our revenues are derived from our scanning center business conducted by HMCA. Our scanning center clients and the Florida facilities
owned by HMCA are experiencing lower reimbursement rates from Medicare, other government programs and private insurance companies.
To the extent possible, we counter these reductions by increasing scanning volume and controlling operating expenses. Inflation
in the cost of both materials and labor have limited our ability to control our costs, negatively impacting our ability to maintain
profitability in this business segment.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">2. Inflation and Increasing Interest
Rates. Inflation has drastically increased our costs for both materials and labor. The Federal Reserve has increased interest rates
substantially in an attempt to control inflation, which in turn has increased the cost of capital. Diagnostic imaging facilities
require significant amounts of capital to operate, particularly in the context of opening new diagnostic imaging centers. These
increased costs make it more difficult to achieve organic growth and extend the time that a new center takes to achieve profitability.
Continued costs increases, coupled with reduced reimbursement rates may threaten the profitability of our current operations and
cause the cost of expansion to become prohibitively high.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">3. Demand for MRI Scanners. The reduced
reimbursement rates have a negative effect on our sales of MRI scanners. With lower revenue projections, prospective customers
would demand lower prices for scanners. Although the reduced reimbursements may not affect foreign demand, a lower number of sales
in the aggregate could reduce economies of scale and consequently, profit margins.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">4. Manufacturing Competition. Many if
not most of our competing scanner manufacturers have significantly greater financial resources, production capacity, and other
resources than we do. Such competitors would include General Electric, Siemens, Hitachi and Phillips. Although Fonar is the only
company which can manufacture and sell the unique Stand-Up&#174; (Upright&#174;) MRI scanner, potential customers must be convinced
that the purchase of a Fonar scanner is their best choice. We believe that with time, that objective will be reached, particularly
with customers scanning patients having neck, back, knee and various orthopedic issues who would benefit from being scanned in
weight-bearing positions.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">5. Dependence on Referrals. HMCA derives
substantially all of its revenue, directly or indirectly, from fees charged for the diagnostic imaging services performed at the
facilities. We depend on referrals of patients from unaffiliated physicians and other third parties to the facilities we manage
or own for the services we perform. If these physicians and other third parties were to reduce the number of patients they refer
or discontinue referring patients, scan volumes could decrease, which would reduce our net revenue and operating margins.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">6. Pressure to Control Healthcare Costs.
One of the principal objectives of health maintenance organizations and preferred provider organizations is to control the cost
of healthcare services. Healthcare providers participating in managed care plans may be required to refer diagnostic imaging tests
to certain providers depending on the plan in which a covered patient is enrolled. In addition, managed care contracting has become
very competitive. The expansion of health maintenance organizations, preferred provider organizations and other managed care organizations
in New York or Florida could have a negative impact on the utilization and pricing of services performed at the facilities HMCA
manages or owns to the extent these organizations exert control over patients&#8217; access to diagnostic imaging services, selections
of the provider of such services and reimbursement rates for those services.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">7. Scanning Facility Competition. The
market for diagnostic imaging services is highly competitive. The facilities we manage or own compete for patients on the basis
of reputation, location and the quality of diagnostic imaging services. Groups of radiologists, established hospitals, clinics
and other independent organizations that own and operate imaging equipment are the principal competitors.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">8. Eligibility Changes to Insurance
Programs. Due to potential decreased availability of healthcare through private employers, the number of patients who are uninsured
or participate in governmental programs may increase. Healthcare reform legislation will continue to increase the participation
of individuals in the Medicaid program in states that elect to participate in the expanded Medicaid coverage. A shift in payor
mix from managed care and other private payors to government payors or an increase in the number of uninsured patients may result
in a reduction in the rates of reimbursement or an increase in uncollectible receivables or uncompensated care, with a corresponding
decrease in net revenue. Policies now being offered under various insurance plans are expected to reduce demand for MRI scans as
they become less affordable. Changes in the eligibility requirements for governmental programs such as the Medicaid program and
state decisions on whether to participate in the expansion of such programs also could increase the number of patients who participate
in such programs and the number of uninsured patients. Even for those patients who remain in private insurance plans, changes to
those plans could increase patient financial responsibility, resulting in a greater risk of uncollectible receivables. These factors
and events could have a material adverse effect on our business, financial condition, and results of operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">9. Current and future changes in Florida
Insurance Law. On March 24, 2023, Florida Governor Ron DeSantis signed the Tort Reform Act. The bill makes sweeping changes to
Florida&#8217;s negligence laws.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">These changes will
negatively impact our Florida diagnostic imaging facilities (both those we own and those we manage) with more unpaid bills, and
lower reimbursement rates. The full extent of those reductions are unclear at this time.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">10. Federal and state privacy and information
security laws. We must comply with numerous federal and state laws and regulations governing the collection, dissemination, access,
use, security and privacy of PHI, including HIPAA and its implementing privacy and security regulations, as amended by the federal
HITECH Act. If we fail to comply with applicable privacy and security laws, regulations and standards, properly maintain the integrity
of our data, protect our proprietary rights to our systems, or defend against cybersecurity attacks, our business, reputation,
results of operations, financial position and cash flows could be materially and adversely affected.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Information security risks have significantly
increased in recent years because of the proliferation of new technologies, the use of the internet and telecommunications technologies
to conduct our operations, and the increased sophistication and activities of organized crime, hackers, terrorists and other external
parties, including foreign state agents. Our operations rely on the secure processing, transmission and storage of confidential,
proprietary and other information in our computer systems and networks.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">11. Other changes in Domestic and Worldwide
Economic Conditions. We are subject to risk arising from adverse changes in general domestic and global economic and other conditions,
including recessions or economic slowdowns, disruptions of credit markets and military conflicts. Turbulence and uncertainty in
the United States and international markets and economies may adversely affect our workforce, liquidity, financial condition, revenues,
profitability and business operations generally.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">FONAR CORPORATION AND SUBSIDIARIES</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="a_013"></span>Item 2 &#8211; Unregistered Sales of
Equity Securities and Use of Proceeds: None</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">In
September 2022, our Board of Directors authorized a program to repurchase up to $9 million of our common stock. Under this program,
we may purchase stock in the open market or through privately negotiated transactions in accordance with applicable securities
laws, including pursuant to pre-arranged stock trading plans. The timing and actual amount of the stock repurchases will depend
on several factors including price, capital availability, regulatory requirements, and other market conditions. We are not obligated
to repurchase a specific number of shares under this program and it may be modified, suspended or discontinued at any time. </span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The following
table summarizes the number of shares repurchased during the three months ended December 31, 2023:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="3" style="color: black; text-align: center">Fiscal Month</td><td style="color: black">&#160;</td>
    <td colspan="3" style="color: black; text-align: center">Total Number of Shares Purchased</td><td style="color: black">&#160;</td>
    <td colspan="3" style="color: black; text-align: center">Average Price Paid per Share</td><td style="color: black">&#160;</td>
    <td colspan="3" style="color: black; text-align: center">Total Number of Shares Purchased as Part of Publicly Announced Programs</td><td style="color: black">&#160;</td>
    <td colspan="3" style="color: black; text-align: center">Maximum Dollar Value that May Still Be Purchased Under the Program (In Thousands)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 30%; color: black; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif; color: black">October 1, 2023 - October 31, 2023</span></td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 3%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 12%; color: black; text-align: right">33,243</td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 3%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">$</td><td style="width: 12%; color: black; text-align: right">14.17</td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 3%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 12%; color: black; text-align: right">33,243</td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 3%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 12%; color: black; text-align: right">6,055</td><td style="width: 1%; color: black; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif; color: black">November 1, 2023 - November 30, 2023</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">30,726</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">$</td><td style="color: black; text-align: right">17.43</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">30,726</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">5,520</td><td style="color: black; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif; color: black">December 1, 2023 - December 31, 2023</span></td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">8,328</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">$</td><td style="color: black; text-align: right">19.74</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">8,328</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">5,355</td><td style="color: black; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif; color: black"><b>Total</b></span></td><td style="color: black; font-weight: bold; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">72,297</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">$</td><td style="color: black; text-align: right">16.20</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">72,297</td><td style="color: black; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="a_014"></span>Item 3 - Defaults Upon Senior Securities:
None</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="a_015"></span>Item 4 - Mine Safety Disclosure: Not
Applicable</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="a_016"></span>Item 5 - Other Information: None</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="a_017"></span>Item 6 - Exhibits and Reports on Form
8-K:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="white-space: nowrap; width: 5%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif; color: black">a) </span></td>
<td style="white-space: nowrap; width: 95%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif; color: black"><a href="fonar_exhibit-31.htm">Exhibit 31.1 Certification. See Exhibits</a></span></td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
<td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif; color: black">b) </span></td>
<td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif; color: black"><a href="fonar_exhibit-32.htm">Exhibit 32.1 Certification. See Exhibits</a></span></td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
<td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif; color: black">c)</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif; color: black"><a href="http://www.sec.gov/Archives/edgar/data/355019/000035501923000059/fonar_8-k.htm">Report on Form 8-K filed on November 14, 2023, Item 2.02: Results of Operations and Financial Condition for the quarter ended September 30, 2023.</a></span></td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="a_018"></span>SIGNATURES</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
<td style="width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">FONAR CORPORATION</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">(Registrant)</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="border-bottom: Black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">By: /s/ Timothy Damadian</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Timothy Damadian</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Chairman of the Board of Directors, President,</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Principal Executive Officer and Treasurer</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="border-bottom: Black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">/s/ Luciano Bonanni</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Luciano Bonanni</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Executive Vice President, Chief Operating Officer,</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Acting Principal Financial Officer</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">Dated: February 14, 2024</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;<span style="font: 10pt Times New Roman, Times, Serif">Page
34</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 3pt; margin-bottom: 3pt"><div style="border-top: Black 2pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>fonar_exhibit-31.htm
<DESCRIPTION>SECTION 302 CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Exhibit
31.1</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">CERTIFICATION</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  </TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Timothy
Damadian and Luciano Bonanni each certify that:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">I
    have reviewed this report on Form 10-Q of Fonar Corporation;</FONT></TD></TR>
  </TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  </TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  </TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">I
    am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
    15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15d-15(f) for the registrant
    and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">designed
    such disclosure controls and procedures or caused such disclosure controls over procedures to be designed under my supervision to
    ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report my conclusions about
    the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report; and</FONT></TD></TR>
  </TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">I
    have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
    and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">all
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  </TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 3.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 3.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 3.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">February
    14, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 50%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">/s/
    Timothy Damadian</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">________________________________</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Timothy
    Damadian</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Principal
    Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">/s/
    Luciano Bonanni</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">________________________________</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: left; padding-left: 5.4pt"><P STYLE="margin-bottom: 0; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Luciano
                                            Bonanni,</FONT></P>
    <P STYLE="margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>
    <P STYLE="margin-bottom: 0; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Acting
    Principal Financial Officer&nbsp;</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt/115% Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>3
<FILENAME>fonar_exhibit-32.htm
<DESCRIPTION>SECTION 906 CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Exhibit
32.1</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">CERTIFICATION
PURSUANT TO</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">18
U.S.C. SECTION 1350,</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">AS
ADOPTED PURSUANT TO</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">In
connection with the Quarterly Report of FONAR Corporation and Subsidiaries (the &ldquo;Company&rdquo;) on Form 10-Q for the fiscal quarter
ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Timothy
Damadian, Principal Executive Officer, and I, Luciano Bonanni, Acting Principal Financial Officer of the Company, certify, pursuant to
18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">The
Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">The
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Company.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; font: 11pt Calibri, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">/s/Timothy
    Damadian</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">________________________________</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Timothy
    Damadian</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Principal
    Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">/s/
    Luciano Bonanni</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">________________________________</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: left; padding-left: 5.4pt"><P STYLE="margin-bottom: 0; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Luciano
    Bonanni&nbsp;</FONT></P>
    <P STYLE="margin-bottom: 0; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Acting
    Principal Financial Officer&nbsp;</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt/115% Arial, Helvetica, Sans-Serif; margin: 0 0 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;February
14, 2024</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">A
signed original of this written statement required by Section 906 has been provided to Fonar Corporation and will be retained by Fonar
Corporation and furnished to the Securities and Exchange Commission or its staff upon request.</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>fonar_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fonar_logo.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" !# ;H# 2(  A$! Q$!_\0
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M1?R76I:O?2WE]<2MEI)9'+LQ/N2:SJ_%L=Q%FF)Q<ZL*LHQ;T2>RZ?\ !/\
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MA^$LYI9EEM)0PN(TY8JRA4BE=);)27O+S4NQW5% (/0T5]B?@!Q/[0GBW5_
M7P/\9>.?#LJ)J.C^&;Z]L7DCW*LL4#NA([C('%?C"O\ P7#_ ."@( SXXT(\
M?] !/\:_8K]KC_DV+XC?]B5JF/\ P$DK^;A<XY'TK\^XUQ^-P5>C&A4<4TV[
M.W4_JKZ.?"O#?$.6YA/,\)3KN$Z:BYQ4K)J3:5^Y]>M_P7$_X* GIXYT,?\
M< 3_ !I#_P %PO\ @H&>GCO1!_W (_\ &OD2C-?$?VYG'_01+[S^DO\ B&?A
M]_T*J'_@M'UW_P /P_\ @H(1@^/-$_\ !!'_ (T?\/PO^"@?_0^:)_X((_\
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M#_HH6N_^$O=?_$U];]=X<_GI?^2GX5_JQXO_ /0+C?\ P&L>N_\ #OS]C/\
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M]#%?DT/B1_==?^#+T?Y'],OP_P#E\)Z0H_Z!<'_HM:W:PO !SX5TG_L%P?\
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MOV.[_P#8C_:,O?A&=4>_TNYLH]2T"]D #RVDC.H#X_B5XW4_[H/>O#:^O/\
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M,D[;K]6>!Q+XB<'<'XR&%S?%>RG./,ERS=U=J]XQ:W3/S8HK]*/^(<#XE_\
M1U&A?^$Q-_\ 'Z/^(<#XE_\ 1U&A?^$Q-_\ 'Z[?]5,]?_+G\8_YGSO_ !'+
MPN_Z&*_\ J__ "!^:]%?I1_Q#@?$O_HZC0O_  F)O_C]'_$.!\2_^CJ-"_\
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H45WY3AZ%+FY();;)(\GB+.LXS>E2>/Q-2MRMVYYRG:]KVYF[7\C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>fonr-20231231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 9a45o7xRiXhun8uGbHdcOa2BGaP9wZ93iekhsGRybTmKbygpa7dhxytA2TGmIU8H -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:FONR="http://fonar.com/20231231" elementFormDefault="qualified" targetNamespace="http://fonar.com/20231231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://fonar.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
          <link:definition>00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/CondensedConsolidatedStatementsOfIncome" id="CondensedConsolidatedStatementsOfIncome">
          <link:definition>00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/CondensedConsolidatedStatementsOfIncomeParenthetical" id="CondensedConsolidatedStatementsOfIncomeParenthetical">
          <link:definition>00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity" id="CondensedConsolidatedStatementOfChangesInEquity">
          <link:definition>00000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
          <link:definition>00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentation" id="DescriptionOfBusinessAndBasisOfPresentation">
          <link:definition>00000008 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable" id="AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable">
          <link:definition>00000010 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/OperatingFinancingLeases" id="OperatingFinancingLeases">
          <link:definition>00000011 - Disclosure - OPERATING &amp; FINANCING LEASES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/Inventories" id="Inventories">
          <link:definition>00000012 - Disclosure - INVENTORIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/OtherIntangibleAssets" id="OtherIntangibleAssets">
          <link:definition>00000013 - Disclosure - OTHER INTANGIBLE ASSETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/OtherCurrentLiabilities" id="OtherCurrentLiabilities">
          <link:definition>00000014 - Disclosure - OTHER CURRENT LIABILITIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/SegmentAndRelatedInformation" id="SegmentAndRelatedInformation">
          <link:definition>00000015 - Disclosure - SEGMENT AND RELATED INFORMATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/RelatedPartyTransaction" id="RelatedPartyTransaction">
          <link:definition>00000016 - Disclosure - RELATED PARTY TRANSACTION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/SupplementalCashFlowInformation" id="SupplementalCashFlowInformation">
          <link:definition>00000017 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>00000019 - Disclosure - INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000020 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableTables" id="AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableTables">
          <link:definition>00000023 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/OperatingFinancingLeasesTables" id="OperatingFinancingLeasesTables">
          <link:definition>00000024 - Disclosure - OPERATING &amp; FINANCING LEASES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/InventoriesTables" id="InventoriesTables">
          <link:definition>00000025 - Disclosure - INVENTORIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/OtherIntangibleAssetsTables" id="OtherIntangibleAssetsTables">
          <link:definition>00000026 - Disclosure - OTHER INTANGIBLE ASSETS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/OtherCurrentLiabilitiesTables" id="OtherCurrentLiabilitiesTables">
          <link:definition>00000027 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/SegmentAndRelatedInformationTables" id="SegmentAndRelatedInformationTables">
          <link:definition>00000028 - Disclosure - SEGMENT AND RELATED INFORMATION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" id="DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative">
          <link:definition>00000029 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details" id="SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details">
          <link:definition>00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share - (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails" id="AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails">
          <link:definition>00000032 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails1" id="AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails1">
          <link:definition>00000033 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetails" id="AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetails">
          <link:definition>00000034 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetailsNarrative" id="AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetailsNarrative">
          <link:definition>00000035 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails" id="OperatingFinancingLeases-LeasePaymentsDetails">
          <link:definition>00000036 - Disclosure - OPERATING &amp; FINANCING LEASES - Lease Payments (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/Inventories-InventoriesDetails" id="Inventories-InventoriesDetails">
          <link:definition>00000037 - Disclosure - INVENTORIES - Inventories (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/OtherIntangibleAssets-OtherIntangibleAssetsNetOfAmortizationDetails" id="OtherIntangibleAssets-OtherIntangibleAssetsNetOfAmortizationDetails">
          <link:definition>00000038 - Disclosure - OTHER INTANGIBLE ASSETS - Other intangible assets net of amortization (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/OtherIntangibleAssetsDetailsNarrative" id="OtherIntangibleAssetsDetailsNarrative">
          <link:definition>00000039 - Disclosure - OTHER INTANGIBLE ASSETS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details" id="OtherCurrentLiabilities-OtherCurrentLiabilities-Details">
          <link:definition>00000040 - Disclosure - OTHER CURRENT LIABILITIES - Other Current Liabilities - (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/SegmentAndRelatedInformation-SummarizedSegments-Details" id="SegmentAndRelatedInformation-SummarizedSegments-Details">
          <link:definition>00000041 - Disclosure - SEGMENT AND RELATED INFORMATION - Summarized Segments - (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/RelatedPartyTransactionDetailsNarrative" id="RelatedPartyTransactionDetailsNarrative">
          <link:definition>00000042 - Disclosure - RELATED PARTY TRANSACTION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/SupplementalCashFlowInformationDetailsNarrative" id="SupplementalCashFlowInformationDetailsNarrative">
          <link:definition>00000043 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>00000044 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fonar.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>00000045 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="fonr-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="fonr-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="fonr-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="fonr-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="FONR_ClassAPreferredStockMember" name="ClassAPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_ClassANonVotingPreferredStockMember" name="ClassANonVotingPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_CommonStocksMember" name="CommonStocksMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_CommonStockholdersMember" name="CommonStockholdersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_ClassANonVotingPreferredStockholdersMember" name="ClassANonVotingPreferredStockholdersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_ControllingInterestMember" name="ControllingInterestMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_CommercialInsuranceManagedCareMember" name="CommercialInsuranceManagedCareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_MedicareMedicaidMember" name="MedicareMedicaidMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_WorkersCompensationPersonalInjuryMember" name="WorkersCompensationPersonalInjuryMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_OtherMember" name="OtherMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_OperatingLeasePaymentsMember" name="OperatingLeasePaymentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_FinancingLeasePaymentsMember" name="FinancingLeasePaymentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_PatentsAndCopyrightsMember" name="PatentsAndCopyrightsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_MedicalEquipmentMember" name="MedicalEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_ManagementOfDiagnosticImagingCentersMember" name="ManagementOfDiagnosticImagingCentersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_MagneticResonanceManagementMember" name="MagneticResonanceManagementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_AccountsReceivableServiceAndRepairFees" name="AccountsReceivableServiceAndRepairFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_AccountReceivableRelatedParties" name="AccountReceivableRelatedParties" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_MedicalReceivable" name="MedicalReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_ManagementAndOtherFees" name="ManagementAndOtherFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" name="ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_AccountsReceivableNetLongTerm" name="AccountsReceivableNetLongTerm" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_NoteReceivableRelatedParty" name="NoteReceivableRelatedParty" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_UnearnedRevenueOnServiceContractsRelatedParty" name="UnearnedRevenueOnServiceContractsRelatedParty" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_CustomerDeposits" name="CustomerDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_AccountsPayableRelatedPartyNoncurrent" name="AccountsPayableRelatedPartyNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscounts" name="PatientFeeRevenueNetOfContractualAllowancesAndDiscounts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_ProductSalesNet" name="ProductSalesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_ServiceAndRepairFeesNet" name="ServiceAndRepairFeesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_ServiceAndRepairFeesRelatedPartiesNet" name="ServiceAndRepairFeesRelatedPartiesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_ManagementAndOtherFeesNet" name="ManagementAndOtherFeesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_ManagementAndOtherFeesRelatedMedicalPracticesNet" name="ManagementAndOtherFeesRelatedMedicalPracticesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_CostsRelatedToProductSales" name="CostsRelatedToProductSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_CostsRelatedToServiceAndRepairFees" name="CostsRelatedToServiceAndRepairFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_CostsRelatedToServiceAndRepairFeesRelatedParties" name="CostsRelatedToServiceAndRepairFeesRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_CostsRelatedToManagementAndOtherFees" name="CostsRelatedToManagementAndOtherFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices" name="CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_OtherIncomeRelatedParty" name="OtherIncomeRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_PurchaseOfTreasuryStockShares" name="PurchaseOfTreasuryStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_CancellationOfShares" name="CancellationOfShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_CancellationOfSharesShares" name="CancellationOfSharesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_ProvisionForBadDebts" name="ProvisionForBadDebts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_GainOnSaleOfEquipmentRelatedParty" name="GainOnSaleOfEquipmentRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_IncreaseDecreaseInNotesReceivable" name="IncreaseDecreaseInNotesReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_IncreaseDecreaseInFinancingLiabilities" name="IncreaseDecreaseInFinancingLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_IncreaseDecreaseInCustomerAdvance" name="IncreaseDecreaseInCustomerAdvance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_DisclosureOperatingFinancingLeasesAbstract" name="DisclosureOperatingFinancingLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_TotalFacilitiesOwnedOrManagedTableTextBlock" name="TotalFacilitiesOwnedOrManagedTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_ScheduleOfPatientFeeRevenueTableTextBlock" name="ScheduleOfPatientFeeRevenueTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_HmcaOwnershipSizeOfImperialManagementServicesPercent" name="HmcaOwnershipSizeOfImperialManagementServicesPercent" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_OwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent" name="OwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_OwnershipInterestOfOriginalInvestorsOfHdm" name="OwnershipInterestOfOriginalInvestorsOfHdm" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_DirectPurchaseOfNoncontrollingInterests" name="DirectPurchaseOfNoncontrollingInterests" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_InvestorsOwnershipInterest" name="InvestorsOwnershipInterest" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_NetIncomeLossAvailableToCommonStockholderBasic" name="NetIncomeLossAvailableToCommonStockholderBasic" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_ConvertibleClassCStock" name="ConvertibleClassCStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_WeightedAverageNumberOfDilutedEarningsPerShare" name="WeightedAverageNumberOfDilutedEarningsPerShare" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_AccountsReceivableNetRelatedParty" name="AccountsReceivableNetRelatedParty" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_ManagementAndOtherFeesNonRelatedParties" name="ManagementAndOtherFeesNonRelatedParties" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscount" name="PatientFeeRevenueNetOfContractualAllowancesAndDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims" name="PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_PercentageOfConsolidatedNetRevenueFromManagementFees" name="PercentageOfConsolidatedNetRevenueFromManagementFees" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_PresentValueDiscount" name="PresentValueDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_PresentValueDiscountFinancingLease" name="PresentValueDiscountFinancingLease" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_StateIncomeTaxesPayable" name="StateIncomeTaxesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_IntersegmentNetRevenues" name="IntersegmentNetRevenues" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_GainOnSaleOfEquipmentsRelatedParty" name="GainOnSaleOfEquipmentsRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_StoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims" name="StoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FONR_CorporateAlternativeMinimumTaxPercentage" name="CorporateAlternativeMinimumTaxPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>fonr-20231231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://fonar.com/role/Cover" xlink:href="fonr-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/CondensedConsolidatedBalanceSheets" xlink:href="fonr-20231231.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="fonr-20231231.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/CondensedConsolidatedStatementsOfIncome" xlink:href="fonr-20231231.xsd#CondensedConsolidatedStatementsOfIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/CondensedConsolidatedStatementsOfIncomeParenthetical" xlink:href="fonr-20231231.xsd#CondensedConsolidatedStatementsOfIncomeParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity" xlink:href="fonr-20231231.xsd#CondensedConsolidatedStatementOfChangesInEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="fonr-20231231.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:href="fonr-20231231.xsd#DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="fonr-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable" xlink:href="fonr-20231231.xsd#AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OperatingFinancingLeases" xlink:href="fonr-20231231.xsd#OperatingFinancingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/Inventories" xlink:href="fonr-20231231.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OtherIntangibleAssets" xlink:href="fonr-20231231.xsd#OtherIntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OtherCurrentLiabilities" xlink:href="fonr-20231231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SegmentAndRelatedInformation" xlink:href="fonr-20231231.xsd#SegmentAndRelatedInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/RelatedPartyTransaction" xlink:href="fonr-20231231.xsd#RelatedPartyTransaction" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SupplementalCashFlowInformation" xlink:href="fonr-20231231.xsd#SupplementalCashFlowInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/CommitmentsAndContingencies" xlink:href="fonr-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/IncomeTaxes" xlink:href="fonr-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SubsequentEvents" xlink:href="fonr-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="fonr-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="fonr-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableTables" xlink:href="fonr-20231231.xsd#AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OperatingFinancingLeasesTables" xlink:href="fonr-20231231.xsd#OperatingFinancingLeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/InventoriesTables" xlink:href="fonr-20231231.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OtherIntangibleAssetsTables" xlink:href="fonr-20231231.xsd#OtherIntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OtherCurrentLiabilitiesTables" xlink:href="fonr-20231231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SegmentAndRelatedInformationTables" xlink:href="fonr-20231231.xsd#SegmentAndRelatedInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:href="fonr-20231231.xsd#DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details" xlink:href="fonr-20231231.xsd#SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="fonr-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails" xlink:href="fonr-20231231.xsd#AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails1" xlink:href="fonr-20231231.xsd#AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetails" xlink:href="fonr-20231231.xsd#AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetailsNarrative" xlink:href="fonr-20231231.xsd#AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails" xlink:href="fonr-20231231.xsd#OperatingFinancingLeases-LeasePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/Inventories-InventoriesDetails" xlink:href="fonr-20231231.xsd#Inventories-InventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OtherIntangibleAssets-OtherIntangibleAssetsNetOfAmortizationDetails" xlink:href="fonr-20231231.xsd#OtherIntangibleAssets-OtherIntangibleAssetsNetOfAmortizationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OtherIntangibleAssetsDetailsNarrative" xlink:href="fonr-20231231.xsd#OtherIntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details" xlink:href="fonr-20231231.xsd#OtherCurrentLiabilities-OtherCurrentLiabilities-Details" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SegmentAndRelatedInformation-SummarizedSegments-Details" xlink:href="fonr-20231231.xsd#SegmentAndRelatedInformation-SummarizedSegments-Details" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/RelatedPartyTransactionDetailsNarrative" xlink:href="fonr-20231231.xsd#RelatedPartyTransactionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SupplementalCashFlowInformationDetailsNarrative" xlink:href="fonr-20231231.xsd#SupplementalCashFlowInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="fonr-20231231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/IncomeTaxesDetailsNarrative" xlink:href="fonr-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_AccountsReceivableServiceAndRepairFees" xlink:label="loc_FONRAccountsReceivableServiceAndRepairFees" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_FONRAccountsReceivableServiceAndRepairFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_AccountReceivableRelatedParties" xlink:label="loc_FONRAccountReceivableRelatedParties" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_FONRAccountReceivableRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_MedicalReceivable" xlink:label="loc_FONRMedicalReceivable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_FONRMedicalReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ManagementAndOtherFees" xlink:label="loc_FONRManagementAndOtherFees" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_FONRManagementAndOtherFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" xlink:label="loc_FONRManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_FONRManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsAndWorkInProcess" xlink:label="loc_us-gaapInventoryFinishedGoodsAndWorkInProcess" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryFinishedGoodsAndWorkInProcess" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_AccountsReceivableNetLongTerm" xlink:label="loc_FONRAccountsReceivableNetLongTerm" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_FONRAccountsReceivableNetLongTerm" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_NoteReceivableRelatedParty" xlink:label="loc_FONRNoteReceivableRelatedParty" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_FONRNoteReceivableRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaapDeferredTaxAssetsDeferredIncome" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDeferredTaxAssetsDeferredIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaapLongTermDebtCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLongTermDebtCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_UnearnedRevenueOnServiceContractsRelatedParty" xlink:label="loc_FONRUnearnedRevenueOnServiceContractsRelatedParty" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_FONRUnearnedRevenueOnServiceContractsRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CustomerDeposits" xlink:label="loc_FONRCustomerDeposits" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_FONRCustomerDeposits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapDeferredRevenueNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapDeferredIncomeTaxesAndOtherLiabilitiesNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapDeferredIncomeTaxesAndOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_AccountsPayableRelatedPartyNoncurrent" xlink:label="loc_FONRAccountsPayableRelatedPartyNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_FONRAccountsPayableRelatedPartyNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOtherLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/CondensedConsolidatedStatementsOfIncome" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscounts" xlink:label="loc_FONRPatientFeeRevenueNetOfContractualAllowancesAndDiscounts" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRevenues" xlink:to="loc_FONRPatientFeeRevenueNetOfContractualAllowancesAndDiscounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ProductSalesNet" xlink:label="loc_FONRProductSalesNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRevenues" xlink:to="loc_FONRProductSalesNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ServiceAndRepairFeesNet" xlink:label="loc_FONRServiceAndRepairFeesNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRevenues" xlink:to="loc_FONRServiceAndRepairFeesNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ServiceAndRepairFeesRelatedPartiesNet" xlink:label="loc_FONRServiceAndRepairFeesRelatedPartiesNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRevenues" xlink:to="loc_FONRServiceAndRepairFeesRelatedPartiesNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ManagementAndOtherFeesNet" xlink:label="loc_FONRManagementAndOtherFeesNet" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRevenues" xlink:to="loc_FONRManagementAndOtherFeesNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ManagementAndOtherFeesRelatedMedicalPracticesNet" xlink:label="loc_FONRManagementAndOtherFeesRelatedMedicalPracticesNet" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRevenues" xlink:to="loc_FONRManagementAndOtherFeesRelatedMedicalPracticesNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostOfOperatingRevenue" xlink:label="loc_us-gaapOtherCostOfOperatingRevenue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapOtherCostOfOperatingRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CostsRelatedToProductSales" xlink:label="loc_FONRCostsRelatedToProductSales" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_FONRCostsRelatedToProductSales" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CostsRelatedToServiceAndRepairFees" xlink:label="loc_FONRCostsRelatedToServiceAndRepairFees" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_FONRCostsRelatedToServiceAndRepairFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CostsRelatedToServiceAndRepairFeesRelatedParties" xlink:label="loc_FONRCostsRelatedToServiceAndRepairFeesRelatedParties" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_FONRCostsRelatedToServiceAndRepairFeesRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CostsRelatedToManagementAndOtherFees" xlink:label="loc_FONRCostsRelatedToManagementAndOtherFees" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_FONRCostsRelatedToManagementAndOtherFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices" xlink:label="loc_FONRCostsRelatedToManagementAndOtherFeesRelatedMedicalPractices" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_FONRCostsRelatedToManagementAndOtherFeesRelatedMedicalPractices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_OtherIncomeRelatedParty" xlink:label="loc_FONROtherIncomeRelatedParty" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_FONROtherIncomeRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaapInvestmentIncomeNet" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapInvestmentIncomeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/CondensedConsolidatedStatementsOfIncomeParenthetical" xlink:title="00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity" xlink:title="00000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:title="00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDepreciationAndAmortization" xlink:label="loc_us-gaapOtherDepreciationAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ProvisionForBadDebts" xlink:label="loc_FONRProvisionForBadDebts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_FONRProvisionForBadDebts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_GainOnSaleOfEquipmentRelatedParty" xlink:label="loc_FONRGainOnSaleOfEquipmentRelatedParty" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_FONRGainOnSaleOfEquipmentRelatedParty" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_IncreaseDecreaseInNotesReceivable" xlink:label="loc_FONRIncreaseDecreaseInNotesReceivable" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_FONRIncreaseDecreaseInNotesReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_FONRIncreaseDecreaseInOperatingLeaseLiabilities" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_FONRIncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_IncreaseDecreaseInFinancingLiabilities" xlink:label="loc_FONRIncreaseDecreaseInFinancingLiabilities" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_FONRIncreaseDecreaseInFinancingLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_IncreaseDecreaseInCustomerAdvance" xlink:label="loc_FONRIncreaseDecreaseInCustomerAdvance" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_FONRIncreaseDecreaseInCustomerAdvance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfConvertiblePreferredStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsForRepurchaseOfConvertiblePreferredStock" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsMinorityInterest" xlink:label="loc_us-gaapPaymentsOfDividendsMinorityInterest" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfDividendsMinorityInterest" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:title="00000008 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable" xlink:title="00000010 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/OperatingFinancingLeases" xlink:title="00000011 - Disclosure - OPERATING &amp; FINANCING LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/Inventories" xlink:title="00000012 - Disclosure - INVENTORIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/OtherIntangibleAssets" xlink:title="00000013 - Disclosure - OTHER INTANGIBLE ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/SegmentAndRelatedInformation" xlink:title="00000015 - Disclosure - SEGMENT AND RELATED INFORMATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/RelatedPartyTransaction" xlink:title="00000016 - Disclosure - RELATED PARTY TRANSACTION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/SupplementalCashFlowInformation" xlink:title="00000017 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/IncomeTaxes" xlink:title="00000019 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/SubsequentEvents" xlink:title="00000020 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableTables" xlink:title="00000023 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/OperatingFinancingLeasesTables" xlink:title="00000024 - Disclosure - OPERATING &amp; FINANCING LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/InventoriesTables" xlink:title="00000025 - Disclosure - INVENTORIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/OtherIntangibleAssetsTables" xlink:title="00000026 - Disclosure - OTHER INTANGIBLE ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000027 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/SegmentAndRelatedInformationTables" xlink:title="00000028 - Disclosure - SEGMENT AND RELATED INFORMATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:title="00000029 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details" xlink:title="00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share - (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails" xlink:title="00000032 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails1" xlink:title="00000033 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetails" xlink:title="00000034 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetailsNarrative" xlink:title="00000035 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails" xlink:title="00000036 - Disclosure - OPERATING &amp; FINANCING LEASES - Lease Payments (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/Inventories-InventoriesDetails" xlink:title="00000037 - Disclosure - INVENTORIES - Inventories (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsAndWorkInProcess" xlink:label="loc_us-gaapInventoryFinishedGoodsAndWorkInProcess" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInventorySupplies" xlink:label="loc_us-gaapOtherInventorySupplies" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryFinishedGoodsAndWorkInProcess" xlink:to="loc_us-gaapOtherInventorySupplies" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryFinishedGoodsAndWorkInProcess" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/OtherIntangibleAssets-OtherIntangibleAssetsNetOfAmortizationDetails" xlink:title="00000038 - Disclosure - OTHER INTANGIBLE ASSETS - Other intangible assets net of amortization (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/OtherIntangibleAssetsDetailsNarrative" xlink:title="00000039 - Disclosure - OTHER INTANGIBLE ASSETS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details" xlink:title="00000040 - Disclosure - OTHER CURRENT LIABILITIES - Other Current Liabilities - (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaapSalesAndExciseTaxPayableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapSalesAndExciseTaxPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_StateIncomeTaxesPayable" xlink:label="loc_FONRStateIncomeTaxesPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_FONRStateIncomeTaxesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrentAndNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SelfInsuranceReserve" xlink:label="loc_us-gaapSelfInsuranceReserve" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapSelfInsuranceReserve" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesNoncurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="loc_us-gaapOtherSundryLiabilitiesCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapOtherSundryLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/SegmentAndRelatedInformation-SummarizedSegments-Details" xlink:title="00000041 - Disclosure - SEGMENT AND RELATED INFORMATION - Summarized Segments - (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/RelatedPartyTransactionDetailsNarrative" xlink:title="00000042 - Disclosure - RELATED PARTY TRANSACTION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/SupplementalCashFlowInformationDetailsNarrative" xlink:title="00000043 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000044 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fonar.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000045 - Disclosure - INCOME TAXES (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>fonr-20231231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://fonar.com/role/Cover" xlink:href="fonr-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/CondensedConsolidatedBalanceSheets" xlink:href="fonr-20231231.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="fonr-20231231.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/CondensedConsolidatedStatementsOfIncome" xlink:href="fonr-20231231.xsd#CondensedConsolidatedStatementsOfIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/CondensedConsolidatedStatementsOfIncomeParenthetical" xlink:href="fonr-20231231.xsd#CondensedConsolidatedStatementsOfIncomeParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity" xlink:href="fonr-20231231.xsd#CondensedConsolidatedStatementOfChangesInEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="fonr-20231231.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:href="fonr-20231231.xsd#DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="fonr-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable" xlink:href="fonr-20231231.xsd#AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OperatingFinancingLeases" xlink:href="fonr-20231231.xsd#OperatingFinancingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/Inventories" xlink:href="fonr-20231231.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OtherIntangibleAssets" xlink:href="fonr-20231231.xsd#OtherIntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OtherCurrentLiabilities" xlink:href="fonr-20231231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SegmentAndRelatedInformation" xlink:href="fonr-20231231.xsd#SegmentAndRelatedInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/RelatedPartyTransaction" xlink:href="fonr-20231231.xsd#RelatedPartyTransaction" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SupplementalCashFlowInformation" xlink:href="fonr-20231231.xsd#SupplementalCashFlowInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/CommitmentsAndContingencies" xlink:href="fonr-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/IncomeTaxes" xlink:href="fonr-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SubsequentEvents" xlink:href="fonr-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="fonr-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="fonr-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableTables" xlink:href="fonr-20231231.xsd#AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OperatingFinancingLeasesTables" xlink:href="fonr-20231231.xsd#OperatingFinancingLeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/InventoriesTables" xlink:href="fonr-20231231.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OtherIntangibleAssetsTables" xlink:href="fonr-20231231.xsd#OtherIntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OtherCurrentLiabilitiesTables" xlink:href="fonr-20231231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SegmentAndRelatedInformationTables" xlink:href="fonr-20231231.xsd#SegmentAndRelatedInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:href="fonr-20231231.xsd#DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details" xlink:href="fonr-20231231.xsd#SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="fonr-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails" xlink:href="fonr-20231231.xsd#AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails1" xlink:href="fonr-20231231.xsd#AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetails" xlink:href="fonr-20231231.xsd#AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetailsNarrative" xlink:href="fonr-20231231.xsd#AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails" xlink:href="fonr-20231231.xsd#OperatingFinancingLeases-LeasePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/Inventories-InventoriesDetails" xlink:href="fonr-20231231.xsd#Inventories-InventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OtherIntangibleAssets-OtherIntangibleAssetsNetOfAmortizationDetails" xlink:href="fonr-20231231.xsd#OtherIntangibleAssets-OtherIntangibleAssetsNetOfAmortizationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OtherIntangibleAssetsDetailsNarrative" xlink:href="fonr-20231231.xsd#OtherIntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details" xlink:href="fonr-20231231.xsd#OtherCurrentLiabilities-OtherCurrentLiabilities-Details" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SegmentAndRelatedInformation-SummarizedSegments-Details" xlink:href="fonr-20231231.xsd#SegmentAndRelatedInformation-SummarizedSegments-Details" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/RelatedPartyTransactionDetailsNarrative" xlink:href="fonr-20231231.xsd#RelatedPartyTransactionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SupplementalCashFlowInformationDetailsNarrative" xlink:href="fonr-20231231.xsd#SupplementalCashFlowInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="fonr-20231231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/IncomeTaxesDetailsNarrative" xlink:href="fonr-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember" xlink:label="loc_us-gaapCommonClassCMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassCMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ClassAPreferredStockMember" xlink:label="loc_FONRClassAPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FONRClassAPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_60" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_60" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_60" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_60" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_60" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_60" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_60" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_60" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_60" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_60" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_60" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_60" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_60" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_60" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_60" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_60" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_60" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_60" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_60" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_60" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_60" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_60" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_60" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_60" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_60" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_60" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_60" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_60" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_60" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_60" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_60" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_60" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_60" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_60" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_60" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_60" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_60" xlink:type="arc" order="57" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ClassANonVotingPreferredStockMember" xlink:label="loc_FONRClassANonVotingPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FONRClassANonVotingPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CommonStocksMember" xlink:label="loc_FONRCommonStocksMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FONRCommonStocksMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember" xlink:label="loc_us-gaapCommonClassCMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassCMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrentAbstract_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapShortTermInvestments_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_AccountsReceivableServiceAndRepairFees" xlink:label="loc_FONRAccountsReceivableServiceAndRepairFees_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_FONRAccountsReceivableServiceAndRepairFees_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_AccountReceivableRelatedParties" xlink:label="loc_FONRAccountReceivableRelatedParties_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_FONRAccountReceivableRelatedParties_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_MedicalReceivable" xlink:label="loc_FONRMedicalReceivable_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_FONRMedicalReceivable_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ManagementAndOtherFees" xlink:label="loc_FONRManagementAndOtherFees_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_FONRManagementAndOtherFees_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" xlink:label="loc_FONRManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_FONRManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsAndWorkInProcess" xlink:label="loc_us-gaapInventoryFinishedGoodsAndWorkInProcess_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapInventoryFinishedGoodsAndWorkInProcess_130" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_130" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapAssetsCurrent_130" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_AccountsReceivableNetLongTerm" xlink:label="loc_FONRAccountsReceivableNetLongTerm_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_FONRAccountsReceivableNetLongTerm_130" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_NoteReceivableRelatedParty" xlink:label="loc_FONRNoteReceivableRelatedParty_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_FONRNoteReceivableRelatedParty_130" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaapDeferredTaxAssetsDeferredIncome_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapDeferredTaxAssetsDeferredIncome_130" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_130" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_130" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset_130" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapGoodwill_130" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_130" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapOtherAssets_130" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapAssets_130" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaapLongTermDebtCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapLongTermDebtCurrent_130" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapAccountsPayableCurrent_130" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapOtherLiabilitiesCurrent_130" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapDeferredRevenueCurrent_130" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_UnearnedRevenueOnServiceContractsRelatedParty" xlink:label="loc_FONRUnearnedRevenueOnServiceContractsRelatedParty_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_FONRUnearnedRevenueOnServiceContractsRelatedParty_130" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_130" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent_130" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CustomerDeposits" xlink:label="loc_FONRCustomerDeposits_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_FONRCustomerDeposits_130" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapLiabilitiesCurrent_130" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract_130" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_130" xlink:to="loc_us-gaapDeferredRevenueNoncurrent_130" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapDeferredIncomeTaxesAndOtherLiabilitiesNoncurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_130" xlink:to="loc_us-gaapDeferredIncomeTaxesAndOtherLiabilitiesNoncurrent_130" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_AccountsPayableRelatedPartyNoncurrent" xlink:label="loc_FONRAccountsPayableRelatedPartyNoncurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_130" xlink:to="loc_FONRAccountsPayableRelatedPartyNoncurrent_130" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_130" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_130" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_130" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent_130" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_130" xlink:to="loc_us-gaapLongTermDebtNoncurrent_130" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_130" xlink:to="loc_us-gaapOtherLiabilities_130" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_130" xlink:to="loc_us-gaapLiabilitiesNoncurrent_130" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_130" xlink:to="loc_us-gaapLiabilities_130" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockValue_130" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockValue_130" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital_130" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_130" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTreasuryStockValue_130" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_130" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMinorityInterest_130" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_130" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_130" xlink:type="arc" order="49" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ClassANonVotingPreferredStockMember" xlink:label="loc_FONRClassANonVotingPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FONRClassANonVotingPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember" xlink:label="loc_us-gaapCommonClassCMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassCMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaapTreasuryStockCommonShares_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTreasuryStockCommonShares_130" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/CondensedConsolidatedStatementsOfIncome" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/CondensedConsolidatedStatementsOfIncomeParenthetical" xlink:title="00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CommonStockholdersMember" xlink:label="loc_FONRCommonStockholdersMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FONRCommonStockholdersMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ClassANonVotingPreferredStockholdersMember" xlink:label="loc_FONRClassANonVotingPreferredStockholdersMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FONRClassANonVotingPreferredStockholdersMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember" xlink:label="loc_us-gaapCommonClassCMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassCMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_130" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity" xlink:title="00000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapTreasuryStockCommonMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapNoncontrollingInterestMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_PurchaseOfTreasuryStockShares" xlink:label="loc_FONRPurchaseOfTreasuryStockShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONRPurchaseOfTreasuryStockShares_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CancellationOfShares" xlink:label="loc_FONRCancellationOfShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONRCancellationOfShares_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CancellationOfSharesShares" xlink:label="loc_FONRCancellationOfSharesShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONRCancellationOfSharesShares_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaapMinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest_70" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:title="00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:title="00000008 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable" xlink:title="00000010 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/OperatingFinancingLeases" xlink:title="00000011 - Disclosure - OPERATING &amp; FINANCING LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/Inventories" xlink:title="00000012 - Disclosure - INVENTORIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/OtherIntangibleAssets" xlink:title="00000013 - Disclosure - OTHER INTANGIBLE ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/SegmentAndRelatedInformation" xlink:title="00000015 - Disclosure - SEGMENT AND RELATED INFORMATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/RelatedPartyTransaction" xlink:title="00000016 - Disclosure - RELATED PARTY TRANSACTION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/SupplementalCashFlowInformation" xlink:title="00000017 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/IncomeTaxes" xlink:title="00000019 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/SubsequentEvents" xlink:title="00000020 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableTables" xlink:title="00000023 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/OperatingFinancingLeasesTables" xlink:title="00000024 - Disclosure - OPERATING &amp; FINANCING LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/InventoriesTables" xlink:title="00000025 - Disclosure - INVENTORIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/OtherIntangibleAssetsTables" xlink:title="00000026 - Disclosure - OTHER INTANGIBLE ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000027 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/SegmentAndRelatedInformationTables" xlink:title="00000028 - Disclosure - SEGMENT AND RELATED INFORMATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:title="00000029 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ControllingInterestMember" xlink:label="loc_FONRControllingInterestMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_FONRControllingInterestMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapNoncontrollingInterestMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_HmcaOwnershipSizeOfImperialManagementServicesPercent" xlink:label="loc_FONRHmcaOwnershipSizeOfImperialManagementServicesPercent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONRHmcaOwnershipSizeOfImperialManagementServicesPercent_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_OwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent" xlink:label="loc_FONROwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONROwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_OwnershipInterestOfOriginalInvestorsOfHdm" xlink:label="loc_FONROwnershipInterestOfOriginalInvestorsOfHdm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONROwnershipInterestOfOriginalInvestorsOfHdm_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_DirectPurchaseOfNoncontrollingInterests" xlink:label="loc_FONRDirectPurchaseOfNoncontrollingInterests_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONRDirectPurchaseOfNoncontrollingInterests_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_InvestorsOwnershipInterest" xlink:label="loc_FONRInvestorsOwnershipInterest_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONRInvestorsOwnershipInterest_60" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details" xlink:title="00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share - (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember" xlink:label="loc_us-gaapCommonClassCMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassCMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_NetIncomeLossAvailableToCommonStockholderBasic" xlink:label="loc_FONRNetIncomeLossAvailableToCommonStockholderBasic_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONRNetIncomeLossAvailableToCommonStockholderBasic_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicShare_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicShare_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ConvertibleClassCStock" xlink:label="loc_FONRConvertibleClassCStock_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONRConvertibleClassCStock_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_WeightedAverageNumberOfDilutedEarningsPerShare" xlink:label="loc_FONRWeightedAverageNumberOfDilutedEarningsPerShare_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONRWeightedAverageNumberOfDilutedEarningsPerShare_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_130" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails" xlink:title="00000032 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" xlink:to="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="loc_us-gaapAccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="loc_us-gaapAccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="loc_us-gaapReceivableTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="loc_us-gaapReceivableTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="loc_us-gaapReceivableTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="loc_us-gaapReceivableTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapReceivableTypeDomain" xlink:to="loc_us-gaapAccountsReceivableMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DoubtfulMember" xlink:label="loc_us-gaapDoubtfulMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapReceivableTypeDomain" xlink:to="loc_us-gaapDoubtfulMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_AccountsReceivableServiceAndRepairFees" xlink:label="loc_FONRAccountsReceivableServiceAndRepairFees_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" xlink:to="loc_FONRAccountsReceivableServiceAndRepairFees_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_AccountsReceivableNetRelatedParty" xlink:label="loc_FONRAccountsReceivableNetRelatedParty_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" xlink:to="loc_FONRAccountsReceivableNetRelatedParty_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_MedicalReceivable" xlink:label="loc_FONRMedicalReceivable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" xlink:to="loc_FONRMedicalReceivable_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ManagementAndOtherFeesNonRelatedParties" xlink:label="loc_FONRManagementAndOtherFeesNonRelatedParties_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" xlink:to="loc_FONRManagementAndOtherFeesNonRelatedParties_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" xlink:label="loc_FONRManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" xlink:to="loc_FONRManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails1" xlink:title="00000033 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetails" xlink:title="00000034 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CommercialInsuranceManagedCareMember" xlink:label="loc_FONRCommercialInsuranceManagedCareMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" xlink:to="loc_FONRCommercialInsuranceManagedCareMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_MedicareMedicaidMember" xlink:label="loc_FONRMedicareMedicaidMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" xlink:to="loc_FONRMedicareMedicaidMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_WorkersCompensationPersonalInjuryMember" xlink:label="loc_FONRWorkersCompensationPersonalInjuryMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" xlink:to="loc_FONRWorkersCompensationPersonalInjuryMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_OtherMember" xlink:label="loc_FONROtherMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" xlink:to="loc_FONROtherMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscount" xlink:label="loc_FONRPatientFeeRevenueNetOfContractualAllowancesAndDiscount_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_FONRPatientFeeRevenueNetOfContractualAllowancesAndDiscount_210" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetailsNarrative" xlink:title="00000035 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails" xlink:title="00000036 - Disclosure - OPERATING &amp; FINANCING LEASES - Lease Payments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_OperatingLeasePaymentsMember" xlink:label="loc_FONROperatingLeasePaymentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_FONROperatingLeasePaymentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_FinancingLeasePaymentsMember" xlink:label="loc_FONRFinancingLeasePaymentsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_FONRFinancingLeasePaymentsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive_30" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_30" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueAfterYearFive_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueAfterYearFive_30" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_PresentValueDiscount" xlink:label="loc_FONRPresentValueDiscount_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONRPresentValueDiscount_30" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_PresentValueDiscountFinancingLease" xlink:label="loc_FONRPresentValueDiscountFinancingLease_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONRPresentValueDiscountFinancingLease_30" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_30" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiability_30" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/Inventories-InventoriesDetails" xlink:title="00000037 - Disclosure - INVENTORIES - Inventories (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/OtherIntangibleAssets-OtherIntangibleAssetsNetOfAmortizationDetails" xlink:title="00000038 - Disclosure - OTHER INTANGIBLE ASSETS - Other intangible assets net of amortization (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_PatentsAndCopyrightsMember" xlink:label="loc_FONRPatentsAndCopyrightsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_FONRPatentsAndCopyrightsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaapNoncompeteAgreementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapNoncompeteAgreementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_110" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/OtherIntangibleAssetsDetailsNarrative" xlink:title="00000039 - Disclosure - OTHER INTANGIBLE ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_PatentsAndCopyrightsMember" xlink:label="loc_FONRPatentsAndCopyrightsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_FONRPatentsAndCopyrightsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details" xlink:title="00000040 - Disclosure - OTHER CURRENT LIABILITIES - Other Current Liabilities - (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/SegmentAndRelatedInformation-SummarizedSegments-Details" xlink:title="00000041 - Disclosure - SEGMENT AND RELATED INFORMATION - Summarized Segments - (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="loc_us-gaapStatementOperatingActivitiesSegmentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementOperatingActivitiesSegmentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaapSegmentOperatingActivitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementOperatingActivitiesSegmentAxis" xlink:to="loc_us-gaapSegmentOperatingActivitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaapSegmentOperatingActivitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementOperatingActivitiesSegmentAxis" xlink:to="loc_us-gaapSegmentOperatingActivitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_MedicalEquipmentMember" xlink:label="loc_FONRMedicalEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentOperatingActivitiesDomain" xlink:to="loc_FONRMedicalEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ManagementOfDiagnosticImagingCentersMember" xlink:label="loc_FONRManagementOfDiagnosticImagingCentersMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentOperatingActivitiesDomain" xlink:to="loc_FONRManagementOfDiagnosticImagingCentersMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_IntersegmentNetRevenues" xlink:label="loc_FONRIntersegmentNetRevenues_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONRIntersegmentNetRevenues_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaapIncomeLossFromContinuingOperations_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperations_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets_130" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/RelatedPartyTransactionDetailsNarrative" xlink:title="00000042 - Disclosure - RELATED PARTY TRANSACTION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_MagneticResonanceManagementMember" xlink:label="loc_FONRMagneticResonanceManagementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_FONRMagneticResonanceManagementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFixedInterestRate" xlink:label="loc_us-gaapDerivativeFixedInterestRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDerivativeFixedInterestRate_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_GainOnSaleOfEquipmentsRelatedParty" xlink:label="loc_FONRGainOnSaleOfEquipmentsRelatedParty_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_FONRGainOnSaleOfEquipmentsRelatedParty_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/SupplementalCashFlowInformationDetailsNarrative" xlink:title="00000043 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000044 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fonar.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000045 - Disclosure - INCOME TAXES (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>fonr-20231231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassBMember_lbl" xml:lang="en-US">Common Class B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember" xlink:label="us-gaap_CommonClassCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassCMember" xlink:to="us-gaap_CommonClassCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassCMember_lbl" xml:lang="en-US">Common Class C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ClassAPreferredStockMember" xlink:label="FONR_ClassAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ClassAPreferredStockMember" xlink:to="FONR_ClassAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_ClassAPreferredStockMember_lbl" xml:lang="en-US">Class A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ClassANonVotingPreferredStockMember" xlink:label="FONR_ClassANonVotingPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ClassANonVotingPreferredStockMember" xlink:to="FONR_ClassANonVotingPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_ClassANonVotingPreferredStockMember_lbl" xml:lang="en-US">Class A Non Voting Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CommonStocksMember" xlink:label="FONR_CommonStocksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_CommonStocksMember" xlink:to="FONR_CommonStocksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="FONR_CommonStocksMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CommonStockholdersMember" xlink:label="FONR_CommonStockholdersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_CommonStockholdersMember" xlink:to="FONR_CommonStockholdersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_CommonStockholdersMember_lbl" xml:lang="en-US">Common Stockholders [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ClassANonVotingPreferredStockholdersMember" xlink:label="FONR_ClassANonVotingPreferredStockholdersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ClassANonVotingPreferredStockholdersMember" xlink:to="FONR_ClassANonVotingPreferredStockholdersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_ClassANonVotingPreferredStockholdersMember_lbl" xml:lang="en-US">Class A Non Voting Preferred Stockholders [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ControllingInterestMember" xlink:label="FONR_ControllingInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ControllingInterestMember" xlink:to="FONR_ControllingInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_ControllingInterestMember_lbl" xml:lang="en-US">Controlling Interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xml:lang="en-US">Receivable Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DoubtfulMember" xlink:label="us-gaap_DoubtfulMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DoubtfulMember" xlink:to="us-gaap_DoubtfulMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DoubtfulMember_lbl" xml:lang="en-US">Doubtful [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" xml:lang="en-US">Health Care Organization, Revenue Sources [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CommercialInsuranceManagedCareMember" xlink:label="FONR_CommercialInsuranceManagedCareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_CommercialInsuranceManagedCareMember" xlink:to="FONR_CommercialInsuranceManagedCareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_CommercialInsuranceManagedCareMember_lbl" xml:lang="en-US">Commercial Insurance Managed Care [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_MedicareMedicaidMember" xlink:label="FONR_MedicareMedicaidMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_MedicareMedicaidMember" xlink:to="FONR_MedicareMedicaidMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_MedicareMedicaidMember_lbl" xml:lang="en-US">Medicare Medicaid [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_WorkersCompensationPersonalInjuryMember" xlink:label="FONR_WorkersCompensationPersonalInjuryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_WorkersCompensationPersonalInjuryMember" xlink:to="FONR_WorkersCompensationPersonalInjuryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_WorkersCompensationPersonalInjuryMember_lbl" xml:lang="en-US">Workers Compensation Personal Injury [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_OtherMember" xlink:label="FONR_OtherMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_OtherMember" xlink:to="FONR_OtherMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_OtherMember_lbl" xml:lang="en-US">Other [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_OperatingLeasePaymentsMember" xlink:label="FONR_OperatingLeasePaymentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_OperatingLeasePaymentsMember" xlink:to="FONR_OperatingLeasePaymentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_OperatingLeasePaymentsMember_lbl" xml:lang="en-US">Operating Lease Payments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_FinancingLeasePaymentsMember" xlink:label="FONR_FinancingLeasePaymentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_FinancingLeasePaymentsMember" xlink:to="FONR_FinancingLeasePaymentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_FinancingLeasePaymentsMember_lbl" xml:lang="en-US">Financing Lease Payments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_PatentsAndCopyrightsMember" xlink:label="FONR_PatentsAndCopyrightsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_PatentsAndCopyrightsMember" xlink:to="FONR_PatentsAndCopyrightsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_PatentsAndCopyrightsMember_lbl" xml:lang="en-US">Patents and copyrights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="us-gaap_NoncompeteAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncompeteAgreementsMember" xlink:to="us-gaap_NoncompeteAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncompeteAgreementsMember_lbl" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="us-gaap_CustomerRelationshipsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerRelationshipsMember_lbl" xml:lang="en-US">Customer Relationships [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="us-gaap_StatementOperatingActivitiesSegmentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis_lbl" xml:lang="en-US">Operating Activities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_MedicalEquipmentMember" xlink:label="FONR_MedicalEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_MedicalEquipmentMember" xlink:to="FONR_MedicalEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_MedicalEquipmentMember_lbl" xml:lang="en-US">Medical Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ManagementOfDiagnosticImagingCentersMember" xlink:label="FONR_ManagementOfDiagnosticImagingCentersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ManagementOfDiagnosticImagingCentersMember" xlink:to="FONR_ManagementOfDiagnosticImagingCentersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_ManagementOfDiagnosticImagingCentersMember_lbl" xml:lang="en-US">Management Of Diagnostic Imaging Centers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_MagneticResonanceManagementMember" xlink:label="FONR_MagneticResonanceManagementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_MagneticResonanceManagementMember" xlink:to="FONR_MagneticResonanceManagementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_MagneticResonanceManagementMember_lbl" xml:lang="en-US">Magnetic Resonance Management [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US">&#160;Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">&#160;Short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_AccountsReceivableServiceAndRepairFees" xlink:label="FONR_AccountsReceivableServiceAndRepairFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_AccountsReceivableServiceAndRepairFees" xlink:to="FONR_AccountsReceivableServiceAndRepairFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_AccountsReceivableServiceAndRepairFees_lbl" xml:lang="en-US">&#160;Accounts receivable &#8211; net</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_AccountReceivableRelatedParties" xlink:label="FONR_AccountReceivableRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_AccountReceivableRelatedParties" xlink:to="FONR_AccountReceivableRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_AccountReceivableRelatedParties_lbl" xml:lang="en-US">&#160;Accounts receivable - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_MedicalReceivable" xlink:label="FONR_MedicalReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_MedicalReceivable" xlink:to="FONR_MedicalReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_MedicalReceivable_lbl" xml:lang="en-US">&#160;Medical receivable &#8211; net</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ManagementAndOtherFees" xlink:label="FONR_ManagementAndOtherFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ManagementAndOtherFees" xlink:to="FONR_ManagementAndOtherFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_ManagementAndOtherFees_lbl" xml:lang="en-US">&#160;Management and other fees receivable &#8211; net</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" xlink:label="FONR_ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" xlink:to="FONR_ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_lbl" xml:lang="en-US">Management and other fees receivable &#8211; related medical practices &#8211; net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsAndWorkInProcess" xlink:label="us-gaap_InventoryFinishedGoodsAndWorkInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsAndWorkInProcess" xlink:to="us-gaap_InventoryFinishedGoodsAndWorkInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsAndWorkInProcess_lbl" xml:lang="en-US">&#160;Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">&#160;Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_AccountsReceivableNetLongTerm" xlink:label="FONR_AccountsReceivableNetLongTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_AccountsReceivableNetLongTerm" xlink:to="FONR_AccountsReceivableNetLongTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_AccountsReceivableNetLongTerm_lbl" xml:lang="en-US">Accounts receivable &#8211; long term</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_NoteReceivableRelatedParty" xlink:label="FONR_NoteReceivableRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_NoteReceivableRelatedParty" xlink:to="FONR_NoteReceivableRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_NoteReceivableRelatedParty_lbl" xml:lang="en-US">&#160;Note receivable &#8211; related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US">&#160;Deferred income tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">&#160;Property and equipment &#8211; net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">&#160;Right-of-use Asset &#8211; operating lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">&#160;Right-of-use Asset &#8211; financing lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">&#160;Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">&#160;Other intangible assets &#8211; net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">&#160;Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">&#160;Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US">Current portion of long-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">&#160;Unearned revenue on service contracts</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_UnearnedRevenueOnServiceContractsRelatedParty" xlink:label="FONR_UnearnedRevenueOnServiceContractsRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_UnearnedRevenueOnServiceContractsRelatedParty" xlink:to="FONR_UnearnedRevenueOnServiceContractsRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_UnearnedRevenueOnServiceContractsRelatedParty_lbl" xml:lang="en-US">&#160;Unearned revenue on service contracts &#8211; related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">&#160;Operating lease liability - current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">&#160;Financing lease liability - current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CustomerDeposits" xlink:label="FONR_CustomerDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_CustomerDeposits" xlink:to="FONR_CustomerDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_CustomerDeposits_lbl" xml:lang="en-US">Customer deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Long-Term Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">&#160;Unearned revenue on service contracts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">&#160;Deferred income tax liability</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_AccountsPayableRelatedPartyNoncurrent" xlink:label="FONR_AccountsPayableRelatedPartyNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_AccountsPayableRelatedPartyNoncurrent" xlink:to="FONR_AccountsPayableRelatedPartyNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_AccountsPayableRelatedPartyNoncurrent_lbl" xml:lang="en-US">&#160;Due to related medical practices</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">&#160;Operating lease liability &#8211; net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">&#160;Financing lease liability &#8211; net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">&#160;Long-term debt, less current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US">&#160;Other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total Long-Term Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">&#160;Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">&#160;Paid-in capital in excess of par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">&#160;Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock, at cost - 4 shares of common stock at December 31, 2023 and 11 shares of common stock at June 30, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">&#160;Total Fonar Corporation&#8217;s Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">&#160;Non controlling interests</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">&#160;Total Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">&#160;Total Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xml:lang="en-US">Treasury stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">REVENUES</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscounts" xlink:label="FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscounts" xlink:to="FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscounts_lbl" xml:lang="en-US">Patient fee revenue &#8211; net of contractual allowances and discounts</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ProductSalesNet" xlink:label="FONR_ProductSalesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ProductSalesNet" xlink:to="FONR_ProductSalesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_ProductSalesNet_lbl" xml:lang="en-US">Product sales &#8211; net</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ServiceAndRepairFeesNet" xlink:label="FONR_ServiceAndRepairFeesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ServiceAndRepairFeesNet" xlink:to="FONR_ServiceAndRepairFeesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_ServiceAndRepairFeesNet_lbl" xml:lang="en-US">Service and repair fees &#8211; net</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ServiceAndRepairFeesRelatedPartiesNet" xlink:label="FONR_ServiceAndRepairFeesRelatedPartiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ServiceAndRepairFeesRelatedPartiesNet" xlink:to="FONR_ServiceAndRepairFeesRelatedPartiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_ServiceAndRepairFeesRelatedPartiesNet_lbl" xml:lang="en-US">Service and repair fees - related parties &#8211; net</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ManagementAndOtherFeesNet" xlink:label="FONR_ManagementAndOtherFeesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ManagementAndOtherFeesNet" xlink:to="FONR_ManagementAndOtherFeesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_ManagementAndOtherFeesNet_lbl" xml:lang="en-US">Management and other fees &#8211; net</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ManagementAndOtherFeesRelatedMedicalPracticesNet" xlink:label="FONR_ManagementAndOtherFeesRelatedMedicalPracticesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ManagementAndOtherFeesRelatedMedicalPracticesNet" xlink:to="FONR_ManagementAndOtherFeesRelatedMedicalPracticesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_ManagementAndOtherFeesRelatedMedicalPracticesNet_lbl" xml:lang="en-US">Management and other fees - related medical practices &#8211; net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total Revenues &#8211; Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">COSTS AND EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostOfOperatingRevenue" xlink:label="us-gaap_OtherCostOfOperatingRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostOfOperatingRevenue" xlink:to="us-gaap_OtherCostOfOperatingRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCostOfOperatingRevenue_lbl" xml:lang="en-US">Costs related to patient fee revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CostsRelatedToProductSales" xlink:label="FONR_CostsRelatedToProductSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_CostsRelatedToProductSales" xlink:to="FONR_CostsRelatedToProductSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_CostsRelatedToProductSales_lbl" xml:lang="en-US">Costs related to product sales</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CostsRelatedToServiceAndRepairFees" xlink:label="FONR_CostsRelatedToServiceAndRepairFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_CostsRelatedToServiceAndRepairFees" xlink:to="FONR_CostsRelatedToServiceAndRepairFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_CostsRelatedToServiceAndRepairFees_lbl" xml:lang="en-US">Costs related to service and repair fees</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CostsRelatedToServiceAndRepairFeesRelatedParties" xlink:label="FONR_CostsRelatedToServiceAndRepairFeesRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_CostsRelatedToServiceAndRepairFeesRelatedParties" xlink:to="FONR_CostsRelatedToServiceAndRepairFeesRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_CostsRelatedToServiceAndRepairFeesRelatedParties_lbl" xml:lang="en-US">Costs related to service and repair fees - related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CostsRelatedToManagementAndOtherFees" xlink:label="FONR_CostsRelatedToManagementAndOtherFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_CostsRelatedToManagementAndOtherFees" xlink:to="FONR_CostsRelatedToManagementAndOtherFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_CostsRelatedToManagementAndOtherFees_lbl" xml:lang="en-US">Costs related to management and other fees</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices" xlink:label="FONR_CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices" xlink:to="FONR_CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices_lbl" xml:lang="en-US">Costs related to management and other fees &#8211; related medical practices</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Total Costs and Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet_lbl" xml:lang="en-US">Income From Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other Income (Expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_OtherIncomeRelatedParty" xlink:label="FONR_OtherIncomeRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_OtherIncomeRelatedParty" xlink:to="FONR_OtherIncomeRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_OtherIncomeRelatedParty_lbl" xml:lang="en-US">Other Income &#8211; Related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xml:lang="en-US">Investment Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income Before Provision for Income Taxes and Non controlling Interests</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net Income &#8211; Non controlling Interests</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income &#8211; Attributable to FONAR</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic Net Income Per Common Share Available to Common Stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted Net Income Per Common Share Available to Common Stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Basic Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Diluted Shares Outstanding - Common Stockholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US">Purchase of Treasury stock</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_PurchaseOfTreasuryStockShares" xlink:label="FONR_PurchaseOfTreasuryStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_PurchaseOfTreasuryStockShares" xlink:to="FONR_PurchaseOfTreasuryStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_PurchaseOfTreasuryStockShares_lbl" xml:lang="en-US">Purchase of Treasury stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CancellationOfShares" xlink:label="FONR_CancellationOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_CancellationOfShares" xlink:to="FONR_CancellationOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_CancellationOfShares_lbl" xml:lang="en-US">Cancellation of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CancellationOfSharesShares" xlink:label="FONR_CancellationOfSharesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_CancellationOfSharesShares" xlink:to="FONR_CancellationOfSharesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_CancellationOfSharesShares_lbl" xml:lang="en-US">Cancellation of shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_lbl" xml:lang="en-US">Distributions - Non controlling interests</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Income - Non controlling interests</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">&#160;Net income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">&#160;Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDepreciationAndAmortization" xlink:label="us-gaap_OtherDepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDepreciationAndAmortization" xlink:to="us-gaap_OtherDepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherDepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization on right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ProvisionForBadDebts" xlink:label="FONR_ProvisionForBadDebts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ProvisionForBadDebts" xlink:to="FONR_ProvisionForBadDebts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_ProvisionForBadDebts_lbl" xml:lang="en-US">Provision for bad debts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred income tax &#8211; net</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_GainOnSaleOfEquipmentRelatedParty" xlink:label="FONR_GainOnSaleOfEquipmentRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_GainOnSaleOfEquipmentRelatedParty" xlink:to="FONR_GainOnSaleOfEquipmentRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="FONR_GainOnSaleOfEquipmentRelatedParty_lbl" xml:lang="en-US">Gain on sale of equipment &#8211; related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US">(Increase) decrease in operating assets, net:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts, medical and management fee receivable(s)</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_IncreaseDecreaseInNotesReceivable" xlink:label="FONR_IncreaseDecreaseInNotesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_IncreaseDecreaseInNotesReceivable" xlink:to="FONR_IncreaseDecreaseInNotesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_IncreaseDecreaseInNotesReceivable_lbl" xml:lang="en-US">Notes receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xml:lang="en-US">Increase (decrease) in operating liabilities, net:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="FONR_IncreaseDecreaseInOperatingLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="FONR_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_IncreaseDecreaseInFinancingLiabilities" xlink:label="FONR_IncreaseDecreaseInFinancingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_IncreaseDecreaseInFinancingLiabilities" xlink:to="FONR_IncreaseDecreaseInFinancingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="FONR_IncreaseDecreaseInFinancingLiabilities_lbl" xml:lang="en-US">Financing lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_IncreaseDecreaseInCustomerAdvance" xlink:label="FONR_IncreaseDecreaseInCustomerAdvance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_IncreaseDecreaseInCustomerAdvance" xlink:to="FONR_IncreaseDecreaseInCustomerAdvance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="FONR_IncreaseDecreaseInCustomerAdvance_lbl" xml:lang="en-US">Customer deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash provided by operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">&#160;Cash Flows from Investing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Cost of patents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">&#160;Cash Flows from Financing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">&#160;Repayment of borrowings and capital lease obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:label="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:to="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock_lbl" xml:lang="en-US">&#160;Purchase of treasury stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsMinorityInterest" xlink:label="us-gaap_PaymentsOfDividendsMinorityInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividendsMinorityInterest" xlink:to="us-gaap_PaymentsOfDividendsMinorityInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDividendsMinorityInterest_lbl" xml:lang="en-US">&#160;Distributions to non controlling interests</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash used in financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">&#160;Net Increase in Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and Cash Equivalents - Beginning of Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and Cash Equivalents - End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">Receivables [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_DisclosureOperatingFinancingLeasesAbstract" xlink:label="FONR_DisclosureOperatingFinancingLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_DisclosureOperatingFinancingLeasesAbstract" xlink:to="FONR_DisclosureOperatingFinancingLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_DisclosureOperatingFinancingLeasesAbstract_lbl" xml:lang="en-US">Operating Financing Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">OPERATING &amp; FINANCING LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">OTHER INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT AND RELATED INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xml:lang="en-US">SUPPLEMENTAL CASH FLOW INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US">BUSINESS COMBINATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Standards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of earning per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of financing receivable noncurrent allowance for credit loss</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_TotalFacilitiesOwnedOrManagedTableTextBlock" xlink:label="FONR_TotalFacilitiesOwnedOrManagedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_TotalFacilitiesOwnedOrManagedTableTextBlock" xlink:to="FONR_TotalFacilitiesOwnedOrManagedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_TotalFacilitiesOwnedOrManagedTableTextBlock_lbl" xml:lang="en-US">Schedule of Future revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ScheduleOfPatientFeeRevenueTableTextBlock" xlink:label="FONR_ScheduleOfPatientFeeRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ScheduleOfPatientFeeRevenueTableTextBlock" xlink:to="FONR_ScheduleOfPatientFeeRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_ScheduleOfPatientFeeRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of patient fee revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee operating leases liability maturity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">Schedule of other intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of summarized segment financial information</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_HmcaOwnershipSizeOfImperialManagementServicesPercent" xlink:label="FONR_HmcaOwnershipSizeOfImperialManagementServicesPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_HmcaOwnershipSizeOfImperialManagementServicesPercent" xlink:to="FONR_HmcaOwnershipSizeOfImperialManagementServicesPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_HmcaOwnershipSizeOfImperialManagementServicesPercent_lbl" xml:lang="en-US">The ownership interest of Imperial Management Services after reorganization of newly expanded HDM</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_OwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent" xlink:label="FONR_OwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_OwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent" xlink:to="FONR_OwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_OwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent_lbl" xml:lang="en-US">The ownership interest of Health Management Corporation of America after reorganization of newly expanded HDM</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_OwnershipInterestOfOriginalInvestorsOfHdm" xlink:label="FONR_OwnershipInterestOfOriginalInvestorsOfHdm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_OwnershipInterestOfOriginalInvestorsOfHdm" xlink:to="FONR_OwnershipInterestOfOriginalInvestorsOfHdm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_OwnershipInterestOfOriginalInvestorsOfHdm_lbl" xml:lang="en-US">The ownership interest of the original investors of HDM</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_DirectPurchaseOfNoncontrollingInterests" xlink:label="FONR_DirectPurchaseOfNoncontrollingInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_DirectPurchaseOfNoncontrollingInterests" xlink:to="FONR_DirectPurchaseOfNoncontrollingInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_DirectPurchaseOfNoncontrollingInterests_lbl" xml:lang="en-US">Direct purchase of Noncontrolling Interests</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Direct ownership interest percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_InvestorsOwnershipInterest" xlink:label="FONR_InvestorsOwnershipInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_InvestorsOwnershipInterest" xlink:to="FONR_InvestorsOwnershipInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_InvestorsOwnershipInterest_lbl" xml:lang="en-US">Investors ownership interest percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_NetIncomeLossAvailableToCommonStockholderBasic" xlink:label="FONR_NetIncomeLossAvailableToCommonStockholderBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_NetIncomeLossAvailableToCommonStockholderBasic" xlink:to="FONR_NetIncomeLossAvailableToCommonStockholderBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_NetIncomeLossAvailableToCommonStockholderBasic_lbl" xml:lang="en-US">Basic Numerator: Net income available to common stockholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Basic Denominator: Weighted average shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US">Basic income per common share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Diluted Denominator: Weighted average shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ConvertibleClassCStock" xlink:label="FONR_ConvertibleClassCStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ConvertibleClassCStock" xlink:to="FONR_ConvertibleClassCStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_ConvertibleClassCStock_lbl" xml:lang="en-US">Convertible Class C Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_WeightedAverageNumberOfDilutedEarningsPerShare" xlink:label="FONR_WeightedAverageNumberOfDilutedEarningsPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_WeightedAverageNumberOfDilutedEarningsPerShare" xlink:to="FONR_WeightedAverageNumberOfDilutedEarningsPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_WeightedAverageNumberOfDilutedEarningsPerShare_lbl" xml:lang="en-US">Total Denominator for Diluted Earnings Per Share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_2_lbl" xml:lang="en-US">Diluted Income per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_lbl" xml:lang="en-US">Shares included upon conversion of Class C Common</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_AccountsReceivableServiceAndRepairFees" xlink:to="FONR_AccountsReceivableServiceAndRepairFees_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="FONR_AccountsReceivableServiceAndRepairFees_2_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_AccountsReceivableNetRelatedParty" xlink:label="FONR_AccountsReceivableNetRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_AccountsReceivableNetRelatedParty" xlink:to="FONR_AccountsReceivableNetRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_AccountsReceivableNetRelatedParty_lbl" xml:lang="en-US">Accounts receivable - Related party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_MedicalReceivable" xlink:to="FONR_MedicalReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="FONR_MedicalReceivable_2_lbl" xml:lang="en-US">Medical Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ManagementAndOtherFeesNonRelatedParties" xlink:label="FONR_ManagementAndOtherFeesNonRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ManagementAndOtherFeesNonRelatedParties" xlink:to="FONR_ManagementAndOtherFeesNonRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_ManagementAndOtherFeesNonRelatedParties_lbl" xml:lang="en-US">Management and other fees receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" xlink:to="FONR_ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="FONR_ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_2_lbl" xml:lang="en-US">Management and other fees receivable from related medical practices ("PC's")</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractReceivableDueOneToTwoYears" xlink:label="us-gaap_ContractReceivableDueOneToTwoYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractReceivableDueOneToTwoYears" xlink:to="us-gaap_ContractReceivableDueOneToTwoYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractReceivableDueOneToTwoYears_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractReceivableDueTwoToThreeYears" xlink:label="us-gaap_ContractReceivableDueTwoToThreeYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractReceivableDueTwoToThreeYears" xlink:to="us-gaap_ContractReceivableDueTwoToThreeYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractReceivableDueTwoToThreeYears_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms" xlink:label="us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms" xlink:to="us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscount" xlink:label="FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscount" xlink:to="FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscount_lbl" xml:lang="en-US">Patient Fee Revenue, net of contractual allowances and discounts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_AccountsReceivableNetLongTerm" xlink:to="FONR_AccountsReceivableNetLongTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="FONR_AccountsReceivableNetLongTerm_2_lbl" xml:lang="en-US">Long term accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims" xlink:label="FONR_PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims" xlink:to="FONR_PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims_lbl" xml:lang="en-US">Percentage of net revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_PercentageOfConsolidatedNetRevenueFromManagementFees" xlink:label="FONR_PercentageOfConsolidatedNetRevenueFromManagementFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_PercentageOfConsolidatedNetRevenueFromManagementFees" xlink:to="FONR_PercentageOfConsolidatedNetRevenueFromManagementFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_PercentageOfConsolidatedNetRevenueFromManagementFees_lbl" xml:lang="en-US">Percentage of consolidated net revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_PresentValueDiscount" xlink:label="FONR_PresentValueDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_PresentValueDiscount" xlink:to="FONR_PresentValueDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_PresentValueDiscount_lbl" xml:lang="en-US">Present value discount</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_PresentValueDiscountFinancingLease" xlink:label="FONR_PresentValueDiscountFinancingLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_PresentValueDiscountFinancingLease" xlink:to="FONR_PresentValueDiscountFinancingLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="FONR_PresentValueDiscountFinancingLease_lbl" xml:lang="en-US">Present value discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease, Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Finance Lease, Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInventorySupplies" xlink:label="us-gaap_OtherInventorySupplies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInventorySupplies" xlink:to="us-gaap_OtherInventorySupplies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherInventorySupplies_lbl" xml:lang="en-US">Purchased parts, components and supplies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work-in-process</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsAndWorkInProcess" xlink:to="us-gaap_InventoryFinishedGoodsAndWorkInProcess_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryFinishedGoodsAndWorkInProcess_2_lbl" xml:lang="en-US">Total Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross other intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Less: Accumulated amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xml:lang="en-US">Other intangible assets-net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued salaries, commissions and payroll taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent_lbl" xml:lang="en-US">Sales tax payable</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_StateIncomeTaxesPayable" xlink:label="FONR_StateIncomeTaxesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_StateIncomeTaxesPayable" xlink:to="FONR_StateIncomeTaxesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_StateIncomeTaxesPayable_lbl" xml:lang="en-US">Income taxes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Legal and other professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounting fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SelfInsuranceReserve" xlink:label="us-gaap_SelfInsuranceReserve" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SelfInsuranceReserve" xlink:to="us-gaap_SelfInsuranceReserve_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SelfInsuranceReserve_lbl" xml:lang="en-US">Self-funded health insurance reserve</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Accrued interest and penalty</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent_lbl" xml:lang="en-US">Other general and administrative expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_2_lbl" xml:lang="en-US">Other Current Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Net revenues from external customers</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_IntersegmentNetRevenues" xlink:label="FONR_IntersegmentNetRevenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_IntersegmentNetRevenues" xlink:to="FONR_IntersegmentNetRevenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_IntersegmentNetRevenues_lbl" xml:lang="en-US">Inter-segment net revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US">(Loss) Income from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US">Capital expenditures</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Sale of price of the equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFixedInterestRate" xlink:label="us-gaap_DerivativeFixedInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFixedInterestRate" xlink:to="us-gaap_DerivativeFixedInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFixedInterestRate_lbl" xml:lang="en-US">Bears interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_GainOnSaleOfEquipmentsRelatedParty" xlink:label="FONR_GainOnSaleOfEquipmentsRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_GainOnSaleOfEquipmentsRelatedParty" xlink:to="FONR_GainOnSaleOfEquipmentsRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_GainOnSaleOfEquipmentsRelatedParty_lbl" xml:lang="en-US">Gain on sale of equipments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Income taxes paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xml:lang="en-US">Stock purchase plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Number of shares repurchased</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_2_lbl" xml:lang="en-US">Number of shares repurchased, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xml:lang="en-US">Shares cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xml:lang="en-US">Shares cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_StoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims" xlink:label="FONR_StoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_StoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims" xlink:to="FONR_StoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_StoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims_lbl" xml:lang="en-US">Liability for individual claims</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth" xlink:label="us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth" xlink:to="us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth_lbl" xml:lang="en-US">Reserve for self-funded</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_lbl" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax component - current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax component - deferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityPolicyholdersSurplus" xlink:label="us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityPolicyholdersSurplus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityPolicyholdersSurplus" xlink:to="us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityPolicyholdersSurplus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityPolicyholdersSurplus_lbl" xml:lang="en-US">Deferred tax liability</link:label>
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CorporateAlternativeMinimumTaxPercentage" xlink:label="FONR_CorporateAlternativeMinimumTaxPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_CorporateAlternativeMinimumTaxPercentage" xlink:to="FONR_CorporateAlternativeMinimumTaxPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_CorporateAlternativeMinimumTaxPercentage_lbl" xml:lang="en-US">Corporate alternative minimum tax percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ClassANonVotingPreferredStockMember" xlink:to="FONR_ClassANonVotingPreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_ClassANonVotingPreferredStockMember_doc" xml:lang="en-US">Class A Non Voting Preferred Stock Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_UnearnedRevenueOnServiceContractsRelatedParty" xlink:to="FONR_UnearnedRevenueOnServiceContractsRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_UnearnedRevenueOnServiceContractsRelatedParty_doc" xml:lang="en-US">This represents the amount of unearned revenue on service contracts related party during period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscounts" xlink:to="FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscounts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscounts_doc" xml:lang="en-US">This represents the amount of patient fee revenue net of contractual allowances and discounts during period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ProductSalesNet" xlink:to="FONR_ProductSalesNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_ProductSalesNet_doc" xml:lang="en-US">This represents the amount of product sales net during period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ServiceAndRepairFeesNet" xlink:to="FONR_ServiceAndRepairFeesNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_ServiceAndRepairFeesNet_doc" xml:lang="en-US">This represents the amount of service and repair fees net during period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ServiceAndRepairFeesRelatedPartiesNet" xlink:to="FONR_ServiceAndRepairFeesRelatedPartiesNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_ServiceAndRepairFeesRelatedPartiesNet_doc" xml:lang="en-US">This represents the amount of service and repair fees related parties net during period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ManagementAndOtherFeesNet" xlink:to="FONR_ManagementAndOtherFeesNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_ManagementAndOtherFeesNet_doc" xml:lang="en-US">This represents the value of management and other fees net during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ManagementAndOtherFeesRelatedMedicalPracticesNet" xlink:to="FONR_ManagementAndOtherFeesRelatedMedicalPracticesNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_ManagementAndOtherFeesRelatedMedicalPracticesNet_doc" xml:lang="en-US">This represents the value of management and other fees related medical practices net during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices" xlink:to="FONR_CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices_doc" xml:lang="en-US">This represents the amount of costs related to management and other fees related medical practices during period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_CancellationOfShares" xlink:to="FONR_CancellationOfShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_CancellationOfShares_doc" xml:lang="en-US">This represents the amount of cancellation of shares during year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ProvisionForBadDebts" xlink:to="FONR_ProvisionForBadDebts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_ProvisionForBadDebts_doc" xml:lang="en-US">This represents the amount of provision for bad debts during period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_HmcaOwnershipSizeOfImperialManagementServicesPercent" xlink:to="FONR_HmcaOwnershipSizeOfImperialManagementServicesPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_HmcaOwnershipSizeOfImperialManagementServicesPercent_doc" xml:lang="en-US">This represents the rate of hmca ownership size of imperial management services percent during period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_OwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent" xlink:to="FONR_OwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_OwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent_doc" xml:lang="en-US">This represents the rate of ownership interest after reorganization for health management corporation of America of newly expanded hdm percent during period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_OwnershipInterestOfOriginalInvestorsOfHdm" xlink:to="FONR_OwnershipInterestOfOriginalInvestorsOfHdm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_OwnershipInterestOfOriginalInvestorsOfHdm_doc" xml:lang="en-US">This represents the rate of ownership interest of original investors of hdm during period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_DirectPurchaseOfNoncontrollingInterests" xlink:to="FONR_DirectPurchaseOfNoncontrollingInterests_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_DirectPurchaseOfNoncontrollingInterests_doc" xml:lang="en-US">This represents the amount of direct purchase of noncontrolling interests during period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_InvestorsOwnershipInterest" xlink:to="FONR_InvestorsOwnershipInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_InvestorsOwnershipInterest_doc" xml:lang="en-US">This represents the rate of investors ownership interest during period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_NetIncomeLossAvailableToCommonStockholderBasic" xlink:to="FONR_NetIncomeLossAvailableToCommonStockholderBasic_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_NetIncomeLossAvailableToCommonStockholderBasic_doc" xml:lang="en-US">This represents the amount of net income loss available to common stockholder basic during period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ConvertibleClassCStock" xlink:to="FONR_ConvertibleClassCStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_ConvertibleClassCStock_doc" xml:lang="en-US">This represents the shares of convertible class c stock during period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_WeightedAverageNumberOfDilutedEarningsPerShare" xlink:to="FONR_WeightedAverageNumberOfDilutedEarningsPerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_WeightedAverageNumberOfDilutedEarningsPerShare_doc" xml:lang="en-US">Weighted average number of diluted earnings per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_AccountsReceivableNetRelatedParty" xlink:to="FONR_AccountsReceivableNetRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_AccountsReceivableNetRelatedParty_doc" xml:lang="en-US">Accounts receivable from service and repair fees of Related Party MRI scanner customers; net of allowances for doubtful accounts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims" xlink:to="FONR_PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims_doc" xml:lang="en-US">Percentage of PCs net revenue derived from nofault and personal injury protection claims.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_PercentageOfConsolidatedNetRevenueFromManagementFees" xlink:to="FONR_PercentageOfConsolidatedNetRevenueFromManagementFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_PercentageOfConsolidatedNetRevenueFromManagementFees_doc" xml:lang="en-US">Percentage of consolidated net revenue from management fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscount" xlink:to="FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscount_doc" xml:lang="en-US">This represents the amount of patient fee revenue net of contractual allowances and discounts during period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_PresentValueDiscount" xlink:to="FONR_PresentValueDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_PresentValueDiscount_doc" xml:lang="en-US">This represents the amount of present value discount during period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_PresentValueDiscountFinancingLease" xlink:to="FONR_PresentValueDiscountFinancingLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_PresentValueDiscountFinancingLease_doc" xml:lang="en-US">This represents the amount of present value discount financing lease during period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_PatentsAndCopyrightsMember" xlink:to="FONR_PatentsAndCopyrightsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_PatentsAndCopyrightsMember_doc" xml:lang="en-US">Patents and copyrights - Member - Custom elements</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_StateIncomeTaxesPayable" xlink:to="FONR_StateIncomeTaxesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_StateIncomeTaxesPayable_doc" xml:lang="en-US">the value of state income taxes payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_IntersegmentNetRevenues" xlink:to="FONR_IntersegmentNetRevenues_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_IntersegmentNetRevenues_doc" xml:lang="en-US">This represents the amount of intersegment net revenues during period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_ManagementOfDiagnosticImagingCentersMember" xlink:to="FONR_ManagementOfDiagnosticImagingCentersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_ManagementOfDiagnosticImagingCentersMember_doc" xml:lang="en-US">Management of Diagnostic Imaging Centers - Member - Custom element</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_StoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims" xlink:to="FONR_StoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FONR_StoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims_doc" xml:lang="en-US">This represents the amount of stop loss umbrella policy with 3 rd paryinsurer to limit maximum potential liability for individual claims during year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_CommonStocksMember" xlink:to="FONR_CommonStocksMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_CommonStocksMember_2_lbl" xml:lang="en-US">Common Stock [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_2_lbl" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_2_lbl" xml:lang="en-US">Treasury Stock, Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_2_lbl" xml:lang="en-US">Costs and Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Interest Expense, Interest Income, Income Taxes, Noncontrolling Interests, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_2_lbl" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_GainOnSaleOfEquipmentRelatedParty" xlink:to="FONR_GainOnSaleOfEquipmentRelatedParty_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_GainOnSaleOfEquipmentRelatedParty_2_lbl" xml:lang="en-US">GainOnSaleOfEquipmentRelatedParty</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_IncreaseDecreaseInFinancingLiabilities" xlink:to="FONR_IncreaseDecreaseInFinancingLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_IncreaseDecreaseInFinancingLiabilities_2_lbl" xml:lang="en-US">IncreaseDecreaseInFinancingLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_IncreaseDecreaseInCustomerAdvance" xlink:to="FONR_IncreaseDecreaseInCustomerAdvance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_IncreaseDecreaseInCustomerAdvance_2_lbl" xml:lang="en-US">IncreaseDecreaseInCustomerAdvance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:to="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock_2_lbl" xml:lang="en-US">Payments for Repurchase of Convertible Preferred Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividendsMinorityInterest" xlink:to="us-gaap_PaymentsOfDividendsMinorityInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDividendsMinorityInterest_2_lbl" xml:lang="en-US">Payments of Ordinary Dividends, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FONR_PresentValueDiscountFinancingLease" xlink:to="FONR_PresentValueDiscountFinancingLease_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FONR_PresentValueDiscountFinancingLease_3_lbl" xml:lang="en-US">PresentValueDiscountFinancingLease</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_2_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_2_lbl" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>fonr-20231231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://fonar.com/role/Cover" xlink:href="fonr-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/CondensedConsolidatedBalanceSheets" xlink:href="fonr-20231231.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="fonr-20231231.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/CondensedConsolidatedStatementsOfIncome" xlink:href="fonr-20231231.xsd#CondensedConsolidatedStatementsOfIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/CondensedConsolidatedStatementsOfIncomeParenthetical" xlink:href="fonr-20231231.xsd#CondensedConsolidatedStatementsOfIncomeParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity" xlink:href="fonr-20231231.xsd#CondensedConsolidatedStatementOfChangesInEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="fonr-20231231.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:href="fonr-20231231.xsd#DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="fonr-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable" xlink:href="fonr-20231231.xsd#AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OperatingFinancingLeases" xlink:href="fonr-20231231.xsd#OperatingFinancingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/Inventories" xlink:href="fonr-20231231.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OtherIntangibleAssets" xlink:href="fonr-20231231.xsd#OtherIntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OtherCurrentLiabilities" xlink:href="fonr-20231231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SegmentAndRelatedInformation" xlink:href="fonr-20231231.xsd#SegmentAndRelatedInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/RelatedPartyTransaction" xlink:href="fonr-20231231.xsd#RelatedPartyTransaction" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SupplementalCashFlowInformation" xlink:href="fonr-20231231.xsd#SupplementalCashFlowInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/CommitmentsAndContingencies" xlink:href="fonr-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/IncomeTaxes" xlink:href="fonr-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SubsequentEvents" xlink:href="fonr-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="fonr-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="fonr-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableTables" xlink:href="fonr-20231231.xsd#AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OperatingFinancingLeasesTables" xlink:href="fonr-20231231.xsd#OperatingFinancingLeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/InventoriesTables" xlink:href="fonr-20231231.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OtherIntangibleAssetsTables" xlink:href="fonr-20231231.xsd#OtherIntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OtherCurrentLiabilitiesTables" xlink:href="fonr-20231231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SegmentAndRelatedInformationTables" xlink:href="fonr-20231231.xsd#SegmentAndRelatedInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:href="fonr-20231231.xsd#DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details" xlink:href="fonr-20231231.xsd#SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="fonr-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails" xlink:href="fonr-20231231.xsd#AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails1" xlink:href="fonr-20231231.xsd#AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetails" xlink:href="fonr-20231231.xsd#AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetailsNarrative" xlink:href="fonr-20231231.xsd#AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails" xlink:href="fonr-20231231.xsd#OperatingFinancingLeases-LeasePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/Inventories-InventoriesDetails" xlink:href="fonr-20231231.xsd#Inventories-InventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OtherIntangibleAssets-OtherIntangibleAssetsNetOfAmortizationDetails" xlink:href="fonr-20231231.xsd#OtherIntangibleAssets-OtherIntangibleAssetsNetOfAmortizationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OtherIntangibleAssetsDetailsNarrative" xlink:href="fonr-20231231.xsd#OtherIntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details" xlink:href="fonr-20231231.xsd#OtherCurrentLiabilities-OtherCurrentLiabilities-Details" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SegmentAndRelatedInformation-SummarizedSegments-Details" xlink:href="fonr-20231231.xsd#SegmentAndRelatedInformation-SummarizedSegments-Details" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/RelatedPartyTransactionDetailsNarrative" xlink:href="fonr-20231231.xsd#RelatedPartyTransactionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/SupplementalCashFlowInformationDetailsNarrative" xlink:href="fonr-20231231.xsd#SupplementalCashFlowInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="fonr-20231231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fonar.com/role/IncomeTaxesDetailsNarrative" xlink:href="fonr-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember" xlink:label="loc_us-gaapCommonClassCMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ClassAPreferredStockMember" xlink:label="loc_FONRClassAPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FONRClassAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ClassANonVotingPreferredStockMember" xlink:label="loc_FONRClassANonVotingPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FONRClassANonVotingPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CommonStocksMember" xlink:label="loc_FONRCommonStocksMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FONRCommonStocksMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember" xlink:label="loc_us-gaapCommonClassCMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_AccountsReceivableServiceAndRepairFees" xlink:label="loc_FONRAccountsReceivableServiceAndRepairFees" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_FONRAccountsReceivableServiceAndRepairFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_AccountReceivableRelatedParties" xlink:label="loc_FONRAccountReceivableRelatedParties" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_FONRAccountReceivableRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_MedicalReceivable" xlink:label="loc_FONRMedicalReceivable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_FONRMedicalReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ManagementAndOtherFees" xlink:label="loc_FONRManagementAndOtherFees" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_FONRManagementAndOtherFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" xlink:label="loc_FONRManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_FONRManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsAndWorkInProcess" xlink:label="loc_us-gaapInventoryFinishedGoodsAndWorkInProcess" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryFinishedGoodsAndWorkInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_AccountsReceivableNetLongTerm" xlink:label="loc_FONRAccountsReceivableNetLongTerm" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_FONRAccountsReceivableNetLongTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_NoteReceivableRelatedParty" xlink:label="loc_FONRNoteReceivableRelatedParty" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_FONRNoteReceivableRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaapDeferredTaxAssetsDeferredIncome" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsDeferredIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaapLongTermDebtCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLongTermDebtCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_UnearnedRevenueOnServiceContractsRelatedParty" xlink:label="loc_FONRUnearnedRevenueOnServiceContractsRelatedParty" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_FONRUnearnedRevenueOnServiceContractsRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CustomerDeposits" xlink:label="loc_FONRCustomerDeposits" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_FONRCustomerDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapDeferredRevenueNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapDeferredIncomeTaxesAndOtherLiabilitiesNoncurrent" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxesAndOtherLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_AccountsPayableRelatedPartyNoncurrent" xlink:label="loc_FONRAccountsPayableRelatedPartyNoncurrent" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_FONRAccountsPayableRelatedPartyNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ClassANonVotingPreferredStockMember" xlink:label="loc_FONRClassANonVotingPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FONRClassANonVotingPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember" xlink:label="loc_us-gaapCommonClassCMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaapTreasuryStockCommonShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTreasuryStockCommonShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/CondensedConsolidatedStatementsOfIncome" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscounts" xlink:label="loc_FONRPatientFeeRevenueNetOfContractualAllowancesAndDiscounts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_FONRPatientFeeRevenueNetOfContractualAllowancesAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ProductSalesNet" xlink:label="loc_FONRProductSalesNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_FONRProductSalesNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ServiceAndRepairFeesNet" xlink:label="loc_FONRServiceAndRepairFeesNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_FONRServiceAndRepairFeesNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ServiceAndRepairFeesRelatedPartiesNet" xlink:label="loc_FONRServiceAndRepairFeesRelatedPartiesNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_FONRServiceAndRepairFeesRelatedPartiesNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ManagementAndOtherFeesNet" xlink:label="loc_FONRManagementAndOtherFeesNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_FONRManagementAndOtherFeesNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ManagementAndOtherFeesRelatedMedicalPracticesNet" xlink:label="loc_FONRManagementAndOtherFeesRelatedMedicalPracticesNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_FONRManagementAndOtherFeesRelatedMedicalPracticesNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaapCostsAndExpensesAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostsAndExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostOfOperatingRevenue" xlink:label="loc_us-gaapOtherCostOfOperatingRevenue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapOtherCostOfOperatingRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CostsRelatedToProductSales" xlink:label="loc_FONRCostsRelatedToProductSales" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_FONRCostsRelatedToProductSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CostsRelatedToServiceAndRepairFees" xlink:label="loc_FONRCostsRelatedToServiceAndRepairFees" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_FONRCostsRelatedToServiceAndRepairFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CostsRelatedToServiceAndRepairFeesRelatedParties" xlink:label="loc_FONRCostsRelatedToServiceAndRepairFeesRelatedParties" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_FONRCostsRelatedToServiceAndRepairFeesRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CostsRelatedToManagementAndOtherFees" xlink:label="loc_FONRCostsRelatedToManagementAndOtherFees" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_FONRCostsRelatedToManagementAndOtherFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices" xlink:label="loc_FONRCostsRelatedToManagementAndOtherFeesRelatedMedicalPractices" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_FONRCostsRelatedToManagementAndOtherFeesRelatedMedicalPractices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_OtherIncomeRelatedParty" xlink:label="loc_FONROtherIncomeRelatedParty" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_FONROtherIncomeRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaapInvestmentIncomeNet" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInvestmentIncomeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/CondensedConsolidatedStatementsOfIncomeParenthetical" xlink:title="00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CommonStockholdersMember" xlink:label="loc_FONRCommonStockholdersMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FONRCommonStockholdersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ClassANonVotingPreferredStockholdersMember" xlink:label="loc_FONRClassANonVotingPreferredStockholdersMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FONRClassANonVotingPreferredStockholdersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember" xlink:label="loc_us-gaapCommonClassCMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity" xlink:title="00000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapTreasuryStockCommonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapNoncontrollingInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_PurchaseOfTreasuryStockShares" xlink:label="loc_FONRPurchaseOfTreasuryStockShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONRPurchaseOfTreasuryStockShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CancellationOfShares" xlink:label="loc_FONRCancellationOfShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONRCancellationOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CancellationOfSharesShares" xlink:label="loc_FONRCancellationOfSharesShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONRCancellationOfSharesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaapMinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:title="00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDepreciationAndAmortization" xlink:label="loc_us-gaapOtherDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOtherDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ProvisionForBadDebts" xlink:label="loc_FONRProvisionForBadDebts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_FONRProvisionForBadDebts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_GainOnSaleOfEquipmentRelatedParty" xlink:label="loc_FONRGainOnSaleOfEquipmentRelatedParty" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_FONRGainOnSaleOfEquipmentRelatedParty" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_IncreaseDecreaseInNotesReceivable" xlink:label="loc_FONRIncreaseDecreaseInNotesReceivable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_FONRIncreaseDecreaseInNotesReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_FONRIncreaseDecreaseInOperatingLeaseLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_FONRIncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_IncreaseDecreaseInFinancingLiabilities" xlink:label="loc_FONRIncreaseDecreaseInFinancingLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_FONRIncreaseDecreaseInFinancingLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_IncreaseDecreaseInCustomerAdvance" xlink:label="loc_FONRIncreaseDecreaseInCustomerAdvance" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_FONRIncreaseDecreaseInCustomerAdvance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfConvertiblePreferredStock" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForRepurchaseOfConvertiblePreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsMinorityInterest" xlink:label="loc_us-gaapPaymentsOfDividendsMinorityInterest" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfDividendsMinorityInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:title="00000008 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable" xlink:title="00000010 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="loc_us-gaapLoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapLoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/OperatingFinancingLeases" xlink:title="00000011 - Disclosure - OPERATING &amp; FINANCING LEASES">
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_DisclosureOperatingFinancingLeasesAbstract" xlink:label="loc_FONRDisclosureOperatingFinancingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FONRDisclosureOperatingFinancingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/Inventories" xlink:title="00000012 - Disclosure - INVENTORIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/OtherIntangibleAssets" xlink:title="00000013 - Disclosure - OTHER INTANGIBLE ASSETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/SegmentAndRelatedInformation" xlink:title="00000015 - Disclosure - SEGMENT AND RELATED INFORMATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/RelatedPartyTransaction" xlink:title="00000016 - Disclosure - RELATED PARTY TRANSACTION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/SupplementalCashFlowInformation" xlink:title="00000017 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaapSupplementalCashFlowElementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="loc_us-gaapCashFlowSupplementalDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowElementsAbstract" xlink:to="loc_us-gaapCashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/IncomeTaxes" xlink:title="00000019 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/SubsequentEvents" xlink:title="00000020 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaapBusinessCombinationsPolicy" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessCombinationsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableTables" xlink:title="00000023 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_TotalFacilitiesOwnedOrManagedTableTextBlock" xlink:label="loc_FONRTotalFacilitiesOwnedOrManagedTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_FONRTotalFacilitiesOwnedOrManagedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ScheduleOfPatientFeeRevenueTableTextBlock" xlink:label="loc_FONRScheduleOfPatientFeeRevenueTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_FONRScheduleOfPatientFeeRevenueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/OperatingFinancingLeasesTables" xlink:title="00000024 - Disclosure - OPERATING &amp; FINANCING LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_DisclosureOperatingFinancingLeasesAbstract" xlink:label="loc_FONRDisclosureOperatingFinancingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FONRDisclosureOperatingFinancingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/InventoriesTables" xlink:title="00000025 - Disclosure - INVENTORIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/OtherIntangibleAssetsTables" xlink:title="00000026 - Disclosure - OTHER INTANGIBLE ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000027 - Disclosure - OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/SegmentAndRelatedInformationTables" xlink:title="00000028 - Disclosure - SEGMENT AND RELATED INFORMATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:title="00000029 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ControllingInterestMember" xlink:label="loc_FONRControllingInterestMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_FONRControllingInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapNoncontrollingInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_HmcaOwnershipSizeOfImperialManagementServicesPercent" xlink:label="loc_FONRHmcaOwnershipSizeOfImperialManagementServicesPercent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONRHmcaOwnershipSizeOfImperialManagementServicesPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_OwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent" xlink:label="loc_FONROwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONROwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_OwnershipInterestOfOriginalInvestorsOfHdm" xlink:label="loc_FONROwnershipInterestOfOriginalInvestorsOfHdm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONROwnershipInterestOfOriginalInvestorsOfHdm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_DirectPurchaseOfNoncontrollingInterests" xlink:label="loc_FONRDirectPurchaseOfNoncontrollingInterests" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONRDirectPurchaseOfNoncontrollingInterests" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_InvestorsOwnershipInterest" xlink:label="loc_FONRInvestorsOwnershipInterest" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONRInvestorsOwnershipInterest" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details" xlink:title="00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share - (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember" xlink:label="loc_us-gaapCommonClassCMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_NetIncomeLossAvailableToCommonStockholderBasic" xlink:label="loc_FONRNetIncomeLossAvailableToCommonStockholderBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONRNetIncomeLossAvailableToCommonStockholderBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ConvertibleClassCStock" xlink:label="loc_FONRConvertibleClassCStock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONRConvertibleClassCStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_WeightedAverageNumberOfDilutedEarningsPerShare" xlink:label="loc_FONRWeightedAverageNumberOfDilutedEarningsPerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONRWeightedAverageNumberOfDilutedEarningsPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:label="loc_us-gaapIncrementalCommonSharesAttributableToConversionOfPreferredStock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails" xlink:title="00000032 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="loc_us-gaapAccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="loc_us-gaapAccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="loc_us-gaapReceivableTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="loc_us-gaapReceivableTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivableTypeDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DoubtfulMember" xlink:label="loc_us-gaapDoubtfulMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivableTypeDomain" xlink:to="loc_us-gaapDoubtfulMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_AccountsReceivableServiceAndRepairFees" xlink:label="loc_FONRAccountsReceivableServiceAndRepairFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" xlink:to="loc_FONRAccountsReceivableServiceAndRepairFees" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_AccountsReceivableNetRelatedParty" xlink:label="loc_FONRAccountsReceivableNetRelatedParty" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" xlink:to="loc_FONRAccountsReceivableNetRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_MedicalReceivable" xlink:label="loc_FONRMedicalReceivable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" xlink:to="loc_FONRMedicalReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ManagementAndOtherFeesNonRelatedParties" xlink:label="loc_FONRManagementAndOtherFeesNonRelatedParties" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" xlink:to="loc_FONRManagementAndOtherFeesNonRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" xlink:label="loc_FONRManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" xlink:to="loc_FONRManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails1" xlink:title="00000033 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractReceivableDueOneToTwoYears" xlink:label="loc_us-gaapContractReceivableDueOneToTwoYears" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapContractReceivableDueOneToTwoYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractReceivableDueTwoToThreeYears" xlink:label="loc_us-gaapContractReceivableDueTwoToThreeYears" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapContractReceivableDueTwoToThreeYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms" xlink:label="loc_us-gaapAccountsReceivableBilledForLongTermContractsOrPrograms" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapAccountsReceivableBilledForLongTermContractsOrPrograms" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetails" xlink:title="00000034 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapDisaggregationOfRevenueLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CommercialInsuranceManagedCareMember" xlink:label="loc_FONRCommercialInsuranceManagedCareMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" xlink:to="loc_FONRCommercialInsuranceManagedCareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_MedicareMedicaidMember" xlink:label="loc_FONRMedicareMedicaidMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" xlink:to="loc_FONRMedicareMedicaidMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_WorkersCompensationPersonalInjuryMember" xlink:label="loc_FONRWorkersCompensationPersonalInjuryMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" xlink:to="loc_FONRWorkersCompensationPersonalInjuryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_OtherMember" xlink:label="loc_FONROtherMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" xlink:to="loc_FONROtherMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscount" xlink:label="loc_FONRPatientFeeRevenueNetOfContractualAllowancesAndDiscount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_FONRPatientFeeRevenueNetOfContractualAllowancesAndDiscount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetailsNarrative" xlink:title="00000035 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_AccountsReceivableNetLongTerm" xlink:label="loc_FONRAccountsReceivableNetLongTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_FONRAccountsReceivableNetLongTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims" xlink:label="loc_FONRPercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_FONRPercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_PercentageOfConsolidatedNetRevenueFromManagementFees" xlink:label="loc_FONRPercentageOfConsolidatedNetRevenueFromManagementFees" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_FONRPercentageOfConsolidatedNetRevenueFromManagementFees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails" xlink:title="00000036 - Disclosure - OPERATING &amp; FINANCING LEASES - Lease Payments (Details)">
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_DisclosureOperatingFinancingLeasesAbstract" xlink:label="loc_FONRDisclosureOperatingFinancingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FONRDisclosureOperatingFinancingLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_OperatingLeasePaymentsMember" xlink:label="loc_FONROperatingLeasePaymentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_FONROperatingLeasePaymentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_FinancingLeasePaymentsMember" xlink:label="loc_FONRFinancingLeasePaymentsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_FONRFinancingLeasePaymentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_PresentValueDiscount" xlink:label="loc_FONRPresentValueDiscount" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONRPresentValueDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_PresentValueDiscountFinancingLease" xlink:label="loc_FONRPresentValueDiscountFinancingLease" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONRPresentValueDiscountFinancingLease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/Inventories-InventoriesDetails" xlink:title="00000037 - Disclosure - INVENTORIES - Inventories (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInventorySupplies" xlink:label="loc_us-gaapOtherInventorySupplies" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapOtherInventorySupplies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsAndWorkInProcess" xlink:label="loc_us-gaapInventoryFinishedGoodsAndWorkInProcess" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoodsAndWorkInProcess" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/OtherIntangibleAssets-OtherIntangibleAssetsNetOfAmortizationDetails" xlink:title="00000038 - Disclosure - OTHER INTANGIBLE ASSETS - Other intangible assets net of amortization (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_PatentsAndCopyrightsMember" xlink:label="loc_FONRPatentsAndCopyrightsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_FONRPatentsAndCopyrightsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaapNoncompeteAgreementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapNoncompeteAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/OtherIntangibleAssetsDetailsNarrative" xlink:title="00000039 - Disclosure - OTHER INTANGIBLE ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_PatentsAndCopyrightsMember" xlink:label="loc_FONRPatentsAndCopyrightsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_FONRPatentsAndCopyrightsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details" xlink:title="00000040 - Disclosure - OTHER CURRENT LIABILITIES - Other Current Liabilities - (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaapSalesAndExciseTaxPayableCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapSalesAndExciseTaxPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_StateIncomeTaxesPayable" xlink:label="loc_FONRStateIncomeTaxesPayable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_FONRStateIncomeTaxesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrentAndNoncurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SelfInsuranceReserve" xlink:label="loc_us-gaapSelfInsuranceReserve" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapSelfInsuranceReserve" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="loc_us-gaapOtherSundryLiabilitiesCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherSundryLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/SegmentAndRelatedInformation-SummarizedSegments-Details" xlink:title="00000041 - Disclosure - SEGMENT AND RELATED INFORMATION - Summarized Segments - (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="loc_us-gaapStatementOperatingActivitiesSegmentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementOperatingActivitiesSegmentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaapSegmentOperatingActivitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOperatingActivitiesSegmentAxis" xlink:to="loc_us-gaapSegmentOperatingActivitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_MedicalEquipmentMember" xlink:label="loc_FONRMedicalEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentOperatingActivitiesDomain" xlink:to="loc_FONRMedicalEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_ManagementOfDiagnosticImagingCentersMember" xlink:label="loc_FONRManagementOfDiagnosticImagingCentersMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentOperatingActivitiesDomain" xlink:to="loc_FONRManagementOfDiagnosticImagingCentersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_IntersegmentNetRevenues" xlink:label="loc_FONRIntersegmentNetRevenues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FONRIntersegmentNetRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaapIncomeLossFromContinuingOperations" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/RelatedPartyTransactionDetailsNarrative" xlink:title="00000042 - Disclosure - RELATED PARTY TRANSACTION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_MagneticResonanceManagementMember" xlink:label="loc_FONRMagneticResonanceManagementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_FONRMagneticResonanceManagementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFixedInterestRate" xlink:label="loc_us-gaapDerivativeFixedInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDerivativeFixedInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_GainOnSaleOfEquipmentsRelatedParty" xlink:label="loc_FONRGainOnSaleOfEquipmentsRelatedParty" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_FONRGainOnSaleOfEquipmentsRelatedParty" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/SupplementalCashFlowInformationDetailsNarrative" xlink:title="00000043 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaapSupplementalCashFlowElementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowElementsAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowElementsAbstract" xlink:to="loc_us-gaapIncomeTaxesPaid" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000044 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaapStockRepurchaseProgramAuthorizedAmount1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_StoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims" xlink:label="loc_FONRStoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_FONRStoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth" xlink:label="loc_us-gaapLiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fonar.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000045 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaapIncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityPolicyholdersSurplus" xlink:label="loc_us-gaapDeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityPolicyholdersSurplus" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityPolicyholdersSurplus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fonr-20231231.xsd#FONR_CorporateAlternativeMinimumTaxPercentage" xlink:label="loc_FONRCorporateAlternativeMinimumTaxPercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_FONRCorporateAlternativeMinimumTaxPercentage" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583899362496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 09, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-10248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">FONAR CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000355019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-2464137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">110 Marcus Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Melville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">11747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">694-2929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FONR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Common Class C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">382,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=FONR_ClassAPreferredStockMember', window );">Class A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,328,294<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=FONR_ClassAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=FONR_ClassAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583898699440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">&#160;Cash and cash equivalents</a></td>
<td class="nump">$ 53,225<span></span>
</td>
<td class="nump">$ 51,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">&#160;Short-term investments</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_AccountsReceivableServiceAndRepairFees', window );">&#160;Accounts receivable &#8211; net</a></td>
<td class="nump">3,881<span></span>
</td>
<td class="nump">3,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_AccountReceivableRelatedParties', window );">&#160;Accounts receivable - related party</a></td>
<td class="nump">60<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_MedicalReceivable', window );">&#160;Medical receivable &#8211; net</a></td>
<td class="nump">22,548<span></span>
</td>
<td class="nump">21,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_ManagementAndOtherFees', window );">&#160;Management and other fees receivable &#8211; net</a></td>
<td class="nump">39,352<span></span>
</td>
<td class="nump">35,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances', window );">Management and other fees receivable &#8211; related medical practices &#8211; net</a></td>
<td class="nump">9,267<span></span>
</td>
<td class="nump">9,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsAndWorkInProcess', window );">&#160;Inventories</a></td>
<td class="nump">2,835<span></span>
</td>
<td class="nump">2,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">&#160;Prepaid expenses and other current assets</a></td>
<td class="nump">1,341<span></span>
</td>
<td class="nump">1,608<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">132,542<span></span>
</td>
<td class="nump">125,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_AccountsReceivableNetLongTerm', window );">Accounts receivable &#8211; long term</a></td>
<td class="nump">376<span></span>
</td>
<td class="nump">710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_NoteReceivableRelatedParty', window );">&#160;Note receivable &#8211; related party</a></td>
<td class="nump">577<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">&#160;Deferred income tax asset</a></td>
<td class="nump">7,758<span></span>
</td>
<td class="nump">10,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">&#160;Property and equipment &#8211; net</a></td>
<td class="nump">20,109<span></span>
</td>
<td class="nump">22,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">&#160;Right-of-use Asset &#8211; operating lease</a></td>
<td class="nump">32,234<span></span>
</td>
<td class="nump">33,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">&#160;Right-of-use Asset &#8211; financing lease</a></td>
<td class="nump">630<span></span>
</td>
<td class="nump">729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">&#160;Goodwill</a></td>
<td class="nump">4,269<span></span>
</td>
<td class="nump">4,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">&#160;Other intangible assets &#8211; net</a></td>
<td class="nump">3,266<span></span>
</td>
<td class="nump">3,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">&#160;Other assets</a></td>
<td class="nump">501<span></span>
</td>
<td class="nump">524<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">&#160;Total Assets</a></td>
<td class="nump">202,262<span></span>
</td>
<td class="nump">200,582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,335<span></span>
</td>
<td class="nump">1,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">3,460<span></span>
</td>
<td class="nump">5,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">&#160;Unearned revenue on service contracts</a></td>
<td class="nump">3,804<span></span>
</td>
<td class="nump">3,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_UnearnedRevenueOnServiceContractsRelatedParty', window );">&#160;Unearned revenue on service contracts &#8211; related party</a></td>
<td class="nump">55<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">&#160;Operating lease liability - current portion</a></td>
<td class="nump">4,658<span></span>
</td>
<td class="nump">3,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">&#160;Financing lease liability - current portion</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_CustomerDeposits', window );">Customer deposits</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">14,179<span></span>
</td>
<td class="nump">15,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-Term Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">&#160;Unearned revenue on service contracts</a></td>
<td class="nump">376<span></span>
</td>
<td class="nump">760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent', window );">&#160;Deferred income tax liability</a></td>
<td class="nump">395<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_AccountsPayableRelatedPartyNoncurrent', window );">&#160;Due to related medical practices</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">&#160;Operating lease liability &#8211; net of current portion</a></td>
<td class="nump">30,299<span></span>
</td>
<td class="nump">32,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">&#160;Financing lease liability &#8211; net of current portion</a></td>
<td class="nump">508<span></span>
</td>
<td class="nump">620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">&#160;Long-term debt, less current portion</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">&#160;Other liabilities</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total Long-Term Liabilities</a></td>
<td class="nump">31,786<span></span>
</td>
<td class="nump">34,130<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">&#160;Total Liabilities</a></td>
<td class="nump">45,965<span></span>
</td>
<td class="nump">49,754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">&#160;Paid-in capital in excess of par value</a></td>
<td class="nump">180,607<span></span>
</td>
<td class="nump">182,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">&#160;Accumulated deficit</a></td>
<td class="num">(16,326)<span></span>
</td>
<td class="num">(24,191)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost - 4 shares of common stock at December 31, 2023 and 11 shares of common stock at June 30, 2023</a></td>
<td class="num">(395)<span></span>
</td>
<td class="num">(516)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">&#160;Total Fonar Corporation&#8217;s Stockholders&#8217; Equity</a></td>
<td class="nump">163,887<span></span>
</td>
<td class="nump">157,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">&#160;Non controlling interests</a></td>
<td class="num">(7,590)<span></span>
</td>
<td class="num">(7,079)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">&#160;Total Stockholders&#8217; Equity</a></td>
<td class="nump">156,297<span></span>
</td>
<td class="nump">150,828<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">&#160;Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">202,262<span></span>
</td>
<td class="nump">200,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=FONR_ClassANonVotingPreferredStockMember', window );">Class A Non Voting Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-Term Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-Term Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=FONR_CommonStocksMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-Term Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-Term Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Common Class C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-Term Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_AccountReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_AccountReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_AccountsPayableRelatedPartyNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_AccountsPayableRelatedPartyNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_AccountsReceivableNetLongTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_AccountsReceivableNetLongTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_AccountsReceivableServiceAndRepairFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_AccountsReceivableServiceAndRepairFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_CustomerDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_CustomerDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_ManagementAndOtherFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_ManagementAndOtherFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_MedicalReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_MedicalReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_NoteReceivableRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_NoteReceivableRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_UnearnedRevenueOnServiceContractsRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents the amount of unearned revenue on service contracts related party during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_UnearnedRevenueOnServiceContractsRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other liabilities expected to be paid after one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsAndWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation reserves of merchandise or goods held by the entity that are readily available for sale and items held by the entity which are partially complete or in the process of being readied for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsAndWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=FONR_ClassANonVotingPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=FONR_ClassANonVotingPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=FONR_CommonStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=FONR_CommonStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583991457344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, shares</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=FONR_ClassANonVotingPreferredStockMember', window );">Class A Non Voting Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">453,000<span></span>
</td>
<td class="nump">453,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">313,000<span></span>
</td>
<td class="nump">313,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">313,000<span></span>
</td>
<td class="nump">313,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">567,000<span></span>
</td>
<td class="nump">567,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">8,500,000<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">6,332,000<span></span>
</td>
<td class="nump">6,462,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">6,328,000<span></span>
</td>
<td class="nump">6,451,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">227,000<span></span>
</td>
<td class="nump">227,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Common Class C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">567,000<span></span>
</td>
<td class="nump">567,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">383,000<span></span>
</td>
<td class="nump">383,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">383,000<span></span>
</td>
<td class="nump">383,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=FONR_ClassANonVotingPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=FONR_ClassANonVotingPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583897911296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscounts', window );">Patient fee revenue &#8211; net of contractual allowances and discounts</a></td>
<td class="nump">$ 8,221<span></span>
</td>
<td class="nump">$ 7,129<span></span>
</td>
<td class="nump">$ 16,896<span></span>
</td>
<td class="nump">$ 13,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_ProductSalesNet', window );">Product sales &#8211; net</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_ServiceAndRepairFeesNet', window );">Service and repair fees &#8211; net</a></td>
<td class="nump">1,778<span></span>
</td>
<td class="nump">1,838<span></span>
</td>
<td class="nump">3,643<span></span>
</td>
<td class="nump">3,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_ServiceAndRepairFeesRelatedPartiesNet', window );">Service and repair fees - related parties &#8211; net</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_ManagementAndOtherFeesNet', window );">Management and other fees &#8211; net</a></td>
<td class="nump">12,316<span></span>
</td>
<td class="nump">12,092<span></span>
</td>
<td class="nump">24,436<span></span>
</td>
<td class="nump">24,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_ManagementAndOtherFeesRelatedMedicalPracticesNet', window );">Management and other fees - related medical practices &#8211; net</a></td>
<td class="nump">2,988<span></span>
</td>
<td class="nump">2,999<span></span>
</td>
<td class="nump">5,975<span></span>
</td>
<td class="nump">5,987<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues &#8211; Net</a></td>
<td class="nump">25,386<span></span>
</td>
<td class="nump">24,256<span></span>
</td>
<td class="nump">51,224<span></span>
</td>
<td class="nump">47,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>COSTS AND EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostOfOperatingRevenue', window );">Costs related to patient fee revenue</a></td>
<td class="nump">4,602<span></span>
</td>
<td class="nump">4,023<span></span>
</td>
<td class="nump">9,029<span></span>
</td>
<td class="nump">7,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_CostsRelatedToProductSales', window );">Costs related to product sales</a></td>
<td class="nump">302<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">405<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_CostsRelatedToServiceAndRepairFees', window );">Costs related to service and repair fees</a></td>
<td class="nump">784<span></span>
</td>
<td class="nump">722<span></span>
</td>
<td class="nump">1,633<span></span>
</td>
<td class="nump">1,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_CostsRelatedToServiceAndRepairFeesRelatedParties', window );">Costs related to service and repair fees - related parties</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_CostsRelatedToManagementAndOtherFees', window );">Costs related to management and other fees</a></td>
<td class="nump">7,208<span></span>
</td>
<td class="nump">6,622<span></span>
</td>
<td class="nump">14,231<span></span>
</td>
<td class="nump">13,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices', window );">Costs related to management and other fees &#8211; related medical practices</a></td>
<td class="nump">1,590<span></span>
</td>
<td class="nump">1,492<span></span>
</td>
<td class="nump">3,109<span></span>
</td>
<td class="nump">2,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">416<span></span>
</td>
<td class="nump">342<span></span>
</td>
<td class="nump">883<span></span>
</td>
<td class="nump">691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">5,587<span></span>
</td>
<td class="nump">6,598<span></span>
</td>
<td class="nump">10,453<span></span>
</td>
<td class="nump">12,932<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total Costs and Expenses</a></td>
<td class="nump">20,501<span></span>
</td>
<td class="nump">20,024<span></span>
</td>
<td class="nump">39,768<span></span>
</td>
<td class="nump">39,304<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet', window );">Income From Operations</a></td>
<td class="nump">4,885<span></span>
</td>
<td class="nump">4,232<span></span>
</td>
<td class="nump">11,456<span></span>
</td>
<td class="nump">8,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other Income (Expense)</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(208)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_OtherIncomeRelatedParty', window );">Other Income &#8211; Related party</a></td>
<td class="nump">577<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">577<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment Income</a></td>
<td class="nump">534<span></span>
</td>
<td class="nump">263<span></span>
</td>
<td class="nump">1,040<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income Before Provision for Income Taxes and Non controlling Interests</a></td>
<td class="nump">5,986<span></span>
</td>
<td class="nump">4,275<span></span>
</td>
<td class="nump">13,016<span></span>
</td>
<td class="nump">8,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for Income Taxes</a></td>
<td class="num">(1,366)<span></span>
</td>
<td class="num">(1,463)<span></span>
</td>
<td class="num">(3,036)<span></span>
</td>
<td class="num">(2,871)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income</a></td>
<td class="nump">4,620<span></span>
</td>
<td class="nump">2,812<span></span>
</td>
<td class="nump">9,980<span></span>
</td>
<td class="nump">5,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net Income &#8211; Non controlling Interests</a></td>
<td class="num">(861)<span></span>
</td>
<td class="num">(580)<span></span>
</td>
<td class="num">(2,115)<span></span>
</td>
<td class="num">(1,183)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income &#8211; Attributable to FONAR</a></td>
<td class="nump">$ 3,759<span></span>
</td>
<td class="nump">$ 2,232<span></span>
</td>
<td class="nump">$ 7,865<span></span>
</td>
<td class="nump">$ 4,279<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_CostsRelatedToManagementAndOtherFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_CostsRelatedToManagementAndOtherFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents the amount of costs related to management and other fees related medical practices during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_CostsRelatedToProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_CostsRelatedToProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_CostsRelatedToServiceAndRepairFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_CostsRelatedToServiceAndRepairFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_CostsRelatedToServiceAndRepairFeesRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_CostsRelatedToServiceAndRepairFeesRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_ManagementAndOtherFeesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents the value of management and other fees net during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_ManagementAndOtherFeesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_ManagementAndOtherFeesRelatedMedicalPracticesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents the value of management and other fees related medical practices net during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_ManagementAndOtherFeesRelatedMedicalPracticesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_OtherIncomeRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_OtherIncomeRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents the amount of patient fee revenue net of contractual allowances and discounts during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_ProductSalesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents the amount of product sales net during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_ProductSalesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_ServiceAndRepairFeesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents the amount of service and repair fees net during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_ServiceAndRepairFeesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_ServiceAndRepairFeesRelatedPartiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents the amount of service and repair fees related parties net during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_ServiceAndRepairFeesRelatedPartiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, nonoperating income (expense) and income (loss) from equity method investments, before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostOfOperatingRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other costs incurred during the reporting period related to other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostOfOperatingRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583895208944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (Parenthetical) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">$ 3,759<span></span>
</td>
<td class="nump">$ 2,232<span></span>
</td>
<td class="nump">$ 7,865<span></span>
</td>
<td class="nump">$ 4,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Basic Shares Outstanding</a></td>
<td class="nump">6,437<span></span>
</td>
<td class="nump">6,527<span></span>
</td>
<td class="nump">6,448<span></span>
</td>
<td class="nump">6,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=FONR_CommonStockholdersMember', window );">Common Stockholders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">$ 3,525<span></span>
</td>
<td class="nump">$ 2,097<span></span>
</td>
<td class="nump">$ 7,375<span></span>
</td>
<td class="nump">$ 4,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic Net Income Per Common Share Available to Common Stockholders</a></td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="nump">$ 1.14<span></span>
</td>
<td class="nump">$ 0.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted Net Income Per Common Share Available to Common Stockholders</a></td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 0.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Basic Shares Outstanding</a></td>
<td class="nump">6,437<span></span>
</td>
<td class="nump">6,527<span></span>
</td>
<td class="nump">6,448<span></span>
</td>
<td class="nump">6,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Diluted Shares Outstanding - Common Stockholders</a></td>
<td class="nump">6,565<span></span>
</td>
<td class="nump">6,655<span></span>
</td>
<td class="nump">6,576<span></span>
</td>
<td class="nump">6,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=FONR_ClassANonVotingPreferredStockholdersMember', window );">Class A Non Voting Preferred Stockholders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
<td class="nump">$ 365<span></span>
</td>
<td class="nump">$ 193<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Common Class C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic Net Income Per Common Share Available to Common Stockholders</a></td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted Net Income Per Common Share Available to Common Stockholders</a></td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Basic Shares Outstanding</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Diluted Shares Outstanding - Common Stockholders</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=FONR_CommonStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=FONR_CommonStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=FONR_ClassANonVotingPreferredStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=FONR_ClassANonVotingPreferredStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583891479904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Treasury Stock, Common [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance, value at Jun. 30, 2022</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 184,531<span></span>
</td>
<td class="num">$ (33,567)<span></span>
</td>
<td class="num">$ (675)<span></span>
</td>
<td class="num">$ (4,054)<span></span>
</td>
<td class="nump">$ 146,236<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Jun. 30, 2022</a></td>
<td class="nump">6,554,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,279<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Purchase of Treasury stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (478)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(478)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_PurchaseOfTreasuryStockShares', window );">Purchase of Treasury stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_CancellationOfShares', window );">Cancellation of shares</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(401)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 402<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_CancellationOfSharesShares', window );">Cancellation of shares, shares</a></td>
<td class="num">(16,062)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,062)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions - Non controlling interests</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,151)<span></span>
</td>
<td class="num">(3,151)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Income - Non controlling interests</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,183<span></span>
</td>
<td class="nump">1,183<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">184,130<span></span>
</td>
<td class="num">(29,288)<span></span>
</td>
<td class="num">$ (751)<span></span>
</td>
<td class="num">(6,022)<span></span>
</td>
<td class="nump">148,070<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2022</a></td>
<td class="nump">6,538,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance, value at Sep. 30, 2022</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">184,531<span></span>
</td>
<td class="num">(31,520)<span></span>
</td>
<td class="num">$ (797)<span></span>
</td>
<td class="num">(5,085)<span></span>
</td>
<td class="nump">147,130<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Sep. 30, 2022</a></td>
<td class="nump">6,554,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,232<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Purchase of Treasury stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (356)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(356)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_PurchaseOfTreasuryStockShares', window );">Purchase of Treasury stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_CancellationOfShares', window );">Cancellation of shares</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(401)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 402<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_CancellationOfSharesShares', window );">Cancellation of shares, shares</a></td>
<td class="num">(16,062)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,062)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions - Non controlling interests</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,517)<span></span>
</td>
<td class="num">(1,517)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Income - Non controlling interests</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">580<span></span>
</td>
<td class="nump">580<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">184,130<span></span>
</td>
<td class="num">(29,288)<span></span>
</td>
<td class="num">$ (751)<span></span>
</td>
<td class="num">(6,022)<span></span>
</td>
<td class="nump">148,070<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2022</a></td>
<td class="nump">6,538,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance, value at Jun. 30, 2023</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">182,613<span></span>
</td>
<td class="num">(24,191)<span></span>
</td>
<td class="num">$ (516)<span></span>
</td>
<td class="num">(7,079)<span></span>
</td>
<td class="nump">150,828<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Jun. 30, 2023</a></td>
<td class="nump">6,450,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,865<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Purchase of Treasury stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (1,885)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,885)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_PurchaseOfTreasuryStockShares', window );">Purchase of Treasury stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_CancellationOfShares', window );">Cancellation of shares</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,006)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,006<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_CancellationOfSharesShares', window );">Cancellation of shares, shares</a></td>
<td class="num">(122,588)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(122,588)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions - Non controlling interests</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,626)<span></span>
</td>
<td class="num">(2,626)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Income - Non controlling interests</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,115<span></span>
</td>
<td class="nump">2,115<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">180,607<span></span>
</td>
<td class="num">(16,326)<span></span>
</td>
<td class="num">$ (395)<span></span>
</td>
<td class="num">(7,590)<span></span>
</td>
<td class="nump">156,297<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2023</a></td>
<td class="nump">6,328,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance, value at Sep. 30, 2023</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">182,613<span></span>
</td>
<td class="num">(20,085)<span></span>
</td>
<td class="num">$ (1,230)<span></span>
</td>
<td class="num">(7,226)<span></span>
</td>
<td class="nump">154,073<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Sep. 30, 2023</a></td>
<td class="nump">6,450,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,759<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Purchase of Treasury stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (1,171)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,171)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_PurchaseOfTreasuryStockShares', window );">Purchase of Treasury stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_CancellationOfShares', window );">Cancellation of shares</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,006)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,006<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_CancellationOfSharesShares', window );">Cancellation of shares, shares</a></td>
<td class="num">(122,588)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(122,588)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions - Non controlling interests</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,225)<span></span>
</td>
<td class="num">(1,225)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Income - Non controlling interests</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">861<span></span>
</td>
<td class="nump">861<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 180,607<span></span>
</td>
<td class="num">$ (16,326)<span></span>
</td>
<td class="num">$ (395)<span></span>
</td>
<td class="num">$ (7,590)<span></span>
</td>
<td class="nump">$ 156,297<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2023</a></td>
<td class="nump">6,328,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_CancellationOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents the amount of cancellation of shares during year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_CancellationOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_CancellationOfSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_CancellationOfSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_PurchaseOfTreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_PurchaseOfTreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583894853408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">&#160;Net income</a></td>
<td class="nump">$ 9,980<span></span>
</td>
<td class="nump">$ 5,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>&#160;Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,415<span></span>
</td>
<td class="nump">2,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization on right-of-use assets</a></td>
<td class="nump">2,146<span></span>
</td>
<td class="nump">2,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_ProvisionForBadDebts', window );">Provision for bad debts</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">2,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax &#8211; net</a></td>
<td class="nump">2,284<span></span>
</td>
<td class="nump">2,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_GainOnSaleOfEquipmentRelatedParty', window );">Gain on sale of equipment &#8211; related party</a></td>
<td class="num">(577)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase) decrease in operating assets, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts, medical and management fee receivable(s)</a></td>
<td class="num">(4,958)<span></span>
</td>
<td class="num">(3,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_IncreaseDecreaseInNotesReceivable', window );">Notes receivable</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(265)<span></span>
</td>
<td class="num">(274)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">22<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase (decrease) in operating liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(244)<span></span>
</td>
<td class="num">(685)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="num">(2,341)<span></span>
</td>
<td class="num">(3,228)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(2,265)<span></span>
</td>
<td class="num">(1,874)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_IncreaseDecreaseInFinancingLiabilities', window );">Financing lease liabilities</a></td>
<td class="num">(108)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_IncreaseDecreaseInCustomerAdvance', window );">Customer deposits</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Other liabilities</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">6,689<span></span>
</td>
<td class="nump">5,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>&#160;Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(192)<span></span>
</td>
<td class="num">(1,362)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Cost of patents</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(212)<span></span>
</td>
<td class="num">(1,436)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>&#160;Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">&#160;Repayment of borrowings and capital lease obligations</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock', window );">&#160;Purchase of treasury stock</a></td>
<td class="num">(1,885)<span></span>
</td>
<td class="num">(478)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsMinorityInterest', window );">&#160;Distributions to non controlling interests</a></td>
<td class="num">(2,626)<span></span>
</td>
<td class="num">(3,151)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(4,532)<span></span>
</td>
<td class="num">(3,644)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">&#160;Net Increase in Cash and Cash Equivalents</a></td>
<td class="nump">1,945<span></span>
</td>
<td class="nump">782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents - Beginning of Period</a></td>
<td class="nump">51,280<span></span>
</td>
<td class="nump">48,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents - End of Period</a></td>
<td class="nump">$ 53,225<span></span>
</td>
<td class="nump">$ 49,505<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_GainOnSaleOfEquipmentRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_GainOnSaleOfEquipmentRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_IncreaseDecreaseInCustomerAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_IncreaseDecreaseInCustomerAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_IncreaseDecreaseInFinancingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_IncreaseDecreaseInFinancingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_IncreaseDecreaseInNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_IncreaseDecreaseInNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_ProvisionForBadDebts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents the amount of provision for bad debts during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_ProvisionForBadDebts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire preferred stock originally issued and identified as a security that can be exchanged for another type of financial security. This repurchased stock is held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsMinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsMinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583902014192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</a></td>
<td class="text"><p id="xdx_804_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zD7NJOEByiPg" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">NOTE 1 &#8211;<span id="xdx_821_zM1J0N2WC2Cf"> DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Description of Business</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective July 1, 2015, the Company
restructured the corporate organization of the management of diagnostic imaging centers segment of our business. The reorganization
was structured to more completely integrate the operations of Health Management Corporation of America and HDM. Imperial contributed
all of its assets (which were utilized in the business of Health Management Corporation of America) to HDM and received a <span id="xdx_90B_ecustom--HmcaOwnershipSizeOfImperialManagementServicesPercent_iI_pip0_dp_c20150701__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ControllingInterestMember_zkhz9tq6PUFh" title="The ownership interest of Imperial Management Services after reorganization of newly expanded HDM">24.2</span>%
interest in HDM. Health Management Corporation of America retained a direct ownership interest of <span id="xdx_901_ecustom--OwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent_iI_pip0_dp_c20150701__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ControllingInterestMember_ziDsZKn2LBv7" title="The ownership interest of Health Management Corporation of America after reorganization of newly expanded HDM">45.8</span>% in HDM, and the original
investors in HDM retained a <span id="xdx_90F_ecustom--OwnershipInterestOfOriginalInvestorsOfHdm_iI_pip0_dp_c20150701__us-gaap--StatementEquityComponentsAxis__us-gaap--NoncontrollingInterestMember_zt4bG1dQeMUk" title="The ownership interest of the original investors of HDM">30.0</span>% ownership interest in the newly expanded HDM. During the fiscal year ended June 30, 2022, the
Company purchased non-controlling interests from the minority shareholders for $<span id="xdx_903_ecustom--DirectPurchaseOfNoncontrollingInterests_pn3n3_c20210701__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ControllingInterestMember_zGebHjWX59Td" title="Direct purchase of Noncontrolling Interests">546,000</span>. Currently the Company has a direct ownership
interest of <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pip0_dp_c20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ControllingInterestMember_zKRpdsQ0eK71" title="Direct ownership interest percentage">70.8</span>% and the investors&#8217; have a <span id="xdx_900_ecustom--InvestorsOwnershipInterest_iI_pip0_dp_c20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--NoncontrollingInterestMember_zEWdxXjPmOU5" title="Investors ownership interest percentage">29.2</span>% ownership interest. The entire management of diagnostic imaging centers
business segment is now being conducted by HDM, operating under the name &#8220;Health Management Company of America&#8221;.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Basis of Presentation</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed
consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial
information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the
information and footnotes required by accounting principles generally accepted in the United States of America for complete financial
statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a
fair presentation have been included. Operating results for the six months ended December 31, 2023, are not necessarily indicative
of the results that may be expected for the fiscal year ending June 30, 2024. For further information, refer to the consolidated
financial statements and footnotes thereto included in the Company&#8217;s Annual Report on Form 10-K filed on September 28, 2023
for the fiscal year ended June 30, 2023.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The global pandemic of COVID-19 has
caused turbulence and uncertainty in the United States and international markets and economies which has adversely affected our
workforce, liquidity, financial conditions, revenues, profitability and business operations. The Company was able to enact certain
decisions to allow the Company to navigate the global pandemic and from further losses, additional decreases in scan volume and
avoid any significant disruption of the business. The Company must now take into account the severity, duration and recurrence
of new strains of the COVID-19 virus which adds a new dimension to the challenges and uncertainty facing our business and the world
economy in general. Although we are unable to predict if there will be additional consequences on our operations from the continuing
global pandemic of COVID-19, the Company believes with positive cash flows, low debt and cash on hand, it will be able to continue
operations going forward.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583898093104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_803_eus-gaap--SignificantAccountingPoliciesTextBlock_z5oIJ2V561of" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 2 -<span id="xdx_820_zeGSqZ9uhMQ3"> SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_z3sxBoQ5ZaXk" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><span id="xdx_860_zCQUcePOn8e4">Principles of Consolidation</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited condensed consolidated
financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships (collectively
the &#8220;Company&#8221;). All significant intercompany accounts and transactions have been eliminated in consolidation.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
























<p id="xdx_847_eus-gaap--RevenueRecognitionPolicyTextBlock_za2twcMHz04j" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><span id="xdx_868_z54JY0l9LKAf">Revenues</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The revenue recognition standard in
ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a
customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires
expanded disclosures regarding the Company&#8217;s revenue recognition policies and significant judgements employed in the determination
of revenue.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our revenues generally relate to net
patient fees&#160;received from various payers and patients themselves under contracts in which our performance obligations are
to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services
are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day.
The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care
health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction
prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care
health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the
services we provide to the related patients typically specify payments at amounts less than our standard charges and generally
provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually
reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes
in managed care contractual terms resulting from contract renegotiations and renewals.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84E_eus-gaap--BusinessCombinationsPolicy_zK3cw6rLlle3" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_86B_zhfHChWzvfrh">BUSINESS COMBINATION</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">When the qualifications for business
combination accounting treatment are met, it requires us to recognize separately from goodwill the assets acquired and the liabilities
assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred
over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates
and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently
uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition
date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the
conclusion of the measurement period of final determination of the values of assets acquired or liabilities assumed, whichever
comes first, any subsequent adjustments are recorded to our consolidated statements of income.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zUietNjjOXEf" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_864_zoDNeMxqPNPc">Earnings Per Share</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic earnings per share (&#8220;EPS&#8221;)
is computed based upon the weighted average number of shares of common stock and stock equivalents outstanding, net of common stock.
In accordance with ASC topic 260-10, &#8220;Participating Securities and the Two-Class method&#8221;, the Company used the Two-Class
method for calculating basic income per share and applied the if converted method in calculating diluted income per share for the
three and six months ended December 31, 2023 and 2022.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Diluted EPS reflects the potential dilution
from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares
outstanding during the period. For the three and six months ended December 31, 2023 and 2022, diluted EPS for common shareholders
includes <span id="xdx_90D_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_pn3n3_c20231001__20231231_zWDdDMNArwzi" title="Shares included upon conversion of Class C Common"><span id="xdx_906_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_pn3n3_c20230701__20231231_zObqDGAhtB9" title="Shares included upon conversion of Class C Common"><span id="xdx_908_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_pn3n3_c20221001__20221231_znE2S1tSW9xl" title="Shares included upon conversion of Class C Common"><span id="xdx_907_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_pn3n3_c20220701__20221231_zuBHVG23ZLM4" title="Shares included upon conversion of Class C Common">128</span></span></span></span> shares upon conversion of Class C Common.</p>




























<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_z0hpep08RVlj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share - (Details)">
<tr style="vertical-align: bottom">
    <td id="xdx_8BB_znGt4olpKusa" style="display: none; padding-top: 0; padding-right: 0; text-align: left">Schedule of earning per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">Three months ended <br/> December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">Three months ended <br/> December 31, 2022</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Class C Common <br/> Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Class C Common <br/> Stock</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">Numerator: <br/> Net income available to common stockholders</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20231001__20231231_z24aXYwIjQak" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">3,759</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zG8ROYPm99jj" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">3,525</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zYeAgS3vtVDj" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">59</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20221001__20221231_zDCm7XWQngv4" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">2,232</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdVoSqQYuEu6" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Common Stock and Basic Numerator: Net income available to common stockholders">2,097</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zVmK7Tx46aDc" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">34</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Weighted average shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20231001__20231231_zujqgbfVHdib" title="Basic Denominator: Weighted average shares outstanding">6,437</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQ3s5Ss1T211" title="Basic Denominator: Weighted average shares outstanding">6,437</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zAdeCfpLn6Nc" title="Basic Denominator: Weighted average shares outstanding">383</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20221001__20221231_zlorfe1PBIP2" title="Basic Denominator: Weighted average shares outstanding">6,527</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2qzTva5HHvj" title="Basic Denominator: Weighted average shares outstanding">6,527</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zI5Yn8RanB8f" title="Basic Denominator: Weighted average shares outstanding">383</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Basic income per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20231001__20231231_zKWdQXgSLdq3" title="Basic income per common share">0.58</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zp7d2uqfUzjc" title="Basic income per common share">0.55</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zgbXQMSjCuVk" title="Basic income per common share">0.16</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20221001__20221231_zeIHjnC2kICf" title="Basic income per common share">0.34</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmSH7f1f7109" title="Basic income per common share">0.32</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z7F2Pqhgpvy1" title="Basic income per common share">0.09</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator: <br/> Weighted average shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2pyXMXkRWo3" title="Diluted Denominator: Weighted average shares outstanding">6,437</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zpTuzrYJwkK3" title="Diluted Denominator: Weighted average shares outstanding">383</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8lgAsR8fRzh" title="Diluted Denominator: Weighted average shares outstanding">6,527</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zqh4XEwVBlVc" title="Diluted Denominator: Weighted average shares outstanding">383</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible Class C Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_ecustom--ConvertibleClassCStock_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoXRWoEMXNbb" title="Convertible Class C Stock">128</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_ecustom--ConvertibleClassCStock_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_ztk1kuEXjKh6" title="Convertible Class C Stock"><span style="-sec-ix-hidden: xdx2ixbrl1091">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_ecustom--ConvertibleClassCStock_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrZgsPwWJQWk" title="Convertible Class C Stock">128</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--ConvertibleClassCStock_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zgXkhSfSxKAk" title="Convertible Class C Stock"><span style="-sec-ix-hidden: xdx2ixbrl1095">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Denominator for diluted earnings per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBPNn6fnSBtc" title="Total Denominator for Diluted Earnings Per Share">6,565</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zrXAnwqNZxD8" title="Total Denominator for Diluted Earnings Per Share">383</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKGI6QcltMc1" title="Total Denominator for Diluted Earnings Per Share">6,655</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z0JBAcMMr25g" title="Total Denominator for Diluted Earnings Per Share">383</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Diluted income per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pip0_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxl63AX6VXg7" title="Diluted Income per Common Share">0.54</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pip0_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zBFs3GvldEoh" title="Diluted Income per Common Share">0.16</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareDiluted_pip0_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2AJgM43Xhcl" title="Diluted Income per Common Share">0.32</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pip0_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zQade4RR3t9e" title="Diluted Income per Common Share">0.09</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">Six months ended <br/> December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">Six months ended <br/> December 31, 2022</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Class C Common <br/> Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Class C Common <br/> Stock</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">Numerator: <br/> Net income available to common stockholders</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20230701__20231231_z4UTQH7hUxL4" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">7,865</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsqY9NXVLV2c" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">7,375</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z3RMb85H0qkl" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">125</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20220701__20221231_zrCyjoAYN5q8" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">4,279</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLw3LCxpKoPj" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Common Stock and Basic Numerator: Net income available to common stockholders">4,020</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zvIHrcyBvIPk" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">66</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Weighted average shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20231231_zmZ93078iO8d" title="Basic Denominator: Weighted average shares outstanding">6,448</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z21yzFIuoLf6" title="Basic Denominator: Weighted average shares outstanding">6,448</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zQA2gc0u4Amk" title="Basic Denominator: Weighted average shares outstanding">383</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220701__20221231_ztm6KSYAChm6" title="Basic Denominator: Weighted average shares outstanding">6,534</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkFlslAJn2qk" title="Basic Denominator: Weighted average shares outstanding">6,534</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zL7NtDF1AoTf" title="Basic Denominator: Weighted average shares outstanding">383</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Basic income per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20230701__20231231_zmW1oBcSsg83" title="Basic income per common share">1.22</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4dCSpS3695b" title="Basic income per common share">1.14</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z7vSLvBYsxqe" title="Basic income per common share">0.33</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20220701__20221231_zJoGxGVg5CHa" title="Basic income per common share">0.65</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIo4QQjg035a" title="Basic income per common share">0.62</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zpvgvPcov6bg" title="Basic income per common share">0.17</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator: <br/> Weighted average shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9evyBlljdUa" title="Diluted Denominator: Weighted average shares outstanding">6,448</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zDfugAnIRGu7" title="Diluted Denominator: Weighted average shares outstanding">383</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2yNF3S72Dh3" title="Diluted Denominator: Weighted average shares outstanding">6,534</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zdvFkKhi6fDf" title="Diluted Denominator: Weighted average shares outstanding">383</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible Class C Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_ecustom--ConvertibleClassCStock_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVjyzxkTFd1" title="Convertible Class C Stock">128</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_ecustom--ConvertibleClassCStock_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zq4Sfu9LeOv5" title="Convertible Class C Stock"><span style="-sec-ix-hidden: xdx2ixbrl1159">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_ecustom--ConvertibleClassCStock_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zz6S4pR8sNT2" title="Convertible Class C Stock">128</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_ecustom--ConvertibleClassCStock_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zsmEWygCsbKi" title="Convertible Class C Stock"><span style="-sec-ix-hidden: xdx2ixbrl1163">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Denominator for diluted earnings per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8meuCzW846g" title="Total Denominator for Diluted Earnings Per Share">6,576</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zC7x0fJBLE45" title="Total Denominator for Diluted Earnings Per Share">383</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znQ1wEDYsoi7" title="Total Denominator for Diluted Earnings Per Share">6,662</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zJ8UZGlHPd3k" title="Total Denominator for Diluted Earnings Per Share">383</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Diluted income per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_pip0_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEoN3hUy1ybk" title="Diluted Income per Common Share">1.12</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_pip0_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zUXFtANM8l4g" title="Diluted Income per Common Share">0.33</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_pip0_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHNRYTugpdhi" title="Diluted Income per Common Share">0.60</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_pip0_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zZd01Sfe84th" title="Diluted Income per Common Share">0.17</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>



<p id="xdx_8A2_zDO6CHuBR1Ub" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>
























<p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z40QeTkHA1Ff" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><span id="xdx_869_zIQBDaKejqX2">Recent Accounting Standards</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2023, the Financial Accounting
Standards Board (&#8220;FASB&#8221;) issued ASU 2023-09, &#8220;Income Taxes (740) &#8220;Improvements to Income Tax Disclosures&#8221;,
which requires the annual financial statements to include consistent categories and greater disaggregation of information in the
rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company&#8217;s annual
reporting beginning after December 15, 2024, with early adoption permitted, and should be applied on a prospective basis, with
a retrospective option. We are currently evaluating the effect that adoption of ASU 2023-09 will have on our disclosures.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2023, FASB issued ASU 2023-07, &#8220;Segment Reporting (Topic
280)&#8221;, which is intended to improve reportable segment disclosure requirements through enhanced disclosures about significant segment
expenses. The amendments require disclosure of significant segment expenses regularly provided to the chief operating decision maker (CODM)
as well as other segment items, extended certain annual disclosures to interim periods, clarify the applicability to single reportable
segment entities, permit, more than one measure of profit or loss to be reported under certain conditions, and require disclosure of the
title and position of the CODM. The effective date for public entities is beginning after December 15, 2023 and interim periods with fiscal
years beginning after December 15, 2024. We expect to adopt the new disclosures as required and are currently evaluating the impact on
the related disclosures.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2016, FASB issued ASU 2016-13, &#8220;Financial
Instruments &#8211; Credit Loses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221;, which replaces the incurred
loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader
range of reasonable and supportable information to assess credit loss estimates. This ASU is effective for fiscal years beginning after
December 15, 2022. The Company adopted this standard on July 1, 2023 using the modified retrospective approach and it did not have a material
impact of the Company&#8217;s financial statements, resulting in no adjustment to prior year earnings.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">FASB, the Emerging Issues Task Force
and the SEC have issued certain other accounting standards, updates, and regulations as of December 31, 2023 that will become effective
in subsequent periods; however, management does not believe that any of those updates would have significantly affected the Company&#8217;s
financial accounting measures or disclosures had they been in effect during 2023 or 2022, and it does not believe that any of those
standards will have a significant impact on our consolidated condensed financial statements at the time they become effective.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583904126880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE</a></td>
<td class="text"><p id="xdx_801_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_zbHoqXT9wLrf" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 3 &#8211;<span id="xdx_822_zTitbNjOT6Rf"> ACCOUNTS RECEIVABLE,
MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Receivables, net is comprised of the
following at December 31, 2023, and June 30, 2023:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock_pn3n3_zrsuW80RcOK6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details)">
<tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B4_z3JRElElnWUa" style="display: none; text-align: left; padding-top: 0; padding-right: 0">Schedule of financing
    receivable noncurrent allowance for credit loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Gross Receivable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Allowance for doubtful accounts</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Net</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Accounts receivable</td><td style="width: 5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--AccountsReceivableServiceAndRepairFees_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Accounts receivable">4,080</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--AccountsReceivableServiceAndRepairFees_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Accounts receivable">199</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--AccountsReceivableServiceAndRepairFees_c20231231_pn3n3" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Accounts receivable">3,881</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts receivable - related party</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--AccountsReceivableNetRelatedParty_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts receivable - Related party">60</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_ecustom--AccountsReceivableNetRelatedParty_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts receivable - Related party"><span style="-sec-ix-hidden: xdx2ixbrl1213">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--AccountsReceivableNetRelatedParty_c20231231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts receivable - Related party">60</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Medical receivable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--MedicalReceivable_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Medical Receivables">22,548</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--MedicalReceivable_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Medical Receivables"><span style="-sec-ix-hidden: xdx2ixbrl1219">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--MedicalReceivable_c20231231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Medical Receivables">22,548</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Management and other fees receivable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ManagementAndOtherFeesNonRelatedParties_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable">51,092</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ManagementAndOtherFeesNonRelatedParties_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable">11,740</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ManagementAndOtherFeesNonRelatedParties_c20231231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable">39,352</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Management and other fees receivable from related medical practices (&#8220;PC&#8217;s&#8221;)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable from related medical practices (&quot;PC's&quot;)">14,480</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable from related medical practices (&quot;PC's&quot;)">5,213</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20231231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable from related medical practices (&quot;PC's&quot;)">9,267</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2023</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Gross Receivable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Allowance for doubtful accounts</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Net</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Accounts receivable</td><td style="width: 5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--AccountsReceivableServiceAndRepairFees_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Accounts receivable">4,060</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--AccountsReceivableServiceAndRepairFees_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Accounts receivable">199</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--AccountsReceivableServiceAndRepairFees_c20230630_pn3n3" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Accounts receivable">3,861</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Medical receivable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--MedicalReceivable_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Medical Receivables">21,259</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--MedicalReceivable_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Medical Receivables"><span style="-sec-ix-hidden: xdx2ixbrl1243">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--MedicalReceivable_c20230630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Medical Receivables">21,259</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Management and other fees receivable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--ManagementAndOtherFeesNonRelatedParties_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable">48,497</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ManagementAndOtherFeesNonRelatedParties_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable">12,609</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ManagementAndOtherFeesNonRelatedParties_c20230630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable">35,888</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Management and other fees receivable from related medical practices (&#8220;PC&#8217;s&#8221;)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable from related medical practices (&quot;PC's&quot;)">13,152</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable from related medical practices (&quot;PC's&quot;)">3,990</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20230630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable from related medical practices (&quot;PC's&quot;)">9,162</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A4_zcjkfdHsFDnb" style="margin-top: 0; margin-bottom: 0">&#160;</p>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Company&#8217;s customers are concentrated in the healthcare industry.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Accounts
Receivable&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p><p style="text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Credit
                                            risk with respect to the Company&#8217;s accounts receivable related to product sales and
                                            service and repair fees is limited due to the customer advances received prior to the commencement
                                            of work performed and the billing of amounts to customers as sub-assemblies are completed.
                                            Service and repair fees are billed on a monthly or quarterly basis and the Company does not
                                            continue providing these services if accounts receivable become past due. The Company controls
                                            credit risk with respect to accounts receivable from service and repair fees through its
                                            credit evaluation process, credit limits, monitoring procedures and reasonably short collection
                                            terms. The Company performs ongoing credit authorizations before a product sales contract
                                            is entered into or service and repair fees are provided.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;&#160;Long
Term Accounts Receivable&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Long term accounts receivable balances at
December 31, 2023 and June 30, 2023 amounted to approximately $<span id="xdx_901_ecustom--AccountsReceivableNetLongTerm_iI_pn3n3_c20231231_z8Tp1YVIbIUl" title="Long term accounts receivable">376
</span>and $<span id="xdx_904_ecustom--AccountsReceivableNetLongTerm_iI_pn3n3_c20230630_zCX0hqWSS1h" title="Long term accounts receivable">710
</span>respectively. The Company will generate revenue from long-term, non-cancellable contracts to provide service and repair services.
Future revenue to be recognized over the following two years as of December 31, 2023 is as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--TotalFacilitiesOwnedOrManagedTableTextBlock_pn3n3_zOPb9OOHAwE4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details 1)">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td id="xdx_8B5_z8RI1U23wU33" style="display: none; text-align: right">Schedule of Future revenue</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 43%; text-align: right">2025</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ContractReceivableDueOneToTwoYears_iI_pn3n3_c20231231_zI9Rs5aCmDnb" style="width: 43%; text-align: right" title="2025">319</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2026</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ContractReceivableDueTwoToThreeYears_iI_pn3n3_c20231231_zOVVUU2LH5sk" style="border-bottom: Black 1pt solid; text-align: right" title="2026">57</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AccountsReceivableBilledForLongTermContractsOrPrograms_pn3n3_c20231231_ztlcCINnoJ1l" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">376</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p id="xdx_8A5_zeSqkM0srNJd" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Medical Receivables</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Medical receivables are due under fee-for-service
contracts from third party payors, such as hospitals, government sponsored healthcare programs, patient&#8217;s legal counsel and
directly from patients. Substantially all the revenue relates to patients residing in Florida. The carrying amount of the medical
receivable is reduced by an allowance that reflects management&#8217;s best estimate of the amounts that will not be collected.
The Company determines allowances for contractual adjustments and uncollectible accounts based on specific agings, specific payor
collection issues that have been identified and based on payor classifications and historical experience at each site.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
























<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Management and Other Fees Receivable</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s receivables from
the related and non-related professional corporations (PC&#8217;s) substantially consist of fees outstanding under management agreements.
Payment of the outstanding fees is dependent on collection by the PC&#8217;s of fees from third party medical reimbursement organizations,
principally insurance companies and health management organizations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Payment of the management fee receivables from the PC&#8217;s
may be impaired by the inability of the PC&#8217;s to collect in a timely manner their medical fees from the third-party payors,
particularly insurance carriers covering automobile no-fault and workers compensation claims due to longer payment cycles and rigorous
informational requirements and certain other disallowed claims. Approximately <span id="xdx_902_ecustom--PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims_pip0_dp_c20231001__20231231_zdLeRFDtzGUf" title="Percentage of net revenue">66</span>% and <span id="xdx_907_ecustom--PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims_pip0_dp_c20221001__20221231_zYJAWfx84oga" title="Percentage of net revenue">67</span>% of the PCs&#8217; net revenues for the
three months ended December 31, 2023 and 2022, respectively, were derived from no-fault and personal injury protection claims.
Approximately <span id="xdx_905_ecustom--PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims_pip0_dp_c20230701__20231231_z9KunA8agoje" title="Percentage of net revenue">67</span>% and <span id="xdx_90C_ecustom--PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims_pip0_dp_c20220701__20221231_zUeZnhDd95nd" title="Percentage of net revenue">68</span>% of the PCs&#8217; net revenue for the six months ended December 31, 2023 and 2022, respectively, were
derived from no-fault and personal injury protection claims. The Company considers the aging of its accounts receivable in determining
the amount of allowance for doubtful accounts. The Company generally takes all legally available steps to collect its receivables.
Credit losses associated with the receivables are provided for in the condensed consolidated financial statements and have historically
been within management&#8217;s expectations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Net revenues from management and other
fees charged to the related PCs accounted for approximately <span id="xdx_90B_ecustom--PercentageOfConsolidatedNetRevenueFromManagementFees_pip0_dp_c20231001__20231231_z6HmEe0zaoW9" title="Percentage of consolidated net revenue">11.8</span>% and <span id="xdx_904_ecustom--PercentageOfConsolidatedNetRevenueFromManagementFees_pip0_dp_c20221001__20221231_zrrNEAwUomGb" title="Percentage of consolidated net revenue">12.4</span>% of the consolidated net revenues for the three months
ended December 31, 2023 and 2022, respectively. Net revenues from management and other fees charged to the related PCs accounted
for approximately <span id="xdx_908_ecustom--PercentageOfConsolidatedNetRevenueFromManagementFees_pip0_dp_c20230701__20231231_zU97CGldWpQa" title="Percentage of consolidated net revenue">11.7</span>% and <span id="xdx_907_ecustom--PercentageOfConsolidatedNetRevenueFromManagementFees_pip0_dp_c20220701__20221231_zSa1MW6kZytj" title="Percentage of consolidated net revenue">12.6</span>% of the consolidated net revenues for the six months ended December 31, 2023 and 2022, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Tallahassee Magnetic Resonance Imaging,
Inc., Stand Up MRI of Boca Raton, Inc. and Stand Up MRI &amp; Diagnostic Center, Inc. (all related medical practices) entered into
a guaranty agreement, pursuant to which they cross guaranteed all management fees which are payable to the Company, which have
arisen under each individual management agreement. Additional Company managed entities also operate under a guaranty agreement,
pursuant to which management fees are payable to the Company.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;&#160;&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s patient fee revenue,
net of contractual allowances and discounts for the three and six months ended December 31, 2023 and 2022 are summarized in the
following table.&#160;</p>


























<table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfPatientFeeRevenueTableTextBlock_zlRut4kBWtai" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details)">
<tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B7_z5TLT0GbxGA4" style="display: none">Schedule of patient fee revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center">For the Three Months Ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Commercial Insurance/ Managed Care</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_znhjakEssmI9" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">1,243</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_zo3vvZD7nGP9" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">958</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Medicare/Medicaid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zJuB4xVfqhE5" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">284</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zXyVF66WunI1" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">247</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Workers&#8217; Compensation/Personal Injury</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_z5wxjXHQ4B2h" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">4,907</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_z4JLoGVYKosf" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">4,262</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherMember_zlC5xC7Qe0B8" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">1,787</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherMember_zKmmXI7dL4E1" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">1,662</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Patient Fee Revenue, net of contractual allowances and discounts</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231_zLIChWdBejDd" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">8,221</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231_zQUZ9qSPnm41" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">7,129</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center">For the Six Months Ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Commercial Insurance/ Managed Care</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_zCMYrCl87ynh" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">2,416</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_zowmtzn9Vbe3" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">1,869</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Medicare/Medicaid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zbVJ4nfhTCx6" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">555</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zjiT9qoryZp9" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">484</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Workers&#8217; Compensation/Personal Injury</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_znpyENPcKD3d" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">10,044</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_zHANQcrYMv6b" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">8,497</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherMember_zwyKUlvde0yi" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">3,881</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherMember_zog5V7oL01Ni" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">2,355</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Patient Fee Revenue, net of contractual allowances and discounts</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231_zNxkXEDlORt9" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">16,896</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231_z6goTqEukcRe" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">13,205</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p id="xdx_8AD_zvmSEl7yCrnc" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//310-10/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583990796256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING &amp; FINANCING LEASES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_DisclosureOperatingFinancingLeasesAbstract', window );"><strong>Operating Financing Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">OPERATING &amp; FINANCING LEASES</a></td>
<td class="text"><p id="xdx_809_eus-gaap--LesseeOperatingLeasesTextBlock_zbguJ97N0ab6" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 4 &#8211;<span id="xdx_828_zm0GT65ONDza"> OPERATING &amp; FINANCING
LEASES</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2019, the Company adopted ASU
2016-02, &#8220;Leases&#8221; (Topic 842). This standard requires lessees to apply a dual approach, classifying leases as either
finance or operating leases based upon the principle of whether or not the lease is effectively a financed purchase by the lessee.
We have also elected the transition package of the practical expedients permitted within the standard which eliminates the requirements
to reassess prior conclusions about lease identification, lease classification and indirect costs.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for its various
operating leases in accordance with Topic 842, as updated by ASU 2016-02. At the inception of a lease, the Company recognizes right-of-use
lease assets and related lease liabilities measured at present value of future lease payments on its balance sheet. Lease expense
is recognized on a straight-line basis over the term of the lease. Our most common initial term varies in length from 2 to 10 years.
Including renewal options negotiated with the landlord, we have a total span of 2 to 16 years at the facilities we lease. The Company
reviewed its contracts with vendors and customers, determining that its right-to-use lease assets consisted of only office space
operating leases. In determining the right-to-use lease assets and liabilities, the Company did recognize lease extension options
which the Company feels would be reasonably exercised. Our incremental borrowing rate (&#8220;IBR&#8221;) used to discount the
stream of operating lease payments is closely related to the interest rates available to the Company.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation of operating and financing
lease payments undiscounted cash flows to lease liabilities recognized as of December 31, 2023 is as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
























<table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_z0fRutkiWkId" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OPERATING &amp; FINANCING LEASES - Lease Payments (Details)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_8B3_zIHJDJmb4wWh" style="display: none; text-align: right">Lessee operating leases liability maturity</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Twelve Months Ending<br/>
December 31,</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Operating Lease<br/>
Payments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Financing Lease<br/>
Payments</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 26%; text-align: right">2024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="width: 26%; text-align: right" title="Lessee, Operating Lease, Liability, to be Paid, Year One">6,319</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="width: 26%; text-align: right" title="Finance Lease, Liability, to be Paid, Year One">244</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="text-align: right" title="Lessee, Operating Lease, Liability, to be Paid, Year Two">5,672</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="text-align: right" title="Finance Lease, Liability, to be Paid, Year Two">244</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2026</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="text-align: right" title="Lessee, Operating Lease, Liability, to be Paid, Year Three">4,902</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="text-align: right" title="Finance Lease, Liability, to be Paid, Year Three">244</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2027</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="text-align: right" title="Lessee, Operating Lease, Liability, to be Paid, Year Four">3,677</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="text-align: right" title="Finance Lease, Liability, to be Paid, Year Four">41</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2028</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="text-align: right" title="Lessee, Operating Lease, Liability, to be Paid, Year Five">3,426</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="text-align: right" title="Finance Lease, Liability, to be Paid, Year Five"><span style="-sec-ix-hidden: xdx2ixbrl1382">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">Thereafter</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="text-align: right" title="Lessee, Operating Lease, Liability, to be Paid, after Year Five">20,698</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="text-align: right" title="Finance Lease, Liability, to be Paid, after Year Five"><span style="-sec-ix-hidden: xdx2ixbrl1386">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">Present value discount</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--PresentValueDiscount_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Present value discount">(9,737</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--PresentValueDiscountFinancingLease_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Present value discount">(43</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">Total lease liability</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingLeaseLiability_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating Lease, Liability">34,957</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FinanceLeaseLiability_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Finance Lease, Liability">730</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_DisclosureOperatingFinancingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_DisclosureOperatingFinancingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583904125168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p id="xdx_800_eus-gaap--InventoryDisclosureTextBlock_zoEL3sLGOCo2" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">NOTE 5 -<span id="xdx_82F_zzvq9GNuB1I"> INVENTORIES</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories included in the accompanying
condensed consolidated balance sheets consist of the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_zGboBOL1Wf87" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVENTORIES - Inventories (Details)">
<tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BF_zkII9TzyV9t7" style="display: none; padding-top: 0; padding-right: 0">Schedule of inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20231231_zWo932XnF1T4" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20230630_z4tq9kpA2VE5" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">December 31,<br/>
2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">June 30,<br/>
2023</td></tr>
<tr id="xdx_40E_eus-gaap--OtherInventorySupplies_iI_maIFGAWzdt0_zhrbC4b89MZc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Purchased parts, components and supplies</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,582</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,346</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--InventoryWorkInProcess_iI_maIFGAWzdt0_zjJwXejdTLQ4" style="vertical-align: bottom; background-color: White">
    <td>Work-in-process</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">253</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">224</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--InventoryFinishedGoodsAndWorkInProcess_iTI_mtIFGAWzdt0_zVRC2sPk6n9l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Inventories</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,835</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,570</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583902009952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">OTHER INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_808_eus-gaap--IntangibleAssetsDisclosureTextBlock_zkobtvaaAgUj" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 6 &#8211;<span id="xdx_823_zlwpLMSMVjic"> OTHER INTANGIBLE ASSETS</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Other intangible assets, net of accumulated
amortization, in the accompanying condensed consolidated balance sheets consist of the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_pn3n3_zHnA5sGQb175" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OTHER INTANGIBLE ASSETS - Other intangible assets net of amortization (Details)">
<tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BF_zyqX1uLwEcw1" style="display: none; text-align: left">Schedule of other intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">December 31,<br/>
2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">June 30, <br/>
2023</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Capitalized software development costs</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_z3x14ASoMG3f" style="width: 12%; text-align: right" title="Gross other intangible assets">7,005</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_pn3n3" style="width: 12%; text-align: right" title="Gross other intangible assets">7,005</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Patents and copyrights</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zvNIq4ynXZx6" style="text-align: right" title="Gross other intangible assets">5,472</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_pn3n3" style="text-align: right" title="Gross other intangible assets">5,452</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Non-compete</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zY8Va9wjG4A8" style="text-align: right" title="Gross other intangible assets">4,150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_pn3n3" style="text-align: right" title="Gross other intangible assets">4,150</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Customer relationships</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zyt57x5TTL6f" style="border-bottom: Black 1pt solid; text-align: right" title="Gross other intangible assets">3,900</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Gross other intangible assets">3,900</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross Other intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231_znsHM6vhm7va" style="text-align: right" title="Gross other intangible assets">20,527</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20230630_zNyHjhgPhRH5" style="text-align: right" title="Gross other intangible assets">20,507</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: Accumulated amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_pn3n3_c20231231_zd56JZnmfOsl" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization">17,261</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20230630_z7jK2eMULv81" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization">17,075</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other Intangible Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_pn3n3_c20231231_z7rZD3VQcbX9" style="border-bottom: Black 2.5pt double; text-align: right" title="Other intangible assets-net">3,266</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20230630_z7nmcTachwOf" style="border-bottom: Black 2.5pt double; text-align: right" title="Other intangible assets-net">3,432</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
























<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization of patents and copyrights
for the three months ended December 31, 2023 and 2022 amounted to $<span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20231001__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zJ6lkEFohRk" title="Amortization of Intangible Assets">43</span> and $<span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20221001__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_z8zEjgXiClC2" title="Amortization of Intangible Assets">47</span>, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization of customer relationships
for the three months ended December 31, 2023 and 2022 amounted to $<span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20231001__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zQ1DhqoXYKRb" title="Amortization of Intangible Assets">50</span> and $<span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20221001__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zXdcADWBVco4" title="Amortization of Intangible Assets">50</span>, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization of patents and copyrights
for the six months ended December 31, 2023 and 2022 amounted to $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20230701__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zG7ggbFFZEt9" title="Amortization of Intangible Assets">86</span> and $<span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20220701__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zXE72AifZQzj" title="Amortization of Intangible Assets">101</span>, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization of customer relationships
for the six months ended December 31, 2023 and 2022 amounted to $<span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20230701__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zSsQLrQlgEbc" title="Amortization of Intangible Assets">100</span> and $<span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20220701__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zGrTy4Lx0aV1" title="Amortization of Intangible Assets">100</span>, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583901193600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_805_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zGPBbxLvokkl" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 7 &#8211;<span id="xdx_82D_zukqRL4aBzLl"> OTHER CURRENT LIABILITIES</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Other current liabilities in the accompanying
condensed consolidated balance sheets consist of the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_pn3n3_zeP1UrQ0Dm77" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OTHER CURRENT LIABILITIES - Other Current Liabilities - (Details)">
<tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B9_zHCcyPHyOwF5" style="display: none; text-align: left">Schedule of other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20231231_zHR1XX7zypxe" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20230630_z9cYelbSkp3g" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">December 31,<br/>
2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">June 30,<br/>
2023</td></tr>
<tr id="xdx_400_eus-gaap--AccruedSalariesCurrent_iI_pn3n3_maOLCzdop_z5WqcgkMCPFc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Accrued salaries, commissions and payroll taxes</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,078</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,413</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_pn3n3_maOLCzdop_zISZUiZsxMgl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Sales tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">193</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--StateIncomeTaxesPayable_iI_pn3n3_maOLCzdop_zh61EtQveQXj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"> Income taxes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">196</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maOLCzdop_zQIGdXEGnn4b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Legal and other professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_pn3n3_maOLCzdop_zmqgUBuULDbi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounting fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--SelfInsuranceReserve_iI_pn3n3_maOLCzdop_zwlv9e72VSwl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Self-funded health insurance reserve</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesNoncurrent_iI_pn3n3_maOLCzdop_zbqhVQUeLE27" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued interest and penalty</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OtherSundryLiabilitiesCurrent_iI_pn3n3_maOLCzdop_zXfcTexvjhL3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other general and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">809</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">574</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OtherLiabilitiesCurrent_iTI_pn3n3_mtOLCzdop_zlJPzs1Vexha" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other Current Liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,460</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,444</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583901229536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT AND RELATED INFORMATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT AND RELATED INFORMATION</a></td>
<td class="text"><p id="xdx_803_eus-gaap--SegmentReportingDisclosureTextBlock_zL0RfZteg9q9" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">NOTE 8 - <span id="xdx_827_z66xBDPQi827">SEGMENT AND RELATED INFORMATION</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Company operates in two industry segments - manufacturing
and the servicing of medical equipment and management of diagnostic imaging centers. The accounting policies of the segments are
the same as those described in the summary of significant accounting policies as disclosed in the Company&#8217;s 10-K as of June
30, 2023. All inter-segment sales are market-based. The Company evaluates performance based on income or loss from operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>
























<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Summarized financial information concerning
the Company&#8217;s reportable segments is shown in the following table:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zsW5z5VdLnKj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT AND RELATED INFORMATION - Summarized Segments - (Details)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BB_zZValMBlhpu2" style="display: none">Schedule
    of summarized segment financial information</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Medical <br/> Equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Management <br/> of Diagnostic <br/> Imaging <br/> Centers</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Totals</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; padding-top: 0; padding-right: 0">For the three months ended Dec. 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Net revenues from external customers</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zYBxfzg2kR0g" style="width: 11%; text-align: right" title="Net revenues from external customers">1,861</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--Revenues_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zSYkIm1RS3h8" style="width: 11%; text-align: right" title="Net revenues from external customers">23,525</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_pn3n3_c20231001__20231231_zlUglcd1BO8b" style="width: 11%; text-align: right" title="Net revenues from external customers">25,386</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Inter-segment net revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_ecustom--IntersegmentNetRevenues_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zk8Xi2CrDcq7" style="text-align: right" title="Inter-segment net revenues">254</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_ecustom--IntersegmentNetRevenues_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zKIEVE9fbm87" style="text-align: right" title="Inter-segment net revenues"><span style="-sec-ix-hidden: xdx2ixbrl1520">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_ecustom--IntersegmentNetRevenues_pn3n3_c20231001__20231231_zddsruZKQpEh" style="text-align: right" title="Inter-segment net revenues">254</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">(Loss) Income from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zr4APB0CFLod" style="text-align: right" title="(Loss) Income from operations">(993</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z9gsBrxFZm04" style="text-align: right" title="(Loss) Income from operations">5,878</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20231001__20231231_zfjpYB9v3j6j" style="text-align: right" title="(Loss) Income from operations">4,885</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zEre8Aww9Vie" style="text-align: right" title="Depreciation and amortization">60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zxaE3s6mMBdj" style="text-align: right" title="Depreciation and amortization">1,160</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20231001__20231231_zYSMpu46ZV3f" style="text-align: right" title="Depreciation and amortization">1,220</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Capital expenditures</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zupZNmxdrKm8" style="text-align: right" title="Capital expenditures">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zyLNYP99ULt5" style="text-align: right" title="Capital expenditures">129</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20231001__20231231_zQmfrNSPnb29" style="text-align: right" title="Capital expenditures">133</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">For the three months ended Dec. 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net revenues from external customers</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--Revenues_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zFxznI4734b1" style="text-align: right" title="Net revenues from external customers">2,035</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zGekRqiHTlgd" style="text-align: right" title="Net revenues from external customers">22,221</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--Revenues_pn3n3_c20221001__20221231_zw6mZEGuNPqf" style="text-align: right" title="Net revenues from external customers">24,256</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Inter-segment net revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_ecustom--IntersegmentNetRevenues_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zvdYFhwzc9jk" style="text-align: right" title="Inter-segment net revenues">245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--IntersegmentNetRevenues_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z09BirmDHQ28" style="text-align: right" title="Inter-segment net revenues"><span style="-sec-ix-hidden: xdx2ixbrl1550">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--IntersegmentNetRevenues_pn3n3_c20221001__20221231_zGwXA4Fbz9da" style="text-align: right" title="Inter-segment net revenues">245</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">(Loss) Income from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_z51YjY3T50Ie" style="text-align: right" title="(Loss) Income from operations">(551</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zmV8AdnXmUV8" style="text-align: right" title="(Loss) Income from operations">4,783</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20221001__20221231_zqQwVfraq8jf" style="text-align: right" title="(Loss) Income from operations">4,232</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_z2XDFJA5yQBg" style="text-align: right" title="Depreciation and amortization">65</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zRsocsNsD02k" style="text-align: right" title="Depreciation and amortization">1,035</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20221001__20221231_zxyeiNq7Y1q7" style="text-align: right" title="Depreciation and amortization">1,100</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Capital expenditures</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zFjPVnk45Ap2" style="text-align: right" title="Capital expenditures">50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zzq5tmVzjiHl" style="text-align: right" title="Capital expenditures">423</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20221001__20221231_zMqTazUcDbfd" style="text-align: right" title="Capital expenditures">473</td><td style="text-align: left">&#160;</td></tr>
</table>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Medical <br/> Equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Management <br/> of Diagnostic <br/> Imaging <br/> Centers</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Totals</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left">For the six months ended Dec. 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Net revenues from external customers</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--Revenues_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zv1hxeQVrfgb" style="width: 11%; text-align: right" title="Net revenues from external customers">3,917</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--Revenues_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zhGblQ8e47t9" style="width: 11%; text-align: right" title="Net revenues from external customers">47,307</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--Revenues_pn3n3_c20230701__20231231_zsrktXjJ68fi" style="width: 11%; text-align: right" title="Net revenues from external customers">51,224</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Inter-segment net revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--IntersegmentNetRevenues_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zTIZOHH4F1cf" style="text-align: right" title="Inter-segment net revenues">508</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_ecustom--IntersegmentNetRevenues_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z9bWZK6jBe96" style="text-align: right" title="Inter-segment net revenues"><span style="-sec-ix-hidden: xdx2ixbrl1580">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--IntersegmentNetRevenues_pn3n3_c20230701__20231231_z4VKmEP61u15" style="text-align: right" title="Inter-segment net revenues">508</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">(Loss) Income from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_z6h1rbd7XwMe" style="text-align: right" title="(Loss) Income from operations">(1,731</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zyePHhZzZMie" style="text-align: right" title="(Loss) Income from operations">13,187</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20230701__20231231_z0McvqgoVuL9" style="text-align: right" title="(Loss) Income from operations">11,456</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zxmEVa14eGrj" style="text-align: right" title="Depreciation and amortization">121</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zxMsCziXPFJ8" style="text-align: right" title="Depreciation and amortization">2,294</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20230701__20231231_z54OR3vVuP95" style="text-align: right" title="Depreciation and amortization">2,415</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Capital expenditures</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zPQA3hOM7Iib" style="text-align: right" title="Capital expenditures">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zdpsXMOLYsPg" style="text-align: right" title="Capital expenditures">192</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20230701__20231231_zvy3SiQL5w2g" style="text-align: right" title="Capital expenditures">212</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">For the six months ended Dec. 31, 2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net revenues from external customers</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--Revenues_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zdd5jVxctIxf" style="text-align: right" title="Net revenues from external customers">3,913</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zBhKNZ7a00N4" style="text-align: right" title="Net revenues from external customers">43,534</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--Revenues_pn3n3_c20220701__20221231_zwhY0pR5Akvf" style="text-align: right" title="Net revenues from external customers">47,447</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Inter-segment net revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_ecustom--IntersegmentNetRevenues_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zoffHxamlESl" style="text-align: right" title="Inter-segment net revenues">490</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--IntersegmentNetRevenues_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z6z2QJQnYWkk" style="text-align: right" title="Inter-segment net revenues"><span style="-sec-ix-hidden: xdx2ixbrl1610">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_ecustom--IntersegmentNetRevenues_pn3n3_c20220701__20221231_zESpkKwQXykg" style="text-align: right" title="Inter-segment net revenues">490</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">(Loss) Income from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zPF7z4Z6W2Lh" style="text-align: right" title="(Loss) Income from operations">(1,353</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zPpoBpVgKqok" style="text-align: right" title="(Loss) Income from operations">9,496</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20220701__20221231_zPYFCNc56th3" style="text-align: right" title="(Loss) Income from operations">8,143</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zPIFykb6hMId" style="text-align: right" title="Depreciation and amortization">137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z8cmlHzT5sL8" style="text-align: right" title="Depreciation and amortization">2,081</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20220701__20221231_zMfkSiLXdYP6" style="text-align: right" title="Depreciation and amortization">2,218</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Capital expenditures</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zpEqtkQ7HQ93" style="text-align: right" title="Capital expenditures">74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zGdkIlgc0f17" style="text-align: right" title="Capital expenditures">1,362</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20220701__20221231_z2Enb1MPBt7l" style="text-align: right" title="Capital expenditures">1,436</td><td style="text-align: left">&#160;</td></tr>
</table>



<p id="xdx_8AF_z37NdTvkcvD9" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583901107344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTION</a></td>
<td class="text"><p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zHWnZ22CaqHa" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">NOTE 9 &#8211; <span id="xdx_82C_zQvkvwl2vwv3">RELATED PARTY TRANSACTION</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">On December 31, 2023, the Company entered into an agreement
with Magnetic Resonance Management, LLC (&#8220;MRM&#8221;) for the sale of a MRI scanner. MRM is owned by the CEO and President of
the Company. The sales price of the equipment was $<span id="xdx_900_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20231231__us-gaap--TypeOfArrangementAxis__custom--MagneticResonanceManagementMember_zfzvHax66Pfi" title="Sale of price of the equipment">577 </span>which
is payable based upon a promissory note dated December 1, 2023. The note bears interest at a rate of <span id="xdx_905_eus-gaap--DerivativeFixedInterestRate_iI_dp_c20231231__us-gaap--TypeOfArrangementAxis__custom--MagneticResonanceManagementMember_zNADqpJm70He" title="Bears interest rate">9</span>%
and is payable in full at the maturity of the note in December 2028. The MRI scanner had zero  basis,which resulted ina gain of
$<span id="xdx_901_ecustom--GainOnSaleOfEquipmentsRelatedParty_pn3n3_c20230701__20231231__us-gaap--TypeOfArrangementAxis__custom--MagneticResonanceManagementMember_zD3aBtiEar0h" title="Gain on sale of equipments">577</span>.
The Company has the option but not the obligation to re-take possession of the scanner in lieu of payment upon maturity of the
note.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583901184640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL CASH FLOW INFORMATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">SUPPLEMENTAL CASH FLOW INFORMATION</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--CashFlowSupplementalDisclosuresTextBlock_zMUapTuqk1c7" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">NOTE 10 &#8211; <span id="xdx_82C_z0YpBtiGdf95">SUPPLEMENTAL CASH FLOW INFORMATION</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December
31, 2023 and December 31, 2022, the Company paid $<span id="xdx_908_eus-gaap--InterestPaidNet_pn3n3_c20230701__20231231_zIq5hehxG7zg" title="Interest paid">58</span> and $<span id="xdx_90F_eus-gaap--InterestPaidNet_pn3n3_c20220701__20221231_zSYfYY2p5XS4" title="Interest paid">27</span> for interest, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December
31, 2023 and December 31, 2022, the Company paid $<span id="xdx_908_eus-gaap--IncomeTaxesPaid_pn3n3_c20230701__20231231_zMiNrxfLyRtg" title="Income taxes paid">150</span> and $<span id="xdx_90A_eus-gaap--IncomeTaxesPaid_pn3n3_c20220701__20221231_zZXAhzt0DVWa" title="Income taxes paid">647</span> for income taxes, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//230/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583901355984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zvzBqLcHjQo1" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">NOTE 11 &#8211; <span id="xdx_82C_zFbmrWQyLhwi">COMMITMENTS AND CONTINGENCIES</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Litigation</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is subject to legal proceedings
and claims arising from the ordinary course of its business, including personal injury, customer contract and employment claims.
In the opinion of management, the aggregate liability, if any, with respect to such actions, will not have a material adverse effect
on the consolidated financial position or results of operations of the Company.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">There were no material changes in litigation
from that reported in our Form 10-K for the fiscal year ended June 30, 2023.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Other Matters</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 13, 2022, the Company adopted
a stock repurchase plan. The plan has no expiration date and cannot determine the number of shares which will be repurchased. On
September 26, 2022, the Board of Directors has approved up to $<span id="xdx_906_eus-gaap--StockRepurchaseProgramAuthorizedAmount1_iI_pn6n6_c20220926_zHN5t317jN9i" title="Stock purchase plan">9</span> million to be repurchased under the plan which will be purchased
on the publicly traded open market at prevailing prices. During the six months ended December 31, 2023 and 2022, the Company repurchased
<span id="xdx_905_eus-gaap--StockRepurchasedDuringPeriodShares_pn3n3_c20230701__20231231_zyBLqJfRvmEf" title="Number of shares repurchased">116</span> and <span id="xdx_907_eus-gaap--StockRepurchasedDuringPeriodShares_pn3n3_c20220701__20221231_zzCeEy7DCR7f" title="Number of shares repurchased">30</span> shares at a cost of $<span id="xdx_908_eus-gaap--StockRepurchasedDuringPeriodValue_pn3n3_c20230701__20231231_ze00iQh7Hz73" title="Number of shares repurchased, value">1,885</span> and $<span id="xdx_901_eus-gaap--StockRepurchasedDuringPeriodValue_pn3n3_c20220701__20221231_z4sW2ojJs1Wb" title="Number of shares repurchased, value">478</span>, respectively. The Company cancelled <span id="xdx_909_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_pn3n3_c20230701__20231231_zJ9Ojs9M54E2" title="Shares cancelled">123</span> shares and <span id="xdx_906_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_pn3n3_c20220701__20221231_zRey31O42mqg" title="Shares cancelled">16</span> shares at a cost of $<span id="xdx_905_eus-gaap--StockRepurchasedAndRetiredDuringPeriodValue_pn3n3_c20230701__20231231_z3F898iE26M3" title="Shares cancelled">2,005</span>
and $<span id="xdx_90C_eus-gaap--StockRepurchasedAndRetiredDuringPeriodValue_pn3n3_c20220701__20221231_z4GUJKnBOll8" title="Shares cancelled">402</span> for the six months ended December 31, 2023 and 2022, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company maintains a self-funded
health insurance program with a stop-loss umbrella policy with a third party insurer to limit the maximum potential liability for
individual claims to $<span id="xdx_90F_ecustom--StoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims_pn3n3_c20230701__20231231_zepMfctlFoL9" title="Liability for individual claims">150</span> per person and for a maximum potential claim liability based on member enrollment. With respect to this
program, the Company considers historical and projected medical utilization data when estimating its health insurance program liability
and related expense. As of December 31, 2023 and June 30, 2023, the Company had approximately $<span id="xdx_905_eus-gaap--LiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth_iI_pn3n3_c20231231_zJtH6cAEXXOa" title="Reserve for self-funded">86</span> and $<span id="xdx_903_eus-gaap--LiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth_iI_pn3n3_c20230630_zmnSW29S6X4j" title="Reserve for self-funded">101</span>, respectively, in reserve
for its self-funded health insurance programs. The reserves are included in &#8220;Other current liabilities&#8221; in the condensed
consolidated balance sheets.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



























<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company regularly analyzes its reserves
for incurred but not reported claims, and for reported but not paid claims related to its reinsurance and self-funded insurance
programs. The Company believes its reserves are adequate. However, significant judgment is involved in assessing these reserves
such as assessing historical paid claims, average lags between the claims&#8217; incurred date, reported dates and paid dates,
and the frequency and severity of claims. There may be differences between actual settlement amounts and recorded reserves and
any resulting adjustments are included in expense once a probable amount is known. There were no significant adjustments recorded
in the periods covered by this report.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583904179584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_805_eus-gaap--IncomeTaxDisclosureTextBlock_z9PIY1Vi0NYh" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">NOTE 12 - <span id="xdx_82A_zgbJBS8rTg9b">INCOME TAXES</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 740-270, &#8220;Income
Taxes &#8211; Interim Reporting&#8221;, the Company is required at the end of each interim period to determine the best estimate
of its annual effective tax rate and apply that rate to year-to-date ordinary income or loss. The resulting tax expense (or benefit)
is adjusted for the tax effect of specific events, if any, required to be discretely recognized in the interim period as they occur.
For the six months ended December 31, 2023 and 2022, the Company recorded income tax expense of $<span id="xdx_907_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_pn3n3_c20230701__20231231_z77gKMqvDt4" title="Income tax expense">3,036</span> in 2023 as compared to $<span id="xdx_908_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_pn3n3_c20220701__20221231_z8TUAeevUDu6" title="Income tax expense">2,871</span>
in 2022. For the three months ended December 31, 2023 and 2022, the Company recorded income tax expense of $<span id="xdx_90E_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_pn3n3_c20231001__20231231_z8UrFTQw6Pr1" title="Income tax expense">1,366</span> and $<span id="xdx_907_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_pn3n3_c20221001__20221231_zsEqBUD1dJfl" title="Income tax expense">1,462</span> respectively.
The six month and three month 2023 provision is comprised of a current income tax component of $<span id="xdx_900_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_c20230701__20231231_z7SZpscRnZs8" title="Income tax component - current">751</span> and a deferred income tax component
of $<span id="xdx_906_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_c20230701__20231231_zABWvBKGT7Ai" title="Income tax component - deferred">2,285</span> and a current income tax component of $<span id="xdx_903_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_c20231001__20231231_z5e5nTcgNSle" title="Income tax component - current">323</span> and a deferred income tax component of $<span id="xdx_90B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_c20231001__20231231_zU1Tpt0sz2gf" title="Income tax component - deferred">1,043</span> respectively. Obligations for
any liability associated with the current income tax provision, has been reduced, primarily resulting from the benefits and utilization
of net operating loss carryforwards.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC Topic 740 prescribes a recognition
threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected
to be taken in a corporate tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained
upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the
benefit recognized and measured pursuant to the interpretation are referred to as unrecognized benefits. A liability is recognized
(or amount of net operating loss carryforward or amount of tax refundable is reduced) for an unrecognized tax benefit because it
represents an enterprise&#8217;s potential future obligation to the taxing authority for a tax position that was not recognized
as a result of applying the provisions of ASC Topic 740. The Company believes there are no uncertain tax positions in prior year
tax filings and therefore it has not recorded a liability for unrecognized tax benefits.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC Topic 740, interest
costs related to unrecognized tax benefits are required to be calculated (if applicable) and would be classified as &#8220;Interest
expense, net&#8221;. Penalties if incurred would be recognized as a component of &#8220;Selling, general and administrative&#8221;
expenses.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company files corporate income tax
returns in the United States (federal) and in various state and local jurisdictions. In most instances, the Company is no longer
subject to federal, state and local income tax examinations by tax authorities for years prior to 2018.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
























<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded a deferred tax
asset of $<span id="xdx_904_eus-gaap--DeferredTaxAssetsNet_iI_pn3n3_c20231231_zJPrUJmNilga" title="Deferred tax asset">7,758</span> and a deferred tax liability of $<span id="xdx_901_eus-gaap--DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityPolicyholdersSurplus_iI_pn3n3_c20231231_zCECO4hJ1tG3" title="Deferred tax liability">395</span> as of December 31, 2023, primarily relating to allowance for doubtful accounts
and tax credits. The net operating losses begin to expire in 2028 for federal tax and state income tax purposes. The Company anticipates
that their Federal operating loss will be utilized in the current fiscal year.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Future ownership changes as determined
under Section 382 of the Internal Revenue code could further limit the utilization of net operating loss carryforwards. As of December
31, 2023, no such changes in ownership have occurred.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Inflation Reduction Act (&#8220;IRA&#8221;)
was enacted on August 16, 2022. The IRA includes provisions imposing a 1% excise tax on share repurchases that occur after December
31, 2022 and introduces a <span id="xdx_90E_ecustom--CorporateAlternativeMinimumTaxPercentage_dp_c20230701__20231231_z1lnHxfgDlI1" title="Corporate alternative minimum tax percentage">15</span>% corporate alternative minimum tax (&#8220;CAMT&#8221;) on adjusted financial statement income. The
CAMT will be effective for tax years beginning after December 31, 2022. Currently, the Company is expecting the IRA not to have
a material impact to the Company&#8217;s financial statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The ultimate realization of deferred tax assets is dependent on the generation
of future taxable income during the periods in which those temporary differences become deductible or when such net operating losses can
be utilized. The Company considers projected future taxable income, the regulatory environment of the industry and tax planning strategies
in making this assessment. At present, the Company believes that it is more likely than not that the benefits from certain deferred tax
asset carryforwards, will not all be fully realized. In recognition of this inherent risk, a valuation allowance was established for separate
state net operating losses that are not expected to be fully utilized. A valuation allowance will be maintained until sufficient positive
evidence exists to support the reversal of the remainder of the valuation.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583901184640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_z6fCf5UJhFC8" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 13 &#8211; <span id="xdx_822_ze5k9iU8ZZ5j">SUBSEQUENT EVENTS</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated events that
occurred subsequent to December 31, 2023 and through the date the condensed consolidated financial statements were issued.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During February 2024, the Company signed
an amendment to a property lease for its principal office in Melville, New York. The agreement extends the term of the lease until
November 2033.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583899293072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_z3sxBoQ5ZaXk" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><span id="xdx_860_zCQUcePOn8e4">Principles of Consolidation</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited condensed consolidated
financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships (collectively
the &#8220;Company&#8221;). All significant intercompany accounts and transactions have been eliminated in consolidation.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
























<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenues</a></td>
<td class="text"><p id="xdx_847_eus-gaap--RevenueRecognitionPolicyTextBlock_za2twcMHz04j" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><span id="xdx_868_z54JY0l9LKAf">Revenues</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The revenue recognition standard in
ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a
customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires
expanded disclosures regarding the Company&#8217;s revenue recognition policies and significant judgements employed in the determination
of revenue.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our revenues generally relate to net
patient fees&#160;received from various payers and patients themselves under contracts in which our performance obligations are
to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services
are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day.
The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care
health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction
prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care
health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the
services we provide to the related patients typically specify payments at amounts less than our standard charges and generally
provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually
reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes
in managed care contractual terms resulting from contract renegotiations and renewals.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">BUSINESS COMBINATION</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--BusinessCombinationsPolicy_zK3cw6rLlle3" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_86B_zhfHChWzvfrh">BUSINESS COMBINATION</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">When the qualifications for business
combination accounting treatment are met, it requires us to recognize separately from goodwill the assets acquired and the liabilities
assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred
over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates
and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently
uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition
date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the
conclusion of the measurement period of final determination of the values of assets acquired or liabilities assumed, whichever
comes first, any subsequent adjustments are recorded to our consolidated statements of income.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zUietNjjOXEf" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_864_zoDNeMxqPNPc">Earnings Per Share</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic earnings per share (&#8220;EPS&#8221;)
is computed based upon the weighted average number of shares of common stock and stock equivalents outstanding, net of common stock.
In accordance with ASC topic 260-10, &#8220;Participating Securities and the Two-Class method&#8221;, the Company used the Two-Class
method for calculating basic income per share and applied the if converted method in calculating diluted income per share for the
three and six months ended December 31, 2023 and 2022.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Diluted EPS reflects the potential dilution
from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares
outstanding during the period. For the three and six months ended December 31, 2023 and 2022, diluted EPS for common shareholders
includes <span id="xdx_90D_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_pn3n3_c20231001__20231231_zWDdDMNArwzi" title="Shares included upon conversion of Class C Common"><span id="xdx_906_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_pn3n3_c20230701__20231231_zObqDGAhtB9" title="Shares included upon conversion of Class C Common"><span id="xdx_908_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_pn3n3_c20221001__20221231_znE2S1tSW9xl" title="Shares included upon conversion of Class C Common"><span id="xdx_907_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_pn3n3_c20220701__20221231_zuBHVG23ZLM4" title="Shares included upon conversion of Class C Common">128</span></span></span></span> shares upon conversion of Class C Common.</p>




























<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_z0hpep08RVlj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share - (Details)">
<tr style="vertical-align: bottom">
    <td id="xdx_8BB_znGt4olpKusa" style="display: none; padding-top: 0; padding-right: 0; text-align: left">Schedule of earning per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">Three months ended <br/> December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">Three months ended <br/> December 31, 2022</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Class C Common <br/> Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Class C Common <br/> Stock</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">Numerator: <br/> Net income available to common stockholders</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20231001__20231231_z24aXYwIjQak" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">3,759</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zG8ROYPm99jj" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">3,525</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zYeAgS3vtVDj" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">59</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20221001__20221231_zDCm7XWQngv4" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">2,232</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdVoSqQYuEu6" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Common Stock and Basic Numerator: Net income available to common stockholders">2,097</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zVmK7Tx46aDc" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">34</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Weighted average shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20231001__20231231_zujqgbfVHdib" title="Basic Denominator: Weighted average shares outstanding">6,437</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQ3s5Ss1T211" title="Basic Denominator: Weighted average shares outstanding">6,437</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zAdeCfpLn6Nc" title="Basic Denominator: Weighted average shares outstanding">383</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20221001__20221231_zlorfe1PBIP2" title="Basic Denominator: Weighted average shares outstanding">6,527</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2qzTva5HHvj" title="Basic Denominator: Weighted average shares outstanding">6,527</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zI5Yn8RanB8f" title="Basic Denominator: Weighted average shares outstanding">383</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Basic income per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20231001__20231231_zKWdQXgSLdq3" title="Basic income per common share">0.58</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zp7d2uqfUzjc" title="Basic income per common share">0.55</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zgbXQMSjCuVk" title="Basic income per common share">0.16</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20221001__20221231_zeIHjnC2kICf" title="Basic income per common share">0.34</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmSH7f1f7109" title="Basic income per common share">0.32</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z7F2Pqhgpvy1" title="Basic income per common share">0.09</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator: <br/> Weighted average shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2pyXMXkRWo3" title="Diluted Denominator: Weighted average shares outstanding">6,437</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zpTuzrYJwkK3" title="Diluted Denominator: Weighted average shares outstanding">383</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8lgAsR8fRzh" title="Diluted Denominator: Weighted average shares outstanding">6,527</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zqh4XEwVBlVc" title="Diluted Denominator: Weighted average shares outstanding">383</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible Class C Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_ecustom--ConvertibleClassCStock_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoXRWoEMXNbb" title="Convertible Class C Stock">128</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_ecustom--ConvertibleClassCStock_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_ztk1kuEXjKh6" title="Convertible Class C Stock"><span style="-sec-ix-hidden: xdx2ixbrl1091">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_ecustom--ConvertibleClassCStock_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrZgsPwWJQWk" title="Convertible Class C Stock">128</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--ConvertibleClassCStock_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zgXkhSfSxKAk" title="Convertible Class C Stock"><span style="-sec-ix-hidden: xdx2ixbrl1095">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Denominator for diluted earnings per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBPNn6fnSBtc" title="Total Denominator for Diluted Earnings Per Share">6,565</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zrXAnwqNZxD8" title="Total Denominator for Diluted Earnings Per Share">383</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKGI6QcltMc1" title="Total Denominator for Diluted Earnings Per Share">6,655</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z0JBAcMMr25g" title="Total Denominator for Diluted Earnings Per Share">383</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Diluted income per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pip0_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxl63AX6VXg7" title="Diluted Income per Common Share">0.54</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pip0_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zBFs3GvldEoh" title="Diluted Income per Common Share">0.16</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareDiluted_pip0_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2AJgM43Xhcl" title="Diluted Income per Common Share">0.32</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pip0_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zQade4RR3t9e" title="Diluted Income per Common Share">0.09</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">Six months ended <br/> December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">Six months ended <br/> December 31, 2022</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Class C Common <br/> Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Class C Common <br/> Stock</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">Numerator: <br/> Net income available to common stockholders</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20230701__20231231_z4UTQH7hUxL4" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">7,865</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsqY9NXVLV2c" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">7,375</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z3RMb85H0qkl" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">125</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20220701__20221231_zrCyjoAYN5q8" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">4,279</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLw3LCxpKoPj" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Common Stock and Basic Numerator: Net income available to common stockholders">4,020</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zvIHrcyBvIPk" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">66</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Weighted average shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20231231_zmZ93078iO8d" title="Basic Denominator: Weighted average shares outstanding">6,448</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z21yzFIuoLf6" title="Basic Denominator: Weighted average shares outstanding">6,448</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zQA2gc0u4Amk" title="Basic Denominator: Weighted average shares outstanding">383</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220701__20221231_ztm6KSYAChm6" title="Basic Denominator: Weighted average shares outstanding">6,534</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkFlslAJn2qk" title="Basic Denominator: Weighted average shares outstanding">6,534</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zL7NtDF1AoTf" title="Basic Denominator: Weighted average shares outstanding">383</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Basic income per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20230701__20231231_zmW1oBcSsg83" title="Basic income per common share">1.22</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4dCSpS3695b" title="Basic income per common share">1.14</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z7vSLvBYsxqe" title="Basic income per common share">0.33</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20220701__20221231_zJoGxGVg5CHa" title="Basic income per common share">0.65</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIo4QQjg035a" title="Basic income per common share">0.62</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zpvgvPcov6bg" title="Basic income per common share">0.17</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator: <br/> Weighted average shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9evyBlljdUa" title="Diluted Denominator: Weighted average shares outstanding">6,448</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zDfugAnIRGu7" title="Diluted Denominator: Weighted average shares outstanding">383</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2yNF3S72Dh3" title="Diluted Denominator: Weighted average shares outstanding">6,534</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zdvFkKhi6fDf" title="Diluted Denominator: Weighted average shares outstanding">383</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible Class C Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_ecustom--ConvertibleClassCStock_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVjyzxkTFd1" title="Convertible Class C Stock">128</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_ecustom--ConvertibleClassCStock_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zq4Sfu9LeOv5" title="Convertible Class C Stock"><span style="-sec-ix-hidden: xdx2ixbrl1159">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_ecustom--ConvertibleClassCStock_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zz6S4pR8sNT2" title="Convertible Class C Stock">128</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_ecustom--ConvertibleClassCStock_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zsmEWygCsbKi" title="Convertible Class C Stock"><span style="-sec-ix-hidden: xdx2ixbrl1163">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Denominator for diluted earnings per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8meuCzW846g" title="Total Denominator for Diluted Earnings Per Share">6,576</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zC7x0fJBLE45" title="Total Denominator for Diluted Earnings Per Share">383</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znQ1wEDYsoi7" title="Total Denominator for Diluted Earnings Per Share">6,662</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zJ8UZGlHPd3k" title="Total Denominator for Diluted Earnings Per Share">383</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Diluted income per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_pip0_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEoN3hUy1ybk" title="Diluted Income per Common Share">1.12</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_pip0_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zUXFtANM8l4g" title="Diluted Income per Common Share">0.33</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_pip0_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHNRYTugpdhi" title="Diluted Income per Common Share">0.60</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_pip0_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zZd01Sfe84th" title="Diluted Income per Common Share">0.17</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>



<p id="xdx_8A2_zDO6CHuBR1Ub" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>
























<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text"><p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z40QeTkHA1Ff" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><span id="xdx_869_zIQBDaKejqX2">Recent Accounting Standards</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2023, the Financial Accounting
Standards Board (&#8220;FASB&#8221;) issued ASU 2023-09, &#8220;Income Taxes (740) &#8220;Improvements to Income Tax Disclosures&#8221;,
which requires the annual financial statements to include consistent categories and greater disaggregation of information in the
rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company&#8217;s annual
reporting beginning after December 15, 2024, with early adoption permitted, and should be applied on a prospective basis, with
a retrospective option. We are currently evaluating the effect that adoption of ASU 2023-09 will have on our disclosures.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2023, FASB issued ASU 2023-07, &#8220;Segment Reporting (Topic
280)&#8221;, which is intended to improve reportable segment disclosure requirements through enhanced disclosures about significant segment
expenses. The amendments require disclosure of significant segment expenses regularly provided to the chief operating decision maker (CODM)
as well as other segment items, extended certain annual disclosures to interim periods, clarify the applicability to single reportable
segment entities, permit, more than one measure of profit or loss to be reported under certain conditions, and require disclosure of the
title and position of the CODM. The effective date for public entities is beginning after December 15, 2023 and interim periods with fiscal
years beginning after December 15, 2024. We expect to adopt the new disclosures as required and are currently evaluating the impact on
the related disclosures.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2016, FASB issued ASU 2016-13, &#8220;Financial
Instruments &#8211; Credit Loses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221;, which replaces the incurred
loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader
range of reasonable and supportable information to assess credit loss estimates. This ASU is effective for fiscal years beginning after
December 15, 2022. The Company adopted this standard on July 1, 2023 using the modified retrospective approach and it did not have a material
impact of the Company&#8217;s financial statements, resulting in no adjustment to prior year earnings.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">FASB, the Emerging Issues Task Force
and the SEC have issued certain other accounting standards, updates, and regulations as of December 31, 2023 that will become effective
in subsequent periods; however, management does not believe that any of those updates would have significantly affected the Company&#8217;s
financial accounting measures or disclosures had they been in effect during 2023 or 2022, and it does not believe that any of those
standards will have a significant impact on our consolidated condensed financial statements at the time they become effective.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583903085616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of earning per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_z0hpep08RVlj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share - (Details)">
<tr style="vertical-align: bottom">
    <td id="xdx_8BB_znGt4olpKusa" style="display: none; padding-top: 0; padding-right: 0; text-align: left">Schedule of earning per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">Three months ended <br/> December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">Three months ended <br/> December 31, 2022</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Class C Common <br/> Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Class C Common <br/> Stock</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">Numerator: <br/> Net income available to common stockholders</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20231001__20231231_z24aXYwIjQak" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">3,759</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zG8ROYPm99jj" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">3,525</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zYeAgS3vtVDj" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">59</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20221001__20221231_zDCm7XWQngv4" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">2,232</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdVoSqQYuEu6" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Common Stock and Basic Numerator: Net income available to common stockholders">2,097</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zVmK7Tx46aDc" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">34</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Weighted average shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20231001__20231231_zujqgbfVHdib" title="Basic Denominator: Weighted average shares outstanding">6,437</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQ3s5Ss1T211" title="Basic Denominator: Weighted average shares outstanding">6,437</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zAdeCfpLn6Nc" title="Basic Denominator: Weighted average shares outstanding">383</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20221001__20221231_zlorfe1PBIP2" title="Basic Denominator: Weighted average shares outstanding">6,527</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2qzTva5HHvj" title="Basic Denominator: Weighted average shares outstanding">6,527</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zI5Yn8RanB8f" title="Basic Denominator: Weighted average shares outstanding">383</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Basic income per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20231001__20231231_zKWdQXgSLdq3" title="Basic income per common share">0.58</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zp7d2uqfUzjc" title="Basic income per common share">0.55</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zgbXQMSjCuVk" title="Basic income per common share">0.16</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20221001__20221231_zeIHjnC2kICf" title="Basic income per common share">0.34</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmSH7f1f7109" title="Basic income per common share">0.32</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z7F2Pqhgpvy1" title="Basic income per common share">0.09</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator: <br/> Weighted average shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2pyXMXkRWo3" title="Diluted Denominator: Weighted average shares outstanding">6,437</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zpTuzrYJwkK3" title="Diluted Denominator: Weighted average shares outstanding">383</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8lgAsR8fRzh" title="Diluted Denominator: Weighted average shares outstanding">6,527</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zqh4XEwVBlVc" title="Diluted Denominator: Weighted average shares outstanding">383</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible Class C Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_ecustom--ConvertibleClassCStock_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoXRWoEMXNbb" title="Convertible Class C Stock">128</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_ecustom--ConvertibleClassCStock_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_ztk1kuEXjKh6" title="Convertible Class C Stock"><span style="-sec-ix-hidden: xdx2ixbrl1091">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_ecustom--ConvertibleClassCStock_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrZgsPwWJQWk" title="Convertible Class C Stock">128</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--ConvertibleClassCStock_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zgXkhSfSxKAk" title="Convertible Class C Stock"><span style="-sec-ix-hidden: xdx2ixbrl1095">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Denominator for diluted earnings per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBPNn6fnSBtc" title="Total Denominator for Diluted Earnings Per Share">6,565</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zrXAnwqNZxD8" title="Total Denominator for Diluted Earnings Per Share">383</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKGI6QcltMc1" title="Total Denominator for Diluted Earnings Per Share">6,655</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z0JBAcMMr25g" title="Total Denominator for Diluted Earnings Per Share">383</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Diluted income per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pip0_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxl63AX6VXg7" title="Diluted Income per Common Share">0.54</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pip0_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zBFs3GvldEoh" title="Diluted Income per Common Share">0.16</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareDiluted_pip0_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2AJgM43Xhcl" title="Diluted Income per Common Share">0.32</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pip0_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zQade4RR3t9e" title="Diluted Income per Common Share">0.09</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">Six months ended <br/> December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">Six months ended <br/> December 31, 2022</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Class C Common <br/> Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Class C Common <br/> Stock</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">Numerator: <br/> Net income available to common stockholders</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20230701__20231231_z4UTQH7hUxL4" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">7,865</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsqY9NXVLV2c" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">7,375</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z3RMb85H0qkl" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">125</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20220701__20221231_zrCyjoAYN5q8" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">4,279</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLw3LCxpKoPj" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Common Stock and Basic Numerator: Net income available to common stockholders">4,020</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zvIHrcyBvIPk" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders">66</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Weighted average shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20231231_zmZ93078iO8d" title="Basic Denominator: Weighted average shares outstanding">6,448</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z21yzFIuoLf6" title="Basic Denominator: Weighted average shares outstanding">6,448</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zQA2gc0u4Amk" title="Basic Denominator: Weighted average shares outstanding">383</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220701__20221231_ztm6KSYAChm6" title="Basic Denominator: Weighted average shares outstanding">6,534</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkFlslAJn2qk" title="Basic Denominator: Weighted average shares outstanding">6,534</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zL7NtDF1AoTf" title="Basic Denominator: Weighted average shares outstanding">383</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Basic income per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20230701__20231231_zmW1oBcSsg83" title="Basic income per common share">1.22</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4dCSpS3695b" title="Basic income per common share">1.14</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z7vSLvBYsxqe" title="Basic income per common share">0.33</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20220701__20221231_zJoGxGVg5CHa" title="Basic income per common share">0.65</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIo4QQjg035a" title="Basic income per common share">0.62</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zpvgvPcov6bg" title="Basic income per common share">0.17</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator: <br/> Weighted average shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9evyBlljdUa" title="Diluted Denominator: Weighted average shares outstanding">6,448</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zDfugAnIRGu7" title="Diluted Denominator: Weighted average shares outstanding">383</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2yNF3S72Dh3" title="Diluted Denominator: Weighted average shares outstanding">6,534</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zdvFkKhi6fDf" title="Diluted Denominator: Weighted average shares outstanding">383</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible Class C Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_ecustom--ConvertibleClassCStock_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVjyzxkTFd1" title="Convertible Class C Stock">128</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_ecustom--ConvertibleClassCStock_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zq4Sfu9LeOv5" title="Convertible Class C Stock"><span style="-sec-ix-hidden: xdx2ixbrl1159">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_ecustom--ConvertibleClassCStock_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zz6S4pR8sNT2" title="Convertible Class C Stock">128</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_ecustom--ConvertibleClassCStock_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zsmEWygCsbKi" title="Convertible Class C Stock"><span style="-sec-ix-hidden: xdx2ixbrl1163">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Denominator for diluted earnings per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8meuCzW846g" title="Total Denominator for Diluted Earnings Per Share">6,576</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zC7x0fJBLE45" title="Total Denominator for Diluted Earnings Per Share">383</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znQ1wEDYsoi7" title="Total Denominator for Diluted Earnings Per Share">6,662</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zJ8UZGlHPd3k" title="Total Denominator for Diluted Earnings Per Share">383</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Diluted income per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_pip0_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEoN3hUy1ybk" title="Diluted Income per Common Share">1.12</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_pip0_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zUXFtANM8l4g" title="Diluted Income per Common Share">0.33</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_pip0_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHNRYTugpdhi" title="Diluted Income per Common Share">0.60</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_pip0_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zZd01Sfe84th" title="Diluted Income per Common Share">0.17</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583902176608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock', window );">Schedule of financing receivable noncurrent allowance for credit loss</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock_pn3n3_zrsuW80RcOK6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details)">
<tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B4_z3JRElElnWUa" style="display: none; text-align: left; padding-top: 0; padding-right: 0">Schedule of financing
    receivable noncurrent allowance for credit loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Gross Receivable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Allowance for doubtful accounts</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Net</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Accounts receivable</td><td style="width: 5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--AccountsReceivableServiceAndRepairFees_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Accounts receivable">4,080</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--AccountsReceivableServiceAndRepairFees_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Accounts receivable">199</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--AccountsReceivableServiceAndRepairFees_c20231231_pn3n3" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Accounts receivable">3,881</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts receivable - related party</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--AccountsReceivableNetRelatedParty_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts receivable - Related party">60</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_ecustom--AccountsReceivableNetRelatedParty_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts receivable - Related party"><span style="-sec-ix-hidden: xdx2ixbrl1213">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--AccountsReceivableNetRelatedParty_c20231231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts receivable - Related party">60</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Medical receivable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--MedicalReceivable_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Medical Receivables">22,548</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--MedicalReceivable_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Medical Receivables"><span style="-sec-ix-hidden: xdx2ixbrl1219">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--MedicalReceivable_c20231231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Medical Receivables">22,548</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Management and other fees receivable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ManagementAndOtherFeesNonRelatedParties_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable">51,092</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ManagementAndOtherFeesNonRelatedParties_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable">11,740</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ManagementAndOtherFeesNonRelatedParties_c20231231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable">39,352</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Management and other fees receivable from related medical practices (&#8220;PC&#8217;s&#8221;)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable from related medical practices (&quot;PC's&quot;)">14,480</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable from related medical practices (&quot;PC's&quot;)">5,213</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20231231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable from related medical practices (&quot;PC's&quot;)">9,267</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2023</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Gross Receivable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Allowance for doubtful accounts</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Net</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Accounts receivable</td><td style="width: 5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--AccountsReceivableServiceAndRepairFees_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Accounts receivable">4,060</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--AccountsReceivableServiceAndRepairFees_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Accounts receivable">199</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--AccountsReceivableServiceAndRepairFees_c20230630_pn3n3" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Accounts receivable">3,861</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Medical receivable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--MedicalReceivable_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Medical Receivables">21,259</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--MedicalReceivable_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Medical Receivables"><span style="-sec-ix-hidden: xdx2ixbrl1243">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--MedicalReceivable_c20230630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Medical Receivables">21,259</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Management and other fees receivable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--ManagementAndOtherFeesNonRelatedParties_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable">48,497</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ManagementAndOtherFeesNonRelatedParties_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable">12,609</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ManagementAndOtherFeesNonRelatedParties_c20230630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable">35,888</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Management and other fees receivable from related medical practices (&#8220;PC&#8217;s&#8221;)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable from related medical practices (&quot;PC's&quot;)">13,152</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable from related medical practices (&quot;PC's&quot;)">3,990</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20230630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable from related medical practices (&quot;PC's&quot;)">9,162</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_TotalFacilitiesOwnedOrManagedTableTextBlock', window );">Schedule of Future revenue</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--TotalFacilitiesOwnedOrManagedTableTextBlock_pn3n3_zOPb9OOHAwE4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details 1)">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td id="xdx_8B5_z8RI1U23wU33" style="display: none; text-align: right">Schedule of Future revenue</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 43%; text-align: right">2025</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ContractReceivableDueOneToTwoYears_iI_pn3n3_c20231231_zI9Rs5aCmDnb" style="width: 43%; text-align: right" title="2025">319</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2026</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ContractReceivableDueTwoToThreeYears_iI_pn3n3_c20231231_zOVVUU2LH5sk" style="border-bottom: Black 1pt solid; text-align: right" title="2026">57</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AccountsReceivableBilledForLongTermContractsOrPrograms_pn3n3_c20231231_ztlcCINnoJ1l" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">376</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_ScheduleOfPatientFeeRevenueTableTextBlock', window );">Schedule of patient fee revenue</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfPatientFeeRevenueTableTextBlock_zlRut4kBWtai" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details)">
<tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B7_z5TLT0GbxGA4" style="display: none">Schedule of patient fee revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center">For the Three Months Ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Commercial Insurance/ Managed Care</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_znhjakEssmI9" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">1,243</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_zo3vvZD7nGP9" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">958</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Medicare/Medicaid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zJuB4xVfqhE5" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">284</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zXyVF66WunI1" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">247</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Workers&#8217; Compensation/Personal Injury</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_z5wxjXHQ4B2h" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">4,907</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_z4JLoGVYKosf" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">4,262</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherMember_zlC5xC7Qe0B8" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">1,787</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherMember_zKmmXI7dL4E1" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">1,662</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Patient Fee Revenue, net of contractual allowances and discounts</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231_zLIChWdBejDd" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">8,221</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231_zQUZ9qSPnm41" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">7,129</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center">For the Six Months Ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Commercial Insurance/ Managed Care</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_zCMYrCl87ynh" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">2,416</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_zowmtzn9Vbe3" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">1,869</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Medicare/Medicaid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zbVJ4nfhTCx6" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">555</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zjiT9qoryZp9" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">484</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Workers&#8217; Compensation/Personal Injury</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_znpyENPcKD3d" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">10,044</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_zHANQcrYMv6b" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">8,497</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherMember_zwyKUlvde0yi" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">3,881</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherMember_zog5V7oL01Ni" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">2,355</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Patient Fee Revenue, net of contractual allowances and discounts</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231_zNxkXEDlORt9" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">16,896</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231_z6goTqEukcRe" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts">13,205</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_ScheduleOfPatientFeeRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_ScheduleOfPatientFeeRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_TotalFacilitiesOwnedOrManagedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_TotalFacilitiesOwnedOrManagedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss of financing receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583901255408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING &amp; FINANCING LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_DisclosureOperatingFinancingLeasesAbstract', window );"><strong>Operating Financing Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee operating leases liability maturity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_z0fRutkiWkId" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OPERATING &amp; FINANCING LEASES - Lease Payments (Details)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_8B3_zIHJDJmb4wWh" style="display: none; text-align: right">Lessee operating leases liability maturity</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Twelve Months Ending<br/>
December 31,</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Operating Lease<br/>
Payments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Financing Lease<br/>
Payments</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 26%; text-align: right">2024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="width: 26%; text-align: right" title="Lessee, Operating Lease, Liability, to be Paid, Year One">6,319</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="width: 26%; text-align: right" title="Finance Lease, Liability, to be Paid, Year One">244</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="text-align: right" title="Lessee, Operating Lease, Liability, to be Paid, Year Two">5,672</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="text-align: right" title="Finance Lease, Liability, to be Paid, Year Two">244</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2026</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="text-align: right" title="Lessee, Operating Lease, Liability, to be Paid, Year Three">4,902</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="text-align: right" title="Finance Lease, Liability, to be Paid, Year Three">244</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2027</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="text-align: right" title="Lessee, Operating Lease, Liability, to be Paid, Year Four">3,677</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="text-align: right" title="Finance Lease, Liability, to be Paid, Year Four">41</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2028</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="text-align: right" title="Lessee, Operating Lease, Liability, to be Paid, Year Five">3,426</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="text-align: right" title="Finance Lease, Liability, to be Paid, Year Five"><span style="-sec-ix-hidden: xdx2ixbrl1382">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">Thereafter</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="text-align: right" title="Lessee, Operating Lease, Liability, to be Paid, after Year Five">20,698</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="text-align: right" title="Finance Lease, Liability, to be Paid, after Year Five"><span style="-sec-ix-hidden: xdx2ixbrl1386">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">Present value discount</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--PresentValueDiscount_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Present value discount">(9,737</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--PresentValueDiscountFinancingLease_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Present value discount">(43</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">Total lease liability</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingLeaseLiability_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating Lease, Liability">34,957</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FinanceLeaseLiability_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Finance Lease, Liability">730</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_DisclosureOperatingFinancingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_DisclosureOperatingFinancingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583901251680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventories</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_zGboBOL1Wf87" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVENTORIES - Inventories (Details)">
<tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BF_zkII9TzyV9t7" style="display: none; padding-top: 0; padding-right: 0">Schedule of inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20231231_zWo932XnF1T4" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20230630_z4tq9kpA2VE5" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">December 31,<br/>
2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">June 30,<br/>
2023</td></tr>
<tr id="xdx_40E_eus-gaap--OtherInventorySupplies_iI_maIFGAWzdt0_zhrbC4b89MZc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Purchased parts, components and supplies</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,582</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,346</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--InventoryWorkInProcess_iI_maIFGAWzdt0_zjJwXejdTLQ4" style="vertical-align: bottom; background-color: White">
    <td>Work-in-process</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">253</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">224</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--InventoryFinishedGoodsAndWorkInProcess_iTI_mtIFGAWzdt0_zVRC2sPk6n9l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Inventories</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,835</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,570</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583901193312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of other intangible assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_pn3n3_zHnA5sGQb175" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OTHER INTANGIBLE ASSETS - Other intangible assets net of amortization (Details)">
<tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BF_zyqX1uLwEcw1" style="display: none; text-align: left">Schedule of other intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">December 31,<br/>
2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">June 30, <br/>
2023</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Capitalized software development costs</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_z3x14ASoMG3f" style="width: 12%; text-align: right" title="Gross other intangible assets">7,005</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_pn3n3" style="width: 12%; text-align: right" title="Gross other intangible assets">7,005</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Patents and copyrights</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zvNIq4ynXZx6" style="text-align: right" title="Gross other intangible assets">5,472</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_pn3n3" style="text-align: right" title="Gross other intangible assets">5,452</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Non-compete</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zY8Va9wjG4A8" style="text-align: right" title="Gross other intangible assets">4,150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_pn3n3" style="text-align: right" title="Gross other intangible assets">4,150</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Customer relationships</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zyt57x5TTL6f" style="border-bottom: Black 1pt solid; text-align: right" title="Gross other intangible assets">3,900</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Gross other intangible assets">3,900</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross Other intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231_znsHM6vhm7va" style="text-align: right" title="Gross other intangible assets">20,527</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20230630_zNyHjhgPhRH5" style="text-align: right" title="Gross other intangible assets">20,507</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: Accumulated amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_pn3n3_c20231231_zd56JZnmfOsl" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization">17,261</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20230630_z7jK2eMULv81" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization">17,075</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other Intangible Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_pn3n3_c20231231_z7rZD3VQcbX9" style="border-bottom: Black 2.5pt double; text-align: right" title="Other intangible assets-net">3,266</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20230630_z7nmcTachwOf" style="border-bottom: Black 2.5pt double; text-align: right" title="Other intangible assets-net">3,432</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583902034272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of other current liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_pn3n3_zeP1UrQ0Dm77" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OTHER CURRENT LIABILITIES - Other Current Liabilities - (Details)">
<tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B9_zHCcyPHyOwF5" style="display: none; text-align: left">Schedule of other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20231231_zHR1XX7zypxe" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20230630_z9cYelbSkp3g" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">December 31,<br/>
2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">June 30,<br/>
2023</td></tr>
<tr id="xdx_400_eus-gaap--AccruedSalariesCurrent_iI_pn3n3_maOLCzdop_z5WqcgkMCPFc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Accrued salaries, commissions and payroll taxes</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,078</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,413</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_pn3n3_maOLCzdop_zISZUiZsxMgl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Sales tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">193</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--StateIncomeTaxesPayable_iI_pn3n3_maOLCzdop_zh61EtQveQXj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"> Income taxes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">196</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maOLCzdop_zQIGdXEGnn4b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Legal and other professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_pn3n3_maOLCzdop_zmqgUBuULDbi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounting fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--SelfInsuranceReserve_iI_pn3n3_maOLCzdop_zwlv9e72VSwl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Self-funded health insurance reserve</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesNoncurrent_iI_pn3n3_maOLCzdop_zbqhVQUeLE27" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued interest and penalty</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OtherSundryLiabilitiesCurrent_iI_pn3n3_maOLCzdop_zXfcTexvjhL3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other general and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">809</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">574</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OtherLiabilitiesCurrent_iTI_pn3n3_mtOLCzdop_zlJPzs1Vexha" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other Current Liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,460</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,444</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583902080144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT AND RELATED INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of summarized segment financial information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zsW5z5VdLnKj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT AND RELATED INFORMATION - Summarized Segments - (Details)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BB_zZValMBlhpu2" style="display: none">Schedule
    of summarized segment financial information</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Medical <br/> Equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Management <br/> of Diagnostic <br/> Imaging <br/> Centers</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Totals</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; padding-top: 0; padding-right: 0">For the three months ended Dec. 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Net revenues from external customers</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zYBxfzg2kR0g" style="width: 11%; text-align: right" title="Net revenues from external customers">1,861</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--Revenues_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zSYkIm1RS3h8" style="width: 11%; text-align: right" title="Net revenues from external customers">23,525</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_pn3n3_c20231001__20231231_zlUglcd1BO8b" style="width: 11%; text-align: right" title="Net revenues from external customers">25,386</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Inter-segment net revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_ecustom--IntersegmentNetRevenues_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zk8Xi2CrDcq7" style="text-align: right" title="Inter-segment net revenues">254</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_ecustom--IntersegmentNetRevenues_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zKIEVE9fbm87" style="text-align: right" title="Inter-segment net revenues"><span style="-sec-ix-hidden: xdx2ixbrl1520">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_ecustom--IntersegmentNetRevenues_pn3n3_c20231001__20231231_zddsruZKQpEh" style="text-align: right" title="Inter-segment net revenues">254</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">(Loss) Income from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zr4APB0CFLod" style="text-align: right" title="(Loss) Income from operations">(993</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z9gsBrxFZm04" style="text-align: right" title="(Loss) Income from operations">5,878</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20231001__20231231_zfjpYB9v3j6j" style="text-align: right" title="(Loss) Income from operations">4,885</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zEre8Aww9Vie" style="text-align: right" title="Depreciation and amortization">60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zxaE3s6mMBdj" style="text-align: right" title="Depreciation and amortization">1,160</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20231001__20231231_zYSMpu46ZV3f" style="text-align: right" title="Depreciation and amortization">1,220</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Capital expenditures</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zupZNmxdrKm8" style="text-align: right" title="Capital expenditures">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zyLNYP99ULt5" style="text-align: right" title="Capital expenditures">129</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20231001__20231231_zQmfrNSPnb29" style="text-align: right" title="Capital expenditures">133</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">For the three months ended Dec. 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net revenues from external customers</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--Revenues_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zFxznI4734b1" style="text-align: right" title="Net revenues from external customers">2,035</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zGekRqiHTlgd" style="text-align: right" title="Net revenues from external customers">22,221</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--Revenues_pn3n3_c20221001__20221231_zw6mZEGuNPqf" style="text-align: right" title="Net revenues from external customers">24,256</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Inter-segment net revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_ecustom--IntersegmentNetRevenues_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zvdYFhwzc9jk" style="text-align: right" title="Inter-segment net revenues">245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--IntersegmentNetRevenues_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z09BirmDHQ28" style="text-align: right" title="Inter-segment net revenues"><span style="-sec-ix-hidden: xdx2ixbrl1550">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--IntersegmentNetRevenues_pn3n3_c20221001__20221231_zGwXA4Fbz9da" style="text-align: right" title="Inter-segment net revenues">245</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">(Loss) Income from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_z51YjY3T50Ie" style="text-align: right" title="(Loss) Income from operations">(551</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zmV8AdnXmUV8" style="text-align: right" title="(Loss) Income from operations">4,783</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20221001__20221231_zqQwVfraq8jf" style="text-align: right" title="(Loss) Income from operations">4,232</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_z2XDFJA5yQBg" style="text-align: right" title="Depreciation and amortization">65</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zRsocsNsD02k" style="text-align: right" title="Depreciation and amortization">1,035</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20221001__20221231_zxyeiNq7Y1q7" style="text-align: right" title="Depreciation and amortization">1,100</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Capital expenditures</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zFjPVnk45Ap2" style="text-align: right" title="Capital expenditures">50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zzq5tmVzjiHl" style="text-align: right" title="Capital expenditures">423</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20221001__20221231_zMqTazUcDbfd" style="text-align: right" title="Capital expenditures">473</td><td style="text-align: left">&#160;</td></tr>
</table>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Medical <br/> Equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Management <br/> of Diagnostic <br/> Imaging <br/> Centers</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Totals</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left">For the six months ended Dec. 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Net revenues from external customers</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--Revenues_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zv1hxeQVrfgb" style="width: 11%; text-align: right" title="Net revenues from external customers">3,917</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--Revenues_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zhGblQ8e47t9" style="width: 11%; text-align: right" title="Net revenues from external customers">47,307</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--Revenues_pn3n3_c20230701__20231231_zsrktXjJ68fi" style="width: 11%; text-align: right" title="Net revenues from external customers">51,224</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Inter-segment net revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--IntersegmentNetRevenues_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zTIZOHH4F1cf" style="text-align: right" title="Inter-segment net revenues">508</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_ecustom--IntersegmentNetRevenues_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z9bWZK6jBe96" style="text-align: right" title="Inter-segment net revenues"><span style="-sec-ix-hidden: xdx2ixbrl1580">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--IntersegmentNetRevenues_pn3n3_c20230701__20231231_z4VKmEP61u15" style="text-align: right" title="Inter-segment net revenues">508</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">(Loss) Income from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_z6h1rbd7XwMe" style="text-align: right" title="(Loss) Income from operations">(1,731</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zyePHhZzZMie" style="text-align: right" title="(Loss) Income from operations">13,187</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20230701__20231231_z0McvqgoVuL9" style="text-align: right" title="(Loss) Income from operations">11,456</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zxmEVa14eGrj" style="text-align: right" title="Depreciation and amortization">121</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zxMsCziXPFJ8" style="text-align: right" title="Depreciation and amortization">2,294</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20230701__20231231_z54OR3vVuP95" style="text-align: right" title="Depreciation and amortization">2,415</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Capital expenditures</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zPQA3hOM7Iib" style="text-align: right" title="Capital expenditures">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zdpsXMOLYsPg" style="text-align: right" title="Capital expenditures">192</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20230701__20231231_zvy3SiQL5w2g" style="text-align: right" title="Capital expenditures">212</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">For the six months ended Dec. 31, 2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net revenues from external customers</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--Revenues_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zdd5jVxctIxf" style="text-align: right" title="Net revenues from external customers">3,913</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zBhKNZ7a00N4" style="text-align: right" title="Net revenues from external customers">43,534</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--Revenues_pn3n3_c20220701__20221231_zwhY0pR5Akvf" style="text-align: right" title="Net revenues from external customers">47,447</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Inter-segment net revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_ecustom--IntersegmentNetRevenues_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zoffHxamlESl" style="text-align: right" title="Inter-segment net revenues">490</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--IntersegmentNetRevenues_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z6z2QJQnYWkk" style="text-align: right" title="Inter-segment net revenues"><span style="-sec-ix-hidden: xdx2ixbrl1610">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_ecustom--IntersegmentNetRevenues_pn3n3_c20220701__20221231_zESpkKwQXykg" style="text-align: right" title="Inter-segment net revenues">490</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">(Loss) Income from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zPF7z4Z6W2Lh" style="text-align: right" title="(Loss) Income from operations">(1,353</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zPpoBpVgKqok" style="text-align: right" title="(Loss) Income from operations">9,496</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20220701__20221231_zPYFCNc56th3" style="text-align: right" title="(Loss) Income from operations">8,143</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zPIFykb6hMId" style="text-align: right" title="Depreciation and amortization">137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z8cmlHzT5sL8" style="text-align: right" title="Depreciation and amortization">2,081</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20220701__20221231_zMfkSiLXdYP6" style="text-align: right" title="Depreciation and amortization">2,218</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Capital expenditures</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zpEqtkQ7HQ93" style="text-align: right" title="Capital expenditures">74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zGdkIlgc0f17" style="text-align: right" title="Capital expenditures">1,362</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20220701__20221231_z2Enb1MPBt7l" style="text-align: right" title="Capital expenditures">1,436</td><td style="text-align: left">&#160;</td></tr>
</table>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583898067296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jul. 01, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Noncontrolling Interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_OwnershipInterestOfOriginalInvestorsOfHdm', window );">The ownership interest of the original investors of HDM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_InvestorsOwnershipInterest', window );">Investors ownership interest percentage</a></td>
<td class="nump">29.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=FONR_ControllingInterestMember', window );">Controlling Interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_HmcaOwnershipSizeOfImperialManagementServicesPercent', window );">The ownership interest of Imperial Management Services after reorganization of newly expanded HDM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_OwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent', window );">The ownership interest of Health Management Corporation of America after reorganization of newly expanded HDM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_DirectPurchaseOfNoncontrollingInterests', window );">Direct purchase of Noncontrolling Interests</a></td>
<td class="nump">$ 546,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Direct ownership interest percentage</a></td>
<td class="nump">70.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_DirectPurchaseOfNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents the amount of direct purchase of noncontrolling interests during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_DirectPurchaseOfNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_HmcaOwnershipSizeOfImperialManagementServicesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents the rate of hmca ownership size of imperial management services percent during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_HmcaOwnershipSizeOfImperialManagementServicesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_InvestorsOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents the rate of investors ownership interest during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_InvestorsOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_OwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents the rate of ownership interest after reorganization for health management corporation of America of newly expanded hdm percent during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_OwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_OwnershipInterestOfOriginalInvestorsOfHdm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents the rate of ownership interest of original investors of hdm during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_OwnershipInterestOfOriginalInvestorsOfHdm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=FONR_ControllingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=FONR_ControllingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583894540032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share - (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_NetIncomeLossAvailableToCommonStockholderBasic', window );">Basic Numerator: Net income available to common stockholders</a></td>
<td class="nump">$ 3,759<span></span>
</td>
<td class="nump">$ 2,232<span></span>
</td>
<td class="nump">$ 7,865<span></span>
</td>
<td class="nump">$ 4,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic Denominator: Weighted average shares outstanding</a></td>
<td class="nump">6,437<span></span>
</td>
<td class="nump">6,527<span></span>
</td>
<td class="nump">6,448<span></span>
</td>
<td class="nump">6,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic income per common share</a></td>
<td class="nump">$ 0.58<span></span>
</td>
<td class="nump">$ 0.34<span></span>
</td>
<td class="nump">$ 1.22<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Common Class C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_NetIncomeLossAvailableToCommonStockholderBasic', window );">Basic Numerator: Net income available to common stockholders</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic Denominator: Weighted average shares outstanding</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic income per common share</a></td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted Denominator: Weighted average shares outstanding</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_ConvertibleClassCStock', window );">Convertible Class C Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_WeightedAverageNumberOfDilutedEarningsPerShare', window );">Total Denominator for Diluted Earnings Per Share</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted Income per Common Share</a></td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_NetIncomeLossAvailableToCommonStockholderBasic', window );">Basic Numerator: Net income available to common stockholders</a></td>
<td class="nump">$ 3,525<span></span>
</td>
<td class="nump">$ 2,097<span></span>
</td>
<td class="nump">$ 7,375<span></span>
</td>
<td class="nump">$ 4,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic Denominator: Weighted average shares outstanding</a></td>
<td class="nump">6,437<span></span>
</td>
<td class="nump">6,527<span></span>
</td>
<td class="nump">6,448<span></span>
</td>
<td class="nump">6,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic income per common share</a></td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="nump">$ 1.14<span></span>
</td>
<td class="nump">$ 0.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted Denominator: Weighted average shares outstanding</a></td>
<td class="nump">6,437<span></span>
</td>
<td class="nump">6,527<span></span>
</td>
<td class="nump">6,448<span></span>
</td>
<td class="nump">6,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_ConvertibleClassCStock', window );">Convertible Class C Stock</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_WeightedAverageNumberOfDilutedEarningsPerShare', window );">Total Denominator for Diluted Earnings Per Share</a></td>
<td class="nump">6,565<span></span>
</td>
<td class="nump">6,655<span></span>
</td>
<td class="nump">6,576<span></span>
</td>
<td class="nump">6,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted Income per Common Share</a></td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 0.60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_ConvertibleClassCStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents the shares of convertible class c stock during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_ConvertibleClassCStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_NetIncomeLossAvailableToCommonStockholderBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents the amount of net income loss available to common stockholder basic during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_NetIncomeLossAvailableToCommonStockholderBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_WeightedAverageNumberOfDilutedEarningsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average number of diluted earnings per share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_WeightedAverageNumberOfDilutedEarningsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583903020608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock', window );">Shares included upon conversion of Class C Common</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583895537408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_AccountsReceivableServiceAndRepairFees', window );">Accounts receivable</a></td>
<td class="nump">$ 3,881<span></span>
</td>
<td class="nump">$ 3,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_AccountsReceivableNetRelatedParty', window );">Accounts receivable - Related party</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_MedicalReceivable', window );">Medical Receivables</a></td>
<td class="nump">22,548<span></span>
</td>
<td class="nump">21,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_ManagementAndOtherFeesNonRelatedParties', window );">Management and other fees receivable</a></td>
<td class="nump">39,352<span></span>
</td>
<td class="nump">35,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances', window );">Management and other fees receivable from related medical practices ("PC's")</a></td>
<td class="nump">9,267<span></span>
</td>
<td class="nump">9,162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_AccountsReceivableServiceAndRepairFees', window );">Accounts receivable</a></td>
<td class="nump">4,080<span></span>
</td>
<td class="nump">4,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_AccountsReceivableNetRelatedParty', window );">Accounts receivable - Related party</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_MedicalReceivable', window );">Medical Receivables</a></td>
<td class="nump">22,548<span></span>
</td>
<td class="nump">21,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_ManagementAndOtherFeesNonRelatedParties', window );">Management and other fees receivable</a></td>
<td class="nump">51,092<span></span>
</td>
<td class="nump">48,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances', window );">Management and other fees receivable from related medical practices ("PC's")</a></td>
<td class="nump">14,480<span></span>
</td>
<td class="nump">13,152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_DoubtfulMember', window );">Doubtful [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_AccountsReceivableServiceAndRepairFees', window );">Accounts receivable</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_AccountsReceivableNetRelatedParty', window );">Accounts receivable - Related party</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_MedicalReceivable', window );">Medical Receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_ManagementAndOtherFeesNonRelatedParties', window );">Management and other fees receivable</a></td>
<td class="nump">11,740<span></span>
</td>
<td class="nump">12,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances', window );">Management and other fees receivable from related medical practices ("PC's")</a></td>
<td class="nump">$ 5,213<span></span>
</td>
<td class="nump">$ 3,990<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_AccountsReceivableNetRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable from service and repair fees of Related Party MRI scanner customers; net of allowances for doubtful accounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_AccountsReceivableNetRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_AccountsReceivableServiceAndRepairFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_AccountsReceivableServiceAndRepairFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_ManagementAndOtherFeesNonRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_ManagementAndOtherFeesNonRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_MedicalReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_MedicalReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_DoubtfulMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_DoubtfulMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583902277984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details 1)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractReceivableDueOneToTwoYears', window );">2025</a></td>
<td class="nump">$ 319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractReceivableDueTwoToThreeYears', window );">2026</a></td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms', window );">Total</a></td>
<td class="nump">$ 376<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount billed to customers under long-term contracts or programs but not paid. Excludes amounts due that have been withheld because of retainage provisions in a contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 910<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482546/910-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractReceivableDueOneToTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of right to consideration in exchange for good or service transferred to customer under long-term contract or program when right to consideration is unconditional, excluding amount withheld under retainage provision in contract, to be collected in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 910<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482546/910-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractReceivableDueOneToTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractReceivableDueTwoToThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of right to consideration in exchange for good or service transferred to customer under long-term contract or program when right to consideration is unconditional, excluding amount withheld under retainage provision in contract, to be collected in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 910<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482546/910-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractReceivableDueTwoToThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583899312848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscount', window );">Patient Fee Revenue, net of contractual allowances and discounts</a></td>
<td class="nump">$ 8,221<span></span>
</td>
<td class="nump">$ 7,129<span></span>
</td>
<td class="nump">$ 16,896<span></span>
</td>
<td class="nump">$ 13,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=FONR_CommercialInsuranceManagedCareMember', window );">Commercial Insurance Managed Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscount', window );">Patient Fee Revenue, net of contractual allowances and discounts</a></td>
<td class="nump">1,243<span></span>
</td>
<td class="nump">958<span></span>
</td>
<td class="nump">2,416<span></span>
</td>
<td class="nump">1,869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=FONR_MedicareMedicaidMember', window );">Medicare Medicaid [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscount', window );">Patient Fee Revenue, net of contractual allowances and discounts</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">555<span></span>
</td>
<td class="nump">484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=FONR_WorkersCompensationPersonalInjuryMember', window );">Workers Compensation Personal Injury [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscount', window );">Patient Fee Revenue, net of contractual allowances and discounts</a></td>
<td class="nump">4,907<span></span>
</td>
<td class="nump">4,262<span></span>
</td>
<td class="nump">10,044<span></span>
</td>
<td class="nump">8,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=FONR_OtherMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscount', window );">Patient Fee Revenue, net of contractual allowances and discounts</a></td>
<td class="nump">$ 1,787<span></span>
</td>
<td class="nump">$ 1,662<span></span>
</td>
<td class="nump">$ 3,881<span></span>
</td>
<td class="nump">$ 2,355<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents the amount of patient fee revenue net of contractual allowances and discounts during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=FONR_CommercialInsuranceManagedCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=FONR_CommercialInsuranceManagedCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=FONR_MedicareMedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=FONR_MedicareMedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=FONR_WorkersCompensationPersonalInjuryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=FONR_WorkersCompensationPersonalInjuryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=FONR_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=FONR_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583899728400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_AccountsReceivableNetLongTerm', window );">Long term accounts receivable</a></td>
<td class="nump">$ 376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims', window );">Percentage of net revenue</a></td>
<td class="nump">66.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_PercentageOfConsolidatedNetRevenueFromManagementFees', window );">Percentage of consolidated net revenue</a></td>
<td class="nump">11.80%<span></span>
</td>
<td class="nump">12.40%<span></span>
</td>
<td class="nump">11.70%<span></span>
</td>
<td class="nump">12.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_AccountsReceivableNetLongTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_AccountsReceivableNetLongTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_PercentageOfConsolidatedNetRevenueFromManagementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of consolidated net revenue from management fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_PercentageOfConsolidatedNetRevenueFromManagementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of PCs net revenue derived from nofault and personal injury protection claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583991447504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OPERATING &amp; FINANCING LEASES - Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=FONR_OperatingLeasePaymentsMember', window );">Operating Lease Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Lessee, Operating Lease, Liability, to be Paid, Year One</a></td>
<td class="nump">$ 6,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Lessee, Operating Lease, Liability, to be Paid, Year Two</a></td>
<td class="nump">5,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Lessee, Operating Lease, Liability, to be Paid, Year Three</a></td>
<td class="nump">4,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Lessee, Operating Lease, Liability, to be Paid, Year Four</a></td>
<td class="nump">3,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">Lessee, Operating Lease, Liability, to be Paid, Year Five</a></td>
<td class="nump">3,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Lessee, Operating Lease, Liability, to be Paid, after Year Five</a></td>
<td class="nump">20,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_PresentValueDiscount', window );">Present value discount</a></td>
<td class="num">(9,737)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">34,957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=FONR_FinancingLeasePaymentsMember', window );">Financing Lease Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Finance Lease, Liability, to be Paid, Year One</a></td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">Finance Lease, Liability, to be Paid, Year Two</a></td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">Finance Lease, Liability, to be Paid, Year Three</a></td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">Finance Lease, Liability, to be Paid, Year Four</a></td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">Finance Lease, Liability, to be Paid, Year Five</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Finance Lease, Liability, to be Paid, after Year Five</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_PresentValueDiscountFinancingLease', window );">Present value discount</a></td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance Lease, Liability</a></td>
<td class="nump">$ 730<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_PresentValueDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents the amount of present value discount during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_PresentValueDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_PresentValueDiscountFinancingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents the amount of present value discount financing lease during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_PresentValueDiscountFinancingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=FONR_OperatingLeasePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=FONR_OperatingLeasePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=FONR_FinancingLeasePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=FONR_FinancingLeasePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583898080640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES - Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInventorySupplies', window );">Purchased parts, components and supplies</a></td>
<td class="nump">$ 2,582<span></span>
</td>
<td class="nump">$ 2,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsAndWorkInProcess', window );">Total Inventories</a></td>
<td class="nump">$ 2,835<span></span>
</td>
<td class="nump">$ 2,570<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsAndWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation reserves of merchandise or goods held by the entity that are readily available for sale and items held by the entity which are partially complete or in the process of being readied for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsAndWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventorySupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventorySupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583899466912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER INTANGIBLE ASSETS - Other intangible assets net of amortization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross other intangible assets</a></td>
<td class="nump">$ 20,527<span></span>
</td>
<td class="nump">$ 20,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="nump">17,261<span></span>
</td>
<td class="nump">17,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangible assets-net</a></td>
<td class="nump">3,266<span></span>
</td>
<td class="nump">3,432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software and Software Development Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross other intangible assets</a></td>
<td class="nump">7,005<span></span>
</td>
<td class="nump">7,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=FONR_PatentsAndCopyrightsMember', window );">Patents and copyrights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross other intangible assets</a></td>
<td class="nump">5,472<span></span>
</td>
<td class="nump">5,452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross other intangible assets</a></td>
<td class="nump">4,150<span></span>
</td>
<td class="nump">4,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross other intangible assets</a></td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=FONR_PatentsAndCopyrightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=FONR_PatentsAndCopyrightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583898067056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER INTANGIBLE ASSETS (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=FONR_PatentsAndCopyrightsMember', window );">Patents and copyrights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=FONR_PatentsAndCopyrightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=FONR_PatentsAndCopyrightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583891466288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES - Other Current Liabilities - (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued salaries, commissions and payroll taxes</a></td>
<td class="nump">$ 2,078<span></span>
</td>
<td class="nump">$ 4,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Sales tax payable</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_StateIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Legal and other professional fees</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent', window );">Accounting fees</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Self-funded health insurance reserve</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Accrued interest and penalty</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other general and administrative expenses</a></td>
<td class="nump">809<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other Current Liabilities</a></td>
<td class="nump">$ 3,460<span></span>
</td>
<td class="nump">$ 5,444<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_StateIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>the value of state income taxes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_StateIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481573/470-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelfInsuranceReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelfInsuranceReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583891602528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT AND RELATED INFORMATION - Summarized Segments - (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenues from external customers</a></td>
<td class="nump">$ 25,386<span></span>
</td>
<td class="nump">$ 24,256<span></span>
</td>
<td class="nump">$ 51,224<span></span>
</td>
<td class="nump">$ 47,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_IntersegmentNetRevenues', window );">Inter-segment net revenues</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="nump">508<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">(Loss) Income from operations</a></td>
<td class="nump">4,885<span></span>
</td>
<td class="nump">4,232<span></span>
</td>
<td class="nump">11,456<span></span>
</td>
<td class="nump">8,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,220<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">2,415<span></span>
</td>
<td class="nump">2,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">473<span></span>
</td>
<td class="nump">212<span></span>
</td>
<td class="nump">1,436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=FONR_MedicalEquipmentMember', window );">Medical Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenues from external customers</a></td>
<td class="nump">1,861<span></span>
</td>
<td class="nump">2,035<span></span>
</td>
<td class="nump">3,917<span></span>
</td>
<td class="nump">3,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_IntersegmentNetRevenues', window );">Inter-segment net revenues</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="nump">508<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">(Loss) Income from operations</a></td>
<td class="num">(993)<span></span>
</td>
<td class="num">(551)<span></span>
</td>
<td class="num">(1,731)<span></span>
</td>
<td class="num">(1,353)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=FONR_ManagementOfDiagnosticImagingCentersMember', window );">Management Of Diagnostic Imaging Centers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenues from external customers</a></td>
<td class="nump">23,525<span></span>
</td>
<td class="nump">22,221<span></span>
</td>
<td class="nump">47,307<span></span>
</td>
<td class="nump">43,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_IntersegmentNetRevenues', window );">Inter-segment net revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">(Loss) Income from operations</a></td>
<td class="nump">5,878<span></span>
</td>
<td class="nump">4,783<span></span>
</td>
<td class="nump">13,187<span></span>
</td>
<td class="nump">9,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,160<span></span>
</td>
<td class="nump">1,035<span></span>
</td>
<td class="nump">2,294<span></span>
</td>
<td class="nump">2,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">$ 423<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
<td class="nump">$ 1,362<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_IntersegmentNetRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents the amount of intersegment net revenues during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_IntersegmentNetRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=FONR_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=FONR_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=FONR_ManagementOfDiagnosticImagingCentersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=FONR_ManagementOfDiagnosticImagingCentersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583894464848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTION (Details Narrative) - Magnetic Resonance Management [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Sale of price of the equipment</a></td>
<td class="nump">$ 577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Bears interest rate</a></td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_GainOnSaleOfEquipmentsRelatedParty', window );">Gain on sale of equipments</a></td>
<td class="nump">$ 577<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_GainOnSaleOfEquipmentsRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_GainOnSaleOfEquipmentsRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed interest rate related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=FONR_MagneticResonanceManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=FONR_MagneticResonanceManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583897609904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL CASH FLOW INFORMATION (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">$ 647<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583899498880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 26, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Number of shares repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Number of shares repurchased, value</a></td>
<td class="nump">$ 1,171<span></span>
</td>
<td class="nump">$ 356<span></span>
</td>
<td class="nump">$ 1,885<span></span>
</td>
<td class="nump">$ 478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Shares cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Shares cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,005<span></span>
</td>
<td class="nump">$ 402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_StoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims', window );">Liability for individual claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth', window );">Reserve for self-funded</a></td>
<td class="nump">$ 86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_StoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents the amount of stop loss umbrella policy with 3 rd paryinsurer to limit maximum potential liability for individual claims during year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_StoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to disability, accident and health insurance insured events that have occurred on or before a particular date (ordinarily, the balance sheet date) and the amount needed to provide for the estimated ultimate cost required to investigate and settle claims relating to insured events that have occurred on or before a particular date (ordinarily, the balance sheet date), whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140583891478416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability', window );">Income tax expense</a></td>
<td class="nump">$ 1,366<span></span>
</td>
<td class="nump">$ 1,462<span></span>
</td>
<td class="nump">$ 3,036<span></span>
</td>
<td class="nump">$ 2,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Income tax component - current</a></td>
<td class="nump">323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Income tax component - deferred</a></td>
<td class="nump">1,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">7,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityPolicyholdersSurplus', window );">Deferred tax liability</a></td>
<td class="nump">$ 395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FONR_CorporateAlternativeMinimumTaxPercentage', window );">Corporate alternative minimum tax percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FONR_CorporateAlternativeMinimumTaxPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FONR_CorporateAlternativeMinimumTaxPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FONR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityPolicyholdersSurplus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability not recognized because of the exceptions to comprehensive recognition of deferred taxes related to a policyholders' surplus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 740<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480135/944-740-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityPolicyholdersSurplus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>56
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MSU-ADOU/GO)UN]T6\5:)45%1#".(@CC_*YZ+#?&J@-.* E84L#<%M.H;>%'
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M6AD+IN)A8LW#!P$Z7/X2G7-=+;\L@NU2OT1Q-['F[NNFF-KFYRL:;G-V4PA
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MKT@;:7+.([Y\$(O[[1&7:O,;XXXA?ZU3;GBD97,I=.X?Z@H!LG*Q83^<*8G
MK"5"O;R^9JE(Q6F6BR(<RBI<,8[_N4"W$N$B2V8\+S9?HHN?:X,,8KHP$/,=
M!%K. G:N/][)[292)2*8M8BX$O-52=$L223)QJE@(EX8'B_1Z7_HN^-V*P2:
M.::]':94 K-6"?6$'3DM.M'+/FBL30MDYP3$T'PRI0F8M2;0ZGNUV([$IW,_
MN)\+VIGW<UTE$]Q.F3"9)J&HZ&=(YM@_6:54;_*W'J+"@O[SO:HI_P6?!+(6
M(5"7V)>WYK50RL/%/37'KO5M"1!V3]Z:L)6$<;OW+]1\UZ1@Y/5N/P=MUVT
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MW^=95KX=R#? MF_\3?X'4$L#!!0    ( +B)3EC)A0,N0P0  ,06   8
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M3-,30??)6\=G*@0-D\,=P6O"X@!Y?T.I>#V)7V3F+ZY'_P%02P,$%     @
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M]'^]/B]G*K#(EAF3,O;B"OCGF:5M!9XV&P8\#!J;K"DUB%OXAU9=!?5/WZU
M41==\">1928LD"SW/!=RYH3?'*]#3!K' PZQ(!Z0EHZ.5K1/_;3OL^#*O$KP
M8H^:AQ8P_S1\WQ0+AF&_7JAZ.T> T*(_V9-1A>Q<61R;E4_+T]=S>^98>WZ!
M3\;%&6JEICC2_<)R"(J"$CP'E?U/ _!J7IR2%C=:KNQ!XU1JF!/LY8*S&<^-
M 'P_EU)O;\P/E&?5H_\ 4$L#!!0    ( +B)3E@7P+:"HP8  ,<.   8
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M7,#%,6R>+E462EUJ4L!@ 1?'S]2%@A QV_"PS@P(0RC&1] Z<[%,4X7=BV[
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MF3^I/T@_BM>?]2_!SFA1F)%76#KLSR8]ZB";]L:JTGV>7BJ+9N4NT;]1^B2
M]RNE;'-#&[3_O^+X?U!+ P04    " "XB4Y8!&W<'MX%  #8#   &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q,2YX;6R=5UEOVS@0?O>O&+B+H@5<'[+C),T!
M)&VZFT6/($FWS[0TLHE*I$I2<;R_?K^A),=ITSSLB\5CCF].CH_7UGWW*^9
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M/HHLD;LC4;XAFK5$Z1&B/GQ1TI8&KF2!Q??XB)3::99N-9NE)PDO,3^#+.E
M&J?9";YL9VGF^7I'^*Z5*M9<"&"R@!MIF5SQA4"8&H/6P"4WN5"FT0A_3Q?&
M:HJ7?PZYH962'9;B<FAH:I;C.*0D,:B?,)Q\>)?TXX\G;.CN;.B>8G_+;9TD
M.JSF[=WC%?3AP[OS-$D^PA%A<&=+U,!?/<B\!SL@Z0U12TJTO*D:P2P6 :N4
MMOP;<QG8(0P0UAU05<WD"Y<KR!7%BS18N)%1@A<.2)DFF,P1?&0;O\>-IW<,
M2R7H-2'X,)C3,U4TI 5MJ<.:!11*6"UHRX73[XU$R.).<,%J;IG@WTB<44N[
M9G3W!3[10U73LV-)J"'1[V'0B>/>M@_N23])ZRZ,<E6_:)?W!GJ=[B!U;2\-
M;I7\Q9F(%J';27IQVP87/I])#XW"N\24O#:0=7Z-X[8-KK4RYIB+*14ZO73@
MNW@0?$9CAC!]=3?LNQN202?M)ZZ+![V@I?PQ[M^3X+3?]WTW2V&Z3T$^K0^:
M&U Y\#=A2XT(59OZZ%(?OO.V2UZ/I4'J]&ND4]0J$MC-H#OX06!^T$G_BT"Z
M"/J]T4+#GW]2W'D?DCAYJX$_+R^A*'+_0P]-M%<B2/;*%T*75X1OJ\5N=5=K
MIVV)>3W>%NHO3*^X-"!P2=#X;$ OKFZ+7SNQJO8%9Z$L&>J')7TOH'8':'^I
ME-U.G(#=%\CD/U!+ P04    " "XB4Y8FRE(YT$#  #F!@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q-"YX;6R55=^/&CD,?N>OL*95G[B=G[#L%I!@RZF<
MMMT5;.\>3O<09CP0-9/,)9FR_/?G9 :.2@M2)43BV/[\.78\X[W2W\T.T<)K
M):29!#MKZ_LP-/D.*V9N5(V2-*72%;,DZFUH:HVL\$Z5"),H&H85XS*8COW9
MLYZ.56,%E_BLP315Q?1ACD+M)T$<' ]6?+NS[B"<CFNVQ37:;_6S)BD\H12\
M0FFXDJ"QG 2S^'Z>.7MO\"?'O3G;@\MDH]1W)RR+21 Y0B@PMPZ!T?(#'U (
M!T0T_NTP@U-(YWB^/Z+_[G.G7#;,X(,2?_'"[B;!*( "2]8(NU+[S]CE,W!X
MN1+&_\.^M4W3 /+&6%5USL2@XK)=V6MW#V<.H^B"0](Y))YW&\BS_,0LFXZU
MVH-VUH3F-CY5[TWDN'1%65M-6DY^=OKT\GFQ@H=OJ]7BZPL\+F?SY>/R9;E8
MCT-+\,XHS#NH>0N57( :PA<E[<[ 0A98_.P?$JT3M^3(;9Y<!?R$^0VD<1^2
M*$FOX*6G7%./-[B ]\P.;"/0 ),%S/)<-TP8^'NV,593=_SS5LHM8OHVHGLQ
M]Z9F.4X">A(&]0\,IA_>Q</HXQ6^V8EO=@W]UVIS%>IMHE^?7A9P"Q_>C9(X
M_@@7P\&3W:&F;M0:I07!V88+;CG=))= .GI;N:IJ)@]<;GNYHOI+@P70SBC!
M"V9)V##!9([@>]5X'3<65.D12B5H/I#[?6]-@Z=H!#J5NA2Y1\V!U8:4KD'^
M:"1"&O5[OJH4S% P369]BE-5W+@9TM:]9@=-L<"R5^+_'I)^=#NB->MG<=I;
M,]<?I'-VKED@21*([]+>4A(2=FY'97PWA&S4>\0M$QZ]Y5MK5:*/2<<EDD,<
MT\^Q4XVTE&5[.L@@CJ+>&D7Y6]FX5P,[9,+NZ%Y-H_UU==6"T9!LXU."7%HD
ME6US0@ID#Y!!UFMKM46)NN/$"IH;W/6X&X" K[6KCH%1= >#VZ/'0W?'CV?5
M?0]I/QM&M [Z69;!6ST=GLV>"O763UA77DJT'4.GT],0G[6SZW_S]@OPA>DM
M)0X"2W*-;F[I(>MVJK:"5;6?9!ME:2[Z+=U7@=H9D+Y4RAX%%^#T:9O^!U!+
M P04    " "XB4Y8*)?[0<<$   O#   &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q-2YX;6RM5]MNXS80??=7$-[%8A=08HF4;#D7 \YEMVG729"D[4/1!T8:
MVT0DTDO2<;)?WR$I.W'AV$'1%_.BF<,S9\@A?;10^L%, 2QYJBMICMM3:V<'
MG8XIIE!SLZ]F(/'+6.F:6QSJ2<?,-/#2.]55A\9QMU-S(=N#(S]WK0=':FXK
M(>%:$S.O:ZZ?3Z!2B^-VTEY.W(C)U+J)SN!HQB=P"_;WV;7&46>%4HH:I!%*
M$@WCX_8P.3A)G;TW^$/ PKSJ$Q?)O5(/;G!1'K=C1P@J**Q#X-@\PBE4E0-"
M&C\:S/9J2>?XNK]$_^ICQUCNN8%35?TI2CL];N=M4L*8SRM[HQ:_0!-/YO *
M51G_2Q;!EM$V*>;&JKIQ1@:UD*'E3XT.KQSR^ T'VCA0SSLLY%F><<L'1UHM
MB';6B.8Z/E3OC>2$=$FYM1J_"O2S@]OS;Z/SRSLRO#PC-^??AW?G9^3B\NO5
MS6AX=W%U>=2QN(@S[10-X$D I&\ =LE(23LUY%R64*[[=Y#<BB%=,CRA6P'/
MH-@G+(D(C2G;@L=6$3./E[T5,4QP4UER S.EK9 3\M?PWEB-^^/O3>$&-+89
MS9V9 S/C!1RW\5 8T(_0'GSZD'3CPRU<TQ77=!OZ?\G.5L#-="^O[LY)3O;(
MCN7(W13(J:IG7#X3+ N:6S!$2&(7"IL2=ZM^)B;H:Q"OYG(^1EWG&F5N<5D2
MBPAN55$XX=68U%"*@E<$?LS%S.?%F:$C5@0_1)M2\(E4QHJ"B)I/G&>!GT";
M?4^)%X6:2Y_*F:H0&EFA6UBK(<,UM/P$K]'!X$=E (^O*;2XA])'X3Z'VN3<
MC9A(,49RCM.&%1"D%*:H$&?EWHCSZ4-.D]ZA(4F\]YLS1+A?YQ):+ [;>)\,
MJPJ=,(:]AB(RJ\#SQ.CU ]@]5VS*_371X9%7<Z\ZJN\KLBS 5Z628(D3LE 8
MGM($61DRUJIN\H0%$,6Z]=&)GV@]%A)]!7<L0FEW-;)0B*>ER]:F<+0_,OR^
M>B6L,,1,U4(N)1BK"@N]4\H;'K1N\1XIYQ6TG*8O!)9A;R32&C7;8O2R$>Z4
MY95I82WVZ]BI!I0JU!IPM8:L58K6)=YH&AY!SJ&1 IY0;XFHH:[B_B$?21+E
MW01;RJ*,9JZ312SOMB[6DB-?@SF;%'^]+O0PC%N?OZ/F7\A%R,&_M$>;S_T^
M(U^PDT5Y+\<VC?(\:YT!'D2,/]Q1N/=Y[<K2SS#QD71C3S)I6DKCUBF?">O.
MS!->S:7 X^5).4H)[;M?QMZK$WVO3C2*F9>'(@<O6!K1;)=.:;:N4YKMUBG+
M$J]3&O5RYEO*Z&Z=,J]/((EZQ6_JE#DE4^JA>^P=6\V(I_]AH[&HG_3\FA&+
M72=SV4RW"YC%^9J .-XM8!+U6) P85&2N[62)$HQ6;M$3$)F(]I/?9LFV5LJ
M4K\?^]1U$_H^K=Z]V9Q6/C]X*%D:1$O3WG:MTGZ\IA6.WZ,5R\*Q[$=IOXMM
M'B4IVZT4ZX5#D3>*)?E;2O7\P8Q8E_HV95VRZ6G0>?6(0QDF_JEJB+]XPGMN
M-;MZ#0_#(_#%/#RE1USC+6E(!6-TC?=[^!;2X7D:!E;-_)/P7EG4W'>G^*('
M[0SP^U@INQRX!5;_$0;_ %!+ P04    " "XB4Y8_M\I*[D"  #A!0  &0
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M(\Q:(08 KZ"$(42Q\79?I>"Z0%W20YNPIRR-(-P_354 !&^IG*>]TMPCJ7O
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M&H$;TV#6@^M&<UG #2YT0_W#A1D<>^1&MN&%Q.R 4;&3?U:MQ3&H-74Q;=]
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MUV50,9AIDS'?)J_#?)(=*]\=D)HPLD]4(K%1<"0FS".A,LHU%0B3I#M9"%-
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MJ)F;R-#$P#;Y;298!%1@D.SP+-,X=(F]Z$IVT=5SD ]]-8.+6V*0C4-X0T
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M!%^W![%&O*JHR K,Q163M="-X4!39CF,4J'+$6LW,/T5QFW!"^HTBR('$@=
M@K[U#:<;*F1;5("><3"3J9YMG"E^X,P$^:L63]A*B=O')XF(=6.*&"^/N(_/
M""73EMHEDI@UU&Q@.  B[0Q)Z5*NT5EW(TO3#7DAV[9]"[&-%8WOONV1I,O+
M;?'XZ[)"[,"+3';B*-F3ES ,L9&#G\J+Y]IN$(!I_S8QYL;'8'X8_HK$>)$=
M)U'3Z<0-]]:^LS6N81[NS5 JP?AH)K=.VLV]PV;<>U9OAN9)*NX+)J&D"S1U
MC_K8V*(91)N-XBLS_,VYPE'2+)<XNU.A%?#[@G.UV>@ W;^!P3]02P,$%
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MK:?8L&K>#_=J!#XQM>0YW3(N*-2[CNC/5=58J8"11=G*<VEH,)3FBB8Q*NM
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M;K 4U+%XD4QT_@N'<JWG0+331J9E,#%(N2C^V6-IQ%& WST1$)0!P>N ]HF
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M$F67.XSXKV\*X,]?"&&GF]1!^5EJ_A]02P,$%     @ N(E.6*8-EO6X @
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M7(8DUP^=?A!F"9ZS+2H+N/OWE8UC&Q ^PI'[@BU[]]$^:^G91<TUXU^2.8!
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M?K_JC'Y' Q:_H"?@$>KX/EO&(D%C\"%8T4D(Z*('@@9A<BDMGQ][Z.+#)?J
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M4D/YYIAK,Q!LD9T439@0+,INYT"GP%,#^7[&I*3F@_3PJ3AL;/\/4$L#!!0
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M _'[DA"^O\D"5"]>)O\"4$L#!!0    ( +B)3EBF:+& /P,  ,D+   9
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M.D_3J6_CQG>OO;ZYV>];:\BG]NV,@/$E XY^#WAM6W7  Y6[M<K=5I7O@"5
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MNKGKWWP<#:X"U)],@KL).O9!8A(+=(,YQ]K,$W2*[B<^.CXZ04>(4'07L:7
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M7"N0Y*H8)[3T8MU>K#LH]NPS9>+5GI:)6-9VL45IJG"]MVOUNNH8@D 2,]&
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M,TQ4[T>N$]3ZBC&YF^@-FK])^!M02P,$%     @ N(E.6)L15/(B!   314
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ML(0TU43J-?ZK.*U:4@./VP?V]R9WE<L*"UBR]&^REKN9-;'0&C:X2.5GMO\
M53Z!YDM8*LPOVI>Q@0I."B%95H'5&V2$EO_XN?+A"*!XN@%>!?#:@-$+ +\"
M^.<JC"K Z%R%H *8U.TR=V-<A"6>3SG;(ZZC%9MN&/<-6OE%J%XG#Y*KIT3A
MY/SCI^6?=S%ZO/T:/Z#7$4A,4H$^8<ZQGL$WZ!WZ\A"AUZ_>H%>(4/2X8X7
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M" "XB4Y8\]!1P!L$  !Y'@  #P   'AL+W=O<FMB;V]K+GAM;,696X_:.!2
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MT-NCWOZ=>L=TK4)\]CS6^/QW4IUN]X;GX^_+Q\G."W7'V<'OL<4O4$L#!!0
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M2P$"% ,4    " "XB4Y8;$R.^NX    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "XB4Y8F5R<(Q &  "<)P
M$P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( +B)3EA'VWE9208  $TD   8              " @0T(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "XB4Y8?;D F6()  #]-P
M&               @(&,#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ N(E.6,F% RY#!   Q!8  !@              ("!)!@  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( +B)3EC,L#B'40<
M . B   8              " @9T<  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    " "XB4Y8IE6Y7]X$  #_%P  &               @($D
M)   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ N(E.6.=[
M-B?'"0  J5,  !@              ("!."D  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( +B)3E@",P2)  <  +<>   8
M  " @34S  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "X
MB4Y8%\"V@J,&  #'#@  &               @(%K.@  >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ N(E.6)^=&? :#@  S"0  !@
M         ("!1$$  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( +B)3ECA)C2ZNPD  +L8   9              " @91/  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ N(E.6 1MW![>!0  V P
M !D              ("!AED  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    " "XB4Y8EL:T)Z<"  "W!0  &0              @(&;7P
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( +B)3E@Y9(#:
M>P,  (T(   9              " @7EB  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ N(E.6)LI2.=! P  Y@8  !D
M ("!*V8  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "X
MB4Y8*)?[0<<$   O#   &0              @(&C:0  >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( +B)3EC^WRDKN0(  .$%   9
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M970R,"YX;6Q02P$"% ,4    " "XB4Y8->DH%VH.   %)P  &0
M    @(%SA0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M +B)3EC9GB(6>@,  " )   9              " @124  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ N(E.6-&VAGUO!   &0P  !D
M             ("!Q9<  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    " "XB4Y8N#764JP"  #G!0  &0              @(%KG   >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( +B)3ECK3()U<@(
M $X%   9              " @4Z?  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ N(E.6*?\B>WI @  *@8  !D              ("!
M]Z$  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "XB4Y8
M(X2X6 <#  !D!@  &0              @($7I0  >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( +B)3EBJNVZAQ ,  .\)   9
M      " @56H  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ N(E.6$B\I59\ P  UPL  !D              ("!4*P  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "XB4Y8T-5GJ44%  "B&@
M&0              @($#L   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( +B)3EBF#9;UN (  /T'   9              " @7^U  !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ N(E.6/'&/UM,
M!   >!0  !D              ("!;K@  'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    " "XB4Y8BNH7LUL"   W!0  &0
M@('QO   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( +B)
M3EB)3Q<#@00  (09   9              " @8._  !X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ N(E.6*9HL8 _ P  R0L  !D
M         ("!.\0  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M    " "XB4Y8>GK'[' #   J#@  &0              @(&QQP  >&PO=V]R
M:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( +B)3E@A!66'@ (  %(&
M   9              " @5C+  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
M4$L! A0#%     @ N(E.6(0?!.C, P  ?A$  !D              ("!#\X
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "XB4Y8BX:/
M.S8#  "7#0  &0              @($2T@  >&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;%!+ 0(4 Q0    ( +B)3EAJ)Q]2;P,  '$*   9
M  " @7_5  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
MN(E.6*B+2TH)!0  D1<  !D              ("!)=D  'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    " "XB4Y8IW8B"JL"   7!@  &0
M            @(%EW@  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( +B)3E@>9,JODP(  %D&   9              " @4?A  !X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ N(E.6)L15/(B!
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M96QS+RYR96QS4$L! A0#%     @ N(E.6//04< ;!   >1X   \
M     ( !</   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( +B)3EBX-L3<
MJ0$  "X;   :              "  ;CT  !X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( +B)3EA3V2LIL@$  %,;   3
M  "  9GV  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     U #4 :@X  'SX
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>141</ContextCount>
  <ElementCount>243</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>30</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/CondensedConsolidatedStatementsOfIncome</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/CondensedConsolidatedStatementsOfIncomeParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentation</Role>
      <ShortName>DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable</Role>
      <ShortName>ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - OPERATING &amp; FINANCING LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/OperatingFinancingLeases</Role>
      <ShortName>OPERATING &amp; FINANCING LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/Inventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - OTHER INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/OtherIntangibleAssets</Role>
      <ShortName>OTHER INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/OtherCurrentLiabilities</Role>
      <ShortName>OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - SEGMENT AND RELATED INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/SegmentAndRelatedInformation</Role>
      <ShortName>SEGMENT AND RELATED INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - RELATED PARTY TRANSACTION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/RelatedPartyTransaction</Role>
      <ShortName>RELATED PARTY TRANSACTION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/SupplementalCashFlowInformation</Role>
      <ShortName>SUPPLEMENTAL CASH FLOW INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://fonar.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableTables</Role>
      <ShortName>ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - OPERATING &amp; FINANCING LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/OperatingFinancingLeasesTables</Role>
      <ShortName>OPERATING &amp; FINANCING LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://fonar.com/role/OperatingFinancingLeases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/InventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://fonar.com/role/Inventories</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - OTHER INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/OtherIntangibleAssetsTables</Role>
      <ShortName>OTHER INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://fonar.com/role/OtherIntangibleAssets</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/OtherCurrentLiabilitiesTables</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://fonar.com/role/OtherCurrentLiabilities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - SEGMENT AND RELATED INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/SegmentAndRelatedInformationTables</Role>
      <ShortName>SEGMENT AND RELATED INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://fonar.com/role/SegmentAndRelatedInformation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative</Role>
      <ShortName>DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://fonar.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails</Role>
      <ShortName>ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails1</Role>
      <ShortName>ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetails</Role>
      <ShortName>ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetailsNarrative</Role>
      <ShortName>ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - OPERATING &amp; FINANCING LEASES - Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails</Role>
      <ShortName>OPERATING &amp; FINANCING LEASES - Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - INVENTORIES - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/Inventories-InventoriesDetails</Role>
      <ShortName>INVENTORIES - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - OTHER INTANGIBLE ASSETS - Other intangible assets net of amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/OtherIntangibleAssets-OtherIntangibleAssetsNetOfAmortizationDetails</Role>
      <ShortName>OTHER INTANGIBLE ASSETS - Other intangible assets net of amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - OTHER INTANGIBLE ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/OtherIntangibleAssetsDetailsNarrative</Role>
      <ShortName>OTHER INTANGIBLE ASSETS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://fonar.com/role/OtherIntangibleAssetsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - OTHER CURRENT LIABILITIES - Other Current Liabilities - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details</Role>
      <ShortName>OTHER CURRENT LIABILITIES - Other Current Liabilities - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - SEGMENT AND RELATED INFORMATION - Summarized Segments - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/SegmentAndRelatedInformation-SummarizedSegments-Details</Role>
      <ShortName>SEGMENT AND RELATED INFORMATION - Summarized Segments - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - RELATED PARTY TRANSACTION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/RelatedPartyTransactionDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://fonar.com/role/RelatedPartyTransaction</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/SupplementalCashFlowInformationDetailsNarrative</Role>
      <ShortName>SUPPLEMENTAL CASH FLOW INFORMATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://fonar.com/role/SupplementalCashFlowInformation</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://fonar.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="fonar_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fonar.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://fonar.com/role/IncomeTaxes</ParentRole>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="fonar_10-q.htm">fonar_10-q.htm</File>
    <File>fonr-20231231.xsd</File>
    <File>fonr-20231231_cal.xml</File>
    <File>fonr-20231231_def.xml</File>
    <File>fonr-20231231_lab.xml</File>
    <File>fonr-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>fonar_logo.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="680">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="32">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>62
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "fonar_10-q.htm": {
   "nsprefix": "FONR",
   "nsuri": "http://fonar.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "fonar_10-q.htm"
     ]
    },
    "schema": {
     "local": [
      "fonr-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "fonr-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "fonr-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "fonr-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fonr-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 190,
   "keyCustom": 53,
   "axisStandard": 9,
   "axisCustom": 0,
   "memberStandard": 13,
   "memberCustom": 16,
   "hidden": {
    "total": 112,
    "http://fasb.org/us-gaap/2023": 76,
    "http://fonar.com/20231231": 31,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "contextCount": 141,
   "entityCount": 1,
   "segmentCount": 30,
   "elementCount": 357,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 680,
    "http://xbrl.sec.gov/dei/2023": 32
   },
   "report": {
    "R1": {
     "role": "http://fonar.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://fonar.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:TreasuryStockCommonShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:TreasuryStockCommonShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome",
     "longName": "00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2023-10-012023-12-31",
      "name": "FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscounts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-012023-12-31",
      "name": "FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscounts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://fonar.com/role/CondensedConsolidatedStatementsOfIncomeParenthetical",
     "longName": "00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2023-10-012023-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-012023-12-31_custom_CommonStockholdersMember",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity",
     "longName": "00000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "AsOf2022-06-30_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-06-30_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "longName": "00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:OtherDepreciationAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentation",
     "longName": "00000008 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION",
     "shortName": "DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://fonar.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable",
     "longName": "00000010 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE",
     "shortName": "ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://fonar.com/role/OperatingFinancingLeases",
     "longName": "00000011 - Disclosure - OPERATING & FINANCING LEASES",
     "shortName": "OPERATING & FINANCING LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://fonar.com/role/Inventories",
     "longName": "00000012 - Disclosure - INVENTORIES",
     "shortName": "INVENTORIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://fonar.com/role/OtherIntangibleAssets",
     "longName": "00000013 - Disclosure - OTHER INTANGIBLE ASSETS",
     "shortName": "OTHER INTANGIBLE ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://fonar.com/role/OtherCurrentLiabilities",
     "longName": "00000014 - Disclosure - OTHER CURRENT LIABILITIES",
     "shortName": "OTHER CURRENT LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://fonar.com/role/SegmentAndRelatedInformation",
     "longName": "00000015 - Disclosure - SEGMENT AND RELATED INFORMATION",
     "shortName": "SEGMENT AND RELATED INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://fonar.com/role/RelatedPartyTransaction",
     "longName": "00000016 - Disclosure - RELATED PARTY TRANSACTION",
     "shortName": "RELATED PARTY TRANSACTION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://fonar.com/role/SupplementalCashFlowInformation",
     "longName": "00000017 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION",
     "shortName": "SUPPLEMENTAL CASH FLOW INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://fonar.com/role/CommitmentsAndContingencies",
     "longName": "00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://fonar.com/role/IncomeTaxes",
     "longName": "00000019 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://fonar.com/role/SubsequentEvents",
     "longName": "00000020 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://fonar.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://fonar.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableTables",
     "longName": "00000023 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Tables)",
     "shortName": "ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://fonar.com/role/OperatingFinancingLeasesTables",
     "longName": "00000024 - Disclosure - OPERATING & FINANCING LEASES (Tables)",
     "shortName": "OPERATING & FINANCING LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://fonar.com/role/InventoriesTables",
     "longName": "00000025 - Disclosure - INVENTORIES (Tables)",
     "shortName": "INVENTORIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://fonar.com/role/OtherIntangibleAssetsTables",
     "longName": "00000026 - Disclosure - OTHER INTANGIBLE ASSETS (Tables)",
     "shortName": "OTHER INTANGIBLE ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://fonar.com/role/OtherCurrentLiabilitiesTables",
     "longName": "00000027 - Disclosure - OTHER CURRENT LIABILITIES (Tables)",
     "shortName": "OTHER CURRENT LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://fonar.com/role/SegmentAndRelatedInformationTables",
     "longName": "00000028 - Disclosure - SEGMENT AND RELATED INFORMATION (Tables)",
     "shortName": "SEGMENT AND RELATED INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative",
     "longName": "00000029 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)",
     "shortName": "DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2015-07-01_us-gaap_NoncontrollingInterestMember",
      "name": "FONR:OwnershipInterestOfOriginalInvestorsOfHdm",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2015-07-01_us-gaap_NoncontrollingInterestMember",
      "name": "FONR:OwnershipInterestOfOriginalInvestorsOfHdm",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://fonar.com/role/SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details",
     "longName": "00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share - (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share - (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2023-10-012023-12-31",
      "name": "FONR:NetIncomeLossAvailableToCommonStockholderBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-012023-12-31",
      "name": "FONR:NetIncomeLossAvailableToCommonStockholderBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://fonar.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2023-10-012023-12-31",
      "name": "us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-012023-12-31",
      "name": "us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails",
     "longName": "00000032 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details)",
     "shortName": "ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "FONR:AccountsReceivableServiceAndRepairFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "FONR:AccountsReceivableNetRelatedParty",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails1",
     "longName": "00000033 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details 1)",
     "shortName": "ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ContractReceivableDueOneToTwoYears",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "FONR:TotalFacilitiesOwnedOrManagedTableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ContractReceivableDueOneToTwoYears",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "FONR:TotalFacilitiesOwnedOrManagedTableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetails",
     "longName": "00000034 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details)",
     "shortName": "ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2023-10-012023-12-31",
      "name": "FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "FONR:ScheduleOfPatientFeeRevenueTableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-012023-12-31",
      "name": "FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "FONR:ScheduleOfPatientFeeRevenueTableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetailsNarrative",
     "longName": "00000035 - Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details Narrative)",
     "shortName": "ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "FONR:AccountsReceivableNetLongTerm",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-012023-12-31",
      "name": "FONR:PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails",
     "longName": "00000036 - Disclosure - OPERATING & FINANCING LEASES - Lease Payments (Details)",
     "shortName": "OPERATING & FINANCING LEASES - Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_OperatingLeasePaymentsMember",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_OperatingLeasePaymentsMember",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://fonar.com/role/Inventories-InventoriesDetails",
     "longName": "00000037 - Disclosure - INVENTORIES - Inventories (Details)",
     "shortName": "INVENTORIES - Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:OtherInventorySupplies",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:OtherInventorySupplies",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://fonar.com/role/OtherIntangibleAssets-OtherIntangibleAssetsNetOfAmortizationDetails",
     "longName": "00000038 - Disclosure - OTHER INTANGIBLE ASSETS - Other intangible assets net of amortization (Details)",
     "shortName": "OTHER INTANGIBLE ASSETS - Other intangible assets net of amortization (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://fonar.com/role/OtherIntangibleAssetsDetailsNarrative",
     "longName": "00000039 - Disclosure - OTHER INTANGIBLE ASSETS (Details Narrative)",
     "shortName": "OTHER INTANGIBLE ASSETS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2023-10-012023-12-31_custom_PatentsAndCopyrightsMember",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-012023-12-31_custom_PatentsAndCopyrightsMember",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details",
     "longName": "00000040 - Disclosure - OTHER CURRENT LIABILITIES - Other Current Liabilities - (Details)",
     "shortName": "OTHER CURRENT LIABILITIES - Other Current Liabilities - (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://fonar.com/role/SegmentAndRelatedInformation-SummarizedSegments-Details",
     "longName": "00000041 - Disclosure - SEGMENT AND RELATED INFORMATION - Summarized Segments - (Details)",
     "shortName": "SEGMENT AND RELATED INFORMATION - Summarized Segments - (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2023-10-012023-12-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-012023-12-31",
      "name": "FONR:IntersegmentNetRevenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://fonar.com/role/RelatedPartyTransactionDetailsNarrative",
     "longName": "00000042 - Disclosure - RELATED PARTY TRANSACTION (Details Narrative)",
     "shortName": "RELATED PARTY TRANSACTION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_MagneticResonanceManagementMember",
      "name": "us-gaap:ConvertibleNotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_MagneticResonanceManagementMember",
      "name": "us-gaap:ConvertibleNotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://fonar.com/role/SupplementalCashFlowInformationDetailsNarrative",
     "longName": "00000043 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Details Narrative)",
     "shortName": "SUPPLEMENTAL CASH FLOW INFORMATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:InterestPaidNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2023-12-31",
      "name": "us-gaap:InterestPaidNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://fonar.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "00000044 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2022-09-26",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-09-26",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://fonar.com/role/IncomeTaxesDetailsNarrative",
     "longName": "00000045 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2023-10-012023-12-31",
      "name": "us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-012023-12-31",
      "name": "us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fonar_10-q.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "FONR_AccountReceivableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "AccountReceivableRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable - related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable Type [Axis]",
        "documentation": "Information by type of receivable."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://fonar.com/role/OtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER CURRENT LIABILITIES",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r415"
     ]
    },
    "FONR_AccountsPayableRelatedPartyNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "AccountsPayableRelatedPartyNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to related medical practices"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableBilledForLongTermContractsOrPrograms",
     "crdr": "debit",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Amount billed to customers under long-term contracts or programs but not paid. Excludes amounts due that have been withheld because of retainage provisions in a contract."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "FONR_AccountsReceivableNetLongTerm": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "AccountsReceivableNetLongTerm",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetailsNarrative",
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable \u2013 long term",
        "verboseLabel": "Long term accounts receivable"
       }
      }
     },
     "auth_ref": []
    },
    "FONR_AccountsReceivableNetRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "AccountsReceivableNetRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable - Related party",
        "documentation": "Accounts receivable from service and repair fees of Related Party MRI scanner customers; net of allowances for doubtful accounts"
       }
      }
     },
     "auth_ref": []
    },
    "FONR_AccountsReceivableServiceAndRepairFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "AccountsReceivableServiceAndRepairFees",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails",
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable \u2013 net",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal and other professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued salaries, commissions and payroll taxes",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r399"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paid-in capital in excess of par value",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r415",
      "r498"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r324",
      "r462",
      "r463",
      "r464",
      "r484",
      "r500"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://fonar.com/role/OtherIntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r32",
      "r36"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://fonar.com/role/RelatedPartyTransactionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r119",
      "r141",
      "r174",
      "r183",
      "r188",
      "r199",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r250",
      "r254",
      "r265",
      "r294",
      "r355",
      "r415",
      "r426",
      "r474",
      "r475",
      "r487"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r125",
      "r141",
      "r199",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r250",
      "r254",
      "r265",
      "r415",
      "r474",
      "r475",
      "r487"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://fonar.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BUSINESS COMBINATION",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r86",
      "r87"
     ]
    },
    "FONR_CancellationOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "CancellationOfShares",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cancellation of shares",
        "documentation": "This represents the amount of cancellation of shares during year."
       }
      }
     },
     "auth_ref": []
    },
    "FONR_CancellationOfSharesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "CancellationOfSharesShares",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cancellation of shares, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and Cash Equivalents - Beginning of Period",
        "periodEndLabel": "Cash and Cash Equivalents - End of Period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r83",
      "r139"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Increase in Cash and Cash Equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r83"
     ]
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "presentation": [
      "http://fonar.com/role/SupplementalCashFlowInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL CASH FLOW INFORMATION",
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "FONR_ClassANonVotingPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "ClassANonVotingPreferredStockMember",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets",
      "http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class A Non Voting Preferred Stock [Member]",
        "documentation": "Class A Non Voting Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "FONR_ClassANonVotingPreferredStockholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "ClassANonVotingPreferredStockholdersMember",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class A Non Voting Preferred Stockholders [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "FONR_ClassAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "ClassAPreferredStockMember",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class A Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets",
      "http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncomeParenthetical",
      "http://fonar.com/role/Cover",
      "http://fonar.com/role/SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r122",
      "r123",
      "r124",
      "r141",
      "r158",
      "r159",
      "r163",
      "r165",
      "r168",
      "r169",
      "r199",
      "r213",
      "r215",
      "r216",
      "r217",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r265",
      "r313",
      "r314",
      "r315",
      "r316",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r343",
      "r364",
      "r385",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r447",
      "r459",
      "r465"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://fonar.com/role/RelatedPartyTransactionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "FONR_CommercialInsuranceManagedCareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "CommercialInsuranceManagedCareMember",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Insurance Managed Care [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://fonar.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r211",
      "r212",
      "r397",
      "r473"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets",
      "http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_CommonClassCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassCMember",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets",
      "http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncomeParenthetical",
      "http://fonar.com/role/Cover",
      "http://fonar.com/role/SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class C [Member]",
        "documentation": "Classification of common stock that has different rights than provided to Class A or B shares, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity",
      "http://fonar.com/role/Cover",
      "http://fonar.com/role/SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r417",
      "r418",
      "r420",
      "r421",
      "r422",
      "r423",
      "r462",
      "r463",
      "r484",
      "r496",
      "r500"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r343"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r61",
      "r343",
      "r361",
      "r500",
      "r501"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock value",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r296",
      "r415"
     ]
    },
    "FONR_CommonStockholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "CommonStockholdersMember",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stockholders [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "FONR_CommonStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "CommonStocksMember",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member] [Default Label]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://fonar.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r400"
     ]
    },
    "us-gaap_ContractReceivableDueOneToTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractReceivableDueOneToTwoYears",
     "crdr": "debit",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of right to consideration in exchange for good or service transferred to customer under long-term contract or program when right to consideration is unconditional, excluding amount withheld under retainage provision in contract, to be collected in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_ContractReceivableDueTwoToThreeYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractReceivableDueTwoToThreeYears",
     "crdr": "debit",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of right to consideration in exchange for good or service transferred to customer under long-term contract or program when right to consideration is unconditional, excluding amount withheld under retainage provision in contract, to be collected in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "FONR_ControllingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "ControllingInterestMember",
     "presentation": [
      "http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Controlling Interest [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "FONR_ConvertibleClassCStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "ConvertibleClassCStock",
     "presentation": [
      "http://fonar.com/role/SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Class C Stock",
        "documentation": "This represents the shares of convertible class c stock during period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/RelatedPartyTransactionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of price of the equipment",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r96",
      "r492"
     ]
    },
    "FONR_CorporateAlternativeMinimumTaxPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "CorporateAlternativeMinimumTaxPercentage",
     "presentation": [
      "http://fonar.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate alternative minimum tax percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Costs and Expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COSTS AND EXPENSES"
       }
      }
     },
     "auth_ref": []
    },
    "FONR_CostsRelatedToManagementAndOtherFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "CostsRelatedToManagementAndOtherFees",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs related to management and other fees"
       }
      }
     },
     "auth_ref": []
    },
    "FONR_CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs related to management and other fees \u2013 related medical practices",
        "documentation": "This represents the amount of costs related to management and other fees related medical practices during period."
       }
      }
     },
     "auth_ref": []
    },
    "FONR_CostsRelatedToProductSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "CostsRelatedToProductSales",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs related to product sales"
       }
      }
     },
     "auth_ref": []
    },
    "FONR_CostsRelatedToServiceAndRepairFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "CostsRelatedToServiceAndRepairFees",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs related to service and repair fees"
       }
      }
     },
     "auth_ref": []
    },
    "FONR_CostsRelatedToServiceAndRepairFeesRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "CostsRelatedToServiceAndRepairFeesRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs related to service and repair fees - related parties"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://fonar.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax component - current",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r461",
      "r480"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "FONR_CustomerDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "CustomerDeposits",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://fonar.com/role/OtherIntangibleAssets-OtherIntangibleAssetsNetOfAmortizationDetails",
      "http://fonar.com/role/OtherIntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://fonar.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax component - deferred",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r479",
      "r480"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income tax \u2013 net",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r92",
      "r108",
      "r243",
      "r244",
      "r461"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income tax liability",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other liabilities expected to be paid after one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unearned revenue on service contracts",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unearned revenue on service contracts",
        "label": "Deferred Revenue, Noncurrent",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income tax asset",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r478"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://fonar.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax asset",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityPolicyholdersSurplus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityPolicyholdersSurplus",
     "crdr": "debit",
     "presentation": [
      "http://fonar.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liability",
        "documentation": "Amount of deferred tax liability not recognized because of the exceptions to comprehensive recognition of deferred taxes related to a policyholders' surplus."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://fonar.com/role/SegmentAndRelatedInformation-SummarizedSegments-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r178"
     ]
    },
    "us-gaap_DerivativeFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeFixedInterestRate",
     "presentation": [
      "http://fonar.com/role/RelatedPartyTransactionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bears interest rate",
        "documentation": "Fixed interest rate related to the interest rate derivative."
       }
      }
     },
     "auth_ref": []
    },
    "FONR_DirectPurchaseOfNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "DirectPurchaseOfNoncontrollingInterests",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Direct purchase of Noncontrolling Interests",
        "documentation": "This represents the amount of direct purchase of noncontrolling interests during period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412"
     ]
    },
    "FONR_DisclosureOperatingFinancingLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "DisclosureOperatingFinancingLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Financing Leases"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r440",
      "r441"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_DoubtfulMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DoubtfulMember",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Doubtful [Member]",
        "documentation": "A category of financing receivables that have all the weaknesses inherent in those classified as substandard, with the added characteristic that the weaknesses make collection or liquidation in full, on the basis of currently existing facts, conditions, and values, highly questionable and improbable."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r470"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic Net Income Per Common Share Available to Common Stockholders",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r156",
      "r158",
      "r163",
      "r164",
      "r165",
      "r166",
      "r263",
      "r264",
      "r289",
      "r305",
      "r402"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncomeParenthetical",
      "http://fonar.com/role/SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted Net Income Per Common Share Available to Common Stockholders",
        "verboseLabel": "Diluted Income per Common Share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r158",
      "r163",
      "r164",
      "r165",
      "r166",
      "r263",
      "r264",
      "r289",
      "r305",
      "r402"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://fonar.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity",
      "http://fonar.com/role/Cover",
      "http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative",
      "http://fonar.com/role/SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r111",
      "r128",
      "r129",
      "r130",
      "r143",
      "r144",
      "r145",
      "r147",
      "r153",
      "r155",
      "r167",
      "r200",
      "r201",
      "r227",
      "r229",
      "r230",
      "r231",
      "r239",
      "r240",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r277",
      "r307",
      "r308",
      "r309",
      "r324",
      "r385"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative"
     ],
     "auth_ref": [
      "r196",
      "r197",
      "r198"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Direct ownership interest percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing lease liability - current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing lease liability \u2013 net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use Asset \u2013 financing lease",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "FONR_FinancingLeasePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "FinancingLeasePaymentsMember",
     "presentation": [
      "http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Lease Payments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/OtherIntangibleAssets-OtherIntangibleAssetsNetOfAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less: Accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r207"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://fonar.com/role/OtherIntangibleAssets-OtherIntangibleAssetsNetOfAmortizationDetails",
      "http://fonar.com/role/OtherIntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r208",
      "r286",
      "r287"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://fonar.com/role/OtherIntangibleAssets-OtherIntangibleAssetsNetOfAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross other intangible assets",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r287"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://fonar.com/role/OtherIntangibleAssets-OtherIntangibleAssetsNetOfAmortizationDetails",
      "http://fonar.com/role/OtherIntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://fonar.com/role/OtherIntangibleAssets-OtherIntangibleAssetsNetOfAmortizationDetails",
      "http://fonar.com/role/OtherIntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r35"
     ]
    },
    "FONR_GainOnSaleOfEquipmentRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "GainOnSaleOfEquipmentRelatedParty",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on sale of equipment \u2013 related party",
        "label": "GainOnSaleOfEquipmentRelatedParty"
       }
      }
     },
     "auth_ref": []
    },
    "FONR_GainOnSaleOfEquipmentsRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "GainOnSaleOfEquipmentsRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/RelatedPartyTransactionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on sale of equipments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r203",
      "r288",
      "r405",
      "r415",
      "r471",
      "r472"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HealthCareOrganizationRevenueSourcesAxis",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Health Care Organization, Revenue Sources [Axis]",
        "documentation": "Information by major payor source of revenue for health care organizations."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HealthCareOrganizationRevenueSourcesDomain",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major payor source of revenue for health care organizations."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "FONR_HmcaOwnershipSizeOfImperialManagementServicesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "HmcaOwnershipSizeOfImperialManagementServicesPercent",
     "presentation": [
      "http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The ownership interest of Imperial Management Services after reorganization of newly expanded HDM",
        "documentation": "This represents the rate of hmca ownership size of imperial management services percent during period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperations",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/SegmentAndRelatedInformation-SummarizedSegments-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Loss) Income from operations",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r74",
      "r85",
      "r148",
      "r149",
      "r150",
      "r151",
      "r162",
      "r165"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income Before Provision for Income Taxes and Non controlling Interests",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r71",
      "r102",
      "r174",
      "r182",
      "r187",
      "r190",
      "r290",
      "r301",
      "r404"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income From Operations",
        "label": "Income (Loss) from Continuing Operations before Interest Expense, Interest Income, Income Taxes, Noncontrolling Interests, Net",
        "documentation": "Amount of income (loss) from continuing operations, nonoperating income (expense) and income (loss) from equity method investments, before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of interest income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "presentation": [
      "http://fonar.com/role/SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic income per common share",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r101",
      "r103",
      "r133",
      "r146",
      "r148",
      "r149",
      "r150",
      "r151",
      "r158",
      "r163",
      "r164",
      "r264",
      "r289",
      "r493"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r369"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r369"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://fonar.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r233",
      "r235",
      "r236",
      "r237",
      "r241",
      "r245",
      "r246",
      "r247",
      "r318"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Provision for Income Taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r109",
      "r154",
      "r155",
      "r179",
      "r234",
      "r242",
      "r306"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability",
     "crdr": "debit",
     "presentation": [
      "http://fonar.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax expense",
        "documentation": "Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/SupplementalCashFlowInformationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes paid",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r22"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts, medical and management fee receivable(s)",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "FONR_IncreaseDecreaseInCustomerAdvance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "IncreaseDecreaseInCustomerAdvance",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Customer deposits",
        "label": "IncreaseDecreaseInCustomerAdvance"
       }
      }
     },
     "auth_ref": []
    },
    "FONR_IncreaseDecreaseInFinancingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "IncreaseDecreaseInFinancingLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Financing lease liabilities",
        "label": "IncreaseDecreaseInFinancingLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "FONR_IncreaseDecreaseInNotesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "IncreaseDecreaseInNotesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Increase) decrease in operating assets, net:"
       }
      }
     },
     "auth_ref": []
    },
    "FONR_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in operating liabilities, net:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other current liabilities",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToConversionOfPreferredStock",
     "presentation": [
      "http://fonar.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares included upon conversion of Class C Common",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r165"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://fonar.com/role/OtherIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER INTANGIBLE ASSETS",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets",
      "http://fonar.com/role/OtherIntangibleAssets-OtherIntangibleAssetsNetOfAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other intangible assets \u2013 net",
        "verboseLabel": "Other intangible assets-net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r34"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest Expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r105",
      "r131",
      "r177",
      "r272",
      "r370",
      "r424",
      "r499"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/SupplementalCashFlowInformationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest paid",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r137",
      "r138"
     ]
    },
    "FONR_IntersegmentNetRevenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "IntersegmentNetRevenues",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/SegmentAndRelatedInformation-SummarizedSegments-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inter-segment net revenues",
        "documentation": "This represents the amount of intersegment net revenues during period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://fonar.com/role/Inventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_InventoryFinishedGoodsAndWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoodsAndWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 8.0
      },
      "http://fonar.com/role/Inventories-InventoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets",
      "http://fonar.com/role/Inventories-InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories",
        "totalLabel": "Total Inventories",
        "documentation": "Amount before valuation reserves of merchandise or goods held by the entity that are readily available for sale and items held by the entity which are partially complete or in the process of being readied for sale."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/Inventories-InventoriesDetails": {
       "parentTag": "us-gaap_InventoryFinishedGoodsAndWorkInProcess",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fonar.com/role/Inventories-InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Work-in-process",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79"
     ]
    },
    "FONR_InvestorsOwnershipInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "InvestorsOwnershipInterest",
     "presentation": [
      "http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investors ownership interest percentage",
        "documentation": "This represents the rate of investors ownership interest during period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://fonar.com/role/OperatingFinancingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee operating leases liability maturity",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://fonar.com/role/OperatingFinancingLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING &amp; FINANCING LEASES",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r141",
      "r199",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r251",
      "r254",
      "r255",
      "r265",
      "r342",
      "r403",
      "r426",
      "r474",
      "r487",
      "r488"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r98",
      "r299",
      "r415",
      "r460",
      "r468",
      "r485"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r115",
      "r141",
      "r199",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r251",
      "r254",
      "r255",
      "r265",
      "r415",
      "r474",
      "r487",
      "r488"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Long-Term Liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r56",
      "r57",
      "r58",
      "r59",
      "r141",
      "r199",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r251",
      "r254",
      "r255",
      "r265",
      "r474",
      "r487",
      "r488"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserve for self-funded",
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to disability, accident and health insurance insured events that have occurred on or before a particular date (ordinarily, the balance sheet date) and the amount needed to provide for the estimated ultimate cost required to investigate and settle claims relating to insured events that have occurred on or before a particular date (ordinarily, the balance sheet date), whether or not reported to the insurer at that date."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r495"
     ]
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE",
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of long-term debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term debt, less current portion",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "FONR_MagneticResonanceManagementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "MagneticResonanceManagementMember",
     "presentation": [
      "http://fonar.com/role/RelatedPartyTransactionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Magnetic Resonance Management [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "FONR_ManagementAndOtherFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "ManagementAndOtherFees",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management and other fees receivable \u2013 net"
       }
      }
     },
     "auth_ref": []
    },
    "FONR_ManagementAndOtherFeesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "ManagementAndOtherFeesNet",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management and other fees \u2013 net",
        "documentation": "This represents the value of management and other fees net during the period."
       }
      }
     },
     "auth_ref": []
    },
    "FONR_ManagementAndOtherFeesNonRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "ManagementAndOtherFeesNonRelatedParties",
     "crdr": "debit",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management and other fees receivable"
       }
      }
     },
     "auth_ref": []
    },
    "FONR_ManagementAndOtherFeesRelatedMedicalPracticesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "ManagementAndOtherFeesRelatedMedicalPracticesNet",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management and other fees - related medical practices \u2013 net",
        "documentation": "This represents the value of management and other fees related medical practices net during the period."
       }
      }
     },
     "auth_ref": []
    },
    "FONR_ManagementOfDiagnosticImagingCentersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "ManagementOfDiagnosticImagingCentersMember",
     "presentation": [
      "http://fonar.com/role/SegmentAndRelatedInformation-SummarizedSegments-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management Of Diagnostic Imaging Centers [Member]",
        "documentation": "Management of Diagnostic Imaging Centers - Member - Custom element"
       }
      }
     },
     "auth_ref": []
    },
    "FONR_ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails",
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management and other fees receivable \u2013 related medical practices \u2013 net",
        "verboseLabel": "Management and other fees receivable from related medical practices (\"PC's\")"
       }
      }
     },
     "auth_ref": []
    },
    "FONR_MedicalEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "MedicalEquipmentMember",
     "presentation": [
      "http://fonar.com/role/SegmentAndRelatedInformation-SummarizedSegments-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Medical Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "FONR_MedicalReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "MedicalReceivable",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails",
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Medical receivable \u2013 net",
        "verboseLabel": "Medical Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "FONR_MedicareMedicaidMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "MedicareMedicaidMember",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Medicare Medicaid [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non controlling interests",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r97",
      "r141",
      "r199",
      "r213",
      "r215",
      "r216",
      "r217",
      "r220",
      "r221",
      "r265",
      "r298",
      "r345"
     ]
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "crdr": "debit",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Distributions - Non controlling interests",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Financing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Investing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r85"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Operating Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity",
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Income \u2013 Attributable to FONAR",
        "label": "Net Income (Loss) Attributable to Parent",
        "verboseLabel": "Net income",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r85",
      "r104",
      "r113",
      "r126",
      "r127",
      "r130",
      "r141",
      "r146",
      "r148",
      "r149",
      "r150",
      "r151",
      "r154",
      "r155",
      "r162",
      "r174",
      "r182",
      "r187",
      "r190",
      "r199",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r264",
      "r265",
      "r304",
      "r363",
      "r383",
      "r384",
      "r404",
      "r424",
      "r474"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity",
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net Income \u2013 Non controlling Interests",
        "label": "Income - Non controlling interests",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r93",
      "r126",
      "r127",
      "r154",
      "r155",
      "r303",
      "r456"
     ]
    },
    "FONR_NetIncomeLossAvailableToCommonStockholderBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "NetIncomeLossAvailableToCommonStockholderBasic",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic Numerator: Net income available to common stockholders",
        "documentation": "This represents the amount of net income loss available to common stockholder basic during period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://fonar.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Standards",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncompeteAgreementsMember",
     "presentation": [
      "http://fonar.com/role/OtherIntangibleAssets-OtherIntangibleAssetsNetOfAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncompete Agreements [Member]",
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity",
      "http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r227",
      "r462",
      "r463",
      "r464",
      "r500"
     ]
    },
    "FONR_NoteReceivableRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "NoteReceivableRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note receivable \u2013 related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability - current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability \u2013 net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "FONR_OperatingLeasePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "OperatingLeasePaymentsMember",
     "presentation": [
      "http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Payments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use Asset \u2013 operating lease",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization on right-of-use assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest and penalty",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r118",
      "r293",
      "r426"
     ]
    },
    "us-gaap_OtherCostOfOperatingRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCostOfOperatingRevenue",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs related to patient fee revenue",
        "documentation": "Other costs incurred during the reporting period related to other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_OtherDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r37",
      "r76"
     ]
    },
    "FONR_OtherIncomeRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "OtherIncomeRelatedParty",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income \u2013 Related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherInventorySupplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherInventorySupplies",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/Inventories-InventoriesDetails": {
       "parentTag": "us-gaap_InventoryFinishedGoodsAndWorkInProcess",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fonar.com/role/Inventories-InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchased parts, components and supplies",
        "documentation": "Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other liabilities",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r292",
      "r338",
      "r339",
      "r426",
      "r497"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets",
      "http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "totalLabel": "Other Current Liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r415"
     ]
    },
    "FONR_OtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "OtherMember",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherSundryLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other general and administrative expenses",
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r38"
     ]
    },
    "FONR_OwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "OwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent",
     "presentation": [
      "http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The ownership interest of Health Management Corporation of America after reorganization of newly expanded HDM",
        "documentation": "This represents the rate of ownership interest after reorganization for health management corporation of America of newly expanded hdm percent during period."
       }
      }
     },
     "auth_ref": []
    },
    "FONR_OwnershipInterestOfOriginalInvestorsOfHdm": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "OwnershipInterestOfOriginalInvestorsOfHdm",
     "presentation": [
      "http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The ownership interest of the original investors of HDM",
        "documentation": "This represents the rate of ownership interest of original investors of hdm during period."
       }
      }
     },
     "auth_ref": []
    },
    "FONR_PatentsAndCopyrightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "PatentsAndCopyrightsMember",
     "presentation": [
      "http://fonar.com/role/OtherIntangibleAssets-OtherIntangibleAssetsNetOfAmortizationDetails",
      "http://fonar.com/role/OtherIntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents and copyrights",
        "documentation": "Patents and copyrights - Member - Custom elements"
       }
      }
     },
     "auth_ref": []
    },
    "FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "PatientFeeRevenueNetOfContractualAllowancesAndDiscount",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patient Fee Revenue, net of contractual allowances and discounts",
        "documentation": "This represents the amount of patient fee revenue net of contractual allowances and discounts during period."
       }
      }
     },
     "auth_ref": []
    },
    "FONR_PatientFeeRevenueNetOfContractualAllowancesAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "PatientFeeRevenueNetOfContractualAllowancesAndDiscounts",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patient fee revenue \u2013 net of contractual allowances and discounts",
        "documentation": "This represents the amount of patient fee revenue net of contractual allowances and discounts during period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfConvertiblePreferredStock",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of treasury stock",
        "label": "Payments for Repurchase of Convertible Preferred Stock",
        "documentation": "The cash outflow to reacquire preferred stock originally issued and identified as a security that can be exchanged for another type of financial security. This repurchased stock is held in treasury."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_PaymentsOfDividendsMinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDividendsMinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Distributions to non controlling interests",
        "label": "Payments of Ordinary Dividends, Noncontrolling Interest",
        "documentation": "Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of patents",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireProductiveAssets",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/SegmentAndRelatedInformation-SummarizedSegments-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital expenditures",
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r481",
      "r482",
      "r483"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "FONR_PercentageOfConsolidatedNetRevenueFromManagementFees": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "PercentageOfConsolidatedNetRevenueFromManagementFees",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of consolidated net revenue",
        "documentation": "Percentage of consolidated net revenue from management fees."
       }
      }
     },
     "auth_ref": []
    },
    "FONR_PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of net revenue",
        "documentation": "Percentage of PCs net revenue derived from nofault and personal injury protection claims."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets",
      "http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r417",
      "r420",
      "r421",
      "r422",
      "r423",
      "r496",
      "r500"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r222"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r343"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r222"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r343",
      "r361",
      "r500",
      "r501"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock value",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r295",
      "r415"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "FONR_PresentValueDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "PresentValueDiscount",
     "crdr": "debit",
     "presentation": [
      "http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Present value discount",
        "documentation": "This represents the amount of present value discount during period."
       }
      }
     },
     "auth_ref": []
    },
    "FONR_PresentValueDiscountFinancingLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "PresentValueDiscountFinancingLease",
     "crdr": "debit",
     "presentation": [
      "http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Present value discount",
        "documentation": "This represents the amount of present value discount financing lease during period.",
        "label": "PresentValueDiscountFinancingLease"
       }
      }
     },
     "auth_ref": []
    },
    "FONR_ProductSalesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "ProductSalesNet",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product sales \u2013 net",
        "documentation": "This represents the amount of product sales net during period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Income",
        "label": "Net income",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r126",
      "r127",
      "r135",
      "r141",
      "r146",
      "r154",
      "r155",
      "r174",
      "r182",
      "r187",
      "r190",
      "r199",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r249",
      "r252",
      "r253",
      "r264",
      "r265",
      "r290",
      "r302",
      "r323",
      "r363",
      "r383",
      "r384",
      "r404",
      "r413",
      "r414",
      "r425",
      "r456",
      "r474"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment \u2013 net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r291",
      "r300",
      "r415"
     ]
    },
    "FONR_ProvisionForBadDebts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "ProvisionForBadDebts",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for bad debts",
        "documentation": "This represents the amount of provision for bad debts during period."
       }
      }
     },
     "auth_ref": []
    },
    "FONR_PurchaseOfTreasuryStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "PurchaseOfTreasuryStockShares",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of Treasury stock, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivableTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivableTypeDomain",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://fonar.com/role/RelatedPartyTransaction"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTION",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r319",
      "r320",
      "r321",
      "r367",
      "r368",
      "r369",
      "r388",
      "r389"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of borrowings and capital lease obligations",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r232",
      "r491"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r91",
      "r297",
      "r310",
      "r311",
      "r317",
      "r344",
      "r415"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r143",
      "r144",
      "r145",
      "r147",
      "r153",
      "r155",
      "r200",
      "r201",
      "r229",
      "r230",
      "r231",
      "r239",
      "r240",
      "r256",
      "r258",
      "r259",
      "r261",
      "r262",
      "r307",
      "r309",
      "r324",
      "r500"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://fonar.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r398",
      "r401"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://fonar.com/role/SegmentAndRelatedInformation-SummarizedSegments-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Revenues \u2013 Net",
        "label": "Net revenues from external customers",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r141",
      "r175",
      "r176",
      "r181",
      "r185",
      "r186",
      "r192",
      "r194",
      "r195",
      "r199",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r265",
      "r290",
      "r474"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesAndExciseTaxPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesAndExciseTaxPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales tax payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-LongTermAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://fonar.com/role/OtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of other current liabilities",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://fonar.com/role/RelatedPartyTransactionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of financing receivable noncurrent allowance for credit loss",
        "documentation": "Tabular disclosure of allowance for credit loss of financing receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r469"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://fonar.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of earning per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r198"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://fonar.com/role/OtherIntangibleAssets-OtherIntangibleAssetsNetOfAmortizationDetails",
      "http://fonar.com/role/OtherIntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r35",
      "r286"
     ]
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://fonar.com/role/OtherIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of other intangible assets",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://fonar.com/role/InventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of inventories",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r67",
      "r68",
      "r69"
     ]
    },
    "FONR_ScheduleOfPatientFeeRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "ScheduleOfPatientFeeRevenueTableTextBlock",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of patient fee revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://fonar.com/role/SegmentAndRelatedInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of summarized segment financial information",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r30"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_SegmentOperatingActivitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentOperatingActivitiesDomain",
     "presentation": [
      "http://fonar.com/role/SegmentAndRelatedInformation-SummarizedSegments-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operations of an entity including continuing and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://fonar.com/role/SegmentAndRelatedInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT AND RELATED INFORMATION",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r180",
      "r184",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r195"
     ]
    },
    "us-gaap_SelfInsuranceReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SelfInsuranceReserve",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Self-funded health insurance reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "FONR_ServiceAndRepairFeesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "ServiceAndRepairFeesNet",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service and repair fees \u2013 net",
        "documentation": "This represents the amount of service and repair fees net during period."
       }
      }
     },
     "auth_ref": []
    },
    "FONR_ServiceAndRepairFeesRelatedPartiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "ServiceAndRepairFeesRelatedPartiesNet",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service and repair fees - related parties \u2013 net",
        "documentation": "This represents the amount of service and repair fees related parties net during period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r454"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://fonar.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r140"
     ]
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://fonar.com/role/OtherIntangibleAssets-OtherIntangibleAssetsNetOfAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "FONR_StateIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "StateIncomeTaxesPayable",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://fonar.com/role/OtherCurrentLiabilities-OtherCurrentLiabilities-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes payable",
        "documentation": "the value of state income taxes payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets",
      "http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncomeParenthetical",
      "http://fonar.com/role/Cover",
      "http://fonar.com/role/SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r122",
      "r123",
      "r124",
      "r141",
      "r158",
      "r159",
      "r163",
      "r165",
      "r168",
      "r169",
      "r199",
      "r213",
      "r215",
      "r216",
      "r217",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r265",
      "r313",
      "r314",
      "r315",
      "r316",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r343",
      "r364",
      "r385",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r447",
      "r459",
      "r465"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity",
      "http://fonar.com/role/Cover",
      "http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative",
      "http://fonar.com/role/SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r15",
      "r111",
      "r128",
      "r129",
      "r130",
      "r143",
      "r144",
      "r145",
      "r147",
      "r153",
      "r155",
      "r167",
      "r200",
      "r201",
      "r227",
      "r229",
      "r230",
      "r231",
      "r239",
      "r240",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r277",
      "r307",
      "r308",
      "r309",
      "r324",
      "r385"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets",
      "http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity",
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncomeParenthetical",
      "http://fonar.com/role/Cover",
      "http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative",
      "http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails",
      "http://fonar.com/role/SegmentAndRelatedInformation-SummarizedSegments-Details",
      "http://fonar.com/role/SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r167",
      "r285",
      "r312",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r365",
      "r366",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r385",
      "r419"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOperatingActivitiesSegmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOperatingActivitiesSegmentAxis",
     "presentation": [
      "http://fonar.com/role/SegmentAndRelatedInformation-SummarizedSegments-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Activities [Axis]",
        "documentation": "Information by continuing and discontinuing operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets",
      "http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity",
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncomeParenthetical",
      "http://fonar.com/role/Cover",
      "http://fonar.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative",
      "http://fonar.com/role/OperatingFinancingLeases-LeasePaymentsDetails",
      "http://fonar.com/role/SegmentAndRelatedInformation-SummarizedSegments-Details",
      "http://fonar.com/role/SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r167",
      "r285",
      "r312",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r365",
      "r366",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r385",
      "r419"
     ]
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock purchase plan",
        "documentation": "Amount of stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "presentation": [
      "http://fonar.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares cancelled",
        "documentation": "Number of shares that have been repurchased and retired during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r60",
      "r61",
      "r91"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://fonar.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares cancelled",
        "label": "Stock Repurchased and Retired During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r60",
      "r61",
      "r91"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://fonar.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares repurchased",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r60",
      "r61",
      "r91",
      "r316",
      "r385",
      "r393"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://fonar.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of Treasury stock",
        "label": "Number of shares repurchased, value",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r60",
      "r61",
      "r91",
      "r324",
      "r385",
      "r393",
      "r425"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Fonar Corporation\u2019s Stockholders\u2019 Equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r64",
      "r65",
      "r88",
      "r345",
      "r361",
      "r386",
      "r387",
      "r415",
      "r426",
      "r460",
      "r468",
      "r485",
      "r500"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets",
      "http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r49",
      "r111",
      "r112",
      "r129",
      "r143",
      "r144",
      "r145",
      "r147",
      "r153",
      "r200",
      "r201",
      "r227",
      "r229",
      "r230",
      "r231",
      "r239",
      "r240",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r266",
      "r267",
      "r271",
      "r277",
      "r308",
      "r309",
      "r322",
      "r345",
      "r361",
      "r386",
      "r387",
      "r395",
      "r425",
      "r460",
      "r468",
      "r485",
      "r500"
     ]
    },
    "FONR_StoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "StoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims",
     "crdr": "credit",
     "presentation": [
      "http://fonar.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for individual claims",
        "documentation": "This represents the amount of stop loss umbrella policy with 3 rd paryinsurer to limit maximum potential liability for individual claims during year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://fonar.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284"
     ]
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowElementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "FONR_TotalFacilitiesOwnedOrManagedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "TotalFacilitiesOwnedOrManagedTableTextBlock",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future revenue"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury stock, shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, at cost - 4 shares of common stock at December 31, 2023 and 11 shares of common stock at June 30, 2023",
        "label": "Treasury Stock, Value",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r39",
      "r40"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://fonar.com/role/RelatedPartyTransactionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "FONR_UnearnedRevenueOnServiceContractsRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "UnearnedRevenueOnServiceContractsRelatedParty",
     "crdr": "credit",
     "calculation": {
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unearned revenue on service contracts \u2013 related party",
        "documentation": "This represents the amount of unearned revenue on service contracts related party during period."
       }
      }
     },
     "auth_ref": []
    },
    "FONR_WeightedAverageNumberOfDilutedEarningsPerShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "WeightedAverageNumberOfDilutedEarningsPerShare",
     "presentation": [
      "http://fonar.com/role/SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Denominator for Diluted Earnings Per Share",
        "documentation": "Weighted average number of diluted earnings per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncomeParenthetical",
      "http://fonar.com/role/SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Diluted Shares Outstanding - Common Stockholders",
        "verboseLabel": "Diluted Denominator: Weighted average shares outstanding",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r165"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://fonar.com/role/CondensedConsolidatedStatementsOfIncomeParenthetical",
      "http://fonar.com/role/SummaryOfSignificantAccountingPolicies-EarningsPerShare-Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Basic Shares Outstanding",
        "verboseLabel": "Basic Denominator: Weighted average shares outstanding",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r165"
     ]
    },
    "FONR_WorkersCompensationPersonalInjuryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fonar.com/20231231",
     "localname": "WorkersCompensationPersonalInjuryMember",
     "presentation": [
      "http://fonar.com/role/AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Workers Compensation Personal Injury [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://fonar.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "740",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480135/944-740-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "310",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "310",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-29"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-10"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)-(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.13)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//230/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-42"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//310-10/tableOfContent"
  },
  "r468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(cc)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>63
<FILENAME>0000355019-24-000009-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000355019-24-000009-xbrl.zip
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M67CHH@4#Q&_ PZQ90"/T?"S %,-:?Z&YF,B@\3BCTJ>COBI_1@HTK28\+ ?
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MG;I!C'$%3\!Q'MJ*$^ RRVX!YG) N1IP[AQ@>L:4*WN'T1[J@[O9UK8KNV[
M,0,Z),'K=L1^$K6\36C9[D#PD0K\FV$RAP#16D@3P1M$'?2U":]-B1+>-I5?
M4C ?='&+);3'_E>:S&=IALO2A<+?Z[2SR,\BZCM]Z-QY6MYTE5B+EJ.-MMF^
M["\G"9"I=O8RKMV" [[E>_ ,_6TM0282& =S.,(2D7M2 ]OB/$F3I9X]&!P:
M;7N$$9ISA1\Q5A6TW(6FC2Q=M_1L<Y1(;S;4AJ_MQI#F_A17FXR<Y#2!(9:@
MF5O].M9Y>.G:PM4&7#(.)V'-^,CG2#0J8S'R?!5@9W4 FC=1-40@2-".9 CK
M#_W?3*-9SQ!HJ@%^N#5D8MECH-:#+$-#J2KE;:=AH^%L7MI#$@Z1^'OWZ'G]
MA=@ $&>$/Z'?).%^Q=J'*%>#$V6,7VN [W858WS!F2W'S.C\X:%_]3+X)256
MCI<A#DJ0F<PIE6?]BG!X<KO=4GN)<"59(LQ$+<(56X3/Q=>[UGVS?O-22+8(
M5X(5X7SFE.'H+)3E^,5X1_-;)JXU,  :*KHF0WS+88JO.;$-2B\^D&..NB.@
M4.5;Q2#?^^05G2 IMF;->0,>E###7)BAF&R>X8(59CM!/:9N2(_=UFN#HM T
MI1_P[I<)4 0TDPF/5L(ZLC[QR9F@+ U]6MZHS+J,D,(S$URF,3E'*5A#KM9>
MK@'^.=<'4$@@@&,,</ O7)XSY39B*M$,WWD8U<H&=C19B>C<GG4:U4:YW:AU
MCJKY=T?L&\UJ[2'=[Q[(+C_.8\EFS\KH=;G=)1H$U,1&L]RL-,J7!+3ZK?:5
M-69AZPH2&]8*4O&OL*O"U^7S6@A;=_+DO* ]GV%30E\%!WD#QBP$]0V:3S1*
M58*Z,X]C="*X2GV$>UQ72%CX1A9VH")/##44HOP7WR/1CI&#E@F6D8>QD+4)
M_ 0&0E!LT=M1[0V!I,,X&/Z%Q18WCYWQ,IIL"X,] " C<D05".:P7'NV$O'U
M5N$G(@R[Q;]Q:]_/B0((AK0G+UE[6FP.\A%R<4^:,6%HT"'LIV-C_Y(.J@,"
M3=88@7D+?A>""(@KL\^YAN>)K4L'DHC5;^EEF3E&"6&3)B%,,B6D([U_2ODH
M)DT^\@F1CPI>_]51>Z.YU)$:DU,N:<)22+RP?%:[4DJ:J+!)$15>'Q)U67W3
M/[V,4&32A*08OI T50,^QU )#VEQS2J/G=%4W)F^@\M<^%S&-0+Z&[$X9V7>
M[525=&%BSK-%6EU6>'FJ2]@V+'B/A,/<RX:N:0-](IOFPSHY"DK,,0H":M1)
MD""4(A($YAL:]8Z6E7B\V1?Q%'XAVY^12,@J.BQ#)\I]=6)8W8-$6]*?5UM
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MWY>$'T03V@T3^Z:*$&67;_INWX5^033[YSLD@0LQ-, _Y_IX'NH),<:DW)$
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M'PPA&IW#QWI,GHTWH+';;+YC4IU^^?+/>/W-WQ5$#'D; "->>Y3@6TCG2P6
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M\,IV[)_5[X0JFAJ&-OCGKH0$4".1URB1?.+"5$0J09-LCR6Q5<R.K2BG#5?
M9LYCSV9.ZY8-B:SL+CDK-^NKLH!A%$*J_^^\;":FLEDD5OMFTN_KS6;=[JX
MH6092RB16II+T&%9T3.Q??[\\)C*-H6)U%K$3]B$0CE+/S59P%))79,)GD?C
MC.MHG)PR^670UBSAIHY.4TDN3M,+I?6$L@<^@URZ(G<*UNKAMF/+W+:[6]I[
MGR=*;YM^<!=S5BU<L;FL#P7]EA8OT\R\V'CH\'!"]*H"_]JK7W8@&;[OXXY.
MT_0RW^?XO(FE)[E\^@]("Z2!G]T<[1X+ZACU><._0 )\]FNE!^'C\?EF4+M+
M3;:Z,G58V^RV/65RT;J6[NU.'!<.G\PN"?4]V&!EU, 'T(JUT_/8)']U\G1)
M!R?U3K5%\BE5$4P\V<)A:R26FDY<,\'K:9:K!!Z36A%+__$*>RTS-0UYR4>9
M/SX>M"RH>_A?$R)E.'*L[2K$[6%%"$5EYJ3,5'A3D SK@,PZ*HMY'Y51TZ,R
MRYBT15&AAHA\IEEU$7RP)N#<5NI= F'HB2"KO QN"_XB#O%IO(4Y@F\>0DS5
MD8:R: 4Y1)RE@>MH3E(LY4)U1K-&GFG9-JM8Y-R4@?1F $PZOB4?RV$+A"S"
M+W"_ZF+/E*UG-(X?3Z@<H1'>+X](K#:B!+QJ@^$?MM0!=ZPR$(9Q\P1T5=50
M;+A;,H6#J(?WDCS6;@>8=PIA-[&9NCLA1"XX)2_O$TH(A^SZEZ38V>)4X>.$
M=%[ O;9VZ1=NI&1-F,#$TI(@\)T03EBM^QW-! /UFQR.2J#6&*F*'3 +O#8B
M]/"Q+B]IN,L3J7=MOLTSX82:PAW )TW9L/84:=6E#VH 8MS7[7BY""] VSDY
M(0'"P7+A'CCOEDC%#_&_L7@9L[,8Y\E&GS=@W2.@@2 Q$COEO&XN/D>*W %Z
M\@2EA>J:&AEDZ]KA.$6NQZ$\6570J0[$/'5@5B+P<2)\UV&)L]NV%;2]L$[E
M% 58#F()V3?8:&4BO)= N@S?0T%%>2$L8C,6BV(+EC>7?B3VS[0NL5,]66W#
MDT@B-@ 7!F)0J-U7BL=,%F/?6(<GMU$,4VM#!(I6![?$A!\TS.J-D;?&X8>(
ML5'(OL,;@)@7T=Y1$39>'4CP.:OX2X)LX0U<)I:A>5)0QUTRM=B[JKW OG3$
M."5+8 _ C()-F<H*&E2)&"F4K3=1,9$!0TWM2H8U=M8:!3<M)4_*VI9/=SPH
MEL>Q!0-E4U0@(J#L)<8PQ- =,PCJ#P[<G2'@+4+^#6_E6W7S>8X2$<;\T]$'
M6=5U)!*;16SF.'AQI&8"PJ=0;ZIL#@BS8_R;*H%1AU?A30:I"QH+GE^0=,V<
MG)^XJ^6SZQK ;I.@P^!?T*KC&BQC:ED.X)E&>"J8VM0*6_8+]SMF5<OPZ "8
MH3LOFPC)FZ29SC["BC!;PH\+((D*<FVBZWU@G:CT;.%P2U"7)Y><W"<8DQ ;
M]E\68I; $%FS;3XX&1E/77MX=$!L&SA9>_O D()9 V_3M2P&.#4PVF#(7!Q'
MTV.W,.AH#O#EKA./2<$ HU)),8&^V!)5F3GM@3?)$K!5MYPI&:F/QT/D;E<7
MIWZ +,.&"&+;L$<\P!^(S5>$."494WKM!=E$P%Y,*>RIR#-0C7=>$T(V2?_,
MG/F>!G $W)A*>F[B^F_ 5W3 :G@>^V;FCWT3KC1\O<>UQBFU<L'>ISA&[?IP
MU+N E>3\EZ6.YT]^Z=98/&N\/F7-_O5MXNB4:MQ=7^?J?_%\MU$YJU;*E4*N
MVJ1RA4+MKMJL5,]B-[6K2H$TA_A\Y+N.%/B_ZX5)/  B3K9GY+W7F=F]3KI+
M+LL>TAHG](^\>IMZXA]??#G,G]M$#C:Q<'O7$6]J2D9,(IKU)%I%>^&F;0_.
MZ9<$#AXYS1KQG), &':*1'II@#%V_]/TO"1.SH@'_+-5KB6I25^%4/\8DW.!
MTLTV!-,2CQCNY*^0(!EVUDZ"<G VY%1>'L7P978&[8H4(4G^C5Y$GG&K)&BQ
M4[<IA<0;:;RB\W9"- W/P=8/8*5V[M%Q;W#(5AGT4217ED2W<K")9&O<SZ5N
MS/[#)7TI!V?7K*X\%Q5S-"WKJF06=55.EY%NC=-<SSR_Z#4+U?1D&7[U6TY?
ME&F-_]X^&WW)>!,SF1E^1:,3D]FH$W.Z,+!-M3O#[+S<)LY3TI2#7^C1G)&R
MC^=ZM\N6!IV_TT%:6W9O+I,C]UL3K?'U=:IP\?AP5;WPPZ*O5+1U*2NWQO=I
M1KP_[W5&%UG?*=NL<71=HIG6^*TK#;J/]$-&>@Z,Z&U[2M==1JXUONF>-U]H
M>GA5\C^26Z\-=5UBN=:XG:HE6;K[>'_KOPC[U+FZ[FI2$/_\+68R9\G7GIH.
M;C6SS:YSU"TF#VQ[^<*L#C*:E'OCHV0O0 RTA\OWVD6]VSOSPUY,$XW5B03E
M)!+4+U!$^,V=-V,74@_.N=/CRI?<4[WM3Y?L8@X&GWW6K4)27>RH$!DN3T92
M3'8N&4G/3*%<\:36F&>-]\[U^9A.^F%P/V<D(/*IY,5?6LY>7>:Z1Z<V2?I^
MIQ]VK0\+50YG,<]0!%[#0#R6:Q0HCN8HU31DK"A1/(3Y2D^V&EXUL8_5*8CA
M!ZH@RJ2P;3]I;-77K:?S.IY_DO(U1EBNZ9MQ2A"[I*L)SV2L'E<L&I*2#Q_K
M.)"*/%9J5 &2'+"J3M,E226L,7&3\ICS!7B<:,\;L \KK%,#.RM"NZS#SWI7
MPB,!9,5DV;RLJ\ZIB1Z;=-<(DMZ15=W4R)E*CR<G,YYU<R^F#NTJB>4W7)G2
MLRGT[*Q.' QE=32MQPLB&&F2%6'C,:1W]H._3>6\9FJ3:K/K%$H395(%5BE%
M!$<*R\<SVJXHZA9=DW9D4EY\@^05G"]$W"-L0K*26/(5<M(QT$49BXC64; C
M8,1I6]56+%DND$X4DQBIA)+!.^XSZJD06H+GO/*$<@P#D3$4 8U(S[0M:TAN
M&UNE4M>[EK\G-B>QM254H[Q[D8J/F')Y\C!*?4,-F]#5I60L'1N@/)2J #7\
MZ"36M(NXR#R3G,Q9)Y56H<"JT-HLB"-O!XA6T>&M"CTJE*2\J3)IZX"44!..
ML= PLC:-^G6-E68@+TY9/TE"W#XMQ+(N;$+?.K(?RKQBS_-5!Z#FI"XB*:"4
MA E6P4$2"0GVU!'[.VJW*UJW!C12[<:-L!\Z_;YC,?3?D\*YJUP1&VJ$C9/3
M0H>O$[0W9+ @#O&P"P36'*J6'J,6ZS.8<),%D_<X:_Z-UDT1>ZHAD4((X>JO
MK_#AM_7^>8;;9QO.M&1>TW#5EA&R3Z[GO^&L.C99];LXD5=;!RR]=:O?:(@W
M_%'8AF('5-YY)=!N.'&Q6]I J"=F&+9"<XXY)E(;<UZ)Y$P>UB9]BX3?>&AA
MFTWXE49.T3 4]]('HB8ZJ4VA,1'%8WCJL?UGZ[LG[BX1^_R T %F2Q+?]<GA
MAJ,7.$W>/H8'4CMD:>K$^]@'>M-K*^90X.WKOS+_KMN'1DX;P/3\IJN1\H1!
MV0(:0Q5S"<8,#9:\64?0Y'0#S>3$M6JB(V*3-^"OWD%+O]WYAW,?"CQTV_:C
MNA4YND-/-CT7>I8\KKI]?D1K?)GHO'/:E2R+B0#K@7.!:+XU[G?/"_V'\5M7
MZQ^=3FZR%6K7><CX [F[MMLXX0'"3*(&KR#>)'":.CKGJ#/6F6Z0N\\%YTH;
MMIF#.%4TR-&@$]Y1)M$])VA%HPY6CR?WN(C:8-1)SA%)J=VZ:\5W[(X:1SM=
M&,,Q^ P(L( &#OXD:=:G=2L*1&6G2)?*&Y9IP;R<.<_G)V?"G[X@Z4 W#L?&
MQUHF!XL,UH6NF<#6'1+'B%NWVL2-A<]V$3/YS.I54O8J3W V"R0#X M,[(G&
MHV?L=K2M(+)#$:P/#R=1#FR.:;.8O-CSA1XOLUGZ:0UQ\M[)*\D^2PJ>6&,;
M<FQR1&Z%WF;[&1MRR:9CYH&B<4+E,+.Q+&;<':O9?"?R8\5'<3MLM)MZS"$^
M"L,DTN<R.?!V$1FSB'QWHL&9OB?;=:[+@DE?&3P(R!VJ5ML01#?P?7R8(Z\G
MU)T=?F"+',1"NOMBY*=5X5^ZDM5#X4HZG"],!62>4%7SHM-F$C9%H%YBT"1I
M.K9]8?N%V=9M;^;FQ$RXC#PUM=E!&*[S+[S[J."#P_)8(?NM$J_A7#6\XM?
M&N*2NDDB,>>\&'??_/+GM,9WDFA4GY]KCP'4=Q=ZL&1KK!:KXO7'ZTWUIG-T
MZE")<Y@H0N<W\U_8D=NA1&>9T]+P+_L\M733<,Y28V#M,7XW24?S-+ E73PB
MS@-"\P"*A4<\BDE:[T =[%(T<0B# :GBP 9;)H_\)+H&7ZFF0<)LH";N> ?W
MUTYBE<\=LE@*,E0(Z"F6HX\9.NX<!M_PV,4J#:V>R@:V/-G&P'8<S7?UN""#
M:4#WVU<%>ZFSW3Y6?YS[TS'KTU;YAI<[)"B&-[0)-RW]=_&2>)KA4);LYTC$
M-^*4,?B%_2@\6G8]29!DTSIQGGN6D^Q MBB*=LEF56OHY-3BVY1GBC9[0#K1
M66(G@!5]#%6$H,2<DW 0?=S$\8D?F(YB,*#9_'<\#[;\6I]_PSAK(B:DF6Y&
M:BVQMX7>D76K\Y$B2;A;8(G@QUPB_;G68C726JGP%AL:GP@*<L)N?9Z\V[[]
M%K-[,O1/UU;<DT')<%3T8;Q<(,\@YD[/&=;5?NQ4:ZJ%"=O(, TWGLOT:ER"
MH>VK<0F&G#@^%(7B=36GO8^ER964AG- 93?Z$DLRNRN68A8HBYQY8YVEN6"H
MGUSLLZFOM5^+9[F^D<_Z27PF$.+9">M9BWBEQ#88H_&0_9#]I#X=#/73.Y46
M]6;^_/Z,33Q=72>_1/W2.VQ?I'_!+&>&MJY#^C*,T*)HYHI39C?+\GE$M<?"
MLKM8&#O9+U\&#'Y>%DOO9EF^#JSV6!9S=,JP7A<IM_B%'5A[_)<30Z[4]9,5
MG7*EUCCS<=-1Z/=B@Q.BU!T F0?/7%^TJ\^#4LW_;B)?>OC8U3U\P&"Q+"JI
M>[&6O$T%V,.7:XU9M3$L*.W[^[M4!'OXV"U[^-C6N%1[8U3N[$GZ$'WNX:-Q
MV)EQ>9GX:/:[0E@]?)G6>$1?W%25?++'!"C;FVM=MC7.WUTE'Z]NT@-Y7WKX
MN-8XU3!NZF--YC/2WO;P >^U%,.I\L-'3_>CI2C('KY":WR;N=&*S^F7<;ZS
M[SU\X&Q2_5&*^] EA@N.]=OV\)5;XVR)&^C79V*M'6 _^U;VXDVM<V]WY6%5
M;@=_@RB$QCZ0[&>ZTQ;-<N9)BQ2S00SJY5OVZE&EC6: K9PDN9V4>HF[<_YG
M4O8%[MI7](3?KA+P_%+V]F*6:P+-7&&>5(ASBF"7W)HD$?$J]Z=3P$J2IX !
MD&5[5/K_.Z*/R+^!9QWGWY.">]9]GKTE#78!84SWA^*0SM3O96RS- ? T1%Y
MS;]4<=(@MYE*'5.?#P#@E[^*./!,UG][R.2J?;8C8;R^Q ]U".6<G_Y0[Y)@
M]/$I]'^.+-B+I7@4+MB)"3_S^=98.3.2JCR\!(\QH4^0]*',C_[%"5KP)F>,
MO14!3_]-AOI_DD%KHKVS.YATV><%T[)T!-'C#\0<B-EK8B;@-^M: 8^GSL_S
MWA(K"6P4NKS_=\0PRU/Z!8!'#AE-<L8Q<[;QW[;VS^GG$X[](96-[FXEOL8!
MU>#E71-AE?4H4N+<.2TSI49;'")!V6&K-MRJ];1U,_A"JY<B@H[D0,R!F+TF
M9GMM78#/9V=:2?H_GC#MF%?S!G[?,AP(86PWXO!OD/A-I_9,.T/L7HOYA=EO
M8O\S3;)\!79S<D;/A4PQWB8G]QEV.JD4EE4AJ[I2=3WG+ P/&<GQXW15Q+ M
M:_!@D_SCW_?*\RT_G:5M=9:Y>+D!%U><&WEQ@)OCP%)\.C+0=+/EAW',/S?4
MF&41M3R=RJZ$I7-)P1?1!R,GKX4 Y'7SD;NN5TPF<6?JM;\W@VSV^?EGR_QD
MQ.\G)OFK#0G4AM0: )S?6!OH<+2!A,^U+GF(IR:0#Q0<5?@KYGJ-Q)MQ7SRH
M@EL5W%SR5Q>21Z<_VRWX$<9\:I8L%@;IQX=;I?>6_%%R['/WV[RPIHY.6<B7
MO<:Q_QAY304@K[Z$,<*]VGB]_6N63&XB\^Y*#NE$^)%*$%9<PZ%ZT-GT3U:/
M4CCJL6%<<S^X3#<_DAQ?[/QL?Q!:7).&&#\9N"($4OTMBCCQ7"%"$<$:VH&8
M S%[38QO1>#3A_F[JLX-U>E%O57G5[YXR749N.&C'!<Q=V6+=75:.1S(60RH
MDKNZX!<)'VI3-JPL_)K/K[UV]_Y<D-IS'M)M#JDU.+[J>LQ&)._F3A:;.3KE
MXLF$5R1G=PRN(57KR\4W$,IL $+I2UITF]!3#9UIL@RS?X(=5.;B(?+9@\AO
M*/*)<$1^PU0G)XB%[O!*X:KSJ<[^R;M_Z<EG@4_0D*%D$@=Q7U?<<SZ(^Z="
M+81U79&YR5=NV,A+:^!7B^&)8(-3[,$&KRV4Z0"$TI>P@WT=-]_XU/GYV_Q)
MVAX(=GAA1X(]B/R&(D^'(_(;AAV5U%\E4^>5?*:[]_(>:-B1"#[L"*XGUCW%
MRCV?:$=J]K_!:%AA=B:.78%'X2E,( 9K$WB_&[L 3_;:@@7WK+!</@BWC[W&
ME?":F-.0!4Q=8\[()J3Y6DIQ(WC3L\< -QY"GSPZI4]2"V':]]/(!R1]=!#2
MYTM,,TP+K/G:O1L_SZ>649+@+P<O&\IVBLBV5S/;0;9W)=L;!B^]]N/M=>.Y
M8-[/=SU'6+"WB%(VE&P.)9OA#I*]AF07_9#L3^41L7+^K!38ETIA/JK>H6!N
M6P?94/K2*'V>/00'Z9N7OGP0TN=+S#!HG*>[3#?-T-D(2W#8,4.&R+97'^5!
MMG<EVQO&#.DR>_/:[PW?1O/GBA$6[.!CABQ*-NW5T1Z%^L9\ XD]AB:"33('
M8@[$[#4Q@;=FVE=Z-^@!BQ!W B-FBR8%VPA^*J 'W9G##D>/UX\O]0=U6A!U
MX !".C18M/2H=><DZ0V[<R(B?6NT*OHC?1L&;\.F.=;^7KR_7'X/T0ORQ"K)
M;'1BM4<N*C0U2/FB!H'DYQFYE]/KF6Y]W-\+3=AAKT)RTUZ%B$B?/R& _QGT
M:S_Y6'J_S\OWG6\A>H$:X<W:!D+*GQ>_SH*W,"2\0N>,\/K:/+&@7(0' =M7
MUE91O\D$M(T[B18\9X%5X*87-5V;9<GP*APH7SR/^@B1?^GZL=INN^XK+Q";
MI1<EO>F/7 R?7(2PLE9E[*?()>NO7&[HDXP7YL4L/3Y?]KFUA)(0;R_^6!<[
MQ]+'<5\2!!$6".MAI8^V)C-TED&.9<!S_IF'Q=GAKA]LZ0YL:2!1O/;4TV_>
M'RYN'U["LZ6[#,53!UNZWJ4\/^5RTZZ:QY=^H]OXN,RM)Y3KVM)4<+8TB*+U
M8FM+AOVZ4QV"^^G@@'Z&\OWZN6[@%C^:)]-!MN,7ISJV/,F<A\((.K[.WU05
MKJLT\L8TO?:6N D&[R>(C*6N8K/E1BX<YT@UA_MFC9M!BGHI'%'?T,UHCSGE
M_;7Z]%',[*V<!UHZ2D?[HNO!)_FNJ*P/BAI(GG)Y5N%N.[)QW6$BJZN[3&O(
MW!'NNUTF^ :BOJ%/HB_RN<[UM<:F>GLKYX'ZI&R4;T$NZ!(,[O+C#W6! 34,
M)UWGG?.:8&]EP!?E/F0ND7OD[A][Z4\GFY6I$#G36=?I#EZPD$A>B4O1Y$K<
MX>K&IM/<_)#6#3U5OJPGSMYDH:1^[O^(@*@&WK">8B)^R>W@&_S4-F83;0MF
M,$SNHG>=3#SV._(N%&[75Y]2[.'JTU83YOR0U@U]PRTOB,EZ/6%DQ2B*:O"^
M(1':9:9_"-SV:<P?Y''G#<Y[$&H\/$SS]9##/Y&R$[QM#^<9,:3=AO2Q'SB[
M:Q)Z0-D-D@@WX,?.:3F@['Z7K3J@[!Z(.1"S+\0<4'87)EV[P6FDT[.C )-W
MS=OS=/_NX^IGP=,ECNDT9'2&ZA=TPQSJ4"IY=)J.9SQ[>CSE[#LB</F"LSLG
ML;Y4OO37O]GJX_W5/?NS0+ALJ0^^R6U>&U*H#8GTC]:&<CC:L&%E+5&_;F=2
MY_3KBWQ0A3#PZ%(<7ACXT9K ^8',.-$$>T"A5A@]J[F_U=1KYD<),CL1Y""
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M@PC_[Y]'XX^79EE@PL.'W&4(SQWP(<,7RTWQWY.-KIF]$FMO*1_Q(1F\$7O
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M1:Z1N[Y7;QN9KO]PY+Y/@!YUSN&!V4ZC'2#H?#@3H+,@]>K;\R/WT)&>(C<
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MQ/)'B'O4%J<L3NBVJLA405D5;J'$R9"XVI/Z3C;GW7UJ#EK9^XMT2_*!S+)
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MMG.O10X6NZO9K4_E5":_O@XO&\SN]A):KA7<D+7#_GV]V#ZNF1N+(%FG^U3
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M?GQ10\/5=2U_!WXXUNU ]QY=>'.]SP9T<$JZY PTB6TB6L%K:LI(=_0K_L!
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M?#OLBT-#&V\KB@XF6&8RH2@=O6V8^L#R/1U%S Y2)'DZ+%//"4G_&7K+@,>
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M2Y-$&QV%Z4Z;^Q:H<Y@]?)&XQ&1T;U*NHU1J?3O^_; ?YA,J3L2(9RXY6="
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M-W7&VJ'<U.+F9M8,%:9(HSVYM)'()7330,!,W<"*%L.5[>$:H0HG(?X'G[<
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M'P)C-6?);Z[5.B.! A8(;%AV5^;7*< LED232Q(%NL7DE$H)\*ZH=8-I.>
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M$.$,>M86I7WLH&T1:X06,&I#2B5B3Y6D3609/\[\(+%K+!\9[6PU^9V\\8V
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M[>;+V?\D=S6S*?DK8I _R2FH*7GZ<)CYC7&E/;J$G&('@NP>?!S'8 4>*_'
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MU.\Q[H8W*WG)*!"6EE+ZK*0$%5\,1<HQHD,@5@JU^88;&#RV''?9==-S'+C
MWNZ:#IWF3#I^FO/4P0R!L4Q=GF$BPL3#N^PE66$O):&0QDWU;<QT'-D,9L=M
MC!IC(P%7LY3DKDR067A3-A4\@RZ:U%"3 ; DSF46[\)B!IF+V<8.C'_[/ 77
M)?7J0\>[U\6P;B#\?YG&8R5XF,?CT IJ1Z8PC$5A)PH?MVVK"0:8L#<]S'5;
M++G(_A9EV/C?4G(Z(OLC##W\I6EA.H,9!5T%X<'Z-$D9::@RTI4R0E18)B49
M28U<]- 6S.2,[4SA@_61/ITIF/RG:#DN8?R\C>O!$\^659E%E*GD\BE$"(/C
M257B'_ +%!DJ_L?_HWZ'QXSX?S[NZ/M31RU0;BG:!I0 ,"GIID8S5WQ)&_H2
M6RF&3["(EX';74H^5";?&(:!+R 3&%0W0=!C'0-Y60#55@KKK6D[O/2U5X?A
M!%JT7K%%0@NVT>AU$+-BF;SG;:?3<VW614;$;>EE,J26+%/,O1$5"9%<P4.U
MZ/<C,L7XAD!> B]*HE B A82&:+A=F]P2B/<2J6\&$/F5!",)CI2(EH-.A8!
M[_W*2!C8,FJ1!.[HNY1SIT:3*)S1B4T]]V2PBF_8;XYYE)G988S#](/ BCVB
M_*HQ@M+D5.>8:T7A87%D XDO>8-;58[H+X^B025?#&R,S 6*D1(JXO-HD?A$
MTJ./%QX&0D".%)Y@QW\&O0YR5 ZX0+&'<SY )J]:8'1XHU&![D(>=+MIL[,_
M=*[Q*?+->Y@1"UAZNR?JZG"Z;]K&V(M8WXBR%WN \<M6QXM$/Q02J5T(,,H;
MOG6OR/^F@^)Z@A(/@1-49M(/T/+RF@RIXQ)K@[)4";@= <.@&Q,9*;% DWA$
M>"-B1*+%NKER\@<\]>+8.7W-H%-+G$$^/W$&Z#5PA?L2AN<I7]#9%U+<09EQ
MM&]7T)\90L^EWVD(/9?^$T)_-2'TE566K/T8#_O$&>D3GU4OKO1:C1GAF?_T
MTZLO!Q=Z[>3P].*8%FFUEQ8C)&A8C@.CP_K<_]M*;]'/703K\)]'AC)M#(^V
M&;;QH^F__].Y[D$>;:,;P($3_]KZ! /PQ=,QO(PQ;S%@$+8M?I)"4WPH<9<=
M<)FV&?L.O#-3^%LL_YSC'MZUH;AD1F[:$5C7#G/O+5RDX%\]?B%+0U0AJ\7$
M.2L_%C%O(XQL0WYU"X?WFU*)+;,@.G/BAFI$P/J3;O+PM\1=S;YX:75#;D/+
MHA4^P?_]$YKX/SYLR3\D%)_>P[G,#NUP56XQQI*Q,S:2UL+UXRK14]$B(H@,
M= $@X-%9A&STZ@AF1FN'PZL)]<^!#F1BJ=A'> "#O*+-I/@/=0O<NS<3*,L@
MO3A#!5W$LED7#-UTS#LKQEI>XXJ,M+T>(E)4,EJ>BRB7"$.THY\F?%[TOA1I
M,MXJ5@$<:3$ )(U"\E^SL@OL3Y!(8XF#% R1J9%VGA'A)'-[[0<>?N_Y#)M(
M0H20)^W*X\#ED%=@<+:I1_Q4SV56.&O<(WN"UOLJ3E/.F_-0L@!'Q%,0X<U$
MK2 "-9LL32D$G2CJL=D/3$6J-L[O;=0][OM3W,=BU,XBO\M37V3+$^-S@% ?
MUVH9K.47!^ (ST/YFF2]3$@8VTK&F7/"OYDCDE76GU:X%FVFZ%6C\>,2?1"3
ME:9O!"'O81%5.,IEIZMAW ZR=/:A95*N^(*E-X=ZA$L6=Y)R#10<$AN&-G\A
M@3=#+$H+U6VWQ1@%QR+N8,]WAQZNBAG/MV#T4?:V1U A8<&B\\EC.3$U:G0H
M[Z4\1<FXIN(<;5*X7=P(SH) 9P4K,\S1=W/.5EHK:A0D!L_65Y!^4\E9C/E;
M$!!Z?@L.=H.SED<4CY)17/ VT@BXIF+M2)2GQ [$CK;'4\MB&&)8P5 ?"I\K
MWB2-A4"UL(VLB!R]%S]T7".+,E(E>8^A3<K:QS8P0IE3Z):*+>");;MN\V./
M$.HW<V3!BMJ/$)2(J+^,6IL+ F3+U))6GC2G(36B1#/P0(Z @\3[I7_'_13W
M#]V2HC:318GA!]%5,<+(:XR<DV,]>1-!@J4S;D+Y]!CZ(E%JF,!0_2,;+OK1
MF/E@#\?*1O9\I4( 9R+N$Z/5POAT2+>88_*7"(@*FS&:K_*Z8D"2T.FGN&3R
M/7D[*<0\ :][V"6!!>+V1/4 <BL=DU'9U'#)._R0,<5.'Q+W/ &"Q4,03TW2
M%:<%;M$ICT?5.#HJ)2#">'*Q0J(!AS\585RT"$=%I;1@A9C>CGZ)=<6BV %;
M/#!!XWDA_3,'(!U@(1;(&RR)C5($K_L"*@:4&LN5MK'&O*O*GRP@0IGQ7*>O
M-;A]S6X2Y/94YLN0[!92*A"4F'J?#[$K?XCAFS_J,0[@KH=F%GEMLK"D __"
M[!,(X8--Q24RL:%21AEQ'#\?-#*QXH79:'MPSF)$W"S10(E+FY5.P\\>N0QX
M:@5.#3:KT:;L@G)S:?2]:(S2QI.TL+#O[!YKW*>(##:EW[L66R'AC8#;V09-
MCB6)E-U"_G./[YTHER1+EK6%%Y3&8)$]DJ>]70>/E-ZZJOJVE1W& BIT5K/?
MH/+-"ZH(!XMIASD#S!T9MH%X>3/#G?/F8HPO%OY(9;/BIQ1;66QOA1$"O\7J
MO%D2>=3PX%5,2H75*""?I(LQ#>BL\)&-6&=<>$PNZ*T]%[0V?(ORFY(H6<6R
M@87MFTSD+$EYKV#_)6F]QDGKQ=CE0!\M,5:P4@4G_0SO8C1OGK@1XE5F$>MQ
MV^JS&>( ,(\GX'5LVNI92*FMY0)^X0AR#&&3/JK7$"I6I6>NFLZ'Y[ZUBZ>X
MHY\A/W>/+;Q(J7V)<*M[:%;N:*>N[&*@T.X)C:6 76.%=LSD'43F(@(X.4L&
M)T[UASYD!ZK_(.Q*+0ZF%9*VHXY4/#!0D2"LE$H4-K+/.2B#:,/4K1C,@(:6
M= )#I/+#I+'@B(A>Q<X<>;#<=G:(]47$<R3.1;):8]$;^M^<*2(JBHP-4G#$
MX9,9HIJ8RN%9?;6TD)F8L;K.:=N0FKX'T?F,C2GV(;3F4.Q^>OX]JC<10F%'
M;-BP%94V;(T8(47DY*(A*MHIC5-VPS5Z&J\ZXL6J4E'Q: G3.?%I64^P??'L
MHM 3')^ :! ,*Q ^8*PB3J&=P<UM25HN5Y*WA)(381B Y'8GK$Q62O-;T2HS
M9"PS[S5CF?F3L5R1.*X_$;E2BKNM3Z4=%GI 777(M&4_[DG"9:'QHM&FEWC5
M2;5E!Q2F<1*NFR1;4#0P8A]F!3_28N-JG[A/-&H7V>T)C*#C-:*+8*B>>,+X
M=O3/OM?KDN'A&Z;->U; 8JGL2:!>*0R(T3#LN-)@4$1VMV$"2E)SQ2X*YHX]
MJEA.2XY *?GG- N10:3XP6]&F9=WP'FW6[S&1]^+6G761-)".^,Y#?"<6)5+
MY$Q'7+MJ,\:AXBA1<272(5:GZWA]2[#))#@!Z*WB-\'1)P"IJ9' ";N/8'U1
MT@7A^R+M@H:?B)+&[$?J+M-1"[68(ZY6[\BBZ43 ,;IX8 7TT/'BP2Z6"+)-
M\7YJO!-R4B3L9^+P-.'0V$-AUF'F5CZ$C$DX;<CD%;3M)E$:42=+K6,_J3V5
MN<D62;M86OHT;9^:DV*_I#*ID4;%T>K+Q8[V(6K2JHWIS"9XDN(VT.BK>J[H
M]HV8A%B' )_^R+MW\ZFE1']EZDB$E89HA6LJ\:'BQH&;(_J;N=XC#VIXQ)MG
M<GRGB(Q$J3CF*(C4GR!4XWZB&8_Y,@X4 ZLBK;Z(>E/[6T/6I^_H>_'FM99R
MKM3NJ?349.E5FZ6.R!;&XQE'7 0%1BENLVYB$Z1,. _T^"A#B507#1'/BP1_
MS'E4'H[",/0LKMXG21-H&B00B"SCV.,9!Q!)_$C6E+8JI?01UO@#: N'IB!<
ML5@0E)6JTEZD%/8!$FH1-<44/AOY&%'ER2&=M[ME'04>: 8QOT@"1$2Y9#SP
M+]*;*66(LK@SQ3V*A.;L;^;.J<!1X>DF.F2,<%)!TW!O4Y-7D'YD/.[HIRX6
M X+89?,")2[\TL]TG$"R+F"1]ZU+C-L%NJA# ,&\PJ*3"W8'5!LA,W7J> %T
M* <7/%I6EQ*!D9#QA\O* /!W829DT#O&XUO9CR' 3IKPQT&T'WA+:B-9?09H
MXJN?8,DI5N0'2DRS$PL6I;"\Y"_8E?:1:7Q*L/;<+BH^W![&:**-!62(6FTL
MRF6Q 4%'I.(FF"W1<(A>,&0H ZI\?AM;N/4ID]Z1&7Y*E82,*P\T5Z//^;UD
MU83&P4U])L887*94"*'!^VP?0)%;/EZ8S9&GXI?4[N"TPNP^B]J..CR$@E'R
M #8,-!U7;Q2#26D]C-#*@4BT3(.,Q[,O-;7XYDOMK%IEL\ D.&+6J8$MAH*5
M*<JG*0-C936\0HJJT2PQ)>U+[>I@[PM3![4FE8: #<L"E-%*&%WL22=Z.XV^
M#)<C%5L+OE2NR0AE60<:)ZKKY6Q1H=7R>5T]%9$9H4$?#BU^O%@MD!5BX3AE
MMF2M/2L"8,5%R&B+K- MK!B&3>S7\<X1ZQJ&K%U@_.)17#0M\:Y1[Z:H9Z%H
M<M:DKH(-GDZ*(?Z)IYQN/8G_M\PW<\QJ2NE1)&T(_4M(QVHJO(;77'#""[ @
M"5@1A1<=N\G7'G^)$)&H6:,E&)2B;[!J"HM=H"&Z&;*PC?FXRI<U%G%G_&D@
M!NHN2ZXD.=3 ZX)V#&W%;U<*HE%(F#.-AKI/Z<TV2!ASYBS?APLA"-48,VIE
MK/O0>!I(/=<"6L#T"EP"9"6>QL8("X<9-@65:8ER+$9)B^79HF:*G3S/IY!%
M$V?=1#YC=%53FGJ<U#A!M*4<IXNGOX<6(3]FK'FJ%5*;WC<CRYD,+#4M@6)Y
M[2-+;<B91+Y[OF,B%YEV( A&]B0)"5T;#- JP;!D08.C%4AF+TD8$KU"D):8
MZJM:CE<?)C+AW=WD&U5F.=:ZE;E ?O2U !03]@$-Z-KQ>UW9$(J3E'%&,L;@
MA0:*01D7MPDJGCAV>WZ]YY")1Y2/"F>9[6HCG'W\9B4)QU<93NP-$>@%'>EA
MO2A;/X, -N <25:U,8Z!Y"D9@DW&2%^4@\,7VNF_&9&=(?.0?:^9A^R?S,-R
MQ/&U%4:MJ=HB%Z^VR,IBBVL7.V('C GVDH,>M0/0=:"[ANJ@KYF%PXMO@G^)
MXN9MK-=_A-5J@4_EFMN\K^5C&^Z2H7JFL9^JN5I4XY--9[/,J-_UP,N@&GK"
M'V&@U^B! \Q+U&7TD&*;$M;6ZU(#F*C=6P0Z[%##;*]QOP-;QTKC&4$L/B:E
MD</>CP!RK(\B=VH09,UO0)W"?+' /]Q\KM7R0H9.$KPZHA_!,'>_XG=%Q3@:
M\[8B0X!(B U!((V<SM3\V^3C"C%[A!_#2"&+%8#?+ZAQ.?$^ Y8+TYI],5HK
M3BS'LDD:&?X/9,#P,* Z&(3<IB0Z74V)2 ^1.CDHT6 %@RE6KC%J9"$XE+>X
M9 0'REX:@EZ@H6)RVP:R+?1&=I"[T0(APZA3&;%!T&5N<AQW98K&\A0PB6K*
MUG5:UGU:*=[D(3,'L?8R 15%7<%0%)QO0[1;IMH3 6'YEFB*RM9^A GCWPU9
MZ:B85"T>'2XNG;N8=&S]:*S.='(Q*;N1E7I2> 8*Z?]MY>2(^,SJ:.^-N;A9
M5>4Q[@:KF(PJ4]5O1^L"GWG9*UD#U1,I+9=,6LZ$K*QH&%66=H1K%^GTSRCG
M! .BT6S(2F 4[\SP24F?$2TF7"95U_700R,R+LI#K6BTQ\:3W>EUP%M&^C?F
M<+"$[S%HU<L0[XM=2QG]M>28X2/5/]1<N(V\7@#J./BH5NA.D_.D ^NWZA^R
MZ7PJFRNGLH7"Q]'::G&8_OY/'S\_QVJ&L64:?4 N/?$)8H6>5:(=?_#6IU.X
M7U$>1*>^;5W\1BC'6('S$B;[]_"0DD1HP2_-9"<^@0+!6Y]RN50VGWMM$__K
M17/&=H6EUS;E=[O7"YAX,94N%!8T[^<KU^_,&AI>BN?-?T6J\P0; \5UI_R5
MX(<8HSQ?/J^)$K3H91-G))TJ98L;-I<1=3==Q95V1D_ZGQU9]UP*J4(V_9*I
M+-.TVVA%)/W92!&-N+AO2A&54[EL><.F\@P]5-DIY3=L%F]H0YZMAG*C]M!:
MC:!9IS:I;F+\)Y.>.&G9GS,:OK1_!O-F![.ZNY>RP8^<JZ[N.>9SS_Z4!RWT
MAOY?G47?_O=/_=-,-_&"9KD.!5K*IK*5D1#"Z[N=BSLO,T??UHYLG*X1)(NO
M/VL]G.7/#W7S(7.^:1" ]!H9YR\MU_9\):__K_9V<OC#JU$8ZH8"JW&,C<XN
MC:85]I4&"PAD"+6JS&B_S>4HQI>C@ %[RFLKL-FW!.D8GG\I/O\BS/_@B8C1
M&+KE@C<BX+U/M/+VMV5G=U\;([ :YT6/8QO'"<]PO4??Z,HW%> ]?,3;/C-$
M"CMY!*N)WZ)JEK]<%(?PL.ED?(Q1[,XZ^LJ&#/]_AM[VK28]P/!O+2:KV[G,
M3COL;'WBLJO#SQE]#[=+]-C=@>=94K;_]X_Q*8%I^*5;/?,"Q<V6Y3QVU7-:
MWJ;7YY39#1CR.#G-#LEI]H^<OATY;7P<)Z8;,#@ID>TP[/[[SS^/CX\[@=78
M:7D/_U3]1AM)L_ZQS);A_X-E7?_D"H5TIO)/&OX?^V<VA_\N5/YA(EW>OF>R
M/-0=K8Q<\3;2O,)OHIR>+']E4-N==/9?Y/4595RG,0[7J'E.5+TA2=VF<LB/
M.332PWD#-MSTHH+<>RTJR/TI*EBO2U&6+L5E[?-)]>KZXJW4#R3VB3A3T-R,
MH3@"2@LNMFDM$>E#%U1RX..CB#Z]ATQ'6')I,C T:\W!NP]RF@ L ,1^YQ8U
ME>:UP@2@9A_0J"]VST7Z.'Q>!+-_GRVK-A@1#'HF*6P8LWNX)YE^?D,9L0-C
MK.F7OV"DEFA>\W7<(BQVQL]]VH?HE'Y\6S,;?=KFS&FBT9(11LL"#\7F3/VY
M3]OM@Y$1_(._]<)V7]\W.H9I&^[;FN7;GMU>V[#A/G1%F==HW5R*R)*)+R#U
MMN9^)BD,#V3;WU.E[>\5<C]@5X&W->U-5D5_M/#<3T,-?-1#CGD/3J^+5*AO
M:X)O>G*1YKFA*C.I:O4]:CI^*EGXN69Z8SJXRMC>(U4<A>7XA-_6?#=# ^UC
MO?2_^J%5]WM(]<)#I_FESW(%$)#E1P7FI+[@[WZFC8(M1W+1QFQ")^Z+GF-M
MB^"B&N(<%M+X@N42 IPY>L-HS)B^,!(P5B/ ^+!8X$-L,<9"^?^JP=#8H-<J
M?O_4/;./9Z$==IQ/_Q]02P,$%     @ N8E.6!<I2,]J"   )ET  !0   !F
M;VYA<E]E>&AI8FET+3,Q+FAT;>V<;4_;.AO'WT_:=["0SA%(@=)MO &&U$$Y
M0^)LW*S2T7EURTF<UH?$SFRGI>?3W]=E.VD+!=JQ>TT@3%H;QP^7GW[Y^[*;
MX\^#/R]/WKXY_MSOG<$GP;_CP<7@LG]RW'&?<+?C;Q]_^GKV-_DV^/NR_W$K
MD<(<DNY^;LB 9TR3+VQ"KF5&1> " O*-*9YL04)(>K4D74]QF@;D,TO'S/"(
M0@HJ]*Y-=D0RJH9<'))]]V_O@(LC8MBMV:4I'\*-?PIM>#+U@5S$#'/>M3&W
M3H[/OWX9S!>ZF]",I]/#Q\T](C:NYO\R9V498*8IA BI,IKZL GCPY$I [=.
M^K<C'G+S]LW[[E[WN(,&0#->N088]#Y=]LEI__+RJG=V=O'ECX];^UOV^MM5
M[[2\_NOB;/#YXU9W?_^WK1]LL5TC<VBUZC*4QL@,0J!-!M=EIF.F,(.T;$Q(
MA#UU/#@K8TQX;$8N66=P=K+DSL8:^G<1ZORH:N%%ZY8,D;(*G<$U_H<]L4ZG
M+/;#N^?VPQ'Q#6A[V4Z[ISO&S<QEG5.'YG_0OHT-D=/^]>#B_.*T-[CX^N51
M4Y>/ESJTJAVO=GA48[;%2',QTG;*+^V4UZ X(!]I1M.W;\YH1F-.!:$B)I=%
M!%\E^20%%8(31J,1B7!0)%-B1M0<MN*D 0.X%2<O59QT]QJA2"Z<92,Z9D2Q
M,6<3%@,_N(:K7"I#I"#G$!?RW?T/D0E<"*K(J51PEQHN12MG6O"TX*G/$'G7
M#/!\HIK%SCI 3#8E-T).4A8/6;# GUA"^4(:$D$NE*/ZF9)"&%4PH@TU+ .!
MAF"B,-P,P^%)$AI!D"(RXP:&D8MW+X)@$=.:JJFS N)E](9!X7,9:PB+P2(H
M-T7[L2",$'$5%1E$$Y 'F!,S128C#AI,%_C?+/V$*>8SP5ID7*<,9)P8PEPP
M(ZBESEF$5GHK(/,<C)0Q5!AF!- XG,XW2(O;%K<M;NLS1-Z_!-PRDG!81T;(
MQAF[ KO2A,4GP&UVGXL$\T3I!]^CM(B!4<#'.48% %BNTBG) 6^(9\1VFE;\
M=79X].D[Y0/G8XZY!QBC2"$"0%<"%&V9VAH543TB22HGNB2R8D.NC:)0&L5
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MJ, HA3 .V/!(X3F(WQ;9&^=%B^R-=T'];(R:@6PVIFF!0G2VQ\.2A$6&CP%
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M81;PFXY8N5$%MDN8[\XM?EMJ!D<+!%>:1Z@?R2]WW#OU&%I(*KR0F5AR)'3
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M)2>XH7YM+H&U/DC"1YG<UWYP\#R$5U%T=TGJ=B$I/5VSBX-9(P5?VSX4,]
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MEIIZ+WVA<2BS'?2(YUBN)R-&:C5@&MT"*XER<5XK2BS=#D-K0KZ<@[+2S%F
M_CW<["Q>#0;5K60$$?S #*'8PFEAZ0)I@#LW0JM_PG7F?# GS9Q^#3V@AMY#
MJR>,>/KJ8VH'DCQ<_*Q/?SA5:N']-NR-!%YC6Z$:AO8PM)WW2A^(W3GHS\\\
M_1/W[K<C]X=&3GU[=40I+>-5 X%QZ4_>S9074P9&!F=STI-SBDW^,D\A20:8
MP6,LH+UL'K^U[@TI8&C^>LNPYM"=@K-UH@5/*]\1:Y><2)-TI3*6J(GO9EC
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M8#NP!@]T!?3DLF;6H,TA;^\Q7,?<1A'=Z1#2 _^*AMBXZ8]AGGU7.<K[$6%
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M;02& ,7\:F(3-A&,;'<2?>-NZI[2E>L'*2DU5[.39>H5Q=SQ_%J.=SS]C8Y
M=IKS7/0?NHW&_#Y-EU<Y5>(L58SL+ ;\N?SM/<S**LO?SWJD?$G6/WFQR>9]
MO$E_WL"<V<QL\.Z6F;^.%57 8MCWQZR;C9JGK;U@P%]Z L090K^'JX&)!YZ4
M4>GR]2=:DMS;=B!!_Y1426_D3E$+07\+.2Z'*CX'YBW1!M;7<A>%@XPSO;^Z
M;2D>:/^VH%+952*J9L9=>.GE,40=_J,)[53N"NA,1T%_DO5B%+UOTB(-8Q]H
MZ7.(A;>>EKQ_2=RQ.FM@X;9 RE,#DSVF2Q)."WW!F"DP"[.7:7(NMZ',FE[L
MR5VRH%PUQ )&VO1F*SNVJ*5SU+NTU\A%_3XD)=X \M)C$V*>@/I= I;;R$>Q
M.X?\39C2\?B4@MS7[PNTM5G DPQ(>#MSOCH:M2[[!X9=F)7IOXG2%X\:('EC
MM#Q):U8:<.4+MOGL.M#.<VT@R'FD]GC,&X/5*WQ<;!A'FV-AW=\6;%5Q!6-B
M$H(&ORK?'_<]\.V E*<$Z6/J(SG"G3F17&&<(:*W[*7CXLVW'EF$+;/BY(WJ
MM* T/$,E8$5E9&HK!DG*@ O'Y )(A!F26[PZC3[%SSB]&PPS(\2)!B'Z^+Y^
MO0%#F*6]RF$!=7NF.G<.J3S?[)&&&WGDC<#AF@P&8X2<4^6Z8_D9[-AM"9-=
MVTHC4VO1<.WXU_AB3C%='_TW7:IGNEME+79<MJ+X@T&;MW:%IE18[T%4<HTV
M&_FWB#9O'YYDK\@"!&\Z!)HW:OA7V"]*BO8>>X6F%-E<C\*;Z>Z_D>=DNY4M
M%_1C82981>3+E7"Y_.08Y.^/S0$RVG,JWCI__3L/H9JS:0%ZY=6_$D.;O=W8
MKB^' #>-;E'S33@#!QHAH/\363@TV/!I-JIF)*.BL,QUC/^[^>V_T[-6(VT0
M7^3WEX%8)T5'%TVW=C]<-]5H9!J="N/=,3SA;;HZR2KF =Y=<=B\?F+(=VB&
M<9:8ET&G/+I8_@$, Q@OT5[3?'N8R"/T?TRE[G S8,X::@VW==1ZB@N^VLT"
M7+R'HVU%4VTK/TU<(5_[R/4IE?G;18O#4HM]D0N8]F.:"$Z[/&0THGOJ>MH<
M+-]Q.%>MM(-*C'ERLKB+I%(J+2$I+7MY6W&9B=7A68Q?Q%8]W4"TKZTDK4,#
M2,%G+.#3[C:%7_%LE3FL!L 1\3CZ;8;)T0[M8XL,.$27B^>0M;0HAJ^(=\$M
M%G 83\D!/Z9>*KC\ J0L8J$XP7$DX7TSLG2KKI,N>I<%_)7$9YR6NF(M))&W
MO0J[<F>##@;+G_0C:X#S7^1V#I7,ZQ7B>BX>@(/"TX2,;Y4AEW;[@TW.,!KB
M8"YN? -,%-[BF-'[]VS\J7H:\O@A-J/#K-TVG6Z$S^:?/SZ^)MQ/,G*65[HF
M(GGA6];#RT=5:,?I05 M5K2:"]TS+DW:>@&)>]@6A(/!.Q&OP)R%=2.QD=;&
MT/AGSUKUS2Y5+6T-/@L\\0L376[2$&)>8QN#X&1<S75+/['NFW-[L9]]<N2/
MQ)%KEI;#0?<.ZCD$6;U*O]?K&W/A18JQ1DX\/J>JLUM+B<Q_@;2E]@7%S]DA
M9!:3J3HE(=%;D."1Y(#1[9Q3@D2:J;!'G\Y.XAB'X/1LZ"$PTY&N%88O5_/1
M?($_U)T>=OU.EB?DL;VY/%+;'C) OPK6WD(2ON)_E$:?)$4VH5Y @CTBXOG%
M9!)CS</O%S'SK4GQ\YVYX<IE.#9 O)=@CRY)#>+,9@%3F]NQM_ETKG@)YIN=
M]7M8A(I"%A7>-II$N[UX+<63Y"AKGEP>W_!+)Y<%/!QV\2=Q0-RE,.V0H>D1
M-5'LM#6J2R4YK>KMB=.*N)\>%1YU7\^Q_8ZRH*V:R_S"Z;* R$'T8#V&%I"_
MO3,Z#NN(8 @DX"=*:.+SZ>S(+;9=2?<7OH(OY5%@?T5PA#LY \NII[>*RI7O
M?/K>)U_1@YG=1&HUTIS?.WT_A+.** SN#@@N^]J%HO&:&4[':S_?[0,:9 $4
MS*6K+&"O-W);$D,+P:S$!")()G8L@,$%:_+IH.U=(0\BO7CON([OY\ SKN_Z
M#LM#'CK]X597,!Q1H;L]HZA,Q1T^+,3SJIT%',0*LX!K_?")FXR8#DIJ1-'D
M=O>B/)IL>7<0]9U#)Z;JND>OW5R4,JBL3)=__>67T&%ZHCM-LP&Y#^FV)N0Q
MD'Z*C*C#'758% WO&1T?&W4=X-TP6+9)>^6@?S)YY]GND%B )X0=K&:'WXM/
M,-"['W>#F&6P#GBC^!S#K)G97:(Y)Y\G7G=Z&IQD#4:>OE+\I5Q-"0$/3-]V
MJ3OW]E%,))=A^H"'@)J,9\+;+Z6>CXT0LF#]1>AO).1:&H4GZ2%A=+/GJ,,.
MUE,Q-!P9H4OS=R3EHHH2K'JE2CW:QA2L)TMUD<H%?S[NMVA!&NQ$UB))=FNT
MT[D-$P(CM*LU2#Z&W#?W .-#XVW&I-[UW].I?H*4+2VK1>'E&*3[V:O$!Z*P
M*G3?X=66KG8\W>TG)B4>%'S-1^Q[P(1, 2=;[B6/X+QCK44&$[_R3+/S@K\H
M&J:C) )QS>)"STL<P^JO9*UF'AUX._<T^'9J]/4J.\^S\0$NOH0)GH5T3I)E
M&J%=2'5H0>.!Y>-ZZ$/C41WF8:L-G:G.;4D5+)WG-CC?CUOH(,DVS % Y+8H
MY!3\F(O<].,?6(?G-T.Q[I2RS=/=]=G,M;\T_*?17*UZE=2TD5LIFU573U7#
M@C;4:%0%QSBL27P1S; =?6E"[^_A7T)I2FJ04;")6CEC)"$#R4UF 5<1T-]W
MU<*RB44:R$G,+&CDTW"K3.D"GLD&BY5N$29'C\+A"TX342'[V'JMUIJW7='.
M8*TWGI VUU N/U$B7,N4>IQ]YUE@\XV2Z)1HGYJ*FQH_'B(*;LW1C,$S<CMA
M \I+9RWK[)5,?QA&>[Q,/D.,VV-E>?18V&#, !'+$$J"X(!X2I<,=M!6(CFD
M'2<I1GDYV,OJF%DV$6;2^S!>,R%6\QX;QN=_AZ1"^,NNT$F\$EUL?FO2NW^^
M.7Q#G4Y"E24\;03;*JJ_CTOT]2\@3IKJ\F<?U8[ 7RI'YOUTM&+(_D/63C6!
M01O.HHRHC+!Y=Q80<1![:*$>IN7\,"TG#&A<R&>(!"GMV)*HQ=DT7Z)_TDN5
MBH;2HA]==],7G]CQB'L<E&_8 >1(L-Z6IEN[@R4<*Y?R&7IVD:+2*6G(>LOL
MUR>*8E\>P*RIMR4L#B[+4:0@'A7Z/408ODCW.5T]4,V<:Y)?U/6O:A89V>Z9
M\Q5H?AVA*Z97Z&W >(&KF+HQ,FQ\4=1;YUM5D&(<HXKB2T!]=5SR49659.H2
M#9C' SJEH3/2A^EG K@KB)U\'N.* _E:YXDA)R99@"D^S;&HJ#BF,N%Z\YY;
M?#E?#IVGX+KPM&.YRP^"7:8T.X='FLI-/=6NQGVK/">-F4E>CC$\UWDSZG$8
M<U8[HMI0MFUQMFS>D3@0,.3OLB;NV_A>FYN8O%T<\D0H$S&;TGV>/HQW]IWN
MA6/*#SWZZ+0_\WVP?1@+N%FRNW_LBQ[%4AY(*L Q96=%T>.4O#FU<9C!?QGU
ML8"M!NP<0B.FP=,PT'>279A[3%E "PO8EMJ&25[D(V@4_S];PC?X9IF_E#"T
M^_S"("$_;^=4#>7PG2!N<%&2#4+O[F8<@RD3=K)SARV3!22P@'6]#9PB0S"3
M.JTS"MY'_-NH>3-$ZA:)BO/_Z/'NT/#XX*B6\..>#*NH6W>_Q? ?"^4\@?]L
M&/XG$'#1\D%%@:3;G4.W@T68V9FT-N*8<N,GV@KOQN$;)ZT6GI_>*1R>,/-H
MZ*29I5L\WVD4^66S]-05:T[!\6CY-OF4'M+*5<XT3DBURR&V?\O,BZ[PL![#
MZ08CGP5%[=1#7!QT)[7E8KKQT+SDZ=Y@''=@Q[4>_X@X4DG/^09AI(YO,7[H
MT5.K%@I'X*"^F)#SL7__[=ERQR?QW-&RNV>J8+9 [!RC)1RO(6OKO6PE1V_Y
MWYVDYW8;=BAT.T12,'3+%>\AITGQ9V'8?>[8<VM0M#2HNO0W1(YJ3E5A?F]>
M,6(!^UK)36&31O_H3V(Y:&(W>XIC5Y*2C[O()*A]D<_<M_,%UU3#R;: LFFR
M+K_8%XXSHO^(!J-ZIM$"E*#?Y%$5*XU6<ERQ@86C\)QK:_L3E?N5R:+JZ@[[
M0QI9 (SGMG8.Z#%A\KA=UA>X@L"A4/?[V3-TETLG,C98BZO)!_4(K*V.1);:
M;T]!^JL9+"!;U9] 6DE_<AE\@O@<6#A,FE"":1(J@Z[##,O8ZLH'Q?QA0U>)
M*\#F7[B0DT20=06FJ%_KS=\A5[IMW@JR,BM8C=@S</D'"ZB!Z19W*UFO'K4G
ML,C@UU\M/<*8PGKKJI)$8W%CS(."K$><)\IEKQS>W)OP0K3H:FP0.?[MO1Z'
M!] 3)"$+5?0NCGX6/2@I2[,BOA>])&XH 6'$Q)=+RBZ?R.W2OP?K@X'P@6&0
MY-#$0=WY!;S6DLK!,,501ZP(V^VR@<']51==WZ9A*/3Z/_5"R215^ZB&MN2L
M^=J63>]$.?S2H_[(@HE )[LBLD+2<<,TC57-%!<.L7NQ86<8-;B%A#J-Y$6'
MP]V;(E/2J\KS)Q^9F'5]07;@WR]\"'XW1S,"C1#\IB;/_"Y8@[\E1UB SMD0
M+-!FN\ " C:1:=!;4K90HK%I!7.=!?2  W^VHYNQI!NXP8!F28T^AM,D]OG-
M,7?;ZCR?)Y]'TY[>--%P.^D2,%RZQTJ^@0"P!PJEXDGZ$S29H8O(HEX$S=0=
M9"3H"*T.U-X9N\],#0@1#IA&<T1.\2GD1KYP?&^E?S+>PMU&NNOIB(1B+=R,
M?]F.E#19$$D6)J[57ORYXJ)?O4&A]PTH3I_[+5 X<B\ML9QR+&JG?#!>7]G4
MH<G*(%'TT*W)=U5"F)3.HAN=*HU7"E0K%UOD9-0-C.2J%$^-5;[Z_"F*@CEX
M^E,4< :QFGSZHX<OECSQ/%B8S''=FR]PJ2X9C7/4MK0STNTZI;LOZ)S*-LQ<
M]A]E/L/?0T1J7*7EUH#['U"B6VRBTY WRZ,4JC[9!!<S#IOJ!(KK7WFQOF!@
M:K3EAO*E8'B4@D?8&GZ><?PN^.+>6*_+Z=S,L5,)V]CWHAUQN3:+ 4?ZJ713
MZ3MYE:F\].0\JIC]AW6\N8X0+1,F7WJ%/:F?=5K&AKCE/1\B V!6)WKM>['Z
MGR<[WS]%)5QOV9+8'YYYD1U&L7$5ZA9#<(IZD9D"*;OW+Y"5B.6+48Y\%L5V
M9<_5*:\M&.6F.D_5]VOX^^[+27 (VD3*DU'G_YP35S$+=._.6=Z,244Y?,G<
M?$K +Q-)"((E1B*ICO_%,"*RY[X(96F_C1A.?DZ^>33!(<Q+^T:7#GK,^& V
M9Q.7M%<R8NZQE."K)JLTVPW?A*!?JB/;5=?*8J6U;T4G.M<*D=-@:G>HC<K9
MN[:J(K8VM-XWFTZ<3F0!I2I[?D4?,M[?Q &O&-KE2JP7RNWPUIC,(/7"C2G5
M5O&99PW&T8D%1/4KU"I<:Q]T[RK$9?COARHED"Y/40S)120CSMZJ%DF3<5EV
M(25,ED3#T3%7*^>I:=/MO6\X9'UQZ\?1VU_L1^Y]>$MJ>,1O>QJG_9J'0_2[
M>ZJW?Q<8MW0WL#[:@RACG./H8!KOEFN9::2\FORH3[NY[ZVI3L@9\N7;,BM"
M)!=B9#,VPFJ"'ZT0J#UBU[7*^TC?Y5$'7J/$(C$N,?'Y:I;HZ6\^YV-(&V96
MEAH/_?,<O_LM=B?$?.HQ4DT.Z;'-"6Z%,<4 'N9Z*O_0^$ ND\,? 5W/@HN0
M&5B+Q,^/K2!)3S_#147GL%4[4V\_"]"&J\PSW+IV'SGWZ 8+^-TFP +"OH+K
ME^%"!;<+!<&NBF&0L 47KNFH=\T0EQ5]K^W$55^.Y4UWG/C7W_7VO1>/A?(S
M@DUU$*:U8"=LG"#'@'F9_<7&ILX+N/]8T_O(N,L,Q=\#8Z"+24VHP]J\-DL:
MV"''$N$ JRT;Z\Q_/C^3_PAPW+D48O1(":Z39Y%WSL'A];, 3SD(<_^I7E-[
M?U*@>N_;;..S)3L*<PH<4;1<GF?ALA=WNF(LXBWNQ]O'F_V0 FG2N<N<7:O(
MHHBD-T_=U;",H.IWM.,D? V"'1)Q _F@H[2[$WI=?O,&0X-V7G*24[]>6\?#
M *!_$D:(KB1B(<5#S9A+TT_?7VMYXJ72\L@!4>ME>]OOQ@O&6;,))0OZQ;[?
M/D7)#6@'[B:SW!_0'3E$)\RM"!)2O#D9KJ2S)56Y(PX\*8$*TG&\CY[ISK@.
M63\,>>CZJ;#QBM"Y]9C$OO*T0'%+F?VQN2A^-:XF_2\Z/WNJ%_)4UK5.@K6R
M( %;G[M,S-W=(:7#&=B-H4GK,03I;MXTEP-()/5(]:[B,45=++PHISBFQP+V
MH*9#FG=F&JDL("X69.Q^52)>DQ_F+(6ER]DD_\UYM"A#*LP @^J2[BE^2>Q=
M'?/*3W7,O+,>MQ1Z3M>8L_WA[C<D\IC/;@'XHFP,Q*?( F@P/3>Z+2G0%>HW
MY8R._KV>T9AJKB=F^^W\YMOLMC]]-CG+WPJV"Y9_6@UZ,S1*J6PL(--O]Q,>
M52R !2!PUYE)+. N_Y 3-9"6HHA!'PB6*OZ[&=#C_--CT)_GBW[XD$C"H=:V
M4%.3&V0=H8NW3QU*/W$H]F(N^I5P]&3UZ2:"K&F#4Y[Q(4N?1)N???VQZLH#
M7RB7#INB=(,?W@Q"*YO^@U!%=T\4YBYGTO\)-DF:1,"U^H7J3L</ZOF1XN7D
MM-%K32DE!8/9%E,R)4]P2 3) #_("0L 7K(+'(U5,#F./_VIVD/@15UO@[%9
M[I'5K>MT+>$C/L;\BMEZ_)A\3AV;TWW)^H_U#5IX=S>#;Z%KY!XLXXNJTGU8
MP.5_V\LM&\G=*.SQ:_/4:!W5.U#))7Z:2]/B%J!./6QJOVTL&:[@=5VZI$6J
M95)^Z6+[@ED@P\A@-'\D_5$:SF/D0P7J-VOH?P!02P,$%     @ N8E.6&@9
M4$ 3#P  \)T  !$   !F;VYR+3(P,C,Q,C,Q+GAS9.U=6W/;-A9^WYG]#UP_
M['1G5E9L)TWCQMVA)<KFK$2JHIRT^]*!2$C"AB14@+2M_OH]X$6BQ(M 64Z9
M6?:A$8%S 'S\#@Z  Q#^^*]GSU4>,>.$^C=G%^=OSA3LV]0A_N+F[,'JJ%9/
MU\^4?_WTU[\H\-_'OW4ZRH!@U[E6^M3NZ/Z<_J@8R,/7RAWV,4,!93\JGY ;
MBA0Z("YF2H]Z*Q<'&#+BFJZ5=^>7%S.ETY$H]Q/V'<H>)OJFW&40K/AUM_OT
M]'3NTT?T1-D7?FY33ZY *T!!R#>EO7E^D_PGISXBW-XH?T!OW]'WSQ/RRS+T
M?PCO9O>.;:++VSLT_O#TGP]7!']9\KO)>C;U_CU;+U;HO;-\7@?JY?3.TQ]^
MN(^K_,CM)?:0 F3X_.9,X$O@/5V=4[;H7KYY<]']932T(KFS6/#ZV27^ER+Q
MBP\?/G2CW%0T)_D\8VY:]%579,\0QYN2(9=4R!.?!\BW=^2=8*.0%7[7C3-W
M1$FAZ/>Q*$E%';PGQ[%]OJ"/7<@ ^<NK5##DG05"JXWP'/%95&B2L2/,69 7
MA,1]H4ZP7F%>*!IG[2@X =M3V'EKD-T5V4+GLO/FJG-UD6H.3&.RK87ZB E3
MC@J_N!1BV,4>]H,!95X?SU'H0OM_#Y%+Y@0[9TJ V ('PC;Y"MFXJJC4NI'O
M4^@$T!.3%)&V6A&P\DT") FKN&;4Q5-HN2)^0"\L*%_D='L4W,B90IR;L_AG
MIJ2T+ ?/B4^B>I,N=Z%T1 <+!4#X&6E^[.X+YTL*.79,_Z?H]XIA#NH1GB$D
M)/J)2+6NC5P[=(]2W;:O2C-)3]_B"UZO[V ?2H<?G+K$00%V;I$K>J&UQ#C@
MZ;L_*"=%S"6P(1PE3IDQC;YF6%I?_++,H=Y7I_!PJPY5HZ<IUKVF32WENP=#
M?>CKD/./EL6C6!PC!F]AB0,"H&0IW562XO?JI?PJW^W4VO(MS??FM7-SKL-D
MR\,5/!<(2_'[5HY?:PK_C#0#N#4'BF[TS)'6]N+3L"K;E0]I2O'][C1\M[WZ
MQ?R;\]X2^0O,=5_[/23!6H;ZO)(4Z]_79%V0WKM7C3O- O(5[><'??IKV]]?
MVM][B"\'+GVJFH,5RTNQ_/Z8OMU3K7ME,#0_M[.R0_SV,;<968GJS/EMR(F/
M.5=]F&-Q FR-,^\@)KB.@A3#/XAE$.&V2WG(L'C0K-Y$'T]UTQ!DWCY8NJ%9
MEJ(:8DYFZ1'%XXEF =VJD&J)+2#6"CT/L;4YM\C"A^6RC?Q M6T:^@'Q%V/H
MFC;!2:>5E)6B\\,^G=;#:*1.?A6D6?J=H0_TG@K>6.WUS =CJAMWRABZ<4_7
MK);' AX3'O@$VY@\HIF+1]@1\Y-M O2^$?+1(O*1\&#"%(8-,,[HQ#R?J"P9
M.[AXLV\'">&6,M%ZFOY)O1UJ_U1&6A_,89A)B[KY2#74NWC4%H_F]%Z;* --
MRRJWUE)@+>9*Q*&ATPZ(#VMD^#'$B*?]O#17BM&+?4;-L391HQ[\=^2M?E0&
MN@$+9O$\U%2K[<^%#.G^(V"D;.-\LPE2/%SN\Z ;GZ"GF)/6A99T"N'#=$#I
M+XAP<9QO0H;%65(T7.6Z0^2E=)B4&'=ZY,DL2YNVE)12T@N96&\/"9H1%ZK&
M65(*,J5H>5M,2^]A,A'#R5!7;_6A/FW[2LFT$2^2D7^"7;%V$]M_S,LL "HE
MI"AZEYLB:G>;L7ZB#:,5G6X,S,FHG=^7$96\_#%BP7K*D,^1O>6H+%.*GN_W
MZ4DI&:N3Z:_*=*(:EMIKB2E=>*U6\:XE<M-@1[X3'1"2(NI]?JDU'@^C:3-,
MJ3=!D+8K'8QQ>1X)HO@4>+4>C5:]V-^NCZL$I)C*Q3AZYFBD3^. E?!Z/3-:
M"FM&NPXNG3>+W8$I>M[.F[<)4B3D(A/)%L!4_:5]YR6N;,;Q[R'@U,0:91,M
MVDN5>?N7N7B ]7!K:3\_B'%?$^N7EH+CPWC'A/-JA?4N<XM_^;">\EU:51N"
M/Y[BJ0B]U2(XT9"B-Q=3J$-O7%%+[NN%;[/DG[1$*>/(13I.'<IM3>B8F&[6
M* [(2-&<CYP<B.^VM$D&>K-,Y9.ER,G%3#)!WY:'VM'?G;Y3(2#%32Y@4A()
M;GDZ(B2<8ZI41(JK7,RD-#S<LG5LG'AGJGI83HJW7 3E0,RX9>]$IW[Z.$#$
MY09B8H+QB&N? LH5(,5W+EA3^U20\EU2L[*INC6&X]>?'0TQ'Y[Y&#-KB1CN
M)*^WSI*TO! 9H[@JB"%)KU([2EJW I4K4>V0F!I):QK'FT:QBSA25\H07A2-
M:MW"5XQ<=(;47TPQ\_+%[?B/KU:;E'WEPF$GCWAT%-%41;1521NK;%O;^J5&
MV.;%US7."SGK?/UXG*QU*A>M?;Z>?;Z"@ZSE!7,!P=/'?5LO][6L:&]V]DIE
M2]E5+I;Y:G;5SO&.VUKH1/^,T3HZ\[+CA^JI2-E#/GYZ:.,!QB=1FY)6USH2
MV:V(3N;W#J\'9*2(S 57LYL4\+0MMB6L_IY%IS#5P($Y5SW* O)'-MY6L;=1
MLR IZG/QV;(]$,@1M2MD4[V"HOH5'P<*G2LHTX363.J;2?%X+R<J174N-%NZ
MW=6.PB_9^>J4I>=[^!'*,E2_S05<RW?+TGZ=5*EDZFS#K"_83.O$<53R!W82
ML3T#.%99R@#R@=8#VVX@L:E22>ML#>"XCSF*7;FLL!3!N4AGZ<<>K3L_S0<@
M9;LE]92DR,T%"@]_(-*R_/*/1HH9KJ,@Q6XN/%?Y44E+;/T/38J)K!*0(J[@
M+-_V0Y3_>Y[$_\1]K!,\5Z)[7*_%Y:$W9YR(FW3/DK0EP_.;,Z".==(K/G\#
MV.?/GIN*B!HJ[G&-R-Y_4TG%:1&(V;E2<O?,0B%TA9F8Z7;3QJ<%!"00ZMGS
M,(JH!^9NW1,B=]&L+G)0P>XK0AZ*\E\#*QAH7:Q[-OU*B'O;6EX#-_2NNKAW
M.^0KP>YO*LFC_MC=O5H7GO>OW_T(P"D+%#]WB6_5U<OQI=%#:D=%5:B(ITZJ
MUQ%)G8O+SM7%^3-WMBVMTXCM:ZC7B%3OB$:47 !=5#\O$Q<_(F.2K;3D(NG*
M2@MUNM@->)IR=!.RUTZ_H U1,;4:<?@NZ[+F'-*,GOE11A!MWK%U'4/(JJ0/
MQ[&QO3!<CHA4/B9!W"%^;+5'6$&^\E(32"X;CR9YXF;RWWHNXER%P7N.&1/7
M&%+[RPA[,W'9MV@H^/PJ">*Z8I/TYBQ@H?":XF+Y:_"FA#K3R.D[(4ON!(@'
M@<U%ZM<.]1#Q]0![0A*PAC,._C84TG>,AJN;L[@X B*'(1C4_T2C8W<'L1P2
M;00H6$I1/VH7W\-0E-.P)B^IZV!6WO#]_$8TO\HVB@'5T6@$1%B1PX0(ANF%
M[@<89NS!/D7E LT X'F8V02YN@\+2S'AB<]O.#W$<-[<)&2; "L^E\*2\RG$
MV052FMN$IG^F[ N8N?@;,-CG46UC>*:^>.W_#=EZ%XN\>!/ 1=L]NP!VDQK1
MR/2TRL[IE+U65\LT <;N69MB& =DF@!CC()-^'.U9F2QW =1*=$$",DI.7%1
M^4KD%'FC@MQ&-'USF,^<]PE:^!3*L74/+<!H>E@,:7MLU-)H!L2%+V[OGV#A
M-3>#6@%1$H)- )0_IFEA]DAL'&WWKA")#F2FJ*2E#T*+(R9!FC6+_^(*0,0S
M$J1XXSR8MN( L?7IT&Z;G]GJ)#F8%6(-Q9<[8KOG-W8RFHJA\$APWF/LY389
M3?GYYL2P$GK&3.RTVU@<E5-=ESZ)%NY"?W%1#7U/><\"#4^_9REW/[M"#<5F
MT  7^I)U"JQ2HJ&H'GR,F(_![S]B/\2FGPP%T2H6C(\7 :VK=#1VFT$_>#WP
MO9 '%!:X?;RBG 2;/EJ0WE0(:6>"B?R^T1G4M^-3=OL][Y!P4\'"M)]  GC,
MQ/*BP\BIU87(W?I(\*YB[SR"FUDU'*E>8X[WE=\(HTYH!Q9RHS%B@S27W%@$
M15//#)+R[&\*T>[4\P"^(N'&HBV>RF405@E\8ZC*)V?58"OU&OL.>K",3YL^
MI5F7L@T/5T@<C^MU9SR[C:Y:)TM)?KLPBU?-1^A]&Z^@>D4J*?LM0RWQ0G7>
M0'D137TQR0=-XBAFT4JF/+NQ;GD<,GN).#;G4X81#]DZVBN-;BK:3G4/"-4.
M6L82/-(_A;V*5^7&I^#,^6[;2_(:2TA1>P\C:@P5,&P_$@Y: \IND=/'L\R*
MJ3BOJ9W]#A'?],4$Q)QO-E>*NKV,8&/M#=R5Z-.XC^-_=5\$GG@^7"PCV%0J
M\VW?W7_=^6M097"K5+X=X-L=6QG,)=+?D#6GT3?5>8Q/\99!S0LVE=3M9QQE
M]V*H4+*83J5HZVB@Y%<*^^@A)6#BT-++X4YI@-P!LA/S,Y]\[)@L.3D47;@Z
MQ<_!K0LSDA1O/947[+D&:3&GB/382^R$8A#)A1:+4=91: C&>\]&@@W&EV1E
MD3^@[;HGFH'<[1HA62:*^SKM3+SY2%WY\/,^\%5<QBG6#6FSTS-\ZAS^G6#*
M%LA/KIV 2=$]1FZPW(+I4;:B+)GHJ>";8)UDS@W\Y*ZUYQ7R'>S<.][>:_I*
M=37RM9ISDY$%B<ZN/<(S9=R<0[-+WTV%0A, ]@G#=K!=?HE]E?R!4+YU\[+B
M#1[ 4QKVJ=J.W!4232#-P$$< QA2SM5'1*(F36GNM+6XM]K>;/?6U6HLA3T*
M#+% W/@2G<?N18W/'&@NSOVS5ZZ?L3CXAQT5F@<^T0C%B2QQ!,T-(77_#NG-
M\=FZ6G\VS,+S$D6K6AG!AAY#*-DDHGYQD%I>O*%XC]N*?ME&=I,]4#)+ 5)A
M:FSSR&XC9'UHW"-V!HQZ!IVCT!6,[QYW'S,:X.AN$W!/Q-L&KTY;Y@OFXZ<;
MJ;*8@&].7>((@]^"$ZBVW2.[Q7&D;C-PQU_&?T(NT+??&XKSFMKS"UJ[N[*O
MPI63;"A**P#+RMR D9PXVJR#2[.;>O0HFK'R^**J;8?)Q.'*LAOK<@MCX(7'
M_:0D&XL39JLK%V;H#]Z,B4V8Z$]*K#^38'DU$:U?$_%I&V93.B0>"4;HF7BA
M-Z;B"Q."W#2,NH85N.X[Y)$X,,#NCC2O6T5CWVP:@,"J"];O1Y?0C(@OL$&O
MW@XWVX6$M/Q7'G0^=N.OQ.'G_P!02P,$%     @ N8E.6.5;QK I%   R@0!
M !4   !F;VYR+3(P,C,Q,C,Q7V-A;"YX;6SM7?]OX[:2__V ^Q]T.>#0!YPW
MZV3;OMUV[T&QY52 8_M93OOZ4\'(M$.L++F4G(W[US]2EAS9$LF1+9E<X!9H
M$SL<<F8^_#)##H<__^-U%5@OF,8D"C]?==^]O[)PZ$=S$BX_7SUZ'=OKN>Z5
M%2<HG*,@"O'GJS"Z^L?__>=_6.S?S__5Z5@#@H/Y)ZL?^1TW7$0_62.TPI^L
M>QQBBI*(_F3]BH(-_R8:D !3JQ>MU@%.,/O#KN%/UO?O;KI/5J<#J/=7',XC
M^CAU]_4^)\DZ_G1]_?7KUW=A](*^1O1+_,Z/5K *O00EFWA?V_O7]]F_'?G/
M 0F_?.+_>T(QMIB^POC3:TP^7_%VLV:_WKZ+Z/+ZYOW[[O6_'H:>_XQ7J$-"
MKC<?7^54O)8JNN['CQ^OT[_F14LE7Y]HD+=Q>YVSLZ^9_95(RA<XB<FG.&5O
M&/DH26%7-F,)2_!/G;Q8AW_5Z=YT;KOO7N/Y5:[\5(,T"O 4+RS^DZ&W;W41
MA8ARM*[Y7ZY[$>N-C,V4YIGBQ><K5H*RJF]NNS>[BO_[H%"R7;->&1/>J:ZL
MZ],:#><XC/&<_1)' 9FC!,_O4,!5YCUCG,1JCJ U7(3=":(X3)YQ0GP4G,][
M975M"<+'(UZQ]N+QPF5ST0J?)("XFLLQ?CX,P#I;%VF\Z#VC<(EC-W3^W)!D
M>YXTPNHN@4T/Q<^#(/IZVJ"6UM0 ^WT<^Y2L^<P\7MQM8A+B.+9#-B!CPIJ<
M4!RSQM.96\7_"54U(("W6:T0W8X7'EF&9,&Z:9C8OA]MPH19%1.F1Y]@I>[K
MU=( VUGE\13[F+R@IP _X#D?8V]?,-4]H! M4_C9AS$;AG2 <8%&)5:SK30@
M]GC-K32FT@$)V83/?AEBMI0K\5'1-<":&[XP#404T%LJBC:A&ZYYEXV0<$DX
M,'$,L 2D1$TQU=M0O@H,"7HB 4D &E*0-3'N\3+KL5,<\)F2&]ET!9JI(+0-
ML)A5SI;09#NC*(R1#^%.0=;(G+EFQ%P%*,@7E3KJ@Y$WLKBN5B1)ES\&%EL7
M^13 /$9 #P20-C)I<"-IAEXADT:I:"-0/L7XSPT3T^%S$F"AJRY_L96XV16Y
MA949UO",+XP-"7%8ES'&!4S$-MIJT=" "06C;M;H@'$F)&C+  $J3$W:GC%2
M@T45<<N&"7#6 -=P60>PCQ-$@GB$*!\<+TKOHX&J+S:?=QQ$0_8YGF#J/2.*
M.QE+S4SQRNHO)FA=$,^KU9C%K#.,PN4,TU6Y.B#0E^;C&U)=UQ3==8U3WD4[
MEZD]J.Z<TVZK+5J7G?3'!&U3OQ.(_4F5-6M[=@J_ [F&4;=EE78JOQWA9+RP
M5Q%-R%]%L^(DZ_6T)MH2N.X0JE5)>Z9Y1_1]'61.K[9E<[ZS,X[(7WB>%0,+
M=F:U[>U.UNUH-:MI?_>ROH%[4G7M[F[6%>*$JIK=_:S+,(!4QB"S!?Q-D (T
M9)\/*/!K@L,YGN?U<%9!\1\)27C)+!ZG:W5X\,Z&*Y7]FI5LBPUP/,<!CS>,
ML?T),6=R/.H[(\_I\]^\\=#MVS/VX<X>VJ.>8WF_.,[,L[Y['-F/?9?]Y6]Y
MT$PN4!#Y!T($/&HG.HJ0R2.@TMB<!8J?T@"=3=Q9(K2^YC!?XR")\V]2X%/0
MLR_^V*U&V?2=UQV@)QRD+?Z1E3LJ=JV%5SXE\"'%?O#8@1<4\$$V0(2F$5Q]
M$OM!%&\H%LM1HXIC&0L=S*:^%=$YII^O]FX.HOY!MRI'3&4EKF.^I*2+"V&]
M):=?T&@E4WFFWNA4<8KP,$ZNK*^8+)^35 (]<'K/S'3C/B2W6>/=C"E&KKHT
M#*0;K2#)Y&P0C_+$/AB/IG^4'3@/TQ?BX]3>6;.NPEVU"KUS:B@Q#(9;/3#4
M$>3"J+RQ4[#=B H.,14,AP_:<5#)W3X I5T,@<HKRL&4_+T^)0MENX!:*S>"
M1+H5%(8I^ >-"I9*>2$MBW?;LC&5=8,)Y6Z@C_E^B1TPCXI;LE)(SJT9AM^/
MFO%K1G\F&53YWM]V0$(2/^/Y?13-N1/Z6T2_N.&$1HQQB8D%I8?A^W>M1E<]
M79B$XH1R>V3NO*ZY&YKW4*"?!B*&X?=1*WXUM& 2>(=!GR(_VA3G4J#[MK4,
M]E38C)N?,X(=E ,:,]Q#F$-2(6S[.A]%":XTQK<"A<L(S/ "J[2M%M.D2:2/
M%YB-O?D,O>:'1;LO#F\SE6<7):$9_J%@V@&*;1)2S(Q88]:+)@%*C4F^";?F
MAB4;S+)%6D9EAGLI7);5 IL$T/Y /SW GW)NQHO'>'<(*T9(06:&@RJ ""2R
M21CM8BUP/82D1&8XH )\ .*:A [WF[Z2(!!#\5;"#,=0H/=C04Q2<D5HB_/J
M!QN>C4$- (S:#*]/Z*[#%6 2< 6O5+*:% L!/;_WFA:/LCPFJ;L07Z3<"JDJ
MJXGKS*WKXZ=$S7958=W;!6*]'_4?B:@F]:/<^YZ@+7<(U>$/@O*Z]Q? N,@%
M-@F:= :J,\Z%!+JW(\#@*$0V"9W<)9_B%QQNU -'5%[W1@08&[G [6_0/888
MT7#?_CC,XA9X7"$_F(H!>W8UZ]"] :'&Y@2AS!M*AWYZ+O16/=\IZ'1O3L"G
M/9 "3(*LZ+K# 9-3Z=ZK ,,%$;[]^;"WB9-HA6D?KZ.85'I=O%RYF.Z]"=BL
M)A+/I%%0D&04A7X-/ZQ8W C[!<*_A,0@MZPLB=R0J2AO4!<[//E)KR;D(0 U
M>U_]F@SRZ<"@UM73Y0[S,X>S:(Q)82N>C2MH#?+OQ$#5D,>\82BPT"#C#D!J
MD ^H'&A@39@$7Z7%!@%/26B0BZB$#J@%DX K[J*"3"Q!>8-<025,<IE-0N=X
M>85O31KE[:GG/(&<)F$!@N$$!"YBLXM&PID[P1H-5K5$9@]M+XG\+\]1P#06
M'Z:GKKB06%%66\3XS@U(64IO?HK9KBRL>U"(]5X."Q>):E(_XCD HA "1[FD
M[N$,QD(DI$E V/,YX2*C8(((<Y-[:$T2)(FE$1+H]C;!L"A$-@F=*4\W$>)Y
MGI&/.<J;U2;UCOMX07PBL7DAM+H]3#!F<$68!-^,,I]J0[>0>:ZJK&XO$@R/
M6- *.#H&62]NF,7037B6+*;6)*'D:9.D>7XC;HOQT](H8%PLW3#!%,>2(==4
M_>99&^?HZ3C;@[A3&31T'T@8T51P%>CEDN89* W")U*,2> 5W"D[G-?Q6=24
MNL<F5#:QA_G-.,MUY&NXSTM5\_/UL6:&[+.F9%O5CUX=9-ZZ/3?SEO7=02M_
MNVAJ,<EK90=2?H!)Z<W8CP=GQ"0<#RQWU!L_./JSC&6'SI(]NK<239Y"3AAH
M3%T#C/-C;YXS- \1VZ#@+:$#&XT\759Z4"<XESRY-MV3ZK'ZBX>39ZJH_9/D
M"8WF&S_Q4)"FX!!A<UQ*]T0OU7FU2.WKLBKIE5BGPM*Z]T)DNE6(J$?'AUFN
MZFF\@E;WOD9=_0O%UY602HR I+SN[0J9UI5BZM*T.)=2+0!DU>@^Y:Z/BUHI
M)KF;O2A.4QEGN7@D1ERYI,83>L[,>+$/W,E04AS6BXAT6W B#*J.[.6"7R!$
MF_.:=?%95+1U!$->1J#;C%,I7L6_'J772/$*(=1M[]4'06]V5S4OH'2O]:O1
M;1@V Y2NG+"'G-5*90HCU6U!UH='=Z93"#<":^H,I(0UZC8UFP)0H3*3K,\I
MCC'CA*>Y[S-+)HC2=%.9 F3[B5(RW7&80'L.)+Q):'DX/7"XQR&S/@/&MCU?
M\02LR>X]$25L4'K=M_F ^-53ATE [HXBAE$<#YCLNU=L-DR4S*V(PO@.+R**
M\Z.E3)3\XXZ\<"W)>64R,UA(B.C69:J-JX^H!#L#&5MZN=+M!)J 26F".MK[
M,/+0U4#%"2<0DP**X'JKK9HFQO@)C7X[0_ADC98RJQG0]PU:V%(;F+$<Y?MC
M.]F4EHF*[MN9XYKJ63!-MN\C9N]K\K8!R7"$I75O<ET00*D>S!NR1U.3;.DX
M*JA[/TS'=%^I*\/,BOP=M)W<"I._HK#NC30=N IU9M)0G=!H01*N&#&BQ3*Z
M[;$ROR>;3Z<C;1!^>S&R^>,.AW@ANX8C)-!M#P&1%8IJU(S)1OM;1Q2#<51,
M]^"JY+K\H, Q3 8-AP,)SKL\<T)5NH<0!+^3-:087[J#T,MAV8!(].^;B=$V
M(QY]O.@]HW")8S<\NIIP(/,/-67F(O=^L4?WCL=$MYQ_/KJSWP\BU'5%W^<O
MS@L>^/[Q%'![MO>+-1B.?S/@J6\V5+F(;,9](4QG=]O'F&<.VP<*V7Y"7A2I
M-.K4\?\6*'"2K8G*-[6"IML,?;RFV"<[I89S>\6O+/V5?E1LN$DI#5@?SX,.
MJARC )4]+U1D7KVC6KLFW5MTYP-^HO(N<LOFA<2LY4%$[]"<9^$27H.J+*I[
MJ^UT;,0RF3?Z2@D_H7ZZDE#WEMK98PNHFO:'TCTBX3CD\;_CQ?Y]/,#)!(!.
M=_S9>8,,K!BC]EY8?^+I/W ?[WZZ8?GM5NG^&(!:=SC:V8.OCI*:1%<P!,OL
M\!=@Y8!Q0@"=[LBS\X8@6#$F+7IEIO/7W:6^JH),]WMX+8RY"K48/I4>/O,>
MIPY1'42KZ;6_L=<"MC)-&0YR'BB2)?Y4/9<(K@ (L\%[-S5U93C.1WGN3S&*
M]J1 ; W>W 'KQ^RE=G>E=-<;0=F6:U0!!-G@#9W:^FK?_:Q@J?+Q O&]PUHU
M #$T=>/G!&WI@'#WB %GZ@3TJHF!P)FXXU-'3(T^9_Z8ESU_X?F3P'B5Z(!0
MF;KO ]:,V2LA6[[I!L]/7 2KJ(&X?FO[/@(MF82N0/!=E.5Y9^&5=6@Z"T?;
M-+9A%MG^GQM",>.509ML)P%*+P3O=V$E9^4UZC#T+%V"ZO%9>FV%&>62E=AW
MPP2%2\*<#973#2 U]+C]#'1%ZC$*5('8>VOGC*FJL@Y=U_S7&3KC1;HEK=Q$
M$%,8.@U)$"O=JI4KPZC^F8^J0409WQOJ/S,[(,T@^L)F3CZX#A]M4<]!\)H,
MG9+@2)^J/"-[P'C1)UP/X3R&YY<'$1L:^%,?9X"*C(*62\W_XW;/"PIP>J ;
M)Y3X"9[S/Z2)FXI?%$I.,"71_-A%<%ZSQ.7LES3 >(H2["P6V)?TDDOSH7L)
MT:/W<FQ_7>_0R/0/)BM39KV>H<P6<_$9K$S9?&S*DP=]'/N4K'D]X\7=)B8A
MCGDBD#L4$[8\L.4^9IHZ#/\]N(?P=ZMC\33L011O*.8?'*\W=2<S=SSB5P[N
M'CUWY'B>98_XHP>>FUY$F$P=SQG-;%ZJK1L6'N]!=#M>>&09D@7QN<^\._-*
MWZD(B%]$Y$"JC\=2>8\/#_;T=\Z[Y]Z/W(';LT<SR^[UQH^CF3NZMR;CH=MS
M':\M<<H13%F^M+<O&&ZB!&NE@)JBN-WWQ^)F<GG6U.DY[J_VW=#Y7^O!Z3.I
MAX7O4E ?[)%]O[M,PS^.9[\X4VO@.$7BMI2RG_S?=MOY$*Y&M=L]%G,\<:9V
MBM[_H-7Z)VO@CNQ1CW\>.K;7'I95D3$'G-X<<^J.?F4*'D];[&!9"@;!'L0!
M>[<E1::@NVQ$C^[=M&-XGC-KEU7)J>8!LQ^JF>T]3J>\SPY=^\X=NK,6->OA
M938BL_!2-UQ$="6>5;O?E^8?YWX_PJ;.,+W;Y8X&X^E#JW-H,1QV1E$8\]2,
M(J9_.&8Z9W1B3V>_6[.I/?+L7KM3_GH=I+,?"O+[<TI=_UB>ZR>383JAL<EN
M?V7N$NKF;YB2-*T"7X-WU_N7.!2N4]W2ZML;/SRXL]V%/]Y7>N-T=7)&;2Y-
MA6P#U6R6EM/LENG,_E>+HV[S%.,_-SQ#)9]MJUF[*2U]WN.=Y_SSD0\VA\^Y
M+?('L4^D=LI-:46#VRG6=WG5K=UQA4DXXW:)0+[2.EA'OEW%K4G7C$$FD[ZT
MS#9MEK6N(Y%])I.ZO%XKK+36I2B8:S+&2XMVP6AK7]-5UIN,V])J+;#A+L-Y
MV9B3\5Y:LH4F7>O<RVP[F0BEE5MAX;4N2(V=@#Y_'SJ(1XCN$@=72UA:]&OO
M#%C?92U9^Z8TKU6=_$GL":;>,Z*XDW%8J8+;"N,"O'QUK+PMBS5FI:VQ+W.5
M:%8$J O<GF6>7 [[9E;RSC *ES-,5^7JI)VD9.,TOLIW+,Z:Q7FS<N:L-^[:
M[U.74G"W6L/MVU%0#5M=PW4L[:DERZQY>_3;Z(FPV:]D#[:FK@O,D2)+OI/^
MR ^4I=VG;'&J#'LVK'CM5EY]^_VC8.IW"K]+Y2I9HT6[GWUZJZ; O[94IYR5
M[8 _^_",Y_=1-.=&WF\1_<(O]44^EF4J@M)K3.ZS9S'="Y2&H8G*ZSYMKX=2
M51(?H1),"GK>,UFW\RDZV^53G9\!EUP)QAP35^XN="J_31_L+B8/DLZ=)3=8
MM O!_L);L\B^.0NE[5DA3JQH8:%"D^VO$Y6BP\R"DE\LW'BYX.I>O0?3$7TO
MP_1#R>L5[\[DJ&9-6(4V#GQ=?>M)@:.,2<6"4D6@9X+-[KYX*$ 4PKZHO.[U
M4('#T8PJE]JD!3!]DS5]=,<G,3\^R^*JE4 I"74OB?40 ^JA_8NN:3[5PF&F
M..@_?5I>5%IW3!Q0^U(9S!LMV;CF^469A<24@ +NE$-G-2&=[DR!)\UN"BU\
M.[BQ8?^67N14$(\JT9T[L$E$*_5C$KP>#A9NR P]?G.:/Q!*7R2WI*I+Z\XC
M6'.YDDAL$C*I5.7[SY#A!B#5G2.P'F9@71@'H+<)YW1;VPL1D^G.&'@"<"H=
M&+--(@L&Z.P.5LE?S#?9%5.XT>7#4T6$ "NQ;\+*V[C$D;$@2A2T'?*A=/PI
MC!J];#B -)(4)EKIW%$=67I)&271IC#Y2N>!TNC32XI6<&E@HE3$;KU%J(HY
MS^86_K\G%&/VS;\!4$L#!!0    ( +F)3E@<CXR:#20  -\Q @ 5    9F]N
M<BTR,#(S,3(S,5]D968N>&UL[5U;<]NXDG[?JOT/W&S5UFS5*HZ=N25G9D_1
MLI2HCBQI)#DYLR\N6()DGE"$!B1]F5^_ "\2):)!D.(%G-(\3&(' +_N#Y=&
MHX'^Y>\O&]MXPM2UB//KF\NW[]X8V%F0I>6L?WUS-^N8L^Y@\,9P/>0LD4T<
M_.L;A[SY^__^^[\9[+]?_J/3,?H6MI<?C1NRZ R<%?F;,4(;_-'XA!U,D4?H
MWXPOR/;Y;TC?LC$UNF2SM;&'V3^$'_YH_/#VZO+!Z'04VOV"G26A=]/!KMU'
MS]NZ'R\NGI^?WSKD"3T3^LU]NR ;M09G'O)\=]?:NY=WT7]A]5]LR_GVD?_O
M ;G88/IRW(\OKO7K&_[=Z+//[]\2NKZX>O?N\N*?M\/9XA%O4,=RN-X6^$U<
MB[<BJG?YX<.'B^!?XZ*IDB\/U(Z_\?XBAK-KF?WKTMM52!;^X2+\QV112])T
M K1K?70#289D@;R@AV0B,L 2_*=.7*S#?]6YO.J\OWS[XB[?Q#P%RJ;$QE.\
M,OB?C.C=5U?$0903>\'_Y:)+6,=E,(,ZCQ2O?GW#2E#6]-7[RZNPX?\\*.2]
M;ED'=BW>_]X8%\4^ZBRQX^(E^XM+;&N)/+R\1C97V>P18\_-1J3:0BUP)XAB
MQWO$GK5 ]NG8A<U5)0@?NGC#ON>.5P,V;6UP(0'@9NH#?CH-BFU6+M)XU7U$
MSAJ[ Z?WAV]YKZ=) S97!S==Y#[V;?)<;%!+6RH!_@UV%]3:\IEYO+KV7<O!
MKFLZ;$"Z%OODA&*7?3R8N;/P%VBJ! %F_F:#Z.MX-;/6CK5BW=3QS,6"^(['
M#) )T^/"PIFZS]=*";"CQMTI7F#K"3W8^!8O^1C;_X*I[A8Y:!W0SWX8LV%(
M^Q@GZF2)5>Y72A![O.4&'5-IWW+8A,_^,L1L*<_D)ZM>"= &SA/3 *$*O450
MM S=<,T/V AQUA8GQG45+ %II;) =7W*5X&AA1XLV_(4-)11K8QQC]=1CYUB
MF\^4W!ZG&Z692J5N"1"CQMD2ZKW.*7)<M%!!EU&ME#ESRRIS%2 [7E3RJ$^M
M>BF+ZV9C><'RQ\ABZR*? MCF4J$'*E0M9=+@1M(<O:A,&JFBI5#YX.(_?"9F
MC\])"@N=N'QM*W&Y*W(%*[/:A^=\82Q)B,.VM#$NU$2LXEL5&AIJ0JG5+M?H
M4$,&5JC* %%46';5ZHR1'!"S*E=LF"C.&LHMU+L!O,$>LFQWA"@?'$^9NX\2
MFJYM/N_T$'78S^X$T]DCHK@302IGBL]LOC9!\Y)X6JO:+&:=(7'6<TPWZ>84
MB:X;1XM4=ZF+[BZU4UZMG4O7'I1WSJGVJQ5:EYW@CPEZ#?:=BMP7:JQ<V[.3
M^+LB:K7:55FE'>%O1]@;K\P-H9[U9]*L*&2]%OM$50+G'4*Y&JG.-.] O\_#
M3/%F*S;G.Z%Q9/V)EU$Q9<%.;+8Z[V3>CI:SF>J]E_D-W$+-5>O=S"M$@:;*
M]7[F!:Q05080T46,450X^6T@F"2.:>%1)#\$D!Y9$W3A/^#.TF*:= -7=O2A
MI!)VK5B.=\&*7D1E+H0-5(][]['.DFR0E1-TNG8-B(,O=39X\\ #:W+!/:Q:
M/59DV_D0!A6JQ^40S\P++:Y3:Y_$*^3;7N%.&5<_Q,Q^;3D6GY^'[,<#W/C%
MP\X2+V/DO$&E\"_/\GC)*'+OTNCP,#^?SZGLKV')"$.,PB:+@T_;/,:-T+3.
MW%C8%7(? HE]M[-&:'O!)\4+;'MN_)M@F@QT&/WB?A<"PD3% _;7G15@HP=L
M!Y^]CPJ+REXTBWJ>#"&0(([*':/=,VW2&'?4313'8M@W/R[8HLCZ1B]<ZUG_
M#DVK&-F*DDVF*B.U$:D$2=TR(&\,0I>8_OKF\MT>BTU<O/SUC4=]@<@U$Q2&
M1/&(6N($!L2+I=+#Q-5*I4^XH&;1=<@"0)5,9@%S37%T!/,F6J$A;H#BI7*2
MMA>R")'JFJ@( /%R]:[-Q-Q?"N"7Q4V\;)XZ^9U*7B DQ-_[QOCC^R7BS#RR
M^'8;F9(0=ZFB%?!V:-0"G,@'!U$ #<YOC4UPNW[6M9'KCE<!8L4%*%VE)8L/
M)*M@@FML?"0@9DUNHK(-+SF@ADDF<OW6FM.X:,4J4Y@OK9>7 .ZUVOJ2+'LO
MZFLU+#"2X2!:75*0P:'3V/*2 -K-P4-4]E[4@33E(0D9' ]%>4B[;_OCT32<
MF,P)*X(IY5=59-84KP%7N/]>5U4KX(;T_7TI_=[%B[=K\G2QQ%;8Y=E?]CV=
M_7 ?NZGFK$6!YEF19(G['YM1=;8_1004TFTI4WNV:DT&9LD!]6VT%NOVH(C6
MRDTCK=3AD4.[B4C!#"4G2K9#U\> *S7UU>>**5Y;KD>#(\Z=0/+)0UA%:Q*R
MD8-+9;ULF([C\^BF+:$9)"1+MD+W*<#@:EFORG_S$?4PM5]5M'Y4N!6*%V&&
M=/]#S88*CQ,)5*6B_./2K="^$#2D_A_K5?_L$=LV]R,B1ZGWI\NW@@( -D3"
M3\V1$%S%NV&BJ?.PJ](Z*@Z10VS\7"\;$TPMPA];H H\'!5N!0,BS)#N/S2A
M^YZS5-5\5+1%>D\B!O=<-6UI8V1]RUT@.\379[\3';DD!$D5;X7ZQ:BK/0?+
M2\'O&%%E G:%6Z3^0\R@\FO: 4=1XWMHTID'*JVU^J6@0?W7M.?M.9[EO?)G
M_$8^X"MFQ8Y+::UO(5A0SS5M=$-0L>O#\?A+A3)='Y9L@;X%@$&=U[3!#8%U
M&7R*[(&SQ"__P*\RI1\5;8'618A!M=>TL0V13:C%;RK/K$7VQ')<M@6*%T(&
M-5_3;C:$-D<O@R43(K@>SO6530!0I04\R)"#=-2TG0T1\KLU=$L2_NXNOTY+
M7[MD*5T"I!5;0$TV?I"@FO:\(4YSN:3\*8SP#R[7I8P60?$6D &A!@_ :MK_
M0NBN\E%PU4H*KN04U+3_A="]ST?!^U92\%Y.04V[X -T7?;7,9V39^#T'2C<
M'O4?80:57^L6.,(62#.F$TJ>K/#-]"P&CFJTAP81<)"+6K?)<3\)S06541"6
M;(_NDX!!G=>Z38Z 38CK(?O_K&V6=2HJWQ[]IV&#+-2T:XYZ!'>C0&%7!T6T
MUG4:*:C>FK;&?,TQ*49PMTZ6T%NYQT!!W=:TSQT2?JKS2!RI#_FXE-8Z%H(%
M]5S7=I7?I7?!Z6'WSUIK]A EI-)R+HMDJ_0KM3R&AX?N^T[D00)._H1%M58U
MC!A4>TU;SEGP4"5_%>>6R4&M?3*30YVGRVFM<  NJ.V:=I<3BGD?P,S(#X+A
M^(,<=+Q:03,U7%YK[6? !EFH:9MY!&_@NCZF>;E(U6H3(V+P("\U;3EG>.&S
MB?+U\NIASM^< 6:BHU):ZUT(%M1S3=O,$9E3Q-,0SEXW#\2&K_ ("FJM;0@O
MJ/":=I0'J,2J/BBBM9+32$'UUK2CC =9[V41I#.#(SI$);56-@@8U'E-.\W]
MQ+96FJO7;9JKUPIS=4T[S1A4&*C/QMWXP;;6!_F$Q"H75&B%]B'<$!&B"])5
M$!'>UTH\@-IG?Q%3("RJM?)AQ*#:Z[H*ZR\M#R]#@-%#X,C>9W\$&,BHI3<9
M*N!!7FH])_V*;?L?#GEV9ABYQ,'+<&,A.ZT JFC-2#9RD(Y:3TZ_$-MW/$2#
MD%L*C UAT1:H7X085'NMAZ116/ENY0JSGLNT+Z[1 A(DP$$N:CT\'3@>IORI
M]2=\@SP4X95Q(:[1 BXDP$$N:@T\#@9JE\FS)O+8@8."+=!\&B^H\%KCC6<;
M9-MQ0C&9P@\*MD#A:;R@PFN-*.YM,%VS:? 3)<_>8W215Z9X8846$ #C!HFH
M-7*X][)_6""\U2AE(56Z#12(04/Z_Z'F:[/[W'=,)F>)*,  7%YK#C)@@RS4
MM$T.\OXDK;( &A=&%@B254MK1I3 @[S4NDU./O,@7983Y;36/0 7U':MN^")
M_V!;B[Y-D-3N3Q1K@:Z/T8*JKG7G>XV<;]3?>HO7"24+C/G!D+L;DPJ;+Z4&
M6D"/NAP@<?5>Q=V_@QZDW77'ON?R*92AE3HN)/5:0%,F?)"=FI^B<O=7]O#R
M^G7*7UCEP1MS_.)=LP]]DQM7F=6UYBJ?%"!EB:WW+Q=' K+/?XO_3?!/!XWF
M2YS$2CHNYJGF7&);RP ZLA&#S99+O#^P.,RJ=&5TC)UN>%JE\>BF-YKU;OC?
M9N/AX,:<LQ^NS:$YZO:,V>=>;SXSOKL;F7<W _8O_WU.P71.P90817^1%$SG
M[!="MAI[-OZ<_:*2R]GG[!?E\E5-]@OI:_\CXGPAW-;/_>R_M*:^*2_R" ".
MGL9F,D66HN+MRLR0!1KTV)>=!F._V7+EXR!5L*GMB6*W%^.%]/JC#FE>BJ3;
M^5E7$N20(1Y^UH&'(NEV+M^UAX@#S/!VHS$J3-=EF_#((6<^\'?R%B(/951>
M6/S^LJ$$2,K[/@ELB)/F#%GD/IK.DO_!,SD^(9N[?OK(HE^0[>,;R^5;4I]*
M-NK*333&7#8AY!2)M-LISAX)]>:8;@;.$W8]*%0W[M>"TJVA"@8/FKWEVEG1
MD;0[Q0O,>LJ#C6>8/ED+S#K0%&]9G^EC+-(^KZU667\R\LH"[@XKX6:/:(IM
M[A*>(.I96:1 M5K%AEP(<"]2+@VW>&DM>+:=& N@^%2Y=J@:@ V>C)2L7.2@
M-0YS&BV#J S)?",NW!(U2["#F[\*='V,(#7$HOXP":*#%]@=8<^T;?+,3Z&D
MQ)S6<HM8+$-0B/)20GZ+&%W< '%8LZ]]IG#W$2\_$;)TF9A?"?TV<(+(!&%<
M<-2 6GW]62X@#N@S:-!!R0R69>]ERX^3XZYZH *IOS*K<FM85)8%HK"4..23
M70V*+H;6T)*#@,()?)3W.VQR'A)GS3=ARMN<1!W]E:XH LA R9[]$?&PT*X7
M1;?R&G"%=N@^"S^H^%+"C(M,/C?1X<\<O822QK_@,57"YS&BFAD5]><KCQP@
M;Z4$+!=;]\D6LWXUL5%@H7+OWY9;JVRPRQ9\N%9K&,L6 J2KE*#G(G2-&6+$
MS[Z'&+EX:JT?O?'JCMDI7':8+VFUUA"F( 7(6"G1SD48"Q]4P/GXDE1J#5N9
M,H!<E1+[7(0KOF%[MFS1DUE1D;A$:U@X! RJO$$?@H><M<6LG% R-O?V7A:V
MSR/DL^E0J=T:JM2% 6ELS'V0V"1+5J%]H=:0DL(,ZK[A?7_6AK\U&E=1=G-A
ML$,+/5BVQ4^4E(,ZX#KZ1W9D80<9:BP4('91W. '+],9)BC<&">*JB9J H#$
M-.8BB!U*$_3*O1K9CDIA^7;1(Y,!9*@Q9T"PV*7ES%C1TQ7:Q9%4")"DQEP
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M=%V&.-RW%PB0D2,^9T/ZLUM((.VLQ7-*CEI2<A0]WH)#1ADJCU^@"I?R8)T
MEDMQ88T)R )=T[F3O ,<'VT RL_7B.:D%!%&X=2J9O_?.>V7C)?$0W&:G28J
M7>A[?](E<\%-/ITO9'>&Q%G/,=VDFY,>M*9NJI=^6;MC<&@&QV;$X(P]NJ;/
M96-((^)A?GUT2)"34%YJ8 ER&BBWT)!W=G==Y@!I )/!W5UR/[K=+_'=%FU0
MFU/AO*0?^X!/TZCVA\JJ4EV_)B1D>.0N_]-:;>Y4X$2R28E*T,XG< @RRZ\M
M+MW,*4,I1!QG'X&5H=-1Q.FDZ7P<41.QFIY9B*S)C)1,0(V&4F5)!Y%X+A4A
MUVZFO"'^@[?R,S-D'99K*DHA!PL"P*5'* !NF70'B*[Y!(_;;)$5;)( =XQ:
MY:;>)RYJH>:4K.SC(V6B1MA+/L^HS-%1O;\&/2*ARI[  &92O@: B52Y-FI>
M+$39!S&0IH4>G!%Q$M1;X&RE6+N5K.00K:9#E0 2[&R+@$7=:4+YN[(+!AE[
MIFV39YXG0LKC:2VWEN,2Q%8X[ZG-55V7X_92[+FM_IE-5<^M<:FW;USJ $\]
MW%G^:Z7-.KB9<&B]IG@=W6:>XB?L^"J.[>R:#6VEQ+@RO-;R6MJXIE7I.MZ%
M*>A$>[]S> N_BR@>)Z[G1Z+,B$_9,B#W,:NWT)@_68DI4E J[=P>*M"S/)!Y
MVFC&F9R;H/S\ZNM.KI=BG5W/M76#FA\EW&S8[&;QIS68C<2-\=#B6G*H&>\3
M9E=MR,]<8,R1_(+5ZL6AD75L+:6DB LW=5WA-!XDLH 39<FZ_TKH-TQ=?J./
M32,!^@G[F01/T?S+IZ]2,A1K-Y4Y_C1V\@@'[NS+?D")[P^EE"1*-/5(R&EJ
M/Q8 4NV/):MVPE"RY9%MOB.D(^R-5\$KKVCA^<C>.W/81IUONOGF'F"A6&/W
M5PT=F.7=MITJHL+!3<L<86HQG:E\)96Y:ZJ/_(3RS'2"/R;H-<BF)?5>I3.B
M9*6=Z1A!ZT;<?-/NJ?.[..=W<2J[K+:7DG^$:UGJ/9)6TOM9 @5Y-?(* 6BS
MO 09U9KQ_:AH7HDK?3T\5="ELQ^G9$IK]=;LC(H#(T*^X9%4:<@[HS9$B+H,
M-3EB#BTY)>W+JC05_I=;_9E"@/IO; T:8M?%^+#?Q,G\7G?&-]^4O7CS9VP_
MX5LVC3Q*S(>B+=[K?GOP),$4=JKU$A_V55P"X7E;TI[H0@)I9UVJ=M??,:+S
M9W+Z@(X:TI[>(O* UJBNPS>35<4&M&<SCQR@]=F*,<J^*?&QY&Y*>V:+202>
MH&@]4N7<*C>A/:?Y)(&X;.RIC#Q=LD]\R06GO"UISVPA@< S.9T'JYQ8U1:T
M)S27(!"1/[5BI";.V4X<J:PE[8DM)!!$\,]:CU0IL:HM:$]H+D$@(C_H/E*#
ME&7E#=>#YK2GN+A4LI-*/4>N(M&YFM&>X/S2E.Y+AN*9*'89B"_(]G%6M)*@
MJ+Z:ER(&M5OR?5@1@,-CA!RZ/JS8/LT+\(,\-.:S 29A>*("*NA+CP)ND!:]
MW"PY5P_M*8%1@X0TD0R/Y^US&,4\XUWB[](8OI^.8_@&HR^]T7P\#9/9)9I)
MQ.I5%)'(PS('CH><-7]NUV2FE^=VA+\-8E7-#:%>%)TLE?'G5)QB$'LY&,W-
MT:=!$)\YF_7F7-[@:X:U^YR!@N\9#O8,LC)0XI--QR[VN<Y9=WS"RV/UI/JS
M<" JU&[ZS4@)2N5G(K/;T"8N,@^EX*N0JCK3/HI2(LCUZRWZ%Z'!B]SRJ,I<
MC6CPS*,R>ZD5*J^N-#HSEZ#?8Q^A3>9S@;D;:B9JLPA;RGS+-*937&=3I.L<
M^UE[Q]#T(<D967G/B/*;._%?;_ 3MLDV2/5%7$E88SREJC;14)!IT1%,BDM9
M]KP/W\3CWC,&J4NVKY2G:I 'H<(5FKH7?"(Y"D*!\W%CB_"(\+C;+?:PN:88
MRV.'HTIPG:;N#)<SK#+D@L@K?%WX]&R!ONN1#:;!6V8\Y].CM<UD3U*IJ;O'
MY="7)1@8_Z"C!?R)$K?8!B>H>7_94!C_"9M9-9D@%G6T:,W%PM_XP3N#2;=5
M(5J!MOYB1$NEU&X'*W!0]EX6ML\SLGTB9/EL!6XA@&R5VFVD5UTNT!QJP(TN
M]#BK/1#P0=73++KGK]N<=?8BG[W(9R_RV8M\]B*?O<AG+_+9BURW%[D&]Z)V
M%G4)WD4=MT>ENZ?:Z1=6%$P_WW!R!SY>'8L.4RBO=_]!.Q:S#&0%@13<4O5N
M9;L^I4&06QBXQJ/#H-_+PJB^?R?>W';OIE/^J-UP8%X/AH-Y&#@6!E)%GS 2
MWV#_5G4@V0S'V3ZBU!X#9T7H)B"M$^9XMO[$RZA8AM3I/,Z]3[M'_*:]H3GO
MW; -?G\\O37G@_&(E]A]PHB_<2#U^:F[_*C/3]WIN;W>P=Z%+9L+SWH*AGH\
M#J5;:^4&]'X"+Z<>-++-(G0"W%E;INR:S6R,\W)!<DJEWRZX.@YUWN=6RW.M
MF]KHS>+>'[X51.XHO*%_7+BAS:SR<$FG0A0(4/;LF)D.<;RZL=#:(:YG+08;
MM&82=-FO,97[%-0;:.H5O4*\Y),*)*O!C/#!4^82<R,N<7^I^Z6C0Z1E!SL
M V,0<!QVG2 Q+*A/7APHK;%N,U%K9YZ%KV$.B>OVF;C\?7[+\=EPC 8V<3*?
ME);5U9BJG#(H1!#42]P-WE*\L*+K:5L;!_IT%.-_5&KK3YZZ%*"AU11]\2,
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MT:<OYIHU,I!#LG1E0'%$ DQ)#2Z+N+ G1OS[/LA+G">O1E((DJYYH8 ZI,9
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MWT%P0P%JR 7V&\K6Z.V[KQZ_1K66X^*_RQ[R(")-XNIU^Y@EBNQ34BE7)-!
MK'D@$0%!!34N\;H#5(DB+NLC.U4/K,2=P>^N"""%51=][T<0A2Y#)%3^7EE[
M"OFSE_")9MY5'$B0B[D._3*0P_#?E0%! 0TP85!2B:):UL>!A+;)VI@[ 1MO
MG8"-H1.P@=@)V-AV C;>.@'U8WF*$!*7%H])O D4R0FUTJY)H8$\Y(=$%!15
MU/B4,:-10:V.ZXR6+,79/%UG^98]_YI\D'BID'.6TU('LTEJ*1,"P1$=,B&M
M)4\ZUQ%&5-HU+_917.*(@ZEN< V2)CVB;$;<K.*,+9;@&^(8Y&%PR ZD0">N
M5N<R;!3;5)>NI]+Y!HR?<9+\6YI]3E<X*+(41WPN1;92I)=WNV/& +N_:48A
M#().-@@56V>HTN5O5 O5:M5,F!<F_90E^[0,<G:6/)=%)H6<6^8H8/89,Q "
MQ!0Y,@5#&F'$I?T<T.;9(YI.%@UXTA0P>G''Q[6UH >GMJ6R@#BC!:@ZPUWE
M_&C[QES+TQ'+$N<!O<4/7P5E4&%3^JL2=WVH4@=Z>)I2)@N(0EJ RO.3C0Y-
M%1/4G/*6,B:?DJ[6)M/L$A](N4\<(T 4<\<T(H#H(<.ER2"3HUK6"Q=6VR!)
M/NR+.,6%NB$:2+GE@A1BGPL]$4!<D.%2<(&)HEK6"Q=F6YS3"QD_YMGG\JG*
MSZKT32'MEAM:R'V.2$4!<46'3\&96@5QG3JEKA_RO+0)Q7F61;6G$E''M%&"
M'7!&D(-$&!4X@2T)#NE\RUU6HH<,?2HP*I\P8MM9(_)])Q,\M^/KII$PI <B
M>*\\C8)<1B&=L/-;1Y2 A;M'!$D01#+"4]]#TFB@6L4Q:]C%KMUQ' -![])3
MGG8PJ[ABD"WXFD<F>1!LL@0I7$[/;NCM#:Z9(KL7T6<VHVYR>W47KR?DN&<L
M 3CH&'<D0'!$"4O5+>[>%> G=][^,8G#ZR0+U+,L/1G'&?-$>(-D>:T ( :(
MJ%0I\I@@8I)>RO]#D/Z6[W=E^+K,LQ!CNLNJ:**5:?[-4MLM9T:YU&>3E2H@
MGHW!JV!@:P)U;%QT6BR?DWETTSC-YI:%OZV> O("%_NRH"TH ::>!=<J.5Y>
ML'!@L,B@T0!$/0N8J@4'IHF8Z@7BRJBC[6E\5K19 ''TX?4>KW%.SQT\X)?R
M WG0;YH1AH6NZ]&;M3O#P9Q1$00)QZ)5#?4*U#6 'ND>L<H$^H4:0<R*_YON
M)T6!RZ**Q9-'FHP['#;,!EF7]]UKX7:OO)<*>J>8#3K5Y0E<YWOOC)D&Q=,D
MC>@_LW_LX^<@H7R_#N+\IR#9XZNX").LV.?#W<L'Z+MDUFBWNFRS5@;#P+&(
MAZS\XQ_>_NF['Z@Z(LTK"ND'W!KRSM+5$^EF/N!\.T^?<5'*]CKJ15UR3P>V
M2S.9'!A&:<#)R<,4+DNB@>)6Y5CFK+,T9W1X2_[+*'&]N+O_M9IZ):.8$!.2
M/B9XA?/G.,2D$I Q">']-<9#AHS2=$&8 URA_!FAYIU.X['*V56;0'EC _WQ
M#__[W=NW/Z 4'SWLU-.LQ7V/$]H#7 9DT*OEEUK%-;%,X(>,4LF#HI(!I#V'
M+LD?S #:$0M'SZXJ>'2+HSBDU]O7SY6Y)A%RQA4EP(8=@@0,/JA@R1E02;L-
M(K=!&FS8EGX2[MA"CZIM4DFZHX$6:LL%J1@00NBP*5C1J+#.;\;6XM9$RP-/
MAL"%0%=1>,EV4H:XN,/E)$FRSP$I636ICC7KEH&G>0E]NAYG$Q"W3^+(L"*,
MJ@)UB[FMHNFN?M(I*\G10T8Z;DF)V=?K.(V+)QQ]S+*H(&_NYRS_;9ZR90QA
MN^=899?#RG$.=0>:=IK>.7X07'E(KTV0+J%W(BYS.L2)9B\[G!:XKKJ].4/%
MB[#2=$G!$:YT^6>A!H9\]ECES*OT$>8&BDX\#:NIWX 9\\Y+&P9ZY)J15?[X
M4V9ED-S8+@BHDE10(ZB_'.!LMHST"6ZR=$/G]^PF;'H*'N?&), U4V(=:>\!
MQAJB<%1<,_65$%5$YUS/Q)R[K,32N9;A9D"CM#/.F"$WA%&+PF"+$9^\":)J
MNG[[26:ZCFY^KN@*>HZCA^"%![_Z"[K4+J3.LM9RV419NM!MM PJWGDW#J><
M?[4HBIDL*H,7WN?QSCDR=-AA0OXE04T'T72M=$='O20**_N#.A6WG6\S^'ZO
M6RT/AF<6(%7];*[(^M>XU@(U [$@  .Z.?(&!P6^CS=/Y6+]B0PJ:%U0O ^#
MCDN^6<'O$DZK (9Q-BCEE&.RE]GZ<E]@WF%OZ);51E%"K7JG'L\GA$<03ZOA
MDG86T+NDTXB#H9P9XVC"K7G"*#"$HU-TG^-$]0;:GUU2:0BJRYOZ-S D&0"2
M,Z(6\E[>\[0DZ&(RO.#=0])<SU["9$^W9ANX8*?J=F;=WIG^O+I9#PR_1H"5
M<X^?48P;,]4\)JPN5SM9JVK^NQ).NU,BM%[GJ?T9#&5$3#IF@)K6UD[,^IC(
M5L]@0YRZUA8WG[D^S8SUT<5]$P>/<1+3S5]VQQYT"BYI80;>I8I:&DRT,$)4
M'87H*/H_#U%/QE_AQU*_-B:5=,H@-=0>=40Q.)Q18E.1A9TWS5*:W9TN?O -
MYQ%1]\Z<>IUF&;S2:7?#PJI"V&G#I 7<:ZBDDF!8I(6G7$[;<6GOO&&])S%X
MZOID,FGG?5DU9*%?*XJ"X8X>GSQ/2[V1(VG5O+.H7G2YQ\\XW1NBCTK8Q^*9
M'+!LS:PO"89!6GCR'O2G% <YS<^=<QU$&K2"'XE!Y-6Q3M.Y-H/4SZ[@+M+J
M+,ZT?JYIE7^D 6<+_P<YUNP%&*7MG7L'0SZ"CT#W$?37<^I(_FIH10U*_M;9
M5 ZH%]J&&M[).0JF8D:IOY[6M+2OZ+)I?:N1@'<"=E=W+.FG5_&UVF9#/9T\
M&.)9@)33[KJ_JG9.VBE:Y^F^*+,MSJ_P+BMB81Y3(>.LC57!:YK1H8!W3NA0
MB7,,7 Q%E9SWV&(]+/0](K0;#'H>!QHGOZW'@?W-VS> QH$=+'>DV,9.B<MT
M//%(#5]!*5'!>_09@W+(,3HW>DDG1V%-D ^&NZT[=L/CKKS'Z081MF;&H15V
M2JAGG#]FI =C/_<@ /4X_7 RHO$=QP_!"R[JXUC2ZF1X1?9F?-!RK),RMMK:
M !,5#P1NO^N\Z;^?^6!5M?#0G6]1\G*,HO.#5E:." >NM%K>V38:JH)?)$Z6
MF?KPN_=XJ9AN,09("ST TV'Z$&A4\L["L4C'SHMU=N'1M?$O8I+,2$VCEO>I
M,CTM#2I@2&F'<^R<&7!*=O>>&)FH$O:UWT?/.[DD&+IIX<E9=M/;ZW-!N%84
MX!@U[+E:;CGPNW?#9M,&&.8H@.FV)4/:I#%FW I@<&H] O4_S!PSM6L,.7QV
M5SK_!HE"9D^]T<5 $K#4L-CW#HD,R[R:]&#79+!4WPH?I9*.4T>IH Y210W%
MP#0^:FQ#OC22J*"BZ)G*>F=+YS(6'55$,:>)^Q4@>_GY!S)@&*( )JPS\[MM
M('%C$D7L]M,@609Q-$^GP2XFT4[AIU+:Z?9U/>3>_G6Y*!C>Z/$I$F 0R<LX
M12&71>0C?J&)$>E8>Q?D0(AUC\L@3G$T"_*4WADV"</]=L_F4*_P.@YC5?_7
M1M$EW>P=Z3+/K 6&A-90E=G5:W$R1F?RWLGWD..@V.>OQC9/)NB27&J@73*)
M4F[(\V=.GA1O:.GJNM)*A,(0JQ+DC> %"DH49D6)+M$_H8)?]D:G#+L-)1&Y
MPB&F5^&B]V\O$"UMEOWG[5N-RO_9IQB]_XZ+>R<D>R]/61+AO*"ICH0=]CI!
MIW?8*('V;K 1I&"-[)3X= .\:](.YVA:7?=&6F4VC_V_?BA0UUSU)>)FO1/K
M-DZSG "9IR4FKU+5J(IB+DFE MFEU% &3/.H *9*P9CRG319DM"ED;A2\C]E
M(%:)>5IE 5GR:?1)6>;QX[ZDZ^0/&9TL:QTQT.M4QOU&NF->B#XZ'F(9>D0]
MPB==% 8<:SLS@),TLF[2S6J>)FNU3BAF<*4ZL*AJB=9RKI?U- &3LC\YN0SR
M1;XJ:7>=]<*7.&=7*%O-;*J5_4T8FQQ2SR&K-,%T+$;!-<PT7P":^>G[Q6_P
MGNS+)]*+^AU'5B]#5/+'0)4#:N8--8 R3@'3R+1JS!TTBB 9-R^*_2BVU0J^
MF=8';F(9EP;-L!Y$6W;%3 DDLQ;[LBA)KX#T:T>\A9Z6;XY)7# 1K:,"FFTB
M3EO*9:VF=]YU%A1'=NFL-#TM[([IS%FH@>&A/5;=BC"D/ES'(\L.G%;#$]]L
MNFX:<8C\LNRT]7D%K\<F>*3MKBFEO?)*W5%3B,+ED[:+)N42D/Z9X(FY<Z97
M\<HH0[=,)P^76^8.F91@D'ICO=7MRD&&TF8UO"_O;7.!#+9RCT%7& RS3 A-
M6PTXL;R3B1]Z9EW$K3E%AU+:[3T)6LC]JQ&DHF!(I,<WI!"71HTX^J56^$_O
M/*I2/Q0& HEB;C?/R4'VM\KU9<!P10%L2)+[V4^SNT^SU9ER#2R#,B;4N\:X
M3O:!R\6ZSO6X#Y+VDO=)&EW%!3_P/O#I.%/.\A$<Z6R3H>! .]ZI=P+PPG07
MMX;6&#=Y7X8G=%O3*&ALLY7/J+9^+G;G6;0/RU60X$*\C%$NXHZ-<G MR_J_
M V&/%)0X"<JD4$'%3GF5CZ*<JQ2UA*_W])[TG)!;5=Y*46?E;@#;E+]"#@8/
M]."&?*BD69UG-]GG-&#X8D8G34L\BB<21:^L43JBY9"@!9=1*JBV_+KL996.
MG3#N-DB##>_^5UFG--%((^R,64; #9N4DC 89((W9$TKSXB3L8/]CN*2'&O%
M]UN>!6I9)X$:11Z=#<^<,KMGH)K: &0&&E';$_-2G2D,U(V)]>#6,/;U,UV@
MFR: M=ET@$J>4:(6:@AP!X  TZPHZ?AQ]K+#:6&<1U*+NUTRT8/N+Y?(9;T'
M(DN PC+)8O6P0I.[*S3[C^7L;G7\C--I$A]1-Q;K)D-=17:%SUH-Y^F0]-"%
MS$AR<3!\,F,45]X( YL&J\Q()UR8+#K7A0?TT56[^Y!U)RUDS;9.VMTE"$;(
M[74(2E'O;+'#9V9*=P+)"4=DPT^S;W(M3YS1N:#@CDP%(H<T.(U<*N23 ]Y8
MU9_4.,SWH0U C).[-X)_?0-?"ANEJ _EICAQY82M\N&K^7VH]#RQ4N^&@HER
M)8CLTR(U,FZKFEOPR##%!,FAKT)I#A0?#4Z/HJG"UI?#7KT#AY-:N%T27H+]
M>UQ@4BQ/=+&=C(F2;$?]J$;MRGDAK8[;234+^/V9-HV"=\:.02ELU:ET^-:&
M5LL[Q5:8Y4GXB%,R;D^(2Y-H&Z<QG0\JXV>LYYJMLM/L&J,<ZF7/L-($0\-1
M<,554:9\@39<G?$RZ!GP3LWA+*7E9*;?>6&;^6!8"PD*=(H+"%GS2LE2BWNG
M"=\J>Y,5Q34I&;I9+4[WA-O53&26%A_P.LMQG0JF E[_R=4[%T+-7D@%R/(H
M3H/\=5[B;2%/*2-9>H4!R?T&;;\O7]P%[@</K&H-X$TH-K53/*B%X3V L)$&
M<2:KERXX3GW7QZ3D?$7)Z("PJ*34 -/%L8(Y9!F_A*/BVE>5[-=GFL)@#^//
MZM[P)AOK*D6=33T8P#;3"@HY[[2P *<E0SW@O^_,G_K/HS4(P,IP/I!RV\I+
M(?8;WIX(M#3!<GAB \6EZLXM &X\$SATHH!36-?EE$BZY8@2:I\G@ICWN&+&
M)A*EEJQB"P"FV';W1O?HCNY@'O!$F&.8@U_=84.4T8_[4D<@ASJJ&&!PLVB9
M9\]Q09Z#R)]U'X ]ADU@##,FS\%D3&Y>2-4,?< I7BNOK5!*NZ]#2L@B_P51
M>#T&'4S)J38%U[RSB4 CN&DU5'C:%7";'VX(K)\*KOX55E03< VI0'H-4#H%
M!$H;A(_(LGZ '9=$.MC-+M]&&X$6L YU0,W?]M0 V*:RY[3-B_'(3"/K8 4Z
M&30+KG291_=?7"_N)O<ZGL!Y_>_ C$3EN#1O_RLJ^+7P\I=!#F&307W!5YV3
M\D-0Q*'"=86LRUJKA=NECU00#(ETZ(948K^A#J&($JK2HS%E-'D.XJ3F5?U+
MYW8"<"2[BI-]J<SLJ)3V2;0!9!W5*E&P9.OC&]*M^O7+)MS/.-X\$2\FSS@/
M-OAN3R^*6ZR%Y(.Z:#?2ADMR'N1>E[*C#( A\B&HA_2N;:#*".+AE=M "T )
M)A7>5O73-K/I:"L >&QRT8+)*A/0N6S ;61S';U%/J/+L9'ZG#M!H=^SYG:\
ML<-YG$6K,LA+W;#OQ+X)'4V\B5/:4T"/04*SO5T 23QO&^L\1S.K>.4W(MD2
MS3+\2!AC3J@+9U+AO=-W3R+T8U9@^WF=]YJYA1C&+#:+2/=X1][%4U#@Z&J?
MTV#$6*:[8MM"S_FUGS9N""V-3@G:++0M8&$!K5*@64'[^;//E?^S>N!BW4OO
M+4VO;J/@+C>H#? V4ZA.VGM'U1JB/5U.E6Y==6:5MD!)PO8OU*-"F5-R.7>G
M3#4PV^.C$B$8E- @$PY\=D0I&YR7_C@.@&#""#Y 9\4!W !S(</P@O<K'-)0
MANEVJ2MZ#H^.LN@^*=4HZT<^3%,TQ:<S[[*;=.J7TNU-G<HVM$[7B?T29^L[
M)M"EL!T@MMD.\%]O_P?0Y>*CIF>JQ1AX90Q^,L_M.)_/L<Q2\UCL=)X-N3+C
M4[[V\WCPIL5\S,":"DT)TO3^@?1JFCN+%NMI4#Q=)]EG4XI7O8K;21HS^'[P
M4,N#:1XL0 KY(9J+ITBWF2HAI@7I&BK2Z%%@;.=UA*,/KY\*',W3)@'I)"SC
MYY@F2#.P[Q!#CC<1'NCHH'\ST@H8_AX,71P/-D1>=PZADR#:FOC>4PMFO1L>
M3K=3 FKXQO_XA[=_^NX'0(L)D^CO>WYRCQTM(H1@QXP>LGM,"RE.<*\S_9"=
M)L:<_[$N(Y*KE]BM >=^)IA:Y<A1>4WM/)QNN\OK1[(+VW@5IM_3OR@RFHR9
M/1<]OJ(F2P,*[**IN^P>5WA'7(G91"#-E+6EPY_?V9^*4C"K.<_P8>&$D.-#
MHP.&\)9 A5FIC@9/7];1\4^[NC+<T(FX>[J#:K$F=7-2%+CL>F=(,S/:C%-:
M'NADCZ8C;<"A[6' AS3N2B+RWYP:NLS6E_L"HX#:.N,-F/S,ZG66?PBB*_RH
MN+Q5*N?R+DPES.Z%F(*0=Z:8D.D/$3\&-%/H(X!#=E=XC?.<=BO&G$LW:KF,
M5)8N= .30<4[N\;A%%M/KM5TZH(7!U?;?0SB=)'2ZSX6:SHCS7+@FA)G62@Y
M"T;6#C21R:@!93%Q%-HAG:@>;;WHI2QTRA#7ND*6;2A)M_@*:;U2VATQL3;7
M,)X?H>\X#<<XMP:).>R4P82^L8B'K/VJ-O U:6GY)T1YW YDF94+&A']CV1%
M;R<AOR+]'H<X?J:+>-8O2J;JEZEJ9_0D%?6@1-0#, NC@TKPHKF=@(YT.W<:
M\/O2:BM?%>=*="GZ<)>56,T\6R5G+;>U TW+;=3P'@='P11V^%.I#G< QC>:
M9B\E#Q+OPK+4\1O1)/#UH:RC #^&B6!E61(K"8#D6K)+M9JT]VP6TMIYN;)?
MNND<TO-.I@F?@!K4XLP*$T6XDNU<!13N\YQ=#G22J;9S#$RJ)-@54-ZQM>\0
MR[4]#TIT+AF&)#)5^%S5P9;GK(;+QV;>.PX>X\1F]7NL$2!#9HV#EN-FB07O
MG<:C8$OV"_-A\U?U /KK_@@Z:4V!'T8O@]>#QM"-'HP!], -N]%SI03ML+(M
M8-6X&>VX&$#6\4O3>7O0J7#CFA29/H"V7>V61>LN*L-GI1ZXO(6O>YZ=$.EL
M\J:_>*VFWWAUCQ,Z1J<T4SM*7>_M]8& !<ZU33)KL'VP[CI.@S3L=S#LO)5K
M>N2:SA4-S61J4$8OXR$/.=:(>N38=%^4V1;GD^B9'HNQ\U%0\L@LA0,:4@TT
MH+26H] *6_4K*13A75;$($?"I).9[TE=.J#S)E/U/GI0.&,<0 STO+>8!X"5
M]]!.&+\<'G=2O(TQ!F >;Y(1TEX;7';U<;AE";JLMN!#92Z_0^L$!_6TA@ P
MV<)1"T9KK( )N =#EQ]&&1[7:^S8'M=S<[].\,K.RSQDD_ ?^SC'Q'U2#<O7
M)7&II!=KUWOA%&]MC &G]_.,=JQW8M%:&\KXYV#DJN1D!=T)N:N4V9)CLRT2
M'FOG:4E\B!\3K%UAM-#SRE&5&UIJ#I7 ,U(!6!A$904[P+\C#T@!#*'LVX>C
M&QBH+?]Q+?X7T8=5XU;V8?<%.XE _ENW\/#[K\UDU[']5ZTA "RV<-2"S1HK
MT/NO9NAV_==V>A12__4>[ZKF9;%F>T+UR^!J<9=4-8'N$E(E"ZV5-^"4<ZQ1
MHNW\8Y;GV6=Z#0_K;8;!+B8AO)J,SQZ3>,/OW?7.N;I#<YWE;:[HQ7J:D?B?
ME[1?L\RK VHLB9FA7V1OQD??=*R3LJZJK0UHG#X0OYSKW:3/)9W1/5F.\),1
MFEZN0MN.-"J&23D-;TBKZ8.V%J[(F*I1@TI.,V0Y'_MY46E:E$.29@+KPQ[=
M-8+:9SVNK_I%C+S4N(TCKW73-P4T\J(^TO_1";?G(,'LQ!RM<R&IV?2'21KU
MO^A(\CLGAFN LY<J RKY\$3>"+XG46*V7F/EJ,TU")>UQ\\+[M9 MPA@U6(O
MOJLS]#5[N4DX8$-7.H9@'SJ/_;)CPCD*X@NJL2>O@!#O%3N%0]+$H;+J@"Y1
M>S\9&9;P6NDIA2@P;@!,KGT:A\:P8T8/&MKPPDWV4WXL@B6 3^+0(F^I1L%I
MQE$C\%ZN4*4TF*EF(T3%B18:9VH-2-FX/^R+.,5%<86+,(]W51I'>N\Q&5XO
MR=LC]8%-/C[@E_)#HI[3.\202R8>[FB7H>.M@&'NP="%%&2SU?1^OGR8+^[0
MXAI]^+2:W\U6*S2YNT(?)JOYBGZ[O)^M9G</$RKEG>2K>)/&ZSBDVT"$^FLB
MMJVRT^L.1CG4N_C 2A,,:4?!%2Y#^'1[.[G_&Z7C:O[Q;GX]GT[N'M!D.EU\
MNGN8WWU$R\7-?#J?K;PSM,WZ8FK9I9)NE_"44/NK=X(8&%:IL0TIU)&$U&K?
M9$%:L+7&ASR(,(GC;.-[!^U57(1)5NQS;(IO!]IR2;FCW.V2\B!#8&A[#'JA
M6\J#X K=SZ:S^4^3#S>S"W0[NR(A\J;S'6O4;R=WDX^SVQF-G>3/Q<./LWMT
M/9MUE<]T3JQUJ-EAWYYKHY->JG Y6MO9R;'Q+C5'R.Q5O7/V,+SJPZ_M'ARN
MZ#\$DZXTQOW3O,:^I$G):5"U<J 7/;4:WBDW"J; M.7L?L+ZA'\,MKL?T/7\
M;G(WI7_?S"8K #W$.BG;:UNIC-E[-!IN#RT:H??/*BK%P7#,C%&55.\5M2J0
MNI02CTS13*_BF6':2*:3A\PQ4Q2;W_U$>FF+>PA#VH]9%GV.DX1T4X?''JQ#
MV$@;+BEWD'M=#HXR (:4AZ 6DLY7-MC:2VL%<3-@XZ/*6W.8M-!T&RVM7>D'
M3:,:&)K:8Q4Z@FQT.[][F-Q]G+,1\&HU>_ ?3JM-Y06]9(MF0P@2TTRA5L/Q
MSE03],&.5)4X&'Z9,0J'2RL-%O1J'4@!;I"@3TRY4<\W=;YJJU650\T4"T_]
M$ ]KV2=^09+U[Q,] 4QE.8M;\K@]_71_3^<I;^:3#_.;^0.$CO *;_AM/#MZ
M8URZ,5VJKA1WNL)H -U;4U3(@B&@ :"P;LC%42,/*4P/?;'OAUII^N2893_4
M0@TL\^S[H:O9QV;%Y7YV,WF879%>Z?7B_A;&GHKNY6(/>9 6]/Q!EIJ7KTUJ
M;M>R[9SH+VSK=<!PSQ*HN.3-+WQC>JBK""D,JIRS#X>C+$ @I65X'*$.GJKV
MX;(.D<O)_</?T,/]Y&XUF8((E*O];I>P2[^"A&XTIHD%9OP+4["T4W7:9(]P
MIM=F6^B!8>,(L$*KW5%%31X)5&M#BJ"U9UW(;7TS+F7;J[L^9C/&J>&I"1M=
M,#P="5C<'KE<WK!M/9,;-)VL?D37-XN?074RI]EV&Y>\XJ71-&/;/W$:]B8(
M#$%TI VG;#W$O1YEQQB P]L#4(LITAH;_ A/UPK0)20KOXUQ=Z01<'S6Q^!1
M%KXL1IOB\71Q>SM_H/&8GZ68+M@F]=D=B!WJS37U(_8?:30<)TTW01_D2E>)
M@R&<&:/DQB^B@8@*T.@H<<F\LJY3\4PQPUJZ6AXRR<P;D$@4FZ&'R7\ "%FK
M_6.!_[$G47GV;#7:5HF['6'K0?='U7)9, PR !1'S[4XXO*0XM/0%^-RBUK>
M)Y_T2RLJ8;",,@]R/ZQF__Z)KJ3,Z-Y(_U&)] Z++(DC=M:6'65\-??Y=2IN
M>_AF\/W^O%H>#*<L0(H74\>D=[]+>*[XG@'O!+O'I&;L\3T.LTT:V[/,0L_M
M,HBE&_W%#X,2&-+9(A67YYB>_P-0=3X!,O9]C%.>H):[H/!8I^ C$X0:N"SC
M@R@-ADI&B$,.-2D;2&?]P_P.QESO+,AI-B::(&WU%.38+F@9M5PRR]*%+KT,
M*F X9H=S2+1:B^910DS/.\WN\.=.)HD\2\G'D*_.<9_L>#?>C-OLJH<YV<^Q
M.LX&&*H>"%R6^H$,1#OYFU9ED$9!'OEO>U?A$X[V"5ZLA_62YO,))VET%2?[
M$D</=,.M<:1ZJ#6GX]CC7.Z-<@\S!8;@Q^$71LB5-3J0P=P>VI%P78 (UZVO
MTQQ'<7F3%04NJOU"#UF3%J"3!...D*G:,SZ._2=X@I\:<;)7(Z\E1YL'6'-.
MY9.N-K6YN?/&'LTU7]E#09)DG^E=RFB=Y2ADB%!"()TIF<H#36Q\'835$8O%
MYQ1'B_PV2(.-H:48K^XLG<H!3C7Y5$;H>J?P@8!U_+S>EW0-,.<S"F<B75OE
MEF1D2FA_C7$UAV&FW AE9X0;[5!#-VM-&&0;"U='M1VW@-;X9'P[2P:?^@3:
MZVU Z@;YUZH+<9 EW[E^+%TU)0 RF/%.Y>.Q#WG-+77N[&;W=!7-K?.O:%N9
M\T[QM@HWR42F!W6-3>I^^KUV3LD[M7I=,+0="5@7@^/* (0;8KIN]3,UD-%K
MG1]D-$>M+?FBZTA75<RU- .2Q..PZ_B<T2/C]*ZN.G],P$P"XO;PX'N5+*)W
M]GTDR0\QZ8?MASLOI_UX>P#Y?[ 3YHI0SRHDK25 56%X$'J>KK-\R]8J/[Q6
M/]K7@I'6_%2 @UR6<W^4*8"T/P2_CO'%?KL-\OAW'*&B2M903;8%"6D1&N-G
MFM/X<1L&=.XE+Y[BW8K ( W;EEYD$R1\+H8B6N'\.0XQG9NG"TFR$?9A=IS-
M=!SC9C/I<8@1[PP^%OF0NP]/A+:UJ>9Z4<KDVB)J3:+:)@K61!#EF  .TOAW
M1FFJE.+/R2O"+[L@C4@5^/'J]DQ$;]RO[U6=4$3W/4#76?XC#I+RJ?5@FN6D
MHK-?29.W)0Z2-[F^HZAG%>@?HZVF8KAYKK.*Y/(U-A7/Q4-A5%2'GMI7;/ZT
M;K7N/(\*5$\$6,D7ZT4>;TA[FM YAX+8*19K\BJLWKU:V5]U,SFDKC,J3:#$
M-\"U9V])?ZE,L8DC9HOQ^FP\O(IS');U9?&D)I)B;B_EKET<W@4Z3M7A+0^C
MG.E<\6"E!X-_X\ *]X@Q;;2KU"FY^@;0',P][/1RR/+U%I=/].Y>6AUH2&_J
M7]5(D$BOVCYIK^]TP^I8MWI;5VV5O9/U4,0*QDI"YJY1/5-P;./Y,.;+*J9.
MVED(-$-NHIY:U#MW[/#);GNHFDP/9+G#)3^[2_<W39Z#.&%3BAE-4Y"EJS(+
M?WO*D@CG;+^@S.&Q%IR1ZC#7&J*-4X=!OH,P"T<^Z&_H;K^EB]99_CVB-\?'
M/"= 4-M$989"9A45K5EMZWO&QNEG'&^>2AQ-G@GF#2;8'W&^6+.-KL5B7Q9T
M.S;I)@@E?9 !Q]=>$TB/68%O-*W58?#E!7^%TVQ+SP;1HJ\-DX)GEOE67Q*J
M6IO>.UPMXZ\)*7A&E3T!5FW@H"><*L*S]Z%XA:.MN,\9,=I%,8V$M0GO\>PX
MW')J5T&,;EFO8Y=IY[K[H%5MR!?J[HBPI3+QQ00NHP-B=YLI. ]>BEX5H2EY
M9$FW&DR3H"BFK.F5M=@J26>])#W4IC<D%_,>)<S8Q&QPC3!BTFB*F/R9J*!G
M^/!4CLR]L1:<4><PUQI*C5.'0;6#, MSJ71K?C=4L4,==0@;=Q#VG#,^ V\J
M@-+Y';DHO/;&!%35KLS;G@,?2P$YHDQPY77Z83[&8TW<I"SS^'%?UJ,_&O(*
MMGBU),_%>4[:5DF+=#*KCOO&IW@%@[[R,2:]AZK3^B'LKN&]*-*93O9TN7&_
M(]4A;*RP+#=5P\J?ZKV6B)OJV-7H[)+T21I)SO*QC7766_0LK?G=7#G*9?V^
M2BM38&K!<?AU>\MJ>Q>(6;Q S"9+,MQ>0MZ:1;\PP_[ST_7> WD%#':+\R9.
M\;S$V^'ZZ7AU'W>NV3HENTW-I N&TR,!#TD\FKC4(&(6M>P]UTBCQMM"JC:^
M$=?O\2Z(\VN,Q15R.S4XO=1#0*N*MG.0_$PC6Q'H'2Z[U[/8>2<H.1N_6CN@
M(=1 PWN & 73@COH$M6W/.VHIH_:?XNC. R2UANA7 0)8'5:C6]8!)5D)_B>
M*\5#N]VPOE.3QI6[+.T0)<;2/536JLZJ\DAG6N+8Z<&HUN/ "LQJMY?2=IZ?
M!%H3 Y8MQ5F+;NA42__*MZI>+&F"9[KAG02T29T315&LQ]F$%D%.Z-$AS$"T
MQ,C?O"G85E%J5S\(??5F.?V?Q9NOO8]MZ HA1=6^FZL]7J3X(7OXG/T-![EJ
M5&.CZ#A_LJ4C@RS*!BWOL6PTU"%?29G_,TR>$> $/7D"'LTT0=4[UQ3.&-DV
MT(/--SE8">/^Y)UQ8J_^0YPD.+K.\ILLW3S@?%N[6"SR99YM\L XAS/6F(\9
MG<,<ELWOC+,$AKE'P9>N/GHG\U5<!)M-CC?5H:INMBC%6]"KN"2F#?@N_73R
M8$AF 5)<'>VJT!GQ2@G,3+?"*6$RV.Y=W/B9V;9UPH)RPXEAL+0; AU!O1N[
MN>HCIDZ$)'=DG+58UR%X'R3MH(MEV"U8^)8-ZPZUY&QBY3A7FP'Y86:\D_1X
M[,)M,%5V0V*M9NP%2C$[21FV)MN$KWQ5)JJLNMY@KYY.KCL>=G/DM32P614[
MK$)6/R* 2B*! F>++>V!L\5Z&19L/I^QYPKG\3/I"I+BNLO6P3ZA,T1$NLC8
MT=Z_[_-7TB$L<4CCY#0)8J'1.X-]=^'I#*^E#5HG- XDE)W>(R' -8_@F0G*
M,R<-[KK47JZ%H]8WZE0[Q=E=*%:]&GL[7H@^UDTIH6V-P"/N2.1Z@H8=8Z=D
MZWE3#B^#5W9)R17MC+R4#Y]Q\HQO2??A236B.=P<F.3#%DY;9R#6V/).^!,Y
M(,]%?($:@XA9O$"-S0MZJ/,1HV401Q>(SH>B1>J_)O =2?C8&C#>C$OF'^ID
ME_%C;8!A^H' APROS'PIO+:MWQ3PP^?LR"C16($8SP<N'A+&*Q-@.'T8[I,$
M;6+..[E-55I/:FMM2"%:0V)+53#D'8?WB#@,@:JC:BI=*3Y%C>=VP,;BKIL'
M1V-J! RE#T5^FHA,#7HGNE6MUA!\A#ZXN*PBM+4R&"*/17Q,= 9!VS$U]YJ\
MZA,$ &X&:G3N.GEH<*8VP%#Z0. G"<W4GG>*V]1I#;7MU:'%9165;77!4'@D
MX".",@C"CJJQ\?,INLS<#-B8W''RX)A,;( A](' 3Q.3B3WO%+>JT6IJVZN#
MB\D**MOJ@J'P2,#'Q&0(A+6ML>S*@Q,%YH$MB-%9ZNXA(;IG" S)CT%_;+#F
M]U' J0&F"F_#_)$V( 5O(]-'&0##\$-0'Q;+3\QGU8XE\H((])^"9(^U>X.E
M<NYV'&E@MCN*)$+>B6-")NP(XJ+HF<HV6VT=EGZ3<X71T]:;H9979LA=T/*D
MKP)J7[ U7#=4.KIA5'0/% %7*>VRL3- [C9K"E'O<<@.WY!"ZLZ7=QI)6^(Q
MK3: _I)UOP@,?73H;/LYWJG#<E8T]]*O]KM=(B:7,0D[C3]:P+WP(Y4$0Q\M
M/*']JF[8XMF>B@N:)W^7I;2GS<XA%96Z=SXU#OV<Y;_-TV6>A63PJG@%*F&W
M:6IU@/O99V628/BDA3?D$Y6YC-/+'9?RE,FZ@4S"8UP\X>ACED7TL)Y]66@U
M'9]J*^D)?EG?]4#4\OSDM1$(M;U-X4H]*DDS^(RC>5H2U#21_Z0H<%G8Y>PU
M&_"3IM?6,7EF7I,VF.@Q&K(N_RXW<<ELH-8(XE; )"'0>'IC2$1@I^JX4VWM
MS*"/;=0#P](18"4]<"TG;TZ7G>"<Q/R89\KNE%D-""%[3EB2D>E\"43L AV2
MD/U6)?*+6PX&3!$R[29AN-_N69+!R3;+R^J2\_%O1VD("#4-CEJ256'E2Z"O
M'KIL9?)[U-%!04?)V["B[](=+F<O]%*,.-W0'O?G.$ED!6JC!R=1QD&HA4E-
M>2BZ3+'_R?$N_1;KH9N*MV%2<IHGS\J!7CX\K0:8\&$%4TABWE&B@P2A#^:?
M<&&8[W&T"I* CJZG^SS'PA*P2=AQ(D8-X$&B18DD'$+IX$FRX5-A5%32;#)T
M&Q?TDB,^&[H+7LDC$U0&+Q F28*$9: B43DN\$/PL@Q>Z0!8SR^CEM/I$#L7
M>G,@>A4PU+/#*<QV4"W*+\JU,Z:76I6D4\4ON7N@9*[ R=;&E:+.]A\8P#:;
M#A1RWBEA 6[(@^K^019H3D6%4[5CRSQ;8Q85@X3FW;%JSY1*'MHU@P.2]DVA
MX9U9HV"*8ZP-33S8W "PZVBSZP" $XX$USM2YD>P;V !#A6EKMGSLJ?^A9!4
MAEEQ7Q'=*P."GRN<D%%*L<_I'HQ[7.!<N<U8+NJTKZ4!V^M@2>3 <$@#3NA*
M$='+]3ZE5Y8^X2 IGU!<:Z*<JWIG$)LGJ2I&O7DG9G?\Z..:A9[SS3,V;@C[
M:'1*8%AGBU0UHHS3$A-,_+J='2:!#\H.K16I'_EKQR=]9\Z@XYQR)O@"W50*
ML*AF0"F?;-W@%.=5ARZ(MG0G2$DWECYCA%\(Z0I]@WGNHAI12!+'@6VX,<&4
MEU EA3J*GDJDRJ$JG2NN?W/\SG650H T?+]W;2+7@M]<AE](R*4#F7!?E&0H
MG9_K6L4YC>T%9G>UM=EII2F'E:+.9E(,8)N9%(6<=T)8@!-G4HCT927>S?CK
M?_C )WENLJ*@R8SI!0-QNB>#F^I$0):J][>:%=WN=;5UI+\L:M+RSK?14(?L
M^XKJ?(VJZ3P6F;)&QSL!K_ NQV',T)#/":8?R$#<8BN&G:K36W-&.-.[.<="
M#]K:_ C,PD4Z'57>5[3<6.&$D?4QWX=L$OYC'^=XF6?1/J2]6.WRO(6>2RY:
MN]$EHE$)3#BT13KDWC38Q72K.1N/1'&YSP&TPNT.Y6F6$!@9'S1-\IQ 9Y<+
M%-7<I.+G!_*I"-A-&99[TD_W(#][UT_]HN1[W$_U%##5YFRN"?6LJX\Z!EC
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MK"CC<+X--@38%#/DBB!HKPJK:$?C'I9V:X"6;FL"5390940=-OU$S?\:>>E
M<>G\CH[<L$_P\*64?84([1@D])E@0N]1SC;MU[#H,DM"@9%!-$-&I"MH[3EL
M>2(\[_L".\M0J@@EB@!(KVQ")AY=9LM@_)3K+USX/]$O5YC/BMU0J]HKLLY0
M '6R )YU0W.??4\ P,O7XQ*FS)G417UQO=>7K'Z[X%ZKX7UZ>HUUK(VQCK"B
M%*#7JP&G2F-*1'WSM\[N44\'$@WU^U<* RH&,T9E@I-*Y0*U2OZK@[Y$I(*
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M,8P7J@:#_J+/;GO6"M)[PW+.]D1 T4B.3'E'[\R<@Q]$,!I-[.-BS>C'@>+
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M5J.CK2R'O?>JR9<, "MY&@1!9,I1)H.=,.(H?@X5MY(;=3YHA6YU$D+C^U$
M(4"G*K>?-%^J0,+8"2CJ^"%9OTJ5DHU#EBBE$/8)J Y-UBY.I3;J5B:I ';Z
MB_JT6+8FE=H'6I#44MA'UOKDV+@4'?A.I2V.&RNG1R&"G9VBGLM8E=H5Q.#?
M/>_4X\?U0MSL@SOG[V!WSK,Y_\]]?S2?=<9WG<&H-[[OYV^><6Z:$\5VS==?
M+DL%L)QEXR?D@;[AY9+(Y@4-]"5?V&I%6WH$/>$H\$;=$9(]TB?A>)5%7HH<
M;Y\5J.LO18;%^'FPY.JF=FW8)@4IZK0!Y=HED-%EM AGCA<G<9(14RR%;2,
M 5ZM6DM 5N5)E ,J+8U]K(< JU'UA  ?)D8T@[M"%ON 7A=\*0PM45&=X$\.
MOZ(\]F$; KE6W9/"+,_ 9X2^JAKLHW9]4O3@H!_N,N7T6U#\8W6]O6<%U.?F
M3=ZC02BV86FF/<"Y02Z!??XV(U&G.?KXB<>Z:.5XM0M6D_8\.3M*(?2[?AWD
M%4$KU "T%8%3-#2=8N<TO[^6+#TJ ?"9#1MVG2(GA-P@-3U$$$I!>VZ0M2E
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MBGKU^ *!@CV0JEY*'XR=#\6Q,QC]PA>M\11M>YDU^77?+,AS1H40EF]XJ4F
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M83"K9:ZS2BELWP9E5RLZ 0/T;\G;Y/-FX0AG%Q8\NMN9^X<P7F]$5@_'VWL
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MPV?ORW0J8D</!]V;P7 P3UQW$X>E]!.=W#?XOR$[*$V<UR3VJ;_L+A8L<CQ
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M U!+ 0(4 Q0    ( +F)3EAB<&T[=2\! ,BF#  .              "  0
M  !F;VYA<E\Q,"UQ+FAT;5!+ 0(4 Q0    ( +F)3E@7*4C/:@@  "9=   4
M              "  :$O 0!F;VYA<E]E>&AI8FET+3,Q+FAT;5!+ 0(4 Q0
M   ( +F)3EC*WO(FRP0  .LB   4              "  3TX 0!F;VYA<E]E
M>&AI8FET+3,R+FAT;5!+ 0(4 Q0    ( +F)3EB-79IP]S4  &@X   .
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M &9O;G(M,C R,S$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( +F)3EBD:PS]&#,
M ($J P 5              "  ;<% @!F;VYR+3(P,C,Q,C,Q7W!R92YX;6Q0
52P4&      D "0!' @   CD"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>fonar_10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:FONR="http://fonar.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="fonr-20231231.xsd" xlink:type="simple"/>
    <context id="From2023-07-01to2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-09_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-09</instant>
        </period>
    </context>
    <context id="AsOf2024-02-09_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-09</instant>
        </period>
    </context>
    <context id="AsOf2024-02-09_us-gaap_CommonClassCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-09</instant>
        </period>
    </context>
    <context id="AsOf2024-02-09_custom_ClassAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-09</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ClassANonVotingPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassANonVotingPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_ClassANonVotingPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassANonVotingPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CommonStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:CommonStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_CommonStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:CommonStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonClassCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonClassCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-10-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012023-12-31_custom_CommonStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:CommonStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_custom_CommonStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:CommonStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012023-12-31_custom_ClassANonVotingPreferredStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassANonVotingPreferredStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_custom_ClassANonVotingPreferredStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassANonVotingPreferredStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012023-12-31_us-gaap_CommonClassCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_us-gaap_CommonClassCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-12-31_custom_CommonStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:CommonStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-12-31_custom_CommonStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:CommonStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-12-31_custom_ClassANonVotingPreferredStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassANonVotingPreferredStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-12-31_custom_ClassANonVotingPreferredStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassANonVotingPreferredStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-12-31_us-gaap_CommonClassCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-12-31_us-gaap_CommonClassCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember-1258588437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2023-10-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012023-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012023-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember-1258588312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2015-07-01_custom_ControllingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">FONR:ControllingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-01</instant>
        </period>
    </context>
    <context id="AsOf2015-07-01_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-01</instant>
        </period>
    </context>
    <context id="From2021-07-012022-06-30_custom_ControllingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">FONR:ControllingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_ControllingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">FONR:ControllingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_DoubtfulMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:DoubtfulMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_DoubtfulMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:DoubtfulMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-10-012023-12-31_custom_CommercialInsuranceManagedCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:CommercialInsuranceManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_custom_CommercialInsuranceManagedCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:CommercialInsuranceManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012023-12-31_custom_MedicareMedicaidMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:MedicareMedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_custom_MedicareMedicaidMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:MedicareMedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012023-12-31_custom_WorkersCompensationPersonalInjuryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:WorkersCompensationPersonalInjuryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_custom_WorkersCompensationPersonalInjuryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:WorkersCompensationPersonalInjuryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012023-12-31_custom_OtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_custom_OtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-12-31_custom_CommercialInsuranceManagedCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:CommercialInsuranceManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-12-31_custom_CommercialInsuranceManagedCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:CommercialInsuranceManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-12-31_custom_MedicareMedicaidMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:MedicareMedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-12-31_custom_MedicareMedicaidMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:MedicareMedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-12-31_custom_WorkersCompensationPersonalInjuryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:WorkersCompensationPersonalInjuryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-12-31_custom_WorkersCompensationPersonalInjuryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:WorkersCompensationPersonalInjuryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-12-31_custom_OtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-12-31_custom_OtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_OperatingLeasePaymentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">FONR:OperatingLeasePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_FinancingLeasePaymentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">FONR:FinancingLeasePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PatentsAndCopyrightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:PatentsAndCopyrightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_PatentsAndCopyrightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:PatentsAndCopyrightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_NoncompeteAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_NoncompeteAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-10-012023-12-31_custom_PatentsAndCopyrightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:PatentsAndCopyrightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_custom_PatentsAndCopyrightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:PatentsAndCopyrightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012023-12-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-12-31_custom_PatentsAndCopyrightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:PatentsAndCopyrightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-12-31_custom_PatentsAndCopyrightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:PatentsAndCopyrightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-12-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-12-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012023-12-31_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">FONR:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012023-12-31_custom_ManagementOfDiagnosticImagingCentersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">FONR:ManagementOfDiagnosticImagingCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">FONR:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_custom_ManagementOfDiagnosticImagingCentersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">FONR:ManagementOfDiagnosticImagingCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-12-31_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">FONR:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-12-31_custom_ManagementOfDiagnosticImagingCentersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">FONR:ManagementOfDiagnosticImagingCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-12-31_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">FONR:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-12-31_custom_ManagementOfDiagnosticImagingCentersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">FONR:ManagementOfDiagnosticImagingCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MagneticResonanceManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FONR:MagneticResonanceManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-07-012023-12-31_custom_MagneticResonanceManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FONR:MagneticResonanceManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
        </entity>
        <period>
            <instant>2022-09-26</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2023-07-01to2023-12-31" id="ixv-6327">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-07-01to2023-12-31" id="ixv-6328">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2023-07-01to2023-12-31" id="ixv-6329">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-07-01to2023-12-31" id="ixv-6330">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2023-07-01to2023-12-31" id="ixv-6331">0000355019</dei:EntityCentralIndexKey>
    <FONR:AccountReceivableRelatedParties
      contextRef="AsOf2023-06-30"
      id="xdx2ixbrl0064"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:NoteReceivableRelatedParty
      contextRef="AsOf2023-06-30"
      id="xdx2ixbrl0088"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:UnearnedRevenueOnServiceContractsRelatedParty
      contextRef="AsOf2023-06-30"
      id="xdx2ixbrl0130"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_custom_ClassANonVotingPreferredStockMember"
      id="xdx2ixbrl0190"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-06-30_custom_ClassANonVotingPreferredStockMember"
      id="xdx2ixbrl0192"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0210"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0212"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember"
      id="xdx2ixbrl0250"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-06-30_us-gaap_CommonClassBMember"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31_us-gaap_CommonClassCMember"
      id="xdx2ixbrl0270"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-06-30_us-gaap_CommonClassCMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-10-012023-12-31"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:OtherIncomeRelatedParty
      contextRef="From2022-10-012022-12-31"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:OtherIncomeRelatedParty
      contextRef="From2022-07-012022-12-31"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0562"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0563"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012023-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0565"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0566"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0569"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-10-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0570"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-10-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-10-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0573"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfShares
      contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0578"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfShares
      contextRef="From2023-10-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0580"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfShares
      contextRef="From2023-10-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0582"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfShares
      contextRef="From2023-10-012023-12-31"
      id="xdx2ixbrl0583"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0589"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2023-10-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0590"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2023-10-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0591"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2023-10-012023-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0592"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0596"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2023-10-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0597"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2023-10-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0598"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2023-10-012023-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0599"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0649"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0650"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012022-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0652"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012022-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0653"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0656"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0657"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0658"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-10-012022-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0660"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfShares
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0665"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfShares
      contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0667"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfShares
      contextRef="From2022-10-012022-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0669"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0676"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0677"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0678"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2022-10-012022-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0679"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0683"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0684"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0685"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2022-10-012022-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0686"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0736"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0737"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0739"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0740"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0743"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-07-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0744"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-07-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0745"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-07-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0747"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfShares
      contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0752"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfShares
      contextRef="From2023-07-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0754"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfShares
      contextRef="From2023-07-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0756"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfShares
      contextRef="From2023-07-01to2023-12-31"
      id="xdx2ixbrl0757"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0763"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2023-07-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0764"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2023-07-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0765"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2023-07-012023-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0766"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0770"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2023-07-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0771"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2023-07-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0772"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2023-07-012023-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0773"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0823"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0824"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0826"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0827"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0830"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-07-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0831"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-07-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0832"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-07-012022-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0834"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfShares
      contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0839"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfShares
      contextRef="From2022-07-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0841"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfShares
      contextRef="From2022-07-012022-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0843"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0850"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2022-07-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0851"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2022-07-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0852"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2022-07-012022-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0853"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0857"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2022-07-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0858"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2022-07-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0859"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2022-07-012022-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0860"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:GainOnSaleOfEquipmentRelatedParty
      contextRef="From2022-07-012022-12-31"
      id="xdx2ixbrl0909"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="From2022-07-012022-12-31"
      id="xdx2ixbrl0927"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:ConvertibleClassCStock
      contextRef="From2023-10-012023-12-31_us-gaap_CommonClassCMember"
      id="xdx2ixbrl1091"
      unitRef="Shares"
      xsi:nil="true"/>
    <FONR:ConvertibleClassCStock
      contextRef="From2022-10-012022-12-31_us-gaap_CommonClassCMember"
      id="xdx2ixbrl1095"
      unitRef="Shares"
      xsi:nil="true"/>
    <FONR:ConvertibleClassCStock
      contextRef="From2023-07-012023-12-31_us-gaap_CommonClassCMember"
      id="xdx2ixbrl1159"
      unitRef="Shares"
      xsi:nil="true"/>
    <FONR:ConvertibleClassCStock
      contextRef="From2022-07-012022-12-31_us-gaap_CommonClassCMember"
      id="xdx2ixbrl1163"
      unitRef="Shares"
      xsi:nil="true"/>
    <FONR:AccountsReceivableNetRelatedParty
      contextRef="AsOf2023-12-31_us-gaap_DoubtfulMember"
      id="xdx2ixbrl1213"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:MedicalReceivable
      contextRef="AsOf2023-12-31_us-gaap_DoubtfulMember"
      id="xdx2ixbrl1219"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:MedicalReceivable
      contextRef="AsOf2023-06-30_us-gaap_DoubtfulMember"
      id="xdx2ixbrl1243"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2023-12-31_custom_FinancingLeasePaymentsMember"
      id="xdx2ixbrl1382"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2023-12-31_custom_FinancingLeasePaymentsMember"
      id="xdx2ixbrl1386"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:IntersegmentNetRevenues
      contextRef="From2023-10-012023-12-31_custom_ManagementOfDiagnosticImagingCentersMember"
      id="xdx2ixbrl1520"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:IntersegmentNetRevenues
      contextRef="From2022-10-012022-12-31_custom_ManagementOfDiagnosticImagingCentersMember"
      id="xdx2ixbrl1550"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:IntersegmentNetRevenues
      contextRef="From2023-07-012023-12-31_custom_ManagementOfDiagnosticImagingCentersMember"
      id="xdx2ixbrl1580"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:IntersegmentNetRevenues
      contextRef="From2022-07-012022-12-31_custom_ManagementOfDiagnosticImagingCentersMember"
      id="xdx2ixbrl1610"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-07-01to2023-12-31" id="ixv-7489">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2023-07-01to2023-12-31" id="ixv-7490">true</dei:DocumentQuarterlyReport>
    <dei:DocumentTransitionReport contextRef="From2023-07-01to2023-12-31" id="ixv-7491">false</dei:DocumentTransitionReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-07-01to2023-12-31" id="ixv-7492">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:EntityFileNumber contextRef="From2023-07-01to2023-12-31" id="ixv-7493">0-10248</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-07-01to2023-12-31" id="ixv-7494">FONAR CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-07-01to2023-12-31" id="ixv-7495">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-07-01to2023-12-31" id="ixv-7496">11-2464137</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-07-01to2023-12-31" id="ixv-7497">110 Marcus Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2023-07-01to2023-12-31" id="ixv-7498">Melville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-07-01to2023-12-31" id="ixv-7499">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-07-01to2023-12-31" id="ixv-7500">11747</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-07-01to2023-12-31" id="ixv-7501">(631)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-07-01to2023-12-31" id="ixv-7502">694-2929</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus contextRef="From2023-07-01to2023-12-31" id="ixv-7503">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-07-01to2023-12-31" id="ixv-7504">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-07-01to2023-12-31" id="ixv-7505">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-07-01to2023-12-31" id="ixv-7506">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-07-01to2023-12-31" id="ixv-7507">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2023-07-01to2023-12-31" id="ixv-7508">false</dei:EntityShellCompany>
    <dei:Security12bTitle contextRef="From2023-07-01to2023-12-31" id="ixv-7509">Common Stock, $.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-07-01to2023-12-31" id="ixv-7510">FONR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-07-01to2023-12-31" id="ixv-7511">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-02-09_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-7512"
      unitRef="Shares">6328294</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-02-09_us-gaap_CommonClassBMember"
      decimals="INF"
      id="ixv-7513"
      unitRef="Shares">146</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-02-09_us-gaap_CommonClassCMember"
      decimals="INF"
      id="ixv-7514"
      unitRef="Shares">382513</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-02-09_custom_ClassAPreferredStockMember"
      decimals="INF"
      id="ixv-7515"
      unitRef="Shares">313438</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7516"
      unitRef="USD">53225000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7517"
      unitRef="USD">51280000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7518"
      unitRef="USD">33000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7519"
      unitRef="USD">33000</us-gaap:ShortTermInvestments>
    <FONR:AccountsReceivableServiceAndRepairFees
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7520"
      unitRef="USD">3881000</FONR:AccountsReceivableServiceAndRepairFees>
    <FONR:AccountsReceivableServiceAndRepairFees
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7521"
      unitRef="USD">3861000</FONR:AccountsReceivableServiceAndRepairFees>
    <FONR:AccountReceivableRelatedParties
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7522"
      unitRef="USD">60000</FONR:AccountReceivableRelatedParties>
    <FONR:MedicalReceivable
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7523"
      unitRef="USD">22548000</FONR:MedicalReceivable>
    <FONR:MedicalReceivable
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7524"
      unitRef="USD">21259000</FONR:MedicalReceivable>
    <FONR:ManagementAndOtherFees
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7525"
      unitRef="USD">39352000</FONR:ManagementAndOtherFees>
    <FONR:ManagementAndOtherFees
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7526"
      unitRef="USD">35888000</FONR:ManagementAndOtherFees>
    <FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7527"
      unitRef="USD">9267000</FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances>
    <FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7528"
      unitRef="USD">9162000</FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances>
    <us-gaap:InventoryFinishedGoodsAndWorkInProcess
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7529"
      unitRef="USD">2835000</us-gaap:InventoryFinishedGoodsAndWorkInProcess>
    <us-gaap:InventoryFinishedGoodsAndWorkInProcess
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7530"
      unitRef="USD">2570000</us-gaap:InventoryFinishedGoodsAndWorkInProcess>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7531"
      unitRef="USD">1341000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7532"
      unitRef="USD">1608000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7533"
      unitRef="USD">132542000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7534"
      unitRef="USD">125661000</us-gaap:AssetsCurrent>
    <FONR:AccountsReceivableNetLongTerm
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7535"
      unitRef="USD">376000</FONR:AccountsReceivableNetLongTerm>
    <FONR:AccountsReceivableNetLongTerm
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7536"
      unitRef="USD">710000</FONR:AccountsReceivableNetLongTerm>
    <FONR:NoteReceivableRelatedParty
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7537"
      unitRef="USD">577000</FONR:NoteReceivableRelatedParty>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7538"
      unitRef="USD">7758000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7539"
      unitRef="USD">10042000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7540"
      unitRef="USD">20109000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7541"
      unitRef="USD">22146000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7542"
      unitRef="USD">32234000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7543"
      unitRef="USD">33069000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7544"
      unitRef="USD">630000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7545"
      unitRef="USD">729000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7546"
      unitRef="USD">4269000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7547"
      unitRef="USD">4269000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7548"
      unitRef="USD">3266000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7549"
      unitRef="USD">3432000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssets
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7550"
      unitRef="USD">501000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7551"
      unitRef="USD">524000</us-gaap:OtherAssets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7552"
      unitRef="USD">202262000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7553"
      unitRef="USD">200582000</us-gaap:Assets>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7554"
      unitRef="USD">45000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7555"
      unitRef="USD">44000</us-gaap:LongTermDebtCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7556"
      unitRef="USD">1335000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7557"
      unitRef="USD">1579000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7558"
      unitRef="USD">3460000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7559"
      unitRef="USD">5444000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7560"
      unitRef="USD">3804000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7561"
      unitRef="USD">3832000</us-gaap:DeferredRevenueCurrent>
    <FONR:UnearnedRevenueOnServiceContractsRelatedParty
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7562"
      unitRef="USD">55000</FONR:UnearnedRevenueOnServiceContractsRelatedParty>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7563"
      unitRef="USD">4658000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7564"
      unitRef="USD">3905000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7565"
      unitRef="USD">222000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7566"
      unitRef="USD">218000</us-gaap:FinanceLeaseLiabilityCurrent>
    <FONR:CustomerDeposits
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7567"
      unitRef="USD">600000</FONR:CustomerDeposits>
    <FONR:CustomerDeposits
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7568"
      unitRef="USD">602000</FONR:CustomerDeposits>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7569"
      unitRef="USD">14179000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7570"
      unitRef="USD">15624000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7571"
      unitRef="USD">376000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7572"
      unitRef="USD">760000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7573"
      unitRef="USD">395000</us-gaap:DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7574"
      unitRef="USD">395000</us-gaap:DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent>
    <FONR:AccountsPayableRelatedPartyNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7575"
      unitRef="USD">93000</FONR:AccountsPayableRelatedPartyNoncurrent>
    <FONR:AccountsPayableRelatedPartyNoncurrent
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7576"
      unitRef="USD">93000</FONR:AccountsPayableRelatedPartyNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7577"
      unitRef="USD">30299000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7578"
      unitRef="USD">32105000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7579"
      unitRef="USD">508000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7580"
      unitRef="USD">620000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7581"
      unitRef="USD">92000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7582"
      unitRef="USD">115000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7583"
      unitRef="USD">23000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7584"
      unitRef="USD">42000</us-gaap:OtherLiabilities>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7585"
      unitRef="USD">31786000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7586"
      unitRef="USD">34130000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7587"
      unitRef="USD">45965000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7588"
      unitRef="USD">49754000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_custom_ClassANonVotingPreferredStockMember"
      decimals="INF"
      id="ixv-7589"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-06-30_custom_ClassANonVotingPreferredStockMember"
      decimals="INF"
      id="ixv-7590"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_ClassANonVotingPreferredStockMember"
      decimals="-3"
      id="ixv-7591"
      unitRef="Shares">453000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-06-30_custom_ClassANonVotingPreferredStockMember"
      decimals="-3"
      id="ixv-7592"
      unitRef="Shares">453000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_custom_ClassANonVotingPreferredStockMember"
      decimals="-3"
      id="ixv-7593"
      unitRef="Shares">313000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_ClassANonVotingPreferredStockMember"
      decimals="-3"
      id="ixv-7594"
      unitRef="Shares">313000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-06-30_custom_ClassANonVotingPreferredStockMember"
      decimals="-3"
      id="ixv-7595"
      unitRef="Shares">313000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-06-30_custom_ClassANonVotingPreferredStockMember"
      decimals="-3"
      id="ixv-7596"
      unitRef="Shares">313000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="ixv-7597"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember"
      decimals="INF"
      id="ixv-7598"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="ixv-7599"
      unitRef="Shares">567000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember"
      decimals="-3"
      id="ixv-7600"
      unitRef="Shares">567000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="ixv-7601"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="ixv-7602"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember"
      decimals="-3"
      id="ixv-7603"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember"
      decimals="-3"
      id="ixv-7604"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-7605"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-7606"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7607"
      unitRef="Shares">8500000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7608"
      unitRef="Shares">8500000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7609"
      unitRef="Shares">6332000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7610"
      unitRef="Shares">6462000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7611"
      unitRef="Shares">6328000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7612"
      unitRef="Shares">6451000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31_custom_CommonStocksMember"
      decimals="-3"
      id="ixv-7613"
      unitRef="USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-06-30_custom_CommonStocksMember"
      decimals="-3"
      id="ixv-7614"
      unitRef="USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="ixv-7615"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-06-30_us-gaap_CommonClassBMember"
      decimals="INF"
      id="ixv-7616"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember"
      decimals="-3"
      id="ixv-7617"
      unitRef="Shares">227000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-06-30_us-gaap_CommonClassBMember"
      decimals="-3"
      id="ixv-7618"
      unitRef="Shares">227000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember"
      decimals="0"
      id="ixv-7619"
      unitRef="Shares">146</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember"
      decimals="0"
      id="ixv-7620"
      unitRef="Shares">146</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-06-30_us-gaap_CommonClassBMember"
      decimals="0"
      id="ixv-7621"
      unitRef="Shares">146</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonClassBMember"
      decimals="0"
      id="ixv-7622"
      unitRef="Shares">146</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="ixv-7623"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-06-30_us-gaap_CommonClassCMember"
      decimals="INF"
      id="ixv-7624"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-7625"
      unitRef="Shares">567000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-06-30_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-7626"
      unitRef="Shares">567000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-7627"
      unitRef="Shares">383000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-7628"
      unitRef="Shares">383000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-06-30_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-7629"
      unitRef="Shares">383000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-7630"
      unitRef="Shares">383000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7631"
      unitRef="USD">180607000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7632"
      unitRef="USD">182613000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7633"
      unitRef="USD">-16326000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7634"
      unitRef="USD">-24191000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7635"
      unitRef="Shares">4000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7636"
      unitRef="Shares">11000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7637"
      unitRef="USD">395000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7638"
      unitRef="USD">516000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7639"
      unitRef="USD">163887000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7640"
      unitRef="USD">157907000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7641"
      unitRef="USD">-7590000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7642"
      unitRef="USD">-7079000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7643"
      unitRef="USD">156297000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7644"
      unitRef="USD">150828000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7645"
      unitRef="USD">202262000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7646"
      unitRef="USD">200582000</us-gaap:LiabilitiesAndStockholdersEquity>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscounts
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7647"
      unitRef="USD">8221000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscounts>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscounts
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7648"
      unitRef="USD">7129000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscounts>
    <FONR:ProductSalesNet
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7649"
      unitRef="USD">55000</FONR:ProductSalesNet>
    <FONR:ProductSalesNet
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7650"
      unitRef="USD">170000</FONR:ProductSalesNet>
    <FONR:ServiceAndRepairFeesNet
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7651"
      unitRef="USD">1778000</FONR:ServiceAndRepairFeesNet>
    <FONR:ServiceAndRepairFeesNet
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7652"
      unitRef="USD">1838000</FONR:ServiceAndRepairFeesNet>
    <FONR:ServiceAndRepairFeesRelatedPartiesNet
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7653"
      unitRef="USD">28000</FONR:ServiceAndRepairFeesRelatedPartiesNet>
    <FONR:ServiceAndRepairFeesRelatedPartiesNet
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7654"
      unitRef="USD">28000</FONR:ServiceAndRepairFeesRelatedPartiesNet>
    <FONR:ManagementAndOtherFeesNet
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7655"
      unitRef="USD">12316000</FONR:ManagementAndOtherFeesNet>
    <FONR:ManagementAndOtherFeesNet
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7656"
      unitRef="USD">12092000</FONR:ManagementAndOtherFeesNet>
    <FONR:ManagementAndOtherFeesRelatedMedicalPracticesNet
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7657"
      unitRef="USD">2988000</FONR:ManagementAndOtherFeesRelatedMedicalPracticesNet>
    <FONR:ManagementAndOtherFeesRelatedMedicalPracticesNet
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7658"
      unitRef="USD">2999000</FONR:ManagementAndOtherFeesRelatedMedicalPracticesNet>
    <us-gaap:Revenues
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7659"
      unitRef="USD">25386000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7660"
      unitRef="USD">24256000</us-gaap:Revenues>
    <us-gaap:OtherCostOfOperatingRevenue
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7661"
      unitRef="USD">4602000</us-gaap:OtherCostOfOperatingRevenue>
    <us-gaap:OtherCostOfOperatingRevenue
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7662"
      unitRef="USD">4023000</us-gaap:OtherCostOfOperatingRevenue>
    <FONR:CostsRelatedToProductSales
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7663"
      unitRef="USD">302000</FONR:CostsRelatedToProductSales>
    <FONR:CostsRelatedToProductSales
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7664"
      unitRef="USD">214000</FONR:CostsRelatedToProductSales>
    <FONR:CostsRelatedToServiceAndRepairFees
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7665"
      unitRef="USD">784000</FONR:CostsRelatedToServiceAndRepairFees>
    <FONR:CostsRelatedToServiceAndRepairFees
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7666"
      unitRef="USD">722000</FONR:CostsRelatedToServiceAndRepairFees>
    <FONR:CostsRelatedToServiceAndRepairFeesRelatedParties
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7667"
      unitRef="USD">12000</FONR:CostsRelatedToServiceAndRepairFeesRelatedParties>
    <FONR:CostsRelatedToServiceAndRepairFeesRelatedParties
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7668"
      unitRef="USD">11000</FONR:CostsRelatedToServiceAndRepairFeesRelatedParties>
    <FONR:CostsRelatedToManagementAndOtherFees
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7669"
      unitRef="USD">7208000</FONR:CostsRelatedToManagementAndOtherFees>
    <FONR:CostsRelatedToManagementAndOtherFees
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7670"
      unitRef="USD">6622000</FONR:CostsRelatedToManagementAndOtherFees>
    <FONR:CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7671"
      unitRef="USD">1590000</FONR:CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices>
    <FONR:CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7672"
      unitRef="USD">1492000</FONR:CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7673"
      unitRef="USD">416000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7674"
      unitRef="USD">342000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7675"
      unitRef="USD">5587000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7676"
      unitRef="USD">6598000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7677"
      unitRef="USD">20501000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7678"
      unitRef="USD">20024000</us-gaap:CostsAndExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7679"
      unitRef="USD">4885000</us-gaap:IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7680"
      unitRef="USD">4232000</us-gaap:IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7681"
      unitRef="USD">-208000</us-gaap:OtherNonoperatingIncomeExpense>
    <FONR:OtherIncomeRelatedParty
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7682"
      unitRef="USD">577000</FONR:OtherIncomeRelatedParty>
    <us-gaap:InterestExpense
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7683"
      unitRef="USD">10000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7684"
      unitRef="USD">12000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7685"
      unitRef="USD">534000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7686"
      unitRef="USD">263000</us-gaap:InvestmentIncomeNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7687"
      unitRef="USD">5986000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7688"
      unitRef="USD">4275000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7689"
      unitRef="USD">1366000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7690"
      unitRef="USD">1463000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7691"
      unitRef="USD">4620000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7692"
      unitRef="USD">2812000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7693"
      unitRef="USD">861000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7694"
      unitRef="USD">580000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7695"
      unitRef="USD">3759000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7696"
      unitRef="USD">2232000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012023-12-31_custom_CommonStockholdersMember"
      decimals="-3"
      id="ixv-7697"
      unitRef="USD">3525000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012022-12-31_custom_CommonStockholdersMember"
      decimals="-3"
      id="ixv-7698"
      unitRef="USD">2097000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012023-12-31_custom_ClassANonVotingPreferredStockholdersMember"
      decimals="-3"
      id="ixv-7699"
      unitRef="USD">175000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012022-12-31_custom_ClassANonVotingPreferredStockholdersMember"
      decimals="-3"
      id="ixv-7700"
      unitRef="USD">101000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012023-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-7701"
      unitRef="USD">59000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012022-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-7702"
      unitRef="USD">34000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-10-012023-12-31_custom_CommonStockholdersMember"
      decimals="INF"
      id="ixv-7703"
      unitRef="USDPShares">0.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-10-012022-12-31_custom_CommonStockholdersMember"
      decimals="INF"
      id="ixv-7704"
      unitRef="USDPShares">0.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-10-012023-12-31_custom_CommonStockholdersMember"
      decimals="INF"
      id="ixv-7705"
      unitRef="USDPShares">0.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-10-012022-12-31_custom_CommonStockholdersMember"
      decimals="INF"
      id="ixv-7706"
      unitRef="USDPShares">0.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-10-012023-12-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="ixv-7707"
      unitRef="USDPShares">0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-10-012023-12-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="ixv-7708"
      unitRef="USDPShares">0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-10-012022-12-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="ixv-7709"
      unitRef="USDPShares">0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-10-012022-12-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="ixv-7710"
      unitRef="USDPShares">0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-10-012023-12-31_custom_CommonStockholdersMember"
      decimals="-3"
      id="ixv-7711"
      unitRef="Shares">6437000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-10-012022-12-31_custom_CommonStockholdersMember"
      decimals="-3"
      id="ixv-7712"
      unitRef="Shares">6527000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-10-012023-12-31_custom_CommonStockholdersMember"
      decimals="-3"
      id="ixv-7713"
      unitRef="Shares">6565000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-10-012022-12-31_custom_CommonStockholdersMember"
      decimals="-3"
      id="ixv-7714"
      unitRef="Shares">6655000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-10-012023-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-7715"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-10-012023-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-7716"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-10-012022-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-7717"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-10-012022-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-7718"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscounts
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7719"
      unitRef="USD">16896000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscounts>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscounts
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7720"
      unitRef="USD">13205000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscounts>
    <FONR:ProductSalesNet
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7721"
      unitRef="USD">219000</FONR:ProductSalesNet>
    <FONR:ProductSalesNet
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7722"
      unitRef="USD">200000</FONR:ProductSalesNet>
    <FONR:ServiceAndRepairFeesNet
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7723"
      unitRef="USD">3643000</FONR:ServiceAndRepairFeesNet>
    <FONR:ServiceAndRepairFeesNet
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7724"
      unitRef="USD">3658000</FONR:ServiceAndRepairFeesNet>
    <FONR:ServiceAndRepairFeesRelatedPartiesNet
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7725"
      unitRef="USD">55000</FONR:ServiceAndRepairFeesRelatedPartiesNet>
    <FONR:ServiceAndRepairFeesRelatedPartiesNet
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7726"
      unitRef="USD">55000</FONR:ServiceAndRepairFeesRelatedPartiesNet>
    <FONR:ManagementAndOtherFeesNet
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7727"
      unitRef="USD">24436000</FONR:ManagementAndOtherFeesNet>
    <FONR:ManagementAndOtherFeesNet
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7728"
      unitRef="USD">24342000</FONR:ManagementAndOtherFeesNet>
    <FONR:ManagementAndOtherFeesRelatedMedicalPracticesNet
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7729"
      unitRef="USD">5975000</FONR:ManagementAndOtherFeesRelatedMedicalPracticesNet>
    <FONR:ManagementAndOtherFeesRelatedMedicalPracticesNet
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7730"
      unitRef="USD">5987000</FONR:ManagementAndOtherFeesRelatedMedicalPracticesNet>
    <us-gaap:Revenues
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7731"
      unitRef="USD">51224000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7732"
      unitRef="USD">47447000</us-gaap:Revenues>
    <us-gaap:OtherCostOfOperatingRevenue
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7733"
      unitRef="USD">9029000</us-gaap:OtherCostOfOperatingRevenue>
    <us-gaap:OtherCostOfOperatingRevenue
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7734"
      unitRef="USD">7822000</us-gaap:OtherCostOfOperatingRevenue>
    <FONR:CostsRelatedToProductSales
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7735"
      unitRef="USD">405000</FONR:CostsRelatedToProductSales>
    <FONR:CostsRelatedToProductSales
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7736"
      unitRef="USD">383000</FONR:CostsRelatedToProductSales>
    <FONR:CostsRelatedToServiceAndRepairFees
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7737"
      unitRef="USD">1633000</FONR:CostsRelatedToServiceAndRepairFees>
    <FONR:CostsRelatedToServiceAndRepairFees
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7738"
      unitRef="USD">1440000</FONR:CostsRelatedToServiceAndRepairFees>
    <FONR:CostsRelatedToServiceAndRepairFeesRelatedParties
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7739"
      unitRef="USD">25000</FONR:CostsRelatedToServiceAndRepairFeesRelatedParties>
    <FONR:CostsRelatedToServiceAndRepairFeesRelatedParties
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7740"
      unitRef="USD">22000</FONR:CostsRelatedToServiceAndRepairFeesRelatedParties>
    <FONR:CostsRelatedToManagementAndOtherFees
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7741"
      unitRef="USD">14231000</FONR:CostsRelatedToManagementAndOtherFees>
    <FONR:CostsRelatedToManagementAndOtherFees
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7742"
      unitRef="USD">13124000</FONR:CostsRelatedToManagementAndOtherFees>
    <FONR:CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7743"
      unitRef="USD">3109000</FONR:CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices>
    <FONR:CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7744"
      unitRef="USD">2890000</FONR:CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7745"
      unitRef="USD">883000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7746"
      unitRef="USD">691000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7747"
      unitRef="USD">10453000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7748"
      unitRef="USD">12932000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7749"
      unitRef="USD">39768000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7750"
      unitRef="USD">39304000</us-gaap:CostsAndExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7751"
      unitRef="USD">11456000</us-gaap:IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7752"
      unitRef="USD">8143000</us-gaap:IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7753"
      unitRef="USD">1000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7754"
      unitRef="USD">-197000</us-gaap:OtherNonoperatingIncomeExpense>
    <FONR:OtherIncomeRelatedParty
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7755"
      unitRef="USD">577000</FONR:OtherIncomeRelatedParty>
    <us-gaap:InterestExpense
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7756"
      unitRef="USD">58000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7757"
      unitRef="USD">27000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7758"
      unitRef="USD">1040000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7759"
      unitRef="USD">414000</us-gaap:InvestmentIncomeNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7760"
      unitRef="USD">13016000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7761"
      unitRef="USD">8333000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7762"
      unitRef="USD">3036000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7763"
      unitRef="USD">2871000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7764"
      unitRef="USD">9980000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7765"
      unitRef="USD">5462000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7766"
      unitRef="USD">2115000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7767"
      unitRef="USD">1183000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7768"
      unitRef="USD">7865000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7769"
      unitRef="USD">4279000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-12-31_custom_CommonStockholdersMember"
      decimals="-3"
      id="ixv-7770"
      unitRef="USD">7375000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-12-31_custom_CommonStockholdersMember"
      decimals="-3"
      id="ixv-7771"
      unitRef="USD">4020000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-12-31_custom_ClassANonVotingPreferredStockholdersMember"
      decimals="-3"
      id="ixv-7772"
      unitRef="USD">365000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-12-31_custom_ClassANonVotingPreferredStockholdersMember"
      decimals="-3"
      id="ixv-7773"
      unitRef="USD">193000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-7774"
      unitRef="USD">125000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-7775"
      unitRef="USD">66000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-07-012023-12-31_custom_CommonStockholdersMember"
      decimals="INF"
      id="ixv-7776"
      unitRef="USDPShares">1.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-07-012022-12-31_custom_CommonStockholdersMember"
      decimals="INF"
      id="ixv-7777"
      unitRef="USDPShares">0.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-07-012023-12-31_custom_CommonStockholdersMember"
      decimals="INF"
      id="ixv-7778"
      unitRef="USDPShares">1.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-07-012022-12-31_custom_CommonStockholdersMember"
      decimals="INF"
      id="ixv-7779"
      unitRef="USDPShares">0.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-07-012023-12-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="ixv-7780"
      unitRef="USDPShares">0.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-07-012023-12-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="ixv-7781"
      unitRef="USDPShares">0.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-07-012022-12-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="ixv-7782"
      unitRef="USDPShares">0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-07-012022-12-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="ixv-7783"
      unitRef="USDPShares">0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-012023-12-31_custom_CommonStockholdersMember"
      decimals="-3"
      id="ixv-7784"
      unitRef="Shares">6448000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-07-012022-12-31_custom_CommonStockholdersMember"
      decimals="-3"
      id="ixv-7785"
      unitRef="Shares">6534000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-07-012023-12-31_custom_CommonStockholdersMember"
      decimals="-3"
      id="ixv-7786"
      unitRef="Shares">6576000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-07-012022-12-31_custom_CommonStockholdersMember"
      decimals="-3"
      id="ixv-7787"
      unitRef="Shares">6662000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-012023-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-7788"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-07-012023-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-7789"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-07-012022-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-7790"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-07-012022-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-7791"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7792"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7793"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7794"
      unitRef="Shares">6450882000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-7795"
      unitRef="USD">182613000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-7796"
      unitRef="USD">182613000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-7797"
      unitRef="USD">-20085000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-7798"
      unitRef="USD">-20085000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-09-30_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7799"
      unitRef="USD">-1230000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-09-30_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7800"
      unitRef="USD">-1230000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7801"
      unitRef="Shares">54674000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-09-30_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="ixv-7802"
      unitRef="USD">-7226000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-09-30_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="ixv-7803"
      unitRef="USD">-7226000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="ixv-7804"
      unitRef="USD">154073000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="ixv-7805"
      unitRef="USD">154073000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-7806"
      unitRef="USD">3759000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7807"
      unitRef="USD">3759000</us-gaap:NetIncomeLoss>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-10-012023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7808"
      unitRef="USD">1171000</us-gaap:StockRepurchasedDuringPeriodValue>
    <FONR:PurchaseOfTreasuryStockShares
      contextRef="From2023-10-012023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7809"
      unitRef="Shares">72297000</FONR:PurchaseOfTreasuryStockShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7810"
      unitRef="USD">1171000</us-gaap:StockRepurchasedDuringPeriodValue>
    <FONR:CancellationOfSharesShares
      contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7811"
      unitRef="Shares">-122588000</FONR:CancellationOfSharesShares>
    <FONR:CancellationOfShares
      contextRef="From2023-10-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-7812"
      unitRef="USD">-2006000</FONR:CancellationOfShares>
    <FONR:CancellationOfShares
      contextRef="From2023-10-012023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7813"
      unitRef="USD">2006000</FONR:CancellationOfShares>
    <FONR:CancellationOfSharesShares
      contextRef="From2023-10-012023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7814"
      unitRef="Shares">-122588000</FONR:CancellationOfSharesShares>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2023-10-012023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="ixv-7815"
      unitRef="USD">1225000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7816"
      unitRef="USD">1225000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2023-10-012023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="ixv-7817"
      unitRef="USD">861000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-7818"
      unitRef="USD">861000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember-1258588312"
      decimals="-3"
      id="ixv-7819"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember-1258588312"
      decimals="-3"
      id="ixv-7820"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember-1258588312"
      decimals="-3"
      id="ixv-7821"
      unitRef="Shares">6328294000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-7822"
      unitRef="USD">180607000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-7823"
      unitRef="USD">180607000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-7824"
      unitRef="USD">-16326000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-7825"
      unitRef="USD">-16326000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7826"
      unitRef="USD">-395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7827"
      unitRef="USD">-395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7828"
      unitRef="Shares">4383000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="ixv-7829"
      unitRef="USD">-7590000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="ixv-7830"
      unitRef="USD">-7590000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7831"
      unitRef="USD">156297000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7832"
      unitRef="USD">156297000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7833"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7834"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7835"
      unitRef="Shares">6554210000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-7836"
      unitRef="USD">184531000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-7837"
      unitRef="USD">184531000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-7838"
      unitRef="USD">-31520000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-7839"
      unitRef="USD">-31520000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-09-30_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7840"
      unitRef="USD">-797000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-09-30_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7841"
      unitRef="USD">-797000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7842"
      unitRef="Shares">20445000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-09-30_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="ixv-7843"
      unitRef="USD">-5085000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-09-30_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="ixv-7844"
      unitRef="USD">-5085000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-09-30"
      decimals="-3"
      id="ixv-7845"
      unitRef="USD">147130000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-09-30"
      decimals="-3"
      id="ixv-7846"
      unitRef="USD">147130000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-7847"
      unitRef="USD">2232000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7848"
      unitRef="USD">2232000</us-gaap:NetIncomeLoss>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-10-012022-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7849"
      unitRef="USD">356000</us-gaap:StockRepurchasedDuringPeriodValue>
    <FONR:PurchaseOfTreasuryStockShares
      contextRef="From2022-10-012022-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7850"
      unitRef="Shares">20819000</FONR:PurchaseOfTreasuryStockShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7851"
      unitRef="USD">356000</us-gaap:StockRepurchasedDuringPeriodValue>
    <FONR:CancellationOfSharesShares
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7852"
      unitRef="Shares">-16062000</FONR:CancellationOfSharesShares>
    <FONR:CancellationOfShares
      contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-7853"
      unitRef="USD">-401000</FONR:CancellationOfShares>
    <FONR:CancellationOfShares
      contextRef="From2022-10-012022-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7854"
      unitRef="USD">402000</FONR:CancellationOfShares>
    <FONR:CancellationOfSharesShares
      contextRef="From2022-10-012022-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7855"
      unitRef="Shares">-16062000</FONR:CancellationOfSharesShares>
    <FONR:CancellationOfShares
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7856"
      unitRef="USD">1000</FONR:CancellationOfShares>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2022-10-012022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="ixv-7857"
      unitRef="USD">1517000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7858"
      unitRef="USD">1517000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2022-10-012022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="ixv-7859"
      unitRef="USD">580000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-7860"
      unitRef="USD">580000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7861"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7862"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7863"
      unitRef="Shares">6538148000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-7864"
      unitRef="USD">184130000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-7865"
      unitRef="USD">184130000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-7866"
      unitRef="USD">-29288000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-7867"
      unitRef="USD">-29288000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7868"
      unitRef="USD">-751000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7869"
      unitRef="USD">-751000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7870"
      unitRef="Shares">25202000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="ixv-7871"
      unitRef="USD">-6022000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="ixv-7872"
      unitRef="USD">-6022000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-7873"
      unitRef="USD">148070000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-7874"
      unitRef="USD">148070000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember-1258588437"
      decimals="-3"
      id="ixv-7875"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember-1258588437"
      decimals="-3"
      id="ixv-7876"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember-1258588437"
      decimals="-3"
      id="ixv-7877"
      unitRef="Shares">6450882000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-7878"
      unitRef="USD">182613000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-7879"
      unitRef="USD">182613000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-7880"
      unitRef="USD">-24191000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-7881"
      unitRef="USD">-24191000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7882"
      unitRef="USD">-516000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7883"
      unitRef="USD">-516000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7884"
      unitRef="Shares">11463000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-06-30_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="ixv-7885"
      unitRef="USD">-7079000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-06-30_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="ixv-7886"
      unitRef="USD">-7079000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7887"
      unitRef="USD">150828000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-7888"
      unitRef="USD">150828000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-7889"
      unitRef="USD">7865000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7890"
      unitRef="USD">7865000</us-gaap:NetIncomeLoss>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-07-012023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7891"
      unitRef="USD">1885000</us-gaap:StockRepurchasedDuringPeriodValue>
    <FONR:PurchaseOfTreasuryStockShares
      contextRef="From2023-07-012023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7892"
      unitRef="Shares">115508000</FONR:PurchaseOfTreasuryStockShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7893"
      unitRef="USD">1885000</us-gaap:StockRepurchasedDuringPeriodValue>
    <FONR:CancellationOfSharesShares
      contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7894"
      unitRef="Shares">-122588000</FONR:CancellationOfSharesShares>
    <FONR:CancellationOfShares
      contextRef="From2023-07-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-7895"
      unitRef="USD">-2006000</FONR:CancellationOfShares>
    <FONR:CancellationOfShares
      contextRef="From2023-07-012023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7896"
      unitRef="USD">2006000</FONR:CancellationOfShares>
    <FONR:CancellationOfSharesShares
      contextRef="From2023-07-012023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7897"
      unitRef="Shares">-122588000</FONR:CancellationOfSharesShares>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2023-07-012023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="ixv-7898"
      unitRef="USD">2626000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7899"
      unitRef="USD">2626000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2023-07-012023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="ixv-7900"
      unitRef="USD">2115000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7901"
      unitRef="USD">2115000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember-1258588312"
      decimals="-3"
      id="ixv-7902"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember-1258588312"
      decimals="-3"
      id="ixv-7903"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember-1258588312"
      decimals="-3"
      id="ixv-7904"
      unitRef="Shares">6328294000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-7905"
      unitRef="USD">180607000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-7906"
      unitRef="USD">180607000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-7907"
      unitRef="USD">-16326000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-7908"
      unitRef="USD">-16326000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7909"
      unitRef="USD">-395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7910"
      unitRef="USD">-395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7911"
      unitRef="Shares">4383000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="ixv-7912"
      unitRef="USD">-7590000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="ixv-7913"
      unitRef="USD">-7590000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7914"
      unitRef="USD">156297000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-7915"
      unitRef="USD">156297000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7916"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7917"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7918"
      unitRef="Shares">6554210000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-7919"
      unitRef="USD">184531000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-7920"
      unitRef="USD">184531000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-7921"
      unitRef="USD">-33567000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-7922"
      unitRef="USD">-33567000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7923"
      unitRef="USD">-675000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7924"
      unitRef="USD">-675000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7925"
      unitRef="Shares">11643000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-06-30_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="ixv-7926"
      unitRef="USD">-4054000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-06-30_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="ixv-7927"
      unitRef="USD">-4054000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-06-30"
      decimals="-3"
      id="ixv-7928"
      unitRef="USD">146236000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-06-30"
      decimals="-3"
      id="ixv-7929"
      unitRef="USD">146236000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-7930"
      unitRef="USD">4279000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7931"
      unitRef="USD">4279000</us-gaap:NetIncomeLoss>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-07-012022-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7932"
      unitRef="USD">478000</us-gaap:StockRepurchasedDuringPeriodValue>
    <FONR:PurchaseOfTreasuryStockShares
      contextRef="From2022-07-012022-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7933"
      unitRef="Shares">29621000</FONR:PurchaseOfTreasuryStockShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7934"
      unitRef="USD">478000</us-gaap:StockRepurchasedDuringPeriodValue>
    <FONR:CancellationOfSharesShares
      contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7935"
      unitRef="Shares">-16062000</FONR:CancellationOfSharesShares>
    <FONR:CancellationOfShares
      contextRef="From2022-07-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-7936"
      unitRef="USD">-401000</FONR:CancellationOfShares>
    <FONR:CancellationOfShares
      contextRef="From2022-07-012022-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7937"
      unitRef="USD">402000</FONR:CancellationOfShares>
    <FONR:CancellationOfSharesShares
      contextRef="From2022-07-012022-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7938"
      unitRef="Shares">-16062000</FONR:CancellationOfSharesShares>
    <FONR:CancellationOfShares
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7939"
      unitRef="USD">1000</FONR:CancellationOfShares>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2022-07-012022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="ixv-7940"
      unitRef="USD">3151000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7941"
      unitRef="USD">3151000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2022-07-012022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="ixv-7942"
      unitRef="USD">1183000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7943"
      unitRef="USD">1183000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7944"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7945"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-7946"
      unitRef="Shares">6538148000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-7947"
      unitRef="USD">184130000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-7948"
      unitRef="USD">184130000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-7949"
      unitRef="USD">-29288000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-7950"
      unitRef="USD">-29288000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7951"
      unitRef="USD">-751000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7952"
      unitRef="USD">-751000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="ixv-7953"
      unitRef="Shares">25202000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="ixv-7954"
      unitRef="USD">-6022000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="ixv-7955"
      unitRef="USD">-6022000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-7956"
      unitRef="USD">148070000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-7957"
      unitRef="USD">148070000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7958"
      unitRef="USD">9980000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7959"
      unitRef="USD">5462000</us-gaap:ProfitLoss>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7960"
      unitRef="USD">2415000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7961"
      unitRef="USD">2218000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7962"
      unitRef="USD">2146000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7963"
      unitRef="USD">2238000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <FONR:ProvisionForBadDebts
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7964"
      unitRef="USD">355000</FONR:ProvisionForBadDebts>
    <FONR:ProvisionForBadDebts
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7965"
      unitRef="USD">2891000</FONR:ProvisionForBadDebts>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7966"
      unitRef="USD">2284000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7967"
      unitRef="USD">2306000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <FONR:GainOnSaleOfEquipmentRelatedParty
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7968"
      unitRef="USD">577000</FONR:GainOnSaleOfEquipmentRelatedParty>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7969"
      unitRef="USD">4958000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7970"
      unitRef="USD">3375000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <FONR:IncreaseDecreaseInNotesReceivable
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7971"
      unitRef="USD">50000</FONR:IncreaseDecreaseInNotesReceivable>
    <FONR:IncreaseDecreaseInNotesReceivable
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7972"
      unitRef="USD">11000</FONR:IncreaseDecreaseInNotesReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7973"
      unitRef="USD">265000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7974"
      unitRef="USD">274000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7975"
      unitRef="USD">-217000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7976"
      unitRef="USD">-60000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7977"
      unitRef="USD">-22000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7978"
      unitRef="USD">-244000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7979"
      unitRef="USD">-685000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7980"
      unitRef="USD">-2341000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7981"
      unitRef="USD">-3228000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <FONR:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7982"
      unitRef="USD">-2265000</FONR:IncreaseDecreaseInOperatingLeaseLiabilities>
    <FONR:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7983"
      unitRef="USD">-1874000</FONR:IncreaseDecreaseInOperatingLeaseLiabilities>
    <FONR:IncreaseDecreaseInFinancingLiabilities
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7984"
      unitRef="USD">108000</FONR:IncreaseDecreaseInFinancingLiabilities>
    <FONR:IncreaseDecreaseInFinancingLiabilities
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7985"
      unitRef="USD">126000</FONR:IncreaseDecreaseInFinancingLiabilities>
    <FONR:IncreaseDecreaseInCustomerAdvance
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7986"
      unitRef="USD">-3000</FONR:IncreaseDecreaseInCustomerAdvance>
    <FONR:IncreaseDecreaseInCustomerAdvance
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7987"
      unitRef="USD">271000</FONR:IncreaseDecreaseInCustomerAdvance>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7988"
      unitRef="USD">-19000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7989"
      unitRef="USD">-33000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7990"
      unitRef="USD">6689000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7991"
      unitRef="USD">5862000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7992"
      unitRef="USD">192000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7993"
      unitRef="USD">1362000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7994"
      unitRef="USD">20000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7995"
      unitRef="USD">74000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7996"
      unitRef="USD">-212000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7997"
      unitRef="USD">-1436000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-7998"
      unitRef="USD">21000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-7999"
      unitRef="USD">15000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-8000"
      unitRef="USD">1885000</us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock>
    <us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-8001"
      unitRef="USD">478000</us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock>
    <us-gaap:PaymentsOfDividendsMinorityInterest
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-8002"
      unitRef="USD">2626000</us-gaap:PaymentsOfDividendsMinorityInterest>
    <us-gaap:PaymentsOfDividendsMinorityInterest
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-8003"
      unitRef="USD">3151000</us-gaap:PaymentsOfDividendsMinorityInterest>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-8004"
      unitRef="USD">-4532000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-8005"
      unitRef="USD">-3644000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-8006"
      unitRef="USD">1945000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-8007"
      unitRef="USD">782000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-8008"
      unitRef="USD">51280000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-06-30"
      decimals="-3"
      id="ixv-8009"
      unitRef="USD">48723000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8010"
      unitRef="USD">53225000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-8011"
      unitRef="USD">49505000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-3464">&lt;p id="xdx_804_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zD7NJOEByiPg" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;NOTE 1 &#x2013;&lt;span id="xdx_821_zM1J0N2WC2Cf"&gt; DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;Description of Business&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Effective July 1, 2015, the Company
restructured the corporate organization of the management of diagnostic imaging centers segment of our business. The reorganization
was structured to more completely integrate the operations of Health Management Corporation of America and HDM. Imperial contributed
all of its assets (which were utilized in the business of Health Management Corporation of America) to HDM and received a &lt;span id="xdx_90B_ecustom--HmcaOwnershipSizeOfImperialManagementServicesPercent_iI_pip0_dp_c20150701__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ControllingInterestMember_zkhz9tq6PUFh" title="The ownership interest of Imperial Management Services after reorganization of newly expanded HDM"&gt;24.2&lt;/span&gt;%
interest in HDM. Health Management Corporation of America retained a direct ownership interest of &lt;span id="xdx_901_ecustom--OwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent_iI_pip0_dp_c20150701__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ControllingInterestMember_ziDsZKn2LBv7" title="The ownership interest of Health Management Corporation of America after reorganization of newly expanded HDM"&gt;45.8&lt;/span&gt;% in HDM, and the original
investors in HDM retained a &lt;span id="xdx_90F_ecustom--OwnershipInterestOfOriginalInvestorsOfHdm_iI_pip0_dp_c20150701__us-gaap--StatementEquityComponentsAxis__us-gaap--NoncontrollingInterestMember_zt4bG1dQeMUk" title="The ownership interest of the original investors of HDM"&gt;30.0&lt;/span&gt;% ownership interest in the newly expanded HDM. During the fiscal year ended June 30, 2022, the
Company purchased non-controlling interests from the minority shareholders for $&lt;span id="xdx_903_ecustom--DirectPurchaseOfNoncontrollingInterests_pn3n3_c20210701__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ControllingInterestMember_zGebHjWX59Td" title="Direct purchase of Noncontrolling Interests"&gt;546,000&lt;/span&gt;. Currently the Company has a direct ownership
interest of &lt;span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pip0_dp_c20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ControllingInterestMember_zKRpdsQ0eK71" title="Direct ownership interest percentage"&gt;70.8&lt;/span&gt;% and the investors&#x2019; have a &lt;span id="xdx_900_ecustom--InvestorsOwnershipInterest_iI_pip0_dp_c20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--NoncontrollingInterestMember_zEWdxXjPmOU5" title="Investors ownership interest percentage"&gt;29.2&lt;/span&gt;% ownership interest. The entire management of diagnostic imaging centers
business segment is now being conducted by HDM, operating under the name &#x201c;Health Management Company of America&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;Basis of Presentation&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying unaudited condensed
consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial
information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the
information and footnotes required by accounting principles generally accepted in the United States of America for complete financial
statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a
fair presentation have been included. Operating results for the six months ended December 31, 2023, are not necessarily indicative
of the results that may be expected for the fiscal year ending June 30, 2024. For further information, refer to the consolidated
financial statements and footnotes thereto included in the Company&#x2019;s Annual Report on Form 10-K filed on September 28, 2023
for the fiscal year ended June 30, 2023.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The global pandemic of COVID-19 has
caused turbulence and uncertainty in the United States and international markets and economies which has adversely affected our
workforce, liquidity, financial conditions, revenues, profitability and business operations. The Company was able to enact certain
decisions to allow the Company to navigate the global pandemic and from further losses, additional decreases in scan volume and
avoid any significant disruption of the business. The Company must now take into account the severity, duration and recurrence
of new strains of the COVID-19 virus which adds a new dimension to the challenges and uncertainty facing our business and the world
economy in general. Although we are unable to predict if there will be additional consequences on our operations from the continuing
global pandemic of COVID-19, the Company believes with positive cash flows, low debt and cash on hand, it will be able to continue
operations going forward.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <FONR:HmcaOwnershipSizeOfImperialManagementServicesPercent
      contextRef="AsOf2015-07-01_custom_ControllingInterestMember"
      decimals="INF"
      id="ixv-8012"
      unitRef="Pure">0.242</FONR:HmcaOwnershipSizeOfImperialManagementServicesPercent>
    <FONR:OwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent
      contextRef="AsOf2015-07-01_custom_ControllingInterestMember"
      decimals="INF"
      id="ixv-8013"
      unitRef="Pure">0.458</FONR:OwnershipInterestAfterReorganizationForHealthManagementCorporationOfAmericaOfNewlyExpandedHdmPercent>
    <FONR:OwnershipInterestOfOriginalInvestorsOfHdm
      contextRef="AsOf2015-07-01_us-gaap_NoncontrollingInterestMember"
      decimals="INF"
      id="ixv-8014"
      unitRef="Pure">0.300</FONR:OwnershipInterestOfOriginalInvestorsOfHdm>
    <FONR:DirectPurchaseOfNoncontrollingInterests
      contextRef="From2021-07-012022-06-30_custom_ControllingInterestMember"
      decimals="-3"
      id="ixv-8015"
      unitRef="USD">546000000</FONR:DirectPurchaseOfNoncontrollingInterests>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-06-30_custom_ControllingInterestMember"
      decimals="INF"
      id="ixv-8016"
      unitRef="Pure">0.708</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <FONR:InvestorsOwnershipInterest
      contextRef="AsOf2022-06-30_us-gaap_NoncontrollingInterestMember"
      decimals="INF"
      id="ixv-8017"
      unitRef="Pure">0.292</FONR:InvestorsOwnershipInterest>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-3484">&lt;p id="xdx_803_eus-gaap--SignificantAccountingPoliciesTextBlock_z5oIJ2V561of" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;NOTE 2 -&lt;span id="xdx_820_zeGSqZ9uhMQ3"&gt; SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_z3sxBoQ5ZaXk" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_860_zCQUcePOn8e4"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The unaudited condensed consolidated
financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships (collectively
the &#x201c;Company&#x201d;). All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
























&lt;p id="xdx_847_eus-gaap--RevenueRecognitionPolicyTextBlock_za2twcMHz04j" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_868_z54JY0l9LKAf"&gt;Revenues&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The revenue recognition standard in
ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a
customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires
expanded disclosures regarding the Company&#x2019;s revenue recognition policies and significant judgements employed in the determination
of revenue.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our revenues generally relate to net
patient fees&#160;received from various payers and patients themselves under contracts in which our performance obligations are
to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services
are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day.
The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care
health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction
prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care
health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the
services we provide to the related patients typically specify payments at amounts less than our standard charges and generally
provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually
reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes
in managed care contractual terms resulting from contract renegotiations and renewals.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--BusinessCombinationsPolicy_zK3cw6rLlle3" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86B_zhfHChWzvfrh"&gt;BUSINESS COMBINATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;When the qualifications for business
combination accounting treatment are met, it requires us to recognize separately from goodwill the assets acquired and the liabilities
assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred
over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates
and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently
uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition
date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the
conclusion of the measurement period of final determination of the values of assets acquired or liabilities assumed, whichever
comes first, any subsequent adjustments are recorded to our consolidated statements of income.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zUietNjjOXEf" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_864_zoDNeMxqPNPc"&gt;Earnings Per Share&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic earnings per share (&#x201c;EPS&#x201d;)
is computed based upon the weighted average number of shares of common stock and stock equivalents outstanding, net of common stock.
In accordance with ASC topic 260-10, &#x201c;Participating Securities and the Two-Class method&#x201d;, the Company used the Two-Class
method for calculating basic income per share and applied the if converted method in calculating diluted income per share for the
three and six months ended December 31, 2023 and 2022.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Diluted EPS reflects the potential dilution
from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares
outstanding during the period. For the three and six months ended December 31, 2023 and 2022, diluted EPS for common shareholders
includes &lt;span id="xdx_90D_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_pn3n3_c20231001__20231231_zWDdDMNArwzi" title="Shares included upon conversion of Class C Common"&gt;&lt;span id="xdx_906_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_pn3n3_c20230701__20231231_zObqDGAhtB9" title="Shares included upon conversion of Class C Common"&gt;&lt;span id="xdx_908_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_pn3n3_c20221001__20221231_znE2S1tSW9xl" title="Shares included upon conversion of Class C Common"&gt;&lt;span id="xdx_907_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_pn3n3_c20220701__20221231_zuBHVG23ZLM4" title="Shares included upon conversion of Class C Common"&gt;128&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares upon conversion of Class C Common.&lt;/p&gt;




























&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_z0hpep08RVlj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share - (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8BB_znGt4olpKusa" style="display: none; padding-top: 0; padding-right: 0; text-align: left"&gt;Schedule of earning per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;Three months ended &lt;br/&gt; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;Three months ended &lt;br/&gt; December 31, 2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class C Common &lt;br/&gt; Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class C Common &lt;br/&gt; Stock&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Basic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Numerator: &lt;br/&gt; Net income available to common stockholders&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20231001__20231231_z24aXYwIjQak" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;3,759&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zG8ROYPm99jj" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;3,525&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zYeAgS3vtVDj" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;59&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20221001__20221231_zDCm7XWQngv4" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;2,232&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdVoSqQYuEu6" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Common Stock and Basic Numerator: Net income available to common stockholders"&gt;2,097&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zVmK7Tx46aDc" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;34&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Weighted average shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20231001__20231231_zujqgbfVHdib" title="Basic Denominator: Weighted average shares outstanding"&gt;6,437&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQ3s5Ss1T211" title="Basic Denominator: Weighted average shares outstanding"&gt;6,437&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zAdeCfpLn6Nc" title="Basic Denominator: Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20221001__20221231_zlorfe1PBIP2" title="Basic Denominator: Weighted average shares outstanding"&gt;6,527&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2qzTva5HHvj" title="Basic Denominator: Weighted average shares outstanding"&gt;6,527&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zI5Yn8RanB8f" title="Basic Denominator: Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Basic income per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20231001__20231231_zKWdQXgSLdq3" title="Basic income per common share"&gt;0.58&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zp7d2uqfUzjc" title="Basic income per common share"&gt;0.55&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zgbXQMSjCuVk" title="Basic income per common share"&gt;0.16&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20221001__20221231_zeIHjnC2kICf" title="Basic income per common share"&gt;0.34&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmSH7f1f7109" title="Basic income per common share"&gt;0.32&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z7F2Pqhgpvy1" title="Basic income per common share"&gt;0.09&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Denominator: &lt;br/&gt; Weighted average shares outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2pyXMXkRWo3" title="Diluted Denominator: Weighted average shares outstanding"&gt;6,437&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zpTuzrYJwkK3" title="Diluted Denominator: Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8lgAsR8fRzh" title="Diluted Denominator: Weighted average shares outstanding"&gt;6,527&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zqh4XEwVBlVc" title="Diluted Denominator: Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Convertible Class C Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ConvertibleClassCStock_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoXRWoEMXNbb" title="Convertible Class C Stock"&gt;128&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_902_ecustom--ConvertibleClassCStock_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_ztk1kuEXjKh6" title="Convertible Class C Stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1091"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ConvertibleClassCStock_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrZgsPwWJQWk" title="Convertible Class C Stock"&gt;128&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ConvertibleClassCStock_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zgXkhSfSxKAk" title="Convertible Class C Stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1095"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total Denominator for diluted earnings per share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBPNn6fnSBtc" title="Total Denominator for Diluted Earnings Per Share"&gt;6,565&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zrXAnwqNZxD8" title="Total Denominator for Diluted Earnings Per Share"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKGI6QcltMc1" title="Total Denominator for Diluted Earnings Per Share"&gt;6,655&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z0JBAcMMr25g" title="Total Denominator for Diluted Earnings Per Share"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Diluted income per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pip0_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxl63AX6VXg7" title="Diluted Income per Common Share"&gt;0.54&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pip0_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zBFs3GvldEoh" title="Diluted Income per Common Share"&gt;0.16&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--EarningsPerShareDiluted_pip0_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2AJgM43Xhcl" title="Diluted Income per Common Share"&gt;0.32&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pip0_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zQade4RR3t9e" title="Diluted Income per Common Share"&gt;0.09&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;



&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;Six months ended &lt;br/&gt; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;Six months ended &lt;br/&gt; December 31, 2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class C Common &lt;br/&gt; Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class C Common &lt;br/&gt; Stock&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Basic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Numerator: &lt;br/&gt; Net income available to common stockholders&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20230701__20231231_z4UTQH7hUxL4" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;7,865&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsqY9NXVLV2c" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;7,375&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z3RMb85H0qkl" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;125&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20220701__20221231_zrCyjoAYN5q8" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;4,279&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLw3LCxpKoPj" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Common Stock and Basic Numerator: Net income available to common stockholders"&gt;4,020&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zvIHrcyBvIPk" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;66&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Weighted average shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20231231_zmZ93078iO8d" title="Basic Denominator: Weighted average shares outstanding"&gt;6,448&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z21yzFIuoLf6" title="Basic Denominator: Weighted average shares outstanding"&gt;6,448&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zQA2gc0u4Amk" title="Basic Denominator: Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220701__20221231_ztm6KSYAChm6" title="Basic Denominator: Weighted average shares outstanding"&gt;6,534&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkFlslAJn2qk" title="Basic Denominator: Weighted average shares outstanding"&gt;6,534&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zL7NtDF1AoTf" title="Basic Denominator: Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Basic income per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20230701__20231231_zmW1oBcSsg83" title="Basic income per common share"&gt;1.22&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4dCSpS3695b" title="Basic income per common share"&gt;1.14&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z7vSLvBYsxqe" title="Basic income per common share"&gt;0.33&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20220701__20221231_zJoGxGVg5CHa" title="Basic income per common share"&gt;0.65&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIo4QQjg035a" title="Basic income per common share"&gt;0.62&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zpvgvPcov6bg" title="Basic income per common share"&gt;0.17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Denominator: &lt;br/&gt; Weighted average shares outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9evyBlljdUa" title="Diluted Denominator: Weighted average shares outstanding"&gt;6,448&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zDfugAnIRGu7" title="Diluted Denominator: Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2yNF3S72Dh3" title="Diluted Denominator: Weighted average shares outstanding"&gt;6,534&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zdvFkKhi6fDf" title="Diluted Denominator: Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Convertible Class C Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_901_ecustom--ConvertibleClassCStock_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVjyzxkTFd1" title="Convertible Class C Stock"&gt;128&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_901_ecustom--ConvertibleClassCStock_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zq4Sfu9LeOv5" title="Convertible Class C Stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1159"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ConvertibleClassCStock_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zz6S4pR8sNT2" title="Convertible Class C Stock"&gt;128&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ConvertibleClassCStock_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zsmEWygCsbKi" title="Convertible Class C Stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1163"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total Denominator for diluted earnings per share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8meuCzW846g" title="Total Denominator for Diluted Earnings Per Share"&gt;6,576&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zC7x0fJBLE45" title="Total Denominator for Diluted Earnings Per Share"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znQ1wEDYsoi7" title="Total Denominator for Diluted Earnings Per Share"&gt;6,662&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zJ8UZGlHPd3k" title="Total Denominator for Diluted Earnings Per Share"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Diluted income per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareDiluted_pip0_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEoN3hUy1ybk" title="Diluted Income per Common Share"&gt;1.12&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_pip0_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zUXFtANM8l4g" title="Diluted Income per Common Share"&gt;0.33&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--EarningsPerShareDiluted_pip0_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHNRYTugpdhi" title="Diluted Income per Common Share"&gt;0.60&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_pip0_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zZd01Sfe84th" title="Diluted Income per Common Share"&gt;0.17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p id="xdx_8A2_zDO6CHuBR1Ub" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
























&lt;p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z40QeTkHA1Ff" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_869_zIQBDaKejqX2"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2023, the Financial Accounting
Standards Board (&#x201c;FASB&#x201d;) issued ASU 2023-09, &#x201c;Income Taxes (740) &#x201c;Improvements to Income Tax Disclosures&#x201d;,
which requires the annual financial statements to include consistent categories and greater disaggregation of information in the
rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company&#x2019;s annual
reporting beginning after December 15, 2024, with early adoption permitted, and should be applied on a prospective basis, with
a retrospective option. We are currently evaluating the effect that adoption of ASU 2023-09 will have on our disclosures.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November 2023, FASB issued ASU 2023-07, &#x201c;Segment Reporting (Topic
280)&#x201d;, which is intended to improve reportable segment disclosure requirements through enhanced disclosures about significant segment
expenses. The amendments require disclosure of significant segment expenses regularly provided to the chief operating decision maker (CODM)
as well as other segment items, extended certain annual disclosures to interim periods, clarify the applicability to single reportable
segment entities, permit, more than one measure of profit or loss to be reported under certain conditions, and require disclosure of the
title and position of the CODM. The effective date for public entities is beginning after December 15, 2023 and interim periods with fiscal
years beginning after December 15, 2024. We expect to adopt the new disclosures as required and are currently evaluating the impact on
the related disclosures.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2016, FASB issued ASU 2016-13, &#x201c;Financial
Instruments &#x2013; Credit Loses (Topic 326): Measurement of Credit Losses on Financial Instruments&#x201d;, which replaces the incurred
loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader
range of reasonable and supportable information to assess credit loss estimates. This ASU is effective for fiscal years beginning after
December 15, 2022. The Company adopted this standard on July 1, 2023 using the modified retrospective approach and it did not have a material
impact of the Company&#x2019;s financial statements, resulting in no adjustment to prior year earnings.&lt;/p&gt;
&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;FASB, the Emerging Issues Task Force
and the SEC have issued certain other accounting standards, updates, and regulations as of December 31, 2023 that will become effective
in subsequent periods; however, management does not believe that any of those updates would have significantly affected the Company&#x2019;s
financial accounting measures or disclosures had they been in effect during 2023 or 2022, and it does not believe that any of those
standards will have a significant impact on our consolidated condensed financial statements at the time they become effective.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




















</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-3488">&lt;p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_z3sxBoQ5ZaXk" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_860_zCQUcePOn8e4"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The unaudited condensed consolidated
financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships (collectively
the &#x201c;Company&#x201d;). All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
























</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-3519">&lt;p id="xdx_847_eus-gaap--RevenueRecognitionPolicyTextBlock_za2twcMHz04j" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_868_z54JY0l9LKAf"&gt;Revenues&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The revenue recognition standard in
ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a
customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires
expanded disclosures regarding the Company&#x2019;s revenue recognition policies and significant judgements employed in the determination
of revenue.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our revenues generally relate to net
patient fees&#160;received from various payers and patients themselves under contracts in which our performance obligations are
to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services
are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day.
The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care
health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction
prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care
health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the
services we provide to the related patients typically specify payments at amounts less than our standard charges and generally
provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually
reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes
in managed care contractual terms resulting from contract renegotiations and renewals.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="From2023-07-01to2023-12-31" id="ixv-3527">&lt;p id="xdx_84E_eus-gaap--BusinessCombinationsPolicy_zK3cw6rLlle3" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86B_zhfHChWzvfrh"&gt;BUSINESS COMBINATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;When the qualifications for business
combination accounting treatment are met, it requires us to recognize separately from goodwill the assets acquired and the liabilities
assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred
over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates
and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently
uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition
date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the
conclusion of the measurement period of final determination of the values of assets acquired or liabilities assumed, whichever
comes first, any subsequent adjustments are recorded to our consolidated statements of income.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-3533">&lt;p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zUietNjjOXEf" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_864_zoDNeMxqPNPc"&gt;Earnings Per Share&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic earnings per share (&#x201c;EPS&#x201d;)
is computed based upon the weighted average number of shares of common stock and stock equivalents outstanding, net of common stock.
In accordance with ASC topic 260-10, &#x201c;Participating Securities and the Two-Class method&#x201d;, the Company used the Two-Class
method for calculating basic income per share and applied the if converted method in calculating diluted income per share for the
three and six months ended December 31, 2023 and 2022.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Diluted EPS reflects the potential dilution
from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares
outstanding during the period. For the three and six months ended December 31, 2023 and 2022, diluted EPS for common shareholders
includes &lt;span id="xdx_90D_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_pn3n3_c20231001__20231231_zWDdDMNArwzi" title="Shares included upon conversion of Class C Common"&gt;&lt;span id="xdx_906_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_pn3n3_c20230701__20231231_zObqDGAhtB9" title="Shares included upon conversion of Class C Common"&gt;&lt;span id="xdx_908_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_pn3n3_c20221001__20221231_znE2S1tSW9xl" title="Shares included upon conversion of Class C Common"&gt;&lt;span id="xdx_907_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_pn3n3_c20220701__20221231_zuBHVG23ZLM4" title="Shares included upon conversion of Class C Common"&gt;128&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares upon conversion of Class C Common.&lt;/p&gt;




























&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_z0hpep08RVlj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share - (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8BB_znGt4olpKusa" style="display: none; padding-top: 0; padding-right: 0; text-align: left"&gt;Schedule of earning per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;Three months ended &lt;br/&gt; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;Three months ended &lt;br/&gt; December 31, 2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class C Common &lt;br/&gt; Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class C Common &lt;br/&gt; Stock&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Basic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Numerator: &lt;br/&gt; Net income available to common stockholders&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20231001__20231231_z24aXYwIjQak" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;3,759&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zG8ROYPm99jj" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;3,525&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zYeAgS3vtVDj" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;59&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20221001__20221231_zDCm7XWQngv4" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;2,232&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdVoSqQYuEu6" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Common Stock and Basic Numerator: Net income available to common stockholders"&gt;2,097&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zVmK7Tx46aDc" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;34&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Weighted average shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20231001__20231231_zujqgbfVHdib" title="Basic Denominator: Weighted average shares outstanding"&gt;6,437&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQ3s5Ss1T211" title="Basic Denominator: Weighted average shares outstanding"&gt;6,437&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zAdeCfpLn6Nc" title="Basic Denominator: Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20221001__20221231_zlorfe1PBIP2" title="Basic Denominator: Weighted average shares outstanding"&gt;6,527&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2qzTva5HHvj" title="Basic Denominator: Weighted average shares outstanding"&gt;6,527&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zI5Yn8RanB8f" title="Basic Denominator: Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Basic income per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20231001__20231231_zKWdQXgSLdq3" title="Basic income per common share"&gt;0.58&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zp7d2uqfUzjc" title="Basic income per common share"&gt;0.55&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zgbXQMSjCuVk" title="Basic income per common share"&gt;0.16&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20221001__20221231_zeIHjnC2kICf" title="Basic income per common share"&gt;0.34&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmSH7f1f7109" title="Basic income per common share"&gt;0.32&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z7F2Pqhgpvy1" title="Basic income per common share"&gt;0.09&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Denominator: &lt;br/&gt; Weighted average shares outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2pyXMXkRWo3" title="Diluted Denominator: Weighted average shares outstanding"&gt;6,437&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zpTuzrYJwkK3" title="Diluted Denominator: Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8lgAsR8fRzh" title="Diluted Denominator: Weighted average shares outstanding"&gt;6,527&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zqh4XEwVBlVc" title="Diluted Denominator: Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Convertible Class C Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ConvertibleClassCStock_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoXRWoEMXNbb" title="Convertible Class C Stock"&gt;128&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_902_ecustom--ConvertibleClassCStock_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_ztk1kuEXjKh6" title="Convertible Class C Stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1091"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ConvertibleClassCStock_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrZgsPwWJQWk" title="Convertible Class C Stock"&gt;128&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ConvertibleClassCStock_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zgXkhSfSxKAk" title="Convertible Class C Stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1095"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total Denominator for diluted earnings per share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBPNn6fnSBtc" title="Total Denominator for Diluted Earnings Per Share"&gt;6,565&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zrXAnwqNZxD8" title="Total Denominator for Diluted Earnings Per Share"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKGI6QcltMc1" title="Total Denominator for Diluted Earnings Per Share"&gt;6,655&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z0JBAcMMr25g" title="Total Denominator for Diluted Earnings Per Share"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Diluted income per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pip0_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxl63AX6VXg7" title="Diluted Income per Common Share"&gt;0.54&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pip0_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zBFs3GvldEoh" title="Diluted Income per Common Share"&gt;0.16&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--EarningsPerShareDiluted_pip0_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2AJgM43Xhcl" title="Diluted Income per Common Share"&gt;0.32&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pip0_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zQade4RR3t9e" title="Diluted Income per Common Share"&gt;0.09&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;



&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;Six months ended &lt;br/&gt; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;Six months ended &lt;br/&gt; December 31, 2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class C Common &lt;br/&gt; Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class C Common &lt;br/&gt; Stock&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Basic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Numerator: &lt;br/&gt; Net income available to common stockholders&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20230701__20231231_z4UTQH7hUxL4" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;7,865&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsqY9NXVLV2c" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;7,375&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z3RMb85H0qkl" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;125&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20220701__20221231_zrCyjoAYN5q8" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;4,279&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLw3LCxpKoPj" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Common Stock and Basic Numerator: Net income available to common stockholders"&gt;4,020&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zvIHrcyBvIPk" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;66&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Weighted average shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20231231_zmZ93078iO8d" title="Basic Denominator: Weighted average shares outstanding"&gt;6,448&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z21yzFIuoLf6" title="Basic Denominator: Weighted average shares outstanding"&gt;6,448&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zQA2gc0u4Amk" title="Basic Denominator: Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220701__20221231_ztm6KSYAChm6" title="Basic Denominator: Weighted average shares outstanding"&gt;6,534&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkFlslAJn2qk" title="Basic Denominator: Weighted average shares outstanding"&gt;6,534&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zL7NtDF1AoTf" title="Basic Denominator: Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Basic income per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20230701__20231231_zmW1oBcSsg83" title="Basic income per common share"&gt;1.22&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4dCSpS3695b" title="Basic income per common share"&gt;1.14&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z7vSLvBYsxqe" title="Basic income per common share"&gt;0.33&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20220701__20221231_zJoGxGVg5CHa" title="Basic income per common share"&gt;0.65&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIo4QQjg035a" title="Basic income per common share"&gt;0.62&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zpvgvPcov6bg" title="Basic income per common share"&gt;0.17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Denominator: &lt;br/&gt; Weighted average shares outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9evyBlljdUa" title="Diluted Denominator: Weighted average shares outstanding"&gt;6,448&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zDfugAnIRGu7" title="Diluted Denominator: Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2yNF3S72Dh3" title="Diluted Denominator: Weighted average shares outstanding"&gt;6,534&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zdvFkKhi6fDf" title="Diluted Denominator: Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Convertible Class C Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_901_ecustom--ConvertibleClassCStock_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVjyzxkTFd1" title="Convertible Class C Stock"&gt;128&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_901_ecustom--ConvertibleClassCStock_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zq4Sfu9LeOv5" title="Convertible Class C Stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1159"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ConvertibleClassCStock_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zz6S4pR8sNT2" title="Convertible Class C Stock"&gt;128&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ConvertibleClassCStock_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zsmEWygCsbKi" title="Convertible Class C Stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1163"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total Denominator for diluted earnings per share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8meuCzW846g" title="Total Denominator for Diluted Earnings Per Share"&gt;6,576&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zC7x0fJBLE45" title="Total Denominator for Diluted Earnings Per Share"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znQ1wEDYsoi7" title="Total Denominator for Diluted Earnings Per Share"&gt;6,662&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zJ8UZGlHPd3k" title="Total Denominator for Diluted Earnings Per Share"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Diluted income per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareDiluted_pip0_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEoN3hUy1ybk" title="Diluted Income per Common Share"&gt;1.12&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_pip0_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zUXFtANM8l4g" title="Diluted Income per Common Share"&gt;0.33&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--EarningsPerShareDiluted_pip0_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHNRYTugpdhi" title="Diluted Income per Common Share"&gt;0.60&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_pip0_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zZd01Sfe84th" title="Diluted Income per Common Share"&gt;0.17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p id="xdx_8A2_zDO6CHuBR1Ub" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
























</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-8018"
      unitRef="Shares">128000</us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-8019"
      unitRef="Shares">128000</us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-8020"
      unitRef="Shares">128000</us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-8021"
      unitRef="Shares">128000</us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-3575">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_z0hpep08RVlj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share - (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8BB_znGt4olpKusa" style="display: none; padding-top: 0; padding-right: 0; text-align: left"&gt;Schedule of earning per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;Three months ended &lt;br/&gt; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;Three months ended &lt;br/&gt; December 31, 2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class C Common &lt;br/&gt; Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class C Common &lt;br/&gt; Stock&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Basic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Numerator: &lt;br/&gt; Net income available to common stockholders&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20231001__20231231_z24aXYwIjQak" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;3,759&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zG8ROYPm99jj" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;3,525&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zYeAgS3vtVDj" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;59&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20221001__20221231_zDCm7XWQngv4" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;2,232&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdVoSqQYuEu6" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Common Stock and Basic Numerator: Net income available to common stockholders"&gt;2,097&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zVmK7Tx46aDc" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;34&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Weighted average shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20231001__20231231_zujqgbfVHdib" title="Basic Denominator: Weighted average shares outstanding"&gt;6,437&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQ3s5Ss1T211" title="Basic Denominator: Weighted average shares outstanding"&gt;6,437&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zAdeCfpLn6Nc" title="Basic Denominator: Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20221001__20221231_zlorfe1PBIP2" title="Basic Denominator: Weighted average shares outstanding"&gt;6,527&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2qzTva5HHvj" title="Basic Denominator: Weighted average shares outstanding"&gt;6,527&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zI5Yn8RanB8f" title="Basic Denominator: Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Basic income per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20231001__20231231_zKWdQXgSLdq3" title="Basic income per common share"&gt;0.58&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zp7d2uqfUzjc" title="Basic income per common share"&gt;0.55&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zgbXQMSjCuVk" title="Basic income per common share"&gt;0.16&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20221001__20221231_zeIHjnC2kICf" title="Basic income per common share"&gt;0.34&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmSH7f1f7109" title="Basic income per common share"&gt;0.32&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z7F2Pqhgpvy1" title="Basic income per common share"&gt;0.09&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Denominator: &lt;br/&gt; Weighted average shares outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2pyXMXkRWo3" title="Diluted Denominator: Weighted average shares outstanding"&gt;6,437&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zpTuzrYJwkK3" title="Diluted Denominator: Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8lgAsR8fRzh" title="Diluted Denominator: Weighted average shares outstanding"&gt;6,527&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zqh4XEwVBlVc" title="Diluted Denominator: Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Convertible Class C Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ConvertibleClassCStock_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoXRWoEMXNbb" title="Convertible Class C Stock"&gt;128&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_902_ecustom--ConvertibleClassCStock_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_ztk1kuEXjKh6" title="Convertible Class C Stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1091"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ConvertibleClassCStock_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrZgsPwWJQWk" title="Convertible Class C Stock"&gt;128&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ConvertibleClassCStock_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zgXkhSfSxKAk" title="Convertible Class C Stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1095"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total Denominator for diluted earnings per share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBPNn6fnSBtc" title="Total Denominator for Diluted Earnings Per Share"&gt;6,565&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zrXAnwqNZxD8" title="Total Denominator for Diluted Earnings Per Share"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKGI6QcltMc1" title="Total Denominator for Diluted Earnings Per Share"&gt;6,655&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z0JBAcMMr25g" title="Total Denominator for Diluted Earnings Per Share"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Diluted income per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pip0_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxl63AX6VXg7" title="Diluted Income per Common Share"&gt;0.54&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pip0_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zBFs3GvldEoh" title="Diluted Income per Common Share"&gt;0.16&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--EarningsPerShareDiluted_pip0_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2AJgM43Xhcl" title="Diluted Income per Common Share"&gt;0.32&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pip0_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zQade4RR3t9e" title="Diluted Income per Common Share"&gt;0.09&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;



&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;Six months ended &lt;br/&gt; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;Six months ended &lt;br/&gt; December 31, 2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class C Common &lt;br/&gt; Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class C Common &lt;br/&gt; Stock&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Basic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Numerator: &lt;br/&gt; Net income available to common stockholders&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20230701__20231231_z4UTQH7hUxL4" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;7,865&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsqY9NXVLV2c" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;7,375&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z3RMb85H0qkl" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;125&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20220701__20221231_zrCyjoAYN5q8" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;4,279&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLw3LCxpKoPj" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Common Stock and Basic Numerator: Net income available to common stockholders"&gt;4,020&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zvIHrcyBvIPk" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Basic Numerator: Net income available to common stockholders"&gt;66&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Weighted average shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20231231_zmZ93078iO8d" title="Basic Denominator: Weighted average shares outstanding"&gt;6,448&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z21yzFIuoLf6" title="Basic Denominator: Weighted average shares outstanding"&gt;6,448&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zQA2gc0u4Amk" title="Basic Denominator: Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220701__20221231_ztm6KSYAChm6" title="Basic Denominator: Weighted average shares outstanding"&gt;6,534&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkFlslAJn2qk" title="Basic Denominator: Weighted average shares outstanding"&gt;6,534&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zL7NtDF1AoTf" title="Basic Denominator: Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Basic income per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20230701__20231231_zmW1oBcSsg83" title="Basic income per common share"&gt;1.22&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4dCSpS3695b" title="Basic income per common share"&gt;1.14&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_z7vSLvBYsxqe" title="Basic income per common share"&gt;0.33&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20220701__20221231_zJoGxGVg5CHa" title="Basic income per common share"&gt;0.65&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIo4QQjg035a" title="Basic income per common share"&gt;0.62&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zpvgvPcov6bg" title="Basic income per common share"&gt;0.17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Denominator: &lt;br/&gt; Weighted average shares outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9evyBlljdUa" title="Diluted Denominator: Weighted average shares outstanding"&gt;6,448&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zDfugAnIRGu7" title="Diluted Denominator: Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2yNF3S72Dh3" title="Diluted Denominator: Weighted average shares outstanding"&gt;6,534&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zdvFkKhi6fDf" title="Diluted Denominator: Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Convertible Class C Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_901_ecustom--ConvertibleClassCStock_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVjyzxkTFd1" title="Convertible Class C Stock"&gt;128&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_901_ecustom--ConvertibleClassCStock_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zq4Sfu9LeOv5" title="Convertible Class C Stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1159"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ConvertibleClassCStock_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zz6S4pR8sNT2" title="Convertible Class C Stock"&gt;128&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ConvertibleClassCStock_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zsmEWygCsbKi" title="Convertible Class C Stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1163"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total Denominator for diluted earnings per share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8meuCzW846g" title="Total Denominator for Diluted Earnings Per Share"&gt;6,576&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zC7x0fJBLE45" title="Total Denominator for Diluted Earnings Per Share"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znQ1wEDYsoi7" title="Total Denominator for Diluted Earnings Per Share"&gt;6,662&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zJ8UZGlHPd3k" title="Total Denominator for Diluted Earnings Per Share"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Diluted income per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareDiluted_pip0_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEoN3hUy1ybk" title="Diluted Income per Common Share"&gt;1.12&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_pip0_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zUXFtANM8l4g" title="Diluted Income per Common Share"&gt;0.33&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--EarningsPerShareDiluted_pip0_c20220701__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHNRYTugpdhi" title="Diluted Income per Common Share"&gt;0.60&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_pip0_c20220701__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassCMember_zZd01Sfe84th" title="Diluted Income per Common Share"&gt;0.17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-8022"
      unitRef="USD">3759000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-8023"
      unitRef="USD">3525000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2023-10-012023-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-8024"
      unitRef="USD">59000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-8025"
      unitRef="USD">2232000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-8026"
      unitRef="USD">2097000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2022-10-012022-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-8027"
      unitRef="USD">34000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-8028"
      unitRef="Shares">6437000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-8029"
      unitRef="Shares">6437000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-10-012023-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-8030"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-8031"
      unitRef="Shares">6527000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-8032"
      unitRef="Shares">6527000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-10-012022-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-8033"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2023-10-012023-12-31"
      decimals="INF"
      id="ixv-8034"
      unitRef="USDPShares">0.58</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-8035"
      unitRef="USDPShares">0.55</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2023-10-012023-12-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="ixv-8036"
      unitRef="USDPShares">0.16</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2022-10-012022-12-31"
      decimals="INF"
      id="ixv-8037"
      unitRef="USDPShares">0.34</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-8038"
      unitRef="USDPShares">0.32</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2022-10-012022-12-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="ixv-8039"
      unitRef="USDPShares">0.09</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-8040"
      unitRef="Shares">6437000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-10-012023-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-8041"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-8042"
      unitRef="Shares">6527000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-10-012022-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-8043"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <FONR:ConvertibleClassCStock
      contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-8044"
      unitRef="Shares">128000</FONR:ConvertibleClassCStock>
    <FONR:ConvertibleClassCStock
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-8045"
      unitRef="Shares">128000</FONR:ConvertibleClassCStock>
    <FONR:WeightedAverageNumberOfDilutedEarningsPerShare
      contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-8046"
      unitRef="Shares">6565000</FONR:WeightedAverageNumberOfDilutedEarningsPerShare>
    <FONR:WeightedAverageNumberOfDilutedEarningsPerShare
      contextRef="From2023-10-012023-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-8047"
      unitRef="Shares">383000</FONR:WeightedAverageNumberOfDilutedEarningsPerShare>
    <FONR:WeightedAverageNumberOfDilutedEarningsPerShare
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-8048"
      unitRef="Shares">6655000</FONR:WeightedAverageNumberOfDilutedEarningsPerShare>
    <FONR:WeightedAverageNumberOfDilutedEarningsPerShare
      contextRef="From2022-10-012022-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-8049"
      unitRef="Shares">383000</FONR:WeightedAverageNumberOfDilutedEarningsPerShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-8050"
      unitRef="USDPShares">0.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-10-012023-12-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="ixv-8051"
      unitRef="USDPShares">0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-8052"
      unitRef="USDPShares">0.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-10-012022-12-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="ixv-8053"
      unitRef="USDPShares">0.09</us-gaap:EarningsPerShareDiluted>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-8054"
      unitRef="USD">7865000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-8055"
      unitRef="USD">7375000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2023-07-012023-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-8056"
      unitRef="USD">125000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-8057"
      unitRef="USD">4279000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-8058"
      unitRef="USD">4020000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2022-07-012022-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-8059"
      unitRef="USD">66000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-8060"
      unitRef="Shares">6448000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-8061"
      unitRef="Shares">6448000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-012023-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-8062"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-8063"
      unitRef="Shares">6534000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-8064"
      unitRef="Shares">6534000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-07-012022-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-8065"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2023-07-01to2023-12-31"
      decimals="INF"
      id="ixv-8066"
      unitRef="USDPShares">1.22</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-8067"
      unitRef="USDPShares">1.14</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2023-07-012023-12-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="ixv-8068"
      unitRef="USDPShares">0.33</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2022-07-012022-12-31"
      decimals="INF"
      id="ixv-8069"
      unitRef="USDPShares">0.65</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-8070"
      unitRef="USDPShares">0.62</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2022-07-012022-12-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="ixv-8071"
      unitRef="USDPShares">0.17</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-8072"
      unitRef="Shares">6448000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-07-012023-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-8073"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-8074"
      unitRef="Shares">6534000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-07-012022-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-8075"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <FONR:ConvertibleClassCStock
      contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-8076"
      unitRef="Shares">128000</FONR:ConvertibleClassCStock>
    <FONR:ConvertibleClassCStock
      contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-8077"
      unitRef="Shares">128000</FONR:ConvertibleClassCStock>
    <FONR:WeightedAverageNumberOfDilutedEarningsPerShare
      contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-8078"
      unitRef="Shares">6576000</FONR:WeightedAverageNumberOfDilutedEarningsPerShare>
    <FONR:WeightedAverageNumberOfDilutedEarningsPerShare
      contextRef="From2023-07-012023-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-8079"
      unitRef="Shares">383000</FONR:WeightedAverageNumberOfDilutedEarningsPerShare>
    <FONR:WeightedAverageNumberOfDilutedEarningsPerShare
      contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-8080"
      unitRef="Shares">6662000</FONR:WeightedAverageNumberOfDilutedEarningsPerShare>
    <FONR:WeightedAverageNumberOfDilutedEarningsPerShare
      contextRef="From2022-07-012022-12-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="ixv-8081"
      unitRef="Shares">383000</FONR:WeightedAverageNumberOfDilutedEarningsPerShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-07-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-8082"
      unitRef="USDPShares">1.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-07-012023-12-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="ixv-8083"
      unitRef="USDPShares">0.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-07-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-8084"
      unitRef="USDPShares">0.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-07-012022-12-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="ixv-8085"
      unitRef="USDPShares">0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-4264">&lt;p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z40QeTkHA1Ff" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_869_zIQBDaKejqX2"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2023, the Financial Accounting
Standards Board (&#x201c;FASB&#x201d;) issued ASU 2023-09, &#x201c;Income Taxes (740) &#x201c;Improvements to Income Tax Disclosures&#x201d;,
which requires the annual financial statements to include consistent categories and greater disaggregation of information in the
rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company&#x2019;s annual
reporting beginning after December 15, 2024, with early adoption permitted, and should be applied on a prospective basis, with
a retrospective option. We are currently evaluating the effect that adoption of ASU 2023-09 will have on our disclosures.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November 2023, FASB issued ASU 2023-07, &#x201c;Segment Reporting (Topic
280)&#x201d;, which is intended to improve reportable segment disclosure requirements through enhanced disclosures about significant segment
expenses. The amendments require disclosure of significant segment expenses regularly provided to the chief operating decision maker (CODM)
as well as other segment items, extended certain annual disclosures to interim periods, clarify the applicability to single reportable
segment entities, permit, more than one measure of profit or loss to be reported under certain conditions, and require disclosure of the
title and position of the CODM. The effective date for public entities is beginning after December 15, 2023 and interim periods with fiscal
years beginning after December 15, 2024. We expect to adopt the new disclosures as required and are currently evaluating the impact on
the related disclosures.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2016, FASB issued ASU 2016-13, &#x201c;Financial
Instruments &#x2013; Credit Loses (Topic 326): Measurement of Credit Losses on Financial Instruments&#x201d;, which replaces the incurred
loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader
range of reasonable and supportable information to assess credit loss estimates. This ASU is effective for fiscal years beginning after
December 15, 2022. The Company adopted this standard on July 1, 2023 using the modified retrospective approach and it did not have a material
impact of the Company&#x2019;s financial statements, resulting in no adjustment to prior year earnings.&lt;/p&gt;
&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;FASB, the Emerging Issues Task Force
and the SEC have issued certain other accounting standards, updates, and regulations as of December 31, 2023 that will become effective
in subsequent periods; however, management does not believe that any of those updates would have significantly affected the Company&#x2019;s
financial accounting measures or disclosures had they been in effect during 2023 or 2022, and it does not believe that any of those
standards will have a significant impact on our consolidated condensed financial statements at the time they become effective.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




















</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-4297">&lt;p id="xdx_801_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_zbHoqXT9wLrf" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;NOTE 3 &#x2013;&lt;span id="xdx_822_zTitbNjOT6Rf"&gt; ACCOUNTS RECEIVABLE,
MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Receivables, net is comprised of the
following at December 31, 2023, and June 30, 2023:&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock_pn3n3_zrsuW80RcOK6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B4_z3JRElElnWUa" style="display: none; text-align: left; padding-top: 0; padding-right: 0"&gt;Schedule of financing
    receivable noncurrent allowance for credit loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Gross Receivable&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Net&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--AccountsReceivableServiceAndRepairFees_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Accounts receivable"&gt;4,080&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--AccountsReceivableServiceAndRepairFees_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Accounts receivable"&gt;199&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--AccountsReceivableServiceAndRepairFees_c20231231_pn3n3" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Accounts receivable"&gt;3,881&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accounts receivable - related party&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--AccountsReceivableNetRelatedParty_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts receivable - Related party"&gt;60&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--AccountsReceivableNetRelatedParty_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts receivable - Related party"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1213"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--AccountsReceivableNetRelatedParty_c20231231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts receivable - Related party"&gt;60&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Medical receivable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--MedicalReceivable_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Medical Receivables"&gt;22,548&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--MedicalReceivable_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Medical Receivables"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1219"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--MedicalReceivable_c20231231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Medical Receivables"&gt;22,548&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Management and other fees receivable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ManagementAndOtherFeesNonRelatedParties_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable"&gt;51,092&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ManagementAndOtherFeesNonRelatedParties_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable"&gt;11,740&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ManagementAndOtherFeesNonRelatedParties_c20231231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable"&gt;39,352&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Management and other fees receivable from related medical practices (&#x201c;PC&#x2019;s&#x201d;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable from related medical practices (&amp;quot;PC's&amp;quot;)"&gt;14,480&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable from related medical practices (&amp;quot;PC's&amp;quot;)"&gt;5,213&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20231231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable from related medical practices (&amp;quot;PC's&amp;quot;)"&gt;9,267&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Gross Receivable&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Net&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--AccountsReceivableServiceAndRepairFees_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Accounts receivable"&gt;4,060&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--AccountsReceivableServiceAndRepairFees_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Accounts receivable"&gt;199&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--AccountsReceivableServiceAndRepairFees_c20230630_pn3n3" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Accounts receivable"&gt;3,861&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Medical receivable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--MedicalReceivable_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Medical Receivables"&gt;21,259&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--MedicalReceivable_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Medical Receivables"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1243"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--MedicalReceivable_c20230630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Medical Receivables"&gt;21,259&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Management and other fees receivable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ManagementAndOtherFeesNonRelatedParties_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable"&gt;48,497&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ManagementAndOtherFeesNonRelatedParties_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable"&gt;12,609&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ManagementAndOtherFeesNonRelatedParties_c20230630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable"&gt;35,888&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Management and other fees receivable from related medical practices (&#x201c;PC&#x2019;s&#x201d;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable from related medical practices (&amp;quot;PC's&amp;quot;)"&gt;13,152&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable from related medical practices (&amp;quot;PC's&amp;quot;)"&gt;3,990&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20230630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable from related medical practices (&amp;quot;PC's&amp;quot;)"&gt;9,162&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A4_zcjkfdHsFDnb" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s customers are concentrated in the healthcare industry.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Accounts
Receivable&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Credit
                                            risk with respect to the Company&#x2019;s accounts receivable related to product sales and
                                            service and repair fees is limited due to the customer advances received prior to the commencement
                                            of work performed and the billing of amounts to customers as sub-assemblies are completed.
                                            Service and repair fees are billed on a monthly or quarterly basis and the Company does not
                                            continue providing these services if accounts receivable become past due. The Company controls
                                            credit risk with respect to accounts receivable from service and repair fees through its
                                            credit evaluation process, credit limits, monitoring procedures and reasonably short collection
                                            terms. The Company performs ongoing credit authorizations before a product sales contract
                                            is entered into or service and repair fees are provided.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&#160;Long
Term Accounts Receivable&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Long term accounts receivable balances at
December 31, 2023 and June 30, 2023 amounted to approximately $&lt;span id="xdx_901_ecustom--AccountsReceivableNetLongTerm_iI_pn3n3_c20231231_z8Tp1YVIbIUl" title="Long term accounts receivable"&gt;376
&lt;/span&gt;and $&lt;span id="xdx_904_ecustom--AccountsReceivableNetLongTerm_iI_pn3n3_c20230630_zCX0hqWSS1h" title="Long term accounts receivable"&gt;710
&lt;/span&gt;respectively. The Company will generate revenue from long-term, non-cancellable contracts to provide service and repair services.
Future revenue to be recognized over the following two years as of December 31, 2023 is as follows:&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--TotalFacilitiesOwnedOrManagedTableTextBlock_pn3n3_zOPb9OOHAwE4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details 1)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_8B5_z8RI1U23wU33" style="display: none; text-align: right"&gt;Schedule of Future revenue&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 43%; text-align: right"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ContractReceivableDueOneToTwoYears_iI_pn3n3_c20231231_zI9Rs5aCmDnb" style="width: 43%; text-align: right" title="2025"&gt;319&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ContractReceivableDueTwoToThreeYears_iI_pn3n3_c20231231_zOVVUU2LH5sk" style="border-bottom: Black 1pt solid; text-align: right" title="2026"&gt;57&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AccountsReceivableBilledForLongTermContractsOrPrograms_pn3n3_c20231231_ztlcCINnoJ1l" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;376&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A5_zeSqkM0srNJd" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;Medical Receivables&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Medical receivables are due under fee-for-service
contracts from third party payors, such as hospitals, government sponsored healthcare programs, patient&#x2019;s legal counsel and
directly from patients. Substantially all the revenue relates to patients residing in Florida. The carrying amount of the medical
receivable is reduced by an allowance that reflects management&#x2019;s best estimate of the amounts that will not be collected.
The Company determines allowances for contractual adjustments and uncollectible accounts based on specific agings, specific payor
collection issues that have been identified and based on payor classifications and historical experience at each site.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
























&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;Management and Other Fees Receivable&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s receivables from
the related and non-related professional corporations (PC&#x2019;s) substantially consist of fees outstanding under management agreements.
Payment of the outstanding fees is dependent on collection by the PC&#x2019;s of fees from third party medical reimbursement organizations,
principally insurance companies and health management organizations.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Payment of the management fee receivables from the PC&#x2019;s
may be impaired by the inability of the PC&#x2019;s to collect in a timely manner their medical fees from the third-party payors,
particularly insurance carriers covering automobile no-fault and workers compensation claims due to longer payment cycles and rigorous
informational requirements and certain other disallowed claims. Approximately &lt;span id="xdx_902_ecustom--PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims_pip0_dp_c20231001__20231231_zdLeRFDtzGUf" title="Percentage of net revenue"&gt;66&lt;/span&gt;% and &lt;span id="xdx_907_ecustom--PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims_pip0_dp_c20221001__20221231_zYJAWfx84oga" title="Percentage of net revenue"&gt;67&lt;/span&gt;% of the PCs&#x2019; net revenues for the
three months ended December 31, 2023 and 2022, respectively, were derived from no-fault and personal injury protection claims.
Approximately &lt;span id="xdx_905_ecustom--PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims_pip0_dp_c20230701__20231231_z9KunA8agoje" title="Percentage of net revenue"&gt;67&lt;/span&gt;% and &lt;span id="xdx_90C_ecustom--PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims_pip0_dp_c20220701__20221231_zUeZnhDd95nd" title="Percentage of net revenue"&gt;68&lt;/span&gt;% of the PCs&#x2019; net revenue for the six months ended December 31, 2023 and 2022, respectively, were
derived from no-fault and personal injury protection claims. The Company considers the aging of its accounts receivable in determining
the amount of allowance for doubtful accounts. The Company generally takes all legally available steps to collect its receivables.
Credit losses associated with the receivables are provided for in the condensed consolidated financial statements and have historically
been within management&#x2019;s expectations.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Net revenues from management and other
fees charged to the related PCs accounted for approximately &lt;span id="xdx_90B_ecustom--PercentageOfConsolidatedNetRevenueFromManagementFees_pip0_dp_c20231001__20231231_z6HmEe0zaoW9" title="Percentage of consolidated net revenue"&gt;11.8&lt;/span&gt;% and &lt;span id="xdx_904_ecustom--PercentageOfConsolidatedNetRevenueFromManagementFees_pip0_dp_c20221001__20221231_zrrNEAwUomGb" title="Percentage of consolidated net revenue"&gt;12.4&lt;/span&gt;% of the consolidated net revenues for the three months
ended December 31, 2023 and 2022, respectively. Net revenues from management and other fees charged to the related PCs accounted
for approximately &lt;span id="xdx_908_ecustom--PercentageOfConsolidatedNetRevenueFromManagementFees_pip0_dp_c20230701__20231231_zU97CGldWpQa" title="Percentage of consolidated net revenue"&gt;11.7&lt;/span&gt;% and &lt;span id="xdx_907_ecustom--PercentageOfConsolidatedNetRevenueFromManagementFees_pip0_dp_c20220701__20221231_zSa1MW6kZytj" title="Percentage of consolidated net revenue"&gt;12.6&lt;/span&gt;% of the consolidated net revenues for the six months ended December 31, 2023 and 2022, respectively.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Tallahassee Magnetic Resonance Imaging,
Inc., Stand Up MRI of Boca Raton, Inc. and Stand Up MRI &amp;amp; Diagnostic Center, Inc. (all related medical practices) entered into
a guaranty agreement, pursuant to which they cross guaranteed all management fees which are payable to the Company, which have
arisen under each individual management agreement. Additional Company managed entities also operate under a guaranty agreement,
pursuant to which management fees are payable to the Company.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s patient fee revenue,
net of contractual allowances and discounts for the three and six months ended December 31, 2023 and 2022 are summarized in the
following table.&#160;&lt;/p&gt;


























&lt;table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfPatientFeeRevenueTableTextBlock_zlRut4kBWtai" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B7_z5TLT0GbxGA4" style="display: none"&gt;Schedule of patient fee revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the Three Months Ended December 31,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Commercial Insurance/ Managed Care&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_znhjakEssmI9" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;1,243&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_zo3vvZD7nGP9" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;958&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Medicare/Medicaid&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zJuB4xVfqhE5" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;284&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zXyVF66WunI1" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;247&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Workers&#x2019; Compensation/Personal Injury&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_z5wxjXHQ4B2h" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;4,907&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_z4JLoGVYKosf" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;4,262&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherMember_zlC5xC7Qe0B8" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;1,787&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherMember_zKmmXI7dL4E1" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;1,662&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Patient Fee Revenue, net of contractual allowances and discounts&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231_zLIChWdBejDd" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;8,221&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231_zQUZ9qSPnm41" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;7,129&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the Six Months Ended December 31,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Commercial Insurance/ Managed Care&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_zCMYrCl87ynh" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;2,416&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_zowmtzn9Vbe3" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;1,869&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Medicare/Medicaid&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zbVJ4nfhTCx6" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;555&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zjiT9qoryZp9" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;484&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Workers&#x2019; Compensation/Personal Injury&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_znpyENPcKD3d" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;10,044&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_zHANQcrYMv6b" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;8,497&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherMember_zwyKUlvde0yi" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;3,881&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherMember_zog5V7oL01Ni" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;2,355&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Patient Fee Revenue, net of contractual allowances and discounts&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231_zNxkXEDlORt9" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;16,896&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231_z6goTqEukcRe" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;13,205&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8AD_zvmSEl7yCrnc" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-4303">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock_pn3n3_zrsuW80RcOK6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B4_z3JRElElnWUa" style="display: none; text-align: left; padding-top: 0; padding-right: 0"&gt;Schedule of financing
    receivable noncurrent allowance for credit loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Gross Receivable&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Net&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--AccountsReceivableServiceAndRepairFees_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Accounts receivable"&gt;4,080&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--AccountsReceivableServiceAndRepairFees_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Accounts receivable"&gt;199&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--AccountsReceivableServiceAndRepairFees_c20231231_pn3n3" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Accounts receivable"&gt;3,881&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accounts receivable - related party&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--AccountsReceivableNetRelatedParty_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts receivable - Related party"&gt;60&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--AccountsReceivableNetRelatedParty_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts receivable - Related party"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1213"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--AccountsReceivableNetRelatedParty_c20231231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts receivable - Related party"&gt;60&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Medical receivable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--MedicalReceivable_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Medical Receivables"&gt;22,548&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--MedicalReceivable_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Medical Receivables"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1219"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--MedicalReceivable_c20231231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Medical Receivables"&gt;22,548&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Management and other fees receivable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ManagementAndOtherFeesNonRelatedParties_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable"&gt;51,092&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ManagementAndOtherFeesNonRelatedParties_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable"&gt;11,740&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ManagementAndOtherFeesNonRelatedParties_c20231231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable"&gt;39,352&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Management and other fees receivable from related medical practices (&#x201c;PC&#x2019;s&#x201d;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable from related medical practices (&amp;quot;PC's&amp;quot;)"&gt;14,480&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable from related medical practices (&amp;quot;PC's&amp;quot;)"&gt;5,213&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20231231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable from related medical practices (&amp;quot;PC's&amp;quot;)"&gt;9,267&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Gross Receivable&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Net&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--AccountsReceivableServiceAndRepairFees_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Accounts receivable"&gt;4,060&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--AccountsReceivableServiceAndRepairFees_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Accounts receivable"&gt;199&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--AccountsReceivableServiceAndRepairFees_c20230630_pn3n3" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Accounts receivable"&gt;3,861&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Medical receivable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--MedicalReceivable_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Medical Receivables"&gt;21,259&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--MedicalReceivable_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Medical Receivables"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1243"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--MedicalReceivable_c20230630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Medical Receivables"&gt;21,259&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Management and other fees receivable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ManagementAndOtherFeesNonRelatedParties_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable"&gt;48,497&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ManagementAndOtherFeesNonRelatedParties_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable"&gt;12,609&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ManagementAndOtherFeesNonRelatedParties_c20230630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable"&gt;35,888&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Management and other fees receivable from related medical practices (&#x201c;PC&#x2019;s&#x201d;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable from related medical practices (&amp;quot;PC's&amp;quot;)"&gt;13,152&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable from related medical practices (&amp;quot;PC's&amp;quot;)"&gt;3,990&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances_c20230630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and other fees receivable from related medical practices (&amp;quot;PC's&amp;quot;)"&gt;9,162&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock>
    <FONR:AccountsReceivableServiceAndRepairFees
      contextRef="AsOf2023-12-31_us-gaap_AccountsReceivableMember"
      decimals="-3"
      id="ixv-8086"
      unitRef="USD">4080000</FONR:AccountsReceivableServiceAndRepairFees>
    <FONR:AccountsReceivableServiceAndRepairFees
      contextRef="AsOf2023-12-31_us-gaap_DoubtfulMember"
      decimals="-3"
      id="ixv-8087"
      unitRef="USD">199000</FONR:AccountsReceivableServiceAndRepairFees>
    <FONR:AccountsReceivableServiceAndRepairFees
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8088"
      unitRef="USD">3881000</FONR:AccountsReceivableServiceAndRepairFees>
    <FONR:AccountsReceivableNetRelatedParty
      contextRef="AsOf2023-12-31_us-gaap_AccountsReceivableMember"
      decimals="-3"
      id="ixv-8089"
      unitRef="USD">60000</FONR:AccountsReceivableNetRelatedParty>
    <FONR:AccountsReceivableNetRelatedParty
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8090"
      unitRef="USD">60000</FONR:AccountsReceivableNetRelatedParty>
    <FONR:MedicalReceivable
      contextRef="AsOf2023-12-31_us-gaap_AccountsReceivableMember"
      decimals="-3"
      id="ixv-8091"
      unitRef="USD">22548000</FONR:MedicalReceivable>
    <FONR:MedicalReceivable
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8092"
      unitRef="USD">22548000</FONR:MedicalReceivable>
    <FONR:ManagementAndOtherFeesNonRelatedParties
      contextRef="AsOf2023-12-31_us-gaap_AccountsReceivableMember"
      decimals="-3"
      id="ixv-8093"
      unitRef="USD">51092000</FONR:ManagementAndOtherFeesNonRelatedParties>
    <FONR:ManagementAndOtherFeesNonRelatedParties
      contextRef="AsOf2023-12-31_us-gaap_DoubtfulMember"
      decimals="-3"
      id="ixv-8094"
      unitRef="USD">11740000</FONR:ManagementAndOtherFeesNonRelatedParties>
    <FONR:ManagementAndOtherFeesNonRelatedParties
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8095"
      unitRef="USD">39352000</FONR:ManagementAndOtherFeesNonRelatedParties>
    <FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances
      contextRef="AsOf2023-12-31_us-gaap_AccountsReceivableMember"
      decimals="-3"
      id="ixv-8096"
      unitRef="USD">14480000</FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances>
    <FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances
      contextRef="AsOf2023-12-31_us-gaap_DoubtfulMember"
      decimals="-3"
      id="ixv-8097"
      unitRef="USD">5213000</FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances>
    <FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8098"
      unitRef="USD">9267000</FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances>
    <FONR:AccountsReceivableServiceAndRepairFees
      contextRef="AsOf2023-06-30_us-gaap_AccountsReceivableMember"
      decimals="-3"
      id="ixv-8099"
      unitRef="USD">4060000</FONR:AccountsReceivableServiceAndRepairFees>
    <FONR:AccountsReceivableServiceAndRepairFees
      contextRef="AsOf2023-06-30_us-gaap_DoubtfulMember"
      decimals="-3"
      id="ixv-8100"
      unitRef="USD">199000</FONR:AccountsReceivableServiceAndRepairFees>
    <FONR:AccountsReceivableServiceAndRepairFees
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-8101"
      unitRef="USD">3861000</FONR:AccountsReceivableServiceAndRepairFees>
    <FONR:MedicalReceivable
      contextRef="AsOf2023-06-30_us-gaap_AccountsReceivableMember"
      decimals="-3"
      id="ixv-8102"
      unitRef="USD">21259000</FONR:MedicalReceivable>
    <FONR:MedicalReceivable
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-8103"
      unitRef="USD">21259000</FONR:MedicalReceivable>
    <FONR:ManagementAndOtherFeesNonRelatedParties
      contextRef="AsOf2023-06-30_us-gaap_AccountsReceivableMember"
      decimals="-3"
      id="ixv-8104"
      unitRef="USD">48497000</FONR:ManagementAndOtherFeesNonRelatedParties>
    <FONR:ManagementAndOtherFeesNonRelatedParties
      contextRef="AsOf2023-06-30_us-gaap_DoubtfulMember"
      decimals="-3"
      id="ixv-8105"
      unitRef="USD">12609000</FONR:ManagementAndOtherFeesNonRelatedParties>
    <FONR:ManagementAndOtherFeesNonRelatedParties
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-8106"
      unitRef="USD">35888000</FONR:ManagementAndOtherFeesNonRelatedParties>
    <FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances
      contextRef="AsOf2023-06-30_us-gaap_AccountsReceivableMember"
      decimals="-3"
      id="ixv-8107"
      unitRef="USD">13152000</FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances>
    <FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances
      contextRef="AsOf2023-06-30_us-gaap_DoubtfulMember"
      decimals="-3"
      id="ixv-8108"
      unitRef="USD">3990000</FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances>
    <FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-8109"
      unitRef="USD">9162000</FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances>
    <FONR:AccountsReceivableNetLongTerm
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8110"
      unitRef="USD">376000</FONR:AccountsReceivableNetLongTerm>
    <FONR:AccountsReceivableNetLongTerm
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-8111"
      unitRef="USD">710000</FONR:AccountsReceivableNetLongTerm>
    <FONR:TotalFacilitiesOwnedOrManagedTableTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-4494">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--TotalFacilitiesOwnedOrManagedTableTextBlock_pn3n3_zOPb9OOHAwE4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details 1)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_8B5_z8RI1U23wU33" style="display: none; text-align: right"&gt;Schedule of Future revenue&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 43%; text-align: right"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ContractReceivableDueOneToTwoYears_iI_pn3n3_c20231231_zI9Rs5aCmDnb" style="width: 43%; text-align: right" title="2025"&gt;319&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ContractReceivableDueTwoToThreeYears_iI_pn3n3_c20231231_zOVVUU2LH5sk" style="border-bottom: Black 1pt solid; text-align: right" title="2026"&gt;57&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AccountsReceivableBilledForLongTermContractsOrPrograms_pn3n3_c20231231_ztlcCINnoJ1l" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;376&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</FONR:TotalFacilitiesOwnedOrManagedTableTextBlock>
    <us-gaap:ContractReceivableDueOneToTwoYears
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8112"
      unitRef="USD">319000</us-gaap:ContractReceivableDueOneToTwoYears>
    <us-gaap:ContractReceivableDueTwoToThreeYears
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8113"
      unitRef="USD">57000</us-gaap:ContractReceivableDueTwoToThreeYears>
    <us-gaap:AccountsReceivableBilledForLongTermContractsOrPrograms
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8114"
      unitRef="USD">376000</us-gaap:AccountsReceivableBilledForLongTermContractsOrPrograms>
    <FONR:PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims
      contextRef="From2023-10-012023-12-31"
      decimals="INF"
      id="ixv-8115"
      unitRef="Pure">0.66</FONR:PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims>
    <FONR:PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims
      contextRef="From2022-10-012022-12-31"
      decimals="INF"
      id="ixv-8116"
      unitRef="Pure">0.67</FONR:PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims>
    <FONR:PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims
      contextRef="From2023-07-01to2023-12-31"
      decimals="INF"
      id="ixv-8117"
      unitRef="Pure">0.67</FONR:PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims>
    <FONR:PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims
      contextRef="From2022-07-012022-12-31"
      decimals="INF"
      id="ixv-8118"
      unitRef="Pure">0.68</FONR:PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims>
    <FONR:PercentageOfConsolidatedNetRevenueFromManagementFees
      contextRef="From2023-10-012023-12-31"
      decimals="INF"
      id="ixv-8119"
      unitRef="Pure">0.118</FONR:PercentageOfConsolidatedNetRevenueFromManagementFees>
    <FONR:PercentageOfConsolidatedNetRevenueFromManagementFees
      contextRef="From2022-10-012022-12-31"
      decimals="INF"
      id="ixv-8120"
      unitRef="Pure">0.124</FONR:PercentageOfConsolidatedNetRevenueFromManagementFees>
    <FONR:PercentageOfConsolidatedNetRevenueFromManagementFees
      contextRef="From2023-07-01to2023-12-31"
      decimals="INF"
      id="ixv-8121"
      unitRef="Pure">0.117</FONR:PercentageOfConsolidatedNetRevenueFromManagementFees>
    <FONR:PercentageOfConsolidatedNetRevenueFromManagementFees
      contextRef="From2022-07-012022-12-31"
      decimals="INF"
      id="ixv-8122"
      unitRef="Pure">0.126</FONR:PercentageOfConsolidatedNetRevenueFromManagementFees>
    <FONR:ScheduleOfPatientFeeRevenueTableTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-4605">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfPatientFeeRevenueTableTextBlock_zlRut4kBWtai" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B7_z5TLT0GbxGA4" style="display: none"&gt;Schedule of patient fee revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the Three Months Ended December 31,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Commercial Insurance/ Managed Care&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_znhjakEssmI9" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;1,243&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_zo3vvZD7nGP9" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;958&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Medicare/Medicaid&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zJuB4xVfqhE5" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;284&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zXyVF66WunI1" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;247&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Workers&#x2019; Compensation/Personal Injury&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_z5wxjXHQ4B2h" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;4,907&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_z4JLoGVYKosf" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;4,262&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherMember_zlC5xC7Qe0B8" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;1,787&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherMember_zKmmXI7dL4E1" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;1,662&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Patient Fee Revenue, net of contractual allowances and discounts&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20231001__20231231_zLIChWdBejDd" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;8,221&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20221001__20221231_zQUZ9qSPnm41" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;7,129&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the Six Months Ended December 31,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Commercial Insurance/ Managed Care&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_zCMYrCl87ynh" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;2,416&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_zowmtzn9Vbe3" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;1,869&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Medicare/Medicaid&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zbVJ4nfhTCx6" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;555&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zjiT9qoryZp9" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;484&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Workers&#x2019; Compensation/Personal Injury&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_znpyENPcKD3d" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;10,044&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_zHANQcrYMv6b" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;8,497&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherMember_zwyKUlvde0yi" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;3,881&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherMember_zog5V7oL01Ni" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;2,355&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Patient Fee Revenue, net of contractual allowances and discounts&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20230701__20231231_zNxkXEDlORt9" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;16,896&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--PatientFeeRevenueNetOfContractualAllowancesAndDiscount_pn3n3_c20220701__20221231_z6goTqEukcRe" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;13,205&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</FONR:ScheduleOfPatientFeeRevenueTableTextBlock>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount
      contextRef="From2023-10-012023-12-31_custom_CommercialInsuranceManagedCareMember"
      decimals="-3"
      id="ixv-8123"
      unitRef="USD">1243000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount
      contextRef="From2022-10-012022-12-31_custom_CommercialInsuranceManagedCareMember"
      decimals="-3"
      id="ixv-8124"
      unitRef="USD">958000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount
      contextRef="From2023-10-012023-12-31_custom_MedicareMedicaidMember"
      decimals="-3"
      id="ixv-8125"
      unitRef="USD">284000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount
      contextRef="From2022-10-012022-12-31_custom_MedicareMedicaidMember"
      decimals="-3"
      id="ixv-8126"
      unitRef="USD">247000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount
      contextRef="From2023-10-012023-12-31_custom_WorkersCompensationPersonalInjuryMember"
      decimals="-3"
      id="ixv-8127"
      unitRef="USD">4907000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount
      contextRef="From2022-10-012022-12-31_custom_WorkersCompensationPersonalInjuryMember"
      decimals="-3"
      id="ixv-8128"
      unitRef="USD">4262000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount
      contextRef="From2023-10-012023-12-31_custom_OtherMember"
      decimals="-3"
      id="ixv-8129"
      unitRef="USD">1787000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount
      contextRef="From2022-10-012022-12-31_custom_OtherMember"
      decimals="-3"
      id="ixv-8130"
      unitRef="USD">1662000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-8131"
      unitRef="USD">8221000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-8132"
      unitRef="USD">7129000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount
      contextRef="From2023-07-012023-12-31_custom_CommercialInsuranceManagedCareMember"
      decimals="-3"
      id="ixv-8133"
      unitRef="USD">2416000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount
      contextRef="From2022-07-012022-12-31_custom_CommercialInsuranceManagedCareMember"
      decimals="-3"
      id="ixv-8134"
      unitRef="USD">1869000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount
      contextRef="From2023-07-012023-12-31_custom_MedicareMedicaidMember"
      decimals="-3"
      id="ixv-8135"
      unitRef="USD">555000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount
      contextRef="From2022-07-012022-12-31_custom_MedicareMedicaidMember"
      decimals="-3"
      id="ixv-8136"
      unitRef="USD">484000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount
      contextRef="From2023-07-012023-12-31_custom_WorkersCompensationPersonalInjuryMember"
      decimals="-3"
      id="ixv-8137"
      unitRef="USD">10044000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount
      contextRef="From2022-07-012022-12-31_custom_WorkersCompensationPersonalInjuryMember"
      decimals="-3"
      id="ixv-8138"
      unitRef="USD">8497000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount
      contextRef="From2023-07-012023-12-31_custom_OtherMember"
      decimals="-3"
      id="ixv-8139"
      unitRef="USD">3881000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount
      contextRef="From2022-07-012022-12-31_custom_OtherMember"
      decimals="-3"
      id="ixv-8140"
      unitRef="USD">2355000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-8141"
      unitRef="USD">16896000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-8142"
      unitRef="USD">13205000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscount>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-4740">&lt;p id="xdx_809_eus-gaap--LesseeOperatingLeasesTextBlock_zbguJ97N0ab6" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;NOTE 4 &#x2013;&lt;span id="xdx_828_zm0GT65ONDza"&gt; OPERATING &amp;amp; FINANCING
LEASES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July 2019, the Company adopted ASU
2016-02, &#x201c;Leases&#x201d; (Topic 842). This standard requires lessees to apply a dual approach, classifying leases as either
finance or operating leases based upon the principle of whether or not the lease is effectively a financed purchase by the lessee.
We have also elected the transition package of the practical expedients permitted within the standard which eliminates the requirements
to reassess prior conclusions about lease identification, lease classification and indirect costs.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for its various
operating leases in accordance with Topic 842, as updated by ASU 2016-02. At the inception of a lease, the Company recognizes right-of-use
lease assets and related lease liabilities measured at present value of future lease payments on its balance sheet. Lease expense
is recognized on a straight-line basis over the term of the lease. Our most common initial term varies in length from 2 to 10 years.
Including renewal options negotiated with the landlord, we have a total span of 2 to 16 years at the facilities we lease. The Company
reviewed its contracts with vendors and customers, determining that its right-to-use lease assets consisted of only office space
operating leases. In determining the right-to-use lease assets and liabilities, the Company did recognize lease extension options
which the Company feels would be reasonably exercised. Our incremental borrowing rate (&#x201c;IBR&#x201d;) used to discount the
stream of operating lease payments is closely related to the interest rates available to the Company.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A reconciliation of operating and financing
lease payments undiscounted cash flows to lease liabilities recognized as of December 31, 2023 is as follows:&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
























&lt;table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_z0fRutkiWkId" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OPERATING &amp;amp; FINANCING LEASES - Lease Payments (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_8B3_zIHJDJmb4wWh" style="display: none; text-align: right"&gt;Lessee operating leases liability maturity&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Twelve Months Ending&lt;br/&gt;
December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Operating Lease&lt;br/&gt;
Payments&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Financing Lease&lt;br/&gt;
Payments&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 26%; text-align: right"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="width: 26%; text-align: right" title="Lessee, Operating Lease, Liability, to be Paid, Year One"&gt;6,319&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="width: 26%; text-align: right" title="Finance Lease, Liability, to be Paid, Year One"&gt;244&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="text-align: right" title="Lessee, Operating Lease, Liability, to be Paid, Year Two"&gt;5,672&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="text-align: right" title="Finance Lease, Liability, to be Paid, Year Two"&gt;244&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2026&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="text-align: right" title="Lessee, Operating Lease, Liability, to be Paid, Year Three"&gt;4,902&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="text-align: right" title="Finance Lease, Liability, to be Paid, Year Three"&gt;244&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2027&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="text-align: right" title="Lessee, Operating Lease, Liability, to be Paid, Year Four"&gt;3,677&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="text-align: right" title="Finance Lease, Liability, to be Paid, Year Four"&gt;41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="text-align: right" title="Lessee, Operating Lease, Liability, to be Paid, Year Five"&gt;3,426&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="text-align: right" title="Finance Lease, Liability, to be Paid, Year Five"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1382"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="text-align: right" title="Lessee, Operating Lease, Liability, to be Paid, after Year Five"&gt;20,698&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="text-align: right" title="Finance Lease, Liability, to be Paid, after Year Five"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1386"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Present value discount&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--PresentValueDiscount_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Present value discount"&gt;(9,737&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--PresentValueDiscountFinancingLease_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Present value discount"&gt;(43&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--OperatingLeaseLiability_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating Lease, Liability"&gt;34,957&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FinanceLeaseLiability_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Finance Lease, Liability"&gt;730&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-4775">&lt;table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_z0fRutkiWkId" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OPERATING &amp;amp; FINANCING LEASES - Lease Payments (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_8B3_zIHJDJmb4wWh" style="display: none; text-align: right"&gt;Lessee operating leases liability maturity&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Twelve Months Ending&lt;br/&gt;
December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Operating Lease&lt;br/&gt;
Payments&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Financing Lease&lt;br/&gt;
Payments&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 26%; text-align: right"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="width: 26%; text-align: right" title="Lessee, Operating Lease, Liability, to be Paid, Year One"&gt;6,319&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="width: 26%; text-align: right" title="Finance Lease, Liability, to be Paid, Year One"&gt;244&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="text-align: right" title="Lessee, Operating Lease, Liability, to be Paid, Year Two"&gt;5,672&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="text-align: right" title="Finance Lease, Liability, to be Paid, Year Two"&gt;244&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2026&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="text-align: right" title="Lessee, Operating Lease, Liability, to be Paid, Year Three"&gt;4,902&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="text-align: right" title="Finance Lease, Liability, to be Paid, Year Three"&gt;244&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2027&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="text-align: right" title="Lessee, Operating Lease, Liability, to be Paid, Year Four"&gt;3,677&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="text-align: right" title="Finance Lease, Liability, to be Paid, Year Four"&gt;41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="text-align: right" title="Lessee, Operating Lease, Liability, to be Paid, Year Five"&gt;3,426&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="text-align: right" title="Finance Lease, Liability, to be Paid, Year Five"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1382"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="text-align: right" title="Lessee, Operating Lease, Liability, to be Paid, after Year Five"&gt;20,698&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="text-align: right" title="Finance Lease, Liability, to be Paid, after Year Five"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1386"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Present value discount&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--PresentValueDiscount_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Present value discount"&gt;(9,737&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--PresentValueDiscountFinancingLease_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Present value discount"&gt;(43&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--OperatingLeaseLiability_c20231231__us-gaap--IncomeStatementLocationAxis__custom--OperatingLeasePaymentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating Lease, Liability"&gt;34,957&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FinanceLeaseLiability_c20231231__us-gaap--IncomeStatementLocationAxis__custom--FinancingLeasePaymentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Finance Lease, Liability"&gt;730&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2023-12-31_custom_OperatingLeasePaymentsMember"
      decimals="-3"
      id="ixv-8143"
      unitRef="USD">6319000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2023-12-31_custom_FinancingLeasePaymentsMember"
      decimals="-3"
      id="ixv-8144"
      unitRef="USD">244000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2023-12-31_custom_OperatingLeasePaymentsMember"
      decimals="-3"
      id="ixv-8145"
      unitRef="USD">5672000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2023-12-31_custom_FinancingLeasePaymentsMember"
      decimals="-3"
      id="ixv-8146"
      unitRef="USD">244000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2023-12-31_custom_OperatingLeasePaymentsMember"
      decimals="-3"
      id="ixv-8147"
      unitRef="USD">4902000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2023-12-31_custom_FinancingLeasePaymentsMember"
      decimals="-3"
      id="ixv-8148"
      unitRef="USD">244000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2023-12-31_custom_OperatingLeasePaymentsMember"
      decimals="-3"
      id="ixv-8149"
      unitRef="USD">3677000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2023-12-31_custom_FinancingLeasePaymentsMember"
      decimals="-3"
      id="ixv-8150"
      unitRef="USD">41000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2023-12-31_custom_OperatingLeasePaymentsMember"
      decimals="-3"
      id="ixv-8151"
      unitRef="USD">3426000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2023-12-31_custom_OperatingLeasePaymentsMember"
      decimals="-3"
      id="ixv-8152"
      unitRef="USD">20698000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <FONR:PresentValueDiscount
      contextRef="AsOf2023-12-31_custom_OperatingLeasePaymentsMember"
      decimals="-3"
      id="ixv-8153"
      unitRef="USD">-9737000</FONR:PresentValueDiscount>
    <FONR:PresentValueDiscountFinancingLease
      contextRef="AsOf2023-12-31_custom_FinancingLeasePaymentsMember"
      decimals="-3"
      id="ixv-8154"
      unitRef="USD">-43000</FONR:PresentValueDiscountFinancingLease>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31_custom_OperatingLeasePaymentsMember"
      decimals="-3"
      id="ixv-8155"
      unitRef="USD">34957000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2023-12-31_custom_FinancingLeasePaymentsMember"
      decimals="-3"
      id="ixv-8156"
      unitRef="USD">730000</us-gaap:FinanceLeaseLiability>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-4900">&lt;p id="xdx_800_eus-gaap--InventoryDisclosureTextBlock_zoEL3sLGOCo2" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;NOTE 5 -&lt;span id="xdx_82F_zzvq9GNuB1I"&gt; INVENTORIES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Inventories included in the accompanying
condensed consolidated balance sheets consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_zGboBOL1Wf87" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVENTORIES - Inventories (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BF_zkII9TzyV9t7" style="display: none; padding-top: 0; padding-right: 0"&gt;Schedule of inventories&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20231231_zWo932XnF1T4" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20230630_z4tq9kpA2VE5" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31,&lt;br/&gt;
2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30,&lt;br/&gt;
2023&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OtherInventorySupplies_iI_maIFGAWzdt0_zhrbC4b89MZc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Purchased parts, components and supplies&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,582&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,346&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--InventoryWorkInProcess_iI_maIFGAWzdt0_zjJwXejdTLQ4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Work-in-process&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;253&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;224&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--InventoryFinishedGoodsAndWorkInProcess_iTI_mtIFGAWzdt0_zVRC2sPk6n9l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total Inventories&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,835&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,570&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-4906">&lt;table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_zGboBOL1Wf87" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVENTORIES - Inventories (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BF_zkII9TzyV9t7" style="display: none; padding-top: 0; padding-right: 0"&gt;Schedule of inventories&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20231231_zWo932XnF1T4" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20230630_z4tq9kpA2VE5" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31,&lt;br/&gt;
2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30,&lt;br/&gt;
2023&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OtherInventorySupplies_iI_maIFGAWzdt0_zhrbC4b89MZc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Purchased parts, components and supplies&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,582&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,346&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--InventoryWorkInProcess_iI_maIFGAWzdt0_zjJwXejdTLQ4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Work-in-process&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;253&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;224&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--InventoryFinishedGoodsAndWorkInProcess_iTI_mtIFGAWzdt0_zVRC2sPk6n9l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total Inventories&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,835&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,570&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:OtherInventorySupplies
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8157"
      unitRef="USD">2582000</us-gaap:OtherInventorySupplies>
    <us-gaap:OtherInventorySupplies
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-8158"
      unitRef="USD">2346000</us-gaap:OtherInventorySupplies>
    <us-gaap:InventoryWorkInProcess
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8159"
      unitRef="USD">253000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-8160"
      unitRef="USD">224000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoodsAndWorkInProcess
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8161"
      unitRef="USD">2835000</us-gaap:InventoryFinishedGoodsAndWorkInProcess>
    <us-gaap:InventoryFinishedGoodsAndWorkInProcess
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-8162"
      unitRef="USD">2570000</us-gaap:InventoryFinishedGoodsAndWorkInProcess>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-4957">&lt;p id="xdx_808_eus-gaap--IntangibleAssetsDisclosureTextBlock_zkobtvaaAgUj" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;NOTE 6 &#x2013;&lt;span id="xdx_823_zlwpLMSMVjic"&gt; OTHER INTANGIBLE ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other intangible assets, net of accumulated
amortization, in the accompanying condensed consolidated balance sheets consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_pn3n3_zHnA5sGQb175" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OTHER INTANGIBLE ASSETS - Other intangible assets net of amortization (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BF_zyqX1uLwEcw1" style="display: none; text-align: left"&gt;Schedule of other intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31,&lt;br/&gt;
2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30, &lt;br/&gt;
2023&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Capitalized software development costs&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_z3x14ASoMG3f" style="width: 12%; text-align: right" title="Gross other intangible assets"&gt;7,005&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_pn3n3" style="width: 12%; text-align: right" title="Gross other intangible assets"&gt;7,005&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Patents and copyrights&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zvNIq4ynXZx6" style="text-align: right" title="Gross other intangible assets"&gt;5,472&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_pn3n3" style="text-align: right" title="Gross other intangible assets"&gt;5,452&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Non-compete&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zY8Va9wjG4A8" style="text-align: right" title="Gross other intangible assets"&gt;4,150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_pn3n3" style="text-align: right" title="Gross other intangible assets"&gt;4,150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Customer relationships&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zyt57x5TTL6f" style="border-bottom: Black 1pt solid; text-align: right" title="Gross other intangible assets"&gt;3,900&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Gross other intangible assets"&gt;3,900&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gross Other intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231_znsHM6vhm7va" style="text-align: right" title="Gross other intangible assets"&gt;20,527&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20230630_zNyHjhgPhRH5" style="text-align: right" title="Gross other intangible assets"&gt;20,507&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: Accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_pn3n3_c20231231_zd56JZnmfOsl" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization"&gt;17,261&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20230630_z7jK2eMULv81" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization"&gt;17,075&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other Intangible Assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_pn3n3_c20231231_z7rZD3VQcbX9" style="border-bottom: Black 2.5pt double; text-align: right" title="Other intangible assets-net"&gt;3,266&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20230630_z7nmcTachwOf" style="border-bottom: Black 2.5pt double; text-align: right" title="Other intangible assets-net"&gt;3,432&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;
























&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Amortization of patents and copyrights
for the three months ended December 31, 2023 and 2022 amounted to $&lt;span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20231001__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zJ6lkEFohRk" title="Amortization of Intangible Assets"&gt;43&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20221001__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_z8zEjgXiClC2" title="Amortization of Intangible Assets"&gt;47&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Amortization of customer relationships
for the three months ended December 31, 2023 and 2022 amounted to $&lt;span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20231001__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zQ1DhqoXYKRb" title="Amortization of Intangible Assets"&gt;50&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20221001__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zXdcADWBVco4" title="Amortization of Intangible Assets"&gt;50&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Amortization of patents and copyrights
for the six months ended December 31, 2023 and 2022 amounted to $&lt;span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20230701__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zG7ggbFFZEt9" title="Amortization of Intangible Assets"&gt;86&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20220701__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zXE72AifZQzj" title="Amortization of Intangible Assets"&gt;101&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Amortization of customer relationships
for the six months ended December 31, 2023 and 2022 amounted to $&lt;span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20230701__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zSsQLrQlgEbc" title="Amortization of Intangible Assets"&gt;100&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20220701__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zGrTy4Lx0aV1" title="Amortization of Intangible Assets"&gt;100&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-4963">&lt;table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_pn3n3_zHnA5sGQb175" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OTHER INTANGIBLE ASSETS - Other intangible assets net of amortization (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BF_zyqX1uLwEcw1" style="display: none; text-align: left"&gt;Schedule of other intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31,&lt;br/&gt;
2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30, &lt;br/&gt;
2023&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Capitalized software development costs&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_z3x14ASoMG3f" style="width: 12%; text-align: right" title="Gross other intangible assets"&gt;7,005&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_pn3n3" style="width: 12%; text-align: right" title="Gross other intangible assets"&gt;7,005&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Patents and copyrights&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zvNIq4ynXZx6" style="text-align: right" title="Gross other intangible assets"&gt;5,472&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_pn3n3" style="text-align: right" title="Gross other intangible assets"&gt;5,452&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Non-compete&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zY8Va9wjG4A8" style="text-align: right" title="Gross other intangible assets"&gt;4,150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_pn3n3" style="text-align: right" title="Gross other intangible assets"&gt;4,150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Customer relationships&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zyt57x5TTL6f" style="border-bottom: Black 1pt solid; text-align: right" title="Gross other intangible assets"&gt;3,900&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Gross other intangible assets"&gt;3,900&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gross Other intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_pn3n3_c20231231_znsHM6vhm7va" style="text-align: right" title="Gross other intangible assets"&gt;20,527&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20230630_zNyHjhgPhRH5" style="text-align: right" title="Gross other intangible assets"&gt;20,507&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: Accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_pn3n3_c20231231_zd56JZnmfOsl" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization"&gt;17,261&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20230630_z7jK2eMULv81" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization"&gt;17,075&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other Intangible Assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_pn3n3_c20231231_z7rZD3VQcbX9" style="border-bottom: Black 2.5pt double; text-align: right" title="Other intangible assets-net"&gt;3,266&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20230630_z7nmcTachwOf" style="border-bottom: Black 2.5pt double; text-align: right" title="Other intangible assets-net"&gt;3,432&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="-3"
      id="ixv-8163"
      unitRef="USD">7005000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-06-30_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="-3"
      id="ixv-8164"
      unitRef="USD">7005000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_custom_PatentsAndCopyrightsMember"
      decimals="-3"
      id="ixv-8165"
      unitRef="USD">5472000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-06-30_custom_PatentsAndCopyrightsMember"
      decimals="-3"
      id="ixv-8166"
      unitRef="USD">5452000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_us-gaap_NoncompeteAgreementsMember"
      decimals="-3"
      id="ixv-8167"
      unitRef="USD">4150000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-06-30_us-gaap_NoncompeteAgreementsMember"
      decimals="-3"
      id="ixv-8168"
      unitRef="USD">4150000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="ixv-8169"
      unitRef="USD">3900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-06-30_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="ixv-8170"
      unitRef="USD">3900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8171"
      unitRef="USD">20527000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-8172"
      unitRef="USD">20507000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8173"
      unitRef="USD">17261000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-8174"
      unitRef="USD">17075000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8175"
      unitRef="USD">3266000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-8176"
      unitRef="USD">3432000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-10-012023-12-31_custom_PatentsAndCopyrightsMember"
      decimals="-3"
      id="ixv-8177"
      unitRef="USD">43000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-10-012022-12-31_custom_PatentsAndCopyrightsMember"
      decimals="-3"
      id="ixv-8178"
      unitRef="USD">47000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-10-012023-12-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="ixv-8179"
      unitRef="USD">50000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-10-012022-12-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="ixv-8180"
      unitRef="USD">50000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-07-012023-12-31_custom_PatentsAndCopyrightsMember"
      decimals="-3"
      id="ixv-8181"
      unitRef="USD">86000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-07-012022-12-31_custom_PatentsAndCopyrightsMember"
      decimals="-3"
      id="ixv-8182"
      unitRef="USD">101000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-07-012023-12-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="ixv-8183"
      unitRef="USD">100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-07-012022-12-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="ixv-8184"
      unitRef="USD">100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-5095">&lt;p id="xdx_805_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zGPBbxLvokkl" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;NOTE 7 &#x2013;&lt;span id="xdx_82D_zukqRL4aBzLl"&gt; OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other current liabilities in the accompanying
condensed consolidated balance sheets consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_pn3n3_zeP1UrQ0Dm77" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OTHER CURRENT LIABILITIES - Other Current Liabilities - (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B9_zHCcyPHyOwF5" style="display: none; text-align: left"&gt;Schedule of other current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20231231_zHR1XX7zypxe" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20230630_z9cYelbSkp3g" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31,&lt;br/&gt;
2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30,&lt;br/&gt;
2023&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--AccruedSalariesCurrent_iI_pn3n3_maOLCzdop_z5WqcgkMCPFc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Accrued salaries, commissions and payroll taxes&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,078&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,413&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_pn3n3_maOLCzdop_zISZUiZsxMgl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Sales tax payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;193&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--StateIncomeTaxesPayable_iI_pn3n3_maOLCzdop_zh61EtQveQXj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt; Income taxes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;196&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maOLCzdop_zQIGdXEGnn4b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Legal and other professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_pn3n3_maOLCzdop_zmqgUBuULDbi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accounting fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--SelfInsuranceReserve_iI_pn3n3_maOLCzdop_zwlv9e72VSwl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Self-funded health insurance reserve&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesNoncurrent_iI_pn3n3_maOLCzdop_zbqhVQUeLE27" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued interest and penalty&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OtherSundryLiabilitiesCurrent_iI_pn3n3_maOLCzdop_zXfcTexvjhL3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other general and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;809&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;574&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OtherLiabilitiesCurrent_iTI_pn3n3_mtOLCzdop_zlJPzs1Vexha" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other Current Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,460&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,444&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-5101">&lt;table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_pn3n3_zeP1UrQ0Dm77" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OTHER CURRENT LIABILITIES - Other Current Liabilities - (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B9_zHCcyPHyOwF5" style="display: none; text-align: left"&gt;Schedule of other current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20231231_zHR1XX7zypxe" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20230630_z9cYelbSkp3g" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31,&lt;br/&gt;
2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30,&lt;br/&gt;
2023&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--AccruedSalariesCurrent_iI_pn3n3_maOLCzdop_z5WqcgkMCPFc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Accrued salaries, commissions and payroll taxes&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,078&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,413&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_pn3n3_maOLCzdop_zISZUiZsxMgl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Sales tax payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;193&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--StateIncomeTaxesPayable_iI_pn3n3_maOLCzdop_zh61EtQveQXj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt; Income taxes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;196&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maOLCzdop_zQIGdXEGnn4b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Legal and other professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_pn3n3_maOLCzdop_zmqgUBuULDbi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accounting fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--SelfInsuranceReserve_iI_pn3n3_maOLCzdop_zwlv9e72VSwl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Self-funded health insurance reserve&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesNoncurrent_iI_pn3n3_maOLCzdop_zbqhVQUeLE27" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued interest and penalty&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OtherSundryLiabilitiesCurrent_iI_pn3n3_maOLCzdop_zXfcTexvjhL3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other general and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;809&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;574&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OtherLiabilitiesCurrent_iTI_pn3n3_mtOLCzdop_zlJPzs1Vexha" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other Current Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,460&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,444&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8185"
      unitRef="USD">2078000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-8186"
      unitRef="USD">4413000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8187"
      unitRef="USD">222000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-8188"
      unitRef="USD">193000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <FONR:StateIncomeTaxesPayable
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8189"
      unitRef="USD">196000</FONR:StateIncomeTaxesPayable>
    <FONR:StateIncomeTaxesPayable
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-8190"
      unitRef="USD">48000</FONR:StateIncomeTaxesPayable>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8191"
      unitRef="USD">11000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-8192"
      unitRef="USD">11000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8193"
      unitRef="USD">54000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-8194"
      unitRef="USD">100000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:SelfInsuranceReserve
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8195"
      unitRef="USD">86000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-8196"
      unitRef="USD">101000</us-gaap:SelfInsuranceReserve>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8197"
      unitRef="USD">4000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-8198"
      unitRef="USD">4000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8199"
      unitRef="USD">809000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-8200"
      unitRef="USD">574000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8201"
      unitRef="USD">3460000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-8202"
      unitRef="USD">5444000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-5212">&lt;p id="xdx_803_eus-gaap--SegmentReportingDisclosureTextBlock_zL0RfZteg9q9" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;NOTE 8 - &lt;span id="xdx_827_z66xBDPQi827"&gt;SEGMENT AND RELATED INFORMATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;The Company operates in two industry segments - manufacturing
and the servicing of medical equipment and management of diagnostic imaging centers. The accounting policies of the segments are
the same as those described in the summary of significant accounting policies as disclosed in the Company&#x2019;s 10-K as of June
30, 2023. All inter-segment sales are market-based. The Company evaluates performance based on income or loss from operations.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
























&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Summarized financial information concerning
the Company&#x2019;s reportable segments is shown in the following table:&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zsW5z5VdLnKj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT AND RELATED INFORMATION - Summarized Segments - (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BB_zZValMBlhpu2" style="display: none"&gt;Schedule
    of summarized segment financial information&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Medical &lt;br/&gt; Equipment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Management &lt;br/&gt; of Diagnostic &lt;br/&gt; Imaging &lt;br/&gt; Centers&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Totals&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; padding-top: 0; padding-right: 0"&gt;For the three months ended Dec. 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Net revenues from external customers&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Revenues_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zYBxfzg2kR0g" style="width: 11%; text-align: right" title="Net revenues from external customers"&gt;1,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--Revenues_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zSYkIm1RS3h8" style="width: 11%; text-align: right" title="Net revenues from external customers"&gt;23,525&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Revenues_pn3n3_c20231001__20231231_zlUglcd1BO8b" style="width: 11%; text-align: right" title="Net revenues from external customers"&gt;25,386&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Inter-segment net revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--IntersegmentNetRevenues_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zk8Xi2CrDcq7" style="text-align: right" title="Inter-segment net revenues"&gt;254&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--IntersegmentNetRevenues_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zKIEVE9fbm87" style="text-align: right" title="Inter-segment net revenues"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1520"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--IntersegmentNetRevenues_pn3n3_c20231001__20231231_zddsruZKQpEh" style="text-align: right" title="Inter-segment net revenues"&gt;254&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;(Loss) Income from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zr4APB0CFLod" style="text-align: right" title="(Loss) Income from operations"&gt;(993&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z9gsBrxFZm04" style="text-align: right" title="(Loss) Income from operations"&gt;5,878&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20231001__20231231_zfjpYB9v3j6j" style="text-align: right" title="(Loss) Income from operations"&gt;4,885&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zEre8Aww9Vie" style="text-align: right" title="Depreciation and amortization"&gt;60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zxaE3s6mMBdj" style="text-align: right" title="Depreciation and amortization"&gt;1,160&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20231001__20231231_zYSMpu46ZV3f" style="text-align: right" title="Depreciation and amortization"&gt;1,220&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Capital expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zupZNmxdrKm8" style="text-align: right" title="Capital expenditures"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zyLNYP99ULt5" style="text-align: right" title="Capital expenditures"&gt;129&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20231001__20231231_zQmfrNSPnb29" style="text-align: right" title="Capital expenditures"&gt;133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;For the three months ended Dec. 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net revenues from external customers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--Revenues_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zFxznI4734b1" style="text-align: right" title="Net revenues from external customers"&gt;2,035&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Revenues_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zGekRqiHTlgd" style="text-align: right" title="Net revenues from external customers"&gt;22,221&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--Revenues_pn3n3_c20221001__20221231_zw6mZEGuNPqf" style="text-align: right" title="Net revenues from external customers"&gt;24,256&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Inter-segment net revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--IntersegmentNetRevenues_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zvdYFhwzc9jk" style="text-align: right" title="Inter-segment net revenues"&gt;245&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--IntersegmentNetRevenues_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z09BirmDHQ28" style="text-align: right" title="Inter-segment net revenues"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1550"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--IntersegmentNetRevenues_pn3n3_c20221001__20221231_zGwXA4Fbz9da" style="text-align: right" title="Inter-segment net revenues"&gt;245&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;(Loss) Income from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_z51YjY3T50Ie" style="text-align: right" title="(Loss) Income from operations"&gt;(551&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zmV8AdnXmUV8" style="text-align: right" title="(Loss) Income from operations"&gt;4,783&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20221001__20221231_zqQwVfraq8jf" style="text-align: right" title="(Loss) Income from operations"&gt;4,232&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_z2XDFJA5yQBg" style="text-align: right" title="Depreciation and amortization"&gt;65&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zRsocsNsD02k" style="text-align: right" title="Depreciation and amortization"&gt;1,035&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20221001__20221231_zxyeiNq7Y1q7" style="text-align: right" title="Depreciation and amortization"&gt;1,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Capital expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zFjPVnk45Ap2" style="text-align: right" title="Capital expenditures"&gt;50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zzq5tmVzjiHl" style="text-align: right" title="Capital expenditures"&gt;423&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20221001__20221231_zMqTazUcDbfd" style="text-align: right" title="Capital expenditures"&gt;473&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Medical &lt;br/&gt; Equipment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Management &lt;br/&gt; of Diagnostic &lt;br/&gt; Imaging &lt;br/&gt; Centers&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Totals&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;For the six months ended Dec. 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Net revenues from external customers&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--Revenues_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zv1hxeQVrfgb" style="width: 11%; text-align: right" title="Net revenues from external customers"&gt;3,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--Revenues_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zhGblQ8e47t9" style="width: 11%; text-align: right" title="Net revenues from external customers"&gt;47,307&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--Revenues_pn3n3_c20230701__20231231_zsrktXjJ68fi" style="width: 11%; text-align: right" title="Net revenues from external customers"&gt;51,224&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Inter-segment net revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--IntersegmentNetRevenues_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zTIZOHH4F1cf" style="text-align: right" title="Inter-segment net revenues"&gt;508&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--IntersegmentNetRevenues_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z9bWZK6jBe96" style="text-align: right" title="Inter-segment net revenues"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1580"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--IntersegmentNetRevenues_pn3n3_c20230701__20231231_z4VKmEP61u15" style="text-align: right" title="Inter-segment net revenues"&gt;508&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;(Loss) Income from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_z6h1rbd7XwMe" style="text-align: right" title="(Loss) Income from operations"&gt;(1,731&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zyePHhZzZMie" style="text-align: right" title="(Loss) Income from operations"&gt;13,187&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20230701__20231231_z0McvqgoVuL9" style="text-align: right" title="(Loss) Income from operations"&gt;11,456&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zxmEVa14eGrj" style="text-align: right" title="Depreciation and amortization"&gt;121&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zxMsCziXPFJ8" style="text-align: right" title="Depreciation and amortization"&gt;2,294&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20230701__20231231_z54OR3vVuP95" style="text-align: right" title="Depreciation and amortization"&gt;2,415&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Capital expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zPQA3hOM7Iib" style="text-align: right" title="Capital expenditures"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zdpsXMOLYsPg" style="text-align: right" title="Capital expenditures"&gt;192&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20230701__20231231_zvy3SiQL5w2g" style="text-align: right" title="Capital expenditures"&gt;212&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;For the six months ended Dec. 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net revenues from external customers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Revenues_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zdd5jVxctIxf" style="text-align: right" title="Net revenues from external customers"&gt;3,913&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--Revenues_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zBhKNZ7a00N4" style="text-align: right" title="Net revenues from external customers"&gt;43,534&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Revenues_pn3n3_c20220701__20221231_zwhY0pR5Akvf" style="text-align: right" title="Net revenues from external customers"&gt;47,447&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Inter-segment net revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--IntersegmentNetRevenues_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zoffHxamlESl" style="text-align: right" title="Inter-segment net revenues"&gt;490&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--IntersegmentNetRevenues_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z6z2QJQnYWkk" style="text-align: right" title="Inter-segment net revenues"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1610"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--IntersegmentNetRevenues_pn3n3_c20220701__20221231_zESpkKwQXykg" style="text-align: right" title="Inter-segment net revenues"&gt;490&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;(Loss) Income from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zPF7z4Z6W2Lh" style="text-align: right" title="(Loss) Income from operations"&gt;(1,353&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zPpoBpVgKqok" style="text-align: right" title="(Loss) Income from operations"&gt;9,496&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20220701__20221231_zPYFCNc56th3" style="text-align: right" title="(Loss) Income from operations"&gt;8,143&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zPIFykb6hMId" style="text-align: right" title="Depreciation and amortization"&gt;137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z8cmlHzT5sL8" style="text-align: right" title="Depreciation and amortization"&gt;2,081&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20220701__20221231_zMfkSiLXdYP6" style="text-align: right" title="Depreciation and amortization"&gt;2,218&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Capital expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zpEqtkQ7HQ93" style="text-align: right" title="Capital expenditures"&gt;74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zGdkIlgc0f17" style="text-align: right" title="Capital expenditures"&gt;1,362&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20220701__20221231_z2Enb1MPBt7l" style="text-align: right" title="Capital expenditures"&gt;1,436&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p id="xdx_8AF_z37NdTvkcvD9" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

















</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-5245">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zsW5z5VdLnKj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT AND RELATED INFORMATION - Summarized Segments - (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BB_zZValMBlhpu2" style="display: none"&gt;Schedule
    of summarized segment financial information&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Medical &lt;br/&gt; Equipment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Management &lt;br/&gt; of Diagnostic &lt;br/&gt; Imaging &lt;br/&gt; Centers&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Totals&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; padding-top: 0; padding-right: 0"&gt;For the three months ended Dec. 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Net revenues from external customers&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Revenues_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zYBxfzg2kR0g" style="width: 11%; text-align: right" title="Net revenues from external customers"&gt;1,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--Revenues_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zSYkIm1RS3h8" style="width: 11%; text-align: right" title="Net revenues from external customers"&gt;23,525&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Revenues_pn3n3_c20231001__20231231_zlUglcd1BO8b" style="width: 11%; text-align: right" title="Net revenues from external customers"&gt;25,386&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Inter-segment net revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--IntersegmentNetRevenues_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zk8Xi2CrDcq7" style="text-align: right" title="Inter-segment net revenues"&gt;254&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--IntersegmentNetRevenues_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zKIEVE9fbm87" style="text-align: right" title="Inter-segment net revenues"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1520"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--IntersegmentNetRevenues_pn3n3_c20231001__20231231_zddsruZKQpEh" style="text-align: right" title="Inter-segment net revenues"&gt;254&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;(Loss) Income from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zr4APB0CFLod" style="text-align: right" title="(Loss) Income from operations"&gt;(993&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z9gsBrxFZm04" style="text-align: right" title="(Loss) Income from operations"&gt;5,878&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20231001__20231231_zfjpYB9v3j6j" style="text-align: right" title="(Loss) Income from operations"&gt;4,885&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zEre8Aww9Vie" style="text-align: right" title="Depreciation and amortization"&gt;60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zxaE3s6mMBdj" style="text-align: right" title="Depreciation and amortization"&gt;1,160&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20231001__20231231_zYSMpu46ZV3f" style="text-align: right" title="Depreciation and amortization"&gt;1,220&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Capital expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zupZNmxdrKm8" style="text-align: right" title="Capital expenditures"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20231001__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zyLNYP99ULt5" style="text-align: right" title="Capital expenditures"&gt;129&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20231001__20231231_zQmfrNSPnb29" style="text-align: right" title="Capital expenditures"&gt;133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;For the three months ended Dec. 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net revenues from external customers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--Revenues_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zFxznI4734b1" style="text-align: right" title="Net revenues from external customers"&gt;2,035&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Revenues_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zGekRqiHTlgd" style="text-align: right" title="Net revenues from external customers"&gt;22,221&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--Revenues_pn3n3_c20221001__20221231_zw6mZEGuNPqf" style="text-align: right" title="Net revenues from external customers"&gt;24,256&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Inter-segment net revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--IntersegmentNetRevenues_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zvdYFhwzc9jk" style="text-align: right" title="Inter-segment net revenues"&gt;245&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--IntersegmentNetRevenues_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z09BirmDHQ28" style="text-align: right" title="Inter-segment net revenues"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1550"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--IntersegmentNetRevenues_pn3n3_c20221001__20221231_zGwXA4Fbz9da" style="text-align: right" title="Inter-segment net revenues"&gt;245&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;(Loss) Income from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_z51YjY3T50Ie" style="text-align: right" title="(Loss) Income from operations"&gt;(551&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zmV8AdnXmUV8" style="text-align: right" title="(Loss) Income from operations"&gt;4,783&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20221001__20221231_zqQwVfraq8jf" style="text-align: right" title="(Loss) Income from operations"&gt;4,232&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_z2XDFJA5yQBg" style="text-align: right" title="Depreciation and amortization"&gt;65&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zRsocsNsD02k" style="text-align: right" title="Depreciation and amortization"&gt;1,035&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20221001__20221231_zxyeiNq7Y1q7" style="text-align: right" title="Depreciation and amortization"&gt;1,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Capital expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zFjPVnk45Ap2" style="text-align: right" title="Capital expenditures"&gt;50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20221001__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zzq5tmVzjiHl" style="text-align: right" title="Capital expenditures"&gt;423&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20221001__20221231_zMqTazUcDbfd" style="text-align: right" title="Capital expenditures"&gt;473&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Medical &lt;br/&gt; Equipment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Management &lt;br/&gt; of Diagnostic &lt;br/&gt; Imaging &lt;br/&gt; Centers&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Totals&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;For the six months ended Dec. 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Net revenues from external customers&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--Revenues_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zv1hxeQVrfgb" style="width: 11%; text-align: right" title="Net revenues from external customers"&gt;3,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--Revenues_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zhGblQ8e47t9" style="width: 11%; text-align: right" title="Net revenues from external customers"&gt;47,307&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--Revenues_pn3n3_c20230701__20231231_zsrktXjJ68fi" style="width: 11%; text-align: right" title="Net revenues from external customers"&gt;51,224&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Inter-segment net revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--IntersegmentNetRevenues_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zTIZOHH4F1cf" style="text-align: right" title="Inter-segment net revenues"&gt;508&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--IntersegmentNetRevenues_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z9bWZK6jBe96" style="text-align: right" title="Inter-segment net revenues"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1580"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--IntersegmentNetRevenues_pn3n3_c20230701__20231231_z4VKmEP61u15" style="text-align: right" title="Inter-segment net revenues"&gt;508&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;(Loss) Income from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_z6h1rbd7XwMe" style="text-align: right" title="(Loss) Income from operations"&gt;(1,731&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zyePHhZzZMie" style="text-align: right" title="(Loss) Income from operations"&gt;13,187&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20230701__20231231_z0McvqgoVuL9" style="text-align: right" title="(Loss) Income from operations"&gt;11,456&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zxmEVa14eGrj" style="text-align: right" title="Depreciation and amortization"&gt;121&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zxMsCziXPFJ8" style="text-align: right" title="Depreciation and amortization"&gt;2,294&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20230701__20231231_z54OR3vVuP95" style="text-align: right" title="Depreciation and amortization"&gt;2,415&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Capital expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zPQA3hOM7Iib" style="text-align: right" title="Capital expenditures"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20230701__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zdpsXMOLYsPg" style="text-align: right" title="Capital expenditures"&gt;192&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20230701__20231231_zvy3SiQL5w2g" style="text-align: right" title="Capital expenditures"&gt;212&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;For the six months ended Dec. 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net revenues from external customers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Revenues_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zdd5jVxctIxf" style="text-align: right" title="Net revenues from external customers"&gt;3,913&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--Revenues_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zBhKNZ7a00N4" style="text-align: right" title="Net revenues from external customers"&gt;43,534&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Revenues_pn3n3_c20220701__20221231_zwhY0pR5Akvf" style="text-align: right" title="Net revenues from external customers"&gt;47,447&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Inter-segment net revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--IntersegmentNetRevenues_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zoffHxamlESl" style="text-align: right" title="Inter-segment net revenues"&gt;490&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--IntersegmentNetRevenues_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z6z2QJQnYWkk" style="text-align: right" title="Inter-segment net revenues"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1610"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--IntersegmentNetRevenues_pn3n3_c20220701__20221231_zESpkKwQXykg" style="text-align: right" title="Inter-segment net revenues"&gt;490&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;(Loss) Income from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zPF7z4Z6W2Lh" style="text-align: right" title="(Loss) Income from operations"&gt;(1,353&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zPpoBpVgKqok" style="text-align: right" title="(Loss) Income from operations"&gt;9,496&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_c20220701__20221231_zPYFCNc56th3" style="text-align: right" title="(Loss) Income from operations"&gt;8,143&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zPIFykb6hMId" style="text-align: right" title="Depreciation and amortization"&gt;137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_z8cmlHzT5sL8" style="text-align: right" title="Depreciation and amortization"&gt;2,081&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DepreciationDepletionAndAmortization_pn3n3_c20220701__20221231_zMfkSiLXdYP6" style="text-align: right" title="Depreciation and amortization"&gt;2,218&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Capital expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--MedicalEquipmentMember_zpEqtkQ7HQ93" style="text-align: right" title="Capital expenditures"&gt;74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20220701__20221231__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--ManagementOfDiagnosticImagingCentersMember_zGdkIlgc0f17" style="text-align: right" title="Capital expenditures"&gt;1,362&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20220701__20221231_z2Enb1MPBt7l" style="text-align: right" title="Capital expenditures"&gt;1,436&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="From2023-10-012023-12-31_custom_MedicalEquipmentMember"
      decimals="-3"
      id="ixv-8203"
      unitRef="USD">1861000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-10-012023-12-31_custom_ManagementOfDiagnosticImagingCentersMember"
      decimals="-3"
      id="ixv-8204"
      unitRef="USD">23525000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-8205"
      unitRef="USD">25386000</us-gaap:Revenues>
    <FONR:IntersegmentNetRevenues
      contextRef="From2023-10-012023-12-31_custom_MedicalEquipmentMember"
      decimals="-3"
      id="ixv-8206"
      unitRef="USD">254000</FONR:IntersegmentNetRevenues>
    <FONR:IntersegmentNetRevenues
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-8207"
      unitRef="USD">254000</FONR:IntersegmentNetRevenues>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2023-10-012023-12-31_custom_MedicalEquipmentMember"
      decimals="-3"
      id="ixv-8208"
      unitRef="USD">-993000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2023-10-012023-12-31_custom_ManagementOfDiagnosticImagingCentersMember"
      decimals="-3"
      id="ixv-8209"
      unitRef="USD">5878000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-8210"
      unitRef="USD">4885000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-10-012023-12-31_custom_MedicalEquipmentMember"
      decimals="-3"
      id="ixv-8211"
      unitRef="USD">60000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-10-012023-12-31_custom_ManagementOfDiagnosticImagingCentersMember"
      decimals="-3"
      id="ixv-8212"
      unitRef="USD">1160000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-8213"
      unitRef="USD">1220000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2023-10-012023-12-31_custom_MedicalEquipmentMember"
      decimals="-3"
      id="ixv-8214"
      unitRef="USD">4000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2023-10-012023-12-31_custom_ManagementOfDiagnosticImagingCentersMember"
      decimals="-3"
      id="ixv-8215"
      unitRef="USD">129000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-8216"
      unitRef="USD">133000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:Revenues
      contextRef="From2022-10-012022-12-31_custom_MedicalEquipmentMember"
      decimals="-3"
      id="ixv-8217"
      unitRef="USD">2035000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-10-012022-12-31_custom_ManagementOfDiagnosticImagingCentersMember"
      decimals="-3"
      id="ixv-8218"
      unitRef="USD">22221000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-8219"
      unitRef="USD">24256000</us-gaap:Revenues>
    <FONR:IntersegmentNetRevenues
      contextRef="From2022-10-012022-12-31_custom_MedicalEquipmentMember"
      decimals="-3"
      id="ixv-8220"
      unitRef="USD">245000</FONR:IntersegmentNetRevenues>
    <FONR:IntersegmentNetRevenues
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-8221"
      unitRef="USD">245000</FONR:IntersegmentNetRevenues>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2022-10-012022-12-31_custom_MedicalEquipmentMember"
      decimals="-3"
      id="ixv-8222"
      unitRef="USD">-551000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2022-10-012022-12-31_custom_ManagementOfDiagnosticImagingCentersMember"
      decimals="-3"
      id="ixv-8223"
      unitRef="USD">4783000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-8224"
      unitRef="USD">4232000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-10-012022-12-31_custom_MedicalEquipmentMember"
      decimals="-3"
      id="ixv-8225"
      unitRef="USD">65000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-10-012022-12-31_custom_ManagementOfDiagnosticImagingCentersMember"
      decimals="-3"
      id="ixv-8226"
      unitRef="USD">1035000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-8227"
      unitRef="USD">1100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2022-10-012022-12-31_custom_MedicalEquipmentMember"
      decimals="-3"
      id="ixv-8228"
      unitRef="USD">50000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2022-10-012022-12-31_custom_ManagementOfDiagnosticImagingCentersMember"
      decimals="-3"
      id="ixv-8229"
      unitRef="USD">423000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-8230"
      unitRef="USD">473000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:Revenues
      contextRef="From2023-07-012023-12-31_custom_MedicalEquipmentMember"
      decimals="-3"
      id="ixv-8231"
      unitRef="USD">3917000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-012023-12-31_custom_ManagementOfDiagnosticImagingCentersMember"
      decimals="-3"
      id="ixv-8232"
      unitRef="USD">47307000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-8233"
      unitRef="USD">51224000</us-gaap:Revenues>
    <FONR:IntersegmentNetRevenues
      contextRef="From2023-07-012023-12-31_custom_MedicalEquipmentMember"
      decimals="-3"
      id="ixv-8234"
      unitRef="USD">508000</FONR:IntersegmentNetRevenues>
    <FONR:IntersegmentNetRevenues
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-8235"
      unitRef="USD">508000</FONR:IntersegmentNetRevenues>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2023-07-012023-12-31_custom_MedicalEquipmentMember"
      decimals="-3"
      id="ixv-8236"
      unitRef="USD">-1731000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2023-07-012023-12-31_custom_ManagementOfDiagnosticImagingCentersMember"
      decimals="-3"
      id="ixv-8237"
      unitRef="USD">13187000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-8238"
      unitRef="USD">11456000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-07-012023-12-31_custom_MedicalEquipmentMember"
      decimals="-3"
      id="ixv-8239"
      unitRef="USD">121000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-07-012023-12-31_custom_ManagementOfDiagnosticImagingCentersMember"
      decimals="-3"
      id="ixv-8240"
      unitRef="USD">2294000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-8241"
      unitRef="USD">2415000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2023-07-012023-12-31_custom_MedicalEquipmentMember"
      decimals="-3"
      id="ixv-8242"
      unitRef="USD">20000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2023-07-012023-12-31_custom_ManagementOfDiagnosticImagingCentersMember"
      decimals="-3"
      id="ixv-8243"
      unitRef="USD">192000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-8244"
      unitRef="USD">212000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:Revenues
      contextRef="From2022-07-012022-12-31_custom_MedicalEquipmentMember"
      decimals="-3"
      id="ixv-8245"
      unitRef="USD">3913000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-07-012022-12-31_custom_ManagementOfDiagnosticImagingCentersMember"
      decimals="-3"
      id="ixv-8246"
      unitRef="USD">43534000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-8247"
      unitRef="USD">47447000</us-gaap:Revenues>
    <FONR:IntersegmentNetRevenues
      contextRef="From2022-07-012022-12-31_custom_MedicalEquipmentMember"
      decimals="-3"
      id="ixv-8248"
      unitRef="USD">490000</FONR:IntersegmentNetRevenues>
    <FONR:IntersegmentNetRevenues
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-8249"
      unitRef="USD">490000</FONR:IntersegmentNetRevenues>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2022-07-012022-12-31_custom_MedicalEquipmentMember"
      decimals="-3"
      id="ixv-8250"
      unitRef="USD">-1353000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2022-07-012022-12-31_custom_ManagementOfDiagnosticImagingCentersMember"
      decimals="-3"
      id="ixv-8251"
      unitRef="USD">9496000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-8252"
      unitRef="USD">8143000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-07-012022-12-31_custom_MedicalEquipmentMember"
      decimals="-3"
      id="ixv-8253"
      unitRef="USD">137000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-07-012022-12-31_custom_ManagementOfDiagnosticImagingCentersMember"
      decimals="-3"
      id="ixv-8254"
      unitRef="USD">2081000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-8255"
      unitRef="USD">2218000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2022-07-012022-12-31_custom_MedicalEquipmentMember"
      decimals="-3"
      id="ixv-8256"
      unitRef="USD">74000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2022-07-012022-12-31_custom_ManagementOfDiagnosticImagingCentersMember"
      decimals="-3"
      id="ixv-8257"
      unitRef="USD">1362000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-8258"
      unitRef="USD">1436000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-5665">&lt;p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zHWnZ22CaqHa" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;NOTE 9 &#x2013; &lt;span id="xdx_82C_zQvkvwl2vwv3"&gt;RELATED PARTY TRANSACTION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;On December 31, 2023, the Company entered into an agreement
with Magnetic Resonance Management, LLC (&#x201c;MRM&#x201d;) for the sale of a MRI scanner. MRM is owned by the CEO and President of
the Company. The sales price of the equipment was $&lt;span id="xdx_900_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20231231__us-gaap--TypeOfArrangementAxis__custom--MagneticResonanceManagementMember_zfzvHax66Pfi" title="Sale of price of the equipment"&gt;577 &lt;/span&gt;which
is payable based upon a promissory note dated December 1, 2023. The note bears interest at a rate of &lt;span id="xdx_905_eus-gaap--DerivativeFixedInterestRate_iI_dp_c20231231__us-gaap--TypeOfArrangementAxis__custom--MagneticResonanceManagementMember_zNADqpJm70He" title="Bears interest rate"&gt;9&lt;/span&gt;%
and is payable in full at the maturity of the note in December 2028. The MRI scanner had zero  basis,which resulted ina gain of
$&lt;span id="xdx_901_ecustom--GainOnSaleOfEquipmentsRelatedParty_pn3n3_c20230701__20231231__us-gaap--TypeOfArrangementAxis__custom--MagneticResonanceManagementMember_zD3aBtiEar0h" title="Gain on sale of equipments"&gt;577&lt;/span&gt;.
The Company has the option but not the obligation to re-take possession of the scanner in lieu of payment upon maturity of the
note.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2023-12-31_custom_MagneticResonanceManagementMember"
      decimals="-3"
      id="ixv-8259"
      unitRef="USD">577000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="AsOf2023-12-31_custom_MagneticResonanceManagementMember"
      decimals="INF"
      id="ixv-8260"
      unitRef="Pure">0.09</us-gaap:DerivativeFixedInterestRate>
    <FONR:GainOnSaleOfEquipmentsRelatedParty
      contextRef="From2023-07-012023-12-31_custom_MagneticResonanceManagementMember"
      decimals="-3"
      id="ixv-8261"
      unitRef="USD">577000</FONR:GainOnSaleOfEquipmentsRelatedParty>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-5674">&lt;p id="xdx_80D_eus-gaap--CashFlowSupplementalDisclosuresTextBlock_zMUapTuqk1c7" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;NOTE 10 &#x2013; &lt;span id="xdx_82C_z0YpBtiGdf95"&gt;SUPPLEMENTAL CASH FLOW INFORMATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the six months ended December
31, 2023 and December 31, 2022, the Company paid $&lt;span id="xdx_908_eus-gaap--InterestPaidNet_pn3n3_c20230701__20231231_zIq5hehxG7zg" title="Interest paid"&gt;58&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--InterestPaidNet_pn3n3_c20220701__20221231_zSYfYY2p5XS4" title="Interest paid"&gt;27&lt;/span&gt; for interest, respectively.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the six months ended December
31, 2023 and December 31, 2022, the Company paid $&lt;span id="xdx_908_eus-gaap--IncomeTaxesPaid_pn3n3_c20230701__20231231_zMiNrxfLyRtg" title="Income taxes paid"&gt;150&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--IncomeTaxesPaid_pn3n3_c20220701__20221231_zZXAhzt0DVWa" title="Income taxes paid"&gt;647&lt;/span&gt; for income taxes, respectively.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:InterestPaidNet
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-8262"
      unitRef="USD">58000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-8263"
      unitRef="USD">27000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-8264"
      unitRef="USD">150000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-8265"
      unitRef="USD">647000</us-gaap:IncomeTaxesPaid>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-5686">&lt;p id="xdx_80C_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zvzBqLcHjQo1" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;NOTE 11 &#x2013; &lt;span id="xdx_82C_zFbmrWQyLhwi"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;Litigation&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is subject to legal proceedings
and claims arising from the ordinary course of its business, including personal injury, customer contract and employment claims.
In the opinion of management, the aggregate liability, if any, with respect to such actions, will not have a material adverse effect
on the consolidated financial position or results of operations of the Company.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;There were no material changes in litigation
from that reported in our Form 10-K for the fiscal year ended June 30, 2023.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;Other Matters&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 13, 2022, the Company adopted
a stock repurchase plan. The plan has no expiration date and cannot determine the number of shares which will be repurchased. On
September 26, 2022, the Board of Directors has approved up to $&lt;span id="xdx_906_eus-gaap--StockRepurchaseProgramAuthorizedAmount1_iI_pn6n6_c20220926_zHN5t317jN9i" title="Stock purchase plan"&gt;9&lt;/span&gt; million to be repurchased under the plan which will be purchased
on the publicly traded open market at prevailing prices. During the six months ended December 31, 2023 and 2022, the Company repurchased
&lt;span id="xdx_905_eus-gaap--StockRepurchasedDuringPeriodShares_pn3n3_c20230701__20231231_zyBLqJfRvmEf" title="Number of shares repurchased"&gt;116&lt;/span&gt; and &lt;span id="xdx_907_eus-gaap--StockRepurchasedDuringPeriodShares_pn3n3_c20220701__20221231_zzCeEy7DCR7f" title="Number of shares repurchased"&gt;30&lt;/span&gt; shares at a cost of $&lt;span id="xdx_908_eus-gaap--StockRepurchasedDuringPeriodValue_pn3n3_c20230701__20231231_ze00iQh7Hz73" title="Number of shares repurchased, value"&gt;1,885&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--StockRepurchasedDuringPeriodValue_pn3n3_c20220701__20221231_z4sW2ojJs1Wb" title="Number of shares repurchased, value"&gt;478&lt;/span&gt;, respectively. The Company cancelled &lt;span id="xdx_909_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_pn3n3_c20230701__20231231_zJ9Ojs9M54E2" title="Shares cancelled"&gt;123&lt;/span&gt; shares and &lt;span id="xdx_906_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_pn3n3_c20220701__20221231_zRey31O42mqg" title="Shares cancelled"&gt;16&lt;/span&gt; shares at a cost of $&lt;span id="xdx_905_eus-gaap--StockRepurchasedAndRetiredDuringPeriodValue_pn3n3_c20230701__20231231_z3F898iE26M3" title="Shares cancelled"&gt;2,005&lt;/span&gt;
and $&lt;span id="xdx_90C_eus-gaap--StockRepurchasedAndRetiredDuringPeriodValue_pn3n3_c20220701__20221231_z4GUJKnBOll8" title="Shares cancelled"&gt;402&lt;/span&gt; for the six months ended December 31, 2023 and 2022, respectively.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company maintains a self-funded
health insurance program with a stop-loss umbrella policy with a third party insurer to limit the maximum potential liability for
individual claims to $&lt;span id="xdx_90F_ecustom--StoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims_pn3n3_c20230701__20231231_zepMfctlFoL9" title="Liability for individual claims"&gt;150&lt;/span&gt; per person and for a maximum potential claim liability based on member enrollment. With respect to this
program, the Company considers historical and projected medical utilization data when estimating its health insurance program liability
and related expense. As of December 31, 2023 and June 30, 2023, the Company had approximately $&lt;span id="xdx_905_eus-gaap--LiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth_iI_pn3n3_c20231231_zJtH6cAEXXOa" title="Reserve for self-funded"&gt;86&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--LiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth_iI_pn3n3_c20230630_zmnSW29S6X4j" title="Reserve for self-funded"&gt;101&lt;/span&gt;, respectively, in reserve
for its self-funded health insurance programs. The reserves are included in &#x201c;Other current liabilities&#x201d; in the condensed
consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



























&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company regularly analyzes its reserves
for incurred but not reported claims, and for reported but not paid claims related to its reinsurance and self-funded insurance
programs. The Company believes its reserves are adequate. However, significant judgment is involved in assessing these reserves
such as assessing historical paid claims, average lags between the claims&#x2019; incurred date, reported dates and paid dates,
and the frequency and severity of claims. There may be differences between actual settlement amounts and recorded reserves and
any resulting adjustments are included in expense once a probable amount is known. There were no significant adjustments recorded
in the periods covered by this report.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="AsOf2022-09-26"
      decimals="-6"
      id="ixv-8266"
      unitRef="USD">9000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-8267"
      unitRef="Shares">116000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-8268"
      unitRef="Shares">30000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-8269"
      unitRef="USD">1885000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-8270"
      unitRef="USD">478000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-8271"
      unitRef="Shares">123000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-8272"
      unitRef="Shares">16000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-8273"
      unitRef="USD">2005000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-8274"
      unitRef="USD">402000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <FONR:StoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-8275"
      unitRef="USD">150000</FONR:StoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8276"
      unitRef="USD">86000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="ixv-8277"
      unitRef="USD">101000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpenseDisabilityAccidentAndHealth>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-5745">&lt;p id="xdx_805_eus-gaap--IncomeTaxDisclosureTextBlock_z9PIY1Vi0NYh" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;NOTE 12 - &lt;span id="xdx_82A_zgbJBS8rTg9b"&gt;INCOME TAXES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In accordance with ASC 740-270, &#x201c;Income
Taxes &#x2013; Interim Reporting&#x201d;, the Company is required at the end of each interim period to determine the best estimate
of its annual effective tax rate and apply that rate to year-to-date ordinary income or loss. The resulting tax expense (or benefit)
is adjusted for the tax effect of specific events, if any, required to be discretely recognized in the interim period as they occur.
For the six months ended December 31, 2023 and 2022, the Company recorded income tax expense of $&lt;span id="xdx_907_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_pn3n3_c20230701__20231231_z77gKMqvDt4" title="Income tax expense"&gt;3,036&lt;/span&gt; in 2023 as compared to $&lt;span id="xdx_908_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_pn3n3_c20220701__20221231_z8TUAeevUDu6" title="Income tax expense"&gt;2,871&lt;/span&gt;
in 2022. For the three months ended December 31, 2023 and 2022, the Company recorded income tax expense of $&lt;span id="xdx_90E_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_pn3n3_c20231001__20231231_z8UrFTQw6Pr1" title="Income tax expense"&gt;1,366&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_pn3n3_c20221001__20221231_zsEqBUD1dJfl" title="Income tax expense"&gt;1,462&lt;/span&gt; respectively.
The six month and three month 2023 provision is comprised of a current income tax component of $&lt;span id="xdx_900_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_c20230701__20231231_z7SZpscRnZs8" title="Income tax component - current"&gt;751&lt;/span&gt; and a deferred income tax component
of $&lt;span id="xdx_906_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_c20230701__20231231_zABWvBKGT7Ai" title="Income tax component - deferred"&gt;2,285&lt;/span&gt; and a current income tax component of $&lt;span id="xdx_903_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_c20231001__20231231_z5e5nTcgNSle" title="Income tax component - current"&gt;323&lt;/span&gt; and a deferred income tax component of $&lt;span id="xdx_90B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_c20231001__20231231_zU1Tpt0sz2gf" title="Income tax component - deferred"&gt;1,043&lt;/span&gt; respectively. Obligations for
any liability associated with the current income tax provision, has been reduced, primarily resulting from the benefits and utilization
of net operating loss carryforwards.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;ASC Topic 740 prescribes a recognition
threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected
to be taken in a corporate tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained
upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the
benefit recognized and measured pursuant to the interpretation are referred to as unrecognized benefits. A liability is recognized
(or amount of net operating loss carryforward or amount of tax refundable is reduced) for an unrecognized tax benefit because it
represents an enterprise&#x2019;s potential future obligation to the taxing authority for a tax position that was not recognized
as a result of applying the provisions of ASC Topic 740. The Company believes there are no uncertain tax positions in prior year
tax filings and therefore it has not recorded a liability for unrecognized tax benefits.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In accordance with ASC Topic 740, interest
costs related to unrecognized tax benefits are required to be calculated (if applicable) and would be classified as &#x201c;Interest
expense, net&#x201d;. Penalties if incurred would be recognized as a component of &#x201c;Selling, general and administrative&#x201d;
expenses.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company files corporate income tax
returns in the United States (federal) and in various state and local jurisdictions. In most instances, the Company is no longer
subject to federal, state and local income tax examinations by tax authorities for years prior to 2018.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
























&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recorded a deferred tax
asset of $&lt;span id="xdx_904_eus-gaap--DeferredTaxAssetsNet_iI_pn3n3_c20231231_zJPrUJmNilga" title="Deferred tax asset"&gt;7,758&lt;/span&gt; and a deferred tax liability of $&lt;span id="xdx_901_eus-gaap--DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityPolicyholdersSurplus_iI_pn3n3_c20231231_zCECO4hJ1tG3" title="Deferred tax liability"&gt;395&lt;/span&gt; as of December 31, 2023, primarily relating to allowance for doubtful accounts
and tax credits. The net operating losses begin to expire in 2028 for federal tax and state income tax purposes. The Company anticipates
that their Federal operating loss will be utilized in the current fiscal year.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Future ownership changes as determined
under Section 382 of the Internal Revenue code could further limit the utilization of net operating loss carryforwards. As of December
31, 2023, no such changes in ownership have occurred.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Inflation Reduction Act (&#x201c;IRA&#x201d;)
was enacted on August 16, 2022. The IRA includes provisions imposing a 1% excise tax on share repurchases that occur after December
31, 2022 and introduces a &lt;span id="xdx_90E_ecustom--CorporateAlternativeMinimumTaxPercentage_dp_c20230701__20231231_z1lnHxfgDlI1" title="Corporate alternative minimum tax percentage"&gt;15&lt;/span&gt;% corporate alternative minimum tax (&#x201c;CAMT&#x201d;) on adjusted financial statement income. The
CAMT will be effective for tax years beginning after December 31, 2022. Currently, the Company is expecting the IRA not to have
a material impact to the Company&#x2019;s financial statements.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The ultimate realization of deferred tax assets is dependent on the generation
of future taxable income during the periods in which those temporary differences become deductible or when such net operating losses can
be utilized. The Company considers projected future taxable income, the regulatory environment of the industry and tax planning strategies
in making this assessment. At present, the Company believes that it is more likely than not that the benefits from certain deferred tax
asset carryforwards, will not all be fully realized. In recognition of this inherent risk, a valuation allowance was established for separate
state net operating losses that are not expected to be fully utilized. A valuation allowance will be maintained until sufficient positive
evidence exists to support the reversal of the remainder of the valuation.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-8278"
      unitRef="USD">3036000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
      contextRef="From2022-07-012022-12-31"
      decimals="-3"
      id="ixv-8279"
      unitRef="USD">2871000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-8280"
      unitRef="USD">1366000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      id="ixv-8281"
      unitRef="USD">1462000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-8282"
      unitRef="USD">751000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2023-07-01to2023-12-31"
      decimals="-3"
      id="ixv-8283"
      unitRef="USD">2285000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-8284"
      unitRef="USD">323000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2023-10-012023-12-31"
      decimals="-3"
      id="ixv-8285"
      unitRef="USD">1043000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8286"
      unitRef="USD">7758000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityPolicyholdersSurplus
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-8287"
      unitRef="USD">395000</us-gaap:DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityPolicyholdersSurplus>
    <FONR:CorporateAlternativeMinimumTaxPercentage
      contextRef="From2023-07-01to2023-12-31"
      decimals="INF"
      id="ixv-8288"
      unitRef="Pure">0.15</FONR:CorporateAlternativeMinimumTaxPercentage>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-07-01to2023-12-31" id="ixv-5801">&lt;p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_z6fCf5UJhFC8" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;NOTE 13 &#x2013; &lt;span id="xdx_822_ze5k9iU8ZZ5j"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has evaluated events that
occurred subsequent to December 31, 2023 and through the date the condensed consolidated financial statements were issued.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During February 2024, the Company signed
an amendment to a property lease for its principal office in Melville, New York. The agreement extends the term of the lease until
November 2033.&lt;/p&gt;

&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
